

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |   |   |
|---|--|---|---|
| (51) International Patent Classification <sup>7</sup> :<br><b>C07K 14/705, C12N 15/12, C12Q 1/68,<br/>C12N 5/10, C07K 16/28, G01N 33/53,<br/>A61K 38/17</b>   |  | A2  | (11) International Publication Number: <b>WO 00/40614</b><br>(43) International Publication Date: 13 July 2000 (13.07.00) |
| (21) International Application Number: PCT/US99/29996<br>(22) International Filing Date: 20 December 1999 (20.12.99)<br><br>(30) Priority Data:<br>60/114,220 30 December 1998 (30.12.98) US<br>60/120,018 29 January 1999 (29.01.99) US<br>60/140,415 22 June 1999 (22.06.99) US<br><br>(71) Applicant (for all designated States except US): BETH ISRAEL<br>DEACONESS MEDICAL CENTER, INC. [US/US]; 330<br>Brookline Avenue, Boston, MA 02215 (US).<br><br>(72) Inventor; and<br>(75) Inventor/Applicant (for US only): SCHARENBERG, Andrew,<br>M. [US/US]; 12 Skyview Road, Lexington, MA 02420 (US).<br><br>(74) Agent: PLUMER, Elizabeth, R.; Wolf, Greenfield & Sacks,<br>P.C., 600 Atlantic Avenue, Boston, MA 02210 (US). |  | (81) Designated States: AU, CA, JP, US, European patent (AT, BE,<br>CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,<br>NL, PT, SE).<br><br>Published<br>Without international search report and to be republished<br>upon receipt of that report. |   |

(54) Title: CHARACTERIZATION OF A CALCIUM CHANNEL FAMILY



(57) Abstract

Nucleic acids encoding SOC/CRAC calcium channel polypeptides, including fragments and biologically functional variants thereof and encoded polypeptides are provided. The nucleic acids and polypeptides disclosed herein are useful as therapeutic and diagnostic agents. Agents that selectively bind to the foregoing polypeptides and genes also are provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

**CHARACTERIZATION OF A CALCIUM CHANNEL FAMILY****Field of the Invention**

This invention relates to nucleic acids coding for a novel family of calcium channel polypeptides, the encoded polypeptides, unique fragments of the foregoing, and methods of making and using same.

**Background of the Invention**

Calcium channels are membrane-spanning, multi-subunit proteins that facilitate the controlled transport ("flux") of  $\text{Ca}^{2+}$  ions into and out of cells. Cells throughout the animal kingdom, and at least some bacterial, fungal and plant cells, possess one or more types of calcium channels. In general, "excitable" cells, such as neurons of the central nervous system, peripheral nerve cells, and muscle cells, including those of skeletal muscles, cardiac muscles, and venous and arterial smooth muscles, possess voltage-dependent calcium channels. In a voltage-dependent calcium channel, the transport of  $\text{Ca}^{2+}$  ions into and out of the cells requires a certain minimal level of depolarization (the difference in potential between the inside of the cell bearing the channel and the extracellular environment) with the rate of  $\text{Ca}^{2+}$  cell flux dependent on the difference in potential. In "non-excitable" cells, calcium influx is thought to occur predominantly in response to stimuli which cause the release of calcium from intracellular stores. This process, termed *store operated calcium influx*, is not well understood.

Characterization of a particular type of calcium channel by analysis of whole cells is complicated by the presence of mixed populations of different types of calcium channels in the majority of cells. Although single-channel recording methods can be used to examine individual calcium channels, such analysis does not reveal information related to the molecular structure or biochemical composition of the channel. Furthermore, in this type of analysis, the channel is isolated from other cellular constituents that might be important for the channel's natural functions and pharmacological interactions. To study the calcium channel structure-function relationship, large amounts of pure channel protein are needed. However, acquiring large amounts of pure protein is difficult in view of the complex nature of these multisubunit proteins, the varying concentrations of calcium channel proteins in tissue sources, the presence of mixed populations of calcium channel proteins in tissues, and the modifications of the native protein that can occur during the isolation procedure.

### Summary of the Invention

The invention is based on the identification of a novel family of calcium channel polypeptides and the molecular cloning and partial characterization of a novel member of this family that is expressed predominantly in human hematopoietic cells, liver, and kidney. This newly identified family of calcium channel polypeptides is designated, "SOC" or "CRAC" or "ICRAC", for Store Operated Channels or Calcium Release Activated Channels. Although not wishing to be bound to any particular theory or mechanism, it is believed that the SOC/CRAC calcium channel polypeptides are transmembrane polypeptides that modulate  $\text{Ca}^{2+}$  flux "into" and "out of" a cell, for example, in certain instances they may be activated upon depletion of  $\text{Ca}^{2+}$  from intracellular calcium stores, allowing  $\text{Ca}^{2+}$  influx into the cell. Accordingly, the compositions disclosed herein are believed to be useful for modulating calcium transport into and out of such intracellular stores and for the treatment of disorders that are characterized by aberrant calcium transport into and out of such intracellular stores. In particular, we believe that the SOC/CRAC calcium channel polypeptides disclosed herein play an important role in the influx of extracellular calcium by mediating the refilling of intracellular calcium stores following their depletion. Accordingly, we believe that the compositions for expressing functional SOC/CRAC calcium channel polypeptides in cells, as disclosed herein, are useful for treating patients having conditions that are characterized by reduced extracellular calcium influx into their SOC/CRAC-expressing cells. Additionally, the compositions of the invention are useful for delivering therapeutic and/or imaging agents to cells which preferentially express SOC/CRAC calcium channel polypeptides and, in particular, for delivering such agents to hematopoietic cells, liver, heart, spleen, and kidney to modulate proliferation and growth of these cells. Moreover, in view of the importance of cellular calcium levels to cell viability, we believe that SOC-2/CRAC-1, SOC-3/CRAC-2, and SOC-4/CRAC-3 as disclosed herein, and/or other members of the SOC/CRAC family of calcium channel polypeptides, represent an ideal target for designing and/or identifying (e.g., from molecular libraries) small molecule inhibitors that block lymphocyte proliferation, as well as other binding agents that selectively bind to SOC/CRAC polypeptides to which drugs or toxins can be conjugated for delivery to SOC/CRAC polypeptide expressing cells.

The invention is based, in part, on the molecular cloning and sequence analysis of the novel SOC/CRAC calcium channel molecules disclosed herein (also referred to as a "SOC-2/CRAC-1 molecule," a "SOC-3/CRAC-2 molecule," and/or "SOC-4/CRAC-3 molecule") that are predominantly expressed in human hematopoietic cells, liver, spleen, heart, and



kidney (SOC-2/CRAC-1), kidney and colon (SOC-3/CRAC-2), and prostate (SOC-4/CRAC-3 molecule). As used herein, a "SOC/CRAC molecule" embraces a "SOC/CRAC calcium channel nucleic acid" (or "SOC/CRAC nucleic acid") and a "SOC/CRAC calcium channel polypeptide" (or "SOC/CRAC polypeptide"). Homologs and alleles also are embraced within the meaning of a SOC/CRAC calcium channel molecule.

According to one aspect of the invention, isolated SOC/CRAC nucleic acids which code for one or more member(s) of the SOC/CRAC family of calcium channel polypeptides or unique fragments thereof are provided. The isolated nucleic acids refer to one or more of the following:

(a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

The invention in another aspect provides an isolated nucleic acid molecule selected from the group consisting of (a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29, and SEQ ID NO:31, (b) complements of (a), provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from a sequence group consisting of (1) sequences having the SEQ. ID NOS. or GenBank accession numbers of Table I, (2) complements of (1), and (3) fragments of (1) and (2).

According to yet another aspect of the invention, isolated SOC/CRAC polypeptides are provided. The isolated SOC/CRAC polypeptide molecules are encoded by one or more SOC/CRAC nucleic acid molecules of the invention. Preferably, the SOC/CRAC polypeptide contains one or more polypeptides selected from the group consisting of the polypeptides having SEQ. ID Nos. 2, 4, 6, 8, 24, 26, 28, 30, and 32. In other embodiments, the isolated polypeptide may be a fragment or variant of the foregoing SOC/CRAC polypeptide molecules of sufficient length to represent a sequence unique within the human genome, and identifying

with a polypeptide that functions as a calcium channel, provided that the fragment excludes a sequence of contiguous amino acids identified in Table II, and/or excludes a sequence of contiguous amino acids encoded for by a nucleic acid sequence identified in Table I. In another embodiment, immunogenic fragments of the polypeptide molecules described above are provided.

According to another aspect of the invention, isolated SOC/CRAC binding agents (e.g., polypeptides) are provided which selectively bind to a SOC/CRAC molecule (e.g., a SOC/CRAC polypeptide encoded by the isolated nucleic acid molecules of the invention). Preferably, the isolated binding agents selectively bind to a polypeptide which comprises the sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32, or unique fragments thereof. In the preferred embodiments, the isolated binding polypeptides include antibodies and fragments of antibodies (e.g., Fab, F(ab)<sub>2</sub>, Fd and antibody fragments which include a CDR3 region which binds selectively to a SOC/CRAC polypeptide). Preferably, the antibodies for human therapeutic applications are human antibodies.

According to another aspect of the invention, a pharmaceutical composition containing a pharmaceutically effective amount of an isolated SOC/CRAC nucleic acid, an isolated SOC/CRAC polypeptide, or an isolated SOC/CRAC binding polypeptide in a pharmaceutically acceptable carrier also is provided. The pharmaceutical compositions are useful in accordance with therapeutic methods disclosed herein.

According to yet another aspect of the invention, a method for isolating a SOC/CRAC molecule is provided. The method involves:

a) contacting a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample that is believed to contain one or more SOC/CRAC molecules, under conditions to form a complex of the SOC/CRAC nucleic acid or the SOC/CRAC binding polypeptide and the SOC/CRAC molecule;

b) detecting the presence of the complex;

c) isolating the SOC/CRAC molecule from the complex; and

d) determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity. As used herein "SOC/CRAC calcium channel activity" refers to the transport of Ca<sup>2+</sup> into and out of intracellular stores that is mediated by a SOC/CRAC

polypeptide. In general, the SOC/CRAC calcium channel activity is initiated by a reduction or depletion of intracellular calcium stores.

In certain embodiments, the SOC/CRAC nucleic acid is a SOC-2/CRAC-1 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 27, or complements thereof); in certain other  
5       embodiments, the SOC/CRAC nucleic acid is a SOC-3/CRAC-2 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 29, or complements thereof); in further embodiments, the SOC/CRAC nucleic acid is a SOC-4/CRAC-3 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 31, or complements thereof). In yet other embodiments, the SOC/CRAC polypeptide  
10       is a SOC-2/CRAC-1 binding polypeptide (e.g., an antibody that selectively binds to a SOC-2/CRAC-1 polypeptide). In yet further embodiments, the SOC/CRAC polypeptide is a SOC-3/CRAC-2 binding polypeptide (e.g., an antibody that selectively binds to a SOC-3/CRAC-2 polypeptide). In some embodiments, the SOC/CRAC polypeptide is a SOC-4/CRAC-3 binding polypeptide (e.g., an antibody that selectively binds to a SOC-4/CRAC-3 polypeptide). In the preferred embodiments, the isolated binding polypeptides include  
15       antibodies and fragments of antibodies (e.g., Fab, F(ab)<sub>2</sub>, Fd and antibody fragments which include a CDR3 region which binds selectively to a SOC-2/CRAC-1, to a SOC-3/CRAC-2, and/or to a SOC-4/CRAC-3 polypeptide). Preferably the isolated binding polypeptides or other binding agents selectively bind to a single SOC/CRAC molecule, i.e., are capable of distinguishing between different members of the SOC/CRAC family. Accordingly, one or  
20       more SOC/CRAC binding agents can be contained in a single composition (e.g., a pharmaceutical composition) to identify multiple SOC/CRAC molecules *in vivo* or *in vitro*.

According to yet another aspect of the invention, a method for identifying agents useful in the modulation of SOC/CRAC calcium channel activity is provided. The method involves:

- 25       a) contacting a SOC/CRAC polypeptide with a candidate agent suspected of modulating SOC/CRAC calcium channel activity, under conditions sufficient to allow the candidate agent to interact selectively with (e.g. bind to) the SOC/CRAC polypeptide;
- b) detecting a Ca<sup>2+</sup> concentration of step (b) associated with the SOC/CRAC calcium channel activity of the SOC/CRAC polypeptide in the presence of the candidate agent; and
- 30       c) comparing the Ca<sup>2+</sup> concentration of step (b) with a control Ca<sup>2+</sup> concentration of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC calcium channel activity.

According to another aspect of the invention, a method for identifying agents useful in the modulation of a SOC/CRAC polypeptide kinase activity is provided. The method involves:

5 a) contacting a SOC/CRAC polypeptide with kinase activity with a candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity;

b) detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and

10 c) comparing the kinase activity of step (b) with a control kinase activity of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC kinase activity. In some embodiments the SOC/CRAC polypeptide comprises amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24), or a fragment thereof that retains the kinase activity.

15 According to yet another aspect of the invention, a method for determining the level of expression of a SOC/CRAC polypeptide in a subject is provided. The method involves:

a) measuring the expression of a SOC/CRAC polypeptide in a test sample, and

20 b) comparing the measured expression of the SOC/CRAC polypeptide in the test sample to the expression of a SOC/CRAC polypeptide in a control containing a known level of expression to determine the level of SOC/CRAC expression in the subject. Expression is defined as SOC/CRAC mRNA expression or SOC/CRAC polypeptide expression. Various methods can be used to measure expression. The preferred embodiments of the invention utilize PCR and Northern blotting for measuring mRNA expression, and monoclonal or polyclonal SOC/CRAC antisera as reagents for measuring SOC/CRAC polypeptide expression. In preferred embodiments, the SOC/CRAC molecule (nucleic acid and/or  
25 polypeptide) is SOC-2/CRAC-1. In other preferred embodiments, the SOC/CRAC molecule is SOC-3/CRAC-2. In yet further preferred embodiments, the SOC/CRAC molecule is SOC-4/CRAC-3. In certain embodiments, the test samples include biopsy samples and biological fluids such as blood. The method is useful, e.g., for assessing the presence or absence or stage of a proliferative disorder in a subject.

30 The invention also contemplates kits comprising a package including assays for SOC/CRAC epitopes, SOC/CRAC nucleic acids, and instructions, and optionally related materials such as controls, for example, a number, color chart, or an epitope of the expression product of the foregoing isolated nucleic acid molecules of the invention for comparing, for

example, the level of SOC/CRAC polypeptides or SOC/CRAC nucleic acid forms (wild-type or mutant) in a test sample to the level in a control sample having a known amount of a SOC/CRAC nucleic acid or SOC/CRAC polypeptide. This comparison can be used to assess in a subject a risk of developing a cancer or the progression of a cancer. The kits may also include assays for other known genes, and expression products thereof, associated with, for example, proliferative disorders (e.g., BRCA, p53, etc.). In a preferred embodiment, the kit comprises a package containing: (a) a binding agent that selectively binds to an isolated nucleic acid of the invention or an expression product thereof to obtain a measured test value, (b) a control containing a known amount of a SOC/CRAC nucleic acid or a SOC/CRAC polypeptide to obtain a measured control value, and (c) instructions for comparing the measured test value to the measured control value to determine the amount of SOC/CRAC nucleic acid or expression product thereof in a sample.

The invention provides isolated nucleic acid molecules, unique fragments thereof, expression vectors containing the foregoing, and host cells containing the foregoing. The invention also provides isolated binding polypeptides and binding agents which bind such polypeptides, including antibodies, and pharmaceutical compositions containing any of the compositions of the invention. The foregoing can be used, *inter alia*, in the diagnosis or treatment of conditions characterized by the aberrant expression levels and/or the presence of mutant forms of a SOC/CRAC nucleic acid or polypeptide. The invention also provides methods for identifying agents that alter the function of the SOC/CRAC polypeptide.

These and other aspects of the invention, as well as various advantages and utilities, will be more apparent with reference to the detailed description of the preferred embodiments.

#### **Brief Description of the Sequences**

SEQ ID NO:1 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:2 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:1).

SEQ ID NO:3 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:4 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:3).

SEQ ID NO:5 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:6 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:5).

-8-

SEQ ID NO:7 is a partial nucleotide sequence of the mouse homologue (mSOC-2/CRAC-1) of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:8 is the predicted amino acid sequence of the translation product of the mSOC-2/CRAC-1 cDNA (SEQ ID NO:7).

5 SEQ ID NO:9 is the nucleotide sequence of the mouse MLSN-1 (SOC-1) cDNA.

SEQ ID NO:10 is the predicted amino acid sequence of the translation product of the mouse MLSN-1 (SOC-1) cDNA (SEQ ID NO:9).

SEQ ID NO:11 is the nucleotide sequence of a human calcium channel cDNA with GenBank Acc. no.: AB001535.

10 SEQ ID NO:12 is the predicted amino acid sequence of the translation product of the human calcium channel cDNA with GenBank Acc. no.: AB001535 (SEQ ID NO:11).

SEQ ID NO:13 is the amino acid sequence of a *C. Elegans* polypeptide at the c05c12.3 locus.

15 SEQ ID NO:14 is the amino acid sequence of a *C. Elegans* polypeptide at the F54D1 locus.

SEQ ID NO:15 is the amino acid sequence of a *C. Elegans* polypeptide at the t01H8 locus.

SEQ ID NO:16 is the nucleotide sequence of a mouse kidney cDNA with GenBank Acc. no.: AI226731.

20 SEQ ID NO:17 is the predicted amino acid sequence of the translation product of the mouse kidney cDNA with GenBank Acc. no.: AI226731 (SEQ ID NO:16).

SEQ ID NO:18 is the nucleotide sequence of a human brain cDNA with GenBank Acc. no.: H18835.

25 SEQ ID NO:19 is the predicted amino acid sequence of the translation product of the human brain cDNA with GenBank Acc. no.: H18835 (SEQ ID NO:18).

SEQ ID NO:20 is the nucleotide sequence of the human EST with GenBank Acc. no.: AA419592.

SEQ ID NO:21 is the nucleotide sequence of the human EST with GenBank Acc. no.: AA419407.

30 SEQ ID NO:22 is the nucleotide sequence of the mouse EST with GenBank Acc. no.: AI098310.

SEQ ID NO:23 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA that contains the SOC-2/CRAC-1 sequences of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.

SEQ ID NO:24 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:23).

SEQ ID NO:25 is a partial nucleotide sequence of the human SOC-3/CRAC-2 cDNA.

SEQ ID NO:26 is the predicted amino acid sequence of the translation product of human SOC-3/CRAC-2 cDNA (SEQ ID NO:25).

SEQ ID NO:27 is the full nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:28 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:27).

SEQ ID NO:29 is the full nucleotide sequence of the human SOC-3/CRAC-2 cDNA.

SEQ ID NO:30 is the predicted amino acid sequence of the translation product of human SOC-3/CRAC-2 cDNA (SEQ ID NO:29).

SEQ ID NO:31 is the full nucleotide sequence of the human SOC-4/CRAC-3 cDNA.

SEQ ID NO:32 is the predicted amino acid sequence of the translation product of human SOC-4/CRAC-3 cDNA (SEQ ID NO:31).

#### **Brief Description of the Drawings**

Figure 1 is a schematic depicting the intron/exon organization of the chicken SOC-2/CRAC-1 genomic sequence, as well as the putative transmembrane (TM) domains, and the targeting constructs utilized in the knockout experiments.

#### **Detailed Description of the Invention**

One aspect of the invention involves the partial cloning of cDNAs encoding members of a novel family of calcium channel polypeptides, referred to herein as "SOC/CRAC" (designated "SOC" or "CRAC" or "ICRAC", for StoRe Operated Channels or Calcium Release Activated Channels, or CECH). Although not intending to be bound to any particular mechanism or theory, we believe that a SOC/CRAC family member is a transmembrane calcium channel that modulates  $\text{Ca}^{2+}$  flux "into" and "out of" a cell; in certain instances it may be activated upon depletion of  $\text{Ca}^{2+}$  from intracellular calcium stores, allowing  $\text{Ca}^{2+}$  influx into the cell.

The first three isolated SOC/CRAC members disclosed herein, define a new family of calcium channels which is distinct from previously described calcium channels, such as voltage gated calcium channels, ryanodine receptor/inositol-1,4,5-triphosphate receptor

channels, and Transient Receptor Potential (TRP) channels. The SOC/CRAC family of calcium channels exhibits high selectivity (with a  $P_{Ca}/P_{Na}$  ratio near 1000), a unitary conductance below the detection level of the patch clamp method (the conductance estimated at approximately 0.2 picosiemens), and are subject to inhibition by high intracellular calcium levels. Although not intending to be bound to any particular mechanism or theory, we believe that SOC/CRAC calcium channels are responsible for the majority of, for example, calcium entry which occurs when intracellular calcium stores are depleted, and that SOC/CRAC currents are important for initiating various types of calcium-dependent processes. Thus, we believe that SOC/CRAC calcium channels play an important role in cellular calcium homeostasis by, e.g., modulating the supply of calcium to refill intracellular stores when depleted.

The isolated full-length sequence of a representative, first member of the SOC/CRAC family, human SOC/CRAC nucleic acid (cDNA), SOC-2/CRAC-1, is represented as the nucleic acid of SEQ ID NO:27. This nucleic acid sequence codes for the SOC-2/CRAC-1 polypeptide with the predicted amino acid sequence disclosed herein as SEQ ID NO:28. A homologous mouse cDNA sequence (>90% identity to the human at the nucleotide level) is represented as the nucleic acid of SEQ ID NO:7, and codes for a unique fragment of a mouse SOC-2/CRAC-1 polypeptide having the predicted, partial amino acid sequence represented as SEQ ID NO:8. Analysis of the SOC-2/CRAC-1 partial sequence by comparison to nucleic acid and protein databases show that SOC-2/CRAC-1 shares a limited homology to mouse MLSN-1 (SOC-1, SEQ ID NOs: 9 and 10). Limited homology is also shared between SOC-2/CRAC-1 and three *C. Elegans* polypeptides (SEQ ID NOs: 13, 14, and 15). We further believe that SOC-2/CRAC-1 plays a role in the regulation of cellular  $Ca^{2+}$  fluxing and, in particular, lymphocyte  $Ca^{2+}$  fluxing.

A second member of the human SOC/CRAC family of calcium channels, SOC-3/CRAC-2, is represented as the nucleic acid of SEQ ID NO:29, and codes for the human SOC-3/CRAC-2 polypeptide having the predicted amino acid sequence represented as SEQ ID NO:30 (this molecule may also be referred to as CECH2). SOC-3/CRAC-2 is predominantly expressed in human hematopoietic cells (including peripheral blood lymphocytes, liver, bone marrow, spleen, thymus, lymph nodes, heart, and kidney. Expression can also be detected (at lesser levels) in brain, skeletal muscle colon, small intestine, placenta, lung, and cells (cell lines) such as HL-60, HeLa, K562, MOLT-4, SW-480, A459, and G361.



A third member of the human SOC/CRAC family of calcium channels, SOC-4/CRAC-3, is represented as the nucleic acid of SEQ ID NO:31, and codes for the human SOC-4/CRAC-3 polypeptide having the predicted amino acid sequence represented as SEQ ID NO:32 (this molecule may also be referred to as CECH6). It specifically expressed in the prostate gland/cells.

As used herein, a SOC/CRAC calcium channel nucleic acid (also referred to herein as a "SOC/CRAC nucleic acid" refers to a nucleic acid molecule which: (1) hybridizes under stringent conditions to one or more of the nucleic acids having the sequences of SEQ. ID NOS. 7, 27, 29, and/or 31 (sequences of the mouse and human SOC-2/CRAC-1, human SOC-3/CRAC-2, and human SOC-4/CRAC-3 nucleic acids), and (2) codes for a SOC-2/CRAC-1, a SOC-3/CRAC-2 or a SOC-4/CRAC-3 calcium channel polypeptide, respectively, or unique fragments of said SOC-2/CRAC-1, SOC-3/CRAC-2, or SOC-4/CRAC-3 polypeptide.

As used herein, a SOC/CRAC calcium channel polypeptide (also referred to herein as a "SOC/CRAC polypeptide") refers to a polypeptide that is coded for by a SOC-2/CRAC-1, a SOC-3/CRAC-2, and/or a SOC-4/CRAC-3 nucleic acid. Preferably, the above-identified SOC/CRAC polypeptides mediate transport of calcium into and out of a cell.

SOC/CRAC polypeptides also are useful as immunogenic molecules for the generation of binding polypeptides (e.g., antibodies) which bind selectively to SOC/CRAC (e.g., SOC-2/CRAC-1, SOC-3/CRAC-2, and/or SOC-4/CRAC-3) polypeptides. Such antibodies can be used in diagnostic assays to identify and/or quantify the presence of a SOC/CRAC polypeptide in a sample, such as a biological fluid or biopsy sample. SOC/CRAC polypeptides further embrace functionally equivalent fragments, variants, and analogs of the preferred SOC/CRAC polypeptides, provided that the fragments, variants, and analogs also are useful in mediating calcium transport into and out of intracellular calcium stores.

As used herein, "SOC/CRAC calcium channel activity" refers to  $\text{Ca}^{2+}$  transport ("Ca<sup>2+</sup> fluxing") across the plasma membrane that is mediated by a SOC/CRAC calcium channel polypeptide. The SOC/CRAC calcium channel polypeptide typically has one or more of the following properties: high selectivity, a unitary conductance below the detection level of the patch clamp method, and are subject to inhibition by high intracellular calcium levels. Such activity can be easily detected using standard methodology well known in the art. See, e.g., the Examples and Neher, E., "Ion channels for communication between and within cells",

Science, 1992; 256:498-502; and Hoth, M., and Penner, R., "Depletion of intracellular calcium stores activates a calcium current in mast cells", Nature, 1992; 355 (6358):353-6.

According to one aspect of the invention, isolated nucleic acid molecules which code for one or more member(s) of the SOC/CRAC family of calcium channel polypeptides are provided. The isolated nucleic acid molecules are selected from the following groups:

(a) nucleic acid molecules which hybridize under stringent conditions to one or more nucleic acid molecules selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

In certain embodiments, the isolated nucleic acid molecule comprises one or more of nucleotides 1-1212 of SEQ ID NO:1; nucleotides 1-739 of SEQ ID NO:3; nucleotides 1-1579 of SEQ ID NO:5; nucleotides 1-5117 of SEQ ID NO:23; the mouse homolog for SOC-2/CRAC-1 corresponding to SEQ ID NO:7; nucleotides 1-2180 of SEQ ID NO:25; nucleotides 382-5976 of SEQ ID NO:27; nucleotides 73-3714 of SEQ ID NO:29; and nucleotides 23-3434 of SEQ ID NO:31. In yet other embodiments, the isolated nucleic acid molecule comprises a molecule which encodes a polypeptide having one or more sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

According to yet another aspect of the invention, an isolated nucleic acid molecule is provided which is selected from the group consisting of:

(a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, (of sufficient length to represent a sequence unique within the human genome); and (b) complements of (a), provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to a sequence in the prior art as represented by the sequence group consisting of: (1) sequences having the SEQ ID NOs or GenBank accession numbers of Table I, (2) complements of (1), and (3) fragments of (1) and (2).

In some embodiments, the sequence of contiguous nucleotides is selected from the group consisting of (1) at least two contiguous nucleotides nonidentical to the sequence group, (2) at least three contiguous nucleotides nonidentical to the sequence group, (3) at least four contiguous nucleotides nonidentical to the sequence group, (4) at least five contiguous nucleotides nonidentical to the sequence group, (5) at least six contiguous nucleotides nonidentical to the sequence group, (6) at least seven contiguous nucleotides nonidentical to the sequence group.

In other embodiments, the unique fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 40 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

According to another aspect of the invention, expression vectors and host cells containing (e.g., transformed or transfected with) expression vectors comprising the nucleic acid molecules disclosed herein operably linked to a promoter are provided. In certain preferred embodiments, the host cells are eukaryotic cells.

The isolated nucleic acid molecules disclosed herein have various utilities, including their use as probes and primers to identify additional members of the SOC/CRAC family of calcium channels, as diagnostic reagents for identifying the presence of SOC/CRAC polypeptides in biological or other samples, and as agents for generating SOC/CRAC binding polypeptides (e.g., antibodies) that can be used as reagents in diagnostic and therapeutic assays to identify the presence, absence, and/or amounts of a SOC/CRAC nucleic acid or polypeptide in a biological or other sample.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulatable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the

material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulatable by standard techniques known to those of ordinary skill in the art.

As used herein with respect to polypeptides (discussed below), the term "isolated" means separated from its native environment in sufficiently pure form so that it can be manipulated or used for any one of the purposes of the invention. Thus, isolated means sufficiently pure to be used (i) to raise and/or isolate antibodies, (ii) as a reagent in an assay, or (iii) for sequencing, etc.

Homologs and alleles of the SOC/CRAC nucleic acids of the invention can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for SOC/CRAC polypeptides and which hybridize to a nucleic acid molecule selected from a group consisting of the nucleic acid of SEQ ID NO:1, the nucleic acid of SEQ ID NO:3, the nucleic acid of SEQ ID NO:5, the nucleic acid of SEQ ID NO:7, the nucleic acid of SEQ ID NO:23, the nucleic acid of SEQ ID NO:25, the nucleic acid of SEQ ID NO:27, the nucleic acid of SEQ ID NO:29, and the nucleic acid of SEQ ID NO:31, under stringent conditions. The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH<sub>2</sub>PO<sub>4</sub>(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, and would result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of the SOC/CRAC nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such

molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and/or SEQ ID NO:31, and SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, respectively. In some instances sequences will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances sequences will share at least 60% nucleotide identity and/or at least 75% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for SOC/CRAC related genes, such as homologs and alleles of SOC-2/CRAC-1 and/or SOC-3/CRAC-2, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film or a phosphorimager plate to detect the radioactive signal.

Given that the expression of the SOC/CRAC gene is prominent in certain human tissues (e.g., SOC-2/CRAC-1: lymphoid tissue/heart, SOC-3/CRAC-2: kidney/colon, SOC-4/CRAC-3: prostate), and given the teachings herein of partial human SOC/CRAC cDNA clones, full-length and other mammalian sequences corresponding to the human SOC/CRAC partial nucleic acid sequences can be isolated from, for example, a cDNA library prepared from one or more of the tissues in which SOC-2/CRAC-1 expression is prominent, SOC-3/CRAC-2 is prominent, and/or SOC-4/CRAC-3 expression is prominent, using standard colony hybridization techniques.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the

art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating SOC/CRAC polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides isolated unique fragments of an isolated nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31. A unique fragment is one that is a 'signature' for the larger nucleic acid. For example, the unique fragment is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the SOC/CRAC nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome.

Unique fragments, however, exclude fragments completely composed of the nucleotide sequences of any of GenBank accession numbers and SEQ ID NOs listed in Table I (SEQ ID NO:9, AB001535, AI226731, H18835, AA419592, AA261842, AA419407, AI098310, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853), or other previously published sequences as of the filing date of this application.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits and SEQ ID NO:9, is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, as demonstrated in the Examples, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the SOC/CRAC polypeptides, useful, for example, in the preparation of antibodies, immunoassays or therapeutic applications. Unique fragments further can be used as antisense molecules to inhibit the expression of SOC/CRAC nucleic acids and polypeptides, respectively.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and complements thereof, will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides long (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases) or more, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide, (provided the sequence is unique as described above). Virtually any segment of the region of SEQ ID NO:1 beginning at nucleotide 1 and ending at nucleotide 1212, or SEQ ID NO:3 beginning at nucleotide 1 and ending at nucleotide 739, or SEQ ID NO:5 beginning at nucleotide 1 and ending at nucleotide 1579, or SEQ ID NO:7 beginning at nucleotide 1 and ending at nucleotide 3532, or SEQ ID NO:23 beginning at nucleotide 1 and ending at nucleotide 5117, SEQ ID NO:25 beginning at nucleotide 1 and ending at nucleotide 2180, SEQ ID NO:27 beginning at nucleotide 1 and ending at nucleotide 7419, or SEQ ID NO:29 beginning at nucleotide 1 and ending at nucleotide 4061, or SEQ ID NO:31 beginning at nucleotide 1 and ending at nucleotide 4646, or complements thereof, that is 20 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique

fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a SOC/CRAC polypeptide, to decrease SOC/CRAC calcium channel activity. When using antisense preparations of the invention, slow intravenous administration is preferred.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nat. Med.* 1(11):1116-1118, 1995). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In



addition, 3'-untranslated regions may be targeted by antisense oligonucleotides. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although, SEQ ID No:1 discloses a cDNA sequence, one of ordinary skill in the art may easily derive the genomic DNA corresponding to this sequence. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31. Similarly, antisense to allelic or homologous SOC/CRAC cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include

-20-

oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding SOC/CRAC polypeptides, together with pharmaceutically acceptable carriers. Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.

The invention also involves expression vectors coding for SOC/CRAC proteins and fragments and variants thereof and host cells containing those expression vectors. Virtually any cells, prokaryotic or eukaryotic, which can be transformed with heterologous DNA or RNA and which can be grown or maintained in culture, may be used in the practice of the invention. Examples include bacterial cells such as *E.coli* and eukaryotic cells such as mouse, hamster, pig, goat, primate, yeast, xenopous, etc. They may be of a wide variety of tissue types, including mast cells, fibroblasts, oocytes and lymphocytes, and they may be primary cells or cell lines. Specific examples include CHO cells and COS cells. Cell-free transcription systems also may be used in lieu of cells.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to,

plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g.,  $\beta$ -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed

and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

According to yet another aspect of the invention, isolated SOC/CRAC polypeptides are provided. Preferably, the isolated SOC/CRAC polypeptides are encoded by the isolated SOC/CRAC nucleic acid molecules disclosed herein. More preferably, the isolated SOC/CRAC polypeptides of the invention are encoded by the nucleic acid molecules having SEQ ID Nos. 1, 3, 5, 7, 23, 25, 27, 29, and 31. In yet other embodiments, the isolated SOC/CRAC polypeptides of the invention have an amino acid sequence selected from the group consisting of SEQ ID Nos. 2, 4, 6, 8, 24, 26, 28, 30 and 32. Preferably, the isolated SOC/CRAC polypeptides are of sufficient length to represent a sequence unique within the human genome. Thus, the preferred embodiments include a sequence of contiguous amino acids which is not identical to a prior art sequence as represented by the sequence group consisting of the contiguous amino acids identified in Table II (SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19 and GenBank Acc. Nos. AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572).

In certain embodiments, the isolated SOC/CRAC polypeptides are immunogenic and can be used to generate binding polypeptides (e.g., antibodies) for use in diagnostic and therapeutic applications. Such binding polypeptides also are useful for detecting the presence, absence, and/or amounts of a SOC/CRAC nucleic acid or polypeptide in a sample such as a biological fluid or biopsy sample. Preferably, the SOC/CRAC polypeptides that are useful for generating binding polypeptides are unique polypeptides and, therefore, binding of the antibody to a SOC/CRAC polypeptide in a sample is selective for the SOC/CRAC polypeptide.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al.,

*Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a SOC/CRAC polypeptide or fragment or variant thereof. The heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen, Carlsbad, CA), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the above described, SOC/CRAC cDNA sequence containing expression vectors, to transfect host cells and cell lines, by these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include dendritic cells, U293 cells, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The invention also permits the construction of SOC/CRAC gene

“knock-outs” in cells and in animals, providing materials for studying certain aspects of SOC/CRAC calcium channel activity.

The invention also provides isolated polypeptides (including whole proteins and partial proteins), encoded by the foregoing SOC/CRAC nucleic acids, and include the polypeptides of SEQ ID NO:2, 4, 6, 8, 24, 26, 28, 30, 32, and unique fragments thereof. Such polypeptides are useful, for example, to regulate calcium transport-mediated cell growth, differentiation and proliferation, to generate antibodies, as components of immunoassays, etc. Polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a SOC/CRAC polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 and 12 amino acids long or more, including each integer up to the full length, >1,000 amino acids long). Virtually any segment of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, excluding the ones that share identity with it (the polypeptides identified in Table II - SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, and GenBank Acc. Nos. AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572) that is 9 or more amino acids in length will be unique.

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include  $\text{Ca}^{2+}$  fluxing, high selectivity, a unitary

conductance below the detection level of the patch clamp method, and/or and are subject to inhibition by high intracellular calcium levels.

One important aspect of a unique fragment is its ability to act as a signature for identifying the polypeptide. Optionally, another aspect of a unique fragment is its ability to provide an immune response in an animal. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the SOC/CRAC polypeptides described above. As used herein, a "variant" of a SOC/CRAC polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a SOC/CRAC polypeptide. Modifications which create a SOC/CRAC polypeptide variant are typically made to the nucleic acid which encodes the SOC/CRAC polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and addition of amino acids or non-amino acid moieties to: 1) reduce or eliminate a calcium channel activity of a SOC/CRAC polypeptide; 2) enhance a property of a SOC/CRAC polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) provide a novel activity or property to a SOC/CRAC polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to a SOC/CRAC polypeptide receptor or other molecule. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the SOC/CRAC amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant SOC/CRAC polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a SOC/CRAC calcium channel polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

5 Variants can include SOC/CRAC polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a SOC/CRAC polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

10 Mutations of a nucleic acid which encodes a SOC/CRAC polypeptide preferably preserve the amino acid reading frame of the coding sequence and, preferably, do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

15 Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant SOC/CRAC polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a SOC/CRAC gene or cDNA clone to enhance expression of the polypeptide.

20 The skilled artisan will realize that conservative amino acid substitutions may be made in SOC/CRAC polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., the variants retain the functional capabilities of the SOC/CRAC polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the SOC/CRAC polypeptides include conservative amino acid substitutions of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32. Conservative substitutions of amino acids

25

30



-27-

include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Thus functionally equivalent variants of SOC/CRAC polypeptides, i.e., variants of SOC/CRAC polypeptides which retain the function of the natural SOC/CRAC polypeptides, are contemplated by the invention. Conservative amino-acid substitutions in the amino acid sequence of SOC/CRAC polypeptides to produce functionally equivalent variants of SOC/CRAC polypeptides typically are made by alteration of a nucleic acid encoding SOC/CRAC polypeptides (e.g., SEQ ID NOs:1, 3, 5, 7, 23, 25, 27, 29, 31). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a SOC/CRAC polypeptide. The activity of functionally equivalent fragments of SOC/CRAC polypeptides can be tested by cloning the gene encoding the altered SOC/CRAC polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered SOC/CRAC polypeptide, and testing for a functional capability of the SOC/CRAC polypeptides as disclosed herein (e.g., SOC/CRAC calcium channel activity).

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of SOC/CRAC polypeptides, including the isolation of the complete SOC/CRAC polypeptide. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated SOC/CRAC molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of SOC/CRAC mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce SOC/CRAC polypeptides. Those skilled in the art also can readily follow known methods for isolating SOC/CRAC polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from SOC/CRAC polypeptides. A dominant negative polypeptide is an

inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative inactive SOC/CRAC calcium channel which interacts normally with the cell membrane but which does not mediate calcium transport can reduce calcium transport in a cell. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

According to another aspect, the invention provides a method for isolating a SOC/CRAC molecule having SOC/CRAC calcium channel activity. The method involves contacting a binding molecule that is a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample containing one or more SOC/CRAC molecules under conditions that allow such binding (see earlier discussion) to form a complex, detecting the presence of the complex, isolating the SOC/CRAC molecule from the complex, and determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity. Thus, the invention is useful for identifying and isolating full length complementary (cDNA) or genomic nucleic acids encoding SOC/CRAC polypeptides having SOC/CRAC calcium channel activity. Identification and isolation of such nucleic acids and polypeptides may be accomplished by hybridizing/binding, under appropriate conditions well known in the art, libraries and/or restriction enzyme-digested human nucleic acids, with a labeled SOC/CRAC molecular probe. As used herein, a "label" includes molecules that are incorporated into, for

example, a SOC/CRAC molecule (nucleic acid or peptide), that can be directly or indirectly detected. A wide variety of detectable labels are well known in the art that can be used, and include labels that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc), or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseshoe peroxidase, etc.). The label may be bound to a SOC/CRAC binding partner, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradioactive energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art. Once a library clone or hybridizing fragment is identified in the hybridization/binding reaction, it can be further isolated by employing standard isolation/cloning techniques known to those of skill in the art. See, generally, Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press. In addition, nucleic acid amplification techniques well known in the art, may also be used to locate splice variants of calcium channel (or calcium channel subunits) with SOC/CRAC calcium channel activity. Size and sequence determinations of the amplification products can reveal splice variants.

The foregoing isolated nucleic acids and polypeptides may then be compared to the nucleic acids and polypeptides of the present invention in order to identify homogeneity or divergence of the sequences, and be further characterized functionally to determine whether they belong to a family of molecules with SOC/CRAC calcium channel activity (for methodology see under the Examples section).

The isolation of the SOC/CRAC cDNA and/or partial sequences thereof also makes it possible for the artisan to diagnose a disorder characterized by an aberrant expression of SOC/CRAC. These methods involve determining expression of the SOC/CRAC gene, and/or SOC/CRAC polypeptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes as exemplified below. In the latter situation, such determination can be carried out via any standard immunological assay using, for example, antibodies which bind to the SOC/CRAC protein.

The invention also embraces isolated peptide binding agents which, for example, can be antibodies or fragments of antibodies ("binding polypeptides"), having the ability to selectively bind to SOC/CRAC polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology. In certain embodiments, the invention excludes binding agents (e.g., antibodies) that bind to the polypeptides encoded by the nucleic acids of SEQ ID NOs: 10, 12, 13, 14, 15, 17, and 19.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs

are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves binding polypeptides of numerous size and type that bind selectively to SOC/CRAC polypeptides, and complexes containing SOC/CRAC polypeptides. These binding polypeptides also may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form, as bacterial flagella peptide display libraries or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptides and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the SOC/CRAC polypeptide or a complex containing a SOC/CRAC polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the SOC/CRAC polypeptide or complex. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear

portion of the sequence that binds to the SOC/CRAC polypeptide or complex can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the SOC/CRAC polypeptides. Thus, the SOC/CRAC polypeptides of the invention, or a fragment thereof, or complexes of SOC/CRAC can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding polypeptides that selectively bind to the SOC/CRAC polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of SOC/CRAC and for other purposes that will be apparent to those of ordinary skill in the art.

A SOC/CRAC polypeptide, or a fragment thereof, also can be used to isolate naturally occurring, polypeptide binding partners which may associate with the SOC/CRAC polypeptide in the membrane of a cell. Isolation of binding partners may be performed according to well-known methods. For example, isolated SOC/CRAC polypeptides can be attached to a substrate, and then a solution suspected of containing an SOC/CRAC binding partner may be applied to the substrate. If the binding partner for SOC/CRAC polypeptides is present in the solution, then it will bind to the substrate-bound SOC/CRAC polypeptide. The binding partner then may be isolated. Other proteins which are binding partners for SOC/CRAC, may be isolated by similar methods without undue experimentation.

The invention also provides novel kits which could be used to measure the levels of the nucleic acids of the invention, expression products of the invention or anti-SOC/CRAC antibodies. In the case of nucleic acid detection, pairs of primers for amplifying SOC/CRAC nucleic acids can be included. The preferred kits would include controls such as known amounts of nucleic acid probes, SOC/CRAC epitopes (such as SOC/CRAC expression products) or anti-SOC/CRAC antibodies, as well as instructions or other printed material. In certain embodiments the printed material can characterize risk of developing a disorder that is characterized by aberrant SOC/CRAC polypeptide expression based upon the outcome of the assay. The reagents may be packaged in containers and/or coated on wells in predetermined amounts, and the kits may include standard materials such as labeled immunological reagents (such as labeled anti-IgG antibodies) and the like. One kit is a packaged polystyrene microtiter plate coated with a SOC/CRAC polypeptide and a container containing labeled anti-human IgG antibodies. A well of the plate is contacted with, for example, serum, washed

and then contacted with the anti-IgG antibody. The label is then detected. A kit embodying features of the present invention is comprised of the following major elements: packaging an agent of the invention, a control agent, and instructions. Packaging is a box-like structure for holding a vial (or number of vials) containing an agent of the invention, a vial (or number of  
5 vials) containing a control agent, and instructions. Individuals skilled in the art can readily modify packaging to suit individual needs.

Another aspect of the invention is a method for determining the level of SOC/CRAC expression in a subject. As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments, human subjects are preferred.  
10 Expression is defined either as SOC/CRAC mRNA expression or SOC/CRAC polypeptide expression. Various methods can be used to measure expression. Preferred embodiments of the invention include PCR and Northern blotting for measuring mRNA expression, and monoclonal or polyclonal SOC/CRAC antisera as reagents to measure SOC/CRAC polypeptide expression. In certain embodiments, test samples such as biopsy samples, and  
15 biological fluids such as blood, are used as test samples. SOC/CRAC expression in a test sample of a subject is compared to SOC/CRAC expression in control sample to, e.g., assess the presence or absence or stage of a proliferative disorder (e.g., a lymphocyte proliferative disorder) in a subject.

SOC/CRAC polypeptides preferably are produced recombinantly, although such  
20 polypeptides may be isolated from biological extracts. Recombinantly produced SOC/CRAC polypeptides include chimeric proteins comprising a fusion of a SOC/CRAC protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the SOC/CRAC polypeptide under assay conditions, or providing a detectable moiety, such as  
25 green fluorescent protein. A polypeptide fused to a SOC/CRAC polypeptide or fragment may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

The invention is also useful in the generation of transgenic non-human animals. As used herein, "transgenic non-human animals" includes non-human animals having one or  
30 more exogenous nucleic acid molecules incorporated in germ line cells and/or somatic cells. Thus the transgenic animal include "knockout" animals having a homozygous or heterozygous gene disruption by homologous recombination, animals having episomal or chromosomally incorporated expression vectors, etc. Knockout animals can be prepared by

homologous recombination using embryonic stem cells as is well known in the art. The recombination may be facilitated using, for example, the cre/lox system or other recombinase systems known to one of ordinary skill in the art. In certain embodiments, the recombinase system itself is expressed conditionally, for example, in certain tissues or cell types, at certain embryonic or post-embryonic developmental stages, inducibly by the addition of a compound which increases or decreases expression, and the like. In general, the conditional expression vectors used in such systems use a variety of promoters which confer the desired gene expression pattern (e.g., temporal or spatial). Conditional promoters also can be operably linked to SOC/CRAC nucleic acid molecules to increase expression of SOC/CRAC in a regulated or conditional manner. *Trans*-acting negative regulators of SOC/CRAC calcium channel activity or expression also can be operably linked to a conditional promoter as described above. Such *trans*-acting regulators include antisense SOC/CRAC nucleic acids molecules, nucleic acid molecules which encode dominant negative SOC/CRAC molecules, ribozyme molecules specific for SOC/CRAC nucleic acids, and the like. The transgenic non-human animals are useful in experiments directed toward testing biochemical or physiological effects of diagnostics or therapeutics for conditions characterized by increased or decreased SOC/CRAC expression. Other uses will be apparent to one of ordinary skill in the art.

The invention further provides efficient methods of identifying agents or lead compounds for agents active at the level of a SOC/CRAC polypeptide (e.g., a SOC/CRAC polypeptide) or SOC/CRAC fragment dependent cellular function. In particular, such functions include interaction with other polypeptides or fragments thereof, and selective binding to certain molecules (e.g., agonists and antagonists). Generally, the screening methods involve assaying for compounds which interfere with SOC/CRAC calcium channel activity, although compounds which enhance SOC/CRAC calcium channel activity also can be assayed using the screening methods. Such methods are adaptable to automated, high throughput screening of compounds. The target therapeutic indications for pharmacological agents detected by the screening methods are limited only in that the target cellular function be subject to modulation by alteration of the formation of a complex comprising a SOC/CRAC polypeptide or fragment thereof and one or more SOC/CRAC binding targets. Target indications include cellular processes modulated by SOC/CRAC such as  $\text{Ca}^{2+}$  fluxing, and affected by SOC/CRAC ability to form complexes with other molecules and polypeptides as, for example, may be present in the cell membrane.



A wide variety of assays for pharmacological agents are provided, including, expression assays, labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays, cell-based assays such as calcium transport assays, etc. For example, two-hybrid screens are used to rapidly examine the effect of transfected nucleic acids on the intracellular binding of SOC/CRAC or SOC/CRAC fragments to specific intracellular targets (e.g. a tyrosine kinase). The transfected nucleic acids can encode, for example, combinatorial peptide libraries or cDNA libraries. Convenient reagents for such assays, e.g., GAL4 fusion proteins, are known in the art. An exemplary cell-based assay involves transfecting a cell with a nucleic acid encoding a SOC/CRAC polypeptide fused to a GAL4 DNA binding domain and a nucleic acid encoding a reporter gene operably linked to a gene expression regulatory region, such as one or more GAL4 binding sites. Activation of reporter gene transcription occurs when the SOC/CRAC and reporter fusion polypeptides bind such as to enable transcription of the reporter gene. Agents which modulate a SOC/CRAC polypeptide mediated cell function are then detected through a change in the expression of reporter gene. Methods for determining changes in the expression of a reporter gene are known in the art.

In an expression system, for example, a SOC/CRAC polypeptide is attached to a membrane, the membrane preferably separating two fluid environments and being otherwise not permeable to  $\text{Ca}^{2+}$ . Such separation is preferred so that a change in  $\text{Ca}^{2+}$  concentration on either side of the membrane is mediated only through the attached SOC/CRAC polypeptide. Preferably, a SOC/CRAC polypeptide is expressed in an intact cell and is present on the cell-membrane (as in physiologic conditions). The cell expressing the SOC/CRAC polypeptide is preferably a eukaryotic cell, and the SOC/CRAC polypeptide is preferably recombinantly expressed, although cells naturally expressing a SOC/CRAC polypeptide may also be used. Synthetic membranes, however, containing SOC/CRAC polypeptides may also be used. See, e.g., K. Kiselyov, et al., Functional interaction between InsP3 receptors and store-operated Htrp3 channels, Nature 396, 478-82 (1998).

The cell expressing the SOC/CRAC polypeptide is incubated under conditions which, in the absence of the candidate agent, permit calcium flux into the cell and allow detection of a reference calcium concentration. For example, depletion of intracellular calcium stores with thapsigargin or other agents (Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997) would produce a given level of SOC/CRAC channel activation and a given reference calcium concentration. Detection of a decrease in the

foregoing activities (i.e., a decrease in the intracellular calcium concentration) relative to the reference calcium concentration indicates that the candidate agent is a lead compound for an agent to inhibit SOC/CRAC calcium channel activity. Preferred SOC/CRAC polypeptides include the polypeptides of claim 15.

5 SOC/CRAC fragments used in the methods, when not produced by a transfected nucleic acid are added to an assay mixture as an isolated polypeptide. SOC/CRAC polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts or chemically synthesized. Recombinantly produced SOC/CRAC polypeptides include chimeric proteins comprising a fusion of a SOC/CRAC  
10 protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the SOC/CRAC polypeptide under assay conditions, or providing a detectable moiety, such as green fluorescent protein or Flag epitope.

The assay mixture is comprised of a SOC/CRAC polypeptide binding target  
15 (candidate agent) capable of interacting with a SOC/CRAC polypeptide. While natural SOC/CRAC binding targets may be used, it is frequently preferred to use portions (e.g., peptides or nucleic acid fragments) or analogs (i.e., agents which mimic the SOC/CRAC binding properties of the natural binding target for purposes of the assay) of the SOC/CRAC binding target so long as the portion or analog provides binding affinity and avidity to the  
20 SOC/CRAC polypeptide (or fragment thereof) measurable in the assay.

The assay mixture also comprises a candidate agent (binding target, e.g., agonist/antagonist). Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or  
25 at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for  
30 structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or

polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids as defined herein are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily modified through conventional chemical, physical, and biochemical means. Further, known agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents. Non-SOC/CRAC calcium channel agonists and antagonists, for example, include agents such as dihydropyridines (DHPs), phenylalkylamines, omega conotoxin (omega.-CgTx) and pyrazonoylguanidines.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein, protein-nucleic acid, and/or protein/membrane component binding association. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease, inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate agent, the SOC/CRAC polypeptide specifically binds the cellular binding target, a portion thereof or analog thereof. The order of addition of components, incubation temperature, time of incubation, and other perimeters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically

are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of specific binding between the SOC/CRAC polypeptide and one or more binding targets is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximum signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as two- or three-hybrid screens. The transcript resulting from a reporter gene transcription assay of SOC/CRAC polypeptide interacting with a target molecule typically encodes a directly or indirectly detectable product, e.g.,  $\beta$ -galactosidase activity, luciferase activity, and the like. For cell-free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc.) or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to a SOC/CRAC binding partner, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly

detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, strepavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

Of particular importance in any of the foregoing assays and binding studies is the use  
5 of a specific sequence motif identified in the SOC-2/CRAC-1 polypeptide sequence as a kinase catalytic domain. According to the invention, amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24) (or a fragment thereof), show a localized homology with the catalytic domains of eukaryotic elongation factor-2 kinase (eEF-2 kinase, GenBank  
10 Acc. no. U93850) and *Dictyostelium* myocin heavy chain kinase A (MHCK A, GenBank Acc. no. U16856), as disclosed in Ryazanov AG, et al., *Proc Natl Acad Sci U S A*, 1997, 94(10):4884-4889. Therefore, according to the invention, a method for identifying agents useful in the modulation of SOC/CRAC polypeptide kinase activity is provided. The method involves contacting a SOC/CRAC polypeptide with kinase activity, that includes, for example, amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24) with a  
15 candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity; detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and comparing the kinase activity in the previous step with a control kinase activity of a SOC/CRAC polypeptide in the absence of the  
20 candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC kinase activity. Other controls for kinase activity can also be performed at the same time, for example, by utilizing eEF-2 kinase and/or *Dictyostelium* MHC Kinase A, in a similar manner to the SOC/CRAC member. Methods for performing such kinase activity assays are well known in the art.

25 The invention thus provides SOC/CRAC-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, SOC/CRAC-specific agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with altered SOC/CRAC and SOC/CRAC calcium channel fluxing characteristics. Novel  
30 SOC/CRAC-specific binding agents include SOC/CRAC-specific antibodies and other natural intracellular and extracellular binding agents identified with assays such as two hybrid screens, and non-natural intracellular and extracellular binding agents identified in screens of chemical libraries and the like.

In general, the specificity of SOC/CRAC binding to a specific molecule is determined by binding equilibrium constants. Targets which are capable of selectively binding a SOC/CRAC polypeptide preferably have binding equilibrium constants of at least about  $10^7$   $M^{-1}$ , more preferably at least about  $10^8$   $M^{-1}$ , and most preferably at least about  $10^9$   $M^{-1}$ . The wide variety of cell based and cell free assays may be used to demonstrate SOC/CRAC-specific binding. Cell based assays include one, two and three hybrid screens, assays in which SOC/CRAC-mediated transcription is inhibited or increased, etc. Cell free assays include SOC/CRAC-protein binding assays, immunoassays, etc. Other assays useful for screening agents which bind SOC/CRAC polypeptides include fluorescence resonance energy transfer (FRET), and electrophoretic mobility shift analysis (EMSA).

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid- $CaPO_4$  precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. For example, where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the anti-inflammatory agent, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones,

polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

Use of a long-term sustained release implant may be particularly suitable for treatment of chronic conditions. Long-term release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above.

The invention also contemplates gene therapy. The procedure for performing *ex vivo* gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject which contains a defective copy of the gene, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* gene therapy using vectors such as adenovirus, retroviruses, herpes virus, and targeted liposomes also is contemplated according to the invention. See, e.g., U.S. Patent Nos. 5,670,488, entitled "Adenovirus Vector for Gene Therapy", issued to Gregory et al., and 5,672,344, entitled "Viral-Mediated Gene Transfer System", issued to Kelley et al.

The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

### Examples

5 As an initial approach to identifying SOC/CRAC channels, we considered publicly available data and hypothesized that the following characteristics are likely to be exhibited by SOC/CRAC calcium channels: i) SOC/CRAC calcium channels would be integral membrane proteins related (probably distantly) to one of the known calcium channel families (e.g. voltage gated, ligand gated, Trp), and therefore should have a pore region formed by a tetramer of 6-7 transmembrane (TM) regions; ii) high calcium selectivity was likely to come  
10 at the price of complexity, and therefore these were likely to be large proteins; iii) the high calcium selectivity of this type of channel was likely to be useful and, therefore, highly conserved; and iv) these channels should be expressed in one or more types of lymphocytes, since ICRAC is best defined in those cell types. Since the full genome of the nematode *C. elegans* is nearing completion, and IP3-dependent calcium signals have recently been shown to be required for one or more aspects of *C. elegans* development, we took the set of proteins encoded by this genome (at the time this search was initiated WORMPEP14 was the available predicted protein set) and began searching for proteins which fit the criteria above. This search began by proceeding in alphabetical order through WORMPEP14 and arbitrarily  
20 excluding all proteins below approximately 1000 amino acids in size, followed by focusing on remaining proteins with clear TM spanning regions similar to those of other calcium channels. We stopped this screen on encountering a protein designated C05C12.3, a predicted protein of 1816 amino acids (SEQ ID NO:13). C05C12.3 was notable because its central pore region had some sequence similarity to but was clearly distinct from members of the Trp family of calcium channels, and the hydrophobicity plot of this region showed a characteristically wide spacing between the fifth and sixth TM regions for the amino acid residues which are thought to line the channel pore region and mediate the calcium selectivity of the channels. In addition, it lacked any ankyrin repeats in the region amino-terminal to its pore region, further distinguishing it from other Trp family proteins.

30 We then used C05C12.3 for BLAST alignment screening of the rest of the *C. elegans* genome and also mammalian databases for homologous proteins, revealing two other *C. elegans* homologues (SEQ ID NO:14 and SEQ ID NO:15), and also a recently cloned mammalian protein named melastatin-1 (MLSN-1/SOC-1, SEQ ID NOs:9 and 10, and



GenBank Acc. No. AF071787). Using these sequences, we subsequently performed an exhaustive screening of publicly accessible EST databases in search of lymphocyte homologues, but were unsuccessful in detecting any homologous transcripts in any lymphocyte lines. Since MLSN-1 (SEQ ID NOs:9 and 10) was expressed exclusively in melanocytes and retina by Northern blot hybridization and by EST database searching, there was no evidence that this type of channel was expressed in the type of cell in which ICRAC-like currents were best defined. Subsequent BLAST searches picked up mouse EST sequence AI098310 (SEQ ID NO:22) from a monocyte cell line. The I.M.A.G.E. consortium clone containing the above-identified EST was then purchased from ATCC (clone ID. 1312756, Manassas, VA) and was further characterized. Using other portions of this sequence in EST searches, we subsequently picked up similar sequences in human B-cells (SEQ ID NOs:20 and 21), and other cell types as well (SEQ ID NOs: 11, 12, 16, 17, 18, and 19). Most of these sequences were subsequently identified to be part of the 3'-UTR or of the carboxy terminal region of the proteins, which are not readily identifiable as Trp channels, providing an explanation for the art's inability to detect any type of Trp related transcripts in lymphocytes. Partial sequences from the 5' and/or 3' ends of the above identified clones were then used to screen leukocyte and kidney cDNA libraries to extend the original sequences more toward the 5' and/or 3' ends.

In view of the foregoing, it was concluded that channels of this type were expressed in many types of lymphocytes, and therefore were members of a new family of SOC/CRAC calcium channels.

#### Experimental Procedures

##### Screening of the cDNA libraries

Leukocyte and kidney cDNA libraries from Life Technologies (Gaithersburg, MD) were screened using the Gene Trapper II methodology (Life Technologies) according to manufacturer's recommendation, using the inserts of I.M.A.G.E. clone ID nos. 1312756 and 1076485 from ATCC (Manassas, VA), under stringent hybridization conditions. Using standard methodology ( *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York), individual cDNA clones were subjected to 3-4 rounds of amplification and purification under the same hybridization conditions.

After excision from the vector and subcloning of inserts into the plasmid forms, several clones were sequenced by the Beth Israel Deaconess Medical Center's Automated

Sequencing Facility. Molecular biological techniques such as restriction enzyme treatment, subcloning, DNA extraction, bacterial culture and purification of DNA fragments were performed according to methods well known in the art. Computer analyses of protein and DNA sequences was done using "Assemblylign" (Oxford Molecular, Campbell, CA). Multiple  
5 alignments of the SOC/CRAC family members were produced using the CLUSTAL facility of the MacVector program. Restriction endonucleases, expression vectors, and modifying enzymes were purchased from commercial sources (Gibco-BRL). Sequencing vectors for DNA were purchased from Stratagene (La Jolla, CA).

Once the first members of what appeared to be a novel family of calcium channel  
10 receptors were identified and characterized, additional BLAST alignments were performed with the newly characterized nucleic acid sequences. An initial match was with genomic DNA fragment NH0332L11 (Genbank Acc. No. AC005538). Using this genomic sequence, promoters were designed and a number of cDNA libraries was surveyed by PCR. A prostate specific message was identified and characterized, leading to the isolation and  
15 characterization of SOC-4/CRAC-3 (SEQ ID NOs: 31 and 32).

### Functional Assays

#### Transient Expression of SOC/CRAC

In our initial transient expression experiments, we expressed or expect to express a SOC/CRAC molecule transiently in RBL-2H3 mast cells, Jurkat T cells, and A20  
20 B-lymphocytes using both electroporation and vaccinia virus-driven expression, and measured the calcium influx produced by depletion of intracellular calcium stores with thapsigargin. Each of the foregoing techniques is well known to those of ordinary skill in the art and can be performed using various methods (see, e.g., Current Methods in Molecular Biology, eds. Ausubal, F.M., et al. 1987, Green Publishers and Wiley Interscience, N.Y.,  
25 N.Y.). Exemplary methods are described herein.

Depletion of intracellular calcium stores is accomplished by treating the cells with 1 micromolar thapsigargin; alternative agents which function to deplete intracellular stores are described in by Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997 and include, for example, ionomycin, cyclopiazonic acid, and DBHQ.

30 Calcium influx is determined by measuring cytoplasmic calcium as indicated using the fura-2 fluorescent calcium indicator (see, e.g., G. Grynkiewicz, M. Poenie, R. Y. Tsien, A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties, J. Biol

Chem 260, 3440-50 (1985), and M. Poenie, R. Tsien, Fura-2: a powerful new tool for measuring and imaging  $[Ca^{2+}]_i$  in single cells, Prog Clin Biol Res 210, 53-6 (1986)).

Patch Clamp Analysis and Determining Selectivity of SOC/CRAC

Patch clamp analysis of cells injected with SOC/CRAC cRNA is performed by using the general patch technique as described in Neher, E., "Ion channels for communication between and within cells", Science, 1992; 256:498-502. Specific techniques for applying the patch clamp analysis to RBL cells are described in Hoth, M., and Penner, R., "Depletion of intracellular calcium stores activates a calcium current in mast cells", Nature, 1992; 355:3535-355. Additional protocols for applying the patch clamp technique to other cell types are described in Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997

An exemplary protocol for patch clamp analysis of SOC/CRAC molecule expressed in RBL-2H3 mast cells using a recombinant vaccinia virus is as follows. The currents elicited by store depletion are determined using the whole cell configuration (Neher, E., Science, 1992; 256:498-502). Currents in SOC/CRAC expressing cells are compared to currents in control cells expressing an irrelevant protein or a classic Trp family calcium channel known as VR1 (M. J. Caterina, et al., The capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments], Nature 389, 816-24 (1997)) in order to assess the contribution of SOC/CRAC expression. In addition, the magnitude of whole cell currents in the presence of extracellular calcium (10 mM), barium (10 mM), or magnesium (10 mM) are compared to determine the relative permeability of the channels to each of these ions (Hoth, M., and Penner, R., Nature, 1992; 355:3535-355) and, thereby, determine the ionic selectivity.

Pharmacologic Behavior of SOC/CRAC

For analysis of the pharmacologic behavior of a SOC/CRAC molecule, a SOC/CRAC molecule is expressed in RBL-2H3 mast cells using a recombinant vaccinia virus, and the degree of calcium influx elicited by store depletion is monitored using a bulk spectrofluorimeter or a fluorescence microscope and the calcium sensitive dye fura-2 (G. Grynkiewicz, M. Poenie, R. Y. Tsien, A new generation of  $Ca^{2+}$  indicators with greatly improved fluorescence properties, J Biol Chem 260, 3440-50 (1985) and M. Poenie, R. Tsien, Fura-2: a powerful new tool for measuring and imaging  $[Ca^{2+}]_i$  in single cells, Prog Clin Biol Res 210, 53-6 (1986)). The level of cytoplasmic calcium in SOC/CRAC expressing cells is compared to the level achieved in control cells expressing an irrelevant protein or a classic Trp. family calcium channels known as VR1 (M. J. Caterina, et al., The

capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments], Nature 389, 816-24 (1997)). These cells then are pre-incubated with the desired pharmacologic reagent, and again the response to store depletion is monitored. Comparison of the effect of depleting stores in SOC/CRAC expressing cells relative to controls in the presence or absence of the pharmacologic reagent is used to assess the ability of that reagent to modulate SOC/CRAC activity. Sphingosine is an exemplary molecule that can be used as pharmacologic reagents for pharmacologic characterization of SOC/CRAC calcium channels. See, e.g., Mathes, C., et al., Calcium release activated calcium current as a direct target for sphingosine, J Biol Chem 273(39):25020-25030 (1998). Other non-specific calcium channel inhibitors that can be used for this purpose include SKR96365 (Calbiochem) and Lanthanum.

#### Bulk Calcium Assays

Bulk calcium assays can be performed in a PTI Deltascan bulk spectrofluorometer using fura-2 as described in Scharenberg AM, et al., EMBO J, 1995, 14(14):3385-94.

#### Gene Targeting

The method (and reagents) described by Buerstedde JM et al, (Cell, 1991, Oct 4;67(1):179-88), was used to generate "knockouts" in cells. Briefly, part of the chicken SOC-2/CRAC-1 genomic sequence coding for the transmembrane region was cloned utilizing the human sequence as the probe in a chicken library screen. Chicken SOC-2/CRAC-1 clones were isolated and characterized using standard methodology. The putative exon and domain arrangement of the chicken SOC-2/CRAC-1, is depicted in Figure 1. The exons coding for TM5 (pore region) and TM6, were replaced with promoter/antibiotic cassettes (see Figure1). These targeting vectors were then used to target (and replace) the endogenous gene in DT-40 cells (chicken B lymphocyte cells).

#### Results

##### Example 1: Transient Expression of SOC/CRAC

In the above-identified cell lines and using both of the foregoing expression techniques, SOC/CRAC expression enhances thapsigargin-dependent influx. In addition, SOC/CRAC expression also enhances the amount of intracellular calcium stores. That this effect is likely due to SOC/CRAC acting as a plasma membrane calcium channel can be confirmed by producing an in-frame carboxy-terminal translational fusion with green fluorescent protein followed by confocal microscopy, revealing that SOC/CRAC is expressed predominantly as a plasma membrane calcium channel.

##### Example 2: Patch Clamp Analysis

The biophysical characteristics of SOC/CRAC enhanced currents when expressed in *Xenopus* oocytes are determined. SOC/CRAC cRNA injection is able to enhance thapsigargin-dependent whole cell currents. In addition, SOC/CRAC does not alter the reversal potential of these currents and the determination of the  $P_{Ca}/P_{Na}$  ratio shows that SOC/CRAC channels are highly calcium selective.

**Example 3: *Pharmacologic Behavior of SOC/CRAC***

The pharmacologic behavior of SOC/CRAC is evaluated as described above. SOC/CRAC-enhanced influx is inhibited by sphingosine in a manner that is substantially the same as that of endogenous thapsigargin-dependent calcium influx.

**Example 4: *Gene targeting***

Transfection of DT-40 cells with the foregoing targeting vectors, selection for antibiotic resistance, and screening, is collectively referred to, herein, as a round of targeting. For the first round of targeting SOC-2/CRAC-1, 18/24 clones with homologous recombination of the targeting construct into one of the endogenous SOC-2/CRAC-1 alleles were obtained. On the second round of targeting (in order to target the second allele and therefore generate a homozygous SOC-2/CRAC-1 mutant cell), 0/48 clones were obtained. These results indicate that a "null" SOC-2/CRAC-1 mutation is detrimental to DT-40 cells, and that SOC-2/CRAC-1 is required for cell viability.

**Table I. Nucleotide Sequences with homologies to SOC/CRAC nucleic acids**

| Sequences with SEQ ID NOs and GenBank accession numbers:   |
|--|
| SEQ ID NO:9, AB001535, AI226731, H18835, AA419592, AA261842, AA419407, AA592910, D86107, AI098310, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853. |

**Table II. Amino Acid Sequences with homologies to SOC/CRAC polypeptides**

| Sequences with SEQ ID NOs and GenBank accession numbers:  |
|---|
| SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572. |

All references, patents, and patent documents disclosed herein are incorporated by reference herein in their entirety.

What is claimed is presented below and is followed by a Sequence Listing. We claim:

Claims

1. An isolated nucleic acid molecule, comprising:

(a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:1.

3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:27.

4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:29.

5. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:31.

6. An isolated nucleic acid molecule selected from the group consisting of

(a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29, and SEQ ID NO:31,

(b) complements of (a),

provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from a sequence group consisting of

(1) sequences having the SEQ. ID NOS. or GenBank accession numbers of Table I,

(2) complements of (1), and

(3) fragments of (1) and (2).

7. The isolated nucleic acid molecule of claim 6, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

- (1) at least two contiguous nucleotides nonidentical to the sequence group,
- (2) at least three contiguous nucleotides nonidentical to the sequence group,
- 5 (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

10 8. The isolated nucleic acid molecule of claim 6, wherein the unique fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

15 9. The isolated nucleic acid molecule of claim 6, wherein the molecule encodes a polypeptide which is immunogenic.

10. An expression vector comprising the isolated nucleic acid molecule of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 operably linked to a promoter.

11. A host cell transformed or transfected with the expression vector of claim 10.

20 12. An isolated polypeptide encoded by the isolated nucleic acid molecule according to anyone of claims 1 or 6, wherein the polypeptide comprises a SOC/CRAC polypeptide or a unique fragment thereof.

13. The isolated polypeptide of claim 12, wherein the isolated polypeptide is encoded by the isolated nucleic acid molecule of claim 2, 3, 4, or 5.

25 14. The isolated polypeptide of claim 13, wherein the isolated polypeptide comprises a polypeptide having the sequence of amino acids selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

15. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, 4, or 5, wherein the polypeptide, or unique fragment thereof is immunogenic.

16. An isolated binding polypeptide which binds selectively to a polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, 4, or 5.

5 17. The isolated binding polypeptide of claim 16, wherein the isolated binding polypeptide binds to a polypeptide having the sequence of amino acids selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

10 18. The isolated binding polypeptide of claim 17, wherein the isolated binding polypeptide is an antibody or an antibody fragment selected from the group consisting of a Fab fragment, a F(ab)<sub>2</sub> fragment or a fragment including a CDR3 region selective for the polypeptide.

15 19. An isolated polypeptide, comprising a unique fragment of the polypeptide of claim 12 of sufficient length to represent a sequence unique within the human genome, provided that the fragment excludes a sequence of contiguous amino acids identified in Table II.

20. A method for isolating a SOC/CRAC molecule having SOC/CRAC calcium channel activity, comprising:

20 a) contacting a binding molecule that is a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample containing one or more SOC/CRAC molecules, under conditions sufficient to form a complex of the SOC/CRAC nucleic acid or the SOC/CRAC binding polypeptide and the SOC/CRAC molecule;

b) detecting the presence of the complex;

c) isolating the SOC/CRAC molecule from the complex; and

25 d) determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity.

21. The method of claim 20, wherein the binding molecule is a SOC/CRAC nucleic acid.

22. The method of claim 20, wherein the binding molecule is a SOC/CRAC binding polypeptide.



23. The method of claim 21, wherein the SOC/CRAC nucleic acid comprises at least 14 nucleotides from any contiguous portion of a sequence of nucleotides selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31.

5 24. A method for identifying agents useful in the modulation of SOC/CRAC calcium channel activity, comprising:

a) contacting a SOC/CRAC polypeptide with a candidate agent suspected of modulating SOC/CRAC calcium channel activity, under conditions sufficient to allow the SOC/CRAC polypeptide to interact selectively with the candidate agent;

10 b) detecting a  $\text{Ca}^{2+}$  concentration associated with SOC/CRAC calcium channel activity of the SOC/CRAC polypeptide in the presence of the candidate agent; and

c) comparing the  $\text{Ca}^{2+}$  concentration of step (b) with a control  $\text{Ca}^{2+}$  concentration of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates SOC/CRAC calcium channel activity.

15

25. A method for determining the level of SOC/CRAC expression in a subject, comprising:

a) measuring the expression of SOC/CRAC in a test sample obtained from the subject, and

20 b) comparing the measured expression of SOC/CRAC in the test sample to the expression of the SOC/CRAC polypeptide in a control to determine the level of SOC/CRAC expression in the subject.

25

26. The method of claim 25, wherein the expression of SOC/CRAC in (b) is SOC/CRAC mRNA expression.

27. The method of claim 25, wherein the expression of SOC/CRAC in (b) is SOC/CRAC polypeptide expression.

28. The method of claim 25, wherein the test sample is tissue.

29. The method of claim 25, wherein the test sample is a biological fluid.

-52-

30. The method of claim 26, wherein SOC/CRAC mRNA expression is measured using the Polymerase Chain Reaction (PCR).

31. The method of claim 26, wherein SOC/CRAC mRNA expression is measured using a method selected from the group consisting of northern blotting, monoclonal antisera to SOC/CRAC and polyclonal antisera to SOC/CRAC.

32. A kit, comprising a package containing:

an agent that selectively binds to the isolated nucleic acid of claim 1 or an expression product thereof, and

a control for comparing to a measured value of binding of said agent to said isolated nucleic acid of claim 1 or expression product thereof.

33. The kit of claim 32, wherein the control comprises an epitope of the expression product of the nucleic acid of claim 1.

34. A pharmaceutical composition comprising:

a pharmaceutically effective amount of an agent comprising of an isolated nucleic acid molecule of claim 1 or an expression product thereof, and

a pharmaceutically acceptable carrier.

35. The pharmaceutical composition of claim 34, wherein the agent is an expression product of the isolated nucleic acid molecule of claim 1.

36. A method for identifying agents useful in the modulation of a SOC/CRAC polypeptide kinase activity, comprising:


a) contacting a SOC/CRAC polypeptide with kinase activity with a candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity;

b) detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and

c) comparing the kinase activity of step (b) with a control kinase activity of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates SOC/CRAC kinase activity.

37. The method of claim 36, wherein the SOC/CRAC polypeptide comprises amino acids 999-1180 of the sequence represented as SEQ ID NO:24, or a fragment thereof that retains the kinase activity.

FIGURE 1.



-1-

## SEQUENCE LISTING

<110> Beth Israel Deaconess Medical Center, Inc.  
Scharenberg, Andrew

<120> CHARACTERIZATION OF A CALCIUM CHANNEL FAMILY

<130> B0662/7026WO/ERP/KA

<150> U.S. 60/114,220

<151> 1998-12-30

<150> U.S. 60/120,018

<151> 1999-01-29

<150> U.S. 60/140,415

<151> 1999-06-22

<160> 32

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1212

<212> DNA

<213> Homo Sapiens

<400> 1

|            |             |             |             |             |            |      |
|------------|-------------|-------------|-------------|-------------|------------|------|
| gcacgaggca | aattttttgt  | tagtacacca  | tctcagccaa  | gttgcaaaaag | ccacttgga  | 60   |
| actggaacca | aagatcaaga  | aactgtttgc  | tctaaaagcta | cagaaggaga  | taatacagaa | 120  |
| tttgaggcat | ttgtaggaca  | cagagatagc  | atggatttac  | agaggtttaa  | agaaacatca | 180  |
| aacaagataa | aaatactatc  | caataacaat  | acttctgaaa  | acactttgaa  | acgagtgagt | 240  |
| tctcttgctg | gattttactga | ctgtcacaga  | acttccattc  | ctgttcattc  | aaaacaagaa | 300  |
| aaaatcagta | gaaggccatc  | taccgaagac  | actcatgaag  | tagattccaa  | agcagcttta | 360  |
| ataccggttt | gtagatttca  | actaaacaga  | tatatattat  | taaatacatt  | aaactttttt | 420  |
| agataagatc | tacaaagtgg  | tgatatttgg  | gactatatca  | aaaattcaaa  | aaaatttttc | 480  |
| ttaagaaaac | tgacttttagc | atagtagcag  | ttacagaaaa  | gtttcttaca  | gtgaatagtc | 540  |
| aggaatttta | aagaaaaatt  | tatgcagaat  | aaaggcagga  | atctcttttt  | gtttgaattg | 600  |
| aagctaatta | tatgaactca  | tttccagcta  | actgcgataa  | tgattgattt  | tgcaaatcc  | 660  |
| ctttaaaagc | acacactgac  | aagacaaaaa  | gctcaggaaa  | aggcagaaaa  | attactcctt | 720  |
| tataatcaag | tattatatat  | aagtcagtgc  | tcataatttt  | gctcaagaaa  | atattgactt | 780  |
| acattcatat | atatctgttc  | tggcatagag  | agattatgtt  | gttaaaatca  | tgttattgaa | 840  |
| aaaagttatt | tcagtgggga  | aagaggttag  | ttaacaaaaga | gattcacagt  | aacaaatcct | 900  |
| cctttctgga | gggactcttc  | ctgaccctga  | gctgcacaac  | tttgcaacaa  | attaaagcct | 960  |
| aaccgaagat | gacctcacia  | tggcaattta  | gaactcatgg  | gagtcaactt  | acataaacgg | 1020 |
| tatttgattt | ctgataagat  | agtggaaatta | ttggttatag  | atgacaaaat  | aagtatgttt | 1080 |
| aaagtgatga | tggacataaa  | aaagttttaa  | atataaaaaca | tgagaaaaaga | aggagatact | 1140 |
| attcaaaaag | actggcaaat  | ttgaaaaact  | agaaataaaa  | aaaaaaaaaa  | aaaatgagcg | 1200 |
| gccgcaagct | tt          |             |             |             |            | 1212 |

<210> 2

<211> 141

<212> PRT

<213> Homo Sapiens

<400> 2

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Arg | Gly | Lys | Phe | Phe | Val | Ser | Thr | Pro | Ser | Gln | Pro | Ser | Cys | Lys |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Ser | His | Leu | Glu | Thr | Gly | Thr | Lys | Asp | Gln | Glu | Thr | Val | Cys | Ser | Lys |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     |     | 30  |     |

-2-

Ala Thr Glu Gly Asp Asn Thr Glu Phe Gly Ala Phe Val Gly His Arg  
           35                          40                          45  
 Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser Asn Lys Ile Lys  
           50                          55                          60  
 Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn Thr Leu Lys Arg Val Ser  
   65                          70                          75                          80  
 Ser Leu Ala Gly Phe Thr Asp Cys His Arg Thr Ser Ile Pro Val His  
                           85                          90                          95  
 Ser Lys Gln Glu Lys Ile Ser Arg Arg Pro Ser Thr Glu Asp Thr His  
                           100                          105                          110  
 Glu Val Asp Ser Lys Ala Ala Leu Ile Pro Val Cys Arg Phe Gln Leu  
           115                          120                          125  
 Asn Arg Tyr Ile Leu Leu Asn Thr Leu Asn Phe Phe Arg  
       130                          135                          140

<210> 3  
 <211> 739  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> unsure  
 <222> (5)...(5)  
 <223> UNKNOWN

<221> unsure  
 <222> (21)...(22)  
 <223> UNKNOWN

<221> unsure  
 <222> (29)...(29)  
 <223> UNKNOWN

<400> 3  
 tcgantaggg gtcttccacc nncatactng gatgatgggt ggtgaagtct atgcatacga 60  
 aattgatgtg tgtgcaaacg attctgttat ccctcaaadc tgtggtcctg ggacgtgggt 120  
 gactccattt cttcaagcag tctacctctt tgwacagtat atcattatgg ttaatcttct 180  
 tattgcattt ytcaacaatg tgtatttaca agtgaaggca attccaata ttgyatggaa 240  
 gtaccagcgt tatcatttta ttatggctta tcatgagaaa ccagttctgc ctccctccact 300  
 tatcattctt agccatatag tttctctggt ttgctgcata tgtaagagaa gaaagaaaga 360  
 taagacttcc gatggaccaa aacttttctt aacagaagaa gatcaaaaaga aacttcatga 420  
 ttttgaagag cagtgtgttg aaatgtattt caatgaaaaa gatgacaaat ttcattctgg 480  
 gagtgaagag agaattcgtg tcacttttga aagagtggaa cagatgtgca ttcagattaa 540  
 agaagttgga gatccgtgtc aactacataa aaagatcatt acaatcatta gattctcaaa 600  
 ttggccattt gcaagatctt tcagccctga cggtagatac attaaaaaca ctactggcc 660  
 aaaagcgtcg gaagctagca aagttcataa tgaaatcaca cgagaactga gcatttccaa 720  
 acacttggct caaaacctt 739

<210> 4  
 <211> 235  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (41)...(41)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (54)...(54)

-3-

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (68)...(68)

&lt;223&gt; UNKNOWN

&lt;400&gt; 4

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Met | Val | Gly | Glu | Val | Tyr | Ala | Tyr | Glu | Ile | Asp | Val | Cys | Ala | Asn |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Asp | Ser | Val | Ile | Pro | Gln | Ile | Cys | Gly | Pro | Gly | Thr | Trp | Leu | Thr | Pro |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Phe | Leu | Gln | Ala | Val | Tyr | Leu | Phe | Xaa | Gln | Tyr | Ile | Ile | Met | Val | Asn |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Leu | Leu | Ile | Ala | Phe | Xaa | Asn | Asn | Val | Tyr | Leu | Gln | Val | Lys | Ala | Ile |
|     |     | 50  |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Ser | Asn | Ile | Xaa | Trp | Lys | Tyr | Gln | Arg | Tyr | His | Phe | Ile | Met | Ala | Tyr |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     | 80  |     |
| His | Glu | Lys | Pro | Val | Leu | Pro | Pro | Pro | Leu | Ile | Ile | Leu | Ser | His | Ile |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Val | Ser | Leu | Phe | Cys | Cys | Ile | Cys | Lys | Arg | Arg | Lys | Lys | Asp | Lys | Thr |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Ser | Asp | Gly | Pro | Lys | Leu | Phe | Leu | Thr | Glu | Glu | Asp | Gln | Lys | Lys | Leu |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| His | Asp | Phe | Glu | Glu | Gln | Cys | Val | Glu | Met | Tyr | Phe | Asn | Glu | Lys | Asp |
|     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Asp | Lys | Phe | His | Ser | Gly | Ser | Glu | Glu | Arg | Ile | Arg | Val | Thr | Phe | Glu |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Arg | Val | Glu | Gln | Met | Cys | Ile | Gln | Ile | Lys | Glu | Val | Gly | Asp | Pro | Cys |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Gln | Leu | His | Lys | Lys | Ile | Ile | Thr | Ile | Ile | Arg | Phe | Ser | Asn | Trp | Pro |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Phe | Ala | Arg | Ser | Phe | Ser | Pro | Asp | Gly | Arg | Tyr | Ile | Lys | Asn | Thr | His |
|     |     | 195 |     |     |     | 200 |     |     |     |     |     | 205 |     |     |     |
| Trp | Pro | Lys | Ala | Ser | Glu | Ala | Ser | Lys | Val | His | Asn | Glu | Ile | Thr | Arg |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Glu | Leu | Ser | Ile | Ser | Lys | His | Leu | Ala | Gln | Asn |     |     |     |     |     |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     |     |

&lt;210&gt; 5

&lt;211&gt; 1579

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (368)...(368)

&lt;223&gt; g or c

&lt;221&gt; unsure

&lt;222&gt; (372)...(372)

&lt;223&gt; g or c

&lt;221&gt; unsure

&lt;222&gt; (374)...(374)

&lt;223&gt; g or a

&lt;221&gt; unsure

&lt;222&gt; (375)...(375)

&lt;223&gt; g or c

-4-

<221> unsure  
 <222> (387)...(387)

<221> unsure  
 <222> (482)...(482)

<400> 5  
 acgtcgccctg caggtaccgg tccggaattc ccggggtcgac ccacgcgtcc ggcatgggtgt 60  
 tgtaaataca cttagctcct ctcttcctca aggtgatctt gaaagtaata atcccttttca 120  
 ttgtaatat ttaatgaaag atgacaaaaga tccccagtggt aatatatttg gtcaagactt 180  
 acctgcagta ccccgagagaa aagaatttaa tttccagag gctgggtcct cttctgggtgc 240  
 cttattccca agtgcgtgtt cccctccaga actgcgacag agactacatg gggtagaact 300  
 cttaaaaata tttaataaaa atcaaaaatt aggcagttca tctactagca taccacatct 360  
 gtcacccsca csarscaaat tttttgntag tacaccatct cagccaagtt gcaaaaagcca 420  
 cttggaaact ggaaccaaag atcaagaaaac tgtttgctct aaagctacag aaggagataa 480  
 tncagaattt ggagcatttg taggacacag agatagcatg gatttacaga ggtttaaaga 540  
 aacatcaaac aagataaaaa tactatccaa taacaatact tctgaaaaca ctttgaaacg 600  
 agtgagttct cttgctggat ttactgactg tcacagaact tccattcctg ttcattcaaa 660  
 acaagaaaaa atcagtagaa ggccatctac cgaagacact catgaagtag attccaaagc 720  
 agctttaata ccggtttgta gatttcaact aaacagatat atattattaa atacattaaa 780  
 cttttttaga taagatctac aaagtgggtga tatttgggac tatatcaaaa attcaaaaaa 840  
 atttttctta agaaaactga ctttagcata gtagcagtta cagaaaagtt tcttacagtg 900  
 aatagtcagg aatttttaaag aaaaatttat gcagaataaa ggcaggaatc tctttttgtt 960  
 tgaattgaag ctaattatat gaactcattt ccagctaact gcgataatga ttgattttgc 1020  
 aaattccctt taaaagcaca cactgacaag acaaaaagct caggaaaagg cagaaaaatt 1080  
 actcctttat aatcaagtat tatatataag tcagtgtctca taattttgct caagaaaata 1140  
 ttgacttaca ttcatatata tctgttctgg catagagaga ttatgttggt aaaatcatgt 1200  
 tattgaaaaa agttatttca gtggggaaaag aggttagtta acaaagagat tcacagtaac 1260  
 aaatccctct tcttgagggg actcttcctg accctgagct gcacaacttt gcaacaaatt 1320  
 aaagcctaac cgaagatgac ctcacaatgg caatttagaa ctcatgggag tcaacttaca 1380  
 taaacgggat ttgatttctg ataagatagt ggaattattg gttatagatg acaaaaataag 1440  
 tatgtttaaa gtgatgatgg acataaaaaa gtttttaata taaaacatga gaaaagaagg 1500  
 agatactatt caaaaagact ggcaaatttg aaaaactaga aataaaaaaa aaaaaaaaaa 1560  
 atgagcggcc gcaagcttt 1579

<210> 6  
 <211> 243  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (103)...(105)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (109)...(109)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (141)...(141)  
 <223> UNKNOWN

<400> 6  
 Val Asn Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Leu Glu Ser Asn  
 1 5 10 15  
 Asn Pro Phe His Cys Asn Ile Leu Met Lys Asp Asp Lys Asp Pro Gln  
 20 25 30  
 Cys Asn Ile Phe Gly Gln Asp Leu Pro Ala Val Pro Gln Arg Lys Glu  
 35 40 45

-5-

Phe Asn Phe Pro Glu Ala Gly Ser Ser Ser Gly Ala Leu Phe Pro Ser  
 50 55 60  
 Ala Val Ser Pro Pro Glu Leu Arg Gln Arg Leu His Gly Val Glu Leu  
 65 70 75 80  
 Leu Lys Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Ser Thr Ser  
 85 90 95  
 Ile Pro His Leu Ser Ser Xaa Xaa Xaa Lys Phe Phe Xaa Ser Thr Pro  
 100 105 110  
 Ser Gln Pro Ser Cys Lys Ser His Leu Glu Thr Gly Thr Lys Asp Gln  
 115 120 125  
 Glu Thr Val Cys Ser Lys Ala Thr Glu Gly Asp Asn Xaa Glu Phe Gly  
 130 135 140  
 Ala Phe Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu  
 145 150 155 160  
 Thr Ser Asn Lys Ile Lys Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn  
 165 170 175  
 Thr Leu Lys Arg Val Ser Ser Leu Ala Gly Phe Thr Asp Cys His Arg  
 180 185 190  
 Thr Ser Ile Pro Val His Ser Lys Gln Glu Lys Ile Ser Arg Arg Pro  
 195 200 205  
 Ser Thr Glu Asp Thr His Glu Val Asp Ser Lys Ala Ala Leu Ile Pro  
 210 215 220  
 Val Cys Arg Phe Gln Leu Asn Arg Tyr Ile Leu Leu Asn Thr Leu Asn  
 225 230 235 240  
 Phe Phe Arg

&lt;210&gt; 7

&lt;211&gt; 3532

&lt;212&gt; DNA

&lt;213&gt; Mus Musculus

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (2420)...(2420)

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; (2434)...(2434)

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; (2461)...(2461)

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; (2466)...(2466)

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; (2470)...(2470)

&lt;223&gt; unknown

&lt;400&gt; 7

|   |     |
|---|-----|
| attatggctt atcatgaaaa accagtcctg cctcctcctc ttatcatcct cagccatata   | 60  |
| gtttcactgt tttgctgtgt atgcaaaaaga agaaagaaaag ataagacttc cgatgggcca | 120 |
| aaacttttct taacagaaga agatcaaaaag aaactccatg attttgaaga gcagtgtgtt  | 180 |
| gagatgtact ttgatgagaa agatgacaaa ttcaattctg ggagtgaaga gagaatccgg   | 240 |
| gtcacttttg aaagagtggg gcagatgagc attcagatta aagaagttgg agatcgtgtc   | 300 |
| aactacataa aaagatcatt acagtcctta gattctcaaa ttggtcatct gcaagatctc   | 360 |



-6-

|            |            |            |             |            |             |      |
|------------|------------|------------|-------------|------------|-------------|------|
| tcagccctaa | cagtagatac | attgaaaaca | cttacagccc  | agaaagcttc | agaagctagt  | 420  |
| aaagtgcaca | atgagatcac | acgagaattg | agtatttcca  | aacacttggc | tcagaatctt  | 480  |
| attgatgatg | ttcctgtaag | acctttgtgg | gaagaacctt  | gtgctgtaaa | cacactgagt  | 540  |
| tcctctcttc | ctcaaggtga | tcgggaaagt | aataatcctt  | ttctttgtaa | tatttttatg  | 600  |
| aaagatgaaa | aagaccccca | atataatctg | tttgacaag   | atttgcccgt | gatacccccag | 660  |
| agaaaagaat | tcaacattcc | agaggctggt | tcctcctgtg  | gtgccttatt | cccaagtgtc  | 720  |
| gtttctcccc | cagaattacg | acagagacga | catggggtag  | aaatgttaaa | aataattta   | 780  |
| aaaaatcaaa | aattaggcag | ttcaccta   | agttcaccac  | atatgtcctc | cccaccaacc  | 840  |
| aaattttctg | tgagtacccc | atcccagcca | agttgcaaaa  | gtcacttggg | atccacaacc  | 900  |
| aaagatcaag | aacccatttt | ctataaagct | gcagaagggg  | ataacataga | atttggagca  | 960  |
| tttgtgggac | acagagatag | tatggactta | cagaggttta  | aagaaacatc | aaacaaaata  | 1020 |
| agagaactgt | tatctaata  | tactcctgaa | aacactctga  | aacatgtggg | tgctgtgga   | 1080 |
| tatagtgaat | gttgaagac  | ttctacttct | cttcactcgg  | tgcaagcaga | aagctgtagt  | 1140 |
| agaagagcgt | cgacggaaga | ctctccagaa | gtcgattcta  | aagcagcttt | gttaccggat  | 1200 |
| tggttacgag | atagaccatc | aaacagagaa | atgccatctg  | aaggaggaa  | attaaatggt  | 1260 |
| cttgcttctc | catttaagcc | cgttttggat | acaaattact  | attattcagc | tgtggaaaga  | 1320 |
| aataacctga | tgaggttgtc | acagagtatt | cccttcgttc  | ctgtacctcc | acgaggcgag  | 1380 |
| cctgtcacag | tgtaccgtct | ggaggagagt | tctcccagta  | tactgaataa | cagcatgtct  | 1440 |
| tcatggtctc | agctaggcct | ctgtgccaaa | attgagtttt  | taagtaaaga | ggaaatggaa  | 1500 |
| ggtggtttac | gaagagcagt | caaaagtgtg | tgtacctggt  | cagagcacga | tatcctgaag  | 1560 |
| tcagggcac  | tctatatcat | taagtcattt | cttcctgagg  | tgataaacac | atggtcaagc  | 1620 |
| atttataaag | aagatacgg  | tctacatctc | tgtctcagag  | aaatacaaca | acagagagca  | 1680 |
| gcacaaaagc | tcacatttgc | ctttaatcag | atgaaacca   | aatccatacc | atattctcca  | 1740 |
| agggttcctg | aagttttcct | gttgtagtgc | cattcagcag  | ggcagtggtt | tgctgtagaa  | 1800 |
| gagtgcata  | ctggtgaatt | tagaaaaata | aacaacaata  | atggtgatga | aatcattcct  | 1860 |
| acaaatactc | tagaagagat | catgctagcc | tttagccact  | ggacctatga | atataccaga  | 1920 |
| ggggagttac | tggtacttga | cttacaagga | gtgggagaaa  | acttgactga | cccatctgta  | 1980 |
| ataaaagctg | aagaaaaaag | atcctgtgac | atggtttttg  | gccctgccaa | tctaggagaa  | 2040 |
| gatgcaataa | aaaacttcaa | gagccaaaca | tccactgtaa  | ttcttgctgt | cgaaagctta  | 2100 |
| aacttccag  | atttgaagag | gaatgactac | acgcccttga  | taaaattata | tttctcagg   | 2160 |
| atgagtcac  | agatttgaat | cttcaatctg | gaaattccac  | caaagaatca | gaagcaacaa  | 2220 |
| attctgttcg | tctgatgta  | tagtgctgag | tcattgggtt  | ttgcctacac | ttcacaaaag  | 2280 |
| tgtaactgtc | agttttcctt | tcgggggaat | tgatgatata  | ggaagatgtg | tgcaaaatga  | 2340 |
| gcttgctggc | cccacacata | gtctagaggt | aatgtttctc  | ttgaaaaacg | cctggagggtg | 2400 |
| gaggctgcag | atgccagtg  | aaagtgtctg | ctgncagaga  | gtcagtgctc | tcgggctggt  | 2460 |
| naaggncggn | acccttgctg | ctgagagtgg | tggttctctt  | cacctgggtg | aggaccatta  | 2520 |
| accaaagtca | agtcttcaga | tttgattggc | gtctcagtca  | cagcccatc  | agctaaggaa  | 2580 |
| actaaattgc | gcagcttttt | aaatggctga | agtcttctc   | agtttgtgct | ctatgataat  | 2640 |
| gatgttagct | ctcaactagg | tggttggtgg | cacgggagaa  | ctactcctta | caattttgct  | 2700 |
| tcacaggcat | gttacaaagc | ctgcactgaa | aaccgtttgt  | cttccctctc | tcctccctc   | 2760 |
| ttttccctgt | agtattgagg | atcaaaccac | gggcctcatg  | aagaccattt | tctaagagac  | 2820 |
| attttattta | agaatcaact | atagagtcta | tgtttatgga  | tacagccagt | ttttgttaaa  | 2880 |
| caaaacctga | attgtgcaaa | agggtttttt | aacattttatc | aatgttaagt | aaaagaaagc  | 2940 |
| catgataaat | aagaattaac | tcactgtttc | atgggtgttt  | cctgtgagga | aggttacagt  | 3000 |
| tgtaacagcc | tgcagttgca | tacatctcca | aagatttaca  | gacttagtgt | atcaaatcag  | 3060 |
| agtgtcatgt | gagctctcac | attgaaaatt | ctataggaat  | gtgtcaatgt | gaattctatt  | 3120 |
| tctggtactt | aagaaatcag | ttgttggtat | atccttatac  | agtataggga | gatcacata   | 3180 |
| caactttatg | ccaataaaat | ctaactta   | tgcccagata  | tttttgcata | tttagcaaca  | 3240 |
| agaaaagctt | atcatttgac | tcaagtttta | tgctttctct  | ttcttttcat | ttcctaggta  | 3300 |
| ctaattttta | tttttatttg | gaaggagcag | tgtaaaagctt | acttgatttc | aatagtgtat  | 3360 |
| ctcatagata | cagacaaggc | cgcagagata | agctgttaaa  | tagtgtttaa | tggtgatgtg  | 3420 |
| gagagaaagg | tgtattactt | aaaaatacta | taccatatac  | gttttgata  | tcattaaatc  | 3480 |
| tttaaaagaa | attaaattta | ttcttggtta | aaaaaaaaa   | aaaaaaaaa  | aa          | 3532 |

<210> 8  
 <211> 475  
 <212> PRT  
 <213> Mus Musculus

<400> 8

-7-

Ile Met Ala Tyr His Glu Lys Pro Val Leu Pro Pro Pro Leu Ile Ile  
 1 5 10 15  
 Leu Ser His Ile Val Ser Leu Phe Cys Cys Val Cys Lys Arg Arg Lys  
 20 25 30  
 Lys Asp Lys Thr Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp  
 35 40 45  
 Gln Lys Lys Leu His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe  
 50 55 60  
 Asp Glu Lys Asp Asp Lys Phe Asn Ser Gly Ser Glu Glu Arg Ile Arg  
 65 70 75 80  
 Val Thr Phe Glu Arg Val Glu Gln Met Ser Ile Gln Ile Lys Glu Val  
 85 90 95  
 Gly Asp Arg Val Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser  
 100 105 110  
 Gln Ile Gly His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu  
 115 120 125  
 Lys Thr Leu Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn  
 130 135 140  
 Glu Ile Thr Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu  
 145 150 155 160  
 Ile Asp Asp Val Pro Val Arg Pro Leu Trp Glu Glu Pro Ser Ala Val  
 165 170 175  
 Asn Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Arg Glu Ser Asn Asn  
 180 185 190  
 Pro Phe Leu Cys Asn Ile Phe Met Lys Asp Glu Lys Asp Pro Gln Tyr  
 195 200 205  
 Asn Leu Phe Gly Gln Asp Leu Pro Val Ile Pro Gln Arg Lys Glu Phe  
 210 215 220  
 Asn Ile Pro Glu Ala Gly Ser Ser Cys Gly Ala Leu Phe Pro Ser Ala  
 225 230 235 240  
 Val Ser Pro Pro Glu Leu Arg Gln Arg Arg His Gly Val Glu Met Leu  
 245 250 255  
 Lys Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Pro Asn Ser Ser  
 260 265 270  
 Pro His Met Ser Ser Pro Pro Thr Lys Phe Ser Val Ser Thr Pro Ser  
 275 280 285  
 Gln Pro Ser Cys Lys Ser His Leu Glu Ser Thr Thr Lys Asp Gln Glu  
 290 295 300  
 Pro Ile Phe Tyr Lys Ala Ala Glu Gly Asp Asn Ile Glu Phe Gly Ala  
 305 310 315 320  
 Phe Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr  
 325 330 335  
 Ser Asn Lys Ile Arg Glu Leu Leu Ser Asn Asp Thr Pro Glu Asn Thr  
 340 345 350  
 Leu Lys His Val Gly Ala Ala Gly Tyr Ser Glu Cys Cys Lys Thr Ser  
 355 360 365  
 Thr Ser Leu His Ser Val Gln Ala Glu Ser Cys Ser Arg Arg Ala Ser  
 370 375 380  
 Thr Glu Asp Ser Pro Glu Val Asp Ser Lys Ala Ala Leu Leu Pro Asp  
 385 390 395 400  
 Trp Leu Arg Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu Gly Gly  
 405 410 415  
 Thr Leu Asn Gly Leu Ala Ser Pro Phe Lys Pro Val Leu Asp Thr Asn  
 420 425 430  
 Tyr Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met Arg Leu Ser Gln  
 435 440 445  
 Ser Ile Pro Phe Val Pro Val Pro Pro Arg Gly Glu Pro Val Thr Val  
 450 455 460  
 Tyr Pro Ser Gly Gly Arg Val Leu Pro Val Tyr  
 465 470 475

<210> 9  
 <211> 5433  
 <212> DNA  
 <213> Mus Musculus

<220>  
 <221> unsure  
 <222> (5094) ... (5094)  
 <223> unknown

<400> 9  
 ggctgaaaga gcctgagctg tgcctctcca ttccactgct gtggcagggc cagaaatctt 60  
 ggatagagaa aaccttttgc aaacgggaat gtatctttgt aattcctagc acgaaagact 120  
 ctaacaggtg ttgctgtggc cagttcacca accagcatat cccccctctg ccaagtgcga 180  
 caccagcaaa aaatgaagag gaaagcaaac aggtggagac tcagcctgag aaatggctctg 240  
 ttgccaagca caccagagc taccacaacag attcctatgg agttcttgaa ttccaggggtg 300  
 gcgcatattc caataaagcc atgtatatcc gtgtatccta tgacaccaag ccagactcac 360  
 tgctccatct catggtgaaa gattggcagc tggaaactccc caagctctta atatctgtgc 420  
 atggaggcct ccagaacttt gagatgcagc ccaagctgaa acaagctctt gggaaaggcc 480  
 tgatcaaggc tgctatgacc accggggcct ggatcttcac cgggggtgtc agcacagggtg 540  
 ttatcagcca cgtaggggat gccttgaaag accactcctc caagtccaga ggccgggttt 600  
 gtgctatagg aattgctcca tggggcatcg tggagaataa ggaagacctg gttggaagg 660  
 atgtaacaag agtgatccag accatgtcca accctctaag taagctctct gtgctcaaca 720  
 actcccacac ccacttcac cttggtgaca atggcaccct gggcaagtat ggcgccgagg 780  
 tgaagctgcg aaggctgctg gaaaagcaca tctccctcca gaagatcaac acaagactgg 840  
 ggcaggcggt gcccctcgtg ggtctcgtgg tggagggggg cctaactgtg gtgtccatcg 900  
 tcttggaata cctgcaagaa gagcctccca tccctgtggt gatttgtgat ggcagcggac 960  
 gtgcctcgga catcctgtcc tttgcgcaca agtactgtga agaaggcggg ataataaatg 1020  
 agtccctcag ggagcagctt ctagttaacca ttcagaaaaa atttaattat aataaggcac 1080  
 aatcacatca gctgtttgca attataatgg agtgcataag gaagaaaaga ctgctcactg 1140  
 tgttcagaat ggggttctgag ggccagcagg acatcgagat ggcaatttta actgccctgc 1200  
 tgaaaggaaac aaacgtatct gctccagatc agctgagctt ggcactggct tggaaaccgcg 1260  
 tggacatagc acgaagccag atctttgtct tttggcccca ctggacgccc ctgggaagcc 1320  
 tggcaccccc gacggacagc aaagccacgg agaaggagaa gaagccaccc atggccacca 1380  
 ccaagggagg aagaggaaaa gggaaaggca agaagaaagg gaaagtgaag gaggaagtgg 1440  
 aggaagaaac tgaccccccg aagatagagc tgctgaactg ggtgaatgct ttggagcaag 1500  
 cgatgctaga tgctttagtc ttagatcgtg tgcactttgt gaagctcctg attgaaaacg 1560  
 gagtgaacat gcaacacttt ctgaccattc cgaggctgga ggagctctat aacacaagac 1620  
 tgggtccacc aaacacactt catctgctgg tgagggatgt gaaaaagagc aaccttccgc 1680  
 ctgattacca catcagcctc atagacatcg ggctcgtgct ggagtacctc atgggaggag 1740  
 cctaccgctg caactacact cggaaaaact ttcggaccct ttacaacaac ttgtttggac 1800  
 caaagaggcc taaagctctt aaacttctgg gaatggaaga tgatgagcct ccagctaaag 1860  
 ggaagaaaaa aaaaaaaaag aaaaaggagg aagagatcga cattgatgtg gacgacctg 1920  
 ccgtgagtcg gttccagtat cccttccacg agctgatggt gtgggcagtg ctgatgaaac 1980  
 gccagaaaat ggcagtgttc ctctggcagc gaggggaaga gagcatggcc aaggccctgg 2040  
 tggcctgcaa gctctacaag gccatggccc acgagtcctc cgagagtgat ctggtggatg 2100  
 acatctccca ggacttggat aacaattcca aagacttcgg ccagcttgct ttggagtatt 2160  
 tagaccagtc ctataagcat gacgagcaga tgcctatgaa actcctgacc tacgagctga 2220  
 aaaaactggag caactcgacc tgcctcaaac tggcctgggc agccaaacac cgggacttca 2280  
 ttgctcacac ctgcagccag atgctgctga ccgatatgtg gatgggaaga ctgcggatgc 2340  
 ggaagaaccc cggcctgaag gttatcatgg ggattcttct acccccacc atcttgtttt 2400  
 tggaatttct cacatatgat gatttctcgt atcaaacatc caaggaaaac gaggatggca 2460  
 aagaaaaaga agaggaaaat acggatgcaa atgcagatgc tggctcaaga aagggggatg 2520  
 aggagaacga gcataaaaaa cagagaagta tcccacgga aacaaagatc tgtgaattct 2580  
 ataacgcgcc cattgtcaag ttctggtttt acacaatatc atacttgggc tacctgctgc 2640  
 tgtttaacta cgtcatcctg gtgcggatgg atggctggcc gtccctccag gagtggatcg 2700  
 tcatctccta catcgtgagc ctggcggttag agaagatacg agagatcctc atgtcagaac 2760  
 caggcaact cagccagaaa atcaaaagttt ggcttcagga gtactggaac atcacagatc 2820  
 tcgtggccat ttccacattc atgattggag caattcttct cctacagaac cagccctaca 2880

-9-

```

tgggctatgg ccgggtgac tactgtgtgg atatcatctt ctggtacatc cgtgtcctgg 2940
acatctttgg tgtaacaag tatctggggc catacgtgat gatattgga aagatgatga 3000
tcgacatgct gtactttgtg gtcacatgac tggctgtgct catgagtttc ggagtagccc 3060
gtcaagccat tctgcatcca gaggagaagc cctcttggaa actggccga aacatcttct 3120
acatgcccta ctggatgac tatggagagg tgtttgcaga ccagatagac ctctacgcca 3180
tggaatttaa tcctccttgt ggtgagaacc tatatgatga ggagggaag cggcttcctc 3240
cctgtatccc cggcgctgg ctactccag cactcatggc gtgctatcta ctggtcgcca 3300
acatcctgct ggtgaacctg ctgattgctg tgttcaacaa tactttcttt gaagtaaaat 3360
caatatccaa ccaggtgtgg aagttccagc gatatcagct gattatgaca tttcatgaca 3420
ggcagtcct gcccccaccg atgatcattt taagccacat ctacatcatc attatgcgtc 3480
tcagcgccg ctgcaggaaa aagagagaag gggaccaaga ggaacgggat cgtggattga 3540
agctcttctc tagcgacgag gagctaaaga ggctgcatga gttcgaggag cagtgcgtgc 3600
aggagcactt ccgggagaag gaggatgagc agcagtcgtc cagcgacgag cgcacccggg 3660
tcacttctga aagattgaa aatatgtcaa tgaggttgga agaaatcaat gaaagagaaa 3720
cttttatgaa aacttcctg cagactgttg accttcgact tgctcagcta gaagaattat 3780
ctaacagaat ggtgaatgct cttgaaaatc ttgcgggaat cgacaggctc gacctgatcc 3840
aggcacggtc ccgggcttct tctgaatgtg aggcaacgta tcttctccg caaagcagca 3900
tcaatagcgc tgatggctac agcttgtatc gatatcattt taacggagaa gagttattat 3960
ttgaggatac atctctctcc acgtcaccag ggacaggagt caggaaaaaa acctgttctc 4020
tccgtataaa ggaagagaag gacgtgaaaa cgcacctagt cccagaatgt cagaacagtc 4080
ttcaccttct actgggcaca agcacatcag caaccocaga tggcagtcac cttgcagtag 4140
atgacttaaa gaacgctgaa gactcaaaat taggtccaga tattgggatt tcaaagggaag 4200
atgatgaaag acagacagac tctaaaaaag aagaaactat ttccccaagt ttaaataaaa 4260
cagatgtgat acatggacag gacaaatcag atgttcaaaa cactcagcta acagtggaaa 4320
cgcaaatat agaaggcact atttctctac ccttggaaaga aaccaaattt acacgctatt 4380
tcccgatga aacgatcaat gcttgtaaaa caatgaagtc cagaagcttc gtctattccc 4440
ggggaagaaa gctggtcggt ggggttaacc aggatgtaga gtacagttca atcacggacc 4500
agcaattgac gacggaatgg caatgccaag ttcaaaagat cacgcgctct catagcacag 4560
atattcctta catttgtgtg gaagctgcag tgcaagctga gcaaaaagag cagtttgtag 4620
atatgcaaga tgaacaccat gtcgtgaag caattcctcg aatccctcgc ttgtccctaa 4680
ccattactga cagaaatggg atgaaaact tactgtctgt gaagccagat caaactttgg 4740
gattcccatc tctcaggtca aaaagttaac atggacatcc taggaatgtg aaatccattc 4800
agggaaagtt agacagatct ggacatgcca gtagtgaag cagcttagta attgtgtctg 4860
gaatgacagc agaagaaaaa aagggttaaga aagagaaagc ttccacagaa actgaatgct 4920
agtctgtttt gtttctttta ttttttttt taacagtcag aaaccacta atgggtgtca 4980
tcttgcccca tcctaaacac atmtccaatt tcctaaaaac attttccctt aaaaaatttt 5040
ggaaattcag acttgattta caatttaatg cactaaaagt agtattttgt tagnatatgt 5100
tagtaggctt agttttttca gttgcagtag tatcaaatga aagtgatgat actgtaacga 5160
agataaattg gctaatacgt atacaagatt atacaatctc tttattactg agggccacca 5220
aatagcctag gaagtgcctc cgagcactga agtcaccatt aggtcactca agaagtaagc 5280
aactagctgg gcacagtggc tcatgcctgt aatcctagca ctttgggagg ccaaggcaga 5340
aagatagctt gagtcaggga gtttgagacc agcctgggca acatagtgat accccatctc 5400
ttaaaaaaaa aaaaaaaaaa ctgccctcgt gcc 5433

```

<210> 10  
 <211> 1533  
 <212> PRT  
 <213> Mus Musculus

<400> 10  
 Met Tyr Ile Arg Val Ser Tyr Asp Thr Lys Pro Asp Ser Leu Leu His  
 1 5 10 15  
 Leu Met Val Lys Asp Trp Gln Leu Glu Leu Pro Lys Leu Leu Ile Ser  
 20 25 30  
 Val His Gly Gly Leu Gln Asn Phe Glu Met Gln Pro Lys Leu Lys Gln  
 35 40 45  
 Val Phe Gly Lys Gly Leu Ile Lys Ala Ala Met Thr Thr Gly Ala Trp  
 50 55 60

-10-

Ile Phe Thr Gly Gly Val Ser Thr Gly Val Ile Ser His Val Gly Asp  
 65 70 75 80  
 Ala Leu Lys Asp His Ser Ser Lys Ser Arg Gly Arg Val Cys Ala Ile  
 85 90 95  
 Gly Ile Ala Pro Trp Gly Ile Val Glu Asn Lys Glu Asp Leu Val Gly  
 100 105 110  
 Lys Asp Val Thr Arg Val Tyr Gln Thr Met Ser Asn Pro Leu Ser Lys  
 115 120 125  
 Leu Ser Val Leu Asn Asn Ser His Thr His Phe Ile Leu Ala Asp Asn  
 130 135 140  
 Gly Thr Leu Gly Lys Tyr Gly Ala Glu Val Lys Leu Arg Arg Leu Leu  
 145 150 155 160  
 Glu Lys His Ile Ser Leu Gln Lys Ile Asn Thr Arg Leu Gly Gln Gly  
 165 170 175  
 Val Pro Leu Val Gly Leu Val Val Glu Gly Gly Pro Asn Val Val Ser  
 180 185 190  
 Ile Val Leu Glu Tyr Leu Gln Glu Glu Pro Pro Ile Pro Val Val Ile  
 195 200 205  
 Cys Asp Gly Ser Gly Arg Ala Ser Asp Ile Leu Ser Phe Ala His Lys  
 210 215 220  
 Tyr Cys Glu Glu Gly Gly Ile Ile Asn Glu Ser Leu Arg Glu Gln Leu  
 225 230 235 240  
 Leu Val Thr Ile Gln Lys Thr Phe Asn Tyr Asn Lys Ala Gln Ser His  
 245 250 255  
 Gln Leu Phe Ala Ile Ile Met Glu Cys Met Lys Lys Lys Glu Leu Val  
 260 265 270  
 Thr Val Phe Arg Met Gly Ser Glu Gly Gln Gln Asp Ile Glu Met Ala  
 275 280 285  
 Ile Leu Thr Ala Leu Leu Lys Gly Thr Asn Val Ser Ala Pro Asp Gln  
 290 295 300  
 Leu Ser Leu Ala Leu Ala Trp Asn Arg Val Asp Ile Ala Arg Ser Gln  
 305 310 315 320  
 Ile Phe Val Phe Gly Pro His Trp Thr Pro Leu Gly Ser Leu Ala Pro  
 325 330 335  
 Pro Thr Asp Ser Lys Ala Thr Glu Lys Glu Lys Lys Pro Pro Met Ala  
 340 345 350  
 Thr Thr Lys Gly Gly Arg Gly Lys Gly Lys Gly Lys Lys Gly Lys  
 355 360 365  
 Val Lys Glu Glu Val Glu Glu Glu Thr Asp Pro Arg Lys Ile Glu Leu  
 370 375 380  
 Leu Asn Trp Val Asn Ala Leu Glu Gln Ala Met Leu Asp Ala Leu Val  
 385 390 395 400  
 Leu Asp Arg Val Asp Phe Val Lys Leu Leu Ile Glu Asn Gly Val Asn  
 405 410 415  
 Met Gln His Phe Leu Thr Ile Pro Arg Leu Glu Glu Leu Tyr Asn Thr  
 420 425 430  
 Arg Leu Gly Pro Pro Asn Thr Leu His Leu Leu Val Arg Asp Val Lys  
 435 440 445  
 Lys Ser Asn Leu Pro Pro Asp Tyr His Ile Ser Leu Ile Asp Ile Gly  
 450 455 460  
 Leu Val Leu Glu Tyr Leu Met Gly Gly Ala Tyr Arg Cys Asn Tyr Thr  
 465 470 475 480  
 Arg Lys Asn Phe Arg Thr Leu Tyr Asn Asn Leu Phe Gly Pro Lys Arg  
 485 490 495  
 Pro Lys Ala Leu Lys Leu Leu Gly Met Glu Asp Asp Glu Pro Pro Ala  
 500 505 510  
 Lys Gly Lys Lys Lys Lys Lys Lys Lys Glu Glu Glu Ile Asp Ile  
 515 520 525  
 Asp Val Asp Asp Pro Ala Val Ser Arg Phe Gln Tyr Pro Phe His Glu  
 530 535 540

-11-

Leu Met Val Trp Ala Val Leu Met Lys Arg Gln Lys Met Ala Val Phe  
 545 550 555 560  
 Leu Trp Gln Arg Gly Glu Glu Ser Met Ala Lys Ala Leu Val Ala Cys  
 565 570 575  
 Lys Leu Tyr Lys Ala Met Ala His Glu Ser Ser Glu Ser Asp Leu Val  
 580 585 590  
 Asp Asp Ile Ser Gln Asp Leu Asp Asn Asn Ser Lys Asp Phe Gly Gln  
 595 600 605  
 Leu Ala Leu Glu Leu Leu Asp Gln Ser Tyr Lys His Asp Glu Gln Ile  
 610 615 620  
 Ala Met Lys Leu Leu Thr Tyr Glu Leu Lys Asn Trp Ser Asn Ser Thr  
 625 630 635 640  
 Cys Leu Lys Leu Ala Val Ala Ala Lys His Arg Asp Phe Ile Ala His  
 645 650 655  
 Thr Cys Ser Gln Met Leu Leu Thr Asp Met Trp Met Gly Arg Leu Arg  
 660 665 670  
 Met Arg Lys Asn Pro Gly Leu Lys Val Ile Met Gly Ile Leu Leu Pro  
 675 680 685  
 Pro Thr Ile Leu Phe Leu Glu Phe Arg Thr Tyr Asp Asp Phe Ser Tyr  
 690 695 700  
 Gln Thr Ser Lys Glu Asn Glu Asp Gly Lys Glu Lys Glu Glu Glu Asn  
 705 710 715 720  
 Thr Asp Ala Asn Ala Asp Ala Gly Ser Arg Lys Gly Asp Glu Glu Asn  
 725 730 735  
 Glu His Lys Lys Gln Arg Ser Ile Pro Ile Gly Thr Lys Ile Cys Glu  
 740 745 750  
 Phe Tyr Asn Ala Pro Ile Val Lys Phe Trp Phe Tyr Thr Ile Ser Tyr  
 755 760 765  
 Leu Gly Tyr Leu Leu Leu Phe Asn Tyr Val Ile Leu Val Arg Met Asp  
 770 775 780  
 Gly Trp Pro Ser Leu Gln Glu Trp Ile Val Ile Ser Tyr Ile Val Ser  
 785 790 795 800  
 Leu Ala Leu Glu Lys Ile Arg Glu Ile Leu Met Ser Glu Pro Gly Lys  
 805 810 815  
 Leu Ser Gln Lys Ile Lys Val Trp Leu Gln Glu Tyr Trp Asn Ile Thr  
 820 825 830  
 Asp Leu Val Ala Ile Ser Thr Phe Met Ile Gly Ala Ile Leu Arg Leu  
 835 840 845  
 Gln Asn Gln Pro Tyr Met Gly Tyr Gly Arg Val Ile Tyr Cys Val Asp  
 850 855 860  
 Ile Ile Phe Trp Tyr Ile Arg Val Leu Asp Ile Phe Gly Val Asn Lys  
 865 870 875 880  
 Tyr Leu Gly Pro Tyr Val Met Met Ile Gly Lys Met Met Ile Asp Met  
 885 890 895  
 Leu Tyr Phe Val Val Ile Met Leu Val Val Leu Met Ser Phe Gly Val  
 900 905 910  
 Ala Arg Gln Ala Ile Leu His Pro Glu Glu Lys Pro Ser Trp Lys Leu  
 915 920 925  
 Ala Arg Asn Ile Phe Tyr Met Pro Tyr Trp Met Ile Tyr Gly Glu Val  
 930 935 940  
 Phe Ala Asp Gln Ile Asp Leu Tyr Ala Met Glu Ile Asn Pro Pro Cys  
 945 950 955 960  
 Gly Glu Asn Leu Tyr Asp Glu Glu Gly Lys Arg Leu Pro Pro Cys Ile  
 965 970 975  
 Pro Gly Ala Trp Leu Thr Pro Ala Leu Met Ala Cys Tyr Leu Leu Val  
 980 985 990  
 Ala Asn Ile Leu Leu Val Asn Leu Leu Ile Ala Val Phe Asn Asn Thr  
 995 1000 1005  
 Phe Phe Glu Val Lys Ser Ile Ser Asn Gln Val Trp Lys Phe Gln Arg  
 1010 1015 1020

-12-

Tyr Gln Leu Ile Met Thr Phe His Asp Arg Pro Val Leu Pro Pro Pro  
 1025 1030 1035 104  
 Met Ile Ile Leu Ser His Ile Tyr Ile Ile Ile Met Arg Leu Ser Gly  
 1045 1050 1055  
 Arg Cys Arg Lys Lys Arg Glu Gly Asp Gln Glu Glu Arg Asp Arg Gly  
 1060 1065 1070  
 Leu Lys Leu Phe Leu Ser Asp Glu Glu Leu Lys Arg Leu His Glu Phe  
 1075 1080 1085  
 Glu Glu Gln Cys Val Gln Glu His Phe Arg Glu Lys Glu Asp Glu Gln  
 1090 1095 1100  
 Gln Ser Ser Ser Asp Glu Arg Ile Arg Val Thr Ser Glu Arg Val Glu  
 1105 1110 1115 112  
 Asn Met Ser Met Arg Leu Glu Glu Ile Asn Glu Arg Glu Thr Phe Met  
 1125 1130 1135  
 Lys Thr Ser Leu Gln Thr Val Asp Leu Arg Leu Ala Gln Leu Glu Glu  
 1140 1145 1150  
 Leu Ser Asn Arg Met Val Asn Ala Leu Glu Asn Leu Ala Gly Ile Asp  
 1155 1160 1165  
 Arg Ser Asp Leu Ile Gln Ala Arg Ser Arg Ala Ser Ser Glu Cys Glu  
 1170 1175 1180  
 Ala Thr Tyr Leu Leu Arg Gln Ser Ser Ile Asn Ser Ala Asp Gly Tyr  
 1185 1190 1195 120  
 Ser Leu Tyr Arg Tyr His Phe Asn Gly Glu Glu Leu Leu Phe Glu Asp  
 1205 1210 1215  
 Thr Ser Leu Ser Thr Ser Pro Gly Thr Gly Val Arg Lys Lys Thr Cys  
 1220 1225 1230  
 Ser Phe Arg Ile Lys Glu Glu Lys Asp Val Lys Thr His Leu Val Pro  
 1235 1240 1245  
 Glu Cys Gln Asn Ser Leu His Leu Ser Leu Gly Thr Ser Thr Ser Ala  
 1250 1255 1260  
 Thr Pro Asp Gly Ser His Leu Ala Val Asp Asp Leu Lys Asn Ala Glu  
 1265 1270 1275 128  
 Glu Ser Lys Leu Gly Pro Asp Ile Gly Ile Ser Lys Glu Asp Asp Glu  
 1285 1290 1295  
 Arg Gln Thr Asp Ser Lys Lys Glu Glu Thr Ile Ser Pro Ser Leu Asn  
 1300 1305 1310  
 Lys Thr Asp Val Ile His Gly Gln Asp Lys Ser Asp Val Gln Asn Thr  
 1315 1320 1325  
 Gln Leu Thr Val Glu Thr Thr Asn Ile Glu Gly Thr Ile Ser Tyr Pro  
 1330 1335 1340  
 Leu Glu Glu Thr Lys Ile Thr Arg Tyr Phe Pro Asp Glu Thr Ile Asn  
 1345 1350 1355 136  
 Ala Cys Lys Thr Met Lys Ser Arg Ser Phe Val Tyr Ser Arg Gly Arg  
 1365 1370 1375  
 Lys Leu Val Gly Gly Val Asn Gln Asp Val Glu Tyr Ser Ser Ile Thr  
 1380 1385 1390  
 Asp Gln Gln Leu Thr Thr Glu Trp Gln Cys Gln Val Gln Lys Ile Thr  
 1395 1400 1405  
 Arg Ser His Ser Thr Asp Ile Pro Tyr Ile Val Ser Glu Ala Ala Val  
 1410 1415 1420  
 Gln Ala Glu Gln Lys Glu Gln Phe Ala Asp Met Gln Asp Glu His His  
 1425 1430 1435 144  
 Val Ala Glu Ala Ile Pro Arg Ile Pro Arg Leu Ser Leu Thr Ile Thr  
 1445 1450 1455  
 Asp Arg Asn Gly Met Glu Asn Leu Leu Ser Val Lys Pro Asp Gln Thr  
 1460 1465 1470  
 Leu Gly Phe Pro Ser Leu Arg Ser Lys Ser Leu His Gly His Pro Arg  
 1475 1480 1485  
 Asn Val Lys Ser Ile Gln Gly Lys Leu Asp Arg Ser Gly His Ala Ser  
 1490 1495 1500

-13-

Ser Val Ser Ser Leu Val Ile Val Ser Gly Met Thr Ala Glu Glu Lys  
 1505 1510 1515 152  
 Lys Val Lys Lys Glu Lys Ala Ser Thr Glu Thr Glu Cys  
 1525 1530

<210> 11  
 <211> 6220  
 <212> DNA  
 <213> Homo Sapiens

<400> 11  
 tgtgcagaat tgtacagttg cgaaaccatg tcgctggcag ctggtgctgg cggaggagac 60  
 ttccctgtgc ggtgctcagt gcatctgcac ccgtggggga gggagctctt tctctggccc 120  
 tgcagtcacc tgaggttggt accattatga acggccgctg ggacccccgc atgtgcatgt 180  
 actccccag agtgctccgg ggccccagcc aagggaacaca tctcacgcag ctgggaacat 240  
 gtgcaggctg atgaagagaa ccgcatgagg gcttcacatg aggaagcatg tggccaggctc 300  
 ctctcagaac atcagcctca tcttctgtgc tctgatctat ttcaccaacc acccatgtg 360  
 tctctagaac ccagtgtag cgagctggag agaggactgt cctgagggca gcaggcctgg 420  
 ttgcagctgg cgtgggggtc tcagaatgga gccctcagcc ctgaggaaag ctggctcgga 480  
 gcaggaggag ggctttgagg ggctgcccag aagggtcact gacctgggga tggctccaa 540  
 tctccggcgc agcaacagca gcctcttcaa gagctggagg ctacagtgc ccttcggcaa 600  
 caatgacaag caagaaagcc tcagttcgtg gattcctgaa aacatcaaga agaaagaatg 660  
 cgtgtatatt gtggaagtt ccaaactgtc tgatgctggg aaggtggtgt gtcagtgtgg 720  
 ctacacgcat gagcagcact tggaggaggc taccaagccc cacaccttc agggcacaca 780  
 gtgggaccca aagaacatg tccaggagat gccaacgat gcctttggcg acatcgtctt 840  
 cacgggctg agccagaagg tgaaaaagta cgtccgagtc tcccaggaca cgcctccag 900  
 cgtgatctac cacctcatga ccagcactg ggggctggac gtccccaatc tcttgatctc 960  
 ggtgaccggg ggggccaaga acttcaacat gaagccgcgg ctgaagagca ttttccgag 1020  
 aggcctggtc aagtggtc agaccacagg ggcctggatc atcacagggg ggtcccaac 1080  
 cggcgtcatg aagcaggtag gcgaggcggg gcgggacttc agcctgagca gcagctacaa 1140  
 ggaaggcgag ctcatcacca tcggagtcgc cacctggggc actgtccacc gccgcgagg 1200  
 cctgatccat cccacgggca gcttccccgc cgagtacata ctggatgagg atggccaagg 1260  
 gaacctgacc tgctagaca gcaaccactc tcacttcac ctcgtggacg acgggaccca 1320  
 cggccagtac ggggtggaga ttcctctgag gaccaggctg gagaagtca tatcgagca 1380  
 gaccaaggaa agaggaggtg tggccatcaa gatccccatc gtgtgcgtg tggcgaggg 1440  
 cggcccgggc acgttgca caatcgacaa gccaccacc aacggcaccc cctgtgtgtg 1500  
 tgtggagggc tcggcccgcg tggccgacgt cattgccag gtggccaacc tgcctgtctc 1560  
 ggacatcact atctccctga tccagcagaa actgagcgtg ttcttccagg agatgtttga 1620  
 gaccttcacg gaaagcagga ttgtcgagt gacaaaaaag atccaagata ttgtccggag 1680  
 gcggcagctg ctgactgtct tccgggaagg caaggatggt cagcaggacg tggatgtggc 1740  
 catcttgca gcttctgta aagcctcacg gagccaagac cactttggcc acgagaactg 1800  
 ggaccaccag ctgaaactgg cagtggcagt gaatcgctg gacattgccc gcagtgagat 1860  
 cttcatggat gagtggcagt ggaagccttc agatctgcac cccacgatga cagctgcact 1920  
 catctccaac aagcctgagt ttgtgaagct cttcctggaa aacgggggtg agctgaagga 1980  
 gtttgtcacc tgggacacct tgctctacct gtacgagaa ctggaccct cctgcctgtt 2040  
 ccacagcaag ctgcaaaagg tgctggtgga ggatcccag cggccggctt gcgcgcccgc 2100  
 ggcgccccgc ctgcagatgc accacgtggc ccagtgctg cgggagctgc tgggggactt 2160  
 cagcgagcgg ctttatcccc ggccccggca caacgaccgg ctgcggctcc tgctgccgt 2220  
 tccccacgtc aagctcaacg tgcaggaggt gagcctcgg tccctctaca agcgttctc 2280  
 aggccatgtg accttcacca tggaccccat ccgtgacct ctcatgtgg ccattgtcca 2340  
 gaaccgtcgg gagctggcag gaatcatctg ggctcagagc caggactgca tcgcagcggc 2400  
 cttggcctgc agcaagatcc tgaaggaaact gtccaaggag gaggaggaca cggacagctc 2460  
 ggaggagatg ctggcgctgg cggaggagta tgagcacaga gccatcgggg tcttcacga 2520  
 gtgctaccgg aaggacgaag agagagcca gaaactgtc acccgctgt ccgaggcctg 2580  
 ggggaagacc acctgcctgc agctcgccct ggaggccaag gacatgaagt ttgtgtctca 2640  
 cgggggcatc caggccttcc tgaccaaggt gtgggtgggc cagctctccg tggacaatgg 2700  
 gctgtggcgt gtgacctgt gcatgctggc cttcccgct ctcctcaccg gcctcatctc 2760  
 cttcaggagg aagaggctgc aggatgtggg caccctcgc gcccgccgc gtgccttctt 2820  
 caccgcaccc gtggtgtct tccacctgaa cactctctc tacttcgct tcctctgct 2880  
 gttcgccctac gtgctcatgg tggacttcca gcctgtgccc tcctggtgag agtgtgccat 2940



-14-

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| ctacctctgg  | ctcttctcct  | tgggtgtgcga | ggagatgcgg  | cagctcttct  | atgacctga   | 3000 |
| cgagtgcggg  | ctgatgaaga  | aggcagcctt  | gtacttcagt  | gacttctgga  | ataagctgga  | 3060 |
| cgtcggcgca  | atcttgctct  | tcgtggcagg  | gctgacctgc  | aggctcatcc  | cggcgacgct  | 3120 |
| gtaccccggg  | cgcgtcatcc  | tctctctgga  | cttcacctcg  | ttctgcctcc  | ggctcatgca  | 3180 |
| catttttacc  | atcagtaaga  | cgctggggcc  | caagatcatc  | attgtgaagc  | ggatgatgaa  | 3240 |
| ggacgtcttc  | ttcttctct   | tcctgctggc  | tgtgtgggtg  | gtgtccttcg  | gggtggccaa  | 3300 |
| gcaggccatc  | ctcatccaca  | acgagcgccg  | ggtggactgg  | ctgttccgag  | gggcccgtct  | 3360 |
| ccactectac  | ctcaccatct  | tcgggcagat  | cccgggctac  | atcgacggtg  | tgaactcaa   | 3420 |
| cccggagcac  | tgagcccca   | atggcaccga  | cccctacaag  | cctaagtgcc  | ccgagagcga  | 3480 |
| cgcgacgcag  | cagagggccg  | ccttccctga  | gtggctgacg  | gtcctctac   | tctgcctcta  | 3540 |
| cctgctcttc  | accaacatcc  | tgtgtctcaa  | cctctcatc   | gccatgttca  | actacacctt  | 3600 |
| ccagcaggtg  | caggagcaca  | cggaccagat  | ttggaagttc  | cagcgccatg  | acctgatcga  | 3660 |
| ggagtaccac  | ggccgccccg  | ccgcgcgcgc  | ccccttcac   | ctcctcagcc  | acctgcagct  | 3720 |
| cttcatcaag  | agggtggtcc  | tgaagactcc  | ggccaagagg  | cacaagcagc  | tcaagaacaa  | 3780 |
| gctggagaag  | aacgaggagg  | cggccctgct  | atcctgggag  | atctacctga  | aggagaacta  | 3840 |
| cctccagaac  | cgacagttcc  | agcaaaagca  | gcggcccgag  | cagaagatcg  | aggacatcag  | 3900 |
| caataagggt  | gacgccatgg  | tggacctgct  | ggacctggac  | ccactgaaga  | ggtcgggctc  | 3960 |
| catggagcag  | aggttggcct  | ccctggagga  | gcaggtggcc  | cagacagccc  | gagccctgca  | 4020 |
| ctggatcgtg  | aggacgctgc  | gggccagcgg  | cttcagctcg  | gaggcgacg   | tccccactct  | 4080 |
| ggcctcccag  | aaggccgcgg  | aggagccgga  | tgctgagccg  | ggaggcagga  | agaagacgga  | 4140 |
| ggagccgggc  | gacagctacc  | acgtgaatgc  | ccggcacctc  | ctctacccca  | actgccctgt  | 4200 |
| cacgcgcttc  | cccgtgcccc  | acgagaaggt  | gcctggggag  | acggagttcc  | tgatctatga  | 4260 |
| cccacccttt  | tacacggcag  | agaggaagga  | cgcggccgcc  | atggacccca  | tgggagacac  | 4320 |
| cctggagcca  | ctgtccacga  | tccagtacaa  | cgtggtggat  | ggcctgaggg  | accgccggag  | 4380 |
| cttccacggg  | cgctacacag  | tgacggccgg  | gttgcccctg  | aaccccatgg  | gccgcacagg  | 4440 |
| actgcgtggg  | cgcgggagcc  | tcagctgctt  | cggacccaac  | cacacgctgt  | accccatggt  | 4500 |
| cacgcggtgg  | aggcggaacg  | aggatggagc  | catctgcagg  | aagagcataa  | agaagatgct  | 4560 |
| ggaagtgtctg | gtgtggaagc  | tccctctctc  | cgagcactgg  | gccctgcttg  | ggggctcccc  | 4620 |
| ggagccaggg  | gagatgctac  | ctcggaaagt  | gaagcggatc  | ctccggcagg  | agcactggcc  | 4680 |
| gtcttttgaa  | aacttgctga  | agtgcggcat  | ggaggtgtac  | aaaggctaca  | tggatgacct  | 4740 |
| gaggaacacg  | gacaatgcct  | ggatcgagac  | ggtggccgtc  | agcgtccact  | tccaggacca  | 4800 |
| gaatgacgtg  | gagctgaaca  | ggctgaactc  | taacctgcac  | gcctgcgact  | cggggggcctc | 4860 |
| catccgatgg  | caggtgggtg  | acaggcgcat  | cccactctat  | gcgaaccaca  | agaccctcct  | 4920 |
| ccagaaggca  | gccgctgagt  | tcggggctca  | ctactgactg  | tgccctcagg  | ctgggcccgt  | 4980 |
| ccagtccata  | gacgttcccc  | ccagaaacca  | gggtttctct  | ctcctgagcc  | tggccaggac  | 5040 |
| tcaggctgtt  | cctggggcct  | gcacatgatg  | gggtttgggtg | gacccagtgc  | ccctcacggc  | 5100 |
| tgccgcaagt  | ctgtgcaga   | tgacctcatg  | acagtgaagg  | ggtcaagggtg | acccgggagg  | 5160 |
| agagctcaag  | acagggcaca  | ggctactcag  | agctgagggg  | cccctgggac  | ccttggccat  | 5220 |
| caggcgaggg  | gctggggcctg | tgacgtggg   | cccttgcca   | gagtccactc  | ccttccctggc | 5280 |
| tgtgtcacc   | cgagcagctc  | atccaccatg  | gaggtcattg  | gcctgaggca  | agttcccccg  | 5340 |
| agagtcggga  | tcccctgtgg  | ccccctcagg  | cctatgtctg  | tgaggaaggg  | gccctgccac  | 5400 |
| tctccccaag  | agggcctcca  | tgtttcgagg  | tgctcaaca   | tggagccttg  | cctggcctgg  | 5460 |
| gctaggggca  | ctgtctgaac  | tctgactgt   | caggataaac  | tccgtggggg  | tacaggagcc  | 5520 |
| cagacaaaagc | ccaggcctgt  | caagagacgc  | agagggcccc  | tgccagggtt  | ggccccaggg  | 5580 |
| accctgggac  | gaggctgcag  | aagctctccc  | tccctactcc  | ctgggagcca  | cgtgctggcc  | 5640 |
| atgtggccag  | ggacggcatg  | agcaggaggc  | ggggacgtgg  | gggcctctctg | gtttggtgtc  | 5700 |
| aacagctcac  | aggagcgtga  | accatgaggg  | ccctcaggag  | gggaacgtgg  | taaaacccaa  | 5760 |
| gacattaaat  | ctgccatctc  | aggcctggct  | ggctcttctg  | tgctttccac  | aaataaagtt  | 5820 |
| cctgacacgt  | ccagggccag  | gggtgtgtg   | acggctgcct  | gaagttctcc  | tcgatcccc   | 5880 |
| ggtgagcttc  | ctgacgcctg  | tggatgtcct  | gcagcccctc  | agccctaccc  | ccaagtttct  | 5940 |
| cctctgacct  | atcagctccc  | tgtcttcatt  | ttcctaaacc  | tgggctccag  | catcgtcccc  | 6000 |
| aagccacca   | ggccaggatg  | caggcatcca  | catgcctcc   | tccttggtct  | cccctgcgtg  | 6060 |
| gtggtgccaa  | tgtgccctgg  | caccctgca   | gaggctccgg  | atggagcctg  | gggctgcctg  | 6120 |
| gccactgagc  | actggccgag  | gtgatgcccc  | cccttccctg  | gacaggcctc  | tgtcttccac  | 6180 |
| ctgacccaaa  | gctctctagc  | caccccttg   | tcccagtat   |             |             | 6220 |

&lt;210&gt; 12

&lt;211&gt; 1503

-15-

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 12

```

Met Glu Pro Ser Ala Leu Arg Lys Ala Gly Ser Glu Gln Glu Glu Gly
 1          5          10          15
Phe Glu Gly Leu Pro Arg Arg Val Thr Asp Leu Gly Met Val Ser Asn
 20          25          30
Leu Arg Arg Ser Asn Ser Ser Leu Phe Lys Ser Trp Arg Leu Gln Cys
 35          40          45
Pro Phe Gly Asn Asn Asp Lys Gln Glu Ser Leu Ser Ser Trp Ile Pro
 50          55          60
Glu Asn Ile Lys Lys Lys Glu Cys Val Tyr Phe Val Glu Ser Ser Lys
 65          70          75          80
Leu Ser Asp Ala Gly Lys Val Val Cys Gln Cys Gly Tyr Thr His Glu
 85          90          95
Gln His Leu Glu Glu Ala Thr Lys Pro His Thr Phe Gln Gly Thr Gln
100          105          110
Trp Asp Pro Lys Lys His Val Gln Glu Met Pro Thr Asp Ala Phe Gly
115          120          125
Asp Ile Val Phe Thr Gly Leu Ser Gln Lys Val Lys Lys Tyr Val Arg
130          135          140
Val Ser Gln Asp Thr Pro Ser Ser Val Ile Tyr His Leu Met Thr Gln
145          150          155          160
His Trp Gly Leu Asp Val Pro Asn Leu Leu Ile Ser Val Thr Gly Gly
165          170          175
Ala Lys Asn Phe Asn Met Lys Pro Arg Leu Lys Ser Ile Phe Arg Arg
180          185          190
Gly Leu Val Lys Val Ala Gln Thr Thr Gly Ala Trp Ile Ile Thr Gly
195          200          205
Gly Ser His Thr Gly Val Met Lys Gln Val Gly Glu Ala Val Arg Asp
210          215          220
Phe Ser Leu Ser Ser Ser Tyr Lys Glu Gly Glu Leu Ile Thr Ile Gly
225          230          235          240
Val Ala Thr Trp Gly Thr Val His Arg Arg Glu Gly Leu Ile His Pro
245          250          255
Thr Gly Ser Phe Pro Ala Glu Tyr Ile Leu Asp Glu Asp Gly Gln Gly
260          265          270
Asn Leu Thr Cys Leu Asp Ser Asn His Ser His Phe Ile Leu Val Asp
275          280          285
Asp Gly Thr His Gly Gln Tyr Gly Val Glu Ile Pro Leu Arg Thr Arg
290          295          300
Leu Glu Lys Phe Ile Ser Glu Gln Thr Lys Glu Arg Gly Gly Val Ala
305          310          315          320
Ile Lys Ile Pro Ile Val Cys Val Val Leu Glu Gly Gly Pro Gly Thr
325          330          335
Leu His Thr Ile Asp Asn Ala Thr Thr Asn Gly Thr Pro Cys Val Val
340          345          350
Val Glu Gly Ser Gly Arg Val Ala Asp Val Ile Ala Gln Val Ala Asn
355          360          365
Leu Pro Val Ser Asp Ile Thr Ile Ser Leu Ile Gln Gln Lys Leu Ser
370          375          380
Val Phe Phe Gln Glu Met Phe Glu Thr Phe Thr Glu Ser Arg Ile Val
385          390          395          400
Glu Trp Thr Lys Lys Ile Gln Asp Ile Val Arg Arg Arg Gln Leu Leu
405          410          415
Thr Val Phe Arg Glu Gly Lys Asp Gly Gln Gln Asp Val Asp Val Ala
420          425          430
Ile Leu Gln Ala Leu Leu Lys Ala Ser Arg Ser Gln Asp His Phe Gly
435          440          445

```

-16-

His Glu Asn Trp Asp His Gln Leu Lys Leu Ala Val Ala Trp Asn Arg  
 450 455 460  
 Val Asp Ile Ala Arg Ser Glu Ile Phe Met Asp Glu Trp Gln Trp Lys  
 465 470 475 480  
 Pro Ser Asp Leu His Pro Thr Met Thr Ala Ala Leu Ile Ser Asn Lys  
 485 490 495  
 Pro Glu Phe Val Lys Leu Phe Leu Glu Asn Gly Val Gln Leu Lys Glu  
 500 505 510  
 Phe Val Thr Trp Asp Thr Leu Leu Tyr Leu Tyr Glu Asn Leu Asp Pro  
 515 520 525  
 Ser Cys Leu Phe His Ser Lys Leu Gln Lys Val Leu Val Glu Asp Pro  
 530 535 540  
 Glu Arg Pro Ala Cys Ala Pro Ala Ala Pro Arg Leu Gln Met His His  
 545 550 555 560  
 Val Ala Gln Val Leu Arg Glu Leu Leu Gly Asp Phe Thr Gln Pro Leu  
 565 570 575  
 Tyr Pro Arg Pro Arg His Asn Asp Arg Leu Arg Leu Leu Leu Pro Val  
 580 585 590  
 Pro His Val Lys Leu Asn Val Gln Gly Val Ser Leu Arg Ser Leu Tyr  
 595 600 605  
 Lys Arg Ser Ser Gly His Val Thr Phe Thr Met Asp Pro Ile Arg Asp  
 610 615 620  
 Leu Leu Ile Trp Ala Ile Val Gln Asn Arg Arg Glu Leu Ala Gly Ile  
 625 630 635 640  
 Ile Trp Ala Gln Ser Gln Asp Cys Ile Ala Ala Ala Leu Ala Cys Ser  
 645 650 655  
 Lys Ile Leu Lys Glu Leu Ser Lys Glu Glu Glu Asp Thr Asp Ser Ser  
 660 665 670  
 Glu Glu Met Leu Ala Leu Ala Glu Glu Tyr Glu His Arg Ala Ile Gly  
 675 680 685  
 Val Phe Thr Glu Cys Tyr Arg Lys Asp Glu Glu Arg Ala Gln Lys Leu  
 690 695 700  
 Leu Thr Arg Val Ser Glu Ala Trp Gly Lys Thr Thr Cys Leu Gln Leu  
 705 710 715 720  
 Ala Leu Glu Ala Lys Asp Met Lys Phe Val Ser His Gly Gly Ile Gln  
 725 730 735  
 Ala Phe Leu Thr Lys Val Trp Trp Gly Gln Leu Ser Val Asp Asn Gly  
 740 745 750  
 Leu Trp Arg Val Thr Leu Cys Met Leu Ala Phe Pro Leu Leu Thr  
 755 760 765  
 Gly Leu Ile Ser Phe Arg Glu Lys Arg Leu Gln Asp Val Gly Thr Pro  
 770 775 780  
 Ala Ala Arg Ala Arg Ala Phe Phe Thr Ala Pro Val Val Val Phe His  
 785 790 795 800  
 Leu Asn Ile Leu Ser Tyr Phe Ala Phe Leu Cys Leu Phe Ala Tyr Val  
 805 810 815  
 Leu Met Val Asp Phe Gln Pro Val Pro Ser Trp Cys Glu Cys Ala Ile  
 820 825 830  
 Tyr Leu Trp Leu Phe Ser Leu Val Cys Glu Glu Met Arg Gln Leu Phe  
 835 840 845  
 Tyr Asp Pro Asp Glu Cys Gly Leu Met Lys Lys Ala Ala Leu Tyr Phe  
 850 855 860  
 Ser Asp Phe Trp Asn Lys Leu Asp Val Gly Ala Ile Leu Leu Phe Val  
 865 870 875 880  
 Ala Gly Leu Thr Cys Arg Leu Ile Pro Ala Thr Leu Tyr Pro Gly Arg  
 885 890 895  
 Val Ile Leu Ser Leu Asp Phe Ile Leu Phe Cys Leu Arg Leu Met His  
 900 905 910  
 Ile Phe Thr Ile Ser Lys Thr Leu Gly Pro Lys Ile Ile Ile Val Lys  
 915 920 925

-17-

Arg Met Met Lys Asp Val Phe Phe Phe Leu Phe Leu Leu Ala Val Trp  
 930 935 940  
 Val Val Ser Phe Gly Val Ala Lys Gln Ala Ile Leu Ile His Asn Glu  
 945 950 955 960  
 Arg Arg Val Asp Trp Leu Phe Arg Gly Ala Val Tyr His Ser Tyr Leu  
 965 970 975  
 Thr Ile Phe Gly Gln Ile Pro Gly Tyr Ile Asp Gly Val Asn Phe Asn  
 980 985 990  
 Pro Glu His Cys Ser Pro Asn Gly Thr Asp Pro Tyr Lys Pro Lys Cys  
 995 1000 1005  
 Pro Glu Ser Asp Ala Thr Gln Gln Arg Pro Ala Phe Pro Glu Trp Leu  
 1010 1015 1020  
 Thr Val Leu Leu Leu Cys Leu Tyr Leu Leu Phe Thr Asn Ile Leu Leu  
 1025 1030 1035 104  
 Leu Asn Leu Leu Ile Ala Met Phe Asn Tyr Thr Phe Gln Gln Val Gln  
 1045 1050 1055  
 Glu His Thr Asp Gln Ile Trp Lys Phe Gln Arg His Asp Leu Ile Glu  
 1060 1065 1070  
 Glu Tyr His Gly Arg Pro Ala Ala Pro Pro Phe Ile Leu Leu Ser  
 1075 1080 1085  
 His Leu Gln Leu Phe Ile Lys Arg Val Val Leu Lys Thr Pro Ala Lys  
 1090 1095 1100  
 Arg His Lys Gln Leu Lys Asn Lys Leu Glu Lys Asn Glu Glu Ala Ala  
 1105 1110 1115 112  
 Leu Leu Ser Trp Glu Ile Tyr Leu Lys Glu Asn Tyr Leu Gln Asn Arg  
 1125 1130 1135  
 Gln Phe Gln Gln Lys Gln Arg Pro Glu Gln Lys Ile Glu Asp Ile Ser  
 1140 1145 1150  
 Asn Lys Val Asp Ala Met Val Asp Leu Leu Asp Leu Asp Pro Leu Lys  
 1155 1160 1165  
 Arg Ser Gly Ser Met Glu Gln Arg Leu Ala Ser Leu Glu Glu Gln Val  
 1170 1175 1180  
 Ala Gln Thr Ala Arg Ala Leu His Trp Ile Val Arg Thr Leu Arg Ala  
 1185 1190 1195 120  
 Ser Gly Phe Ser Ser Glu Ala Asp Val Pro Thr Leu Ala Ser Gln Lys  
 1205 1210 1215  
 Ala Ala Glu Glu Pro Asp Ala Glu Pro Gly Gly Arg Lys Lys Thr Glu  
 1220 1225 1230  
 Glu Pro Gly Asp Ser Tyr His Val Asn Ala Arg His Leu Leu Tyr Pro  
 1235 1240 1245  
 Asn Cys Pro Val Thr Arg Phe Pro Val Pro Asn Glu Lys Val Pro Trp  
 1250 1255 1260  
 Glu Thr Glu Phe Leu Ile Tyr Asp Pro Pro Phe Tyr Thr Ala Glu Arg  
 1265 1270 1275 128  
 Lys Asp Ala Ala Ala Met Asp Pro Met Gly Asp Thr Leu Glu Pro Leu  
 1285 1290 1295  
 Ser Thr Ile Gln Tyr Asn Val Val Asp Gly Leu Arg Asp Arg Arg Ser  
 1300 1305 1310  
 Phe His Gly Pro Tyr Thr Val Gln Ala Gly Leu Pro Leu Asn Pro Met  
 1315 1320 1325  
 Gly Arg Thr Gly Leu Arg Gly Arg Gly Ser Leu Ser Cys Phe Gly Pro  
 1330 1335 1340  
 Asn His Thr Leu Tyr Pro Met Val Thr Arg Trp Arg Arg Asn Glu Asp  
 1345 1350 1355 136  
 Gly Ala Ile Cys Arg Lys Ser Ile Lys Lys Met Leu Glu Val Leu Val  
 1365 1370 1375  
 Val Lys Leu Pro Leu Ser Glu His Trp Ala Leu Pro Gly Gly Ser Arg  
 1380 1385 1390  
 Glu Pro Gly Glu Met Leu Pro Arg Lys Leu Lys Arg Ile Leu Arg Gln  
 1395 1400 1405

-18-

Glu His Trp Pro Ser Phe Glu Asn Leu Leu Lys Cys Gly Met Glu Val  
 1410 1415 1420  
 Tyr Lys Gly Tyr Met Asp Asp Pro Arg Asn Thr Asp Asn Ala Trp Ile  
 1425 1430 1435 144  
 Glu Thr Val Ala Val Ser Val His Phe Gln Asp Gln Asn Asp Val Glu  
 1445 1450 1455  
 Leu Asn Arg Leu Asn Ser Asn Leu His Ala Cys Asp Ser Gly Ala Ser  
 1460 1465 1470  
 Ile Arg Trp Gln Val Val Asp Arg Arg Ile Pro Leu Tyr Ala Asn His  
 1475 1480 1485  
 Lys Thr Leu Leu Gln Lys Ala Ala Glu Phe Gly Ala His Tyr  
 1490 1495 1500

<210> 13  
 <211> 1816  
 <212> PRT  
 <213> C. Elegans

<400> 13  
 Met Ile Thr Asp Lys Asn Leu Phe Ser Arg Leu Leu Ile Lys Lys Asn  
 1 5 10 15  
 Pro Ile Arg Met His Ser Pro Ser Phe Ser Phe Ser Leu Ile Thr Ser  
 20 25 30  
 Leu Phe Phe Thr Gln Phe Phe Met Phe Gln Leu Ser Ser Met Ala Tyr  
 35 40 45  
 Phe Phe Leu Thr Leu Ile Ala Gly Val Thr His Phe Tyr Phe Pro Glu  
 50 55 60  
 Lys Leu Leu Gly Lys Ser Glu Asn Leu Asp His Arg Tyr Gln Ser Ser  
 65 70 75 80  
 Glu Gln Lys Val Leu Ile Glu Trp Thr Glu Asn Lys Ala Val Ala Glu  
 85 90 95  
 Ser Leu Arg Ala Asn Ser Val Thr Val Glu Glu Asn Glu Ser Glu Arg  
 100 105 110  
 Glu Thr Glu Thr Gln Thr Lys Arg Arg Arg Lys Lys Gln Arg Ser Thr  
 115 120 125  
 Ser Ser Asp Lys Ala Pro Leu Asn Ser Ala Pro Arg His Val Gln Lys  
 130 135 140  
 Phe Asp Trp Lys Asp Met Leu His Leu Ala Asp Ile Ser Gly Arg Lys  
 145 150 155 160  
 Arg Gly Asn Ser Thr Thr Ser His Ser Gly His Ala Thr Arg Ala Gly  
 165 170 175  
 Ser Leu Lys Gly Lys Asn Trp Ile Glu Cys Arg Leu Lys Met Arg Gln  
 180 185 190  
 Cys Ser Tyr Phe Val Pro Ser Gln Arg Phe Ser Glu Arg Cys Gly Cys  
 195 200 205  
 Gly Lys Glu Arg Ser Lys His Thr Glu Glu Val Leu Glu Arg Ser Gln  
 210 215 220  
 Asn Lys Asn His Pro Leu Asn His Leu Thr Leu Pro Gly Ile His Glu  
 225 230 235 240  
 Val Asp Thr Thr Asp Ala Asp Ala Asp Asn Glu Val Asn Leu Thr  
 245 250 255  
 Pro Gly Arg Trp Ser Ile Gln Ser His Thr Glu Ile Val Pro Thr Asp  
 260 265 270  
 Ala Tyr Gly Asn Ile Val Phe Glu Gly Thr Ala His His Ala Gln Tyr  
 275 280 285  
 Ala Arg Ile Ser Phe Asp Ser Asp Pro Arg Asp Ile Val His Leu Met  
 290 295 300  
 Met Lys Val Trp Lys Leu Lys Pro Pro Lys Leu Ile Ile Thr Ile Asn  
 305 310 315 320  
 Gly Gly Leu Thr Lys Phe Asp Leu Gln Pro Lys Leu Ala Arg Thr Phe

-19-

325 330 335  
 Arg Lys Gly Ile Met Lys Ile Ala Lys Ser Thr Asp Ala Trp Ile Ile  
 340 345 350  
 Thr Ser Gly Leu Asp Glu Gly Val Val Lys His Leu Asp Ser Ala Leu  
 355 360 365  
 His Ala Leu Glu Phe Trp Ser Phe Gly Leu Phe Trp Val Ile Gln Leu  
 370 375 380  
 Asp Val Leu Leu Ala His Ser Met Phe Ile Pro Arg Gly Ser Leu Phe  
 385 390 395 400  
 Asp His Gly Asn His Thr Ser Lys Asn His Val Val Ala Ile Gly Ile  
 405 410 415  
 Ala Ser Trp Gly Met Leu Lys Gln Arg Ser Arg Phe Val Gly Lys Asp  
 420 425 430  
 Ser Thr Val Thr Tyr Ala Thr Asn Val Phe Asn Asn Thr Arg Leu Lys  
 435 440 445  
 Glu Leu Asn Asp Asn His Ser Tyr Phe Leu Phe Ser Asp Asn Gly Thr  
 450 455 460  
 Val Asn Arg Tyr Gly Ala Glu Ile Ile Met Arg Lys Arg Leu Glu Ala  
 465 470 475 480  
 Tyr Leu Ala Gln Gly Asp Lys Lys Arg Ser Ala Ile Pro Leu Val Cys  
 485 490 495  
 Val Val Leu Glu Gly Gly Ala Phe Thr Ile Lys Met Val His Asp Tyr  
 500 505 510  
 Val Thr Thr Ile Pro Arg Ile Pro Val Ile Val Cys Asp Gly Ser Gly  
 515 520 525  
 Arg Ala Ala Asp Ile Leu Ala Phe Ala His Gln Ala Val Ser Gln Asn  
 530 535 540  
 Gly Phe Leu Ser Asp Asn Ile Arg Asn Gln Leu Val Asn Ile Val Arg  
 545 550 555 560  
 Arg Ile Phe Gly Tyr Asp Pro Lys Thr Ala Gln Lys Leu Ile Lys Gln  
 565 570 575  
 Ile Val Glu Cys Ser Thr Asn Lys Ser Leu Met Thr Ile Phe Arg Leu  
 580 585 590  
 Gly Glu Ser Ser Arg Glu Asp Leu Asp His Val Ile Met Ser Cys Leu  
 595 600 605  
 Leu Lys Gly Gln Asn Leu Ser Pro Pro Glu Gln Leu Gln Leu Ala Leu  
 610 615 620  
 Ala Trp Asn Arg Ala Asp Ile Ala Arg Thr Glu Ile Phe Ala Asn Gly  
 625 630 635 640  
 Thr Glu Trp Thr Thr Gln Asp Leu His Asn Ala Met Ile Glu Ala Leu  
 645 650 655  
 Ser Asn Asp Arg Ile Asp Phe Val His Leu Leu Leu Glu Asn Gly Val  
 660 665 670  
 Ser Met Gln Lys Phe Leu Thr Tyr Gly Arg Leu Glu His Leu Tyr Asn  
 675 680 685  
 Thr Asp Lys Gly Pro Gln Asn Thr Leu Arg Thr Asn Leu Leu Val Asp  
 690 695 700  
 Ser Lys His His Ile Lys Leu Val Glu Val Gly Arg Leu Val Glu Asn  
 705 710 715 720  
 Leu Met Gly Asn Leu Tyr Lys Ser Asn Tyr Thr Lys Glu Glu Phe Lys  
 725 730 735  
 Asn Gln Tyr Phe Leu Phe Asn Asn Arg Lys Gln Phe Gly Lys Arg Val  
 740 745 750  
 His Ser Asn Ser Asn Gly Gly Arg Asn Asp Val Ile Gly Pro Ser Gly  
 755 760 765  
 Asp Ala Gly Arg Glu Arg Met Ser Ser Met Gln Ile Ser Leu Ile Asn  
 770 775 780  
 Asn Ala Arg Asn Ser Ile Ile Ser Leu Phe Asn Gly Gly Gly Arg Lys  
 785 790 795 800  
 Arg Glu Ser Asp Asp Glu Asp Asp Phe Ser Asn Leu Glu Glu Glu Ala

-20-

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |     |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----|
|      |      |      |      | 805  |      |      |      |      | 810  |      |      |      |      | 815  |     |
| Asn  | Met  | Asp  | Phe  | Thr  | Phe  | Arg  | Tyr  | Pro  | Tyr  | Ser  | Asp  | Leu  | Met  | Ile  | Trp |
|      |      |      | 820  |      |      |      |      |      | 825  |      |      |      | 830  |      |     |
| Ala  | Val  | Leu  | Thr  | Lys  | Arg  | Gln  | Lys  | Met  | Ala  | Lys  | Leu  | Met  | Trp  | Thr  | His |
|      |      | 835  |      |      |      |      | 840  |      |      |      |      | 845  |      |      |     |
| Gly  | Glu  | Glu  | Gly  | Met  | Ala  | Lys  | Ala  | Leu  | Val  | Ala  | Ser  | Arg  | Leu  | Tyr  | Val |
|      | 850  |      |      |      |      | 855  |      |      |      |      | 860  |      |      |      |     |
| Ser  | Leu  | Ala  | Lys  | Thr  | Ala  | Ser  | Leu  | Ala  | Thr  | Gly  | Glu  | Ile  | Gly  | Met  | Ser |
| 865  |      |      |      | 870  |      |      |      |      |      | 875  |      |      |      | 880  |     |
| Gln  | Asp  | Phe  | Thr  | Glu  | Phe  | Ser  | Asp  | Glu  | Phe  | Ser  | Glu  | Leu  | Ala  | Val  | Glu |
|      |      |      | 885  |      |      |      |      |      | 890  |      |      |      |      | 895  |     |
| Val  | Leu  | Glu  | Tyr  | Cys  | Thr  | Lys  | His  | Gly  | Arg  | Asp  | Gln  | Thr  | Leu  | Arg  | Leu |
|      |      | 900  |      |      |      |      |      | 905  |      |      |      |      | 910  |      |     |
| Leu  | Thr  | Cys  | Glu  | Leu  | Ala  | Asn  | Trp  | Gly  | Asp  | Glu  | Thr  | Cys  | Leu  | Ser  | Leu |
|      | 915  |      |      |      |      | 920  |      |      |      |      |      | 925  |      |      |     |
| Ala  | Ala  | Asn  | Asn  | Gly  | His  | Arg  | Lys  | Phe  | Leu  | Ala  | His  | Pro  | Cys  | Cys  | Gln |
|      | 930  |      |      |      |      | 935  |      |      |      |      | 940  |      |      |      |     |
| Met  | Leu  | Leu  | Ser  | Asp  | Leu  | Trp  | Gln  | Gly  | Gly  | Leu  | Leu  | Met  | Lys  | Asn  | Asn |
| 945  |      |      |      |      | 950  |      |      |      |      | 955  |      |      |      |      | 960 |
| Gln  | Asn  | Ser  | Lys  | Val  | Leu  | Thr  | Cys  | Leu  | Ala  | Ala  | Pro  | Pro  | Leu  | Ile  | Phe |
|      |      |      | 965  |      |      |      |      |      | 970  |      |      |      |      | 975  |     |
| Leu  | Leu  | Gly  | Phe  | Lys  | Thr  | Lys  | Glu  | Gln  | Leu  | Met  | Leu  | Gln  | Pro  | Lys  | Thr |
|      |      | 980  |      |      |      |      |      | 985  |      |      |      |      | 990  |      |     |
| Ala  | Ala  | Glu  | His  | Asp  | Glu  | Glu  | Met  | Ser  | Asp  | Ser  | Glu  | Met  | Asn  | Ser  | Ala |
|      | 995  |      |      |      |      |      | 1000 |      |      |      |      | 1005 |      |      |     |
| Glu  | Asp  | Thr  | Asp  | Thr  | Ser  | Ser  | Asp  | Ser  | Ser  | Ser  | Asp  | Ser  | Asp  | Asp  | Ser |
|      | 1010 |      |      |      |      | 1015 |      |      |      |      | 1020 |      |      |      |     |
| Asp  | Glu  | Glu  | Asp  | Ala  | Lys  | Leu  | Arg  | Ala  | Gln  | Ser  | Leu  | Ser  | Ala  | Asp  | Gln |
| 1025 |      |      |      |      | 1030 |      |      |      |      | 1035 |      |      |      |      | 104 |
| Pro  | Leu  | Ser  | Ile  | His  | Arg  | Leu  | Val  | Arg  | Asp  | Lys  | Leu  | Asn  | Phe  | Ser  | Glu |
|      |      |      | 1045 |      |      |      |      |      | 1050 |      |      |      |      | 1055 |     |
| Lys  | Lys  | Lys  | Pro  | Asp  | Met  | Gly  | Ile  | Ser  | Arg  | Ile  | Val  | Val  | Ala  | Pro  | Pro |
|      |      | 1060 |      |      |      |      |      | 1065 |      |      |      |      | 1070 |      |     |
| Ile  | Val  | Thr  | Gly  | Arg  | Asn  | Arg  | Ala  | Arg  | Thr  | Met  | Ser  | Ile  | Lys  | Lys  | Ser |
|      | 1075 |      |      |      |      |      | 1080 |      |      |      |      | 1085 |      |      |     |
| Lys  | Lys  | Asn  | Val  | Ile  | Lys  | Pro  | Pro  | Ala  | Cys  | Leu  | Lys  | Ile  | Glu  | Thr  | Ser |
|      | 1090 |      |      |      |      | 1095 |      |      |      |      | 1100 |      |      |      |     |
| Asp  | Asp  | Asp  | Glu  | Gln  | Glu  | Gln  | Lys  | Lys  | Ala  | Thr  | Glu  | Met  | Cys  | Lys  | Ser |
| 1105 |      |      |      | 1110 |      |      |      |      |      | 1115 |      |      |      |      | 112 |
| Thr  | Phe  | Phe  | Asp  | Phe  | Phe  | Phe  | Asp  | Phe  | Pro  | Tyr  | Ile  | Asn  | Arg  | Thr  | Gly |
|      |      |      | 1125 |      |      |      |      |      | 1130 |      |      |      |      | 1135 |     |
| Lys  | Arg  | Gly  | Ser  | Val  | Ala  | Val  | Ala  | Met  | Asn  | His  | Asp  | Asp  | Met  | Tyr  | Ile |
|      |      | 1140 |      |      |      |      |      | 1145 |      |      |      |      | 1150 |      |     |
| Asp  | Pro  | Ser  | Glu  | Glu  | Leu  | Asp  | Thr  | Gln  | Thr  | Arg  | Gln  | Lys  | Ser  | Ser  | Arg |
|      | 1155 |      |      |      |      | 1160 |      |      |      |      |      | 1165 |      |      |     |
| Glu  | Phe  | Ser  | Ser  | Ser  | Arg  | Asn  | Val  | Thr  | Val  | Gln  | Val  | Tyr  | Thr  | Gln  | Arg |
|      | 1170 |      |      |      |      | 1175 |      |      |      |      | 1180 |      |      |      |     |
| Pro  | Leu  | Ser  | Trp  | Lys  | Lys  | Lys  | Ile  | Met  | Glu  | Phe  | Tyr  | Lys  | Ala  | Pro  | Ile |
| 1185 |      |      |      | 1190 |      |      |      |      |      | 1195 |      |      |      |      | 120 |
| Thr  | Thr  | Tyr  | Trp  | Leu  | Trp  | Phe  | Phe  | Ala  | Phe  | Ile  | Trp  | Phe  | Leu  | Ile  | Leu |
|      |      |      | 1205 |      |      |      |      |      | 1210 |      |      |      |      | 1215 |     |
| Leu  | Thr  | Tyr  | Asn  | Leu  | Leu  | Val  | Lys  | Thr  | Gln  | Arg  | Ile  | Ala  | Ser  | Trp  | Ser |
|      |      | 1220 |      |      |      |      |      |      | 1225 |      |      |      | 1230 |      |     |
| Glu  | Trp  | Tyr  | Val  | Phe  | Ala  | Tyr  | Ile  | Phe  | Val  | Trp  | Thr  | Leu  | Glu  | Ile  | Gly |
|      | 1235 |      |      |      |      |      | 1240 |      |      |      |      | 1245 |      |      |     |
| Arg  | Lys  | Val  | Val  | Ser  | Thr  | Ile  | Met  | Met  | Asp  | Thr  | Ser  | Lys  | Pro  | Val  | Leu |
|      | 1250 |      |      |      |      | 1255 |      |      |      |      |      | 1260 |      |      |     |
| Lys  | Gln  | Leu  | Arg  | Val  | Phe  | Phe  | Phe  | Gln  | Tyr  | Arg  | Asn  | Gly  | Leu  | Leu  | Ala |
| 1265 |      |      |      | 1270 |      |      |      |      |      | 1275 |      |      |      |      | 128 |
| Phe  | Gly  | Leu  | Leu  | Thr  | Tyr  | Leu  | Ile  | Ala  | Tyr  | Phe  | Ile  | Arg  | Leu  | Ser  | Pro |

-21-

|      |     |     |     |      |      |     |     |     |      |      |     |     |     |      |     |
|------|-----|-----|-----|------|------|-----|-----|-----|------|------|-----|-----|-----|------|-----|
|      |     |     |     | 1285 |      |     |     |     | 1290 |      |     |     |     | 1295 |     |
| Thr  | Thr | Lys | Thr | Leu  | Gly  | Arg | Ile | Leu | Ile  | Ile  | Cys | Asn | Ser | Val  | Ile |
|      |     |     |     | 1300 |      |     |     |     | 1305 |      |     |     |     | 1310 |     |
| Trp  | Ser | Leu | Lys | Leu  | Val  | Asp | Tyr | Leu | Ser  | Val  | Gln | Gln | Gly | Leu  | Gly |
|      |     |     |     | 1315 |      |     |     |     | 1320 |      |     |     |     | 1325 |     |
| Pro  | Tyr | Ile | Asn | Ile  | Val  | Ala | Glu | Met | Ile  | Pro  | Thr | Met | Ile | Pro  | Leu |
|      |     |     |     | 1330 |      |     |     |     | 1335 |      |     |     |     | 1340 |     |
| Cys  | Val | Leu | Val | Phe  | Ile  | Thr | Leu | Tyr | Ala  | Phe  | Gly | Leu | Leu | Arg  | Gln |
| 1345 |     |     |     |      | 1350 |     |     |     |      | 1355 |     |     |     |      | 136 |
| Ser  | Ile | Thr | Tyr | Pro  | Tyr  | Glu | Asp | Trp | His  | Trp  | Ile | Leu | Val | Arg  | Asn |
|      |     |     |     | 1365 |      |     |     |     | 1370 |      |     |     |     | 1375 |     |
| Ile  | Phe | Leu | Gln | Pro  | Tyr  | Phe | Met | Leu | Tyr  | Gly  | Glu | Val | Tyr | Ala  | Ala |
|      |     |     |     | 1380 |      |     |     |     | 1385 |      |     |     |     | 1390 |     |
| Glu  | Ile | Asp | Thr | Cys  | Gly  | Asp | Glu | Ile | Trp  | Gln  | Thr | His | Glu | Asp  | Glu |
|      |     |     |     | 1395 |      |     |     |     | 1400 |      |     |     |     | 1405 |     |
| Asn  | Ile | Pro | Ile | Ser  | Met  | Leu | Asn | Val | Thr  | His  | Glu | Thr | Cys | Val  | Pro |
|      |     |     |     | 1410 |      |     |     |     | 1415 |      |     |     |     | 1420 |     |
| Gly  | Tyr | Trp | Ile | Ala  | Pro  | Val | Gly | Leu | Thr  | Val  | Phe | Met | Leu | Ala  | Thr |
| 1425 |     |     |     |      | 1430 |     |     |     |      | 1435 |     |     |     |      | 144 |
| Asn  | Val | Leu | Leu | Met  | Asn  | Val | Met | Val | Ala  | Gly  | Cys | Thr | Tyr | Ile  | Phe |
|      |     |     |     | 1445 |      |     |     |     | 1450 |      |     |     |     | 1455 |     |
| Glu  | Lys | His | Ile | Gln  | Ser  | Thr | Arg | Glu | Ile  | Phe  | Leu | Phe | Glu | Arg  | Tyr |
|      |     |     |     | 1460 |      |     |     |     | 1465 |      |     |     |     | 1470 |     |
| Gly  | Gln | Val | Met | Glu  | Tyr  | Glu | Ser | Thr | Pro  | Trp  | Leu | Pro | Pro | Pro  | Phe |
|      |     |     |     | 1475 |      |     |     |     | 1480 |      |     |     |     | 1485 |     |
| Thr  | Ile | Ile | Tyr | His  | Val  | Ile | Trp | Leu | Phe  | Lys  | Leu | Ile | Lys | Ser  | Ser |
|      |     |     |     | 1490 |      |     |     |     | 1495 |      |     |     |     | 1500 |     |
| Ser  | Arg | Met | Phe | Glu  | Arg  | Lys | Asn | Leu | Phe  | Asp  | Gln | Ser | Leu | Lys  | Leu |
| 1505 |     |     |     |      | 1510 |     |     |     |      | 1515 |     |     |     |      | 152 |
| Phe  | Leu | Ser | Pro | Asp  | Glu  | Met | Glu | Lys | Val  | His  | Thr | Phe | Glu | Glu  | Glu |
|      |     |     |     | 1525 |      |     |     |     | 1530 |      |     |     |     | 1535 |     |
| Ser  | Val | Glu | Asp | Met  | Lys  | Arg | Glu | Thr | Glu  | Lys  | Lys | Asn | Leu | Ser  | Ser |
|      |     |     |     | 1540 |      |     |     |     | 1545 |      |     |     |     | 1550 |     |
| Asn  | Asp | Glu | Arg | Ile  | His  | Arg | Thr | Ala | Glu  | Arg  | Thr | Asp | Ala | Ile  | Leu |
|      |     |     |     | 1555 |      |     |     |     | 1560 |      |     |     |     | 1565 |     |
| Asn  | Arg | Val | Ser | His  | Leu  | Thr | Gln | Leu | Glu  | Phe  | Thr | Leu | Lys | Glu  | Glu |
|      |     |     |     | 1570 |      |     |     |     | 1575 |      |     |     |     | 1580 |     |
| Ile  | Arg | Glu | Leu | Glu  | His  | Lys | Met | Lys | Asn  | Met  | Asp | Ser | Arg | His  | Lys |
| 1585 |     |     |     |      | 1590 |     |     |     |      | 1595 |     |     |     |      | 160 |
| Glu  | Gln | Met | Asn | Leu  | Met  | Leu | Asp | Met | Asn  | Lys  | Lys | Leu | Gly | Lys  | Phe |
|      |     |     |     | 1605 |      |     |     |     | 1610 |      |     |     |     | 1615 |     |
| Ile  | Ser | Gly | Lys | Tyr  | Lys  | Arg | Gly | Ser | Phe  | Gly  | Gly | Ser | Gly | Ser  | Asp |
|      |     |     |     | 1620 |      |     |     |     | 1625 |      |     |     |     | 1630 |     |
| Gly  | Gly | Gly | Gly | Ser  | Ser  | Asp | Asn | Ser | Lys  | Leu  | Glu | Pro | Asn | Asn  | Ser |
|      |     |     |     | 1635 |      |     |     |     | 1640 |      |     |     |     | 1645 |     |
| Val  | Pro | Met | Ile | Thr  | Val  | Asp | Gly | Pro | Ser  | Pro  | Ile | Gly | Ser | Arg  | Arg |
|      |     |     |     | 1650 |      |     |     |     | 1655 |      |     |     |     | 1660 |     |
| Thr  | Ser | Gly | Gln | Tyr  | Leu  | Lys | Arg | Asp | Ser  | Leu  | Gln | Ala | Lys | Lys  | Lys |
| 1665 |     |     |     |      | 1670 |     |     |     |      | 1675 |     |     |     |      | 168 |
| Ile  | Thr | Glu | Asn | Arg  | Arg  | Ser | Ser | Leu | Glu  | Gln  | Pro | Lys | Ile | Pro  | Ser |
|      |     |     |     | 1685 |      |     |     |     | 1690 |      |     |     |     | 1695 |     |
| Ile  | Gln | Phe | Asn | Leu  | Met  | Glu | Asp | Gln | Asp  | Glu  | Ser | Ala | Ala | Glu  | Ser |
|      |     |     |     | 1700 |      |     |     |     | 1705 |      |     |     |     | 1710 |     |
| Ala  | Thr | Glu | Glu | Val  | Ser  | Ile | Ser | Ile | Pro  | Val  | Pro | Gln | Met | Arg  | Val |
|      |     |     |     | 1715 |      |     |     |     | 1720 |      |     |     |     | 1725 |     |
| Arg  | Gln | Val | Thr | Glu  | Ser  | Asp | Lys | Ser | Asp  | Leu  | Ser | Glu | Asp | Asp  | Leu |
|      |     |     |     | 1730 |      |     |     |     | 1735 |      |     |     |     | 1740 |     |
| Ile  | Thr | Arg | Glu | Asp  | Ala  | Pro | Pro | Thr | Ser  | Ile  | Asn | Leu | Pro | Arg  | Gly |
| 1745 |     |     |     |      | 1750 |     |     |     |      | 1755 |     |     |     |      | 176 |
| Pro  | Arg | Arg | His | Ala  | Leu  | Tyr | Ser | Thr | Ile  | Ala  | Asp | Ala | Ile | Glu  | Thr |



-22-

1765 1770 1775  
 Glu Asp Asp Phe Tyr Ala Asp Ser Pro Val Pro Met Pro Met Thr Pro  
 1780 1785 1790  
 Val Gln Pro Ala Asp Gly Ser Phe Phe Gly Glu Asn Asp Ser Arg Tyr  
 1795 1800 1805  
 Gln Arg Asp Asp Ser Asp Tyr Glu  
 1810 1815

<210> 14  
 <211> 1387  
 <212> PRT  
 <213> C. Elegans

<400> 14  
 Met Arg Lys Ser Arg Arg Val Arg Lys Leu Val Arg His Ala Ser Leu  
 1 5 10 15  
 Ile Glu Asn Ile Arg His Arg Thr Ser Phe Leu Arg Leu Asn  
 20 25 30  
 Ala Pro Arg Asn Ser Met Cys Asn Ala Asn Thr Val His Ser Ile Ser  
 35 40 45  
 Ser Phe Arg Ser Asp His Leu Ser Arg Lys Ser Thr His Lys Phe Leu  
 50 55 60  
 Asp Asn Pro Asn Leu Phe Ala Ile Glu Leu Thr Glu Lys Leu Ser Pro  
 65 70 75 80  
 Pro Trp Ile Glu Asn Thr Phe Glu Lys Arg Glu Cys Ile Arg Phe Ala  
 85 90 95  
 Ala Leu Pro Lys Asp Pro Glu Arg Cys Gly Cys Gly Arg Pro Leu Ser  
 100 105 110  
 Ala His Thr Pro Ala Ser Thr Phe Ser Thr Leu Pro Val His Leu  
 115 120 125  
 Leu Glu Lys Glu Gln Gln Thr Trp Thr Ile Ala Asn Asn Thr Gln Thr  
 130 135 140  
 Ser Thr Thr Asp Ala Phe Gly Thr Ile Val Phe Gln Gly Gly Ala His  
 145 150 155 160  
 Ala His Lys Ala Gln Tyr Val Arg Leu Ser Tyr Asp Ser Glu Pro Leu  
 165 170 175  
 Asp Val Met Tyr Leu Met Glu Lys Val Trp Gly Leu Glu Ala Pro Arg  
 180 185 190  
 Leu Val Ile Thr Val His Gly Gly Met Ser Asn Phe Glu Leu Glu Glu  
 195 200 205  
 Arg Leu Gly Arg Leu Phe Arg Lys Gly Met Leu Lys Ala Ala Gln Thr  
 210 215 220  
 Thr Gly Ala Trp Ile Ile Thr Ser Gly Leu Asp Ser Gly Val Val Arg  
 225 230 235 240  
 His Val Ala Lys Ala Leu Asp Glu Ala Gly Ile Ser Ala Arg Met Arg  
 245 250 255  
 Ser Gln Ile Val Thr Ile Gly Ile Ala Pro Trp Gly Val Ile Lys Arg  
 260 265 270  
 Lys Glu Arg Leu Ile Arg Gln Asn Glu His Val Tyr Tyr Asp Val His  
 275 280 285  
 Ser Leu Ser Val Asn Ala Asn Val Gly Ile Leu Asn Asp Arg His Ser  
 290 295 300  
 Tyr Phe Leu Leu Ala Asp Asn Gly Thr Val Gly Arg Phe Gly Ala Asp  
 305 310 315 320  
 Leu His Leu Arg Gln Asn Leu Glu Asn His Ile Ala Thr Phe Gly Cys  
 325 330 335  
 Asn Gly Arg Lys Val Pro Val Val Cys Thr Leu Leu Glu Gly Gly Ile  
 340 345 350  
 Ser Ser Ile Asn Ala Ile His Asp Tyr Val Thr Met Lys Pro Asp Ile  
 355 360 365

-23-

Pro Ala Ile Val Cys Asp Gly Ser Gly Arg Ala Ala Asp Ile Ile Ser  
 370 375 380  
 Phe Ala Ala Arg Tyr Ile Asn Ser Asp Gly Thr Phe Ala Ala Glu Val  
 385 390 395 400  
 Gly Glu Lys Leu Arg Asn Leu Ile Lys Met Val Phe Pro Glu Thr Asp  
 405 410 415  
 Gln Glu Glu Met Phe Arg Lys Ile Thr Glu Cys Val Ile Arg Asp Asp  
 420 425 430  
 Leu Leu Arg Ile Phe Arg Tyr Gly Gln Glu Glu Glu Glu Asp Val Asp  
 435 440 445  
 Phe Val Ile Leu Ser Thr Val Leu Gln Lys Gln Asn Leu Pro Pro Asp  
 450 455 460  
 Glu Gln Leu Ala Leu Thr Leu Ser Trp Asn Arg Val Asp Leu Ala Lys  
 465 470 475 480  
 Ser Cys Leu Phe Ser Asn Gly Arg Lys Trp Ser Ser Asp Val Leu Glu  
 485 490 495  
 Lys Ala Met Asn Asp Ala Leu Tyr Trp Asp Arg Val Asp Phe Val Glu  
 500 505 510  
 Cys Leu Leu Glu Asn Gly Val Ser Met Lys Asn Phe Leu Ser Ile Asn  
 515 520 525  
 Arg Leu Glu Asn Leu Tyr Asn Met Asp Asp Ile Asn Ser Ala His Ser  
 530 535 540  
 Val Arg Asn Trp Met Glu Asn Phe Asp Ser Met Asp Pro His Thr Tyr  
 545 550 555 560  
 Leu Thr Ile Pro Met Ile Gly Gln Val Val Glu Lys Leu Met Gly Asn  
 565 570 575  
 Ala Phe Gln Leu Tyr Tyr Thr Ser Arg Ser Phe Lys Gly Lys Tyr Asp  
 580 585 590  
 Arg Tyr Lys Arg Ile Asn Gln Ser Ser Tyr Phe His Arg Lys Arg Lys  
 595 600 605  
 Ile Val Gln Lys Glu Leu Phe Lys Lys Lys Ser Asp Asp Gln Ile Asn  
 610 615 620  
 Asp Asn Glu Glu Glu Asp Phe Ser Phe Ala Tyr Pro Phe Asn Asp Leu  
 625 630 635 640  
 Leu Ile Trp Ala Val Leu Thr Ser Arg His Gly Met Ala Glu Cys Met  
 645 650 655  
 Trp Val His Gly Glu Asp Ala Met Ala Lys Cys Leu Leu Ala Ile Arg  
 660 665 670  
 Leu Tyr Lys Ala Thr Ala Lys Ile Ala Glu Asp Glu Tyr Leu Asp Val  
 675 680 685  
 Glu Glu Ala Lys Arg Leu Phe Asp Asn Ala Val Lys Cys Arg Glu Asp  
 690 695 700  
 Ala Ile Glu Leu Leu Asp Gln Cys Tyr Arg Ala Asp His Asp Arg Thr  
 705 710 715 720  
 Leu Arg Leu Leu Arg Met Glu Leu Pro His Trp Gly Asn Asn Asn Cys  
 725 730 735  
 Leu Ser Leu Ala Val Leu Ala Asn Thr Lys Thr Phe Leu Ala His Pro  
 740 745 750  
 Cys Cys Gln Ile Leu Leu Ala Glu Leu Trp His Gly Ser Leu Lys Val  
 755 760 765  
 Arg Ser Gly Ser Asn Val Arg Val Leu Thr Ala Leu Ile Cys Pro Pro  
 770 775 780  
 Ala Ile Leu Phe Met Ala Tyr Lys Pro Lys His Ser Lys Thr Ala Arg  
 785 790 795 800  
 Leu Leu Ser Glu Glu Thr Pro Glu Gln Leu Pro Tyr Pro Arg Glu Ser  
 805 810 815  
 Ile Thr Ser Thr Thr Ser Asn Arg Tyr Arg Tyr Ser Lys Gly Pro Glu  
 820 825 830  
 Glu Gln Lys Glu Thr Leu Leu Glu Lys Gly Ser Tyr Thr Lys Lys Val  
 835 840 845

-24-

Thr Ile Ile Ser Ser Arg Lys Asn Ser Gly Val Ala Ser Val Tyr Gly  
 850 855 860  
 Ser Ala Ser Ser Met Met Phe Lys Arg Glu Pro Gln Leu Asn Lys Phe  
 865 870 875 880  
 Glu Arg Phe Arg Ala Phe Tyr Ser Ser Pro Ile Thr Lys Phe Trp Ser  
 885 890 895  
 Trp Cys Ile Ala Phe Leu Ile Phe Leu Thr Thr Gln Thr Cys Ile Leu  
 900 905 910  
 Leu Leu Glu Thr Ser Leu Lys Pro Ser Lys Tyr Glu Trp Ile Thr Phe  
 915 920 925  
 Ile Tyr Thr Val Thr Leu Ser Val Glu His Ile Arg Lys Leu Met Thr  
 930 935 940  
 Ser Glu Gly Ser Arg Ile Asn Glu Lys Val Lys Val Phe Tyr Ala Lys  
 945 950 955 960  
 Trp Tyr Asn Ile Trp Thr Ser Ala Ala Leu Leu Phe Phe Leu Val Gly  
 965 970 975  
 Tyr Gly Phe Arg Leu Val Pro Met Tyr Arg His Ser Trp Gly Arg Val  
 980 985 990  
 Leu Leu Ser Phe Ser Asn Val Leu Phe Tyr Met Lys Ile Phe Glu Tyr  
 995 1000 1005  
 Leu Ser Val His Pro Leu Leu Gly Pro Tyr Ile Gln Met Ala Ala Lys  
 1010 1015 1020  
 Met Val Trp Ser Met Cys Tyr Ile Cys Val Leu Leu Leu Val Pro Leu  
 1025 1030 1035 104  
 Met Ala Phe Gly Val Asn Arg Gln Ala Leu Thr Glu Pro Asn Val Lys  
 1045 1050 1055  
 Asp Trp His Trp Leu Leu Val Arg Asn Ile Phe Tyr Lys Pro Tyr Phe  
 1060 1065 1070  
 Met Leu Tyr Gly Glu Val Tyr Ala Gly Glu Ile Asp Thr Cys Gly Asp  
 1075 1080 1085  
 Glu Gly Ile Arg Cys Phe Pro Gly Tyr Phe Ile Pro Pro Leu Leu Met  
 1090 1095 1100  
 Val Ile Phe Leu Leu Val Ala Asn Ile Leu Leu Leu Asn Leu Leu Ile  
 1105 1110 1115 112  
 Ala Ile Phe Asn Asn Ile Tyr Asn Asp Ser Ile Glu Lys Ser Lys Glu  
 1125 1130 1135  
 Ile Trp Leu Phe Gln Arg Tyr Gln Gln Leu Met Glu Tyr His Asp Ser  
 1140 1145 1150  
 Pro Phe Leu Pro Pro Pro Phe Ser Ile Phe Ala His Val Tyr His Phe  
 1155 1160 1165  
 Ile Asp Tyr Leu Tyr Asn Leu Arg Arg Pro Asp Thr Lys Arg Phe Arg  
 1170 1175 1180  
 Ser Glu His Ser Ile Lys Leu Ser Val Thr Glu Asp Glu Met Lys Arg  
 1185 1190 1195 120  
 Ile Gln Asp Phe Glu Glu Asp Cys Ile Asp Thr Leu Thr Arg Ile Arg  
 1205 1210 1215  
 Lys Leu Lys Leu Asn Thr Lys Glu Pro Leu Ser Val Thr Asp Leu Thr  
 1220 1225 1230  
 Glu Leu Thr Cys Gln Arg Val His Asp Leu Met Gln Glu Asn Phe Leu  
 1235 1240 1245  
 Leu Lys Ser Arg Val Tyr Asp Ile Glu Thr Lys Ile Asp His Ile Ser  
 1250 1255 1260  
 Asn Ser Ser Asp Glu Val Val Gln Ile Leu Lys Asn Lys Lys Leu Ser  
 1265 1270 1275 128  
 Gln Asn Phe Ala Ala Ser Ser Leu Ser Leu Pro Asp Thr Ser Ile Glu  
 1285 1290 1295  
 Val Pro Lys Ile Thr Lys Thr Leu Ile Asp Cys His Leu Ser Pro Val  
 1300 1305 1310  
 Ser Ile Glu Asp Arg Leu Ala Thr Arg Ser Pro Leu Leu Ala Asn Leu  
 1315 1320 1325

-25-

Gln Arg Asp His Thr Leu Arg Lys Leu Pro Thr Trp Glu Thr Ser Thr  
 1330 1335 1340  
 Ala Ser Thr Ser Ser Phe Glu Phe Val Phe Tyr Phe Thr Arg His Glu  
 1345 1350 1355 136  
 Gly Asn Glu Asn Lys Tyr Glu Phe Lys Lys Leu Glu Lys Gly Gly Phe  
 1365 1370 1375  
 Trp Arg Asn Asn Tyr Val Ile Ser Trp Arg Leu  
 1380 1385

<210> 15  
 <211> 1868  
 <212> PRT  
 <213> C. Elegans

<400> 15  
 Met Asn Leu Cys Tyr Arg Arg His Arg Tyr Ala Ser Ser Pro Glu Val  
 1 5 10 15  
 Trp Cys Thr Met Glu Ser Asp Glu Leu Gly Val Thr Arg Tyr Leu Gln  
 20 25 30  
 Ser Lys Gly Gly Asp Gln Val Pro Pro Thr Ser Thr Thr Gly Gly  
 35 40 45  
 Ala Gly Gly Asp Gly Asn Ala Val Pro Thr Thr Ser Gln Ala Gln Ala  
 50 55 60  
 Gln Thr Phe Asn Ser Gly Arg Gln Thr Thr Gly Met Ser Ser Gly Asp  
 65 70 75 80  
 Arg Leu Asn Glu Asp Val Ser Ala Thr Ala Asn Ser Ala Gln Leu Val  
 85 90 95  
 Leu Pro Thr Pro Leu Phe Asn Gln Met Arg Phe Thr Glu Ser Asn Met  
 100 105 110  
 Ser Leu Asn Arg His Asn Trp Val Arg Glu Thr Phe Thr Arg Arg Glu  
 115 120 125  
 Cys Ser Arg Phe Ile Ala Ser Ser Arg Asp Leu His Lys Cys Gly Cys  
 130 135 140  
 Gly Arg Thr Arg Asp Ala His Arg Asn Ile Pro Glu Leu Thr Ser Glu  
 145 150 155 160  
 Phe Leu Arg Gln Lys Arg Ser Val Ala Ala Leu Glu Gln Gln Arg Ser  
 165 170 175  
 Ile Ser Asn Val Asn Asp Asp Ile Asn Thr Gln Asn Met Tyr Thr Lys  
 180 185 190  
 Arg Gly Ala Asn Glu Lys Trp Ser Leu Arg Lys His Thr Val Ser Leu  
 195 200 205  
 Ala Thr Asn Ala Phe Gly Gln Val Glu Phe Gln Gly Gly Pro His Pro  
 210 215 220  
 Tyr Lys Ala Gln Tyr Val Arg Val Asn Phe Asp Thr Glu Pro Ala Tyr  
 225 230 235 240  
 Ile Met Ser Leu Phe Glu His Val Trp Gln Ile Ser Pro Pro Arg Leu  
 245 250 255  
 Ile Ile Thr Val His Gly Gly Thr Ser Asn Phe Asp Leu Gln Pro Lys  
 260 265 270  
 Leu Ala Arg Val Phe Arg Lys Gly Leu Leu Lys Ala Ala Ser Thr Thr  
 275 280 285  
 Gly Ala Trp Ile Ile Thr Ser Gly Cys Asp Thr Gly Val Val Lys His  
 290 295 300  
 Val Ala Ala Ala Leu Glu Gly Ala Gln Ser Ala Gln Arg Asn Lys Ile  
 305 310 315 320  
 Val Cys Ile Gly Ile Ala Pro Trp Gly Leu Leu Lys Lys Arg Glu Asp  
 325 330 335  
 Phe Ile Gly Gln Asp Lys Thr Val Pro Tyr Tyr Pro Ser Ser Ser Lys  
 340 345 350  
 Gly Arg Phe Thr Gly Leu Asn Asn Arg His Ser Tyr Phe Leu Leu Val

-26-

```

      355              360              365
Asp Asn Gly Thr Val Gly Arg Tyr Gly Ala Glu Val Ile Leu Arg Lys
      370              375              380
Arg Leu Glu Met Tyr Ile Ser Gln Lys Gln Lys Ile Phe Gly Gly Thr
385              390              395              400
Arg Ser Val Pro Val Val Cys Val Val Leu Glu Gly Gly Ser Cys Thr
      405              410              415
Ile Arg Ser Val Leu Asp Tyr Val Thr Asn Val Pro Arg Val Pro Val
      420              425              430
Val Val Cys Asp Gly Ser Gly Arg Ala Ala Asp Leu Leu Ala Phe Ala
      435              440              445
His Gln Asn Val Thr Glu Asp Gly Leu Leu Pro Asp Asp Ile Arg Arg
      450              455              460
Gln Val Leu Leu Leu Val Glu Thr Thr Phe Gly Cys Ser Glu Ala Ala
465              470              475              480
Ala His Arg Leu Leu His Glu Leu Thr Val Cys Ala Gln His Lys Asn
      485              490              495
Leu Leu Thr Ile Phe Arg Leu Gly Glu Gln Gly Glu His Asp Val Asp
      500              505              510
His Ala Ile Leu Thr Ala Leu Leu Lys Gly Gln Asn Leu Ser Ala Ala
      515              520              525
Asp Gln Leu Ala Leu Ala Leu Ala Trp Asn Arg Val Asp Ile Ala Arg
      530              535              540
Ser Asp Val Phe Ala Met Gly His Glu Trp Pro Gln Ala Ala Leu His
545              550              555              560
Asn Ala Met Met Glu Ala Leu Ile His Asp Arg Val Asp Phe Val Arg
      565              570              575
Leu Leu Leu Glu Gln Gly Ile Asn Met Gln Lys Phe Leu Thr Ile Ser
      580              585              590
Arg Leu Asp Glu Leu Tyr Asn Thr Asp Lys Gly Pro Pro Asn Thr Leu
      595              600              605
Phe Tyr Ile Val Arg Asp Val Val Arg Val Arg Gln Gly Tyr Arg Phe
      610              615              620
Lys Leu Pro Asp Ile Gly Leu Val Ile Glu Lys Leu Met Gly Asn Ser
625              630              635              640
Tyr Gln Cys Ser Tyr Thr Thr Ser Glu Phe Arg Asp Lys Tyr Lys Gln
      645              650              655
Arg Met Lys Arg Val Lys His Ala Gln Lys Lys Ala Met Gly Val Phe
      660              665              670
Ser Ser Arg Pro Ser Arg Thr Gly Ser Gly Ile Ala Ser Arg Gln Ser
      675              680              685
Thr Glu Gly Met Gly Gly Val Gly Gly Gly Ser Ser Val Ala Gly Val
      690              695              700
Phe Gly Asn Ser Phe Gly Asn Gln Asp Pro Pro Leu Asp Pro His Val
705              710              715              720
Asn Arg Ser Ala Leu Ser Gly Ser Arg Ala Leu Ser Asn His Ile Leu
      725              730              735
Trp Arg Ser Ala Phe Arg Gly Asn Phe Pro Ala Asn Pro Met Arg Pro
      740              745              750
Pro Asn Leu Gly Asp Ser Arg Asp Cys Gly Ser Glu Phe Asp Glu Glu
      755              760              765
Leu Ser Leu Thr Ser Ala Ser Asp Gly Ser Gln Thr Glu Pro Asp Phe
      770              775              780
Arg Tyr Pro Tyr Ser Glu Leu Met Ile Trp Ala Val Leu Thr Lys Arg
785              790              795              800
Gln Asp Met Ala Met Cys Met Trp Gln His Gly Glu Glu Ala Met Ala
      805              810              815
Lys Ala Leu Val Ala Cys Arg Leu Tyr Lys Ser Leu Ala Thr Glu Ala
      820              825              830
Ala Glu Asp Tyr Leu Glu Val Glu Ile Cys Glu Glu Leu Lys Lys Tyr

```

-27-

|   |      |      |
|---|------|------|
| 835   | 840  | 845  |
| Ala Glu Glu Phe Arg Ile Leu Ser Leu Glu Leu Leu Asp His Cys Tyr |      |      |
| 850   | 855  | 860  |
| His Val Asp Asp Ala Gln Thr Leu Gln Leu Leu Thr Tyr Glu Leu Ser |      |      |
| 865   | 870  | 875  |
| Asn Trp Ser Asn Glu Thr Cys Leu Ala Leu Ala Val Ile Val Asn Asn |      |      |
| 885   | 890  | 895  |
| Lys His Phe Leu Ala His Pro Cys Cys Gln Ile Leu Leu Ala Asp Leu |      |      |
| 900   | 905  | 910  |
| Trp His Gly Gly Leu Arg Met Arg Thr His Ser Asn Ile Lys Val Val |      |      |
| 915   | 920  | 925  |
| Leu Gly Leu Ile Cys Pro Pro Phe Ile Gln Met Leu Glu Phe Lys Thr |      |      |
| 930   | 935  | 940  |
| Arg Glu Glu Leu Leu Asn Gln Pro Gln Thr Ala Ala Glu His Gln Asn |      |      |
| 945   | 950  | 955  |
| Asp Met Asn Tyr Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser     |      |      |
| 965   | 970  | 975  |
| Ser Ser Ser Ser Ser Asp Ser Ser Ser Phe Glu Asp Asp Asp Asp Glu |      |      |
| 980   | 985  | 990  |
| Asn Asn Ala His Asn His Asp Gln Lys Arg Thr Arg Lys Thr Ser Gln |      |      |
| 995   | 1000 | 1005 |
| Gly Ser Ala Gln Ser Leu Asn Ile Thr Ser Leu Phe His Ser Arg Arg |      |      |
| 1010  | 1015 | 1020 |
| Arg Lys Ala Lys Lys Asn Glu Lys Cys Asp Arg Glu Thr Asp Ala Ser |      |      |
| 1025  | 1030 | 1035 |
| Ala Cys Glu Ala Gly Asn Arg Gln Ile Gln Asn Gly Gly Leu Thr Ala |      |      |
| 1045  | 1050 | 1055 |
| Glu Tyr Gly Thr Phe Gly Glu Ser Asn Gly Val Ser Pro Pro Pro Pro |      |      |
| 1060  | 1065 | 1070 |
| Tyr Met Arg Ala Asn Ser Arg Ser Arg Tyr Asn Asn Arg Ser Asp Met |      |      |
| 1075  | 1080 | 1085 |
| Ser Lys Thr Ser Ser Val Ile Phe Gly Ser Asp Pro Asn Leu Ser Lys |      |      |
| 1090  | 1095 | 1100 |
| Leu Gln Lys Ser Asn Ile Thr Ser Thr Asp Arg Pro Asn Pro Met Glu |      |      |
| 1105  | 1110 | 1115 |
| Gln Phe Gln Gly Thr Arg Lys Ile Lys Met Arg Arg Arg Phe Tyr Glu |      |      |
| 1125  | 1130 | 1135 |
| Phe Tyr Ser Ala Pro Ile Ser Thr Phe Trp Ser Trp Thr Ile Ser Phe |      |      |
| 1140  | 1145 | 1150 |
| Ile Leu Phe Ile Thr Phe Phe Thr Tyr Thr Leu Leu Val Lys Thr Pro |      |      |
| 1155  | 1160 | 1165 |
| Pro Arg Pro Thr Val Ile Glu Tyr Ile Leu Ile Ala Tyr Val Ala Ala |      |      |
| 1170  | 1175 | 1180 |
| Phe Gly Leu Glu Gln Val Arg Lys Ile Ile Met Ser Asp Ala Lys Pro |      |      |
| 1185  | 1190 | 1195 |
| Phe Tyr Glu Lys Ile Arg Thr Tyr Val Cys Ser Phe Trp Asn Cys Val |      |      |
| 1205  | 1210 | 1215 |
| Thr Ile Leu Ala Ile Ile Phe Tyr Ile Val Gly Phe Phe Met Arg Cys |      |      |
| 1220  | 1225 | 1230 |
| Phe Gly Ser Val Ala Tyr Gly Arg Val Ile Leu Ala Cys Asp Ser Val |      |      |
| 1235  | 1240 | 1245 |
| Leu Trp Thr Met Lys Leu Leu Asp Tyr Met Ser Val His Pro Lys Leu |      |      |
| 1250  | 1255 | 1260 |
| Gly Pro Tyr Val Thr Met Ala Gly Lys Met Ile Gln Asn Met Ser Tyr |      |      |
| 1265  | 1270 | 1275 |
| Ile Ile Val Met Leu Val Val Thr Leu Leu Ser Phe Gly Leu Ala Arg |      |      |
| 1285  | 1290 | 1295 |
| Gln Ser Ile Thr Tyr Pro Asp Glu Thr Trp His Trp Ile Leu Val Arg |      |      |
| 1300  | 1305 | 1310 |
| Asn Ile Phe Leu Lys Pro Tyr Phe Met Leu Tyr Gly Glu Val Tyr Ala |      |      |

-28-

1315 1320 1325  
Asp Glu Ile Asp Thr Cys Gly Asp Glu Ala Trp Asp Gln His Leu Glu  
1330 1335 1340  
Asn Gly Gly Pro Val Ile Leu Gly Asn Gly Thr Thr Gly Leu Ser Cys  
1345 1350 1355 136  
Val Pro Gly Tyr Trp Ile Pro Pro Leu Leu Met Thr Phe Phe Leu Leu  
1365 1370 1375  
Ile Ala Asn Ile Leu Leu Met Ser Met Leu Ile Ala Ile Phe Asn His  
1380 1385 1390  
Ile Phe Asp Ala Thr Asp Glu Met Ser Gln Gln Ile Trp Leu Phe Gln  
1395 1400 1405  
Arg Tyr Lys Gln Val Met Glu Tyr Glu Ser Thr Pro Phe Leu Pro Pro  
1410 1415 1420  
Pro Leu Thr Pro Leu Tyr His Gly Val Leu Ile Leu Gln Phe Val Arg  
1425 1430 1435 144  
Thr Arg Leu Ser Cys Ser Lys Ser Gln Glu Arg Asn Pro Ile Leu Leu  
1445 1450 1455  
Leu Lys Ile Ala Glu Leu Phe Leu Asp Asn Asp Gln Ile Glu Lys Leu  
1460 1465 1470  
His Asp Phe Glu Glu Asp Cys Met Glu Asp Leu Ala Arg Gln Lys Leu  
1475 1480 1485  
Asn Glu Lys Asn Thr Ser Asn Glu Gln Arg Ile Leu Arg Ala Asp Ile  
1490 1495 1500  
Arg Thr Asp Gln Ile Leu Asn Arg Leu Ile Asp Leu Gln Ala Lys Glu  
1505 1510 1515 152  
Ser Met Gly Arg Asp Val Ile Asn Asp Val Glu Ser Arg Leu Ala Ser  
1525 1530 1535  
Val Glu Lys Ala Gln Asn Glu Ile Leu Glu Cys Val Arg Ala Leu Leu  
1540 1545 1550  
Asn Gln Asn Asn Ala Pro Thr Ala Ile Gly Arg Cys Phe Ser Pro Ser  
1555 1560 1565  
Pro Asp Pro Leu Val Glu Thr Ala Asn Gly Thr Pro Gly Pro Leu Leu  
1570 1575 1580  
Leu Lys Leu Pro Gly Thr Asp Pro Ile Leu Glu Glu Lys Asp His Asp  
1585 1590 1595 160  
Ser Gly Glu Asn Ser Asn Ser Leu Pro Pro Gly Arg Ile Arg Arg Asn  
1605 1610 1615  
Arg Thr Ala Thr Ile Cys Gly Gly Tyr Val Ser Glu Glu Arg Asn Met  
1620 1625 1630  
Met Leu Leu Ser Pro Lys Pro Ser Asp Val Ser Gly Ile Pro Gln Gln  
1635 1640 1645  
Arg Leu Met Ser Val Thr Ser Met Asp Pro Leu Pro Leu Pro Leu Ala  
1650 1655 1660  
Lys Leu Ser Thr Met Ser Ile Arg Arg Arg His Glu Glu Tyr Thr Ser  
1665 1670 1675 168  
Ile Thr Asp Ser Ile Ala Ile Arg His Pro Glu Arg Arg Ile Arg Asn  
1685 1690 1695  
Asn Arg Ser Asn Ser Ser Glu His Asp Glu Ser Ala Val Asp Ser Glu  
1700 1705 1710  
Gly Gly Gly Asn Val Thr Ser Ser Pro Arg Lys Arg Ser Thr Arg Asp  
1715 1720 1725  
Leu Arg Met Thr Pro Ser Ser Gln Val Glu Glu Ser Thr Ser Arg Asp  
1730 1735 1740  
Gln Ile Phe Glu Ile Asp His Pro Glu His Glu Glu Asp Glu Ala Gln  
1745 1750 1755 176  
Ala Asp Cys Glu Leu Thr Asp Val Ile Thr Glu Glu Glu Asp Glu Glu  
1765 1770 1775  
Glu Asp Asp Glu Glu Asp Asp Ser His Glu Arg His His Ile His Pro  
1780 1785 1790  
Arg Arg Lys Ser Ser Arg Gln Asn Arg Gln Pro Ser His Thr Leu Glu

-29-

1795 1800 1805  
 Thr Asp Leu Ser Glu Gly Glu Glu Val Asp Pro Leu Asp Val Leu Lys  
 1810 1815 1820  
 Met Lys Glu Leu Pro Ile Ile His Gln Ile Leu Asn Glu Glu Glu Gln  
 1825 1830 1835 184  
 Ala Gly Ala Pro His Ser Thr Pro Val Ile Ala Ser Pro Ser Ser Ser  
 1845 1850 1855  
 Arg Ala Asp Leu Thr Ser Gln Lys Cys Ser Asp Val  
 1860 1865

<210> 16  
 <211> 489  
 <212> DNA  
 <213> Mus Musculus

<400> 16  
 ccctgaaaga ctcgacttct gctgctagcg ctggagctga gttagttttg agaaggtttc 60  
 ccggggctgt ccttggttcgg tggcccgtgc caccgcctcc ggagacgctt tccgatagat 120  
 ggctgcaggc cgcgagggtg gaggaggagc cgctgccctt ccggagtccg ccccgtaggg 180  
 agaatgtccc agaaatcctg gatagagagc actttgacca agagggagtg tgtatatatt 240  
 ataccaagct ccaaagacc cccacagatgt cttccaggat gtcagatttg tcagcaactt 300  
 gtcagatgtt tctgtggtcg tttggtcaag caacatgcat gctttactgc aagtcttgcc 360  
 atgaaatact cagatgtgaa attgggtgaa cactttaacc aggcaataga agaatggtct 420  
 gtggaaaagc acacggagca gagcccaaca gatgcttatg gtagcatcaa ttttcaaggg 480  
 ggttctcat 489

<210> 17  
 <211> 102  
 <212> PRT  
 <213> Mus Musculus

<400> 17  
 Met Ser Gln Lys Ser Trp Ile Glu Ser Thr Leu Thr Lys Arg Glu Cys  
 1 5 10 15  
 Val Tyr Ile Ile Pro Ser Ser Lys Asp Pro His Arg Cys Leu Pro Gly  
 20 25 30  
 Cys Gln Ile Cys Gln Gln Leu Val Arg Cys Phe Cys Gly Arg Leu Val  
 35 40 45  
 Lys Gln His Ala Cys Phe Thr Ala Ser Leu Ala Met Lys Tyr Ser Asp  
 50 55 60  
 Val Lys Leu Gly Glu His Phe Asn Gln Ala Ile Glu Glu Trp Ser Val  
 65 70 75 80  
 Glu Lys His Thr Glu Gln Ser Pro Thr Asp Ala Tyr Gly Val Ile Asn  
 85 90 95  
 Phe Gln Gly Gly Ser His  
 100

<210> 18  
 <211> 410  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> unsure  
 <222> (6)...(6)

<221> unsure  
 <222> (58)...(58)

<221> unsure



&lt;222&gt; (89)...(89)

&lt;221&gt; unsure

&lt;222&gt; (406)...(406)

&lt;400&gt; 18

|            |            |            |            |             |             |     |
|------------|------------|------------|------------|-------------|-------------|-----|
| gccgcnggag | cctgagcgga | gggtgtgcgc | agcctcgcca | gcggggggccc | cgggctgngc  | 60  |
| cattgcctca | ctgagccagc | gcctgcctnc | tacctcgccg | acagctggaa  | ccagtgcgac  | 120 |
| ctagtggctc | tcacctgctt | cctcctgggc | gtgggctgcc | ggctgacccc  | gggtttgtac  | 180 |
| cacctgggcc | gcaactgtct | ctgcatcgac | ttcatgggtt | tcacgggtgcg | gctgcttcac  | 240 |
| atcttcacgg | tcaacaaaca | gctggggccc | aagatcgcca | tcgtgagcaa  | gatgatgaag  | 300 |
| gacgtgttct | tcttcctctt | cttcctcggc | gtgtggctgg | tagctatggg  | ttggggccacg | 360 |
| gaggggttcc | tgaggccacg | ggacagtgac | ttcccaagta | tcctgncgcc  |             | 410 |

&lt;210&gt; 19

&lt;211&gt; 131

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (15)...(15)

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (25)...(25)

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (131)...(131)

&lt;223&gt; UNKNOWN

&lt;400&gt; 19

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Glu | Gly | Val | Arg | Ser | Leu | Ala | Ser | Gly | Gly | Pro | Gly | Leu | Xaa | His |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Cys | Leu | Thr | Glu | Pro | Ala | Pro | Ala | Xaa | Tyr | Leu | Ala | Asp | Ser | Trp | Asn |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Gln | Cys | Asp | Leu | Val | Ala | Leu | Thr | Cys | Phe | Leu | Leu | Gly | Val | Gly | Cys |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Arg | Leu | Thr | Pro | Gly | Leu | Tyr | His | Leu | Gly | Arg | Thr | Val | Leu | Cys | Ile |
|     |     | 50  |     |     |     | 55  |     |     |     | 60  |     |     |     |     |     |
| Asp | Phe | Met | Val | Phe | Thr | Val | Arg | Leu | Leu | His | Ile | Phe | Thr | Val | Asn |
|     |     | 65  |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Lys | Gln | Leu | Gly | Pro | Lys | Ile | Val | Ile | Val | Ser | Lys | Met | Met | Lys | Asp |
|     |     |     | 85  |     |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Val | Phe | Phe | Phe | Leu | Phe | Phe | Leu | Gly | Val | Trp | Leu | Val | Ala | Met | Gly |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Trp | Ala | Thr | Glu | Gly | Phe | Leu | Arg | Pro | Arg | Asp | Ser | Asp | Phe | Pro | Ser |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Ile | Leu | Xaa |     |     |     |     |     |     |     |     |     |     |     |     |     |
|     |     | 130 |     |     |     |     |     |     |     |     |     |     |     |     |     |

&lt;210&gt; 20

&lt;211&gt; 389

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 20

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| caaatttttt | gttagtacac | catctcatcc | aaattgcaaa | agtcacatgg | aaactggaac | 60  |
| caaagatcaa | gaaactgttt | gctctaaagc | tacagaagga | gataatacag | aatttgagac | 120 |

-31-

|              |            |            |            |            |            |     |
|--------------|------------|------------|------------|------------|------------|-----|
| attttagtagga | cacagagata | gcatggattt | acagagggtt | aaagaaacat | caaacaagat | 180 |
| aaaaatacta   | tccaataaca | atacttctga | aaacactttg | aaacgagtga | gttctcttgc | 240 |
| tggttttact   | gactgtcaca | gaacttccat | tcctgttcat | tcaaaacgag | aaaagatcag | 300 |
| tagaaggcca   | tctaccgaag | acactcatga | agtagattcc | aaagcagctt | taataccggt | 360 |
| ttgttagattt  | caactaaaca | gatataat   |            |            |            | 389 |

<210> 21  
 <211> 415  
 <212> DNA  
 <213> Homo Sapiens

|             |            |            |            |            |             |     |
|-------------|------------|------------|------------|------------|-------------|-----|
| <400> 21    |            |            |            |            |             |     |
| atttctagtt  | tttcaaattt | gccagtcttt | ttgaatagta | tctccttctt | ttctcatggt  | 60  |
| ttatatttaa  | aactttttta | tgtccatcat | cactttaaac | atacttattt | tgatcatctat | 120 |
| aaccaataat  | tccactatct | tatcagaaat | caaataccgt | ttatgtaagt | tgactcccat  | 180 |
| gagttctaaa  | ttgccattgt | gaggtcatct | tcggttaggc | tttaatttgt | tgcaaagttg  | 240 |
| tgcagctcag  | ggtcaggaag | agtccctcca | gaaaggagga | tttgttactg | tgaatctctt  | 300 |
| tggttaactaa | cctctttccc | cactgaaata | acttttttca | ataacatgat | tttaacaaca  | 360 |
| taatctctct  | atgccagaac | agatatatat | gaatgtaagt | caatattttc | ttgag       | 415 |

<210> 22  
 <211> 405  
 <212> DNA  
 <213> Mus Musculus

|            |            |            |            |             |            |     |
|------------|------------|------------|------------|-------------|------------|-----|
| <400> 22   |            |            |            |             |            |     |
| ttattatggc | ttatcatgaa | aaaccagtcc | tgccctctcc | tcttatcatc  | ctcagccata | 60  |
| tagtttcact | gttttgctgt | gtatgcaaaa | gaagaaagaa | agataagact  | tccgatgggc | 120 |
| caaaactttt | cttaacagaa | gaagatcaaa | agaaactcca | tgattttgaa  | gagcagtgtg | 180 |
| ttgagatgta | ctttgatgag | aaagatgaca | aattcaattc | tgggagtga   | gagagaatcc | 240 |
| gggtcacttt | tgaaagagt  | gagcagatga | gcattcagat | taaagaagtt  | ggagatcgtg | 300 |
| tcaactacat | aaaaagatca | ttacagtctt | tagattctca | aattgggtcat | ctgcaagatc | 360 |
| tctcagccct | aacagtagat | acattgaaaa | cacttacagc | ccaga       |            | 405 |

<210> 23  
 <211> 5117  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> unsure  
 <222> (2382)...(2382)  
 <223> unknown

<221> unsure  
 <222> (4664)...(4664)  
 <223> unknown

<221> unsure  
 <222> (4682)...(4682)  
 <223> unknown

<221> unsure  
 <222> (4702)...(4702)  
 <223> unknown

<221> unsure  
 <222> (5038)...(5039)  
 <223> unknown

-32-

<221> unsure  
 <222> (5056)...(5056)  
 <223> unknown

<221> unsure  
 <222> (5071)...(5072)

<400> 23

|             |             |             |            |             |             |      |
|-------------|-------------|-------------|------------|-------------|-------------|------|
| gatggcaaca  | tgggtgaagaa | tcaatggcta  | aagcattagt | tgccgtgtaag | atctatcggt  | 60   |
| caatggcata  | tgaagcaaaag | cagagtgaacc | tggtagatga | tacttcagaa  | gaactaaaac  | 120  |
| agtattccaa  | tgatttttgg  | cagttggccg  | ttgaattatt | agaacagtc   | ttcagacaag  | 180  |
| atgaaacat   | ggctatgaaa  | ttgctcactt  | atgaactgaa | gaactggagt  | aattcaacct  | 240  |
| gccttaagtt  | agcagtttct  | tcaagactta  | gaccttttgt | agctcacacc  | tgtacacaaa  | 300  |
| tgttgttatc  | tgatatgtgg  | atgggaaggc  | tgaatatgag | gaaaaattcc  | tggtacaagg  | 360  |
| tcatactaag  | catttttagtt | ccacctgcca  | tattgctgtt | agagtataaa  | actaaggctg  | 420  |
| aaatgtocca  | tatcccacaa  | tctcaagatg  | ctcatcagat | gacaatggat  | gacagcgaaa  | 480  |
| acaactttca  | gaacataaca  | gaagagatcc  | ccatggaagt | gtttaaagaa  | gtacggattt  | 540  |
| tggtatgtaa  | tgaaggaaaag | aatgagatgg  | agatacaaat | gaaatcaaaa  | aagcttccaa  | 600  |
| ttacgcgaaa  | gttttatgcc  | ttttatcatg  | caccaattgt | aaaattctgg  | tttaacacgt  | 660  |
| tggtatattt  | aggattttctg | atgctttata  | catttgtggt | tcttgtacaa  | atggaacagt  | 720  |
| taccttcagt  | tcaagaatgg  | attgttattg  | cttatatttt | tacttatgcc  | attgagaaaag | 780  |
| tccgtgagat  | ctttatgtct  | gaagctggga  | aagtaaacca | gaagattaaa  | gtatggttta  | 840  |
| gtgattactt  | caacatcagt  | gatacaattg  | ccataatttc | tttcttcatt  | ggatttggac  | 900  |
| taagatttgg  | agcaaaatgg  | aactttgcaa  | atgcatatga | taatcatggt  | tttgtggctg  | 960  |
| gaagattaat  | ttactgtctt  | aacataatat  | tttggatatg | gcgtttgcta  | gattttctag  | 1020 |
| ctgtaaatca  | acaggcagga  | ccttatgtaa  | tgatgattgg | aaaaatggtg  | gccaatatgt  | 1080 |
| tctacattgt  | agtgattatg  | gctcttgtat  | tacttagttt | tggtgttccc  | agaaaggcaa  | 1140 |
| tactttatcc  | tcatgaagca  | ccatcttgga  | ctcttgctaa | agatatagtt  | tttcacccat  | 1200 |
| actggatgat  | ttttggtgaa  | gtttatgcat  | acgaaattga | tgtgtgtgca  | aatgattctg  | 1260 |
| ttatccctca  | aatctgtggt  | cctgggacgt  | ggttgactcc | atttcttcaa  | gcagtctacc  | 1320 |
| tctttgtaca  | gtatatcatt  | atgggttaatc | ttcttattgc | atttttcaac  | aatgtgtatt  | 1380 |
| tacaagtga   | ggcaatttcc  | aatattgtat  | ggaagtacca | gcgttatcat  | tttattatgg  | 1440 |
| cttatcatga  | gaaaccagtt  | ctgcctcctc  | cacttatcat | tcttagccat  | atagtttctc  | 1500 |
| tgttttgctg  | catatgtaag  | agaagaaaaga | aagataagac | ttccgatgga  | ccaaaacttt  | 1560 |
| tcttaacaga  | agaagatcaa  | aagaaacttc  | atgattttga | agagcagtgt  | gttgaaatgt  | 1620 |
| atttcaatga  | aaaagatgac  | aaatttcatt  | ctgggagtga | agagagaatt  | cgtgtcactt  | 1680 |
| ttgaaagagt  | ggaacagatg  | tgcattcaga  | ttaaagaagt | tgagatcgt   | gtcaactaca  | 1740 |
| taaaaagatc  | attacaatca  | ttagattctc  | aaattggcca | tttgcaagat  | ctttcagccc  | 1800 |
| tgacggtaga  | tacattaaaa  | acactcactg  | cccagaaagc | gtcgggaagc  | agcaaagtcc  | 1860 |
| ataatgaaat  | cacacgagaa  | ctgagcattt  | ccaaacactt | ggctcaaaac  | cttattgatg  | 1920 |
| atggtcctgt  | aagaccttct  | gtatggaaaa  | agcatggtgt | tgtaaatata  | cttagctcct  | 1980 |
| ctcttcctca  | aggatgatct  | gaaagtaata  | atccttttca | ttgtaatat   | ttaatgaaag  | 2040 |
| ctgacaaaaga | tccccagtg   | aatatatattg | gtcaagaact | acctgcagta  | ccccagagaa  | 2100 |
| aagaatttaa  | ttttccagag  | gctggttctt  | cttctggtgc | cttattccca  | agtgtgtttt  | 2160 |
| cccctccaga  | actgcgacag  | agactacatg  | gggtagaact | cttaaaaaata | tttaataaaa  | 2220 |
| atcaaaaaatt | aggcagttca  | tctactagca  | taccacatct | gtcatcccca  | ccaaccaa    | 2280 |
| tttttgttag  | tacaccatct  | cagccaagtt  | gcaaaagcca | cttggaact   | ggaaccaaag  | 2340 |
| atcaagaaaac | tgtttgcctt  | aaagctacag  | aaggagataa | tncagaattt  | ggagcatttg  | 2400 |
| taggacacag  | agatagcatg  | gatttacaga  | ggtttaaaga | aacatcaa    | aagataaaaa  | 2460 |
| tactatccaa  | taacaatact  | tctgaaaaca  | ctttgaaacg | agttagttct  | cttgctggat  | 2520 |
| ttactgactg  | tcacagaact  | tccattcctg  | ttcattcaaa | acaagcagaa  | aaaatcagta  | 2580 |
| gaaggccatc  | taccgaagac  | actcatgaag  | tagattccaa | agcagcttta  | ataccggatt  | 2640 |
| ggttacaaga  | tagaccatca  | aacagagaaa  | tgcatctga  | agaaggaa    | ttaaatggtc  | 2700 |
| tcacttctcc  | atttaagcca  | gctatggata  | caaattacta | ttattcagct  | gtggaaagaa  | 2760 |
| ataacttgat  | gaggttatca  | cagagcatc   | catttacacc | tgtgcctcca  | agaggggagc  | 2820 |
| ctgtcacagt  | gtatcgttg   | gaagagagtt  | cacccaacat | actaaataac  | agcatgtctt  | 2880 |
| cttggtcaca  | actaggcctc  | tgtgccaaaa  | tagagttttt | aagcaaagag  | gagatgggag  | 2940 |
| gagggtttacg | aagagctgtc  | aaagtacagt  | gtacctggtc | agaacatgat  | atcctcaaat  | 3000 |
| cagggcatct  | ttatattatc  | aaatcttttc  | ttccagaggt | ggttaataca  | tggtcaagta  | 3060 |
| tttataaaga  | agatacagtt  | ctgcatctct  | gtctgagaga | aattcaacaa  | cagagagcag  | 3120 |

-33-

```

cacaaaagct tacgtttgcc tttaatcaaa tgaaacccaa atccatacca tattctccaa 3180
ggttccttga agttttcctg ctgtattgcc attcagcagg acagtgggtt gctgtggaag 3240
aatgtatgac tggagaattt agaaaataca acaataataa tggagatgag attattccaa 3300
ctaatactct ggaagagatc atgctagcct ttagccactg gacttacgaa tatacaagag 3360
gggagtactt ggtacttgat ttgcaagggt ttggtgaaaa ttgactgac ccatctgtga 3420
taaaagcaga agaaaagaga tcctgtgata tggtttttgg cccagcaaat ctaggagaag 3480
atgcaattaa aaacttcaga gcaaaacatc actgtaattc ttgctgtaga aagcttaaac 3540
ttccagatct gaagaggaat gattatacgc ctgataaaaat tatatttcct caggatgagc 3600
cttcagattt gaatcttcag cctggaaaatt ccaccaaaaga atcagaatca gctaattctg 3660
ttcgtctgat gttataatat taatattact gaatcattgg ttttgctgc acctcacaga 3720
aatgttactg tgtcactttt ccctcgggag gaaattgttt ggtaatatag aaagggtgat 3780
gcaagttgaa tttgctgact ccagcacagt taaaagggtca atattctttt gacctgatta 3840
atcagtcaga aagtcacctat aggatagagc tggcagctga gaaattttaa aggtaattga 3900
taattagtat ttgtaacttt ttaaagggtc ctttgtatag cagaggatct catttgactt 3960
tgttttgatg aggggtgatgc cctctcttat gtggtacaat accattaacc aaaggtaggt 4020
gtccatgcag attttattgg cagctgtttt attgccattc aactagggaa atgaagaaat 4080
cacgcagcct tttggttaaa tggcagtc aaattttcctc agtgtattta gtgtgttcag 4140
tgatgatatc actggttccc aactagatgc ttgttgcca cgggaaggga aatgacttgt 4200
tctaattcta ggttcacaga ggtatgagaa gcctgaactg aagaccattt tcaagaggga 4260
cggatattat gaatcagggt taggtcccat atttaaagat agagccagtt ttttttttaa 4320
atagaaccca aattgtgtaa aaatgttaat tgggtttttt aaacattgtt ttatcaagtc 4380
actgttaagt agaagaaagc catggtaaac tgatacataa cctaaattat aaaagcagaa 4440
acctaactca ctctcaagg gaagttacct tttgaggaaa gttaaagtac tttttccct 4500
atctgtatct atagcaacaa cccagaactt acaaacttct ccaaagattt tattgattgt 4560
tatatcaaat cagaatgtaa acatgaactc ttgcatatat ttaaaattgt gttggaacat 4620
ttgaacatga atgctgtttg ggtacttaag aaattrattc agtnggatta tcattatgtg 4680
anactggcag attgcagtgc anccttatgc caataaaatg taatttaaca gccccagata 4740
ttgttgaaata ttcaacaata acaagaaaag cttttcatct aagttttatg ctttaatttt 4800
ttttcttttt ttttcttttt cttttgtttc cttggtacta attttaattt ttatttgga 4860
gggagcagta taaagcttat ttgtatttag tagtgtatct catagataca gacaaggcaa 4920
gagatgataa gctgtttaaa tagtgtttaa tattgattgg ggggtggggag aaagaaaaag 4980
tgtattactt aaagatacta tatacgtttt gtatatcatt aaatctttta aagaaatnna 5040
ataaatttat tgtttncaaa aaaaaaaccc nntaaaaaaa aaagggcggc ccctctagag 5100
gatccctcga ggggccc 5117

```

<210> 24  
 <211> 1224  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (794) ... (794)  
 <223> UNKNOWN

<400> 24  
 Trp Gln His Gly Glu Ser Met Ala Lys Ala Leu Val Ala Cys Lys  
 1 5 10 15  
 Ile Tyr Arg Ser Met Ala Tyr Glu Ala Lys Gln Ser Asp Leu Val Asp  
 20 25 30  
 Asp Thr Ser Glu Glu Leu Lys Gln Tyr Ser Asn Asp Phe Gly Gln Leu  
 35 40 45  
 Ala Val Glu Leu Leu Glu Gln Ser Phe Arg Gln Asp Glu Thr Met Ala  
 50 55 60  
 Met Lys Leu Leu Thr Tyr Glu Leu Lys Asn Trp Ser Asn Ser Thr Cys  
 65 70 75 80  
 Leu Lys Leu Ala Val Ser Ser Arg Leu Arg Pro Phe Val Ala His Thr  
 85 90 95

-34-

Cys Thr Gln Met Leu Leu Ser Asp Met Trp Met Gly Arg Leu Asn Met  
 100 105 110  
 Arg Lys Asn Ser Trp Tyr Lys Val Ile Leu Ser Ile Leu Val Pro Pro  
 115 120 125  
 Ala Ile Leu Leu Leu Glu Tyr Lys Thr Lys Ala Glu Met Ser His Ile  
 130 135 140  
 Pro Gln Ser Gln Asp Ala His Gln Met Thr Met Asp Ser Glu Asn  
 145 150 155 160  
 Asn Phe Gln Asn Ile Thr Glu Glu Ile Pro Met Glu Val Phe Lys Glu  
 165 170 175  
 Val Arg Ile Leu Asp Ser Asn Glu Gly Lys Asn Glu Met Glu Ile Gln  
 180 185 190  
 Met Lys Ser Lys Lys Leu Pro Ile Thr Arg Lys Phe Tyr Ala Phe Tyr  
 195 200 205  
 His Ala Pro Ile Val Lys Phe Trp Phe Asn Thr Leu Ala Tyr Leu Gly  
 210 215 220  
 Phe Leu Met Leu Tyr Thr Phe Val Val Leu Val Gln Met Glu Gln Leu  
 225 230 235 240  
 Pro Ser Val Gln Glu Trp Ile Val Ile Ala Tyr Ile Phe Thr Tyr Ala  
 245 250 255  
 Ile Glu Lys Val Arg Glu Ile Phe Met Ser Glu Ala Gly Lys Val Asn  
 260 265 270  
 Gln Lys Ile Lys Val Trp Phe Ser Asp Tyr Phe Asn Ile Ser Asp Thr  
 275 280 285  
 Ile Ala Ile Ile Ser Phe Phe Ile Gly Phe Gly Leu Arg Phe Gly Ala  
 290 295 300  
 Lys Trp Asn Phe Ala Asn Ala Tyr Asp Asn His Val Phe Val Ala Gly  
 305 310 315 320  
 Arg Leu Ile Tyr Cys Leu Asn Ile Ile Phe Trp Tyr Val Arg Leu Leu  
 325 330 335  
 Asp Phe Leu Ala Val Asn Gln Gln Ala Gly Pro Tyr Val Met Met Ile  
 340 345 350  
 Gly Lys Met Val Ala Asn Met Phe Tyr Ile Val Val Ile Met Ala Leu  
 355 360 365  
 Val Leu Leu Ser Phe Gly Val Pro Arg Lys Ala Ile Leu Tyr Pro His  
 370 375 380  
 Glu Ala Pro Ser Trp Thr Leu Ala Lys Asp Ile Val Phe His Pro Tyr  
 385 390 395 400  
 Trp Met Ile Phe Gly Glu Val Tyr Ala Tyr Glu Ile Asp Val Cys Ala  
 405 410 415  
 Asn Asp Ser Val Ile Pro Gln Ile Cys Gly Pro Gly Thr Trp Leu Thr  
 420 425 430  
 Pro Phe Leu Gln Ala Val Tyr Leu Phe Val Gln Tyr Ile Ile Met Val  
 435 440 445  
 Asn Leu Leu Ile Ala Phe Phe Asn Asn Val Tyr Leu Gln Val Lys Ala  
 450 455 460  
 Ile Ser Asn Ile Val Trp Lys Tyr Gln Arg Tyr His Phe Ile Met Ala  
 465 470 475 480  
 Tyr His Glu Lys Pro Val Leu Pro Pro Pro Leu Ile Ile Leu Ser His  
 485 490 495  
 Ile Val Ser Leu Phe Cys Cys Ile Cys Lys Arg Arg Lys Lys Asp Lys  
 500 505 510  
 Thr Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp Gln Lys Lys  
 515 520 525  
 Leu His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe Asn Glu Lys  
 530 535 540  
 Asp Asp Lys Phe His Ser Gly Ser Glu Glu Arg Ile Arg Val Thr Phe  
 545 550 555 560  
 Glu Arg Val Glu Gln Met Cys Ile Gln Ile Lys Glu Val Gly Asp Arg  
 565 570 575

-35-

Val Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser Gln Ile Gly  
 580 585 590  
 His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu Lys Thr Leu  
 595 600 605  
 Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn Glu Ile Thr  
 610 615 620  
 Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu Ile Asp Asp  
 625 630 635 640  
 Gly Pro Val Arg Pro Ser Val Trp Lys Lys His Gly Val Val Asn Thr  
 645 650 655  
 Leu Ser Ser Ser Leu Pro Gln Gly Asp Leu Glu Ser Asn Asn Pro Phe  
 660 665 670  
 His Cys Asn Ile Leu Met Lys Asp Lys Asp Pro Gln Cys Asn Ile  
 675 680 685  
 Phe Gly Gln Asp Leu Pro Ala Val Pro Gln Arg Lys Glu Phe Asn Phe  
 690 695 700  
 Pro Glu Ala Gly Ser Ser Ser Gly Ala Leu Phe Pro Ser Ala Val Ser  
 705 710 715 720  
 Pro Pro Glu Leu Arg Gln Arg Leu His Gly Val Glu Leu Leu Lys Ile  
 725 730 735  
 Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Ser Thr Ser Ile Pro His  
 740 745 750  
 Leu Ser Ser Pro Pro Thr Lys Phe Phe Val Ser Thr Pro Ser Gln Pro  
 755 760 765  
 Ser Cys Lys Ser His Leu Glu Thr Gly Thr Lys Asp Gln Glu Thr Val  
 770 775 780  
 Cys Ser Lys Ala Thr Glu Gly Asp Asn Xaa Glu Phe Gly Ala Phe Val  
 785 790 795 800  
 Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser Asn  
 805 810 815  
 Lys Ile Lys Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn Thr Leu Lys  
 820 825 830  
 Arg Val Ser Ser Leu Ala Gly Phe Thr Asp Cys His Arg Thr Ser Ile  
 835 840 845  
 Pro Val His Ser Lys Gln Ala Glu Lys Ile Ser Arg Arg Pro Ser Thr  
 850 855 860  
 Glu Asp Thr His Glu Val Asp Ser Lys Ala Ala Leu Ile Pro Asp Trp  
 865 870 875 880  
 Leu Gln Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu Glu Gly Thr  
 885 890 895  
 Leu Asn Gly Leu Thr Ser Pro Phe Lys Pro Ala Met Asp Thr Asn Tyr  
 900 905 910  
 Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met Arg Leu Ser Gln Ser  
 915 920 925  
 Ile Pro Phe Thr Pro Val Pro Pro Arg Gly Glu Pro Val Thr Val Tyr  
 930 935 940  
 Arg Leu Glu Glu Ser Ser Pro Asn Ile Leu Asn Asn Ser Met Ser Ser  
 945 950 955 960  
 Trp Ser Gln Leu Gly Leu Cys Ala Lys Ile Glu Phe Leu Ser Lys Glu  
 965 970 975  
 Glu Met Gly Gly Gly Leu Arg Arg Ala Val Lys Val Gln Cys Thr Trp  
 980 985 990  
 Ser Glu His Asp Ile Leu Lys Ser Gly His Leu Tyr Ile Ile Lys Ser  
 995 1000 1005  
 Phe Leu Pro Glu Val Val Asn Thr Trp Ser Ser Ile Tyr Lys Glu Asp  
 1010 1015 1020  
 Thr Val Leu His Leu Cys Leu Arg Glu Ile Gln Gln Gln Arg Ala Ala  
 1025 1030 1035 104  
 Gln Lys Leu Thr Phe Ala Phe Asn Gln Met Lys Pro Lys Ser Ile Pro  
 1045 1050 1055

-36-

Tyr Ser Pro Arg Phe Leu Glu Val Phe Leu Leu Tyr Cys His Ser Ala  
 1060 1065 1070  
 Gly Gln Trp Phe Ala Val Glu Glu Cys Met Thr Gly Glu Phe Arg Lys  
 1075 1080 1085  
 Tyr Asn Asn Asn Asn Gly Asp Glu Ile Ile Pro Thr Asn Thr Leu Glu  
 1090 1095 1100  
 Glu Ile Met Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr Arg Gly  
 1105 1110 1115 112  
 Glu Leu Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn Leu Thr Asp  
 1125 1130 1135  
 Pro Ser Val Ile Lys Ala Glu Glu Lys Arg Ser Cys Asp Met Val Phe  
 1140 1145 1150  
 Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Lys Asn Phe Arg Ala Lys  
 1155 1160 1165  
 His His Cys Asn Ser Cys Cys Arg Lys Leu Lys Leu Pro Asp Leu Lys  
 1170 1175 1180  
 Arg Asn Asp Tyr Thr Pro Asp Lys Ile Ile Phe Pro Gln Asp Glu Pro  
 1185 1190 1195 120  
 Ser Asp Leu Asn Leu Gln Pro Gly Asn Ser Thr Lys Glu Ser Glu Ser  
 1205 1210 1215  
 Ala Asn Ser Val Arg Leu Met Leu  
 1220

<210> 25  
 <211> 2180  
 <212> DNA  
 <213> Homo Sapiens

<400> 25  
 tcgaggccaa gaattcggca cgagggcctc gggcaggccc cctggagcga cctgcttctt 60  
 tgggcactgt tgctgaacag ggcacagatg gccatgtact tctgggagat gggttccaat 120  
 gcagtttctt cagctcttgg ggcctgtttg ctgctccggg tgatggcacg cctggagcct 180  
 gacgctgagg aggcagcacg gaggaaagac ctggcggttca agtttgaggg gatgggcgtt 240  
 gacctctttg gcgagtgtta tcgcagcagt gaggtgaggg ctgcccgctt cctcctccgt 300  
 cgctgcccgc tctgggggga tgccacttgc ctccagctgg ccatgcaagc tgacgcccgt 360  
 gccttctttg ccaggatgg ggtacagtct ctgctgacac agaagtgggt gggagatatg 420  
 gccagcacta caccatctg ggcctgtgtt ctgccttct tttgcctcc actcatctac 480  
 acccgctca tcaccttcag gaaatcagaa gaggagccca cacgggagga gctagagttt 540  
 gacatggata gtgtcattaa tggggaaggg cctgtcggga cggcggaacc agccgagaag 600  
 acgcccgtgg gggctccgcg ccagtcgggc cgtccgggtt gctcggggg ccgctgaggg 660  
 gggcgccggt gcctacgccg ctggttccac ttctggggcg cgcgggtgac catcttcatg 720  
 ggcaacgtgg tcagctacct gctgttctct ctgcttttct cgcgggtgct gctcgtggat 780  
 ttccagccgg cgcgcgccg ctccctggag ctgctgtct atttctgggc tttcacgctg 840  
 ctgtgcgagg aactgcgcca gggcctgagc ggaggcgggg gcagcctcgc cagcgggggc 900  
 cccgggcctg gccatgcctc actgagccag cgctgcgcc tctacctgc cgacagctgg 960  
 aaccagtgcg acctagtggc tctcacctgc ttccctctgg gcgtgggctg ccggtgacc 1020  
 ccgggtttgt accacctggg ccgcaactgt ctctgcatcg acttcatggt tttcacgggtg 1080  
 cggctgcttc acatcttcac ggtcaacaaa cagctggggc ccaagatcgt catcgtgagc 1140  
 aagatgatga aggacgtgtt cttcttctc ttcttctcgc gcgtgtggct ggtagcctat 1200  
 ggcggtggcca cggaggggct cctgagggca cgggacagt acttcccaag tatcctgcgc 1260  
 cgctgttct accgtcccta cctgcagatc ttccggcaga tccccagga ggacatggac 1320  
 gtggccctca tggagcacag caactgctcg tcggagcccg gcttctgggc acaccctct 1380  
 ggggcccagg cgggcacctg cgtctcccag tatgccaaact ggctgggtgt gctgctcctc 1440  
 gtcattcttc tgctcgtggc caacatcctg ctggtcaact tgctcattgc catgttcagt 1500  
 tacacattcg gcaaagtaca gggcaacagc gatctctact ggaaggcgca gcgttaccgc 1560  
 ctcatccggg aattccactc tcggcccgcg ctggccccgc cctttatcgt catctcccac 1620  
 ttgcgcctcc tgctcaggca attgtgcagg cgaccscgga gccccagcc gtcctcccgc 1680  
 gccctcgagc atttccgggt ttacctttct aagggaagcc agcgggaagct gctaactgtg 1740  
 gaatcggtgc ataaggagaa ctttctgctg gcacgcgcta gggacaagcg ggagagcgac 1800  
 tccgagmgtc tgaagcgcac gtcccagaag gtggacttgg cactgaaaca gctgggacac 1860

-37-

```

atccgcgagt acgaacagcg cctgaaagtg ctggagcggg aggtccagca gtgtacctcg 1920
gccccgcac ctggtggcct tgctcttgag gtgagcccca tgtccatctg ggccactgtc 1980
aggaccacct ttgggagtgt catccttaca aaccacagca tgcccggtc ctcccagaac 2040
cagtcccagc ctgggaggat caaggcctgg atcccrggcc gttatccatc tggaggctgc 2100
agggtccttg gggtaacagg gaccacagac ccctcaccac tcacagattc ctcacactgg 2160
ggaataaag ccatttcaga 2180

```

<210> 26  
 <211> 725  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (553)...(553)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (603)...(603)  
 <223> UNKNOWN

<400> 26

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Arg | Pro | Arg | Ile | Arg | His | Glu | Gly | Leu | Gly | Gln | Ala | Pro | Trp | Ser |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Asp | Leu | Leu | Leu | Trp | Ala | Leu | Leu | Leu | Asn | Arg | Ala | Gln | Met | Ala | Met |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Tyr | Phe | Trp | Glu | Met | Gly | Ser | Asn | Ala | Val | Ser | Ser | Ala | Leu | Gly | Ala |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Cys | Leu | Leu | Leu | Arg | Val | Met | Ala | Arg | Leu | Glu | Pro | Asp | Ala | Glu | Glu |
| 50  |     |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Ala | Ala | Arg | Arg | Lys | Asp | Leu | Ala | Phe | Lys | Phe | Glu | Gly | Met | Gly | Val |
| 65  |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     |     | 80  |
| Asp | Leu | Phe | Gly | Glu | Cys | Tyr | Arg | Ser | Ser | Glu | Val | Arg | Ala | Ala | Arg |
|     |     |     | 85  |     |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Leu | Leu | Leu | Arg | Arg | Cys | Pro | Leu | Trp | Gly | Asp | Ala | Thr | Cys | Leu | Gln |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Leu | Ala | Met | Gln | Ala | Asp | Ala | Arg | Ala | Phe | Phe | Ala | Gln | Asp | Gly | Val |
|     |     | 115 |     |     |     | 120 |     |     |     |     |     | 125 |     |     |     |
| Gln | Ser | Leu | Leu | Thr | Gln | Lys | Trp | Trp | Gly | Asp | Met | Ala | Ser | Thr | Thr |
| 130 |     |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Pro | Ile | Trp | Ala | Leu | Val | Leu | Ala | Phe | Phe | Cys | Pro | Pro | Leu | Ile | Tyr |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Thr | Arg | Leu | Ile | Thr | Phe | Arg | Lys | Ser | Glu | Glu | Pro | Thr | Arg | Glu |     |
|     |     |     | 165 |     |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Glu | Leu | Glu | Phe | Asp | Met | Asp | Ser | Val | Ile | Asn | Gly | Glu | Gly | Pro | Val |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Gly | Thr | Ala | Asp | Pro | Ala | Glu | Lys | Thr | Pro | Leu | Gly | Val | Pro | Arg | Gln |
|     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Ser | Gly | Arg | Pro | Gly | Cys | Cys | Gly | Gly | Arg | Cys | Gly | Gly | Arg | Arg | Cys |
| 210 |     |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Leu | Arg | Arg | Trp | Phe | His | Phe | Trp | Gly | Ala | Pro | Val | Thr | Ile | Phe | Met |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
| Gly | Asn | Val | Val | Ser | Tyr | Leu | Leu | Phe | Leu | Leu | Leu | Phe | Ser | Arg | Val |
|     |     |     | 245 |     |     |     |     |     | 250 |     |     |     |     | 255 |     |
| Leu | Leu | Val | Asp | Phe | Gln | Pro | Ala | Pro | Pro | Gly | Ser | Leu | Glu | Leu | Leu |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Leu | Tyr | Phe | Trp | Ala | Phe | Thr | Leu | Leu | Cys | Glu | Glu | Leu | Arg | Gln | Gly |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Leu | Ser | Gly | Gly | Gly | Gly | Ser | Leu | Ala | Ser | Gly | Gly | Pro | Gly | Pro | Gly |
| 290 |     |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |



-38-

His Ala Ser Leu Ser Gln Arg Leu Arg Leu Tyr Leu Ala Asp Ser Trp  
 305 310 315 320  
 Asn Gln Cys Asp Leu Val Ala Leu Thr Cys Phe Leu Leu Gly Val Gly  
 325 330 335  
 Cys Arg Leu Thr Pro Gly Leu Tyr His Leu Gly Arg Thr Val Leu Cys  
 340 345 350  
 Ile Asp Phe Met Val Phe Thr Val Arg Leu Leu His Ile Phe Thr Val  
 355 360 365  
 Asn Lys Gln Leu Gly Pro Lys Ile Val Ile Val Ser Lys Met Met Lys  
 370 375 380  
 Asp Val Phe Phe Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr  
 385 390 395 400  
 Gly Val Ala Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro  
 405 410 415  
 Ser Ile Leu Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gln Ile Phe Gly  
 420 425 430  
 Gln Ile Pro Gln Glu Asp Met Asp Val Ala Leu Met Glu His Ser Asn  
 435 440 445  
 Cys Ser Ser Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gln Ala  
 450 455 460  
 Gly Thr Cys Val Ser Gln Tyr Ala Asn Trp Leu Val Val Leu Leu Leu  
 465 470 475 480  
 Val Ile Phe Leu Leu Val Ala Asn Ile Leu Leu Val Asn Leu Leu Ile  
 485 490 495  
 Ala Met Phe Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu  
 500 505 510  
 Tyr Trp Lys Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg  
 515 520 525  
 Pro Ala Leu Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu  
 530 535 540  
 Leu Arg Gln Leu Cys Arg Arg Pro Xaa Ser Pro Gln Pro Ser Ser Pro  
 545 550 555 560  
 Ala Leu Glu His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys  
 565 570 575  
 Leu Leu Thr Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg  
 580 585 590  
 Ala Arg Asp Lys Arg Glu Ser Asp Ser Glu Xaa Leu Lys Arg Thr Ser  
 595 600 605  
 Gln Lys Val Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr  
 610 615 620  
 Glu Gln Arg Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Thr Ser  
 625 630 635 640  
 Ala Pro Ala Pro Gly Gly Leu Val Leu Glu Val Ser Pro Met Ser Ile  
 645 650 655  
 Trp Ala Thr Val Arg Thr Thr Phe Gly Ser Val Ile Leu Thr Asn His  
 660 665 670  
 Ser Met Pro Gly Ser Ser Gln Asn Gln Ser Gln Pro Gly Arg Ile Lys  
 675 680 685  
 Ala Trp Ile Pro Gly Arg Tyr Pro Ser Gly Gly Cys Arg Val Leu Gly  
 690 695 700  
 Val Thr Gly Thr Thr Asp Pro Ser Pro Leu Thr Asp Ser Ser His Trp  
 705 710 715 720  
 Gly Asn Lys Ala Ile  
 725

&lt;210&gt; 27

&lt;211&gt; 7419

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 27

|            |            |             |            |             |            |      |
|------------|------------|-------------|------------|-------------|------------|------|
| cggggaccga | tccagcctcc | ggactctagc  | ctaggctttt | gcaaaaagct  | atttaggtga | 60   |
| cactatagaa | ggtacgcctg | caggtaccgg  | tccggaattc | ccgggtcgac  | ccacgcgtcc | 120  |
| gcagccccgt | cgccggcgga | ggcgggcg    | ggcgcgtncc | ctgtggccag  | tcacccggag | 180  |
| gagttggtcg | cacaattatg | aaagactcgg  | cttctgctgc | tagcgccgga  | gctgagttag | 240  |
| ttctgagaag | gtttccctgg | gcgttccttg  | tccggcggcc | tctgctgccg  | cctccggaga | 300  |
| cgcttccccg | tagatggcta | caggccgcgg  | aggaggagga | ggtggagttg  | ctgcccttcc | 360  |
| ggagtccgcc | ccgtgaggag | aatgtcccag  | aaatcctgga | tagaaagcac  | tttgaccaag | 420  |
| agggaaatgt | tatatattat | accaagttcc  | aaggaccctc | acagatgcct  | tccaggatgt | 480  |
| caaatttgtc | agcaactcgt | caggtgtttt  | tgtggtcgct | tgggtcaagca | acatgcttgt | 540  |
| tttactgcaa | gtcttgccat | gaaatactca  | gatgtgaaat | tgggtgacca  | ttttaatcag | 600  |
| gcaatagaag | aatggtctgt | ggaaaagcat  | acagaacaga | gcccaacgga  | tgcttatgga | 660  |
| gtcataaatt | ttcaaggggg | ttctcattcc  | tacagagcta | agtatgtgag  | gctatcatat | 720  |
| gacaccaaac | ctgaagtcac | tctgcaactt  | ctgcttaaa  | aatggcaaat  | ggagttaccc | 780  |
| aaacttggtt | tctctgtaca | tgggggcacg  | cagaaatttg | agcttcaccc  | acgaatcaag | 840  |
| cagttgcttg | gaaaaggtct | tattaaagct  | gcagttacaa | ctggagcctg  | gattttaact | 900  |
| ggaggagtaa | acacaggtgt | ggcaaaacat  | gttgagatg  | ccctcaaaga  | acatgcttcc | 960  |
| agatcatctc | gaaagatttg | cactatcggg  | atagctccat | ggggagtgat  | tgaaaacaga | 1020 |
| aatgatcttg | ttgggagaga | tgtggttgct  | ccttatcaaa | ccttattgaa  | ccccctgagc | 1080 |
| aaattgaatg | ttttgaataa | tctgcattcc  | catttcata  | tgggtgatga  | tggcactgtt | 1140 |
| ggaaagtatg | gggcggaagt | cagactgaga  | agagaacttg | aaaaaactat  | taatcagcaa | 1200 |
| agaattcatg | ctaggattgg | ccaggggtgc  | cctgtggtgg | cacttatatt  | tgagggtggg | 1260 |
| ccaaatgtta | tcctcacagt | tcttgaatac  | cttcaggaaa | gccccctgt   | tccagtagtt | 1320 |
| gtgtgtgaag | gaacaggcag | agctgcagat  | ctgctagcgt | atattcataa  | acaaacagaa | 1380 |
| gaaggaggga | atcttcttga | tgcagcagag  | ccgatatta  | tttccactat  | caaaaaaaca | 1440 |
| tttaactttg | gccagaatga | agcacttcac  | ttatttcaaa | cactgatgga  | gtgcatgaaa | 1500 |
| agaaaggagc | ttatcactgt | tttccatatt  | gggtcagatg | aacatcaaga  | tatagatgta | 1560 |
| gcaatactta | ctgcactgct | aaaaggtact  | aatgcactcg | catttgacca  | gcttatcctt | 1620 |
| acattggcat | gggatagagt | tgacattgcc  | aaaaatcatg | tatttgttta  | tggacagcag | 1680 |
| tggctggttg | gactccttga | acaagctatg  | cctgatgctc | ttgtaatgga  | tagagttgca | 1740 |
| tttgtaaaac | ttcttattga | aaatggagta  | agcatgcata | aattccttac  | cattccgaga | 1800 |
| ctggaagaac | tttacaacac | taaacaaggt  | ccaactaatc | caatgctgtt  | tcatcttggt | 1860 |
| cgagacgtca | aacagggaag | tcttcctcca  | ggatataaga | tcactctgat  | tgatatagga | 1920 |
| cttgttattg | aatatctcat | gggaggaacc  | tacagatgca | cctatactag  | gaaacgtttt | 1980 |
| cgattatata | ataatagtct | tgggtgaaat  | aatcggaggt | ctggccgaaa  | tacctccagc | 2040 |
| agcactcctc | agttgcgaaa | gagtcatgaa  | tcttttgcca | atagggcaga  | taaaaaggaa | 2100 |
| aaaatgaggc | ataaccattt | cattaagaca  | gcacagccct | tccgaccaa   | gattgataca | 2160 |
| gttatggaag | aaggaaagaa | gaaaagaacc  | aaagatgaaa | ttgtagacat  | tgatgatcca | 2220 |
| gaaaccaagc | gctttcctta | tccacttaat  | gaacttttaa | tttgggcttg  | ccttatgaag | 2280 |
| aggcaggtca | tggcccgttt | tttatggcaa  | catggtgaag | aatcaatggc  | taaagcatta | 2340 |
| gttgcttgta | agatctatcg | ttcaatggca  | tatgaagcaa | agcagagtga  | cctggtagat | 2400 |
| gatacttcag | aagaactaaa | acagtattcc  | aatgattttg | gtcagttggc  | cgttgaatta | 2460 |
| ttagaacagt | ccttcagaca | agatgaaacc  | atggctatga | aattgctcac  | ttatgaactg | 2520 |
| aagaactgga | gtaattcaac | ctgccttaag  | ttagcagttt | cttcaagact  | tagacctttt | 2580 |
| gtagctcaca | cctgtacaca | aatgttgtta  | tctgatattg | ggatgggaag  | gctgaatatg | 2640 |
| aggaaaaatt | cctggtacaa | ggtcatacta  | agcattttag | ttccacctgc  | catattgctg | 2700 |
| ttagagtata | aaactaaggc | tgaaatgtcc  | catatcccac | aatctcaaga  | tgctcatcag | 2760 |
| atgacaatgg | atgacagcga | aaacaacttt  | cagaacataa | cagaagagat  | ccccatggaa | 2820 |
| gtgtttaaag | aagtacggat | tttggatagt  | aatgaaggaa | agaatgagat  | ggagatacaa | 2880 |
| atgaaatcaa | aaaagcttcc | aattacgcga  | aagttttatg | ccttttatca  | tgcaccaatt | 2940 |
| gtaaaattct | ggtttaacac | gttggcatat  | ttaggatttc | tgatgcttta  | tacatttgtg | 3000 |
| gttcttgtac | aaatggaaca | gttaccttca  | gttcaagaat | ggattgttat  | tgcttatatt | 3060 |
| tttacttatg | ccattgagaa | agtccgtgag  | atctttatgt | ctgaagctgg  | gaaagttaac | 3120 |
| cagaagatta | aagtatgggt | tagtgattac  | ttcaacatca | gtgatacaat  | tgccataatt | 3180 |
| tctttcttca | ttggatttgg | actaagattt  | ggagcaaaat | ggaactttgc  | aaatgcatat | 3240 |
| gataatcatg | tttttgtggc | tggaaagatta | atttactgtc | ttaacataat  | attttggtat | 3300 |
| gtgcgtttgc | tagattttct | agctgtaaat  | caacaggcag | gaccttatgt  | aatgatgatt | 3360 |
| ggaaaaatgg | tggccaatat | gttctacatt  | gtagtgatta | tggctcttgt  | attacttagt | 3420 |
| tttgggtgtc | ccgaaaaggc | aatactttat  | cctcatgaag | caccatcttg  | gactcttgct | 3480 |
| aaagatatag | tttttcaccc | atactggatg  | atttttggtg | aagtttatgc  | atacgaaatt | 3540 |

|             |             |             |            |             |             |      |
|-------------|-------------|-------------|------------|-------------|-------------|------|
| gatgtgtgtg  | caaatgattc  | tggtatccct  | caaatctgtg | gtcctgggac  | gtggttgact  | 3600 |
| ccatttcttc  | aagcagtcta  | cctcttttga  | cagtatatca | ttatggttaa  | tcttcttatt  | 3660 |
| gcatttttca  | acaatgtgta  | tttacaagtg  | aaggcaattt | ccaatattgt  | atggaagtac  | 3720 |
| cagcgttatc  | attttattat  | ggcttatcat  | gagaaaccag | ttctgcctcc  | tccacttatc  | 3780 |
| attcttagcc  | atatagtttc  | tctgttttgc  | tgcatatgta | agagaagaaa  | gaaagataag  | 3840 |
| acttccgatg  | gacccaaaact | tttcttaaca  | gaagaagatc | aaaagaaaact | tcatgatttt  | 3900 |
| gaagagcagt  | gtgttgaaat  | gtatttcaat  | gaaaaagatg | acaaatttca  | ttctgggagt  | 3960 |
| gaagagagaa  | ttcgtgtcac  | ttttgaaaga  | gtggaacaga | tgtgcattca  | gattaaagaa  | 4020 |
| gttgagagatc | gtgtcaacta  | cataaaaaaga | tcattacaat | cattagattc  | tcaaattggc  | 4080 |
| catttgcaag  | atctttcagc  | cctgacggta  | gatacattaa | aaacactcac  | tgcccagaaa  | 4140 |
| gcgtcggaag  | ctagcaaagt  | tcataatgaa  | atcacacgag | aactgagcat  | ttccaaacac  | 4200 |
| ttggctcaaa  | accttattga  | tgatggctct  | gtaagacctt | ctgtatggaa  | aaagcatggg  | 4260 |
| gttgtaaata  | cacttagctc  | ctctcttctc  | caaggtgatc | ttgaaagtaa  | taatcctttt  | 4320 |
| cattgtaata  | ttttaatgaa  | agatgacaaa  | gatccccagt | gtaatatatt  | tggtaagac   | 4380 |
| ttacctgcag  | taccccagag  | aaaagaattt  | aattttccag | aggctgggtc  | ctcttctggt  | 4440 |
| gccttattcc  | caagtgtgtg  | ttcccctcca  | gaactgcgac | agagactaca  | tggggtagaa  | 4500 |
| ctcttaaaaa  | tatttaataa  | aatcaaaaa   | ttaggcagtt | catctactag  | cataccacat  | 4560 |
| ctgtcatccc  | caccaaccaa  | attttttgtt  | agtacaccat | ctcagccaag  | ttgcaaaaagc | 4620 |
| cacttggaag  | ctggaaccaa  | agatcaagaa  | actgtttgct | ctaaagctac  | agaaggagat  | 4680 |
| aatacagaat  | ttggagcatt  | tgtaggacac  | agagatagca | tggatttaca  | gaggtttaaa  | 4740 |
| gaaacatcaa  | acaagataaa  | aatactatcc  | aataacaata | cttctgaaaa  | cactttgaaa  | 4800 |
| cgagtgaagt  | ctcttgctgg  | atttactgac  | tgtcacagaa | cttccattcc  | tgttcattca  | 4860 |
| aaacaagcag  | aaaaaatcag  | tagaaggcca  | tctaccgaag | acactcatga  | agtagattcc  | 4920 |
| aaagcagctt  | taataccgga  | ttggttacaa  | gatagaccaa | caaacagaga  | aatgcacatc  | 4980 |
| gaagaaggaa  | cattaaatgg  | tctcacttct  | ccatttaagc | cagctatgga  | tacaaattac  | 5040 |
| tattattcag  | ctgtggaaag  | aaataacttg  | atgaggttat | cacagagcat  | tccatttaca  | 5100 |
| cctgtgcctc  | caagagggga  | gcctgtcaca  | gtgtatcggt | tgggaagagag | ttcacccaac  | 5160 |
| atactaaata  | acagcatgtc  | ttcttggtca  | caactaggcc | tctgtgccaa  | aatagagttt  | 5220 |
| ttaagcaaaag | aggagatggg  | aggagggtta  | cgaagagctg | tcaaagtaca  | gtgtacctgg  | 5280 |
| tcagaacatg  | atatacctcaa | atcagggcatt | ctttatatta | tcaaatcttt  | tcttccagag  | 5340 |
| gtggttaata  | catggtcaag  | tatttataaa  | gaagatacag | ttctgcatct  | ctgtctgaga  | 5400 |
| gaaattcaac  | aacagagagc  | agcacaaaag  | cttacgtttg | cctttaatca  | aatgaaaccc  | 5460 |
| aaatccatac  | catattctcc  | aaggttcctt  | gaagttttcc | tgctgtattg  | ccattcagca  | 5520 |
| ggacagtggg  | ttgctgtgga  | agaatgtatg  | actggagaa  | ttagaaaata  | caacaataat  | 5580 |
| aatggagatg  | agattattcc  | aactaatact  | ctggaagaga | tcatgctagc  | cttagccac   | 5640 |
| tggacttacg  | aatatacaag  | aggggagtta  | ctggactttg | atttgcaagg  | tgttggtgaa  | 5700 |
| aatttgactg  | acccatctgt  | gataaaagca  | gaagaaaaga | gatcctgtga  | tatggttttt  | 5760 |
| ggcccagcaa  | atctaggaga  | agatgcaatt  | aaaaacttca | gagcaaaaca  | tactgtaat   | 5820 |
| tcttgctgta  | gaaagcttaa  | acttccagat  | ctgaagagga | atgattatac  | gcctgataaa  | 5880 |
| attatatttc  | ctcaggatga  | gccttcagat  | ttgaatcttc | agcctggaaa  | ttccacccaa  | 5940 |
| gaatcagaat  | caactaattc  | tgttcgtctg  | atgtttataa | attaatatta  | ctgaatcatt  | 6000 |
| ggttttgcct  | gcacctcaca  | gaaatgttac  | tgtgtcactt | ttccctcgga  | aggaaattgt  | 6060 |
| ttggtaatat  | agaaaggtgt  | atgcaagttg  | aatttgctga | ctccagcaca  | gttaaaaggt  | 6120 |
| caatattctt  | ttgacctgat  | taatcagtca  | gaaagtcctt | ataggataga  | gctggcagct  | 6180 |
| gagaaatttt  | aaaggtaatt  | gataattagt  | atgttgaact | ttttaaaagg  | ctctttgtat  | 6240 |
| agcagaggat  | ctcaatttgac | tttgttttga  | tgagggtgat | gccctctctt  | atgtggtaca  | 6300 |
| ataccattaa  | ccaaaggtag  | gtgtccatgc  | agattttatt | ggcagctggt  | ttattgccat  | 6360 |
| tcaactaggg  | aaatgaagaa  | atcacgcagc  | cttttggtta | aatggcagtc  | aaaattttcc  | 6420 |
| tcagtgtatt  | tagtgtgttc  | agtgatgata  | tcactgggtc | ccaactagat  | gcttgttggc  | 6480 |
| cacgggaagg  | gaaatgactt  | gttctaattc  | taggttcaca | gaggtatgag  | aagcctgaac  | 6540 |
| tgaagaccat  | tttcaagagg  | gacggtat    | atgaatcagg | gttaggctcc  | atattttaaag | 6600 |
| atagagccag  | tttttttttt  | aaatagaacc  | caaatgtgtg | aaaaatgtta  | attgggtttt  | 6660 |
| ttaaacattg  | ttttatcaag  | tcactgttaa  | gtagaagaaa | gccatggtta  | actgatacat  | 6720 |
| aacctaaatt  | ataaaaagcag | aaaccttaact | cactcgtcaa | gggaagttac  | cttttgagga  | 6780 |
| aagttaaagt  | acttttttcc  | ctatctgtat  | ctatagcaac | aaccagaaac  | ttacaaactt  | 6840 |
| ctccaaagat  | tttattgatt  | gttatatcaa  | atcagaatgt | aaacatgaac  | tcttgcatat  | 6900 |
| atttaaaatt  | gtgttggaac  | atgtgaacat  | gaatgctgtt | tgggtactta  | agaaattrat  | 6960 |
| tcagtnngat  | tatcattatg  | tganactggc  | agattgcagt | gcanccttat  | gccaaataaaa | 7020 |
| tgtaatattar | cagccccaga  | tattgttgaa  | tattcaacaa | taacaagaaa  | agcttttcat  | 7080 |
| ctaagtttta  | tgctttaatt  | tttttctttt  | tttttctttt | ttcttttgtt  | tccttggtac  | 7140 |

-41-

|             |            |            |            |            |            |      |
|-------------|------------|------------|------------|------------|------------|------|
| taattttaat  | ttttatttgg | aagggagcag | tataaagctt | atttgatatt | agtagtgat  | 7200 |
| ctcatagata  | cagacaaggc | aagagatgat | aagctgttta | aatagtgtt  | aatattgatt | 7260 |
| gggggtgggg  | agaaagaaaa | agtgtattac | ttaaagatac | tatatacskt | ttktatatca | 7320 |
| ttaaattcttt | aaaagaaatn | naataaattt | attgttttnc | aaaaaaaaac | ccnntaaaaa | 7380 |
| aaaaagggcg  | gcccctctag | aggatccctc | gaggggccc  |            |            | 7419 |

<210> 28  
 <211> 1865  
 <212> PRT  
 <213> Homo Sapiens

<400> 28

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ser | Gln | Lys | Ser | Trp | Ile | Glu | Ser | Thr | Leu | Thr | Lys | Arg | Glu | Cys |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Val | Tyr | Ile | Ile | Pro | Ser | Ser | Lys | Asp | Pro | His | Arg | Cys | Leu | Pro | Gly |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Cys | Gln | Ile | Cys | Gln | Gln | Leu | Val | Arg | Cys | Phe | Cys | Gly | Arg | Leu | Val |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Lys | Gln | His | Ala | Cys | Phe | Thr | Ala | Ser | Leu | Ala | Met | Lys | Tyr | Ser | Asp |
|     |     | 50  |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Val | Lys | Leu | Gly | Asp | His | Phe | Asn | Gln | Ala | Ile | Glu | Glu | Trp | Ser | Val |
|     |     | 65  |     |     | 70  |     |     |     |     | 75  |     |     |     | 80  |     |
| Glu | Lys | His | Thr | Glu | Gln | Ser | Pro | Thr | Asp | Ala | Tyr | Gly | Val | Ile | Asn |
|     |     |     | 85  |     |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Phe | Gln | Gly | Gly | Ser | His | Ser | Tyr | Arg | Ala | Lys | Tyr | Val | Arg | Leu | Ser |
|     |     | 100 |     |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Tyr | Asp | Thr | Lys | Pro | Glu | Val | Ile | Leu | Gln | Leu | Leu | Leu | Lys | Glu | Trp |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Gln | Met | Glu | Leu | Pro | Lys | Leu | Val | Ile | Ser | Val | His | Gly | Gly | Met | Gln |
|     |     | 130 |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Lys | Phe | Glu | Leu | His | Pro | Arg | Ile | Lys | Gln | Leu | Leu | Gly | Lys | Gly | Leu |
|     |     | 145 |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Ile | Lys | Ala | Ala | Val | Thr | Thr | Gly | Ala | Trp | Ile | Leu | Thr | Gly | Gly | Val |
|     |     |     | 165 |     |     |     |     | 170 |     |     |     |     |     | 175 |     |
| Asn | Thr | Gly | Val | Ala | Lys | His | Val | Gly | Asp | Ala | Leu | Lys | Glu | His | Ala |
|     |     | 180 |     |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Ser | Arg | Ser | Ser | Arg | Lys | Ile | Cys | Thr | Ile | Gly | Ile | Ala | Pro | Trp | Gly |
|     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Val | Ile | Glu | Asn | Arg | Asn | Asp | Leu | Val | Gly | Arg | Asp | Val | Val | Ala | Pro |
|     |     | 210 |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Tyr | Gln | Thr | Leu | Leu | Asn | Pro | Leu | Ser | Lys | Leu | Asn | Val | Leu | Asn | Asn |
|     |     | 225 |     |     | 230 |     |     |     |     | 235 |     |     |     | 240 |     |
| Leu | His | Ser | His | Phe | Ile | Leu | Val | Asp | Asp | Gly | Thr | Val | Gly | Lys | Tyr |
|     |     |     | 245 |     |     |     |     |     | 250 |     |     |     |     | 255 |     |
| Gly | Ala | Glu | Val | Arg | Leu | Arg | Arg | Glu | Leu | Glu | Lys | Thr | Ile | Asn | Gln |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Gln | Arg | Ile | His | Ala | Arg | Ile | Gly | Gln | Gly | Val | Pro | Val | Val | Ala | Leu |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Ile | Phe | Glu | Gly | Gly | Pro | Asn | Val | Ile | Leu | Thr | Val | Leu | Glu | Tyr | Leu |
|     |     | 290 |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Gln | Glu | Ser | Pro | Pro | Val | Pro | Val | Val | Val | Cys | Glu | Gly | Thr | Gly | Arg |
|     |     | 305 |     |     | 310 |     |     |     |     | 315 |     |     |     | 320 |     |
| Ala | Ala | Asp | Leu | Leu | Ala | Tyr | Ile | His | Lys | Gln | Thr | Glu | Glu | Gly | Gly |
|     |     |     | 325 |     |     |     |     |     | 330 |     |     |     |     | 335 |     |
| Asn | Leu | Pro | Asp | Ala | Ala | Glu | Pro | Asp | Ile | Ile | Ser | Thr | Ile | Lys | Lys |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |
| Thr | Phe | Asn | Phe | Gly | Gln | Asn | Glu | Ala | Leu | His | Leu | Phe | Gln | Thr | Leu |
|     |     | 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |     |     |

-42-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Cys | Met | Lys | Arg | Lys | Glu | Leu | Ile | Thr | Val | Phe | His | Ile | Gly |
| 370 |     |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |
| Ser | Asp | Glu | His | Gln | Asp | Ile | Asp | Val | Ala | Ile | Leu | Thr | Ala | Leu | Leu |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Lys | Gly | Thr | Asn | Ala | Ser | Ala | Phe | Asp | Gln | Leu | Ile | Leu | Thr | Leu | Ala |
|     |     |     | 405 |     |     |     |     |     | 410 |     |     |     |     |     | 415 |
| Trp | Asp | Arg | Val | Asp | Ile | Ala | Lys | Asn | His | Val | Phe | Val | Tyr | Gly | Gln |
|     |     |     | 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Gln | Trp | Leu | Val | Gly | Ser | Leu | Glu | Gln | Ala | Met | Leu | Asp | Ala | Leu | Val |
|     |     |     | 435 |     |     |     | 440 |     |     |     |     | 445 |     |     |     |
| Met | Asp | Arg | Val | Ala | Phe | Val | Lys | Leu | Leu | Ile | Glu | Asn | Gly | Val | Ser |
| 450 |     |     |     |     |     |     | 455 |     |     |     | 460 |     |     |     |     |
| Met | His | Lys | Phe | Leu | Thr | Ile | Pro | Arg | Leu | Glu | Glu | Leu | Tyr | Asn | Thr |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Lys | Gln | Gly | Pro | Thr | Asn | Pro | Met | Leu | Phe | His | Leu | Val | Arg | Asp | Val |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Lys | Gln | Gly | Asn | Leu | Pro | Pro | Gly | Tyr | Lys | Ile | Thr | Leu | Ile | Asp | Ile |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Gly | Leu | Val | Ile | Glu | Tyr | Leu | Met | Gly | Gly | Thr | Tyr | Arg | Cys | Thr | Tyr |
|     |     |     | 515 |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| Thr | Arg | Lys | Arg | Phe | Arg | Leu | Ile | Tyr | Asn | Ser | Leu | Gly | Gly | Asn | Asn |
| 530 |     |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |
| Arg | Arg | Ser | Gly | Arg | Asn | Thr | Ser | Ser | Ser | Thr | Pro | Gln | Leu | Arg | Lys |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Ser | His | Glu | Ser | Phe | Gly | Asn | Arg | Ala | Asp | Lys | Lys | Glu | Lys | Met | Arg |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |
| His | Asn | His | Phe | Ile | Lys | Thr | Ala | Gln | Pro | Phe | Arg | Pro | Lys | Ile | Asp |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Thr | Val | Met | Glu | Glu | Gly | Lys | Lys | Arg | Thr | Lys | Asp | Glu | Ile | Val |     |
|     |     | 595 |     |     |     | 600 |     |     |     |     | 605 |     |     |     |     |
| Asp | Ile | Asp | Asp | Pro | Glu | Thr | Lys | Arg | Phe | Pro | Tyr | Pro | Leu | Asn | Glu |
|     |     |     |     |     | 610 |     | 615 |     |     |     | 620 |     |     |     |     |
| Leu | Leu | Ile | Trp | Ala | Cys | Leu | Met | Lys | Arg | Gln | Val | Met | Ala | Arg | Phe |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Leu | Trp | Gln | His | Gly | Glu | Glu | Ser | Met | Ala | Lys | Ala | Leu | Val | Ala | Cys |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |
| Lys | Ile | Tyr | Arg | Ser | Met | Ala | Tyr | Glu | Ala | Lys | Gln | Ser | Asp | Leu | Val |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Asp | Asp | Thr | Ser | Glu | Glu | Leu | Lys | Gln | Tyr | Ser | Asn | Asp | Phe | Gly | Gln |
|     |     |     | 675 |     |     |     | 680 |     |     |     |     | 685 |     |     |     |
| Leu | Ala | Val | Glu | Leu | Leu | Glu | Gln | Ser | Phe | Arg | Gln | Asp | Glu | Thr | Met |
|     |     |     | 690 |     |     | 695 |     |     |     |     | 700 |     |     |     |     |
| Ala | Met | Lys | Leu | Leu | Thr | Tyr | Glu | Leu | Lys | Asn | Trp | Ser | Asn | Ser | Thr |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     |     | 720 |
| Cys | Leu | Lys | Leu | Ala | Val | Ser | Ser | Arg | Leu | Arg | Pro | Phe | Val | Ala | His |
|     |     |     |     | 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |
| Thr | Cys | Thr | Gln | Met | Leu | Leu | Ser | Asp | Met | Trp | Met | Gly | Arg | Leu | Asn |
|     |     |     | 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |
| Met | Arg | Lys | Asn | Ser | Trp | Tyr | Lys | Val | Ile | Leu | Ser | Ile | Leu | Val | Pro |
|     |     | 755 |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |
| Pro | Ala | Ile | Leu | Leu | Leu | Glu | Tyr | Lys | Thr | Lys | Ala | Glu | Met | Ser | His |
|     |     |     | 770 |     |     | 775 |     |     |     |     | 780 |     |     |     |     |
| Ile | Pro | Gln | Ser | Gln | Asp | Ala | His | Gln | Met | Thr | Met | Asp | Asp | Ser | Glu |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     |     | 800 |
| Asn | Asn | Phe | Gln | Asn | Ile | Thr | Glu | Glu | Ile | Pro | Met | Glu | Val | Phe | Lys |
|     |     |     |     | 805 |     |     |     |     | 810 |     |     |     |     | 815 |     |
| Glu | Val | Arg | Ile | Leu | Asp | Ser | Asn | Glu | Gly | Lys | Asn | Glu | Met | Glu | Ile |
|     |     |     | 820 |     |     |     |     | 825 |     |     |     | 830 |     |     |     |
| Gln | Met | Lys | Ser | Lys | Lys | Leu | Pro | Ile | Thr | Arg | Lys | Phe | Tyr | Ala | Phe |
|     |     | 835 |     |     |     |     | 840 |     |     |     |     | 845 |     |     |     |

-43-

Tyr His Ala Pro Ile Val Lys Phe Trp Phe Asn Thr Leu Ala Tyr Leu  
 850 855 860  
 Gly Phe Leu Met Leu Tyr Thr Phe Val Val Leu Val Gln Met Glu Gln  
 865 870 875 880  
 Leu Pro Ser Val Gln Glu Trp Ile Val Ile Ala Tyr Ile Phe Thr Tyr  
 885 890 895  
 Ala Ile Glu Lys Val Arg Glu Ile Phe Met Ser Glu Ala Gly Lys Val  
 900 905 910  
 Asn Gln Lys Ile Lys Val Trp Phe Ser Asp Tyr Phe Asn Ile Ser Asp  
 915 920 925  
 Thr Ile Ala Ile Ile Ser Phe Phe Ile Gly Phe Gly Leu Arg Phe Gly  
 930 935 940  
 Ala Lys Trp Asn Phe Ala Asn Ala Tyr Asp Asn His Val Phe Val Ala  
 945 950 955 960  
 Gly Arg Leu Ile Tyr Cys Leu Asn Ile Ile Phe Trp Tyr Val Arg Leu  
 965 970 975  
 Leu Asp Phe Leu Ala Val Asn Gln Gln Ala Gly Pro Tyr Val Met Met  
 980 985 990  
 Ile Gly Lys Met Val Ala Asn Met Phe Tyr Ile Val Val Ile Met Ala  
 995 1000 1005  
 Leu Val Leu Leu Ser Phe Gly Val Pro Arg Lys Ala Ile Leu Tyr Pro  
 1010 1015 1020  
 His Glu Ala Pro Ser Trp Thr Leu Ala Lys Asp Ile Val Phe His Pro  
 1025 1030 1035 1040  
 Tyr Trp Met Ile Phe Gly Glu Val Tyr Ala Tyr Glu Ile Asp Val Cys  
 1045 1050 1055  
 Ala Asn Asp Ser Val Ile Pro Gln Ile Cys Gly Pro Gly Thr Trp Leu  
 1060 1065 1070  
 Thr Pro Phe Leu Gln Ala Val Tyr Leu Phe Val Gln Tyr Ile Ile Met  
 1075 1080 1085  
 Val Asn Leu Leu Ile Ala Phe Phe Asn Asn Val Tyr Leu Gln Val Lys  
 1090 1095 1100  
 Ala Ile Ser Asn Ile Val Trp Lys Tyr Gln Arg Tyr His Phe Ile Met  
 1105 1110 1115 1120  
 Ala Tyr His Glu Lys Pro Val Leu Pro Pro Pro Leu Ile Ile Leu Ser  
 1125 1130 1135  
 His Ile Val Ser Leu Phe Cys Cys Ile Cys Lys Arg Arg Lys Lys Asp  
 1140 1145 1150  
 Lys Thr Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp Gln Lys  
 1155 1160 1165  
 Lys Leu His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe Asn Glu  
 1170 1175 1180  
 Lys Asp Asp Lys Phe His Ser Gly Ser Glu Glu Arg Ile Arg Val Thr  
 1185 1190 1195 1200  
 Phe Glu Arg Val Glu Gln Met Cys Ile Gln Ile Lys Glu Val Gly Asp  
 1205 1210 1215  
 Arg Val Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser Gln Ile  
 1220 1225 1230  
 Gly His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu Lys Thr  
 1235 1240 1245  
 Leu Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn Glu Ile  
 1250 1255 1260  
 Thr Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu Ile Asp  
 1265 1270 1275 1280  
 Asp Gly Pro Val Arg Pro Ser Val Trp Lys Lys His Gly Val Val Asn  
 1285 1290 1295  
 Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Leu Glu Ser Asn Asn Pro  
 1300 1305 1310  
 Phe His Cys Asn Ile Leu Met Lys Asp Asp Lys Asp Pro Gln Cys Asn  
 1315 1320 1325

-44-

Ile Phe Gly Gln Asp Leu Pro Ala Val Pro Gln Arg Lys Glu Phe Asn  
 1330 1335 1340  
 Phe Pro Glu Ala Gly Ser Ser Gly Ala Leu Phe Pro Ser Ala Val  
 1345 1350 1355 1360  
 Ser Pro Pro Glu Leu Arg Gln Arg Leu His Gly Val Glu Leu Leu Lys  
 1365 1370 1375  
 Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Ser Thr Ser Ile Pro  
 1380 1385 1390  
 His Leu Ser Ser Pro Pro Thr Lys Phe Phe Val Ser Thr Pro Ser Gln  
 1395 1400 1405  
 Pro Ser Cys Lys Ser His Leu Glu Thr Gly Thr Lys Asp Gln Glu Thr  
 1410 1415 1420  
 Val Cys Ser Lys Ala Thr Glu Gly Asp Asn Thr Glu Phe Gly Ala Phe  
 1425 1430 1435 1440  
 Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser  
 1445 1450 1455  
 Asn Lys Ile Lys Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn Thr Leu  
 1460 1465 1470  
 Lys Arg Val Ser Ser Leu Ala Gly Phe Thr Asp Cys His Arg Thr Ser  
 1475 1480 1485  
 Ile Pro Val His Ser Lys Gln Ala Glu Lys Ile Ser Arg Arg Pro Ser  
 1490 1495 1500  
 Thr Glu Asp Thr His Glu Val Asp Ser Lys Ala Ala Leu Ile Pro Asp  
 1505 1510 1515 1520  
 Trp Leu Gln Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu Glu Gly  
 1525 1530 1535  
 Thr Leu Asn Gly Leu Thr Ser Pro Phe Lys Pro Ala Met Asp Thr Asn  
 1540 1545 1550  
 Tyr Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met Arg Leu Ser Gln  
 1555 1560 1565  
 Ser Ile Pro Phe Thr Pro Val Pro Pro Arg Gly Glu Pro Val Thr Val  
 1570 1575 1580  
 Tyr Arg Leu Glu Glu Ser Ser Pro Asn Ile Leu Asn Asn Ser Met Ser  
 1585 1590 1595 1600  
 Ser Trp Ser Gln Leu Gly Leu Cys Ala Lys Ile Glu Phe Leu Ser Lys  
 1605 1610 1615  
 Glu Glu Met Gly Gly Gly Leu Arg Arg Ala Val Lys Val Gln Cys Thr  
 1620 1625 1630  
 Trp Ser Glu His Asp Ile Leu Lys Ser Gly His Leu Tyr Ile Ile Lys  
 1635 1640 1645  
 Ser Phe Leu Pro Glu Val Val Asn Thr Trp Ser Ser Ile Tyr Lys Glu  
 1650 1655 1660  
 Asp Thr Val Leu His Leu Cys Leu Arg Glu Ile Gln Gln Gln Arg Ala  
 1665 1670 1675 1680  
 Ala Gln Lys Leu Thr Phe Ala Phe Asn Gln Met Lys Pro Lys Ser Ile  
 1685 1690 1695  
 Pro Tyr Ser Pro Arg Phe Leu Glu Val Phe Leu Leu Tyr Cys His Ser  
 1700 1705 1710  
 Ala Gly Gln Trp Phe Ala Val Glu Glu Cys Met Thr Gly Glu Phe Arg  
 1715 1720 1725  
 Lys Tyr Asn Asn Asn Asn Gly Asp Glu Ile Ile Pro Thr Asn Thr Leu  
 1730 1735 1740  
 Glu Glu Ile Met Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr Arg  
 1745 1750 1755 1760  
 Gly Glu Leu Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn Leu Thr  
 1765 1770 1775  
 Asp Pro Ser Val Ile Lys Ala Glu Glu Lys Arg Ser Cys Asp Met Val  
 1780 1785 1790  
 Phe Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Lys Asn Phe Arg Ala  
 1795 1800 1805

-45-

Lys His His Cys Asn Ser Cys Cys Arg Lys Leu Lys Leu Pro Asp Leu  
 1810 1815 1820  
 Lys Arg Asn Asp Tyr Thr Pro Asp Lys Ile Ile Phe Pro Gln Asp Glu  
 1825 1830 1835 1840  
 Pro Ser Asp Leu Asn Leu Gln Pro Gly Asn Ser Thr Lys Glu Ser Glu  
 1845 1850 1855  
 Ser Thr Asn Ser Val Arg Leu Met Leu  
 1860 1865

<210> 29  
 <211> 4061  
 <212> DNA  
 <213> Homo Sapiens

<400> 29  
 ggtctggaag cagagccggc ggagggagcg cgggggccct gggctgcagg aggttgccgc 60  
 ggccgcgcca gcatggtggt gccggagaag gagcagagct ggatcccca gatcttcaag 120  
 aagaagacct gcacgacgtt catagttagc tccacagatc cgggagggac cttgtgccag 180  
 tgtgggcgcc cccggaccgc ccaccccgca gtggccatgg aggatgcctt cggggcagcc 240  
 gtggtgaccg tbtgggacag cgatgcacac accacggaga agcccaccga tgcctacgga 300  
 gagctggact tcacgggggc cggccgcaag cacagcaatt tcctccggct ctctgaccga 360  
 acggatccag ctgcagttta tagtctggtc acacgcacat ggggcttccg tgccccgaac 420  
 ctggtggtgt cagtgtctgg ggatcgggg ggccccgtcc tccagacctg gctgcaggac 480  
 ctgctgcgtc gtgggctggt gcgggctgcc cagagcacag gagcctggat tgtactggtg 540  
 ggtctgcaca cgggcatcgg ccggcatgtt ggtgtggctg tacgggacca tcagatggcc 600  
 agcactgggg gcaccaaggt ggtggccatg ggtgtggccc cctggggtgt ggtccggaat 660  
 agagacaccc tcacaaaccc caagggctcg ttccctgcga ggtaccgggtg gcgcggtgac 720  
 ccggaggacg ggtccagtt tccctggac tacaactact cggccttctt cctggtggac 780  
 gacggcacac acggctgcct ggggggcgag aaccgcttcc gcttgcgcct ggagtcctac 840  
 atctcacagc agaagacggg cgtgggaggg actggaattg acatccctgt cctgctcctc 900  
 ctgattgatg gtgatgagaa gatgttgacg cgaatagaga acgccacca ggctcagctc 960  
 ccatgtctcc tctgtgctgg ctacggggga gctgcggact gcctggcgga gaccctggaa 1020  
 gacactctgg cccaggggag tgggggagcc aggcaaggcg aagcccgaga tcgaatcagg 1080  
 cgtttctttc ccaaagggga ccttgaggtc ctgcaggccc aggtggagag gattatgacc 1140  
 cggaaggagc tcctgacagt ctattcttct gaggatgggt ctgaggaatt cgagaccata 1200  
 gttttgaagg cccttgtaga ggctgtggg agctcggagg cctcagccta cctggatgag 1260  
 ctgcgtttgg ctgtggcttg gaaccgcgtg gacattgccc agagtgaact ctttcggggg 1320  
 gacatccaat ggcggtcctt ccatctcgaa gcttccctca tggacgccct gctgaatgac 1380  
 cggcctgagt tctgtcgctt gctcatttcc caccggcctca gcctgggcca cttcctgacc 1440  
 ccgatgcgac tggcccaact ctacagcgcg gcgcctcca actcgctcat ccgcaacctt 1500  
 ttggaccagg cgtccacag cgcaggcacc aaagccccag ccctaaaagg gggagctgcg 1560  
 gagctccggc cccctgacgt ggggcatgtg ctgaggatgc tgcctgggaa gatgtgcgag 1620  
 ccgaggtacc cctccggggg ccctggggac cctcaccag gccagggctt cggggagagc 1680  
 atgtatctgc tctcgacaa ggccacctcg ccgctctcgc tggatgctgg cctcgggcag 1740  
 gccccttga gcgacctgt tctttgggca ctgttgctga acagggcaca gatggccatg 1800  
 tacttctggg agatgggttc caatgcagtt tcctcagctc ttggggcctg ttgctgctc 1860  
 cgggtgatgg cagccttggg gcctgacgt gaggagggag cagggaggaa agacctggcg 1920  
 ttcaagtttg aggggatggg cgttgacctc tttggcagat gctatcgag cagtgggtg 1980  
 agggctgccc gcctcctcct ccgtcgctgc ccgctctggg gggatgccac ttgcctccag 2040  
 ctggccatgc aagctgacgc ccgtgccttc tttggccagg atggggtaca gtctctgctg 2100  
 acacagaagt ggtggggaga tatggccagc actacacca tctgggccct ggttctcgcc 2160  
 ttcttttgcc ctccactcat ctacaccgc ctcacacct tcaggaaatc agaagaggag 2220  
 cccacacggg agagctaga gttgacatg ctatagtgtc ttaattggga agggcctgtc 2280  
 gggacggcgg acccagccga gaagacgcg ctgggggtcc cgcgccagtc gggccgtccg 2340  
 ggttgctgcg ggggcccgtg cggggggcgc cgggtgcctac gccgctggtt ccacttctgg 2400  
 ggcgcgccgg tgacctctt catgggcaac gtggtcagct acctgctgtt cctgctgctt 2460  
 ttctcgcggg tgctgctcgt ggatttccag ccggcgccgc ccggtccctt ggagctgctg 2520  
 ctctatttct gggctttcac gctgctgtgc gaggaactgc gccaggccct gaggcggagg 2580  
 gggggcagcc tcgccaaggg gggccccggg cctggccatg cctcactgag ccagcgctg 2640  
 cgctctacc tcgcccagag ctggaaccag tgcgacctag tggctctcac ctgcttctc 2700



-46-

```

ctgggcgtgg gctgccggct gaccccggtg ttgtaccacc tgggccgcac tgtcctctgc 2760
atcgacttca tggttttcac ggtgcggtcg cttcacatct tcacgggtcaa caaacagctg 2820
gggccaaga tcgtcatcgt gagcaagatg atgaaggacg tgttcttctt cctcttcttc 2880
ctcggcggtg ggctggtagc ctatggcggt gccacggagg ggctcctgag gccacgggac 2940
agtgaattcc caagtatcct gcgcgcgctc ttctaccgtc cctacctgca gatcttcggg 3000
cagattcccc aggaggacat ggacgtggcc ctcatggagc acagcaactg ctcgtcggag 3060
cccggcttct gggcacaccc tcttggggcc caggcgggca cctgcgtctc ccagtatgcc 3120
aactggctgg tgggtgctgt cctcgtcatc ttctgctcgt tggccaacat cctgctggtc 3180
aacttgctca ttgccatgtt cagttacaca ttcgggcaaag tacagggcaa cagcgatctc 3240
tactggaagg cgacgcgtta ccgcctcatc cgggaattcc actctcggcc cgcgctggcc 3300
ccgcccttta tcgtcatctc ccacttgctc ctcctgctca ggcaattgtg caggcgaccc 3360
cggagccccc agccgtcttc cccggccctc gagcatttcc ggggtttacct ttctaaggaa 3420
gccgagcggg agctgctaac gtgggaatcg gtgcataagg agaactttct gctggcacgc 3480
gctagggaca agcgggagag cgactccgag cgtctgaaag gcacgtccca gaaggtggac 3540
ttggcactga aacagctggg acacatccgc gagtacgaac agcgctgaa agtgctggag 3600
cgggaggtcc agcagtgtag ccgcgtcctg ggggtgggtg ccgaggccct gagccgctct 3660
gccttgctgc cccaggtgg gccgccaccc cctgacctgc ctgggtccaa agactgagcc 3720
ctgctggcgg acttcaagga gaagccccc caggggattt tgctcctaga gtaaggctca 3780
tctgggcctc ggcccccgca cctggtggcc ttgtccttga ggtgagcccc atgtccatct 3840
gggccactgt caggaccacc tttgggagtg tcatccttac aaaccacagc atgcccggt 3900
cctcccagaa ccagtcaccg cctgggagga tcaaggcctg gatcccgggc cgttatccat 3960
ctggaggtcg cagggtcctt ggggtaacag ggaccacaga cccctcacca ctcacagatt 4020
cctcacactg gggaaataaa gccatttcag aggaaaaaaa a 4061

```

&lt;210&gt; 30

&lt;211&gt; 1214

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 30

```

Met Val Val Pro Glu Lys Glu Gln Ser Trp Ile Pro Lys Ile Phe Lys
1      5      10      15
Lys Lys Thr Cys Thr Thr Phe Ile Val Asp Ser Thr Asp Pro Gly Gly
20      25      30
Thr Leu Cys Gln Cys Gly Arg Pro Arg Thr Ala His Pro Ala Val Ala
35      40      45
Met Glu Asp Ala Phe Gly Ala Ala Val Val Thr Val Trp Asp Ser Asp
50      55      60
Ala His Thr Thr Glu Lys Pro Thr Asp Ala Tyr Gly Glu Leu Asp Phe
65      70      75      80
Thr Gly Ala Gly Arg Lys His Ser Asn Phe Leu Arg Leu Ser Asp Arg
85      90      95
Thr Asp Pro Ala Ala Val Tyr Ser Leu Val Thr Arg Thr Trp Gly Phe
100     105     110
Arg Ala Pro Asn Leu Val Val Ser Val Leu Gly Gly Ser Gly Gly Pro
115     120     125
Val Leu Gln Thr Trp Leu Gln Asp Leu Leu Arg Arg Gly Leu Val Arg
130     135     140
Ala Ala Gln Ser Thr Gly Ala Trp Ile Val Thr Gly Gly Leu His Thr
145     150     155     160
Gly Ile Gly Arg His Val Gly Val Ala Val Arg Asp His Gln Met Ala
165     170     175
Ser Thr Gly Gly Thr Lys Val Val Ala Met Gly Val Ala Pro Trp Gly
180     185     190
Val Val Arg Asn Arg Asp Thr Leu Ile Asn Pro Lys Gly Ser Phe Pro
195     200     205
Ala Arg Tyr Arg Trp Arg Gly Asp Pro Glu Asp Gly Val Gln Phe Pro
210     215     220
Leu Asp Tyr Asn Tyr Ser Ala Phe Phe Leu Val Asp Asp Gly Thr His
225     230     235     240

```

|         |         |         |         |         |         |         |         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Gly 300 | Cys 301 | Leu 302 | Gly 303 | Gly 245 | Glu 304 | Asn 305 | Arg 306 | Phe 307 | Arg 250 | Leu 308 | Arg 309 | Leu 310 | Glu 311 | Ser 255 | Tyr 312 |
| Ile 313 | Ser 314 | Gln 260 | Gln 260 | Lys 315 | Thr 316 | Gly 317 | Val 318 | Gly 265 | Gly 319 | Thr 320 | Gly 321 | Ile 322 | Asp 270 | Ile 323 | Pro 324 |
| Val 325 | Leu 275 | Leu 275 | Leu 275 | Leu 326 | Ile 327 | Asp 328 | Gly 280 | Asp 265 | Glu 329 | Lys 330 | Met 331 | Leu 285 | Thr 332 | Arg 333 | Ile 334 |
| Glu 290 | Asn 290 | Ala 291 | Thr 292 | Gln 293 | Ala 294 | Gln 295 | Leu 296 | Pro 297 | Cys 298 | Leu 300 | Leu 300 | Val 301 | Ala 302 | Gly 303 | Ser 304 |
| Gly 305 | Gly 305 | Ala 306 | Ala 307 | Asp 308 | Cys 309 | Leu 310 | Ala 311 | Glu 312 | Thr 313 | Leu 315 | Glu 315 | Asp 316 | Thr 317 | Leu 318 | Ala 319 |
| Pro 320 | Gly 320 | Ser 321 | Gly 322 | Gly 323 | Ala 324 | Arg 325 | Gln 326 | Gly 327 | Glu 328 | Ala 330 | Arg 330 | Asp 331 | Arg 332 | Ile 333 | Arg 334 |
| Arg 335 | Phe 335 | Phe 336 | Pro 337 | Lys 338 | Gly 339 | Asp 340 | Leu 341 | Glu 342 | Val 343 | Leu 344 | Gln 345 | Ala 346 | Gln 347 | Val 348 | Glu 349 |
| Arg 350 | Ile 350 | Met 351 | Thr 352 | Arg 353 | Lys 354 | Glu 355 | Leu 356 | Leu 357 | Thr 358 | Val 359 | Tyr 360 | Ser 361 | Ser 362 | Glu 363 | Asp 364 |
| Gly 365 | Ser 365 | Glu 366 | Glu 367 | Phe 368 | Glu 369 | Thr 370 | Ile 371 | Val 372 | Leu 373 | Lys 374 | Ala 375 | Leu 376 | Val 377 | Lys 378 | Ala 379 |
| Cys 380 | Gly 380 | Ser 381 | Ser 382 | Glu 383 | Ala 384 | Ser 385 | Ala 386 | Tyr 387 | Leu 388 | Asp 389 | Glu 390 | Leu 391 | Arg 392 | Leu 393 | Ala 394 |
| Val 395 | Ala 395 | Trp 396 | Asn 397 | Arg 398 | Val 399 | Asp 400 | Ile 401 | Ala 402 | Gln 403 | Ser 404 | Glu 405 | Leu 406 | Phe 407 | Arg 408 | Gly 409 |
| Asp 410 | Ile 410 | Gln 411 | Trp 412 | Arg 413 | Ser 414 | Phe 415 | His 416 | Leu 417 | Glu 418 | Ala 419 | Ser 420 | Leu 421 | Met 422 | Asp 423 | Ala 424 |
| Leu 425 | Leu 425 | Asn 426 | Asp 427 | Arg 428 | Pro 429 | Glu 430 | Phe 431 | Val 432 | Arg 433 | Leu 434 | Leu 435 | Ile 436 | Ser 437 | His 438 | Gly 439 |
| Leu 440 | Ser 440 | Leu 441 | Gly 442 | His 443 | Phe 444 | Leu 445 | Thr 446 | Pro 447 | Met 448 | Arg 449 | Leu 450 | Ala 451 | Gln 452 | Leu 453 | Tyr 454 |
| Ser 455 | Ala 455 | Ala 456 | Pro 457 | Ser 458 | Asn 459 | Ser 460 | Leu 461 | Ile 462 | Arg 463 | Asn 464 | Leu 465 | Leu 466 | Asp 467 | Gln 468 | Ala 469 |
| Ser 470 | His 470 | Ser 471 | Ala 472 | Gly 473 | Thr 474 | Lys 475 | Ala 476 | Pro 477 | Ala 478 | Leu 479 | Lys 480 | Gly 481 | Gly 482 | Ala 483 | Ala 484 |
| Glu 485 | Leu 485 | Arg 486 | Pro 487 | Pro 488 | Asp 489 | Val 490 | Gly 491 | His 492 | Val 493 | Leu 494 | Arg 495 | Met 496 | Leu 497 | Leu 498 | Gly 499 |
| Lys 500 | Met 500 | Cys 501 | Ala 502 | Pro 503 | Arg 504 | Tyr 505 | Pro 506 | Ser 507 | Gly 508 | Gly 509 | Ala 510 | Trp 511 | Asp 512 | Pro 513 | His 514 |
| Pro 515 | Gly 515 | Gln 516 | Gly 517 | Phe 518 | Gly 519 | Glu 520 | Ser 521 | Met 522 | Tyr 523 | Leu 524 | Leu 525 | Ser 526 | Asp 527 | Lys 528 | Ala 529 |
| Thr 530 | Ser 530 | Pro 531 | Leu 532 | Ser 533 | Leu 534 | Asp 535 | Ala 536 | Gly 537 | Leu 538 | Gly 539 | Gln 540 | Ala 541 | Pro 542 | Trp 543 | Ser 544 |
| Asp 545 | Leu 545 | Leu 546 | Leu 547 | Trp 548 | Ala 549 | Leu 550 | Leu 551 | Leu 552 | Asn 553 | Arg 554 | Ala 555 | Gln 556 | Met 557 | Ala 558 | Met 559 |
| Tyr 560 | Phe 560 | Trp 561 | Glu 562 | Met 563 | Gly 564 | Ser 565 | Asn 566 | Ala 567 | Val 568 | Ser 569 | Ser 570 | Ala 571 | Leu 572 | Gly 573 | Ala 574 |
| Cys 575 | Leu 575 | Leu 576 | Leu 577 | Arg 578 | Val 579 | Met 580 | Ala 581 | Arg 582 | Leu 583 | Glu 584 | Pro 585 | Asp 586 | Ala 587 | Glu 588 | Glu 589 |
| Ala 590 | Ala 590 | Arg 591 | Arg 592 | Lys 593 | Asp 594 | Leu 595 | Ala 596 | Phe 597 | Lys 598 | Phe 599 | Glu 600 | Gly 601 | Met 602 | Gly 603 | Val 604 |
| Asp 605 | Leu 6   |         |         |         |         |         |         |         |         |         |         |         |         |         |         |

|      |     |     |      |     |      |     |      |      |      |      |     |      |      |      |      |
|------|-----|-----|------|-----|------|-----|------|------|------|------|-----|------|------|------|------|
| Glu  | Leu | Glu | Phe  | Asp | Met  | Asp | Ser  | Val  | Ile  | Asn  | Gly | Glu  | Gly  | Pro  | Val  |
|      |     |     |      | 725 |      |     |      |      | 730  |      |     |      |      | 735  |      |
| Gly  | Thr | Ala | Asp  | Pro | Ala  | Glu | Lys  | Thr  | Pro  | Leu  | Gly | Val  | Pro  | Arg  | Gln  |
|      |     |     | 740  |     |      |     |      | 745  |      |      |     |      | 750  |      |      |
| Ser  | Gly | Arg | Pro  | Gly | Cys  | Cys | Gly  | Gly  | Arg  | Cys  | Gly | Gly  | Arg  | Arg  | Cys  |
|      |     |     | 755  |     |      |     | 760  |      |      |      |     | 765  |      |      |      |
| Leu  | Arg | Arg | Trp  | Phe | His  | Phe | Trp  | Gly  | Ala  | Pro  | Val | Thr  | Ile  | Phe  | Met  |
|      |     |     | 770  |     |      | 775 |      |      |      |      | 780 |      |      |      |      |
| Gly  | Asn | Val | Val  | Ser | Tyr  | Leu | Leu  | Phe  | Leu  | Leu  | Leu | Phe  | Ser  | Arg  | Val  |
| 785  |     |     |      |     | 790  |     |      |      |      | 795  |     |      |      |      | 800  |
| Leu  | Leu | Val | Asp  | Phe | Gln  | Pro | Ala  | Pro  | Pro  | Gly  | Ser | Leu  | Glu  | Leu  | Leu  |
|      |     |     | 805  |     |      |     |      | 810  |      |      |     |      |      | 815  |      |
| Leu  | Tyr | Phe | Trp  | Ala | Phe  | Thr | Leu  | Leu  | Cys  | Glu  | Glu | Leu  | Arg  | Gln  | Gly  |
|      |     |     | 820  |     |      |     | 825  |      |      |      |     | 830  |      |      |      |
| Leu  | Ser | Gly | Gly  | Gly | Gly  | Ser | Leu  | Ala  | Ser  | Gly  | Gly | Pro  | Gly  | Pro  | Gly  |
|      |     | 835 |      |     |      |     | 840  |      |      |      |     | 845  |      |      |      |
| His  | Ala | Ser | Leu  | Ser | Gln  | Arg | Leu  | Arg  | Leu  | Tyr  | Leu | Ala  | Asp  | Ser  | Trp  |
|      |     | 850 |      |     |      | 855 |      |      |      |      | 860 |      |      |      |      |
| Asn  | Gln | Cys | Asp  | Leu | Val  | Ala | Leu  | Thr  | Cys  | Phe  | Leu | Leu  | Gly  | Val  | Gly  |
| 865  |     |     |      |     | 870  |     |      |      |      | 875  |     |      |      |      | 880  |
| Cys  | Arg | Leu | Thr  | Pro | Gly  | Leu | Tyr  | His  | Leu  | Gly  | Arg | Thr  | Val  | Leu  | Cys  |
|      |     |     | 885  |     |      |     |      |      | 890  |      |     |      |      | 895  |      |
| Ile  | Asp | Phe | Met  | Val | Phe  | Thr | Val  | Arg  | Leu  | Leu  | His | Ile  | Phe  | Thr  | Val  |
|      |     |     | 900  |     |      |     |      | 905  |      |      |     | 910  |      |      |      |
| Asn  | Lys | Gln | Leu  | Gly | Pro  | Lys | Ile  | Val  | Ile  | Val  | Ser | Lys  | Met  | Met  | Lys  |
|      |     | 915 |      |     |      |     | 920  |      |      |      |     | 925  |      |      |      |
| Asp  | Val | Phe | Phe  | Phe | Leu  | Phe | Phe  | Leu  | Gly  | Val  | Trp | Leu  | Val  | Ala  | Tyr  |
|      |     | 930 |      |     |      | 935 |      |      |      |      | 940 |      |      |      |      |
| Gly  | Val | Ala | Thr  | Glu | Gly  | Leu | Leu  | Arg  | Pro  | Arg  | Asp | Ser  | Asp  | Phe  | Pro  |
| 945  |     |     |      |     | 950  |     |      |      |      | 955  |     |      |      |      | 960  |
| Ser  | Ile | Leu | Arg  | Arg | Val  | Phe | Tyr  | Arg  | Pro  | Tyr  | Leu | Gln  | Ile  | Phe  | Gly  |
|      |     |     | 965  |     |      |     |      |      | 970  |      |     |      |      | 975  |      |
| Gln  | Ile | Pro | Gln  | Glu | Asp  | Met | Asp  | Val  | Ala  | Leu  | Met | Glu  | His  | Ser  | Asn  |
|      |     |     | 980  |     |      |     |      | 985  |      |      |     |      | 990  |      |      |
| Cys  | Ser | Ser | Glu  | Pro | Gly  | Phe | Trp  | Ala  | His  | Pro  | Pro | Gly  | Ala  | Gln  | Ala  |
|      |     | 995 |      |     |      |     | 1000 |      |      |      |     | 1005 |      |      |      |
| Gly  | Thr | Cys | Val  | Ser | Gln  | Tyr | Ala  | Asn  | Trp  | Leu  | Val | Val  | Leu  | Leu  | Leu  |
|      |     |     | 1010 |     |      |     | 1015 |      |      |      |     | 1020 |      |      |      |
| Val  | Ile | Phe | Leu  | Leu | Val  | Ala | Asn  | Ile  | Leu  | Leu  | Val | Asn  | Leu  | Leu  | Ile  |
| 1025 |     |     |      |     | 1030 |     |      |      |      | 1035 |     |      |      |      | 1040 |
| Ala  | Met | Phe | Ser  | Tyr | Thr  | Phe | Gly  | Lys  | Val  | Gln  | Gly | Asn  | Ser  | Asp  | Leu  |
|      |     |     | 1045 |     |      |     |      |      | 1050 |      |     |      |      | 1055 |      |
| Tyr  | Trp | Lys | Ala  | Gln | Arg  | Tyr | Arg  | Leu  | Ile  | Arg  | Glu | Phe  | His  | Ser  | Arg  |
|      |     |     | 1060 |     |      |     |      | 1065 |      |      |     |      | 1070 |      |      |

Pro Gly Gly Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp  
1205 1210

<210> 31  
<211> 4646  
<212> DNA  
<213> Homo Sapiens

<400> 31

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| tcgaccacag  | cgtccgcccc  | cgcgtccgcc  | cacgcgtccg  | cccacgcgtc  | cgcccacgcg  | 60   |
| tccgccccag  | cgtccggggg  | gaaagmramy  | cmgycktsms  | aaaaaccgtc  | acttaggaaa  | 120  |
| agatgtcctt  | tcgggcagcc  | aggctcagca  | tgaggaaacag | aaggaaatgac | actctggaca  | 180  |
| gcacccggag  | cctgtactcc  | agcgcgtctc  | ggagcacaga  | cttgtcttac  | agtgaagcgc  | 240  |
| acttggtgaa  | ttttattcaa  | gcaaatttta  | agaaacgaga  | atgtgtcttc  | tttaccaaaag | 300  |
| attccaaggc  | cacggagaat  | gtgtgcaagt  | gtggctatgc  | ccagagccag  | cacatggaaag | 360  |
| gcacccagat  | caaccaaaagt | gagaaatgga  | actacaagaa  | acacaccaag  | gaatttccta  | 420  |
| ccgacgcctt  | tggggatatt  | cagtttgaga  | cactggggaa  | gaaagggaaag | tatatagctc  | 480  |
| tgtcctgcga  | cacggacgcg  | gaaatccttt  | acgagctgct  | gaccagcac   | tggcacctga  | 540  |
| aaacacccaa  | cctggtcatt  | tctgtgaccg  | ggggcgccaa  | gaacttcgcc  | ctgaagccgc  | 600  |
| gcatgcgcaa  | gatcttcagc  | cggctcatct  | acatcgcgca  | gtccaaaggt  | gcttggattc  | 660  |
| tcacgggagg  | caccatttat  | ggcctgatga  | agtagatcgg  | ggaggtgggt  | agagataaca  | 720  |
| ccatcagcag  | gagttcagag  | gagaatattg  | tgccatttgg  | catagcagct  | tggggcatgg  | 780  |
| tctccaaccg  | ggacaccctc  | atcaggaatt  | gcgatgctga  | gggtattttt  | ttagcccagt  | 840  |
| accttatgga  | tgacttcaca  | agagatccac  | tgtgtatcct  | ggacaacaac  | cacacacatt  | 900  |
| tgctgctcgt  | ggacaatggc  | tgtcatggac  | atcccactgt  | cgaagcaaag  | ctccggaatc  | 960  |
| agctagagaa  | gtatatctct  | gagcgacta   | ttcaagattc  | caactatggt  | ggcaagatcc  | 1020 |
| ccattgtgtg  | ttttgcccaa  | ggaggtggaa  | aagagacttt  | gaaagccatc  | aatacctcca  | 1080 |
| tcaaaaataa  | aattccttgt  | gtggtgggtg  | aaggctcggg  | ccagatcgct  | gatgtgatcg  | 1140 |
| ctagcctggt  | ggaggtggag  | gatgcctga   | catcttctgc  | cgtaaggag   | aagctgggtc  | 1200 |
| gctttttacc  | cgcacgggtg  | tcccggctgc  | ctgaggagga  | gactgagagt  | tggatcaaat  | 1260 |
| ggctcaaaag  | aattctcgaa  | tgttctcacc  | tattaacagt  | tattaaaatg  | gaagaagctg  | 1320 |
| gggatgaaat  | tgtgagcaat  | gccatctcct  | acgctctata  | caaagccttc  | agcaccagtg  | 1380 |
| agcaagacaa  | ggataactgg  | aatgggcagc  | tgaagcttct  | gctggagtgg  | aaccagctgg  | 1440 |
| acttagccaa  | tgatgagatt  | ttcaccaatg  | accgcccag   | ggagtctgct  | gaccttcaag  | 1500 |
| aagtcatggt  | tacggctctc  | ataaaggaga  | gacccaagtt  | tgtccgcctc  | tttctggaga  | 1560 |
| atggcttgaa  | cctacggaag  | tttctcacc   | atgatgtcct  | cactgaactc  | ttctccaacc  | 1620 |
| acttcagcac  | gcttgtgtac  | cggaaatctgc | agatcgccaa  | gaattcctat  | aatgatgcc   | 1680 |
| tcctcacgtt  | tgtctggaaa  | ctggttgoga  | acttccgaag  | aggcttccgg  | aaggagaca   | 1740 |
| gaaatggccg  | ggacgagatg  | gacatagAAC  | tccacgacgt  | gtctcctatt  | actcggcacc  | 1800 |
| ccctgcaagc  | tctcttcac   | tgggccattc  | ttcagaataa  | gaaggaaact  | tccaaagtca  | 1860 |
| tttgggagca  | gaccaggggc  | tgcactctgg  | cagccctggg  | agccagcaag  | cttctgaaga  | 1920 |
| ctctggccaa  | agtgaagaac  | gacatcaatg  | ctgctgggga  | gtccgaggag  | ctggactaatg | 1980 |
| agtagagac   | ccgggctgtt  | gagctgttca  | ctgagtgtta  | cagcagcgat  | gaagacttgg  | 2040 |
| cagaacagct  | gctggtctat  | tcctgtgaag  | cttgggggtg  | aagcaactgt  | ctggagctgg  | 2100 |
| cggtggaggc  | cacagaccag  | catttcacg   | cccagcctgg  | ggtccagaat  | tttctttcta  | 2160 |
| agcaatggta  | tggagagatt  | tcccagagaca | ccaagaactg  | gaagattatc  | ctgtgtctgt  | 2220 |
| ttattatacc  | cttgggtggc  | tgtggccttg  | tatcatttag  | gaagaaacct  | gtcgacaagc  | 2280 |
| acaagaagct  | gctttgttac  | tatgtggcgt  | tcttcacctc  | ccccttcgtg  | gtcttctcct  | 2340 |
| ggaatgtggt  | cttctacatc  | gccttcctcc  | tgtgttttgc  | ctacgtgctg  | ctcatggatt  | 2400 |
| tccattcggg  | gccacacccc  | cccgagctgg  | tctgtactc   | gctggctctt  | gtcctcttct  | 2460 |
| gtgatgaagt  | gagacagtgg  | tacgtaaatg  | gggtgaatta  | ttttactgac  | ctgtggaatg  | 2520 |
| tgtatggacac | gctggggcct  | ttttacttca  | tagcaggaat  | tgtatttcgg  | ctccactctt  | 2580 |
| ctaataaaaag | ctctttgtat  | tctggacgag  | tcattttctg  | tctggactac  | attattttca  | 2640 |
| ctctaagatt  | gatccacatt  | tttactgtaa  | gcagaaactt  | aggacccaag  | attataatgc  | 2700 |
| tgacagggat  | gctgatcgat  | gtgttcttct  | tctgttctct  | ctttgcggtg  | tggatgggtg  | 2760 |
| cctttggcgt  | ggccaggcaa  | gggatcctta  | ggcagaatga  | gcagcgctgg  | aggtggatat  | 2820 |
| tccgttcggg  | catctacgag  | ccctacctgg  | ccatgttcgg  | ccaggtgccc  | agtacgtgg   | 2880 |
| atggtaccac  | gtatgacttt  | gcccactgca  | ccttactctg  | gaatgagtc   | aagccactgt  | 2940 |
| gtgtggagct  | ggatgagcac  | aacctgcccc  | ggttccccga  | gtggatcacc  | atccccctgg  | 3000 |
| tgtgcatcta  | catgttatcc  | accaacatcc  | tgtgtgtcaa  | cctgctggtc  | gccatgtttg  | 3060 |

-50-

```

gctacacggt gggcaccgtc caggagaaca atgaccaggt ctggaagttc cagaggtact 3120
tcctggtgca ggagtactgc agccgcctca atatcccctt ccccttcacg gtcttcgctt 3180
acttctacat ggtggtgaag aagtgttca agtgttgctg caaggagaaa aacatggagt 3240
cttctgtctg ctgtttcaaa aatgaagaca atgagactct ggcatgggag ggtgtcatga 3300
aggaaaacta ccttgtcaag atcaacacaa aagccaacga cacctcagag gaaatgaggc 3360
atcgatttag acaactggat acaaagctta atgatctcaa gggctcttctg aaagagattg 3420
ctaataaaat caaataaaac tgtatgaact ctaatggaga aaaatctaata tatagcaaga 3480
tcatattaag gaatgctgat gaacaatttt gctatcgact actaaatgag agattttcag 3540
acccctgggt acatgggtgga tgattttaaa tcaccctagt gtgctgagac cttgagaata 3600
aagtgtgtga ttggtttcat acttgaagac ggatataaag gaagaatatt tcctttatgt 3660
gtttctccag aatgggtgcct gtttctctct gtgtctcaat gcctgggact ggaggttgat 3720
agtttaagtg tggtcttacc gcctcctttt tcctttaatc ttatttttga tgaacacata 3780
tataggagaa catctatcct atgaataaga acctgggtcat gctttactcc tgtattgtta 3840
ttttgttcat ttccaattga ttctctactt ttcccttttt tgtattatgt gactaattag 3900
ttggcatatt gtwaaaagtc tctcaaatta ggcagatttc taaaacatgc tgcagcaaga 3960
ggaccccgcct ctcttcagga aaagtgtttt catttctcag gatgcttctt acctgtcaga 4020
ggagggtgaca aggcagtctc ttgctctctt ggactcacca ggctcctatt gaaggaacca 4080
ccccatttcc taaatatgtg aaaagtcgcc caaaatgcaa ccttgaaagg cactactgac 4140
tttgttctta ttggatactc ctcttattta ttatttttcc attaaaaata atagctggct 4200
attatagaaa atttagacca tacagagatg tagaaagaac ataaattgtc cccattacct 4260
taaggtaatc actgctaaca atttctggat ggtttttcaa gtctattttt tttctatgta 4320
tgtctcaatt ctctttcaaa attttacaga atgttatcat actacatata tactttttat 4380
gtaagctttt tcacttagta ttttatcaaa tatgttttta ttatattcat agccttctta 4440
aacattatat caataattgc ataataggca acctctagcg attaccataa ttttgctcat 4500
tgaaggctat ctccagttga tcattgggat gagcatcttt gtgcatgaat cctattgctg 4560
tatttgggaa aattttccaa ggtttagattc caataaatat ctatttatta ttaaaaaaaa 4620
aaaaaaaaag gcggccgctc tagagt 4646

```

&lt;210&gt; 32

&lt;211&gt; 1104

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 32

```

Met Ser Phe Arg Ala Ala Arg Leu Ser Met Arg Asn Arg Arg Asn Asp
 1          5          10          15
Thr Leu Asp Ser Thr Arg Thr Leu Tyr Ser Ser Ala Ser Arg Ser Thr
 20          25          30
Asp Leu Ser Tyr Ser Glu Ser Asp Leu Val Asn Phe Ile Gln Ala Asn
 35          40          45
Phe Lys Lys Arg Glu Cys Val Phe Phe Thr Lys Asp Ser Lys Ala Thr
 50          55          60
Glu Asn Val Cys Lys Cys Gly Tyr Ala Gln Ser Gln His Met Glu Gly
 65          70          75          80
Thr Gln Ile Asn Gln Ser Glu Lys Trp Asn Tyr Lys Lys His Thr Lys
 85          90          95
Glu Phe Pro Thr Asp Ala Phe Gly Asp Ile Gln Phe Glu Thr Leu Gly
100          105          110
Lys Lys Gly Lys Tyr Ile Arg Leu Ser Cys Asp Thr Asp Ala Glu Ile
115          120          125
Leu Tyr Glu Leu Leu Thr Gln His Trp His Leu Lys Thr Pro Asn Leu
130          135          140
Val Ile Ser Val Thr Gly Gly Ala Lys Asn Phe Ala Leu Lys Pro Arg
145          150          155          160
Met Arg Lys Ile Phe Ser Arg Leu Ile Tyr Ile Ala Gln Ser Lys Gly
165          170          175
Ala Trp Ile Leu Thr Gly Gly Thr His Tyr Gly Leu Met Lys Tyr Ile
180          185          190
Gly Glu Val Val Arg Asp Asn Thr Ile Ser Arg Ser Ser Glu Glu Asn
195          200          205

```

-51-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Val | Ala | Ile | Gly | Ile | Ala | Ala | Trp | Gly | Met | Val | Ser | Asn | Arg | Asp |
| 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |     |
| Thr | Leu | Ile | Arg | Asn | Cys | Asp | Ala | Glu | Gly | Tyr | Phe | Leu | Ala | Gln | Tyr |
| 225 |     |     |     | 230 |     |     |     |     |     | 235 |     |     |     |     | 240 |
| Leu | Met | Asp | Asp | Phe | Thr | Arg | Asp | Pro | Leu | Cys | Ile | Leu | Asp | Asn | Asn |
|     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |
| His | Thr | His | Leu | Leu | Leu | Val | Asp | Asn | Gly | Cys | His | Gly | His | Pro | Thr |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Val | Glu | Ala | Lys | Leu | Arg | Asn | Gln | Leu | Glu | Lys | Tyr | Ile | Ser | Glu | Arg |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     |     | 285 |     |     |
| Thr | Ile | Gln | Asp | Ser | Asn | Tyr | Gly | Gly | Lys | Ile | Pro | Ile | Val | Cys | Phe |
| 290 |     |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Ala | Gln | Gly | Gly | Gly | Lys | Glu | Thr | Leu | Lys | Ala | Ile | Asn | Thr | Ser | Ile |
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |
| Lys | Asn | Lys | Ile | Pro | Cys | Val | Val | Val | Glu | Gly | Ser | Gly | Gln | Ile | Ala |
|     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |
| Asp | Val | Ile | Ala | Ser | Leu | Val | Glu | Val | Glu | Asp | Ala | Leu | Thr | Ser | Ser |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |
| Ala | Val | Lys | Glu | Lys | Leu | Val | Arg | Phe | Leu | Pro | Arg | Thr | Val | Ser | Arg |
|     |     | 355 |     |     |     |     | 360 |     |     |     |     |     | 365 |     |     |
| Leu | Pro | Glu | Glu | Glu | Thr | Glu | Ser | Trp | Ile | Lys | Trp | Leu | Lys | Glu | Ile |
| 370 |     |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |
| Leu | Glu | Cys | Ser | His | Leu | Leu | Thr | Val | Ile | Lys | Met | Glu | Glu | Ala | Gly |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Asp | Glu | Ile | Val | Ser | Asn | Ala | Ile | Ser | Tyr | Ala | Leu | Tyr | Lys | Ala | Phe |
|     |     |     |     | 405 |     |     |     |     | 410 |     |     |     |     | 415 |     |
| Ser | Thr | Ser | Glu | Gln | Asp | Lys | Asp | Asn | Trp | Asn | Gly | Gln | Leu | Lys | Leu |
|     |     |     | 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Leu | Leu | Glu | Trp | Asn | Gln | Leu | Asp | Leu | Ala | Asn | Asp | Glu | Ile | Phe | Thr |
|     |     |     | 435 |     |     |     | 440 |     |     |     |     | 445 |     |     |     |
| Asn | Asp | Arg | Arg | Trp | Glu | Ser | Ala | Asp | Leu | Gln | Glu | Val | Met | Phe | Thr |
| 450 |     |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Ala | Leu | Ile | Lys | Asp | Arg | Pro | Lys | Phe | Val | Arg | Leu | Phe | Leu | Glu | Asn |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Gly | Leu | Asn | Leu | Arg | Lys | Phe | Leu | Thr | His | Asp | Val | Leu | Thr | Glu | Leu |
|     |     |     |     | 485 |     |     |     | 490 |     |     |     |     |     | 495 |     |
| Phe | Ser | Asn | His | Phe | Ser | Thr | Leu | Val | Tyr | Arg | Asn | Leu | Gln | Ile | Ala |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Lys | Asn | Ser | Tyr | Asn | Asp | Ala | Leu | Leu | Thr | Phe | Val | Trp | Lys | Leu | Val |
|     |     | 515 |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| Ala | Asn | Phe | Arg | Arg | Gly | Phe | Arg | Lys | Glu | Asp | Arg | Asn | Gly | Arg | Asp |
| 530 |     |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |
| Glu | Met | Asp | Ile | Glu | Leu | His | Asp | Val | Ser | Pro | Ile | Thr | Arg | His | Pro |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Leu | Gln | Ala | Leu | Phe | Ile | Trp | Ala | Ile | Leu | Gln | Asn | Lys | Lys | Glu | Leu |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |
| Ser | Lys | Val | Ile | Trp | Glu | Gln | Thr | Arg | Gly | Cys | Thr | Leu | Ala | Ala | Leu |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Gly | Ala | Ser | Lys | Leu | Leu | Lys | Thr | Leu | Ala | Lys | Val | Lys | Asn | Asp | Ile |
|     |     | 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |
| Asn | Ala | Ala | Gly | Glu | Ser | Glu | Glu | Leu | Ala | Asn | Glu | Tyr | Glu | Thr | Arg |
| 610 |     |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |
| Ala | Val | Glu | Leu | Phe | Thr | Glu | Cys | Tyr | Ser | Ser | Asp | Glu | Asp | Leu | Ala |
| 625 |     |     |     |     | 630 |     |     |     |     |     | 635 |     |     |     | 640 |
| Glu | Gln | Leu | Leu | Val | Tyr | Ser | Cys | Glu | Ala | Trp | Gly | Gly | Ser | Asn | Cys |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |
| Leu | Glu | Leu | Ala | Val | Glu | Ala | Thr | Asp | Gln | His | Phe | Ile | Ala | Gln | Pro |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Gly | Val | Gln | Asn | Phe | Leu | Ser | Lys | Gln | Trp | Tyr | Gly | Glu | Ile | Ser | Arg |
|     |     |     | 675 |     |     |     | 680 |     |     |     |     |     | 685 |     |     |

-52-

Asp Thr Lys Asn Trp Lys Ile Ile Leu Cys Leu Phe Ile Ile Pro Leu  
 690 695 700  
 Val Gly Cys Gly Phe Val Ser Phe Arg Lys Lys Pro Val Asp Lys His  
 705 710 715 720  
 Lys Lys Leu Leu Trp Tyr Tyr Val Ala Phe Phe Thr Ser Pro Phe Val  
 725 730 735  
 Val Phe Ser Trp Asn Val Val Phe Tyr Ile Ala Phe Leu Leu Leu Phe  
 740 745 750  
 Ala Tyr Val Leu Leu Met Asp Phe His Ser Val Pro His Pro Pro Glu  
 755 760 765  
 Leu Val Leu Tyr Ser Leu Val Phe Val Leu Phe Cys Asp Glu Val Arg  
 770 775 780  
 Gln Trp Tyr Val Asn Gly Val Asn Tyr Phe Thr Asp Leu Trp Asn Val  
 785 790 795 800  
 Met Asp Thr Leu Gly Leu Phe Tyr Phe Ile Ala Gly Ile Val Phe Arg  
 805 810 815  
 Leu His Ser Ser Asn Lys Ser Ser Leu Tyr Ser Gly Arg Val Ile Phe  
 820 825 830  
 Cys Leu Asp Tyr Ile Ile Phe Thr Leu Arg Leu Ile His Ile Phe Thr  
 835 840 845  
 Val Ser Arg Asn Leu Gly Pro Lys Ile Ile Met Leu Gln Arg Met Leu  
 850 855 860  
 Ile Asp Val Phe Phe Phe Leu Phe Leu Phe Ala Val Trp Met Val Ala  
 865 870 875 880  
 Phe Gly Val Ala Arg Gln Gly Ile Leu Arg Gln Asn Glu Gln Arg Trp  
 885 890 895  
 Arg Trp Ile Phe Arg Ser Val Ile Tyr Glu Pro Tyr Leu Ala Met Phe  
 900 905 910  
 Gly Gln Val Pro Ser Asp Val Asp Gly Thr Thr Tyr Asp Phe Ala His  
 915 920 925  
 Cys Thr Phe Thr Gly Asn Glu Ser Lys Pro Leu Cys Val Glu Leu Asp  
 930 935 940  
 Glu His Asn Leu Pro Arg Phe Pro Glu Trp Ile Thr Ile Pro Leu Val  
 945 950 955 960  
 Cys Ile Tyr Met Leu Ser Thr Asn Ile Leu Leu Val Asn Leu Leu Val  
 965 970 975  
 Ala Met Phe Gly Tyr Thr Val Gly Thr Val Gln Glu Asn Asn Asp Gln  
 980 985 990  
 Val Trp Lys Phe Gln Arg Tyr Phe Leu Val Gln Glu Tyr Cys Ser Arg  
 995 1000 1005  
 Leu Asn Ile Pro Phe Pro Phe Ile Val Phe Ala Tyr Phe Tyr Met Val  
 1010 1015 1020  
 Val Lys Lys Cys Phe Lys Cys Cys Cys Lys Glu Lys Asn Met Glu Ser  
 1025 1030 1035 104  
 Ser Val Cys Cys Phe Lys Asn Glu Asp Asn Glu Thr Leu Ala Trp Glu  
 1045 1050 1055  
 Gly Val Met Lys Glu Asn Tyr Leu Val Lys Ile Asn Thr Lys Ala Asn  
 1060 1065 1070  
 Asp Thr Ser Glu Glu Met Arg His Arg Phe Arg Gln Leu Asp Thr Lys  
 1075 1080 1085  
 Leu Asn Asp Leu Lys Gly Leu Leu Lys Glu Ile Ala Asn Lys Ile Lys  
 1090 1095 1100

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 July 2000 (13.07.2000)

PCT

(10) International Publication Number  
WO 00/40614 A3

(51) International Patent Classification<sup>7</sup>: C07K 14/705,  
C12N 15/12, C12Q 1/68, C12N 5/10, C07K 16/28, G01N  
33/53, A61K 38/17

(74) Agent: PLUMER, Elizabeth, R.; Wolf, Greenfield &  
Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(21) International Application Number: PCT/US99/29996

(81) Designated States (*national*): AU, CA, JP, US.

(22) International Filing Date:  
20 December 1999 (20.12.1999)

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(25) Filing Language: English

Published:

(26) Publication Language: English

— with international search report

(30) Priority Data:  
60/114,220 30 December 1998 (30.12.1998) US  
60/120,018 29 January 1999 (29.01.1999) US  
60/140,415 22 June 1999 (22.06.1999) US

(88) Date of publication of the international search report:  
22 February 2001

(48) Date of publication of this corrected version:  
30 August 2001

(71) Applicant (*for all designated States except US*): BETH  
ISRAEL DEACONESS MEDICAL CENTER, INC.  
[US/US]; 1 Deaconess Road, Boston, MA 02215 (US).


(15) Information about Correction:  
see PCT Gazette No. 35/2001 of 30 August 2001, Section  
II

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): SCHARENBERG,  
Andrew, M. [US/US]; 12 Skyview Road, Lexington, MA  
02420 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: CHARACTERIZATION OF THE SOC/CRAC CALCIUM CHANNEL PROTEIN FAMILY



(57) Abstract: Nucleic acids encoding SOC/CRAC calcium channel polypeptides, including fragments and biologically functional variants thereof and encoded polypeptides are provided. The nucleic acids and polypeptides disclosed herein are useful as therapeutic and diagnostic agents. Agents that selectively bind to the foregoing polypeptides and genes also are provided.



## CHARACTERIZATION OF A CALCIUM CHANNEL FAMILY

### Field of the Invention

This invention relates to nucleic acids coding for a novel family of calcium channel polypeptides, the encoded polypeptides, unique fragments of the foregoing, and methods of making and using same.

### Background of the Invention

Calcium channels are membrane-spanning, multi-subunit proteins that facilitate the controlled transport ("flux") of  $\text{Ca}^{2+}$  ions into and out of cells. Cells throughout the animal kingdom, and at least some bacterial, fungal and plant cells, possess one or more types of calcium channels. In general, "excitable" cells, such as neurons of the central nervous system, peripheral nerve cells, and muscle cells, including those of skeletal muscles, cardiac muscles, and venous and arterial smooth muscles, possess voltage-dependent calcium channels. In a voltage-dependent calcium channel, the transport of  $\text{Ca}^{2+}$  ions into and out of the cells requires a certain minimal level of depolarization (the difference in potential between the inside of the cell bearing the channel and the extracellular environment) with the rate of  $\text{Ca}^{2+}$  cell flux dependent on the difference in potential. In "non-excitable" cells, calcium influx is thought to occur predominantly in response to stimuli which cause the release of calcium from intracellular stores. This process, termed *store operated calcium influx*, is not well understood.

Characterization of a particular type of calcium channel by analysis of whole cells is complicated by the presence of mixed populations of different types of calcium channels in the majority of cells. Although single-channel recording methods can be used to examine individual calcium channels, such analysis does not reveal information related to the molecular structure or biochemical composition of the channel. Furthermore, in this type of analysis, the channel is isolated from other cellular constituents that might be important for the channel's natural functions and pharmacological interactions. To study the calcium channel structure-function relationship, large amounts of pure channel protein are needed. However, acquiring large amounts of pure protein is difficult in view of the complex nature of these multisubunit proteins, the varying concentrations of calcium channel proteins in tissue sources, the presence of mixed populations of calcium channel proteins in tissues, and the modifications of the native protein that can occur during the isolation procedure.

**Summary of the Invention**

The invention is based on the identification of a novel family of calcium channel polypeptides and the molecular cloning and partial characterization of a novel member of this family that is expressed predominantly in human hematopoietic cells, liver, and kidney. This newly identified family of calcium channel polypeptides is designated, "SOC" or "CRAC" or "ICRAC", for Store Operated Channels or Calcium Release Activated Channels. Although not wishing to be bound to any particular theory or mechanism, it is believed that the SOC/CRAC calcium channel polypeptides are transmembrane polypeptides that modulate  $\text{Ca}^{2+}$  flux "into" and "out of" a cell, for example, in certain instances they may be activated upon depletion of  $\text{Ca}^{2+}$  from intracellular calcium stores, allowing  $\text{Ca}^{2+}$  influx into the cell. Accordingly, the compositions disclosed herein are believed to be useful for modulating calcium transport into and out of such intracellular stores and for the treatment of disorders that are characterized by aberrant calcium transport into and out of such intracellular stores. In particular, we believe that the SOC/CRAC calcium channel polypeptides disclosed herein play an important role in the influx of extracellular calcium by mediating the refilling of intracellular calcium stores following their depletion. Accordingly, we believe that the compositions for expressing functional SOC/CRAC calcium channel polypeptides in cells, as disclosed herein, are useful for treating patients having conditions that are characterized by reduced extracellular calcium influx into their SOC/CRAC-expressing cells. Additionally, the compositions of the invention are useful for delivering therapeutic and/or imaging agents to cells which preferentially express SOC/CRAC calcium channel polypeptides and, in particular, for delivering such agents to hematopoietic cells, liver, heart, spleen, and kidney to modulate proliferation and growth of these cells. Moreover, in view of the importance of cellular calcium levels to cell viability, we believe that SOC-2/CRAC-1, SOC-3/CRAC-2, and SOC-4/CRAC-3 as disclosed herein, and/or other members of the SOC/CRAC family of calcium channel polypeptides, represent an ideal target for designing and/or identifying (e.g., from molecular libraries) small molecule inhibitors that block lymphocyte proliferation, as well as other binding agents that selectively bind to SOC/CRAC polypeptides to which drugs or toxins can be conjugated for delivery to SOC/CRAC polypeptide expressing cells.

The invention is based, in part, on the molecular cloning and sequence analysis of the novel SOC/CRAC calcium channel molecules disclosed herein (also referred to as a "SOC-2/CRAC-1 molecule," a "SOC-3/CRAC-2 molecule," and/or "SOC-4/CRAC-3 molecule") that are predominantly expressed in human hematopoietic cells, liver, spleen, heart, and

kidney (SOC-2/CRAC-1), kidney and colon (SOC-3/CRAC-2), and prostate (SOC-4/CRAC-3 molecule). As used herein, a "SOC/CRAC molecule" embraces a "SOC/CRAC calcium channel nucleic acid" (or "SOC/CRAC nucleic acid") and a "SOC/CRAC calcium channel polypeptide" (or "SOC/CRAC polypeptide"). Homologs and alleles also are embraced within the meaning of a SOC/CRAC calcium channel molecule.

According to one aspect of the invention, isolated SOC/CRAC nucleic acids which code for one or more member(s) of the SOC/CRAC family of calcium channel polypeptides or unique fragments thereof are provided. The isolated nucleic acids refer to one or more of the following:

(a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

The invention in another aspect provides an isolated nucleic acid molecule selected from the group consisting of (a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29, and SEQ ID NO:31, (b) complements of (a), provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from a sequence group consisting of (1) sequences having the SEQ. ID NOS. or GenBank accession numbers of Table I, (2) complements of (1), and (3) fragments of (1) and (2).

According to yet another aspect of the invention, isolated SOC/CRAC polypeptides are provided. The isolated SOC/CRAC polypeptide molecules are encoded by one or more SOC/CRAC nucleic acid molecules of the invention. Preferably, the SOC/CRAC polypeptide contains one or more polypeptides selected from the group consisting of the polypeptides having SEQ. ID Nos. 2, 4, 6, 8, 24, 26, 28, 30, and 32. In other embodiments, the isolated polypeptide may be a fragment or variant of the foregoing SOC/CRAC polypeptide molecules of sufficient length to represent a sequence unique within the human genome, and identifying

with a polypeptide that functions as a calcium channel, provided that the fragment excludes a sequence of contiguous amino acids identified in Table II. and/or excludes a sequence of contiguous amino acids encoded for by a nucleic acid sequence identified in Table I. In another embodiment, immunogenic fragments of the polypeptide molecules described above are provided.

According to another aspect of the invention, isolated SOC/CRAC binding agents (e.g., polypeptides) are provided which selectively bind to a SOC/CRAC molecule (e.g., a SOC/CRAC polypeptide encoded by the isolated nucleic acid molecules of the invention). Preferably, the isolated binding agents selectively bind to a polypeptide which comprises the sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32, or unique fragments thereof. In the preferred embodiments, the isolated binding polypeptides include antibodies and fragments of antibodies (e.g., Fab, F(ab)<sub>2</sub>, Fd and antibody fragments which include a CDR3 region which binds selectively to a SOC/CRAC polypeptide). Preferably, the antibodies for human therapeutic applications are human antibodies.

According to another aspect of the invention, a pharmaceutical composition containing a pharmaceutically effective amount of an isolated SOC/CRAC nucleic acid, an isolated SOC/CRAC polypeptide, or an isolated SOC/CRAC binding polypeptide in a pharmaceutically acceptable carrier also is provided. The pharmaceutical compositions are useful in accordance with therapeutic methods disclosed herein.

According to yet another aspect of the invention, a method for isolating a SOC/CRAC molecule is provided. The method involves:

a) contacting a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample that is believed to contain one or more SOC/CRAC molecules, under conditions to form a complex of the SOC/CRAC nucleic acid or the SOC/CRAC binding polypeptide and the SOC/CRAC molecule;

b) detecting the presence of the complex;

c) isolating the SOC/CRAC molecule from the complex; and

d) determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity. As used herein "SOC/CRAC calcium channel activity" refers to the transport of Ca<sup>2+</sup> into and out of intracellular stores that is mediated by a SOC/CRAC

polypeptide. In general, the SOC/CRAC calcium channel activity is initiated by a reduction or depletion of intracellular calcium stores.

In certain embodiments, the SOC/CRAC nucleic acid is a SOC-2/CRAC-1 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 27, or complements thereof); in certain other  
5       embodiments, the SOC/CRAC nucleic acid is a SOC-3/CRAC-2 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 29, or complements thereof); in further embodiments, the SOC/CRAC nucleic acid is a SOC-4/CRAC-3 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 31, or complements thereof). In yet other embodiments, the SOC/CRAC polypeptide is a SOC-2/CRAC-1 binding polypeptide (e.g., an antibody that selectively binds to a SOC-  
10       2/CRAC-1 polypeptide). In yet further embodiments, the SOC/CRAC polypeptide is a SOC-3/CRAC-2 binding polypeptide (e.g., an antibody that selectively binds to a SOC-3/CRAC-2 polypeptide). In some embodiments, the SOC/CRAC polypeptide is a SOC-4/CRAC-3 binding polypeptide (e.g., an antibody that selectively binds to a SOC-4/CRAC-3 polypeptide). In the preferred embodiments, the isolated binding polypeptides include  
15       antibodies and fragments of antibodies (e.g., Fab, F(ab)<sub>2</sub>, Fd and antibody fragments which include a CDR3 region which binds selectively to a SOC-2/CRAC-1, to a SOC-3/CRAC-2, and/or to a SOC-4/CRAC-3 polypeptide). Preferably the isolated binding polypeptides or other binding agents selectively bind to a single SOC/CRAC molecule, i.e., are capable of distinguishing between different members of the SOC/CRAC family. Accordingly, one or  
20       more SOC/CRAC binding agents can be contained in a single composition (e.g., a pharmaceutical composition) to identify multiple SOC/CRAC molecules *in vivo* or *in vitro*.

According to yet another aspect of the invention, a method for identifying agents useful in the modulation of SOC/CRAC calcium channel activity is provided. The method involves:

- 25       a) contacting a SOC/CRAC polypeptide with a candidate agent suspected of modulating SOC/CRAC calcium channel activity, under conditions sufficient to allow the candidate agent to interact selectively with (e.g. bind to) the SOC/CRAC polypeptide;
- b) detecting a Ca<sup>2+</sup> concentration of step (b) associated with the SOC/CRAC calcium channel activity of the SOC/CRAC polypeptide in the presence of the candidate agent; and
- 30       c) comparing the Ca<sup>2+</sup> concentration of step (b) with a control Ca<sup>2+</sup> concentration of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC calcium channel activity.

According to another aspect of the invention, a method for identifying agents useful in the modulation of a SOC/CRAC polypeptide kinase activity is provided. The method involves:

- a) contacting a SOC/CRAC polypeptide with kinase activity with a candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity;
- b) detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and
- c) comparing the kinase activity of step (b) with a control kinase activity of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC kinase activity. In some embodiments the SOC/CRAC polypeptide comprises amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24), or a fragment thereof that retains the kinase activity.

According to yet another aspect of the invention, a method for determining the level of expression of a SOC/CRAC polypeptide in a subject is provided. The method involves:

- a) measuring the expression of a SOC/CRAC polypeptide in a test sample, and
- b) comparing the measured expression of the SOC/CRAC polypeptide in the test sample to the expression of a SOC/CRAC polypeptide in a control containing a known level of expression to determine the level of SOC/CRAC expression in the subject. Expression is defined as SOC/CRAC mRNA expression or SOC/CRAC polypeptide expression. Various methods can be used to measure expression. The preferred embodiments of the invention utilize PCR and Northern blotting for measuring mRNA expression, and monoclonal or polyclonal SOC/CRAC antisera as reagents for measuring SOC/CRAC polypeptide expression. In preferred embodiments, the SOC/CRAC molecule (nucleic acid and/or polypeptide) is SOC-2/CRAC-1. In other preferred embodiments, the SOC/CRAC molecule is SOC-3/CRAC-2. In yet further preferred embodiments, the SOC/CRAC molecule is SOC-4/CRAC-3. In certain embodiments, the test samples include biopsy samples and biological fluids such as blood. The method is useful, e.g., for assessing the presence or absence or stage of a proliferative disorder in a subject.

The invention also contemplates kits comprising a package including assays for SOC/CRAC epitopes, SOC/CRAC nucleic acids, and instructions, and optionally related materials such as controls, for example, a number, color chart, or an epitope of the expression product of the foregoing isolated nucleic acid molecules of the invention for comparing, for

example, the level of SOC/CRAC polypeptides or SOC/CRAC nucleic acid forms (wild-type or mutant) in a test sample to the level in a control sample having a known amount of a SOC/CRAC nucleic acid or SOC/CRAC polypeptide. This comparison can be used to assess in a subject a risk of developing a cancer or the progression of a cancer. The kits may also include assays for other known genes, and expression products thereof, associated with, for example, proliferative disorders (e.g., BRCA, p53, etc.). In a preferred embodiment, the kit comprises a package containing: (a) a binding agent that selectively binds to an isolated nucleic acid of the invention or an expression product thereof to obtain a measured test value, (b) a control containing a known amount of a SOC/CRAC nucleic acid or a SOC/CRAC polypeptide to obtain a measured control value, and (c) instructions for comparing the measured test value to the measured control value to determine the amount of SOC/CRAC nucleic acid or expression product thereof in a sample.

The invention provides isolated nucleic acid molecules, unique fragments thereof, expression vectors containing the foregoing, and host cells containing the foregoing. The invention also provides isolated binding polypeptides and binding agents which bind such polypeptides, including antibodies, and pharmaceutical compositions containing any of the compositions of the invention. The foregoing can be used, *inter alia*, in the diagnosis or treatment of conditions characterized by the aberrant expression levels and/or the presence of mutant forms of a SOC/CRAC nucleic acid or polypeptide. The invention also provides methods for identifying agents that alter the function of the SOC/CRAC polypeptide.

These and other aspects of the invention, as well as various advantages and utilities, will be more apparent with reference to the detailed description of the preferred embodiments.

#### **Brief Description of the Sequences**

SEQ ID NO:1 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:2 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:1).

SEQ ID NO:3 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:4 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:3).

SEQ ID NO:5 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:6 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:5).

SEQ ID NO:7 is a partial nucleotide sequence of the mouse homologue (mSOC-2/CRAC-1) of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:8 is the predicted amino acid sequence of the translation product of the mSOC-2/CRAC-1 cDNA (SEQ ID NO:7).

5 SEQ ID NO:9 is the nucleotide sequence of the mouse MLSN-1 (SOC-1) cDNA.

SEQ ID NO:10 is the predicted amino acid sequence of the translation product of the mouse MLSN-1 (SOC-1) cDNA (SEQ ID NO:9).

SEQ ID NO:11 is the nucleotide sequence of a human calcium channel cDNA with GenBank Acc. no.: AB001535.

10 SEQ ID NO:12 is the predicted amino acid sequence of the translation product of the human calcium channel cDNA with GenBank Acc. no.: AB001535 (SEQ ID NO:11).

SEQ ID NO:13 is the amino acid sequence of a *C. Elegans* polypeptide at the c05c12.3 locus.

15 SEQ ID NO:14 is the amino acid sequence of a *C. Elegans* polypeptide at the F54D1 locus.

SEQ ID NO:15 is the amino acid sequence of a *C. Elegans* polypeptide at the t01H8 locus.

SEQ ID NO:16 is the nucleotide sequence of a mouse kidney cDNA with GenBank Acc. no.: AI226731.

20 SEQ ID NO:17 is the predicted amino acid sequence of the translation product of the mouse kidney cDNA with GenBank Acc. no.: AI226731 (SEQ ID NO:16).

SEQ ID NO:18 is the nucleotide sequence of a human brain cDNA with GenBank Acc. no.: H18835.

25 SEQ ID NO:19 is the predicted amino acid sequence of the translation product of the human brain cDNA with GenBank Acc. no.: H18835 (SEQ ID NO:18).

SEQ ID NO:20 is the nucleotide sequence of the human EST with GenBank Acc. no.: AA419592.

SEQ ID NO:21 is the nucleotide sequence of the human EST with GenBank Acc. no.: AA419407.

30 SEQ ID NO:22 is the nucleotide sequence of the mouse EST with GenBank Acc. no.: AI098310.



-9-

SEQ ID NO:23 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA that contains the SOC-2/CRAC-1 sequences of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.

SEQ ID NO:24 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:23).

SEQ ID NO:25 is a partial nucleotide sequence of the human SOC-3/CRAC-2 cDNA.

SEQ ID NO:26 is the predicted amino acid sequence of the translation product of human SOC-3/CRAC-2 cDNA (SEQ ID NO:25).

SEQ ID NO:27 is the full nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:28 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:27).

SEQ ID NO:29 is the full nucleotide sequence of the human SOC-3/CRAC-2 cDNA.

SEQ ID NO:30 is the predicted amino acid sequence of the translation product of human SOC-3/CRAC-2 cDNA (SEQ ID NO:29).

SEQ ID NO:31 is the full nucleotide sequence of the human SOC-4/CRAC-3 cDNA.

SEQ ID NO:32 is the predicted amino acid sequence of the translation product of human SOC-4/CRAC-3 cDNA (SEQ ID NO:31).

#### **Brief Description of the Drawings**

Figure 1 is a schematic depicting the intron/exon organization of the chicken SOC-2/CRAC-1 genomic sequence, as well as the putative transmembrane (TM) domains, and the targeting constructs utilized in the knockout experiments.

#### **Detailed Description of the Invention**

One aspect of the invention involves the partial cloning of cDNAs encoding members of a novel family of calcium channel polypeptides, referred to herein as "SOC/CRAC" (designated "SOC" or "CRAC" or "ICRAC", for Sore Operated Channels or Calcium Release Activated Channels, or CECH). Although not intending to be bound to any particular mechanism or theory, we believe that a SOC/CRAC family member is a transmembrane calcium channel that modulates  $\text{Ca}^{2+}$  flux "into" and "out of" a cell; in certain instances it may be activated upon depletion of  $\text{Ca}^{2+}$  from intracellular calcium stores, allowing  $\text{Ca}^{2+}$  influx into the cell.

The first three isolated SOC/CRAC members disclosed herein, define a new family of calcium channels which is distinct from previously described calcium channels, such as voltage gated calcium channels, ryanodine receptor/inositol-1,4,5-triphosphate receptor

channels, and Transient Receptor Potential (TRP) channels. The SOC/CRAC family of calcium channels exhibits high selectivity (with a  $P_{Ca}/P_{Na}$  ratio near 1000), a unitary conductance below the detection level of the patch clamp method (the conductance estimated at approximately 0.2 picosiemens), and are subject to inhibition by high intracellular calcium levels. Although not intending to be bound to any particular mechanism or theory, we believe that SOC/CRAC calcium channels are responsible for the majority of, for example, calcium entry which occurs when intracellular calcium stores are depleted, and that SOC/CRAC currents are important for initiating various types of calcium-dependent processes. Thus, we believe that SOC/CRAC calcium channels play an important role in cellular calcium homeostasis by, e.g., modulating the supply of calcium to refill intracellular stores when depleted.

The isolated full-length sequence of a representative, first member of the SOC/CRAC family, human SOC/CRAC nucleic acid (cDNA), SOC-2/CRAC-1, is represented as the nucleic acid of SEQ ID NO:27. This nucleic acid sequence codes for the SOC-2/CRAC-1 polypeptide with the predicted amino acid sequence disclosed herein as SEQ ID NO:28. A homologous mouse cDNA sequence (>90% identity to the human at the nucleotide level) is represented as the nucleic acid of SEQ ID NO:7, and codes for a unique fragment of a mouse SOC-2/CRAC-1 polypeptide having the predicted, partial amino acid sequence represented as SEQ ID NO:8. Analysis of the SOC-2/CRAC-1 partial sequence by comparison to nucleic acid and protein databases show that SOC-2/CRAC-1 shares a limited homology to mouse MLSN-1 (SOC-1, SEQ ID NOs: 9 and 10). Limited homology is also shared between SOC-2/CRAC-1 and three *C. Elegans* polypeptides (SEQ ID NOs: 13, 14, and 15). We further believe that SOC-2/CRAC-1 plays a role in the regulation of cellular  $Ca^{2+}$  fluxing and, in particular, lymphocyte  $Ca^{2+}$  fluxing.

A second member of the human SOC/CRAC family of calcium channels, SOC-3/CRAC-2, is represented as the nucleic acid of SEQ ID NO:29, and codes for the human SOC-3/CRAC-2 polypeptide having the predicted amino acid sequence represented as SEQ ID NO:30 (this molecule may also be referred to as CECH2). SOC-3/CRAC-2 is predominantly expressed in human hematopoietic cells (including peripheral blood lymphocytes, liver, bone marrow, spleen, thymus, lymph nodes, heart, and kidney. Expression can also be detected (at lesser levels) in brain, skeletal muscle colon, small intestine, placenta, lung, and cells (cell lines) such as HL-60, HeLa, K562, MOLT-4, SW-480, A459, and G361.

A third member of the human SOC/CRAC family of calcium channels, SOC-4/CRAC-3, is represented as the nucleic acid of SEQ ID NO:31, and codes for the human SOC-4/CRAC-3 polypeptide having the predicted amino acid sequence represented as SEQ ID NO:32 (this molecule may also be referred to as CECH6). It specifically expressed in the prostate gland/cells.

As used herein, a SOC/CRAC calcium channel nucleic acid (also referred to herein as a "SOC/CRAC nucleic acid" refers to a nucleic acid molecule which: (1) hybridizes under stringent conditions to one or more of the nucleic acids having the sequences of SEQ. ID NOS. 7, 27, 29, and/or 31 (sequences of the mouse and human SOC-2/CRAC-1, human SOC-3/CRAC-2, and human SOC-4/CRAC-3 nucleic acids), and (2) codes for a SOC-2/CRAC-1, a SOC-3/CRAC-2 or a SOC-4/CRAC-3 calcium channel polypeptide, respectively, or unique fragments of said SOC-2/CRAC-1, SOC-3/CRAC-2, or SOC-4/CRAC-3 polypeptide.

As used herein, a SOC/CRAC calcium channel polypeptide (also referred to herein as a "SOC/CRAC polypeptide") refers to a polypeptide that is coded for by a SOC-2/CRAC-1, a SOC-3/CRAC-2, and/or a SOC-4/CRAC-3 nucleic acid. Preferably, the above-identified SOC/CRAC polypeptides mediate transport of calcium into and out of a cell.

SOC/CRAC polypeptides also are useful as immunogenic molecules for the generation of binding polypeptides (e.g., antibodies) which bind selectively to SOC/CRAC (e.g., SOC-2/CRAC-1, SOC-3/CRAC-2, and/or SOC-4/CRAC-3) polypeptides. Such antibodies can be used in diagnostic assays to identify and/or quantify the presence of a SOC/CRAC polypeptide in a sample, such as a biological fluid or biopsy sample. SOC/CRAC polypeptides further embrace functionally equivalent fragments, variants, and analogs of the preferred SOC/CRAC polypeptides, provided that the fragments, variants, and analogs also are useful in mediating calcium transport into and out of intracellular calcium stores.

As used herein, "SOC/CRAC calcium channel activity" refers to  $\text{Ca}^{2+}$  transport (" $\text{Ca}^{2+}$  fluxing") across the plasma membrane that is mediated by a SOC/CRAC calcium channel polypeptide. The SOC/CRAC calcium channel polypeptide typically has one or more of the following properties: high selectivity, a unitary conductance below the detection level of the patch clamp method, and are subject to inhibition by high intracellular calcium levels. Such activity can be easily detected using standard methodology well known in the art. See, e.g., the Examples and Neher, E., "Ion channels for communication between and within cells",

Science, 1992; 256:498-502; and Hoth, M., and Penner, R., "Depletion of intracellular calcium stores activates a calcium current in mast cells", Nature, 1992; 355 (6358):353-6.

According to one aspect of the invention, isolated nucleic acid molecules which code for one or more member(s) of the SOC/CRAC family of calcium channel polypeptides are provided. The isolated nucleic acid molecules are selected from the following groups:

(a) nucleic acid molecules which hybridize under stringent conditions to one or more nucleic acid molecules selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

In certain embodiments, the isolated nucleic acid molecule comprises one or more of nucleotides 1-1212 of SEQ ID NO:1; nucleotides 1-739 of SEQ ID NO:3; nucleotides 1-1579 of SEQ ID NO:5; nucleotides 1-5117 of SEQ ID NO:23; the mouse homolog for SOC-2/CRAC-1 corresponding to SEQ ID NO:7; nucleotides 1-2180 of SEQ ID NO:25; nucleotides 382-5976 of SEQ ID NO:27; nucleotides 73-3714 of SEQ ID NO:29; and nucleotides 23-3434 of SEQ ID NO:31. In yet other embodiments, the isolated nucleic acid molecule comprises a molecule which encodes a polypeptide having one or more sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

According to yet another aspect of the invention, an isolated nucleic acid molecule is provided which is selected from the group consisting of:

(a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, (of sufficient length to represent a sequence unique within the human genome); and (b) complements of (a), provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to a sequence in the prior art as represented by the sequence group consisting of: (1) sequences having the SEQ ID NOs or GenBank accession numbers of Table I, (2) complements of (1), and (3) fragments of (1) and (2).

In some embodiments, the sequence of contiguous nucleotides is selected from the group consisting of (1) at least two contiguous nucleotides nonidentical to the sequence group, (2) at least three contiguous nucleotides nonidentical to the sequence group, (3) at least four contiguous nucleotides nonidentical to the sequence group, (4) at least five contiguous  
5 nucleotides nonidentical to the sequence group, (5) at least six contiguous nucleotides nonidentical to the sequence group, (6) at least seven contiguous nucleotides nonidentical to the sequence group.

In other embodiments, the unique fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16  
10 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 40 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

According to another aspect of the invention, expression vectors and host cells containing (e.g., transformed or transfected with) expression vectors comprising the nucleic  
15 acid molecules disclosed herein operably linked to a promoter are provided. In certain preferred embodiments, the host cells are eukaryotic cells.

The isolated nucleic acid molecules disclosed herein have various utilities, including their use as probes and primers to identify additional members of the SOC/CRAC family of calcium channels, as diagnostic reagents for identifying the presence of SOC/CRAC  
20 polypeptides in biological or other samples, and as agents for generating SOC/CRAC binding polypeptides (e.g., antibodies) that can be used as reagents in diagnostic and therapeutic assays to identify the presence, absence, and/or amounts of a SOC/CRAC nucleic acid or polypeptide in a biological or other sample.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified  
25 *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulatable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain  
30 reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the

material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulatable by standard techniques known to those of ordinary skill in the art.

As used herein with respect to polypeptides (discussed below), the term "isolated" means separated from its native environment in sufficiently pure form so that it can be manipulated or used for any one of the purposes of the invention. Thus, isolated means sufficiently pure to be used (i) to raise and/or isolate antibodies, (ii) as a reagent in an assay, or (iii) for sequencing, etc.

Homologs and alleles of the SOC/CRAC nucleic acids of the invention can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for SOC/CRAC polypeptides and which hybridize to a nucleic acid molecule selected from a group consisting of the nucleic acid of SEQ ID NO:1, the nucleic acid of SEQ ID NO:3, the nucleic acid of SEQ ID NO:5, the nucleic acid of SEQ ID NO:7, the nucleic acid of SEQ ID NO:23, the nucleic acid of SEQ ID NO:25, the nucleic acid of SEQ ID NO:27, the nucleic acid of SEQ ID NO:29, and the nucleic acid of SEQ ID NO:31, under stringent conditions. The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH<sub>2</sub>PO<sub>4</sub>(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, and would result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of the SOC/CRAC nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such

molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and/or SEQ ID NO:31, and SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, respectively. In some instances sequences will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances sequences will share at least 60% nucleotide identity and/or at least 75% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVetor sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for SOC/CRAC related genes, such as homologs and alleles of SOC-2/CRAC-1 and/or SOC-3/CRAC-2, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film or a phosphorimager plate to detect the radioactive signal.

Given that the expression of the SOC/CRAC gene is prominent in certain human tissues (e.g., SOC-2/CRAC-1: lymphoid tissue/heart, SOC-3/CRAC-2: kidney/colon, SOC-4/CRAC-3: prostate), and given the teachings herein of partial human SOC/CRAC cDNA clones, full-length and other mammalian sequences corresponding to the human SOC/CRAC partial nucleic acid sequences can be isolated from, for example, a cDNA library prepared from one or more of the tissues in which SOC-2/CRAC-1 expression is prominent, SOC-3/CRAC-2 is prominent, and/or SOC-4/CRAC-3 expression is prominent, using standard colony hybridization techniques.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the

art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating SOC/CRAC polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides isolated unique fragments of an isolated nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31. A unique fragment is one that is a 'signature' for the larger nucleic acid. For example, the unique fragment is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the SOC/CRAC nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome.

Unique fragments, however, exclude fragments completely composed of the nucleotide sequences of any of GenBank accession numbers and SEQ ID NOs listed in Table I (SEQ ID NO:9, AB001535, AI226731, H18835, AA419592, AA261842, AA419407, AI098310, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853), or other previously published sequences as of the filing date of this application.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits and SEQ ID NO:9, is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.



Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, as demonstrated in the Examples, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the SOC/CRAC polypeptides, useful, for example, in the preparation of antibodies, immunoassays or therapeutic applications. Unique fragments further can be used as antisense molecules to inhibit the expression of SOC/CRAC nucleic acids and polypeptides, respectively.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and complements thereof, will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides long (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases) or more, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide, (provided the sequence is unique as described above). Virtually any segment of the region of SEQ ID NO:1 beginning at nucleotide 1 and ending at nucleotide 1212, or SEQ ID NO:3 beginning at nucleotide 1 and ending at nucleotide 739, or SEQ ID NO:5 beginning at nucleotide 1 and ending at nucleotide 1579, or SEQ ID NO:7 beginning at nucleotide 1 and ending at nucleotide 3532, or SEQ ID NO:23 beginning at nucleotide 1 and ending at nucleotide 5117, SEQ ID NO:25 beginning at nucleotide 1 and ending at nucleotide 2180, SEQ ID NO:27 beginning at nucleotide 1 and ending at nucleotide 7419, or SEQ ID NO:29 beginning at nucleotide 1 and ending at nucleotide 4061, or SEQ ID NO:31 beginning at nucleotide 1 and ending at nucleotide 4646, or complements thereof, that is 20 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique

fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

As mentioned above, the invention embraces antisense oligonucleotides that  
5 selectively bind to a nucleic acid molecule encoding a SOC/CRAC polypeptide, to decrease SOC/CRAC calcium channel activity. When using antisense preparations of the invention, slow intravenous administration is preferred.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified  
10 oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those  
15 skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more  
20 to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the  
25 present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nat. Med.* 1(11):1116-1118, 1995). Most preferably, the  
30 antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In

addition, 3'-untranslated regions may be targeted by antisense oligonucleotides. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although, SEQ ID No:1 discloses a cDNA sequence, one of ordinary skill in the art may easily derive the genomic DNA corresponding to this sequence. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31. Similarly, antisense to allelic or homologous SOC/CRAC cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include

oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding SOC/CRAC polypeptides, together with pharmaceutically acceptable carriers. Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.

The invention also involves expression vectors coding for SOC/CRAC proteins and fragments and variants thereof and host cells containing those expression vectors. Virtually any cells, prokaryotic or eukaryotic, which can be transformed with heterologous DNA or RNA and which can be grown or maintained in culture, may be used in the practice of the invention. Examples include bacterial cells such as E.coli and eukaryotic cells such as mouse, hamster, pig, goat, primate, yeast, xenopous, etc. They may be of a wide variety of tissue types, including mast cells, fibroblasts, oocytes and lymphocytes, and they may be primary cells or cell lines. Specific examples include CHO cells and COS cells. Cell-free transcription systems also may be used in lieu of cells.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to,

plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g.,  $\beta$ -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed

and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene.

5 Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

According to yet another aspect of the invention, isolated SOC/CRAC polypeptides  
10 are provided. Preferably, the isolated SOC/CRAC polypeptides are encoded by the isolated SOC/CRAC nucleic acid molecules disclosed herein. More preferably, the isolated SOC/CRAC polypeptides of the invention are encoded by the nucleic acid molecules having SEQ ID Nos. 1, 3, 5, 7, 23, 25, 27, 29, and 31. In yet other embodiments, the isolated SOC/CRAC polypeptides of the invention have an amino acid sequence selected from the  
15 group consisting of SEQ ID Nos. 2, 4, 6, 8, 24, 26, 28, 30 and 32. Preferably, the isolated SOC/CRAC polypeptides are of sufficient length to represent a sequence unique within the human genome. Thus, the preferred embodiments include a sequence of contiguous amino acids which is not identical to a prior art sequence as represented by the sequence group consisting of the contiguous amino acids identified in Table II (SEQ ID NO:10, SEQ ID  
20 NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19 and GenBank Acc. Nos. AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572).

In certain embodiments, the isolated SOC/CRAC polypeptides are immunogenic and  
25 can be used to generate binding polypeptides (e.g., antibodies) for use in diagnostic and therapeutic applications. Such binding polypeptides also are useful for detecting the presence, absence, and/or amounts of a SOC/CRAC nucleic acid or polypeptide in a sample such as a biological fluid or biopsy sample. Preferably, the SOC/CRAC polypeptides that are useful for generating binding polypeptides are unique polypeptides and, therefore, binding of the  
30 antibody to a SOC/CRAC polypeptide in a sample is selective for the SOC/CRAC polypeptide.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al.,

*Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a SOC/CRAC polypeptide or fragment or variant thereof. The heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen, Carlsbad, CA), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the above described, SOC/CRAC cDNA sequence containing expression vectors, to transfect host cells and cell lines, by these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include dendritic cells, U293 cells, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The invention also permits the construction of SOC/CRAC gene

"knock-outs" in cells and in animals, providing materials for studying certain aspects of SOC/CRAC calcium channel activity.

The invention also provides isolated polypeptides (including whole proteins and partial proteins), encoded by the foregoing SOC/CRAC nucleic acids, and include the polypeptides of SEQ ID NO:2, 4, 6, 8, 24, 26, 28, 30, 32, and unique fragments thereof. Such polypeptides are useful, for example, to regulate calcium transport-mediated cell growth, differentiation and proliferation, to generate antibodies, as components of immunoassays, etc. Polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a SOC/CRAC polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 and 12 amino acids long or more, including each integer up to the full length, >1,000 amino acids long). Virtually any segment of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, excluding the ones that share identity with it (the polypeptides identified in Table II - SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, and GenBank Acc. Nos. AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572) that is 9 or more amino acids in length will be unique.

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include  $\text{Ca}^{2+}$  fluxing, high selectivity, a unitary



conductance below the detection level of the patch clamp method, and/or and are subject to inhibition by high intracellular calcium levels.

One important aspect of a unique fragment is its ability to act as a signature for identifying the polypeptide. Optionally, another aspect of a unique fragment is its ability to provide an immune response in an animal. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the SOC/CRAC polypeptides described above. As used herein, a "variant" of a SOC/CRAC polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a SOC/CRAC polypeptide. Modifications which create a SOC/CRAC polypeptide variant are typically made to the nucleic acid which encodes the SOC/CRAC polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and addition of amino acids or non-amino acid moieties to:

- 1) reduce or eliminate a calcium channel activity of a SOC/CRAC polypeptide;
- 2) enhance a property of a SOC/CRAC polypeptide, such as protein stability in an expression system or the stability of protein-protein binding;
- 3) provide a novel activity or property to a SOC/CRAC polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or
- 4) to provide equivalent or better binding to a SOC/CRAC polypeptide receptor or other molecule.

Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the SOC/CRAC amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant SOC/CRAC polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a SOC/CRAC calcium channel polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

Variants can include SOC/CRAC polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a SOC/CRAC polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encodes a SOC/CRAC polypeptide preferably preserve the amino acid reading frame of the coding sequence and, preferably, do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant SOC/CRAC polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a SOC/CRAC gene or cDNA clone to enhance expression of the polypeptide.

The skilled artisan will realize that conservative amino acid substitutions may be made in SOC/CRAC polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., the variants retain the functional capabilities of the SOC/CRAC polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the SOC/CRAC polypeptides include conservative amino acid substitutions of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32. Conservative substitutions of amino acids

include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Thus functionally equivalent variants of SOC/CRAC polypeptides, i.e., variants of SOC/CRAC polypeptides which retain the function of the natural SOC/CRAC polypeptides, are contemplated by the invention. Conservative amino-acid substitutions in the amino acid sequence of SOC/CRAC polypeptides to produce functionally equivalent variants of SOC/CRAC polypeptides typically are made by alteration of a nucleic acid encoding SOC/CRAC polypeptides (e.g., SEQ ID NOs:1, 3, 5, 7, 23, 25, 27, 29, 31). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a SOC/CRAC polypeptide. The activity of functionally equivalent fragments of SOC/CRAC polypeptides can be tested by cloning the gene encoding the altered SOC/CRAC polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered SOC/CRAC polypeptide, and testing for a functional capability of the SOC/CRAC polypeptides as disclosed herein (e.g., SOC/CRAC calcium channel activity).

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of SOC/CRAC polypeptides, including the isolation of the complete SOC/CRAC polypeptide. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated SOC/CRAC molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of SOC/CRAC mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce SOC/CRAC polypeptides. Those skilled in the art also can readily follow known methods for isolating SOC/CRAC polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from SOC/CRAC polypeptides. A dominant negative polypeptide is an

inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative inactive SOC/CRAC calcium channel which interacts normally with the cell membrane but which does not mediate calcium transport can reduce calcium transport in a cell. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

According to another aspect, the invention provides a method for isolating a SOC/CRAC molecule having SOC/CRAC calcium channel activity. The method involves contacting a binding molecule that is a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample containing one or more SOC/CRAC molecules under conditions that allow such binding (see earlier discussion) to form a complex, detecting the presence of the complex, isolating the SOC/CRAC molecule from the complex, and determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity. Thus, the invention is useful for identifying and isolating full length complementary (cDNA) or genomic nucleic acids encoding SOC/CRAC polypeptides having SOC/CRAC calcium channel activity. Identification and isolation of such nucleic acids and polypeptides may be accomplished by hybridizing/binding, under appropriate conditions well known in the art, libraries and/or restriction enzyme-digested human nucleic acids, with a labeled SOC/CRAC molecular probe. As used herein, a "label" includes molecules that are incorporated into, for

example, a SOC/CRAC molecule (nucleic acid or peptide), that can be directly or indirectly detected. A wide variety of detectable labels are well known in the art that can be used, and include labels that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc), or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseshoe peroxidase, etc.). The label may be bound to a SOC/CRAC binding partner, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradioactive energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art. Once a library clone or hybridizing fragment is identified in the hybridization/binding reaction, it can be further isolated by employing standard isolation/cloning techniques known to those of skill in the art. See, generally, Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press. In addition, nucleic acid amplification techniques well known in the art, may also be used to locate splice variants of calcium channel (or calcium channel subunits) with SOC/CRAC calcium channel activity. Size and sequence determinations of the amplification products can reveal splice variants.

The foregoing isolated nucleic acids and polypeptides may then be compared to the nucleic acids and polypeptides of the present invention in order to identify homogeneity or divergence of the sequences, and be further characterized functionally to determine whether they belong to a family of molecules with SOC/CRAC calcium channel activity (for methodology see under the Examples section).

The isolation of the SOC/CRAC cDNA and/or partial sequences thereof also makes it possible for the artisan to diagnose a disorder characterized by an aberrant expression of SOC/CRAC. These methods involve determining expression of the SOC/CRAC gene, and/or SOC/CRAC polypeptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes as exemplified below. In the latter situation, such determination can be carried out via any standard immunological assay using, for example, antibodies which bind to the SOC/CRAC protein.

The invention also embraces isolated peptide binding agents which, for example, can be antibodies or fragments of antibodies ("binding polypeptides"), having the ability to selectively bind to SOC/CRAC polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology. In certain embodiments, the invention excludes binding agents (e.g., antibodies) that bind to the polypeptides encoded by the nucleic acids of SEQ ID NOs: 10, 12, 13, 14, 15, 17, and 19.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs

-31-

are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies,  
5 including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by  
10 homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which  
15 the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves binding polypeptides of numerous size and type that bind selectively to SOC/CRAC polypeptides, and complexes containing SOC/CRAC polypeptides. These binding polypeptides also may be derived also from sources other than antibody  
20 technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form, as bacterial flagella peptide display libraries or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptides and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional  
25 procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the SOC/CRAC polypeptide or a complex containing a SOC/CRAC polypeptide. This process can be repeated through several  
30 cycles of reselection of phage that bind to the SOC/CRAC polypeptide or complex. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear

portion of the sequence that binds to the SOC/CRAC polypeptide or complex can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to  
5 identify polypeptides that bind to the SOC/CRAC polypeptides. Thus, the SOC/CRAC polypeptides of the invention, or a fragment thereof, or complexes of SOC/CRAC can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding polypeptides that selectively bind to the SOC/CRAC polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for  
10 interfering directly with the functioning of SOC/CRAC and for other purposes that will be apparent to those of ordinary skill in the art.

A SOC/CRAC polypeptide, or a fragment thereof, also can be used to isolate naturally occurring, polypeptide binding partners which may associate with the SOC/CRAC polypeptide in the membrane of a cell. Isolation of binding partners may be performed  
15 according to well-known methods. For example, isolated SOC/CRAC polypeptides can be attached to a substrate, and then a solution suspected of containing an SOC/CRAC binding partner may be applied to the substrate. If the binding partner for SOC/CRAC polypeptides is present in the solution, then it will bind to the substrate-bound SOC/CRAC polypeptide. The binding partner then may be isolated. Other proteins which are binding partners for  
20 SOC/CRAC, may be isolated by similar methods without undue experimentation.

The invention also provides novel kits which could be used to measure the levels of the nucleic acids of the invention, expression products of the invention or anti-SOC/CRAC antibodies. In the case of nucleic acid detection, pairs of primers for amplifying SOC/CRAC nucleic acids can be included. The preferred kits would include controls such as known  
25 amounts of nucleic acid probes, SOC/CRAC epitopes (such as SOC/CRAC expression products) or anti-SOC/CRAC antibodies, as well as instructions or other printed material. In certain embodiments the printed material can characterize risk of developing a disorder that is characterized by aberrant SOC/CRAC polypeptide expression based upon the outcome of the assay. The reagents may be packaged in containers and/or coated on wells in predetermined  
30 amounts, and the kits may include standard materials such as labeled immunological reagents (such as labeled anti-IgG antibodies) and the like. One kit is a packaged polystyrene microtiter plate coated with a SOC/CRAC polypeptide and a container containing labeled anti-human IgG antibodies. A well of the plate is contacted with, for example, serum, washed



and then contacted with the anti-IgG antibody. The label is then detected. A kit embodying features of the present invention is comprised of the following major elements: packaging an agent of the invention, a control agent, and instructions. Packaging is a box-like structure for holding a vial (or number of vials) containing an agent of the invention. a vial (or number of  
5 vials) containing a control agent, and instructions. Individuals skilled in the art can readily modify packaging to suit individual needs.

Another aspect of the invention is a method for determining the level of SOC/CRAC expression in a subject. As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments, human subjects are preferred.  
10 Expression is defined either as SOC/CRAC mRNA expression or SOC/CRAC polypeptide expression. Various methods can be used to measure expression. Preferred embodiments of the invention include PCR and Northern blotting for measuring mRNA expression, and monoclonal or polyclonal SOC/CRAC antisera as reagents to measure SOC/CRAC polypeptide expression. In certain embodiments, test samples such as biopsy samples, and  
15 biological fluids such as blood, are used as test samples. SOC/CRAC expression in a test sample of a subject is compared to SOC/CRAC expression in control sample to, e.g., assess the presence or absence or stage of a proliferative disorder (e.g., a lymphocyte proliferative disorder) in a subject.

SOC/CRAC polypeptides preferably are produced recombinantly, although such  
20 polypeptides may be isolated from biological extracts. Recombinantly produced SOC/CRAC polypeptides include chimeric proteins comprising a fusion of a SOC/CRAC protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the SOC/CRAC polypeptide under assay conditions, or providing a detectable moiety, such as  
25 green fluorescent protein. A polypeptide fused to a SOC/CRAC polypeptide or fragment may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

The invention is also useful in the generation of transgenic non-human animals. As used herein, "transgenic non-human animals" includes non-human animals having one or  
30 more exogenous nucleic acid molecules incorporated in germ line cells and/or somatic cells. Thus the transgenic animal include "knockout" animals having a homozygous or heterozygous gene disruption by homologous recombination, animals having episomal or chromosomally incorporated expression vectors, etc. Knockout animals can be prepared by

homologous recombination using embryonic stem cells as is well known in the art. The recombination may be facilitated using, for example, the cre/lox system or other recombinase systems known to one of ordinary skill in the art. In certain embodiments, the recombinase system itself is expressed conditionally, for example, in certain tissues or cell types, at certain embryonic or post-embryonic developmental stages, inducibly by the addition of a compound which increases or decreases expression, and the like. In general, the conditional expression vectors used in such systems use a variety of promoters which confer the desired gene expression pattern (e.g., temporal or spatial). Conditional promoters also can be operably linked to SOC/CRAC nucleic acid molecules to increase expression of SOC/CRAC in a regulated or conditional manner. *Trans*-acting negative regulators of SOC/CRAC calcium channel activity or expression also can be operably linked to a conditional promoter as described above. Such *trans*-acting regulators include antisense SOC/CRAC nucleic acids molecules, nucleic acid molecules which encode dominant negative SOC/CRAC molecules, ribozyme molecules specific for SOC/CRAC nucleic acids, and the like. The transgenic non-human animals are useful in experiments directed toward testing biochemical or physiological effects of diagnostics or therapeutics for conditions characterized by increased or decreased SOC/CRAC expression. Other uses will be apparent to one of ordinary skill in the art.

The invention further provides efficient methods of identifying agents or lead compounds for agents active at the level of a SOC/CRAC polypeptide (e.g., a SOC/CRAC polypeptide) or SOC/CRAC fragment dependent cellular function. In particular, such functions include interaction with other polypeptides or fragments thereof, and selective binding to certain molecules (e.g., agonists and antagonists). Generally, the screening methods involve assaying for compounds which interfere with SOC/CRAC calcium channel activity, although compounds which enhance SOC/CRAC calcium channel activity also can be assayed using the screening methods. Such methods are adaptable to automated, high throughput screening of compounds. The target therapeutic indications for pharmacological agents detected by the screening methods are limited only in that the target cellular function be subject to modulation by alteration of the formation of a complex comprising a SOC/CRAC polypeptide or fragment thereof and one or more SOC/CRAC binding targets. Target indications include cellular processes modulated by SOC/CRAC such as  $\text{Ca}^{2+}$  fluxing, and affected by SOC/CRAC ability to form complexes with other molecules and polypeptides as, for example, may be present in the cell membrane.

A wide variety of assays for pharmacological agents are provided, including, expression assays, labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays, cell-based assays such as calcium transport assays, etc. For example, two-hybrid screens are used to rapidly examine the effect of transfected nucleic acids on the intracellular binding of SOC/CRAC or SOC/CRAC fragments to specific intracellular targets (e.g. a tyrosine kinase). The transfected nucleic acids can encode, for example, combinatorial peptide libraries or cDNA libraries. Convenient reagents for such assays, e.g., GAL4 fusion proteins, are known in the art. An exemplary cell-based assay involves transfecting a cell with a nucleic acid encoding a SOC/CRAC polypeptide fused to a GAL4 DNA binding domain and a nucleic acid encoding a reporter gene operably linked to a gene expression regulatory region, such as one or more GAL4 binding sites. Activation of reporter gene transcription occurs when the SOC/CRAC and reporter fusion polypeptides bind such as to enable transcription of the reporter gene. Agents which modulate a SOC/CRAC polypeptide mediated cell function are then detected through a change in the expression of reporter gene. Methods for determining changes in the expression of a reporter gene are known in the art.

In an expression system, for example, a SOC/CRAC polypeptide is attached to a membrane, the membrane preferably separating two fluid environments and being otherwise not permeable to  $\text{Ca}^{2+}$ . Such separation is preferred so that a change in  $\text{Ca}^{2+}$  concentration on either side of the membrane is mediated only through the attached SOC/CRAC polypeptide. Preferably, a SOC/CRAC polypeptide is expressed in an intact cell and is present on the cell-membrane (as in physiologic conditions). The cell expressing the SOC/CRAC polypeptide is preferably a eukaryotic cell, and the SOC/CRAC polypeptide is preferably recombinantly expressed, although cells naturally expressing a SOC/CRAC polypeptide may also be used. Synthetic membranes, however, containing SOC/CRAC polypeptides may also be used. See, e.g., K. Kiselyov, et al., Functional interaction between InsP3 receptors and store-operated Htrp3 channels, Nature 396, 478-82 (1998).

The cell expressing the SOC/CRAC polypeptide is incubated under conditions which, in the absence of the candidate agent, permit calcium flux into the cell and allow detection of a reference calcium concentration. For example, depletion of intracellular calcium stores with thapsigargin or other agents (Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997) would produce a given level of SOC/CRAC channel activation and a given reference calcium concentration. Detection of a decrease in the

foregoing activities (i.e., a decrease in the intracellular calcium concentration) relative to the reference calcium concentration indicates that the candidate agent is a lead compound for an agent to inhibit SOC/CRAC calcium channel activity. Preferred SOC/CRAC polypeptides include the polypeptides of claim 15.

5 SOC/CRAC fragments used in the methods, when not produced by a transfected nucleic acid are added to an assay mixture as an isolated polypeptide. SOC/CRAC polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts or chemically synthesized. Recombinantly produced SOC/CRAC polypeptides include chimeric proteins comprising a fusion of a SOC/CRAC  
10 protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the SOC/CRAC polypeptide under assay conditions, or providing a detectable moiety, such as green fluorescent protein or Flag epitope.

The assay mixture is comprised of a SOC/CRAC polypeptide binding target  
15 (candidate agent) capable of interacting with a SOC/CRAC polypeptide. While natural SOC/CRAC binding targets may be used, it is frequently preferred to use portions (e.g., peptides or nucleic acid fragments) or analogs (i.e., agents which mimic the SOC/CRAC binding properties of the natural binding target for purposes of the assay) of the SOC/CRAC binding target so long as the portion or analog provides binding affinity and avidity to the  
20 SOC/CRAC polypeptide (or fragment thereof) measurable in the assay.

The assay mixture also comprises a candidate agent (binding target, e.g., agonist/antagonist). Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or  
25 at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for  
30 structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or

polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids as defined herein are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily modified through conventional chemical, physical, and biochemical means. Further, known agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents. Non-SOC/CRAC calcium channel agonists and antagonists, for example, include agents such as dihydropyridines (DHPs), phenylalkylamines, omega conotoxin (omega-CgTx) and pyrazonoylguanidines.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein, protein-nucleic acid, and/or protein/membrane component binding association. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease, inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate agent, the SOC/CRAC polypeptide specifically binds the cellular binding target, a portion thereof or analog thereof. The order of addition of components, incubation temperature, time of incubation, and other perimeters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically

are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of specific binding between the SOC/CRAC polypeptide and one or more binding targets is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximum signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as two- or three-hybrid screens. The transcript resulting from a reporter gene transcription assay of SOC/CRAC polypeptide interacting with a target molecule typically encodes a directly or indirectly detectable product, e.g.,  $\beta$ -galactosidase activity, luciferase activity, and the like. For cell-free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc.) or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to a SOC/CRAC binding partner, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly

detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, strepavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

Of particular importance in any of the foregoing assays and binding studies is the use  
5 of a specific sequence motif identified in the SOC-2/CRAC-1 polypeptide sequence as a kinase catalytic domain. According to the invention, amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24) (or a fragment thereof), show a localized homology with the catalytic domains of eukaryotic elongation factor-2 kinase (eEF-2 kinase, GenBank  
10 Acc. no. U93850) and *Dictyostelium* myocin heavy chain kinase A (MHCK A, GenBank Acc. no. U16856), as disclosed in Ryazanov AG, et al., *Proc Natl Acad Sci U S A*, 1997, 94(10):4884-4889. Therefore, according to the invention, a method for identifying agents useful in the modulation of SOC/CRAC polypeptide kinase activity is provided. The method involves contacting a SOC/CRAC polypeptide with kinase activity, that includes, for example, amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24) with a  
15 candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity; detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and comparing the kinase activity in the previous step with a control kinase activity of a SOC/CRAC polypeptide in the absence of the  
20 candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC kinase activity. Other controls for kinase activity can also be performed at the same time, for example, by utilizing eEF-2 kinase and/or *Dictyostelium* MHC Kinase A, in a similar manner to the SOC/CRAC member. Methods for performing such kinase activity assays are well known in the art.

25 The invention thus provides SOC/CRAC-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, SOC/CRAC-specific agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with altered SOC/CRAC and SOC/CRAC calcium channel fluxing characteristics. Novel  
30 SOC/CRAC-specific binding agents include SOC/CRAC-specific antibodies and other natural intracellular and extracellular binding agents identified with assays such as two hybrid screens, and non-natural intracellular and extracellular binding agents identified in screens of chemical libraries and the like.

In general, the specificity of SOC/CRAC binding to a specific molecule is determined by binding equilibrium constants. Targets which are capable of selectively binding a SOC/CRAC polypeptide preferably have binding equilibrium constants of at least about  $10^7$   $M^{-1}$ , more preferably at least about  $10^8$   $M^{-1}$ , and most preferably at least about  $10^9$   $M^{-1}$ . The wide variety of cell based and cell free assays may be used to demonstrate SOC/CRAC-specific binding. Cell based assays include one, two and three hybrid screens, assays in which SOC/CRAC-mediated transcription is inhibited or increased, etc. Cell free assays include SOC/CRAC-protein binding assays, immunoassays, etc. Other assays useful for screening agents which bind SOC/CRAC polypeptides include fluorescence resonance energy transfer (FRET), and electrophoretic mobility shift analysis (EMSA).

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid- $CaPO_4$  precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. For example, where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the anti-inflammatory agent, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones,



polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

Use of a long-term sustained release implant may be particularly suitable for treatment of chronic conditions. Long-term release, as used herein, means that the implant is constructed and arranged to delivery therapeutic levels of the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above.

The invention also contemplates gene therapy. The procedure for performing *ex vivo* gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject which contains a defective copy of the gene, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* gene therapy using vectors such as adenovirus, retroviruses, herpes virus, and targeted liposomes also is contemplated according to the invention. See, e.g., U.S. Patent Nos. 5,670,488, entitled "Adenovirus Vector for Gene Therapy", issued to Gregory et al., and 5,672,344, entitled "Viral-Mediated Gene Transfer System", issued to Kelley et al.

The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

### Examples

5 As an initial approach to identifying SOC/CRAC channels, we considered publicly available data and hypothesized that the following characteristics are likely to be exhibited by SOC/CRAC calcium channels: i) SOC/CRAC calcium channels would be integral membrane proteins related (probably distantly) to one of the known calcium channel families (e.g. voltage gated, ligand gated, Trp), and therefore should have a pore region formed by a tetramer of 6-7 transmembrane (TM) regions; ii) high calcium selectivity was likely to come at the price of complexity, and therefore these were likely to be large proteins; iii) the high calcium selectivity of this type of channel was likely to be useful and, therefore, highly conserved; and iv) these channels should be expressed in one or more types of lymphocytes, since ICRAC is best defined in those cell types. Since the full genome of the nematode *C. elegans* is nearing completion, and IP3-dependent calcium signals have recently been shown to be required for one or more aspects of *C. elegans* development, we took the set of proteins encoded by this genome (at the time this search was initiated WORMPEP14 was the available predicted protein set) and began searching for proteins which fit the criteria above. This search began by proceeding in alphabetical order through WORMPEP14 and arbitrarily excluding all proteins below approximately 1000 amino acids in size, followed by focusing on remaining proteins with clear TM spanning regions similar to those of other calcium channels. We stopped this screen on encountering a protein designated C05C12.3, a predicted protein of 1816 amino acids (SEQ ID NO:13). C05C12.3 was notable because its central pore region had some sequence similarity to but was clearly distinct from members of the Trp family of calcium channels, and the hydrophobicity plot of this region showed a characteristically wide spacing between the fifth and sixth TM regions for the amino acid residues which are thought to line the channel pore region and mediate the calcium selectivity of the channels. In addition, it lacked any ankyrin repeats in the region amino-terminal to its pore region, further distinguishing it from other Trp family proteins.

30 We then used C05C12.3 for BLAST alignment screening of the rest of the *C. elegans* genome and also mammalian databases for homologous proteins, revealing two other *C. elegans* homologues (SEQ ID NO:14 and SEQ ID NO:15), and also a recently cloned mammalian protein named melastatin-1 (MLSN-1/SOC-1, SEQ ID NOs:9 and 10, and

GenBank Acc. No. AF071787). Using these sequences, we subsequently performed an exhaustive screening of publicly accessible EST databases in search of lymphocyte homologues, but were unsuccessful in detecting any homologous transcripts in any lymphocyte lines. Since MLSN-1 (SEQ ID NOs:9 and 10) was expressed exclusively in melanocytes and retina by Northern blot hybridization and by EST database searching, there was no evidence that this type of channel was expressed in the type of cell in which ICRAC-like currents were best defined. Subsequent BLAST searches picked up mouse EST sequence AI098310 (SEQ ID NO:22) from a monocyte cell line. The I.M.A.G.E. consortium clone containing the above-identified EST was then purchased from ATCC (clone ID. 1312756, Manassas, VA) and was further characterized. Using other portions of this sequence in EST searches, we subsequently picked up similar sequences in human B-cells (SEQ ID NOs:20 and 21), and other cell types as well (SEQ ID NOs: 11, 12, 16, 17, 18, and 19). Most of these sequences were subsequently identified to be part of the 3'-UTR or of the carboxy terminal region of the proteins, which are not readily identifiable as Trp channels, providing an explanation for the art's inability to detect any type of Trp related transcripts in lymphocytes. Partial sequences from the 5' and/or 3' ends of the above identified clones were then used to screen leukocyte and kidney cDNA libraries to extend the original sequences more toward the 5' and/or 3' ends.

In view of the foregoing, it was concluded that channels of this type were expressed in many types of lymphocytes, and therefore were members of a new family of SOC/CRAC calcium channels.

#### Experimental Procedures Screening of the cDNA libraries

Leukocyte and kidney cDNA libraries from Life Technologies (Gaithersburg, MD) were screened using the Gene Trapper II methodology (Life Technologies) according to manufacturer's recommendation, using the inserts of I.M.A.G.E. clone ID nos. 1312756 and 1076485 from ATCC (Manassas, VA), under stringent hybridization conditions. Using standard methodology ( *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York), individual cDNA clones were subjected to 3-4 rounds of amplification and purification under the same hybridization conditions.

After excision from the vector and subcloning of inserts into the plasmid forms, several clones were sequenced by the Beth Israel Deaconess Medical Center's Automated

Sequencing Facility. Molecular biological techniques such as restriction enzyme treatment, subcloning, DNA extraction, bacterial culture and purification of DNA fragments were performed according to methods well known in the art. Computer analyses of protein and DNA sequences was done using "Assemblylign" (Oxford Molecular, Campbell, CA). Multiple  
5 alignments of the SOC/CRAC family members were produced using the CLUSTAL facility of the MacVector program. Restriction endonucleases, expression vectors, and modifying enzymes were purchased from commercial sources (Gibco-BRL). Sequencing vectors for DNA were purchased from Stratagene (La Jolla, CA).

Once the first members of what appeared to be a novel family of calcium channel  
10 receptors were identified and characterized, additional BLAST alignments were performed with the newly characterized nucleic acid sequences. An initial match was with genomic DNA fragment NH0332L11 (Genbank Acc. No. AC005538). Using this genomic sequence, promoters were designed and a number of cDNA libraries was surveyed by PCR. A prostate specific message was identified and characterized, leading to the isolation and  
15 characterization of SOC-4/CRAC-3 (SEQ ID NOs: 31 and 32).

### Functional Assays

#### Transient Expression of SOC/CRAC

In our initial transient expression experiments, we expressed or expect to express a SOC/CRAC molecule transiently in RBL-2H3 mast cells, Jurkat T cells, and A20  
20 B-lymphocytes using both electroporation and vaccinia virus-driven expression, and measured the calcium influx produced by depletion of intracellular calcium stores with thapsigargin. Each of the foregoing techniques is well known to those of ordinary skill in the art and can be performed using various methods (see, e.g., Current Methods in Molecular Biology, eds. Ausubal, F.M., et al. 1987, Green Publishers and Wiley Interscience, N.Y.,  
25 N.Y.). Exemplary methods are described herein.

Depletion of intracellular calcium stores is accomplished by treating the cells with 1 micromolar thapsigargin; alternative agents which function to deplete intracellular stores are described in by Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997 and include, for example, ionomycin, cyclopiazonic acid, and DBHQ.

30 Calcium influx is determined by measuring cytoplasmic calcium as indicated using the fura-2 fluorescent calcium indicator (see, e.g., G. Grynkiewicz, M. Poenie, R. Y. Tsien, A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties, J. Biol

Chem 260, 3440-50 (1985), and M. Poenie, R. Tsien, Fura-2: a powerful new tool for measuring and imaging  $[Ca^{2+}]_i$  in single cells, Prog Clin Biol Res 210, 53-6 (1986)).

Patch Clamp Analysis and Determining Selectivity of SOC/CRAC

Patch clamp analysis of cells injected with SOC/CRAC cRNA is performed by using  
5 the general patch technique as described in Neher, E., "Ion channels for communication between and within cells", Science, 1992; 256:498-502. Specific techniques for applying the patch clamp analysis to RBL cells are described in Hoth, M., and Penner, R., "Depletion of intracellular calcium stores activates a calcium current in mast cells", Nature, 1992; 355:3535-3555. Additional protocols for applying the patch clamp technique to other cell  
10 types are described in Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997

An exemplary protocol for patch clamp analysis of SOC/CRAC molecule expressed in RBL-2H3 mast cells using a recombinant vaccinia virus is as follows. The currents elicited by store depletion are determined using the whole cell configuration (Neher, E., Science,  
15 1992; 256:498-502). Currents in SOC/CRAC expressing cells are compared to currents in control cells expressing an irrelevant protein or a classic Trp family calcium channel known as VR1 (M. J. Caterina, et al., The capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments], Nature 389, 816-24 (1997)) in order to assess the contribution of SOC/CRAC expression. In addition, the magnitude of whole cell currents in the presence of  
20 extracellular calcium (10 mM), barium (10 mM), or magnesium (10 mM) are compared to determine the relative permeability of the channels to each of these ions (Hoth, M., and Penner, R., Nature, 1992; 355:3535-3555) and, thereby, determine the ionic selectivity.

Pharmacologic Behavior of SOC/CRAC

For analysis of the pharmacologic behavior of a SOC/CRAC molecule, a SOC/CRAC  
25 molecule is expressed in RBL-2H3 mast cells using a recombinant vaccinia virus, and the degree of calcium influx elicited by store depletion is monitored using a bulk spectrofluorimeter or a fluorescence microscope and the calcium sensitive dye fura-2 (G. Grynkiewicz, M. Poenie, R. Y. Tsien, A new generation of  $Ca^{2+}$  indicators with greatly improved fluorescence properties, J Biol Chem 260, 3440-50 (1985) and M. Poenie, R.  
30 Tsien, Fura-2: a powerful new tool for measuring and imaging  $[Ca^{2+}]_i$  in single cells, Prog Clin Biol Res 210, 53-6 (1986)). The level of cytoplasmic calcium in SOC/CRAC expressing cells is compared to the level achieved in control cells expressing an irrelevant protein or a classic Trp. family calcium channels known as VR1 (M. J. Caterina, et al., The

capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments], Nature 389, 816-24 (1997)). These cells then are pre-incubated with the desired pharmacologic reagent, and again the response to store depletion is monitored. Comparison of the effect of depleting stores in SOC/CRAC expressing cells relative to controls in the presence or absence of the pharmacologic reagent is used to assess the ability of that reagent to modulate SOC/CRAC activity. Sphingosine is an exemplary molecule that can be used as pharmacologic reagents for pharmacologic characterization of SOC/CRAC calcium channels. See, e.g., Mathes, C., et al., Calcium release activated calcium current as a direct target for sphingosine, J Biol Chem 273(39):25020-25030 (1998). Other non-specific calcium channel inhibitors that can be used for this purpose include SKR96365 (Calbiochem) and Lanthanum.

#### Bulk Calcium Assays

Bulk calcium assays can be performed in a PTI Deltascan bulk spectrofluorometer using fura-2 as described in Scharenberg AM, et al., EMBO J, 1995, 14(14):3385-94.

#### Gene Targeting

The method (and reagents) described by Buerstedde JM et al, (Cell, 1991, Oct 4;67(1):179-88), was used to generate "knockouts" in cells. Briefly, part of the chicken SOC-2/CRAC-1 genomic sequence coding for the transmembrane region was cloned utilizing the human sequence as the probe in a chicken library screen. Chicken SOC-2/CRAC-1 clones were isolated and characterized using standard methodology. The putative exon and domain arrangement of the chicken SOC-2/CRAC-1, is depicted in Figure 1. The exons coding for TM5 (pore region) and TM6, were replaced with promoter/antibiotic cassettes (see Figure1). These targeting vectors were then used to target (and replace) the endogenous gene in DT-40 cells (chicken B lymphocyte cells).

#### Results

##### Example 1: Transient Expression of SOC/CRAC

In the above-identified cell lines and using both of the foregoing expression techniques, SOC/CRAC expression enhances thapsigargin-dependent influx. In addition, SOC/CRAC expression also enhances the amount of intracellular calcium stores. That this effect is likely due to SOC/CRAC acting as a plasma membrane calcium channel can be confirmed by producing an in-frame carboxy-terminal translational fusion with green fluorescent protein followed by confocal microscopy, revealing that SOC/CRAC is expressed predominantly as a plasma membrane calcium channel.

##### Example 2: Patch Clamp Analysis

The biophysical characteristics of SOC/CRAC enhanced currents when expressed in *Xenopus* oocytes are determined. SOC/CRAC cRNA injection is able to enhance thapsigargin-dependent whole cell currents. In addition, SOC/CRAC does not alter the reversal potential of these currents and the determination of the  $P_{Ca}/P_{Na}$  ratio shows that SOC/CRAC channels are highly calcium selective.

**Example 3: *Pharmacologic Behavior of SOC/CRAC***

The pharmacologic behavior of SOC/CRAC is evaluated as described above. SOC/CRAC-enhanced influx is inhibited by sphingosine in a manner that is substantially the same as that of endogenous thapsigargin-dependent calcium influx.

**Example 4: *Gene targeting***

Transfection of DT-40 cells with the foregoing targeting vectors, selection for antibiotic resistance, and screening, is collectively referred to, herein, as a round of targeting. For the first round of targeting SOC-2/CRAC-1, 18/24 clones with homologous recombination of the targeting construct into one of the endogenous SOC-2/CRAC-1 alleles were obtained. On the second round of targeting (in order to target the second allele and therefore generate a homozygous SOC-2/CRAC-1 mutant cell), 0/48 clones were obtained. These results indicate that a "null" SOC-2/CRAC-1 mutation is detrimental to DT-40 cells, and that SOC-2/CRAC-1 is required for cell viability.

**Table I. Nucleotide Sequences with homologies to SOC/CRAC nucleic acids**

|  |
|--|
| Sequences with SEQ ID NOs and GenBank accession numbers:   |
| SEQ ID NO:9, AB001535, AI226731, H18835, AA419592, AA261842, AA419407, AA592910, D86107, AI098310, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853. |

**Table II. Amino Acid Sequences with homologies to SOC/CRAC polypeptides**

|   |
|---|
| Sequences with SEQ ID NOs and GenBank accession numbers:  |
| SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572. |

All references, patents, and patent documents disclosed herein are incorporated by reference herein in their entirety.

What is claimed is presented below and is followed by a Sequence Listing. We claim:

Claims

1. An isolated nucleic acid molecule, comprising:

(a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:1.

3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:27.

4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:29.

5. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:31.

6. An isolated nucleic acid molecule selected from the group consisting of

(a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29, and SEQ ID NO:31,

(b) complements of (a),

provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from a sequence group consisting of

(1) sequences having the SEQ. ID NOS. or GenBank accession numbers of Table I,

(2) complements of (1), and

(3) fragments of (1) and (2).



7. The isolated nucleic acid molecule of claim 6, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

- (1) at least two contiguous nucleotides nonidentical to the sequence group,
- (2) at least three contiguous nucleotides nonidentical to the sequence group,
- (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

8. The isolated nucleic acid molecule of claim 6, wherein the unique fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

9. The isolated nucleic acid molecule of claim 6, wherein the molecule encodes a polypeptide which is immunogenic.

10. An expression vector comprising the isolated nucleic acid molecule of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 operably linked to a promoter.

11. A host cell transformed or transfected with the expression vector of claim 10.

12. An isolated polypeptide encoded by the isolated nucleic acid molecule according to anyone of claims 1 or 6, wherein the polypeptide comprises a SOC/CRAC polypeptide or a unique fragment thereof.

13. The isolated polypeptide of claim 12, wherein the isolated polypeptide is encoded by the isolated nucleic acid molecule of claim 2, 3, 4, or 5.

14. The isolated polypeptide of claim 13, wherein the isolated polypeptide comprises a polypeptide having the sequence of amino acids selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

15. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, 4, or 5, wherein the polypeptide, or unique fragment thereof is immunogenic.

16. An isolated binding polypeptide which binds selectively to a polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, 4, or 5.

5 17. The isolated binding polypeptide of claim 16, wherein the isolated binding polypeptide binds to a polypeptide having the sequence of amino acids selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

10 18. The isolated binding polypeptide of claim 17, wherein the isolated binding polypeptide is an antibody or an antibody fragment selected from the group consisting of a Fab fragment, a F(ab)<sub>2</sub> fragment or a fragment including a CDR3 region selective for the polypeptide.

15 19. An isolated polypeptide, comprising a unique fragment of the polypeptide of claim 12 of sufficient length to represent a sequence unique within the human genome, provided that the fragment excludes a sequence of contiguous amino acids identified in Table II.

20. A method for isolating a SOC/CRAC molecule having SOC/CRAC calcium channel activity, comprising:

20 a) contacting a binding molecule that is a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample containing one or more SOC/CRAC molecules, under conditions sufficient to form a complex of the SOC/CRAC nucleic acid or the SOC/CRAC binding polypeptide and the SOC/CRAC molecule;

b) detecting the presence of the complex;

c) isolating the SOC/CRAC molecule from the complex; and

25 d) determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity.

21. The method of claim 20, wherein the binding molecule is a SOC/CRAC nucleic acid.

22. The method of claim 20, wherein the binding molecule is a SOC/CRAC binding polypeptide.

23. The method of claim 21, wherein the SOC/CRAC nucleic acid comprises at least 14 nucleotides from any contiguous portion of a sequence of nucleotides selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31.

5 24. A method for identifying agents useful in the modulation of SOC/CRAC calcium channel activity, comprising:

a) contacting a SOC/CRAC polypeptide with a candidate agent suspected of modulating SOC/CRAC calcium channel activity, under conditions sufficient to allow the SOC/CRAC polypeptide to interact selectively with the candidate agent;

10 b) detecting a  $\text{Ca}^{2+}$  concentration associated with SOC/CRAC calcium channel activity of the SOC/CRAC polypeptide in the presence of the candidate agent; and

c) comparing the  $\text{Ca}^{2+}$  concentration of step (b) with a control  $\text{Ca}^{2+}$  concentration of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates SOC/CRAC calcium channel activity.

15

25. A method for determining the level of SOC/CRAC expression in a subject, comprising:

a) measuring the expression of SOC/CRAC in a test sample obtained from the subject, and

20 b) comparing the measured expression of SOC/CRAC in the test sample to the expression of the SOC/CRAC polypeptide in a control to determine the level of SOC/CRAC expression in the subject.

25

26. The method of claim 25, wherein the expression of SOC/CRAC in (b) is SOC/CRAC mRNA expression.

27. The method of claim 25, wherein the expression of SOC/CRAC in (b) is SOC/CRAC polypeptide expression.

28. The method of claim 25, wherein the test sample is tissue.

29. The method of claim 25, wherein the test sample is a biological fluid.

30. The method of claim 26, wherein SOC/CRAC mRNA expression is measured using the Polymerase Chain Reaction (PCR).

31. The method of claim 26, wherein SOC/CRAC mRNA expression is measured using a method selected from the group consisting of northern blotting, monoclonal antisera to SOC/CRAC and polyclonal antisera to SOC/CRAC.

32. A kit, comprising a package containing:

an agent that selectively binds to the isolated nucleic acid of claim 1 or an expression product thereof, and

a control for comparing to a measured value of binding of said agent to said isolated nucleic acid of claim 1 or expression product thereof.

33. The kit of claim 32, wherein the control comprises an epitope of the expression product of the nucleic acid of claim 1.

34. A pharmaceutical composition comprising:

a pharmaceutically effective amount of an agent comprising of an isolated nucleic acid molecule of claim 1 or an expression product thereof, and

a pharmaceutically acceptable carrier.

35. The pharmaceutical composition of claim 34, wherein the agent is an expression product of the isolated nucleic acid molecule of claim 1.

36. A method for identifying agents useful in the modulation of a SOC/CRAC polypeptide kinase activity, comprising:

a) contacting a SOC/CRAC polypeptide with kinase activity with a candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity;

b) detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and

c) comparing the kinase activity of step (b) with a control kinase activity of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates SOC/CRAC kinase activity.

37. The method of claim 36, wherein the SOC/CRAC polypeptide comprises amino acids 999-1180 of the sequence represented as SEQ ID NO:24, or a fragment thereof that retains the kinase activity.

1/1




Fig. 1

-1-  
SEQUENCE LISTING

<110> Beth Israel Deaconess Medical Center, Inc.  
Scharenberg, Andrew

<120> CHARACTERIZATION OF A CALCIUM CHANNEL FAMILY

<130> B0662/7026WO/ERP/KA

<150> U.S. 60/114,220

<151> 1998-12-30

<150> U.S. 60/120,018

<151> 1999-01-29

<150> U.S. 60/140,415

<151> 1999-06-22

<160> 32

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1212

<212> DNA

<213> Homo Sapiens

<400> 1

```
gcacgaggca aattttttgt tagtacacca tctcagccaa gttgcaaaag ccacttggaa      60
actggaacca aagatcaaga aactgtttgc tctaaagcta cagaaggaga taatacagaa      120
tttgagcat ttgtaggaca cagagatagc atggatttac agaggtttaa agaaacatca      180
aacaagataa aaatactatc caataacaat acttctgaaa acactttgaa acgagtgagt      240
tctcttgctg gatttactga ctgtcacaga acttccattc ctgttcattc aaaacaagaa      300
aaaatcagta gaaggccatc taccgaagac actcatgaag tagattccaa agcagcttta      360
ataccggttt gtagatttca actaaacaga tatatatatt taaatacatt aaactttttt      420
agataagatc tacaaagtgg tgatatttgg gactatatca aaaattcaaa aaaatttttc      480
ttaagaaaaa tgacttttagc atagtagcag ttacagaaaa gtttcttaca gtgaatagtc      540
aggaatttta aagaaaaatt tatgcagaat aaaggcagga atctcttttt gtttgaattg      600
aagctaatta tatgaactca tttccagcta actgcgataa tgattgattt tgcaaattcc      660
ctttaaaagc acacactgac aagacaaaaa gctcaggaaa aggcagaaaa attactcctt      720
tataatcaag tattatatat aagtcagtgc tcataatttt gctcaagaaa atattgactt      780
acattcatat atatctgttc tggcatagag agattatggt gttaaaatca tgttattgaa      840
aaaagtattt tcagtgggga aagagggttag ttaacaaaga gattcacagt aacaaatcct      900
cctttctgga gggactcttc ctgaccctga gctgcacaac tttgcaacaa attaaagcct      960
aaccgaagat gacctcaca tggcaattta gaactcatgg gagtcaactt acataaacgg      1020
tatttgattt ctgataagat agtggaaatta ttggttatag atgacaaaat aagtatgttt      1080
aaagtgatga tggacataaa aaagttttaa atataaaaca tgagaaaaga aggagatact      1140
attcaaaaag actggcaaat ttgaaaaact agaaaataaaa aaaaaaaaaa aaaatgagcg      1200
gccgcaagct tt                                     1212
```

<210> 2

<211> 141

<212> PRT

<213> Homo Sapiens

<400> 2

```
Ala Arg Gly Lys Phe Phe Val Ser Thr Pro Ser Gln Pro Ser Cys Lys
 1           5           10          15
Ser His Leu Glu Thr Gly Thr Lys Asp Gln Glu Thr Val Cys Ser Lys
          20          25          30
```

-2-

Ala Thr Glu Gly Asp Asn Thr Glu Phe Gly Ala Phe Val Gly His Arg  
           35                          40                          45  
 Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser Asn Lys Ile Lys  
           50                          55                          60  
 Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn Thr Leu Lys Arg Val Ser  
           65                          70                          75                          80  
 Ser Leu Ala Gly Phe Thr Asp Cys His Arg Thr Ser Ile Pro Val His  
                           85                          90                          95  
 Ser Lys Gln Glu Lys Ile Ser Arg Arg Pro Ser Thr Glu Asp Thr His  
                           100                          105                          110  
 Glu Val Asp Ser Lys Ala Ala Leu Ile Pro Val Cys Arg Phe Gln Leu  
                           115                          120                          125  
 Asn Arg Tyr Ile Leu Leu Asn Thr Leu Asn Phe Phe Arg  
           130                          135                          140

<210> 3  
 <211> 739  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> unsure  
 <222> (5)...(5)  
 <223> UNKNOWN

<221> unsure  
 <222> (21)...(22)  
 <223> UNKNOWN

<221> unsure  
 <222> (29)...(29)  
 <223> UNKNOWN

<400> 3  
 tcgantaggg gtcttccacc nncatactng gatgatgggt ggtgaagtct atgcatacga 60  
 aattgatgtg tgtgcaaacg attctgttat ccctcaaadc tgtgggtcctg ggacgtgggt 120  
 gactccattt ctccaagcag tctacctctt tgwacagtat atcattatgg ttaattcttct 180  
 tattgcattt ytcaacaatg tgtattttaca agtgaaggca atttccaata ttgyatggaa 240  
 gtaccagcgt tatcatttta ttatggctta tcatgagaaa ccagttctgc ctccctccact 300  
 tatcattctt agccatatag tttctctggt ttgctgcata tgtaagagaa gaaagaaaga 360  
 taagacttcc gatggaccaa aacttttctt aacagaagaa gatcaaaaaga aacttcatga 420  
 ttttgaagag cagtgtgttg aaatgtattt caatgaaaaa gatgacaaat ttcattctgg 480  
 gagtgaagag agaattcgtg tcaacttttga aagagtggaa cagatgtgca ttcagattaa 540  
 agaagttgga gatccgtgtc aactacataa aaagatcatt acaatcatta gattctcaaa 600  
 ttggccattt gcaagatctt tcagccctga cggtagatac attaaaaaca ctcaactggcc 660  
 aaaagcgtcg gaagctagca aagttcataa tgaaatcaca cgagaactga gcatttccaa 720  
 acacttggct caaaacctt 739

<210> 4  
 <211> 235  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (41)...(41)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (54)...(54)

-3-

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (68)...(68)

&lt;223&gt; UNKNOWN

&lt;400&gt; 4

```

Met Met Val Gly Glu Val Tyr Ala Tyr Glu Ile Asp Val Cys Ala Asn
 1          5          10          15
Asp Ser Val Ile Pro Gln Ile Cys Gly Pro Gly Thr Trp Leu Thr Pro
 20          25          30
Phe Leu Gln Ala Val Tyr Leu Phe Xaa Gln Tyr Ile Ile Met Val Asn
 35          40          45
Leu Leu Ile Ala Phe Xaa Asn Asn Val Tyr Leu Gln Val Lys Ala Ile
 50          55          60
Ser Asn Ile Xaa Trp Lys Tyr Gln Arg Tyr His Phe Ile Met Ala Tyr
 65          70          75          80
His Glu Lys Pro Val Leu Pro Pro Pro Leu Ile Ile Leu Ser His Ile
 85          90          95
Val Ser Leu Phe Cys Cys Ile Cys Lys Arg Arg Lys Lys Asp Lys Thr
 100          105          110
Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp Gln Lys Lys Leu
 115          120          125
His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe Asn Glu Lys Asp
 130          135          140
Asp Lys Phe His Ser Gly Ser Glu Glu Arg Ile Arg Val Thr Phe Glu
 145          150          155          160
Arg Val Glu Gln Met Cys Ile Gln Ile Lys Glu Val Gly Asp Pro Cys
 165          170          175
Gln Leu His Lys Lys Ile Ile Thr Ile Ile Arg Phe Ser Asn Trp Pro
 180          185          190
Phe Ala Arg Ser Phe Ser Pro Asp Gly Arg Tyr Ile Lys Asn Thr His
 195          200          205
Trp Pro Lys Ala Ser Glu Ala Ser Lys Val His Asn Glu Ile Thr Arg
 210          215          220
Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn
 225          230          235

```

&lt;210&gt; 5

&lt;211&gt; 1579

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (368)...(368)

&lt;223&gt; g or c

&lt;221&gt; unsure

&lt;222&gt; (372)...(372)

&lt;223&gt; g or c

&lt;221&gt; unsure

&lt;222&gt; (374)...(374)

&lt;223&gt; g or a

&lt;221&gt; unsure

&lt;222&gt; (375)...(375)

&lt;223&gt; g or c



-4-

<221> unsure  
 <222> (387)...(387)

<221> unsure  
 <222> (482)...(482)

<400> 5

```

acgtgcgctg caggtaccgg tccggaattc cggggtcgac ccacgcgtcc ggcatggtgt      60
tgtaaatata cttagctcct ctcttcctca aggtgatctt gaaagtaata atccttttca      120
ttgtaatat ttaatgaaag atgacaaaga tccccagtgt aatatatttg gtcaagactt      180
acctgcagta cccagagaa aagaatttaa tttccagag gctgggtcct cttctgggtgc      240
cttattccca agtgctgttt cccctccaga actgcgacag agactacatg gggtagaact      300
cttaaaaaa ttaataaaaa atcaaaaatt aggcagttca tctactagca taccacatct      360
gtcatccsca csarscaa attttgn tagtaccatct cagccaagtt gcaaaaagcca      420
cttggaact ggaaccaa atcaagaaac tggttgctct aaagctacag aaggagataa      480
tncagaattt ggagcatttg taggacacag agatagcatg gatttacaga ggttaaaga      540
aacatcaa acagataaaaa tactatccaa taacaatact tctgaaaaca ctttgaaacg      600
agtgagttct cttgctggat ttactgactg tcacagaact tccattcctg ttcattcaaa      660
acaagaaaa atcagtagaa ggccatctac cgaagacact catgaagtag attccaaagc      720
agctttaata cgggtttgta gatttcaact aaacagatat atattattaa atacattaaa      780
cttttttaga taagatctac aaagtggtag tatttgggac tatatcaaaa attcaaaaaa      840
atttttctta agaaaactga ctttagcata gtagcagtta cagaaaagtt tcttacagtg      900
aatagtcagg aattttaaag aaaaatttat gcagaataaa ggcaggaatc tctttttggt      960
tgaattgaag ctaattatat gaactcatct ccagctaact gcgataatga ttgattttgc      1020
aaattccctt taaaagcaca cactgacaag acaaaaagct caggaaaagg cagaaaaatt      1080
actcctttat aatcaagtat tatatataag tcagtgtcga taattttgct caagaaaata      1140
ttgacttaca ttcatatata tctgttctgg catagagaga ttatgttggt aaaatcatgt      1200
tattgaaaaa agttatttca gtggggaaaag aggttagtta acaaaagatg tcacagtaac      1260
aaatcctcct ttctggaggg actcttcctg accctgagct gcacaacttt gcaacaaatt      1320
aaagcctaac cgaagatgac ctcacaatgg caatttagaa ctcatgggag tcaacttaca      1380
taaacggtat ttgatttctg ataagatagt ggaattattg gttatagatg acaaaaataag      1440
tatgtttaaa gtgatgatgg acataaaaaa gttttaaata taaaacatga gaaaagaagg      1500
agatactatt caaaaagact ggcaaatgtg aaaaactaga aataaaaaaa aaaaaaaaaa      1560
atgagcggcc gcaagcttt
  
```

<210> 6  
 <211> 243  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (103)...(105)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (109)...(109)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (141)...(141)  
 <223> UNKNOWN

<400> 6

```

Val Asn Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Leu Glu Ser Asn
  1              5              10              15
Asn Pro Phe His Cys Asn Ile Leu Met Lys Asp Asp Lys Asp Pro Gln
  20              25              30
Cys Asn Ile Phe Gly Gln Asp Leu Pro Ala Val Pro Gln Arg Lys Glu
  35              40              45
  
```

-5-

Phe Asn Phe Pro Glu Ala Gly Ser Ser Ser Gly Ala Leu Phe Pro Ser  
 50 55 60  
 Ala Val Ser Pro Pro Glu Leu Arg Gln Arg Leu His Gly Val Glu Leu  
 65 70 75 80  
 Leu Lys Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Ser Thr Ser  
 85 90 95  
 Ile Pro His Leu Ser Ser Xaa Xaa Xaa Lys Phe Phe Xaa Ser Thr Pro  
 100 105 110  
 Ser Gln Pro Ser Cys Lys Ser His Leu Glu Thr Gly Thr Lys Asp Gln  
 115 120 125  
 Glu Thr Val Cys Ser Lys Ala Thr Glu Gly Asp Asn Xaa Glu Phe Gly  
 130 135 140  
 Ala Phe Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu  
 145 150 155 160  
 Thr Ser Asn Lys Ile Lys Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn  
 165 170 175  
 Thr Leu Lys Arg Val Ser Ser Leu Ala Gly Phe Thr Asp Cys His Arg  
 180 185 190  
 Thr Ser Ile Pro Val His Ser Lys Gln Glu Lys Ile Ser Arg Arg Pro  
 195 200 205  
 Ser Thr Glu Asp Thr His Glu Val Asp Ser Lys Ala Ala Leu Ile Pro  
 210 215 220  
 Val Cys Arg Phe Gln Leu Asn Arg Tyr Ile Leu Leu Asn Thr Leu Asn  
 225 230 235 240  
 Phe Phe Arg

<210> 7  
 <211> 3532  
 <212> DNA  
 <213> Mus Musculus

<220>  
 <221> unsure  
 <222> (2420)... (2420)  
 <223> unknown

<221> unsure  
 <222> (2434)... (2434)  
 <223> unknown

<221> unsure  
 <222> (2461)... (2461)  
 <223> unknown

<221> unsure  
 <222> (2466)... (2466)  
 <223> unknown

<221> unsure  
 <222> (2470)... (2470)  
 <223> unknown

<400> 7  
 attatggctt atcatgaaaa accagtcctg cctcctcctc ttatcatcct cagccatata 60  
 gtttactgtg tttgctgtgt atgcaaaaaga agaaagaaag ataagacttc cgatgggcca 120  
 aaacttttct taacagaaga agatcaaaaag aaactccatg attttgaaga gcagtgtgtt 180  
 gagatgtact ttgatgagaa agatgacaaa ttcaattctg ggagtgaaga gagaatccgg 240  
 gtcacttttg aaagagtggg gcagatgagc attcagatta aagaagttgg agatcgtgtc 300  
 aactacataa aaagatcatt acagtcctta gattctcaaa ttgggtcatct gcaagatctc 360

-6-

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| tcagccctaa  | cagtagatac  | attgaaaaca  | cttacagccc  | agaaaagcttc | agaagctagt  | 420  |
| aaagtgcaca  | atgagatcac  | acgagaattg  | agtatttcca  | aacacttggc  | tcagaatctt  | 480  |
| attgatgatg  | ttcctgtaag  | acctttgtgg  | gaagaacctta | gtgctgtaaa  | cacactgagt  | 540  |
| tcctctcttc  | ctcaagggtga | tcgggaaagt  | aataatcctt  | ttcctttgtaa | tatttttatg  | 600  |
| aaagatgaaa  | aagaccccca  | atataatctg  | tttggaacag  | atttgcccg   | gataccccag  | 660  |
| agaaaagaat  | tcaacattcc  | agaggctggt  | tcctcctgtg  | gtgccttatt  | cccaagtgt   | 720  |
| gtttctcccc  | cagaattacg  | acagagacga  | catggggtag  | aaatgttaaa  | aataattta   | 780  |
| aaaaatcaaa  | aattaggcag  | ttcaccta    | agtccaccac  | atatgtcctc  | cccaccaacc  | 840  |
| aaattttctg  | tgagtacccc  | atcccagcca  | agttgcaaaa  | gtcacttggg  | atccacaacc  | 900  |
| aaagatcaag  | aacccatttt  | ctataaagct  | gcagaagggg  | ataacataga  | atttggagca  | 960  |
| tttgtgggac  | acagagatag  | tatggactta  | cagagggtta  | aagaaacatc  | aaacaaaata  | 1020 |
| agagaactgt  | tatctaataga | tactcctgaa  | aacactctga  | aacatgtggg  | tgctgtctga  | 1080 |
| tatagtgaat  | gttgtaagac  | ttctacttct  | cttactctgg  | tgcaagcaga  | aagctgtagt  | 1140 |
| agaagagcgt  | cgacggaaga  | ctctccagaa  | gtcgattcta  | aagcagcttt  | gttaccggat  | 1200 |
| tggttacgag  | atagaccatc  | aaacagagaa  | atgccatctg  | aaggaggaac  | attaaatggt  | 1260 |
| cttgcttctc  | catttaagcc  | cgttttggat  | acaaattact  | attattcagc  | tgtggaaga   | 1320 |
| aataacctga  | tgaggttgct  | acagagtatt  | cccttcgttc  | ctgtacctcc  | acgaggcgag  | 1380 |
| cctgtcacag  | tgtaccgtct  | ggaggagagt  | tctcccagta  | tactgaataa  | cagcatgtct  | 1440 |
| tcattgtctc  | agctaggcct  | ctgtgcaaaa  | attgagtttt  | taagtaaaga  | ggaaatggaa  | 1500 |
| ggtgtgttac  | gaagagcagt  | caaagtgtctg | tgtacctggt  | cagagcacga  | tatcctgaag  | 1560 |
| tcagggcac   | tctatatcat  | taagtcattt  | cttctgagg   | tgataaacac  | atggtcaagc  | 1620 |
| atttataaag  | aagatcgggt  | tctacatctc  | tgctcagag   | aaatacaaca  | acagagagca  | 1680 |
| gcacaaaagc  | tcacatttgc  | ctttaatcag  | atgaaaccca  | aatccatacc  | atattctcca  | 1740 |
| aggttccttg  | aagttttcct  | gttgtagtgc  | cattcagcag  | ggcagtggtt  | tgctgtagaa  | 1800 |
| gagtgcata   | ctggtgaatt  | tagaaaatac  | aacaacaata  | atggtgatga  | aatcattcct  | 1860 |
| acaaatactc  | tagaagagat  | catgctagcc  | tttagccact  | ggacctatga  | atataccaga  | 1920 |
| ggggagttac  | tggtacttga  | cttacaagga  | gtgggagaaa  | acttgactga  | cccatctgta  | 1980 |
| ataaaaagctg | aagaaaaaag  | atcctgtgac  | atggtttttg  | gccctgcaa   | tctaggagaa  | 2040 |
| gatgcaataa  | aaaacttcaa  | gagccaaaca  | tcactgttaa  | ttcttgctgt  | cgaaagctta  | 2100 |
| aacttcccag  | atttgaagag  | gaatgactac  | acgcccctga  | taaaattata  | tttctcagg   | 2160 |
| atgagtcac   | agatttgaat  | cttcaatctg  | gaaattccac  | caaagaatca  | gaagcaacaa  | 2220 |
| attctgttcg  | tctgatgtta  | tagtgctgag  | tcattgggtt  | ttgcctacac  | ttcacaaaag  | 2280 |
| tgtaactgtc  | agttttcctt  | tcgggggaat  | tgatgatata  | ggaagatgtg  | tgcaaatga   | 2340 |
| gcttgctggc  | cccacacata  | gtctagaggt  | aatgtttctca | ttgaaaaacg  | cctggagggtg | 2400 |
| gaggctgcag  | atgccagtg   | aaagtgttag  | ctgncagaga  | gtcagtgctc  | tcgggctggt  | 2460 |
| naaggncggn  | acccttgctg  | ctgagagtgg  | tggttctctt  | cacctggtgc  | aggaccatta  | 2520 |
| accaaagtca  | agtcttcaga  | tttgattggc  | tgctcagtc   | cagcccattc  | agctaaggaa  | 2580 |
| actaaattgc  | gcagcttttt  | aaatggctga  | agtcttcctc  | agtttgtgct  | ctatgataat  | 2640 |
| gatgttagct  | ctcaactagg  | tgtttggtgc  | cacgggagaa  | ctactcctta  | caattttgct  | 2700 |
| tcacaggcat  | gttacaagc   | ctgcactgaa  | aaccgtttgt  | cttccctctc  | tcctccctc   | 2760 |
| ttttccctgt  | agtattgagg  | atcaaacc    | gggcctcatg  | aagaccattt  | tctaagagac  | 2820 |
| attttattta  | agaatcaact  | atagagtcta  | tgtttatgga  | tacagccagt  | ttttgttaaa  | 2880 |
| caaaacctga  | attgtgcaaa  | agggtttttt  | aacatttatc  | aatgttaagt  | aaaagaaagc  | 2940 |
| catgataaat  | aagaattaac  | tcactgttca  | atgggtgttt  | cctgtgagga  | agggttacagt | 3000 |
| tgtaacagcc  | tgcaagtgtga | tacatctcca  | aagatttaca  | gacttagtgt  | atcaaatcag  | 3060 |
| agtgtcatgt  | gagctctcac  | attgaaaatt  | ctataggaat  | gtgtcaatgt  | gaattctatt  | 3120 |
| tctgtgactt  | aagaaatcag  | ttgttggtat  | atccttatac  | agtataggga  | gatcacaata  | 3180 |
| caactttatg  | ccaataaaat  | ctaactta    | tgcccagata  | tttttgcata  | tttagcaaca  | 3240 |
| agaaaagctt  | atcatttgac  | tcaagtttta  | tgctttctct  | ttcttttcat  | ttcctaggta  | 3300 |
| ctaattttta  | tttttatttg  | gaaggagcag  | tgtaaaagctt | acttgatttc  | aatagtgtat  | 3360 |
| ctcatagata  | cagacaaggc  | cgcagagata  | agctgttaaa  | tagtgtttta  | tggtgatgtg  | 3420 |
| gagagaaagg  | tgtattactt  | aaaaatacta  | taccatatac  | gttttgtata  | tcattaaatc  | 3480 |
| tttaaaagaa  | attaaattta  | ttcttggtta  | aaaaaaaaaa  | aaaaaaaaaa  | aa          | 3532 |

&lt;210&gt; 8

&lt;211&gt; 475

&lt;212&gt; PRT

&lt;213&gt; Mus Musculus

&lt;400&gt; 8

-7-

Ile Met Ala Tyr His Glu Lys Pro Val Leu Pro Pro Pro Leu Ile Ile  
 1 5 10 15  
 Leu Ser His Ile Val Ser Leu Phe Cys Val Cys Lys Arg Arg Lys  
 20 25 30  
 Lys Asp Lys Thr Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp  
 35 40 45  
 Gln Lys Lys Leu His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe  
 50 55 60  
 Asp Glu Lys Asp Asp Lys Phe Asn Ser Gly Ser Glu Glu Arg Ile Arg  
 65 70 75 80  
 Val Thr Phe Glu Arg Val Glu Gln Met Ser Ile Gln Ile Lys Glu Val  
 85 90 95  
 Gly Asp Arg Val Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser  
 100 105 110  
 Gln Ile Gly His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu  
 115 120 125  
 Lys Thr Leu Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn  
 130 135 140  
 Glu Ile Thr Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu  
 145 150 155 160  
 Ile Asp Asp Val Pro Val Arg Pro Leu Trp Glu Glu Pro Ser Ala Val  
 165 170 175  
 Asn Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Arg Glu Ser Asn Asn  
 180 185 190  
 Pro Phe Leu Cys Asn Ile Phe Met Lys Asp Glu Lys Asp Pro Gln Tyr  
 195 200 205  
 Asn Leu Phe Gly Gln Asp Leu Pro Val Ile Pro Gln Arg Lys Glu Phe  
 210 215 220  
 Asn Ile Pro Glu Ala Gly Ser Ser Cys Gly Ala Leu Phe Pro Ser Ala  
 225 230 235 240  
 Val Ser Pro Pro Glu Leu Arg Gln Arg Arg His Gly Val Glu Met Leu  
 245 250 255  
 Lys Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Pro Asn Ser Ser  
 260 265 270  
 Pro His Met Ser Ser Pro Pro Thr Lys Phe Ser Val Ser Thr Pro Ser  
 275 280 285  
 Gln Pro Ser Cys Lys Ser His Leu Glu Ser Thr Thr Lys Asp Gln Glu  
 290 295 300  
 Pro Ile Phe Tyr Lys Ala Ala Glu Gly Asp Asn Ile Glu Phe Gly Ala  
 305 310 315 320  
 Phe Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr  
 325 330 335  
 Ser Asn Lys Ile Arg Glu Leu Leu Ser Asn Asp Thr Pro Glu Asn Thr  
 340 345 350  
 Leu Lys His Val Gly Ala Ala Gly Tyr Ser Glu Cys Cys Lys Thr Ser  
 355 360 365  
 Thr Ser Leu His Ser Val Gln Ala Glu Ser Cys Ser Arg Arg Ala Ser  
 370 375 380  
 Thr Glu Asp Ser Pro Glu Val Asp Ser Lys Ala Ala Leu Leu Pro Asp  
 385 390 395 400  
 Trp Leu Arg Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu Gly Gly  
 405 410 415  
 Thr Leu Asn Gly Leu Ala Ser Pro Phe Lys Pro Val Leu Asp Thr Asn  
 420 425 430  
 Tyr Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met Arg Leu Ser Gln  
 435 440 445  
 Ser Ile Pro Phe Val Pro Val Pro Pro Arg Gly Glu Pro Val Thr Val  
 450 455 460  
 Tyr Pro Ser Gly Gly Arg Val Leu Pro Val Tyr  
 465 470 475

<210> 9  
 <211> 5433  
 <212> DNA  
 <213> Mus Musculus

<220>  
 <221> unsure  
 <222> (5094)...(5094)  
 <223> unknown

<400> 9

|             |            |            |             |            |             |      |
|-------------|------------|------------|-------------|------------|-------------|------|
| ggctgaaaga  | gcctgagctg | tgcctctcca | ttccactgct  | gtggcagggg | cagaaatctt  | 60   |
| ggatagagaa  | aaccttttgc | aaacgggaat | gtatctttgt  | aattcctagc | acgaaagact  | 120  |
| ctaacaggtg  | ttgctgtggc | cagttcacca | accagcatat  | ccccctctg  | ccaagtgcaa  | 180  |
| caccagcaa   | aaatgaagag | gaaagcaaac | aggtggagac  | tcagcctgag | aaatggctctg | 240  |
| ttgccaagca  | caccagagc  | taccaaacag | attcctatgg  | agttcttgaa | ttccaggggtg | 300  |
| gcggatattc  | caataaagcc | atgtatatcc | gtgtatccta  | tgacaccaag | ccagactcac  | 360  |
| tgctccatct  | catggtgaaa | gattggcagc | tggaactccc  | caagctctta | atatctgtgc  | 420  |
| atggaggcct  | ccagaacttt | gagatgcagc | ccaagctgaa  | acaagctctt | gggaaaggcc  | 480  |
| tgatcaaggc  | tgctatgacc | accggggcct | ggatcttcac  | cgggggtgtc | agcacagggtg | 540  |
| ttatcagcca  | cgtaggggat | gccttgaaa  | accactcctc  | caagtccaga | ggccgggttt  | 600  |
| gtgctatagg  | aattgctcca | tggggcatcg | tggagaataa  | ggaagacctg | gttgaaaagg  | 660  |
| atgtaacaag  | agtgtaccag | accatgtcca | accctctaag  | taagctctct | gtgctcaaca  | 720  |
| actccacac   | ccacttcac  | ctggctgaca | atggcacctc  | gggcaagtat | ggcgccgagg  | 780  |
| tgaagctgcg  | aaggctgctg | gaaaagcaca | tctccctcca  | gaagatcaac | acaagactgg  | 840  |
| ggcagggcgt  | gcccctcgtg | ggtctcgtgg | tggagggggg  | ccctaacgtg | gtgtccatcg  | 900  |
| tcttggaata  | cctgcaagaa | gagcctccca | tccctgtgg   | gatttgtgat | ggcagcggac  | 960  |
| gtgcctcgga  | catcctgtcc | tttgcgcaca | agtactgtga  | agaaggcgga | ataataaatg  | 1020 |
| agtcctcag   | ggagcagctt | ctagtacca  | ttcagaaaac  | atttaattat | aataaggcac  | 1080 |
| aatcacatca  | gctgtttgca | attataatgg | agtgcataaa  | gaagaaagaa | ctcgtcactg  | 1140 |
| tgttcagaat  | gggttctgag | ggccagcagg | acatcgagat  | ggcaatttta | actgccctgc  | 1200 |
| tgaaggaac   | aaacgtatct | gctccagatc | agctgagctt  | ggcactggct | tggaaaccgg  | 1260 |
| tggacatagc  | acgaagccag | atctttgtct | ttgggcccc   | ctggacgccc | ctgggaagcc  | 1320 |
| tggcaccccc  | gacggacagc | aaagccacgg | agaaggagaa  | gaagccaccc | atggccacca  | 1380 |
| ccaagggagg  | aagaggaaaa | gggaaaggca | agaagaaagg  | gaaagtgaag | gaggaaagtg  | 1440 |
| aggaagaaac  | tgaccccg   | aagatagagc | tgctgaactg  | ggtgaatgct | ttggagcaag  | 1500 |
| cgatgctaga  | tgctttagtc | ttagatcgtg | tcgactttgt  | gaagctcctg | attgaaaacg  | 1560 |
| gagtgaacat  | gcaacacttt | ctgaccattc | cgaggctgga  | ggagctctat | aacacaagac  | 1620 |
| tgggtccacc  | aaacacactt | catctgctgg | tgagggatgt  | gaaaaagagc | aaccttccgc  | 1680 |
| ctgattacca  | catcagcctc | atagacatcg | ggctcgtgct  | ggagtacctc | atgggaggag  | 1740 |
| cctaccgctg  | caactacact | cggaaaaact | ttcggaccct  | ttacaacaac | ttgtttggac  | 1800 |
| caaagaggcc  | taaagctctt | aaacttctgg | gaatggaaga  | tgatgagcct | ccagctaaag  | 1860 |
| ggaagaaaaa  | aaaaaaaaag | aaaaaggagg | aagagatcga  | cattgatgtg | gacgacctg   | 1920 |
| ccgtgagtcg  | gttccagtat | cccttccacg | agctgatggt  | gtgggcagtg | ctgatgaaac  | 1980 |
| gccagaaaat  | ggcagtgttc | ctctggcagc | gaggggaaga  | gagcatggcc | aaggccctgg  | 2040 |
| tggcctgcaa  | gctctacaag | gccatggccc | acgagtcctc  | cgagagtgat | ctgggtggatg | 2100 |
| acatctccca  | ggacttggat | aacaattcca | aagacttcgg  | ccagcttgct | ttggagttat  | 2160 |
| tagaccagtc  | ctataagcat | gacgagcaga | tcgctatgaa  | actcctgacc | tacgagctga  | 2220 |
| aaaactggag  | caactcgacc | tgccctcaac | tggccgtggc  | agccaaacac | cgggacttca  | 2280 |
| ttgtctcac   | ctgcagccag | atgctgctga | ccgatatgtg  | gatgggaaga | ctgcggatgc  | 2340 |
| ggaagaaccc  | cggcctgaag | gttatcatgg | ggattcttct  | acccccacc  | atcttgtttt  | 2400 |
| tggaatttcg  | cacatatgat | gatttctcgt | atcaaaccatc | caaggaaaac | gaggatggca  | 2460 |
| aagaaaaaga  | agaggaaaat | acggatgcaa | atgcagatgc  | tggctcaaga | aagggggatg  | 2520 |
| aggagaacga  | gcataaaaaa | cagagaagta | ttcccatcgg  | aacaaagatc | tgtgaattct  | 2580 |
| ataacgcgcc  | cattgtcaag | tictgtttt  | acacaatata  | atacttgggc | tacctgtctg  | 2640 |
| tgtttaacta  | cgtcatcctg | gtgcggatgg | atggctggcc  | gtccctccag | gagtggtcgt  | 2700 |
| tcattctcta  | catcgtgagc | ctggcgttag | agaagatagc  | agagatcctc | atgtcagaac  | 2760 |
| caggcaaaact | cagccagaaa | atcaaagtgt | ggcttcagga  | gtactggaac | atcacagatc  | 2820 |
| tcgtggccat  | ttccacattc | atgattggag | caattcttct  | cctacagaac | cagccctaca  | 2880 |

-9-

```

tgggctatgg ccgggtgatc tactgtgtgg atatcatctt ctggtacatc cgtgtcctgg 2940
acatcttttg tgtcaacaag tatctggggc catacgtgat gatgattgga aagatgatga 3000
tcgacatgct gtacttttgg gtcacatgac tggctgtgct catgagtttc ggagtagccc 3060
gtcaagccat tctgcatcca gaggagaagc cctcttgaa actggcccga aacatcttct 3120
acatgcccta ctggatgatc tatggagagg tgtttgcaga ccagatagac ctctacgcca 3180
tggaaattaa tctccttgt ggtgagaacc tatatgatga ggagggcaag cggcttcctc 3240
cctgtatccc cggcgctgg ctactccag cactcatggc gtgctatcta ctggtcgcca 3300
acatcctgct ggtgaacctg ctgattgctg tgttcaacaa tactttcttt gaagtaaaat 3360
caatatccaa ccaggtgtgg aagtccagc gatatcagct gattatgaca ttcatgaca 3420
ggccagtcct gccccaccg atgatcattt taagccacat ctacatcatc attatgcgtc 3480
tcagcgccg ctgcaggaaa aagagagaag gggaccaaga ggaacgggat cgtggattga 3540
agctcttct tagcgacgag gagctaaaga ggtgcatga gttcgaggag cagtgcgtgc 3600
aggagcactt ccgggagaag gaggatgagc agcagtcgtc cagcgacgag cgcacccggg 3660
tcacttctga aagagttgaa aatatgtcaa tgaggttggg agaaatcaat gaaagagaaa 3720
cttttatgaa aacttcctg cagactgttg accttcgact tgctcagcta gaagaattat 3780
ctaacagaat ggtgaatgct cttgaaaate ttgcgggaat cgacaggtct gacctgatcc 3840
aggcacggtc ccgggcttct tctgaatgtg aggcaacgta tcttctccgg caaagcagca 3900
tcaatagcgc tgatggctac agcttgatc gatatactt taacggagaa gagttattat 3960
ttgaggatac atctctctcc acgtcaccag ggacaggagt caggaaaaaa acctgttctt 4020
tccgtataaa ggaagagaag gacgtgaaaa cgcacctagt ccagaaatgt cagaacagtc 4080
ttcacctttc actgggcaca agcacatcag caaccccaga tggcagtcac cttgcagtag 4140
atgacttaaa gaacgctgaa gagtcaaaat taggtccaga tattgggatt tcaaaggaa 4200
atgatgaaag acagacagac tctaaaaaag aagaaactat ttcccaagt ttaataaaaa 4260
cagatgtgat acatggacag gacaaatcag atgttcaaaa cactcagcta acagtggaaa 4320
cgacaaatat agaaggcact atttcctatc ccttggaaga aaccaaatt acacgctatt 4380
tcccgatga aacgatcaat gcttgtaaaa caatgaagtc cagaagcttc gtctattccc 4440
ggggaagaaa gctggctggt ggggttaacc aggatgtaga gtacagttca atcacggacc 4500
agcaattgac gacggaatgg caatgccaa ttcaaaagat cacgcgctct catagcacag 4560
atattcctta cattgtgtcg gaagctgcag tgcaagctga gcaaaaagag cagtttgcag 4620
atatgcaaga tgaacaccat gtgctgaag caattcctcg aatccctcgc ttgtccctaa 4680
ccattactga cagaaatggg atggaaaact tactgtctgt gaagccagat caaactttgg 4740
gattcccatc tctcaggtca aaaagtttac atggacatcc taggaatgtg aaatccattc 4800
agggaaagtt agacgatct ggacatgcca gtatgtgaag cagcttagta attgtgtctg 4860
gaatgacagc agaagaaaaa aaggttaaga aagagaaaagc ttccacagaa actgaatgct 4920
agtctgtttt gtttctttta ttttttttt taacagtcag aaaccacta atgggtgtca 4980
tcttgcccca tctaaacac atmtccaatt tctaaaaaac attttccctt aaaaaatttt 5040
ggaaattcag acttgattta caatttaatg cactaaaaag agtattttgt tagnatatgt 5100
tagtaggctt agttttttca gttgcagtag tatcaaatga aagtgatgat actgtaacga 5160
agataaattg gctaatacgt atacaagatt atacaatctc ttattactg agggccacca 5220
aatagcctag gaagtgcct cgagcactga agtcaccatt aggtcactca agaagtaagc 5280
aactagctgg gcacagtggc tcatgcctgt aatcctagca ctttgggagg ccaaggcaga 5340
aagatagctt gagtccagga gtttgagacc agcctgggca acatagtgat accccatctc 5400
ttaaaaaaaaa aaaaaaaaaa ctgccctcgt gcc 5433

```

&lt;210&gt; 10

&lt;211&gt; 1533

&lt;212&gt; PRT

&lt;213&gt; Mus Musculus

&lt;400&gt; 10

```

Met Tyr Ile Arg Val Ser Tyr Asp Thr Lys Pro Asp Ser Leu Leu His
 1             5             10             15
Leu Met Val Lys Asp Trp Gln Leu Glu Leu Pro Lys Leu Leu Ile Ser
          20          25          30
Val His Gly Gly Leu Gln Asn Phe Glu Met Gln Pro Lys Leu Lys Gln
          35          40          45
Val Phe Gly Lys Gly Leu Ile Lys Ala Ala Met Thr Thr Gly Ala Trp
          50          55          60

```

-10-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Phe | Thr | Gly | Gly | Val | Ser | Thr | Gly | Val | Ile | Ser | His | Val | Gly | Asp |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Ala | Leu | Lys | Asp | His | Ser | Ser | Lys | Ser | Arg | Gly | Arg | Val | Cys | Ala | Ile |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Gly | Ile | Ala | Pro | Trp | Gly | Ile | Val | Glu | Asn | Lys | Glu | Asp | Leu | Val | Gly |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Lys | Asp | Val | Thr | Arg | Val | Tyr | Gln | Thr | Met | Ser | Asn | Pro | Leu | Ser | Lys |
|     |     | 115 |     |     |     | 120 |     |     |     |     |     | 125 |     |     |     |
| Leu | Ser | Val | Leu | Asn | Asn | Ser | His | Thr | His | Phe | Ile | Leu | Ala | Asp | Asn |
|     |     | 130 |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Gly | Thr | Leu | Gly | Lys | Tyr | Gly | Ala | Glu | Val | Lys | Leu | Arg | Arg | Leu | Leu |
| 145 |     |     |     | 150 |     |     |     |     |     | 155 |     |     |     |     | 160 |
| Glu | Lys | His | Ile | Ser | Leu | Gln | Lys | Ile | Asn | Thr | Arg | Leu | Gly | Gln | Gly |
|     |     |     | 165 |     |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Val | Pro | Leu | Val | Gly | Leu | Val | Val | Glu | Gly | Gly | Pro | Asn | Val | Val | Ser |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Ile | Val | Leu | Glu | Tyr | Leu | Gln | Glu | Pro | Pro | Ile | Pro | Val | Val | Ile |     |
|     |     | 195 |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     |
| Cys | Asp | Gly | Ser | Gly | Arg | Ala | Ser | Asp | Ile | Leu | Ser | Phe | Ala | His | Lys |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Tyr | Cys | Glu | Glu | Gly | Gly | Ile | Ile | Asn | Glu | Ser | Leu | Arg | Glu | Gln | Leu |
| 225 |     |     |     | 230 |     |     |     |     |     | 235 |     |     |     |     | 240 |
| Leu | Val | Thr | Ile | Gln | Lys | Thr | Phe | Asn | Tyr | Asn | Lys | Ala | Gln | Ser | His |
|     |     |     | 245 |     |     |     |     |     | 250 |     |     |     |     | 255 |     |
| Gln | Leu | Phe | Ala | Ile | Ile | Met | Glu | Cys | Met | Lys | Lys | Lys | Glu | Leu | Val |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Thr | Val | Phe | Arg | Met | Gly | Ser | Glu | Gly | Gln | Gln | Asp | Ile | Glu | Met | Ala |
|     |     | 275 |     |     |     | 280 |     |     |     |     |     | 285 |     |     |     |
| Ile | Leu | Thr | Ala | Leu | Leu | Lys | Gly | Thr | Asn | Val | Ser | Ala | Pro | Asp | Gln |
|     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Leu | Ser | Leu | Ala | Leu | Ala | Trp | Asn | Arg | Val | Asp | Ile | Ala | Arg | Ser | Gln |
| 305 |     |     |     | 310 |     |     |     |     |     | 315 |     |     |     |     | 320 |
| Ile | Phe | Val | Phe | Gly | Pro | His | Trp | Thr | Pro | Leu | Gly | Ser | Leu | Ala | Pro |
|     |     |     | 325 |     |     |     |     |     | 330 |     |     |     |     | 335 |     |
| Pro | Thr | Asp | Ser | Lys | Ala | Thr | Glu | Lys | Glu | Lys | Lys | Pro | Pro | Met | Ala |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |
| Thr | Thr | Lys | Gly | Gly | Arg | Gly | Lys | Gly | Lys | Gly | Lys | Lys | Lys | Gly | Lys |
|     |     | 355 |     |     |     | 360 |     |     |     |     |     | 365 |     |     |     |
| Val | Lys | Glu | Glu | Val | Glu | Glu | Glu | Thr | Asp | Pro | Arg | Lys | Ile | Glu | Leu |
|     | 370 |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |
| Leu | Asn | Trp | Val | Asn | Ala | Leu | Glu | Gln | Ala | Met | Leu | Asp | Ala | Leu | Val |
| 385 |     |     |     | 390 |     |     |     |     |     | 395 |     |     |     |     | 400 |
| Leu | Asp | Arg | Val | Asp | Phe | Val | Lys | Leu | Leu | Ile | Glu | Asn | Gly | Val | Asn |
|     |     |     | 405 |     |     |     |     |     | 410 |     |     |     |     | 415 |     |
| Met | Gln | His | Phe | Leu | Thr | Ile | Pro | Arg | Leu | Glu | Glu | Leu | Tyr | Asn | Thr |
|     |     |     | 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Arg | Leu | Gly | Pro | Pro | Asn | Thr | Leu | His | Leu | Leu | Val | Arg | Asp | Val | Lys |
|     |     | 435 |     |     |     | 440 |     |     |     |     |     | 445 |     |     |     |
| Lys | Ser | Asn | Leu | Pro | Pro | Asp | Tyr | His | Ile | Ser | Leu | Ile | Asp | Ile | Gly |
|     | 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Leu | Val | Leu | Glu | Tyr | Leu | Met | Gly | Gly | Ala | Tyr | Arg | Cys | Asn | Tyr | Thr |
| 465 |     |     |     | 470 |     |     |     |     |     | 475 |     |     |     |     | 480 |
| Arg | Lys | Asn | Phe | Arg | Thr | Leu | Tyr | Asn | Asn | Leu | Phe | Gly | Pro | Lys | Arg |
|     |     |     | 485 |     |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Pro | Lys | Ala | Leu | Lys | Leu | Leu | Gly | Met | Glu | Asp | Asp | Glu | Pro | Pro | Ala |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Lys | Gly | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Glu | Glu | Glu | Ile | Asp | Ile |
|     | 515 |     |     |     |     | 520 |     |     |     |     |     | 525 |     |     |     |
| Asp | Val | Asp | Asp | Pro | Ala | Val | Ser | Arg | Phe | Gln | Tyr | Pro | Phe | His | Glu |
|     | 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |

-11-

|     |      |     |     |     |     |     |      |     |     |     |     |      |     |     |     |
|-----|------|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|------|-----|-----|-----|
| Leu | Met  | Val | Trp | Ala | Val | Leu | Met  | Lys | Arg | Gln | Lys | Met  | Ala | Val | Phe |
| 545 |      |     |     |     | 550 |     |      |     |     | 555 |     |      |     |     | 560 |
| Leu | Trp  | Gln | Arg | Gly | Glu | Glu | Ser  | Met | Ala | Lys | Ala | Leu  | Val | Ala | Cys |
|     |      |     |     | 565 |     |     |      |     |     | 570 |     |      |     |     | 575 |
| Lys | Leu  | Tyr | Lys | Ala | Met | Ala | His  | Glu | Ser | Ser | Glu | Ser  | Asp | Leu | Val |
|     |      |     | 580 |     |     |     |      | 585 |     |     |     |      | 590 |     |     |
| Asp | Asp  | Ile | Ser | Gln | Asp | Leu | Asp  | Asn | Asn | Ser | Lys | Asp  | Phe | Gly | Gln |
|     |      | 595 |     |     |     |     | 600  |     |     |     |     | 605  |     |     |     |
| Leu | Ala  | Leu | Glu | Leu | Leu | Asp | Gln  | Ser | Tyr | Lys | His | Asp  | Glu | Gln | Ile |
|     | 610  |     |     |     |     | 615 |      |     |     |     | 620 |      |     |     |     |
| Ala | Met  | Lys | Leu | Leu | Thr | Tyr | Glu  | Leu | Lys | Asn | Trp | Ser  | Asn | Ser | Thr |
| 625 |      |     |     |     | 630 |     |      |     |     | 635 |     |      |     |     | 640 |
| Cys | Leu  | Lys | Leu | Ala | Val | Ala | Ala  | Lys | His | Arg | Asp | Phe  | Ile | Ala | His |
|     |      |     |     | 645 |     |     |      |     |     | 650 |     |      |     |     | 655 |
| Thr | Cys  | Ser | Gln | Met | Leu | Leu | Thr  | Asp | Met | Trp | Met | Gly  | Arg | Leu | Arg |
|     |      |     | 660 |     |     |     |      | 665 |     |     |     |      | 670 |     |     |
| Met | Arg  | Lys | Asn | Pro | Gly | Leu | Lys  | Val | Ile | Met | Gly | Ile  | Leu | Leu | Pro |
|     |      | 675 |     |     |     |     | 680  |     |     |     |     | 685  |     |     |     |
| Pro | Thr  | Ile | Leu | Phe | Leu | Glu | Phe  | Arg | Thr | Tyr | Asp | Asp  | Phe | Ser | Tyr |
|     | 690  |     |     |     |     | 695 |      |     |     |     | 700 |      |     |     |     |
| Gln | Thr  | Ser | Lys | Glu | Asn | Glu | Asp  | Gly | Lys | Glu | Lys | Glu  | Glu | Glu | Asn |
| 705 |      |     |     |     | 710 |     |      |     |     | 715 |     |      |     |     | 720 |
| Thr | Asp  | Ala | Asn | Ala | Asp | Ala | Gly  | Ser | Arg | Lys | Gly | Asp  | Glu | Glu | Asn |
|     |      |     |     | 725 |     |     |      |     |     | 730 |     |      |     |     | 735 |
| Glu | His  | Lys | Lys | Gln | Arg | Ser | Ile  | Pro | Ile | Gly | Thr | Lys  | Ile | Cys | Glu |
|     |      |     | 740 |     |     |     |      | 745 |     |     |     |      | 750 |     |     |
| Phe | Tyr  | Asn | Ala | Pro | Ile | Val | Lys  | Phe | Trp | Phe | Tyr | Thr  | Ile | Ser | Tyr |
|     |      | 755 |     |     |     |     | 760  |     |     |     |     | 765  |     |     |     |
| Leu | Gly  | Tyr | Leu | Leu | Leu | Phe | Asn  | Tyr | Val | Ile | Leu | Val  | Arg | Met | Asp |
|     | 770  |     |     |     |     | 775 |      |     |     |     | 780 |      |     |     |     |
| Gly | Trp  | Pro | Ser | Leu | Gln | Glu | Trp  | Ile | Val | Ile | Ser | Tyr  | Ile | Val | Ser |
| 785 |      |     |     |     | 790 |     |      |     |     | 795 |     |      |     |     | 800 |
| Leu | Ala  | Leu | Glu | Lys | Ile | Arg | Glu  | Ile | Leu | Met | Ser | Glu  | Pro | Gly | Lys |
|     |      |     |     | 805 |     |     |      |     |     | 810 |     |      |     |     | 815 |
| Leu | Ser  | Gln | Lys | Ile | Lys | Val | Trp  | Leu | Gln | Glu | Tyr | Trp  | Asn | Ile | Thr |
|     |      |     | 820 |     |     |     |      | 825 |     |     |     |      | 830 |     |     |
| Asp | Leu  | Val | Ala | Ile | Ser | Thr | Phe  | Met | Ile | Gly | Ala | Ile  | Leu | Arg | Leu |
|     |      | 835 |     |     |     |     | 840  |     |     |     |     | 845  |     |     |     |
| Gln | Asn  | Gln | Pro | Tyr | Met | Gly | Tyr  | Gly | Arg | Val | Ile | Tyr  | Cys | Val | Asp |
|     | 850  |     |     |     |     | 855 |      |     |     |     | 860 |      |     |     |     |
| Ile | Ile  | Phe | Trp | Tyr | Ile | Arg | Val  | Leu | Asp | Ile | Phe | Gly  | Val | Asn | Lys |
| 865 |      |     |     |     | 870 |     |      |     |     | 875 |     |      |     |     | 880 |
| Tyr | Leu  | Gly | Pro | Tyr | Val | Met | Met  | Ile | Gly | Lys | Met | Met  | Ile | Asp | Met |
|     |      |     | 885 |     |     |     |      |     | 890 |     |     |      |     | 895 |     |
| Leu | Tyr  | Phe | Val | Val | Ile | Met | Leu  | Val | Val | Leu | Met | Ser  | Phe | Gly | Val |
|     |      |     | 900 |     |     |     |      | 905 |     |     |     |      | 910 |     |     |
| Ala | Arg  | Gln | Ala | Ile | Leu | His | Pro  | Glu | Glu | Lys | Pro | Ser  | Trp | Lys | Leu |
|     |      | 915 |     |     |     |     | 920  |     |     |     |     | 925  |     |     |     |
| Ala | Arg  | Asn | Ile | Phe | Tyr | Met | Pro  | Tyr | Trp | Met | Ile | Tyr  | Gly | Glu | Val |
|     |      | 930 |     |     |     | 935 |      |     |     |     | 940 |      |     |     |     |
| Phe | Ala  | Asp | Gln | Ile | Asp | Leu | Tyr  | Ala | Met | Glu | Ile | Asn  | Pro | Pro | Cys |
| 945 |      |     |     |     | 950 |     |      |     |     | 955 |     |      |     |     | 960 |
| Gly | Glu  | Asn | Leu | Tyr | Asp | Glu | Glu  | Gly | Lys | Arg | Leu | Pro  | Pro | Cys | Ile |
|     |      |     | 965 |     |     |     |      |     | 970 |     |     |      |     | 975 |     |
| Pro | Gly  | Ala | Trp | Leu | Thr | Pro | Ala  | Leu | Met | Ala | Cys | Tyr  | Leu | Leu | Val |
|     |      |     | 980 |     |     |     |      | 985 |     |     |     |      | 990 |     |     |
| Ala | Asn  | Ile | Leu | Leu | Val | Asn | Leu  | Leu | Ile | Ala | Val | Phe  | Asn | Asn | Thr |
|     |      | 995 |     |     |     |     | 1000 |     |     |     |     | 1005 |     |     |     |
| Phe | Phe  | Glu | Val | Lys | Ser | Ile | Ser  | Asn | Gln | Val | Trp | Lys  | Phe | Gln | Arg |
|     | 1010 |     |     |     |     |     | 1015 |     |     |     |     | 1020 |     |     |     |



-12-

Tyr Gln Leu Ile Met Thr Phe His Asp Arg Pro Val Leu Pro Pro Pro  
 1025 1030 1035 104  
 Met Ile Ile Leu Ser His Ile Tyr Ile Ile Met Arg Leu Ser Gly  
 1045 1050 1055  
 Arg Cys Arg Lys Lys Arg Glu Gly Asp Gln Glu Glu Arg Asp Arg Gly  
 1060 1065 1070  
 Leu Lys Leu Phe Leu Ser Asp Glu Glu Leu Lys Arg Leu His Glu Phe  
 1075 1080 1085  
 Glu Glu Gln Cys Val Gln Glu His Phe Arg Glu Lys Glu Asp Glu Gln  
 1090 1095 1100  
 Gln Ser Ser Ser Asp Glu Arg Ile Arg Val Thr Ser Glu Arg Val Glu  
 1105 1110 1115 112  
 Asn Met Ser Met Arg Leu Glu Glu Ile Asn Glu Arg Glu Thr Phe Met  
 1125 1130 1135  
 Lys Thr Ser Leu Gln Thr Val Asp Leu Arg Leu Ala Gln Leu Glu Glu  
 1140 1145 1150  
 Leu Ser Asn Arg Met Val Asn Ala Leu Glu Asn Leu Ala Gly Ile Asp  
 1155 1160 1165  
 Arg Ser Asp Leu Ile Gln Ala Arg Ser Arg Ala Ser Ser Glu Cys Glu  
 1170 1175 1180  
 Ala Thr Tyr Leu Leu Arg Gln Ser Ser Ile Asn Ser Ala Asp Gly Tyr  
 1185 1190 1195 120  
 Ser Leu Tyr Arg Tyr His Phe Asn Gly Glu Glu Leu Leu Phe Glu Asp  
 1205 1210 1215  
 Thr Ser Leu Ser Thr Ser Pro Gly Thr Gly Val Arg Lys Lys Thr Cys  
 1220 1225 1230  
 Ser Phe Arg Ile Lys Glu Glu Lys Asp Val Lys Thr His Leu Val Pro  
 1235 1240 1245  
 Glu Cys Gln Asn Ser Leu His Leu Ser Leu Gly Thr Ser Thr Ser Ala  
 1250 1255 1260  
 Thr Pro Asp Gly Ser His Leu Ala Val Asp Asp Leu Lys Asn Ala Glu  
 1265 1270 1275 128  
 Glu Ser Lys Leu Gly Pro Asp Ile Gly Ile Ser Lys Glu Asp Asp Glu  
 1285 1290 1295  
 Arg Gln Thr Asp Ser Lys Lys Glu Glu Thr Ile Ser Pro Ser Leu Asn  
 1300 1305 1310  
 Lys Thr Asp Val Ile His Gly Gln Asp Lys Ser Asp Val Gln Asn Thr  
 1315 1320 1325  
 Gln Leu Thr Val Glu Thr Thr Asn Ile Glu Gly Thr Ile Ser Tyr Pro  
 1330 1335 1340  
 Leu Glu Glu Thr Lys Ile Thr Arg Tyr Phe Pro Asp Glu Thr Ile Asn  
 1345 1350 1355 136  
 Ala Cys Lys Thr Met Lys Ser Arg Ser Phe Val Tyr Ser Arg Gly Arg  
 1365 1370 1375  
 Lys Leu Val Gly Gly Val Asn Gln Asp Val Glu Tyr Ser Ser Ile Thr  
 1380 1385 1390  
 Asp Gln Gln Leu Thr Thr Glu Trp Gln Cys Gln Val Gln Lys Ile Thr  
 1395 1400 1405  
 Arg Ser His Ser Thr Asp Ile Pro Tyr Ile Val Ser Glu Ala Ala Val  
 1410 1415 1420  
 Gln Ala Glu Gln Lys Glu Gln Phe Ala Asp Met Gln Asp Glu His His  
 1425 1430 1435 144  
 Val Ala Glu Ala Ile Pro Arg Ile Pro Arg Leu Ser Leu Thr Ile Thr  
 1445 1450 1455  
 Asp Arg Asn Gly Met Glu Asn Leu Leu Ser Val Lys Pro Asp Gln Thr  
 1460 1465 1470  
 Leu Gly Phe Pro Ser Leu Arg Ser Lys Ser Leu His Gly His Pro Arg  
 1475 1480 1485  
 Asn Val Lys Ser Ile Gln Gly Lys Leu Asp Arg Ser Gly His Ala Ser  
 1490 1495 1500

-13-

Ser Val Ser Ser Leu Val Ile Val Ser Gly Met Thr Ala Glu Glu Lys  
 1505 1510 1515 152  
 Lys Val Lys Lys Glu Lys Ala Ser Thr Glu Thr Glu Cys  
 1525 1530

<210> 11  
 <211> 6220  
 <212> DNA  
 <213> Homo Sapiens

<400> 11  
 tgtgcagaat tgtacagtgc cgaaaccatg tgcgtggcag ctggtgctgg cgggtggagac 60  
 ttccctgtgc ggtgctcagt gcatctgcac ccgtggggga gggagctctt tctctggccc 120  
 tgcagtcacc tgaggttgtt accattatga acggccgctg ggacccccgc atgtgcatgt 180  
 actccccag agtgtccggg ggccccagcc aagggaacaca tctcacgcag ctgggaacat 240  
 gtgcaggctg atgaagagaa ccggatgagg gcttcacatg aggaagcatg tggccaggtc 300  
 ctctcagaac atcagcctca tcttcctgtc tctgatctat ttaccaacc accccatgtg 360  
 tctctagaac cccagtgtag cgagctggag agaggactgt cctgagggca gcaggcctgg 420  
 ttgcagctgg cgtgggggtc tcagaatgga gccctcagcc ctgaggaaag ctggctcgga 480  
 gcaggaggag ggctttgagg ggctgcccag aagggtcact gacctgggga tggctctcaa 540  
 tctccggcgc agcaacagca gcctcttcaa gagctggagg ctacagtgcc ccttcggcaa 600  
 caatgacaa caagaaagcc tcagtctgtg gattcctgaa aacatcaaga agaaagaatg 660  
 cgtgtatttt gtggaaaagt ccaaaactgtc tgatgctggg aagggtggtg gtcaagtgtg 720  
 ctacacgcat gagcagcact tggaggaggc taccaagccc cacaccttc agggcacaca 780  
 gtgggaccca aagaaacatg tccaggagat gccaacgat gcctttggcg acatcgtctt 840  
 cacgggctg agccagaagg tgaaaaagta cgtccgagtc tcccaggaca cgcctccag 900  
 cgtgatctac cacctcatga cccagcactg ggggctggac gtccccaatc tcttgatctc 960  
 ggtgaccggg ggggccaaga acttcaacat gaagccgctg ctgaagagca ttttcgcag 1020  
 aggcctggtc aagggtgctc agaccacagg ggcttggatc atcacagggg ggtcccacac 1080  
 cggcgtcatg aagcaggtag gcgaggcggg gcgggacttc agcctgagca gcagctacaa 1140  
 ggaaggcgag ctcatcacca tcggagtcgc cacctggggc actgtccacc gccgcgaggg 1200  
 cctgatccat cccacgggca gcttccccgc cgagtacata ctggatgagg atggccaagg 1260  
 gaacctgacc tgcctagaca gcaaccactc tcacttcatc ctctgtagc acgggaccca 1320  
 cggccagtac ggggtggaga ttctctgag gaccaggctg gagaagttca tatcgagca 1380  
 gaccaaggaa agaggagggt tggccatcaa gatccccatc gtgtgcgtgg tgcaggagg 1440  
 cggccccggc acgttgacaa ccacgcacaa cgccaccacc aacggcacc cctgtgtgg 1500  
 tgtggagggc tcgggcccgc tggccgacgt cattgcccag gtggccaacc tgcctgtctc 1560  
 ggacatcact atctccctga tccagcagaa actgagcgtg ttcttcagg agatgtttga 1620  
 gaccttcacg gaaagcagga ttgtcgagt gacaaaaaag atccaagata ttgtccggag 1680  
 gcggcagctg ctgactgtct tccgggaagg caaggatggt cagcaggacg tggatgtggc 1740  
 catcttgca gcttgcgtga aagcctcacg gaggcaagac cactttggcc acgagaactg 1800  
 ggaccaccag ctgaaactgg cagtggcatg gaatcgctg gacattgccc gcagtgcag 1860  
 ctctcatgat gagggtgagt ggaagccttc agatctgcac cccacgatga cagctgcact 1920  
 catctccaac aagcctgagt ttgtgaagct cttcctggaa aacgggggtg agctgaagga 1980  
 gtttgtcacc tgggacacct tgctctacct gtacgagaa ctggacccct cctgcctgtt 2040  
 ccacagcaag ctgcaaaagg tgctggtgga ggatcccag cgcccggctt gcgcgcccgc 2100  
 ggcccccgc ctgcagatgc accacgtggc ccagggtgct cgaggagctg tgggggactt 2160  
 cagcagccg ctttatcccc ggccccggca caacgaccg ctgcggctcc tgctgccctg 2220  
 tccccacgtc aagctcaacg tgcaggaggt gagcctccg tccctctaca agcgttctc 2280  
 aggcatgtg accttacca tggaccccat ccgtgacct ctcatttggg ccattgtcca 2340  
 gaaccgtcgg gagctggcag gaatcatctg ggctcagagc caggactgca tcgcagcggc 2400  
 cttggcctgc agcaagatcc tgaaggaact gtccaaggag gaggaggaca cggacagctc 2460  
 ggaggagatg ctggcgctgg cgaggagta tgagcacaga gccatcgggg tcttcaccga 2520  
 gtgctaccg aaggacgaag agagagccca gaaactgct acccgctgt ccgaggcctg 2580  
 ggggaagacc acctgcctgc agctgcctt ggaggccaag gacatgaagt ttgtgtctca 2640  
 cgggggcatc caggccttcc tgaccaaggt gtggtggggc cagctctccg tggacaatgg 2700  
 gctgtggcgt gtgacctgt gcatgctggc ctcccgctg ctctcaccg gcctcatctc 2760  
 cttcaggag aagaggctgc aggatgtggg ccccccgcg gcccgcgccc gtgccttctt 2820  
 caccgcaccc gtggtggtct tccacctgaa catcctctcc tacttcgct tctctgcct 2880  
 gttcgccatc gtgctcatgg tggacttcca gcctgtgccc tcctggtgcg agtgtgccat 2940

|             |             |            |             |             |             |      |
|-------------|-------------|------------|-------------|-------------|-------------|------|
| ctacctctgg  | ctcttctcct  | tggtgtgcga | ggagatgcgg  | cagctcttct  | atgacctga   | 3000 |
| cgagtgcggg  | ctgatgaaga  | aggcagcctt | gtacttcagt  | gacttctgga  | ataagctgga  | 3060 |
| cgtcggcgca  | atcttgctct  | tcgtggcagg | gctgacctgc  | aggctcatcc  | cgcgacgct   | 3120 |
| gtaccccggg  | cgcgctcatcc | tctctctgga | cttcatcctg  | ttctgcctcc  | ggctcatgca  | 3180 |
| catttttacc  | atcagtaaga  | cgctggggcc | caagatcatc  | attgtgaagc  | ggatgatgaa  | 3240 |
| ggacgtcttc  | ttcttctcct  | tcctgctggc | tgtgtgggtg  | gtgtccttcg  | gggtggccaa  | 3300 |
| gcaggccatc  | ctcatccaca  | acgagcgccg | ggtggactgg  | ctgttccgag  | ggccgctcta  | 3360 |
| ccactcctac  | ctcaccatct  | tcgggcagat | cccgggctac  | atcgacggtg  | tgaacttcaa  | 3420 |
| ccggagcac   | tgcagcccca  | atggcaccca | ccctacaag   | cctaagtgc   | ccgagagcga  | 3480 |
| cgcgacgcag  | cagagcccg   | ccttccctga | ctggctgacg  | gtcctcctac  | tctgcctcta  | 3540 |
| cctgctcttc  | accaacatcc  | tgctgctcaa | cctcctcatc  | gccatgttca  | actacacctt  | 3600 |
| ccagcaggtg  | caggagcaca  | cggaccagat | ttggaagtgc  | cagcgccatg  | acctgatcga  | 3660 |
| ggagtaccac  | ggccgccccg  | ccgcgcgcgc | ccccttcctc  | ctcctcagcc  | acctgcagct  | 3720 |
| cttcatcaag  | aggggtggtc  | tgaagactcc | ggccaagagg  | cacaagcagc  | tcaagaacaa  | 3780 |
| gctggagaag  | aacgaggagg  | cggccctgct | atcctgggag  | atctacctga  | aggagaacta  | 3840 |
| cctccagaac  | cgacagtctc  | agcaaaagca | gcggcccgag  | cagaagatcg  | aggacatcag  | 3900 |
| caataaaggt  | gacgcatggt  | tggacctgct | ggacctggac  | ccactgaaga  | ggtcgggctc  | 3960 |
| catggagcag  | aggttggcct  | ccctggagga | gcaggtggcc  | cagacagccc  | gagccctgca  | 4020 |
| ctggatcgtg  | aggacgtgc   | gggccagcgg | cttcagctcg  | gaggcggacg  | tccccactct  | 4080 |
| ggcctcccag  | aaggcccgcg  | aggagccgga | tgctgagccg  | ggaggcagga  | agaagacgga  | 4140 |
| ggagccgggc  | gacagctacc  | acgtgaatgc | ccggcacctc  | ctctacccca  | actgccctgt  | 4200 |
| cacgcgcttc  | cccgtgcccc  | acgagaaggt | gccctgggag  | acggagtctc  | tgatctatga  | 4260 |
| cccacccttt  | tacacggcag  | agaggaagga | cgcggccgcc  | atggacccca  | tgggagacac  | 4320 |
| cctggagcca  | ctgtccacga  | tccagtacaa | cgctgggtat  | ggcctgaggg  | accgcccag   | 4380 |
| cttccacggg  | cgctacacag  | tgagggccgg | gttgcccctg  | aaccccatgg  | gccgcacagg  | 4440 |
| actgcgtggg  | cgcgggagcc  | tcagctgctt | cggacccaac  | cacacgctgt  | accccatggt  | 4500 |
| cacgcggttg  | agggcgaacg  | aggatggagc | catctgcagg  | aagagcataa  | agaagatgct  | 4560 |
| ggaagtgtctg | gtggtgaagc  | tccctctctc | cgagcactgg  | gccctgcctg  | ggggtctccc  | 4620 |
| ggagccaggg  | gagatgctac  | ctcggaagct | gaagcggatc  | ctccggcagg  | agcactggcc  | 4680 |
| gtcttttgaa  | aacttgctga  | agtgcggcat | ggaggtgtac  | aaaggctaca  | tggatgaccc  | 4740 |
| gaggaacacg  | gacaatgcct  | ggatcgagac | gttgcccgctc | agcgtccact  | tccaggacca  | 4800 |
| gaatgacgtg  | gagctgaaca  | ggctgaactc | taacctgcac  | gcctgcgact  | cgggggcttc  | 4860 |
| catccgatgg  | caggtgggtg  | acaggcgcat | cccactctat  | gcgaaccaca  | agaccctcct  | 4920 |
| ccagaaggca  | gccgctgagt  | tcggggctca | ctactgactg  | tgccctcagg  | ctgggaggct  | 4980 |
| ccagtccata  | gacgttcccc  | ccagaaacca | gggttctctc  | ctcctgagcc  | tggccaggac  | 5040 |
| tcaggctgtt  | cctgggcccct | gcacatgatg | gggtttgggtg | gacccagtgc  | ccctcacggc  | 5100 |
| tgccgcaagt  | ctgtctgaga  | tgacctcatg | aactggaagg  | ggtcaagggtg | accgggagg   | 5160 |
| agagctcaag  | acagggcaca  | ggctactcag | agctgagggg  | cccctgggac  | ccttggccat  | 5220 |
| caggcgaggg  | gctgggcctg  | tgacgtggg  | cccttggcca  | gagtcactc   | ccttccctggc | 5280 |
| tgtgtcacc   | cgagcagctc  | atccaccatg | gaggtcattg  | gcctgaggca  | agttcccccg  | 5340 |
| agagtcggga  | tcccctgttg  | ccccctcagg | cctatgtctg  | tgaggaaggg  | gccctgccac  | 5400 |
| tctccccaag  | agggcctcca  | tgtttcgagg | tgccctcaaca | tggagccttg  | cctggccttg  | 5460 |
| gctaggggca  | ctgtctgaac  | tccgtactgt | caggataaac  | tccgtggggg  | tacaggagcc  | 5520 |
| cagacaaagc  | ccaggccctgt | caagagacgc | agagggcccc  | tgccagggtt  | ggccccagg   | 5580 |
| accctgggac  | gaggtgtcag  | aagctctccc | tccctactcc  | ctgggagcca  | cgtgctggcc  | 5640 |
| atgtggccag  | ggacggcatg  | agcaggaggc | ggggacgtgg  | gggccttctg  | gtttggtgtc  | 5700 |
| aacagctcac  | aggagcgtga  | accatgaggg | ccctcaggag  | gggaacgtgg  | taaaacccaa  | 5760 |
| gacattaaat  | ctgccatctc  | aggcctggct | ggctcttctg  | tgctttccac  | aaataaagtt  | 5820 |
| cctgacacgt  | ccaggggccag | gggtgtgtg  | acggctgect  | gaagtctctc  | tcgatcccc   | 5880 |
| ggtgagcttc  | ctgcagcctg  | tggatgtcct | agcccccctc  | agccctaccc  | ccaagtttct  | 5940 |
| cctctgaccc  | atcagctccc  | tgtcttcatt | ttcctaaacc  | tgggtccag   | catcgtcccc  | 6000 |
| aagcccacca  | ggccaggatg  | caggcatcca | catgccctcc  | tccttggctt  | cccctgcgtg  | 6060 |
| gtggtgccaa  | tgtgccctgg  | cacccctgca | gaggctccgg  | atggagcctg  | gggctgcctg  | 6120 |
| gccactgagc  | actggccgag  | gtgatgccca | cccttccctg  | gacaggcctc  | tgtcttccac  | 6180 |
| ctgacccaaa  | gctctctagc  | caccccttgc | tccccagtat  |             |             | 6220 |

&lt;210&gt; 12

&lt;211&gt; 1503

-15-

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 12

```

Met Glu Pro Ser Ala Leu Arg Lys Ala Gly Ser Glu Gln Glu Gly
 1          5          10          15
Phe Glu Gly Leu Pro Arg Arg Val Thr Asp Leu Gly Met Val Ser Asn
          20          25          30
Leu Arg Arg Ser Asn Ser Ser Leu Phe Lys Ser Trp Arg Leu Gln Cys
          35          40          45
Pro Phe Gly Asn Asn Asp Lys Gln Glu Ser Leu Ser Ser Trp Ile Pro
          50          55          60
Glu Asn Ile Lys Lys Lys Glu Cys Val Tyr Phe Val Glu Ser Ser Lys
          65          70          75          80
Leu Ser Asp Ala Gly Lys Val Val Cys Gln Cys Gly Tyr Thr His Glu
          85          90          95
Gln His Leu Glu Glu Ala Thr Lys Pro His Thr Phe Gln Gly Thr Gln
          100          105          110
Trp Asp Pro Lys Lys His Val Gln Glu Met Pro Thr Asp Ala Phe Gly
          115          120          125
Asp Ile Val Phe Thr Gly Leu Ser Gln Lys Val Lys Lys Tyr Val Arg
          130          135          140
Val Ser Gln Asp Thr Pro Ser Ser Val Ile Tyr His Leu Met Thr Gln
          145          150          155          160
His Trp Gly Leu Asp Val Pro Asn Leu Leu Ile Ser Val Thr Gly Gly
          165          170          175
Ala Lys Asn Phe Asn Met Lys Pro Arg Leu Lys Ser Ile Phe Arg Arg
          180          185          190
Gly Leu Val Lys Val Ala Gln Thr Thr Gly Ala Trp Ile Ile Thr Gly
          195          200          205
Gly Ser His Thr Gly Val Met Lys Gln Val Gly Glu Ala Val Arg Asp
          210          215          220
Phe Ser Leu Ser Ser Ser Tyr Lys Glu Gly Glu Leu Ile Thr Ile Gly
          225          230          235          240
Val Ala Thr Trp Gly Thr Val His Arg Arg Glu Gly Leu Ile His Pro
          245          250          255
Thr Gly Ser Phe Pro Ala Glu Tyr Ile Leu Asp Glu Asp Gly Gln Gly
          260          265          270
Asn Leu Thr Cys Leu Asp Ser Asn His Ser His Phe Ile Leu Val Asp
          275          280          285
Asp Gly Thr His Gly Gln Tyr Gly Val Glu Ile Pro Leu Arg Thr Arg
          290          295          300
Leu Glu Lys Phe Ile Ser Glu Gln Thr Lys Glu Arg Gly Gly Val Ala
          305          310          315          320
Ile Lys Ile Pro Ile Val Cys Val Val Leu Glu Gly Gly Pro Gly Thr
          325          330          335
Leu His Thr Ile Asp Asn Ala Thr Thr Asn Gly Thr Pro Cys Val Val
          340          345          350
Val Glu Gly Ser Gly Arg Val Ala Asp Val Ile Ala Gln Val Ala Asn
          355          360          365
Leu Pro Val Ser Asp Ile Thr Ile Ser Leu Ile Gln Gln Lys Leu Ser
          370          375          380
Val Phe Phe Gln Glu Met Phe Glu Thr Phe Thr Glu Ser Arg Ile Val
          385          390          395          400
Glu Trp Thr Lys Lys Ile Gln Asp Ile Val Arg Arg Arg Gln Leu Leu
          405          410          415
Thr Val Phe Arg Glu Gly Lys Asp Gly Gln Gln Asp Val Asp Val Ala
          420          425          430
Ile Leu Gln Ala Leu Leu Lys Ala Ser Arg Ser Gln Asp His Phe Gly
          435          440          445

```

-16-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Glu | Asn | Trp | Asp | His | Gln | Leu | Lys | Leu | Ala | Val | Ala | Trp | Asn | Arg |
| 450 |     |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Val | Asp | Ile | Ala | Arg | Ser | Glu | Ile | Phe | Met | Asp | Glu | Trp | Gln | Trp | Lys |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Pro | Ser | Asp | Leu | His | Pro | Thr | Met | Thr | Ala | Ala | Leu | Ile | Ser | Asn | Lys |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Pro | Glu | Phe | Val | Lys | Leu | Phe | Leu | Glu | Asn | Gly | Val | Gln | Leu | Lys | Glu |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Phe | Val | Thr | Trp | Asp | Thr | Leu | Leu | Tyr | Leu | Tyr | Glu | Asn | Leu | Asp | Pro |
|     |     | 515 |     |     |     | 520 |     |     |     |     | 525 |     |     |     |     |
| Ser | Cys | Leu | Phe | His | Ser | Lys | Leu | Gln | Lys | Val | Leu | Val | Glu | Asp | Pro |
| 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |     |
| Glu | Arg | Pro | Ala | Cys | Ala | Pro | Ala | Ala | Pro | Arg | Leu | Gln | Met | His | His |
| 545 |     |     |     | 550 |     |     |     |     |     | 555 |     |     |     |     | 560 |
| Val | Ala | Gln | Val | Leu | Arg | Glu | Leu | Leu | Gly | Asp | Phe | Thr | Gln | Pro | Leu |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |
| Tyr | Pro | Arg | Pro | Arg | His | Asn | Asp | Arg | Leu | Arg | Leu | Leu | Leu | Pro | Val |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Pro | His | Val | Lys | Leu | Asn | Val | Gln | Gly | Val | Ser | Leu | Arg | Ser | Leu | Tyr |
|     |     | 595 |     |     |     | 600 |     |     |     |     | 605 |     |     |     |     |
| Lys | Arg | Ser | Ser | Gly | His | Val | Thr | Phe | Thr | Met | Asp | Pro | Ile | Arg | Asp |
| 610 |     |     |     |     | 615 |     |     |     |     |     | 620 |     |     |     |     |
| Leu | Leu | Ile | Trp | Ala | Ile | Val | Gln | Asn | Arg | Arg | Glu | Leu | Ala | Gly | Ile |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Ile | Trp | Ala | Gln | Ser | Gln | Asp | Cys | Ile | Ala | Ala | Ala | Leu | Ala | Cys | Ser |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |
| Lys | Ile | Leu | Lys | Glu | Leu | Ser | Lys | Glu | Glu | Glu | Asp | Thr | Asp | Ser | Ser |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Glu | Glu | Met | Leu | Ala | Leu | Ala | Glu | Glu | Tyr | Glu | His | Arg | Ala | Ile | Gly |
|     |     | 675 |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |
| Val | Phe | Thr | Glu | Cys | Tyr | Arg | Lys | Asp | Glu | Glu | Arg | Ala | Gln | Lys | Leu |
| 690 |     |     |     |     |     | 695 |     |     |     |     | 700 |     |     |     |     |
| Leu | Thr | Arg | Val | Ser | Glu | Ala | Trp | Gly | Lys | Thr | Thr | Cys | Leu | Gln | Leu |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     |     | 720 |
| Ala | Leu | Glu | Ala | Lys | Asp | Met | Lys | Phe | Val | Ser | His | Gly | Gly | Ile | Gln |
|     |     |     |     | 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |
| Ala | Phe | Leu | Thr | Lys | Val | Trp | Trp | Gly | Gln | Leu | Ser | Val | Asp | Asn | Gly |
|     |     |     | 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |
| Leu | Trp | Arg | Val | Thr | Leu | Cys | Met | Leu | Ala | Phe | Pro | Leu | Leu | Leu | Thr |
|     |     | 755 |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |
| Gly | Leu | Ile | Ser | Phe | Arg | Glu | Lys | Arg | Leu | Gln | Asp | Val | Gly | Thr | Pro |
| 770 |     |     |     |     | 775 |     |     |     |     |     | 780 |     |     |     |     |
| Ala | Ala | Arg | Ala | Arg | Ala | Phe | Phe | Thr | Ala | Pro | Val | Val | Val | Phe | His |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     |     | 800 |
| Leu | Asn | Ile | Leu | Ser | Tyr | Phe | Ala | Phe | Leu | Cys | Leu | Phe | Ala | Tyr | Val |
|     |     |     |     | 805 |     |     |     |     | 810 |     |     |     |     | 815 |     |
| Leu | Met | Val | Asp | Phe | Gln | Pro | Val | Pro | Ser | Trp | Cys | Glu | Cys | Ala | Ile |
|     |     |     | 820 |     |     |     |     | 825 |     |     |     |     | 830 |     |     |
| Tyr | Leu | Trp | Leu | Phe | Ser | Leu | Val | Cys | Glu | Glu | Met | Arg | Gln | Leu | Phe |
|     |     | 835 |     |     |     |     | 840 |     |     |     |     | 845 |     |     |     |
| Tyr | Asp | Pro | Asp | Glu | Cys | Gly | Leu | Met | Lys | Lys | Ala | Ala | Leu | Tyr | Phe |
| 850 |     |     |     |     |     | 855 |     |     |     |     | 860 |     |     |     |     |
| Ser | Asp | Phe | Trp | Asn | Lys | Leu | Asp | Val | Gly | Ala | Ile | Leu | Leu | Phe | Val |
| 865 |     |     |     |     | 870 |     |     |     |     | 875 |     |     |     |     | 880 |
| Ala | Gly | Leu | Thr | Cys | Arg | Leu | Ile | Pro | Ala | Thr | Leu | Tyr | Pro | Gly | Arg |
|     |     |     |     | 885 |     |     |     |     | 890 |     |     |     |     | 895 |     |
| Val | Ile | Leu | Ser | Leu | Asp | Phe | Ile | Leu | Phe | Cys | Leu | Arg | Leu | Met | His |
|     |     |     | 900 |     |     |     |     | 905 |     |     |     |     |     | 910 |     |
| Ile | Phe | Thr | Ile | Ser | Lys | Thr | Leu | Gly | Pro | Lys | Ile | Ile | Ile | Val | Lys |
|     |     | 915 |     |     |     |     | 920 |     |     |     |     |     | 925 |     |     |

-17-

Arg Met Met Lys Asp Val Phe Phe Phe Leu Phe Leu Leu Ala Val Trp  
 930 935 940  
 Val Val Ser Phe Gly Val Ala Lys Gln Ala Ile Leu Ile His Asn Glu  
 945 950 955 960  
 Arg Arg Val Asp Trp Leu Phe Arg Gly Ala Val Tyr His Ser Tyr Leu  
 965 970 975  
 Thr Ile Phe Gly Gln Ile Pro Gly Tyr Ile Asp Gly Val Asn Phe Asn  
 980 985 990  
 Pro Glu His Cys Ser Pro Asn Gly Thr Asp Pro Tyr Lys Pro Lys Cys  
 995 1000 1005  
 Pro Glu Ser Asp Ala Thr Gln Gln Arg Pro Ala Phe Pro Glu Trp Leu  
 1010 1015 1020  
 Thr Val Leu Leu Leu Cys Leu Tyr Leu Leu Phe Thr Asn Ile Leu Leu  
 1025 1030 1035 104  
 Leu Asn Leu Leu Ile Ala Met Phe Asn Tyr Thr Phe Gln Gln Val Gln  
 1045 1050 1055  
 Glu His Thr Asp Gln Ile Trp Lys Phe Gln Arg His Asp Leu Ile Glu  
 1060 1065 1070  
 Glu Tyr His Gly Arg Pro Ala Ala Pro Pro Pro Phe Ile Leu Leu Ser  
 1075 1080 1085  
 His Leu Gln Leu Phe Ile Lys Arg Val Val Leu Lys Thr Pro Ala Lys  
 1090 1095 1100  
 Arg His Lys Gln Leu Lys Asn Lys Leu Glu Lys Asn Glu Glu Ala Ala  
 1105 1110 1115 112  
 Leu Leu Ser Trp Glu Ile Tyr Leu Lys Glu Asn Tyr Leu Gln Asn Arg  
 1125 1130 1135  
 Gln Phe Gln Gln Lys Gln Arg Pro Glu Gln Lys Ile Glu Asp Ile Ser  
 1140 1145 1150  
 Asn Lys Val Asp Ala Met Val Asp Leu Leu Asp Leu Asp Pro Leu Lys  
 1155 1160 1165  
 Arg Ser Gly Ser Met Glu Gln Arg Leu Ala Ser Leu Glu Glu Gln Val  
 1170 1175 1180  
 Ala Gln Thr Ala Arg Ala Leu His Trp Ile Val Arg Thr Leu Arg Ala  
 1185 1190 1195 120  
 Ser Gly Phe Ser Ser Glu Ala Asp Val Pro Thr Leu Ala Ser Gln Lys  
 1205 1210 1215  
 Ala Ala Glu Glu Pro Asp Ala Glu Pro Gly Gly Arg Lys Lys Thr Glu  
 1220 1225 1230  
 Glu Pro Gly Asp Ser Tyr His Val Asn Ala Arg His Leu Leu Tyr Pro  
 1235 1240 1245  
 Asn Cys Pro Val Thr Arg Phe Pro Val Pro Asn Glu Lys Val Pro Trp  
 1250 1255 1260  
 Glu Thr Glu Phe Leu Ile Tyr Asp Pro Pro Phe Tyr Thr Ala Glu Arg  
 1265 1270 1275 128  
 Lys Asp Ala Ala Ala Met Asp Pro Met Gly Asp Thr Leu Glu Pro Leu  
 1285 1290 1295  
 Ser Thr Ile Gln Tyr Asn Val Val Asp Gly Leu Arg Asp Arg Arg Ser  
 1300 1305 1310  
 Phe His Gly Pro Tyr Thr Val Gln Ala Gly Leu Pro Leu Asn Pro Met  
 1315 1320 1325  
 Gly Arg Thr Gly Leu Arg Gly Arg Gly Ser Leu Ser Cys Phe Gly Pro  
 1330 1335 1340  
 Asn His Thr Leu Tyr Pro Met Val Thr Arg Trp Arg Arg Asn Glu Asp  
 1345 1350 1355 136  
 Gly Ala Ile Cys Arg Lys Ser Ile Lys Lys Met Leu Glu Val Leu Val  
 1365 1370 1375  
 Val Lys Leu Pro Leu Ser Glu His Trp Ala Leu Pro Gly Gly Ser Arg  
 1380 1385 1390  
 Glu Pro Gly Glu Met Leu Pro Arg Lys Leu Lys Arg Ile Leu Arg Gln  
 1395 1400 1405

-18-

Glu His Trp Pro Ser Phe Glu Asn Leu Leu Lys Cys Gly Met Glu Val  
 1410 1415 1420  
 Tyr Lys Gly Tyr Met Asp Asp Pro Arg Asn Thr Asp Asn Ala Trp Ile  
 1425 1430 1435 144  
 Glu Thr Val Ala Val Ser Val His Phe Gln Asp Gln Asn Asp Val Glu  
 1445 1450 1455  
 Leu Asn Arg Leu Asn Ser Asn Leu His Ala Cys Asp Ser Gly Ala Ser  
 1460 1465 1470  
 Ile Arg Trp Gln Val Val Asp Arg Arg Ile Pro Leu Tyr Ala Asn His  
 1475 1480 1485  
 Lys Thr Leu Leu Gln Lys Ala Ala Ala Glu Phe Gly Ala His Tyr  
 1490 1495 1500

<210> 13  
 <211> 1816  
 <212> PRT  
 <213> C. Elegans

<400> 13  
 Met Ile Thr Asp Lys Asn Leu Phe Ser Arg Leu Leu Ile Lys Lys Asn  
 1 5 10 15  
 Pro Ile Arg Met His Ser Pro Ser Phe Ser Phe Ser Leu Ile Thr Ser  
 20 25 30  
 Leu Phe Phe Thr Gln Phe Phe Met Phe Gln Leu Ser Ser Met Ala Tyr  
 35 40 45  
 Phe Phe Leu Thr Leu Ile Ala Gly Val Thr His Phe Tyr Phe Pro Glu  
 50 55 60  
 Lys Leu Leu Gly Lys Ser Glu Asn Leu Asp His Arg Tyr Gln Ser Ser  
 65 70 75 80  
 Glu Gln Lys Val Leu Ile Glu Trp Thr Glu Asn Lys Ala Val Ala Glu  
 85 90 95  
 Ser Leu Arg Ala Asn Ser Val Thr Val Glu Glu Asn Glu Ser Glu Arg  
 100 105 110  
 Glu Thr Glu Thr Gln Thr Lys Arg Arg Arg Lys Lys Gln Arg Ser Thr  
 115 120 125  
 Ser Ser Asp Lys Ala Pro Leu Asn Ser Ala Pro Arg His Val Gln Lys  
 130 135 140  
 Phe Asp Trp Lys Asp Met Leu His Leu Ala Asp Ile Ser Gly Arg Lys  
 145 150 155 160  
 Arg Gly Asn Ser Thr Thr Ser His Ser Gly His Ala Thr Arg Ala Gly  
 165 170 175  
 Ser Leu Lys Gly Lys Asn Trp Ile Glu Cys Arg Leu Lys Met Arg Gln  
 180 185 190  
 Cys Ser Tyr Phe Val Pro Ser Gln Arg Phe Ser Glu Arg Cys Gly Cys  
 195 200 205  
 Gly Lys Glu Arg Ser Lys His Thr Glu Glu Val Leu Glu Arg Ser Gln  
 210 215 220  
 Asn Lys Asn His Pro Leu Asn His Leu Thr Leu Pro Gly Ile His Glu  
 225 230 235 240  
 Val Asp Thr Thr Asp Ala Asp Ala Asp Asp Asn Glu Val Asn Leu Thr  
 245 250 255  
 Pro Gly Arg Trp Ser Ile Gln Ser His Thr Glu Ile Val Pro Thr Asp  
 260 265 270  
 Ala Tyr Gly Asn Ile Val Phe Glu Gly Thr Ala His His Ala Gln Tyr  
 275 280 285  
 Ala Arg Ile Ser Phe Asp Ser Asp Pro Arg Asp Ile Val His Leu Met  
 290 295 300  
 Met Lys Val Trp Lys Leu Lys Pro Pro Lys Leu Ile Ile Thr Ile Asn  
 305 310 315 320  
 Gly Gly Leu Thr Lys Phe Asp Leu Gln Pro Lys Leu Ala Arg Thr Phe

-19-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|     |     |     |     | 325 |     |     |     |     |     | 330 |     |     |     |     | 335 |
| Arg | Lys | Gly | Ile | Met | Lys | Ile | Ala | Lys | Ser | Thr | Asp | Ala | Trp | Ile | Ile |
|     |     |     | 340 |     |     |     |     |     | 345 |     |     |     |     | 350 |     |
| Thr | Ser | Gly | Leu | Asp | Glu | Gly | Val | Val | Lys | His | Leu | Asp | Ser | Ala | Leu |
|     |     | 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |     |     |
| His | Ala | Leu | Glu | Phe | Trp | Ser | Phe | Gly | Leu | Phe | Trp | Val | Ile | Gln | Leu |
|     | 370 |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |
| Asp | Val | Leu | Leu | Ala | His | Ser | Met | Phe | Ile | Pro | Arg | Gly | Ser | Leu | Phe |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     | 400 |     |
| Asp | His | Gly | Asn | His | Thr | Ser | Lys | Asn | His | Val | Val | Ala | Ile | Gly | Ile |
|     |     |     | 405 |     |     |     |     |     | 410 |     |     |     |     | 415 |     |
| Ala | Ser | Trp | Gly | Met | Leu | Lys | Gln | Arg | Ser | Arg | Phe | Val | Gly | Lys | Asp |
|     |     | 420 |     |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Ser | Thr | Val | Thr | Tyr | Ala | Thr | Asn | Val | Phe | Asn | Asn | Thr | Arg | Leu | Lys |
|     |     | 435 |     |     |     |     | 440 |     |     |     |     | 445 |     |     |     |
| Glu | Leu | Asn | Asp | Asn | His | Ser | Tyr | Phe | Leu | Phe | Ser | Asp | Asn | Gly | Thr |
|     | 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Val | Asn | Arg | Tyr | Gly | Ala | Glu | Ile | Ile | Met | Arg | Lys | Arg | Leu | Glu | Ala |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     | 480 |     |
| Tyr | Leu | Ala | Gln | Gly | Asp | Lys | Lys | Arg | Ser | Ala | Ile | Pro | Leu | Val | Cys |
|     |     |     | 485 |     |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Val | Val | Leu | Glu | Gly | Gly | Ala | Phe | Thr | Ile | Lys | Met | Val | His | Asp | Tyr |
|     |     | 500 |     |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Val | Thr | Thr | Ile | Pro | Arg | Ile | Pro | Val | Ile | Val | Cys | Asp | Gly | Ser | Gly |
|     | 515 |     |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| Arg | Ala | Ala | Asp | Ile | Leu | Ala | Phe | Ala | His | Gln | Ala | Val | Ser | Gln | Asn |
|     | 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |
| Gly | Phe | Leu | Ser | Asp | Asn | Ile | Arg | Asn | Gln | Leu | Val | Asn | Ile | Val | Arg |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     | 560 |     |
| Arg | Ile | Phe | Gly | Tyr | Asp | Pro | Lys | Thr | Ala | Gln | Lys | Leu | Ile | Lys | Gln |
|     |     |     | 565 |     |     |     |     |     | 570 |     |     |     |     | 575 |     |
| Ile | Val | Glu | Cys | Ser | Thr | Asn | Lys | Ser | Leu | Met | Thr | Ile | Phe | Arg | Leu |
|     |     | 580 |     |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Gly | Glu | Ser | Ser | Arg | Glu | Asp | Leu | Asp | His | Val | Ile | Met | Ser | Cys | Leu |
|     | 595 |     |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |
| Leu | Lys | Gly | Gln | Asn | Leu | Ser | Pro | Pro | Glu | Gln | Leu | Gln | Leu | Ala | Leu |
|     | 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |
| Ala | Trp | Asn | Arg | Ala | Asp | Ile | Ala | Arg | Thr | Glu | Ile | Phe | Ala | Asn | Gly |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     | 640 |     |
| Thr | Glu | Trp | Thr | Thr | Gln | Asp | Leu | His | Asn | Ala | Met | Ile | Glu | Ala | Leu |
|     |     |     | 645 |     |     |     |     |     | 650 |     |     |     |     | 655 |     |
| Ser | Asn | Asp | Arg | Ile | Asp | Phe | Val | His | Leu | Leu | Leu | Glu | Asn | Gly | Val |
|     |     | 660 |     |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Ser | Met | Gln | Lys | Phe | Leu | Thr | Tyr | Gly | Arg | Leu | Glu | His | Leu | Tyr | Asn |
|     | 675 |     |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |
| Thr | Asp | Lys | Gly | Pro | Gln | Asn | Thr | Leu | Arg | Thr | Asn | Leu | Leu | Val | Asp |
|     | 690 |     |     |     |     | 695 |     |     |     |     | 700 |     |     |     |     |
| Ser | Lys | His | His | Ile | Lys | Leu | Val | Glu | Val | Gly | Arg | Leu | Val | Glu | Asn |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     | 720 |     |
| Leu | Met | Gly | Asn | Leu | Tyr | Lys | Ser | Asn | Tyr | Thr | Lys | Glu | Glu | Phe | Lys |
|     |     |     | 725 |     |     |     |     |     | 730 |     |     |     |     | 735 |     |
| Asn | Gln | Tyr | Phe | Leu | Phe | Asn | Asn | Arg | Lys | Gln | Phe | Gly | Lys | Arg | Val |
|     |     | 740 |     |     |     |     |     | 745 |     |     |     |     | 750 |     |     |
| His | Ser | Asn | Ser | Asn | Gly | Gly | Arg | Asn | Asp | Val | Ile | Gly | Pro | Ser | Gly |
|     | 755 |     |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |
| Asp | Ala | Gly | Arg | Glu | Arg | Met | Ser | Ser | Met | Gln | Ile | Ser | Leu | Ile | Asn |
|     | 770 |     |     |     |     | 775 |     |     |     |     | 780 |     |     |     |     |
| Asn | Ala | Arg | Asn | Ser | Ile | Ile | Ser | Leu | Phe | Asn | Gly | Gly | Gly | Arg | Lys |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     | 800 |     |
| Arg | Glu | Ser | Asp | Asp | Glu | Asp | Asp | Phe | Ser | Asn | Leu | Glu | Glu | Glu | Ala |



|      |     |     |     |     |     |     |     |     |     |      |     |     |     |      |     |  |  |
|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|------|-----|--|--|
| 805  |     |     |     |     |     |     |     |     |     | 810  |     |     |     | 815  |     |  |  |
| Asn  | Met | Asp | Phe | Thr | Phe | Arg | Tyr | Pro | Tyr | Ser  | Asp | Leu | Met | Ile  | Trp |  |  |
| 820  |     |     |     |     |     |     |     |     |     | 825  |     |     |     | 830  |     |  |  |
| Ala  | Val | Leu | Thr | Lys | Arg | Gln | Lys | Met | Ala | Lys  | Leu | Met | Trp | Thr  | His |  |  |
| 835  |     |     |     |     |     |     |     |     |     | 840  |     |     |     | 845  |     |  |  |
| Gly  | Glu | Glu | Gly | Met | Ala | Lys | Ala | Leu | Val | Ala  | Ser | Arg | Leu | Tyr  | Val |  |  |
| 850  |     |     |     |     |     |     |     |     |     | 855  |     |     |     | 860  |     |  |  |
| Ser  | Leu | Ala | Lys | Thr | Ala | Ser | Leu | Ala | Thr | Gly  | Glu | Ile | Gly | Met  | Ser |  |  |
| 865  |     |     |     |     |     |     |     |     |     | 870  |     |     |     | 875  |     |  |  |
| Gln  | Asp | Phe | Thr | Glu | Phe | Ser | Asp | Glu | Phe | Ser  | Glu | Leu | Ala | Val  | Glu |  |  |
| 885  |     |     |     |     |     |     |     |     |     | 890  |     |     |     | 895  |     |  |  |
| Val  | Leu | Glu | Tyr | Cys | Thr | Lys | His | Gly | Arg | Asp  | Gln | Thr | Leu | Arg  | Leu |  |  |
| 900  |     |     |     |     |     |     |     |     |     | 905  |     |     |     | 910  |     |  |  |
| Leu  | Thr | Cys | Glu | Leu | Ala | Asn | Trp | Gly | Asp | Glu  | Thr | Cys | Leu | Ser  | Leu |  |  |
| 915  |     |     |     |     |     |     |     |     |     | 920  |     |     |     | 925  |     |  |  |
| Ala  | Ala | Asn | Asn | Gly | His | Arg | Lys | Phe | Leu | Ala  | His | Pro | Cys | Cys  | Gln |  |  |
| 930  |     |     |     |     |     |     |     |     |     | 935  |     |     |     | 940  |     |  |  |
| Met  | Leu | Leu | Ser | Asp | Leu | Trp | Gln | Gly | Gly | Leu  | Leu | Met | Lys | Asn  | Asn |  |  |
| 945  |     |     |     |     |     |     |     |     |     | 950  |     |     |     | 955  |     |  |  |
| Gln  | Asn | Ser | Lys | Val | Leu | Thr | Cys | Leu | Ala | Ala  | Pro | Pro | Leu | Ile  | Phe |  |  |
| 965  |     |     |     |     |     |     |     |     |     | 970  |     |     |     | 975  |     |  |  |
| Leu  | Leu | Gly | Phe | Lys | Thr | Lys | Glu | Gln | Leu | Met  | Leu | Gln | Pro | Lys  | Thr |  |  |
| 980  |     |     |     |     |     |     |     |     |     | 985  |     |     |     | 990  |     |  |  |
| Ala  | Ala | Glu | His | Asp | Glu | Glu | Met | Ser | Asp | Ser  | Glu | Met | Asn | Ser  | Ala |  |  |
| 995  |     |     |     |     |     |     |     |     |     | 1000 |     |     |     | 1005 |     |  |  |
| Glu  | Asp | Thr | Asp | Thr | Ser | Ser | Asp | Ser | Ser | Ser  | Asp | Ser | Asp | Asp  | Ser |  |  |
| 1010 |     |     |     |     |     |     |     |     |     | 1015 |     |     |     | 1020 |     |  |  |
| Asp  | Glu | Glu | Asp | Ala | Lys | Leu | Arg | Ala | Gln | Ser  | Leu | Ser | Ala | Asp  | Gln |  |  |
| 1025 |     |     |     |     |     |     |     |     |     | 1030 |     |     |     | 1035 |     |  |  |
| Pro  | Leu | Ser | Ile | His | Arg | Leu | Val | Arg | Asp | Lys  | Leu | Asn | Phe | Ser  | Glu |  |  |
| 1045 |     |     |     |     |     |     |     |     |     | 1050 |     |     |     | 1055 |     |  |  |
| Lys  | Lys | Lys | Pro | Asp | Met | Gly | Ile | Ser | Arg | Ile  | Val | Val | Ala | Pro  | Pro |  |  |
| 1060 |     |     |     |     |     |     |     |     |     | 1065 |     |     |     | 1070 |     |  |  |
| Ile  | Val | Thr | Gly | Arg | Asn | Arg | Ala | Arg | Thr | Met  | Ser | Ile | Lys | Lys  | Ser |  |  |
| 1075 |     |     |     |     |     |     |     |     |     | 1080 |     |     |     | 1085 |     |  |  |
| Lys  | Lys | Asn | Val | Ile | Lys | Pro | Pro | Ala | Cys | Leu  | Lys | Ile | Glu | Thr  | Ser |  |  |
| 1090 |     |     |     |     |     |     |     |     |     | 1095 |     |     |     | 1100 |     |  |  |
| Asp  | Asp | Asp | Glu | Gln | Glu | Gln | Lys | Lys | Ala | Thr  | Glu | Met | Cys | Lys  | Ser |  |  |
| 1105 |     |     |     |     |     |     |     |     |     | 1110 |     |     |     | 1115 |     |  |  |
| Thr  | Phe | Phe | Asp | Phe | Phe | Phe | Asp | Phe | Pro | Tyr  | Ile | Asn | Arg | Thr  | Gly |  |  |
| 1125 |     |     |     |     |     |     |     |     |     | 1130 |     |     |     | 1135 |     |  |  |
| Lys  | Arg | Gly | Ser | Val | Ala | Val | Ala | Met | Asn | His  | Asp | Asp | Met | Tyr  | Ile |  |  |
| 1140 |     |     |     |     |     |     |     |     |     | 1145 |     |     |     | 1150 |     |  |  |
| Asp  | Pro | Ser | Glu | Glu | Leu | Asp | Thr | Gln | Thr | Arg  | Gln | Lys | Ser | Ser  | Arg |  |  |
| 1155 |     |     |     |     |     |     |     |     |     | 1160 |     |     |     | 1165 |     |  |  |
| Glu  | Phe | Ser | Ser | Ser | Arg | Asn | Val | Thr | Val | Gln  | Val | Tyr | Thr | Gln  | Arg |  |  |
| 1170 |     |     |     |     |     |     |     |     |     | 1175 |     |     |     | 1180 |     |  |  |
| Pro  | Leu | Ser | Trp | Lys | Lys | Lys | Ile | Met | Glu | Phe  | Tyr | Lys | Ala | Pro  | Ile |  |  |
| 1185 |     |     |     |     |     |     |     |     |     | 1190 |     |     |     | 1195 |     |  |  |
| Thr  | Thr | Tyr | Trp | Leu | Trp | Phe | Phe | Ala | Phe | Ile  | Trp | Phe | Leu | Ile  | Leu |  |  |
| 1205 |     |     |     |     |     |     |     |     |     | 1210 |     |     |     | 1215 |     |  |  |
| Leu  | Thr | Tyr | Asn | Leu | Leu | Val | Lys | Thr | Gln | Arg  | Ile | Ala | Ser | Trp  | Ser |  |  |
| 1220 |     |     |     |     |     |     |     |     |     | 1225 |     |     |     | 1230 |     |  |  |
| Glu  | Trp | Tyr | Val | Phe | Ala | Tyr | Ile | Phe | Val | Trp  | Thr | Leu | Glu | Ile  | Gly |  |  |
| 1235 |     |     |     |     |     |     |     |     |     | 1240 |     |     |     | 1245 |     |  |  |
| Arg  | Lys | Val | Val | Ser | Thr | Ile | Met | Met | Asp | Thr  | Ser | Lys | Pro | Val  | Leu |  |  |
| 1250 |     |     |     |     |     |     |     |     |     | 1255 |     |     |     | 1260 |     |  |  |
| Lys  | Gln |     |     |     |     |     |     |     |     |      |     |     |     |      |     |  |  |

-21-

|     |     |     |     |      |     |     |     |      |     |      |      |      |      |     |      |
|-----|-----|-----|-----|------|-----|-----|-----|------|-----|------|------|------|------|-----|------|
|     |     |     |     | 1285 |     |     |     | 1290 |     |      |      | 1295 |      |     |      |
| Thr | Thr | Lys | Thr | Leu  | Gly | Arg | Ile | Leu  | Ile | Ile  | Cys  | Asn  | Ser  | Val | Ile  |
|     |     |     |     | 1300 |     |     |     | 1305 |     |      |      |      | 1310 |     |      |
| Trp | Ser | Leu | Lys | Leu  | Val | Asp | Tyr | Leu  | Ser | Val  | Gln  | Gln  | Gly  | Leu | Gly  |
|     |     |     |     | 1315 |     |     |     | 1320 |     |      |      |      | 1325 |     |      |
| Pro | Tyr | Ile | Asn | Ile  | Val | Ala | Glu | Met  | Ile | Pro  | Thr  | Met  | Ile  | Pro | Leu  |
|     |     |     |     | 1330 |     |     |     | 1335 |     |      |      |      | 1340 |     |      |
| Cys | Val | Leu | Val | Phe  | Ile | Thr | Leu | Tyr  | Ala | Phe  | Gly  | Leu  | Leu  | Arg | Gln  |
|     |     |     |     | 1345 |     |     |     |      |     |      | 1355 |      |      |     | 136  |
| Ser | Ile | Thr | Tyr | Pro  | Tyr | Glu | Asp | Trp  | His | Trp  | Ile  | Leu  | Val  | Arg | Asn  |
|     |     |     |     | 1365 |     |     |     |      |     | 1370 |      |      |      |     | 1375 |
| Ile | Phe | Leu | Gln | Pro  | Tyr | Phe | Met | Leu  | Tyr | Gly  | Glu  | Val  | Tyr  | Ala | Ala  |
|     |     |     |     | 1380 |     |     |     | 1385 |     |      |      |      |      |     | 1390 |
| Glu | Ile | Asp | Thr | Cys  | Gly | Asp | Glu | Ile  | Trp | Gln  | Thr  | His  | Glu  | Asp | Glu  |
|     |     |     |     | 1395 |     |     |     | 1400 |     |      |      |      | 1405 |     |      |
| Asn | Ile | Pro | Ile | Ser  | Met | Leu | Asn | Val  | Thr | His  | Glu  | Thr  | Cys  | Val | Pro  |
|     |     |     |     | 1410 |     |     |     | 1415 |     |      |      |      | 1420 |     |      |
| Gly | Tyr | Trp | Ile | Ala  | Pro | Val | Gly | Leu  | Thr | Val  | Phe  | Met  | Leu  | Ala | Thr  |
|     |     |     |     | 1425 |     |     |     | 1430 |     |      |      | 1435 |      |     | 144  |
| Asn | Val | Leu | Leu | Met  | Asn | Val | Met | Val  | Ala | Gly  | Cys  | Thr  | Tyr  | Ile | Phe  |
|     |     |     |     | 1445 |     |     |     |      |     | 1450 |      |      |      |     | 1455 |
| Glu | Lys | His | Ile | Gln  | Ser | Thr | Arg | Glu  | Ile | Phe  | Leu  | Phe  | Glu  | Arg | Tyr  |
|     |     |     |     | 1460 |     |     |     | 1465 |     |      |      |      |      |     | 1470 |
| Gly | Gln | Val | Met | Glu  | Tyr | Glu | Ser | Thr  | Pro | Trp  | Leu  | Pro  | Pro  | Pro | Phe  |
|     |     |     |     | 1475 |     |     |     | 1480 |     |      |      |      | 1485 |     |      |
| Thr | Ile | Ile | Tyr | His  | Val | Ile | Trp | Leu  | Phe | Lys  | Leu  | Ile  | Lys  | Ser | Ser  |
|     |     |     |     | 1490 |     |     |     | 1495 |     |      |      |      | 1500 |     |      |
| Ser | Arg | Met | Phe | Glu  | Arg | Lys | Asn | Leu  | Phe | Asp  | Gln  | Ser  | Leu  | Lys | Leu  |
|     |     |     |     | 1505 |     |     |     | 1510 |     |      |      |      | 1515 |     | 152  |
| Phe | Leu | Ser | Pro | Asp  | Glu | Met | Glu | Lys  | Val | His  | Thr  | Phe  | Glu  | Glu | Glu  |
|     |     |     |     | 1525 |     |     |     |      |     | 1530 |      |      |      |     | 1535 |
| Ser | Val | Glu | Asp | Met  | Lys | Arg | Glu | Thr  | Glu | Lys  | Lys  | Asn  | Leu  | Ser | Ser  |
|     |     |     |     | 1540 |     |     |     | 1545 |     |      |      |      | 1550 |     |      |
| Asn | Asp | Glu | Arg | Ile  | His | Arg | Thr | Ala  | Glu | Arg  | Thr  | Asp  | Ala  | Ile | Leu  |
|     |     |     |     | 1555 |     |     |     | 1560 |     |      |      |      | 1565 |     |      |
| Asn | Arg | Val | Ser | His  | Leu | Thr | Gln | Leu  | Glu | Phe  | Thr  | Leu  | Lys  | Glu | Glu  |
|     |     |     |     | 1570 |     |     |     | 1575 |     |      |      |      | 1580 |     |      |
| Ile | Arg | Glu | Leu | Glu  | His | Lys | Met | Lys  | Asn | Met  | Asp  | Ser  | Arg  | His | Lys  |
|     |     |     |     | 1585 |     |     |     | 1590 |     |      |      | 1595 |      |     | 160  |
| Glu | Gln | Met | Asn | Leu  | Met | Leu | Asp | Met  | Asn | Lys  | Lys  | Leu  | Gly  | Lys | Phe  |
|     |     |     |     | 1605 |     |     |     |      |     | 1610 |      |      |      |     | 1615 |
| Ile | Ser | Gly | Lys | Tyr  | Lys | Arg | Gly | Ser  | Phe | Gly  | Gly  | Ser  | Gly  | Ser | Asp  |
|     |     |     |     | 1620 |     |     |     | 1625 |     |      |      |      |      |     | 1630 |
| Gly | Gly | Gly | Gly | Ser  | Ser | Asp | Asn | Ser  | Lys | Leu  | Glu  | Pro  | Asn  | Asn | Ser  |
|     |     |     |     | 1635 |     |     |     | 1640 |     |      |      |      | 1645 |     |      |
| Val | Pro | Met | Ile | Thr  | Val | Asp | Gly | Pro  | Ser | Pro  | Ile  | Gly  | Ser  | Arg | Arg  |
|     |     |     |     | 1650 |     |     |     | 1655 |     |      |      |      | 1660 |     |      |
| Thr | Ser | Gly | Gln | Tyr  | Leu | Lys | Arg | Asp  | Ser | Leu  | Gln  | Ala  | Lys  | Lys | Lys  |
|     |     |     |     | 1665 |     |     |     | 1670 |     |      |      |      | 1675 |     | 168  |
| Ile | Thr | Glu | Asn | Arg  | Ser | Ser | Leu | Glu  | Gln | Pro  | Lys  | Ile  | Pro  | Ser |      |
|     |     |     |     | 1685 |     |     |     | 1690 |     |      |      |      | 1695 |     |      |
| Ile | Gln | Phe | Asn | Leu  | Met | Glu | Asp | Gln  | Asp | Glu  | Ser  | Ala  | Ala  | Glu | Ser  |
|     |     |     |     | 1700 |     |     |     | 1705 |     |      |      |      | 1710 |     |      |
| Ala | Thr | Glu | Glu | Val  | Ser | Ile | Ser | Ile  | Pro | Val  | Pro  | Gln  | Met  | Arg | Val  |
|     |     |     |     | 1715 |     |     |     | 1720 |     |      |      |      | 1725 |     |      |
| Arg | Gln | Val | Thr | Glu  | Ser | Asp | Lys | Ser  | Asp | Leu  | Ser  | Glu  | Asp  | Asp | Leu  |
|     |     |     |     | 1730 |     |     |     | 1735 |     |      |      |      | 1740 |     |      |
| Ile | Thr | Arg | Glu | Asp  | Ala | Pro | Pro | Thr  | Ser | Ile  | Asn  | Leu  | Pro  | Arg | Gly  |
|     |     |     |     | 1745 |     |     |     | 1750 |     |      |      | 1755 |      |     | 176  |
| Pro | Arg | Arg | His | Ala  | Leu | Tyr | Ser | Thr  | Ile | Ala  | Asp  | Ala  | Ile  | Glu | Thr  |

```
<210> 14
<211> 1387
<212> PRT
<213> C. Elegans
```

|          |     |     |         |         |         |        |        |        |         |         |        |     |         |         |         |  |
|----------|-----|-----|---------|---------|---------|--------|--------|--------|---------|---------|--------|-----|---------|---------|---------|--|
| <400> 14 |     |     |         |         |         |        |        |        |         |         |        |     |         |         |         |  |
| Met 1    | Arg | Lys | Ser 5   | Arg     | Arg     | Val    | Arg    | Lys    | Leu 10  | Val     | Arg    | His | Ala     | Ser 15  | Leu     |  |
| Ile      | Glu | Asn | Ile 20  | Arg     | His     | Arg    | Thr    | Ser 25 | Ser     | Phe     | Leu    | Arg | Leu 30  | Leu     | Asn     |  |
| Ala      | Pro | Arg | Asn 35  | Ser     | Met     | Cys    | Asn 40 | Ala    | Asn     | Thr     | Val    | His | Ser 45  | Ile     | Ser     |  |
| Ser      | Phe | Arg | Ser 50  | Asp     | His     | Leu 55 | Ser    | Arg    | Lys     | Ser     | Thr 60 | His | Lys     | Phe     | Leu     |  |
| Asp 65   | Asn | Pro | Asn     | Leu     | Phe 70  | Ala    | Ile    | Glu    | Leu     | Thr 75  | Glu    | Lys | Leu     | Ser     | Pro 80  |  |
| Pro      | Trp | Ile | Glu 85  | Asn     | Thr     | Phe    | Glu    | Lys    | Arg 90  | Glu     | Cys    | Ile | Arg     | Phe 95  | Ala     |  |
| Ala      | Leu | Pro | Lys 100 | Asp     | Pro     | Glu    | Arg    | Cys    | Gly 105 | Cys     | Gly    | Arg | Pro 110 | Leu     | Ser     |  |
| Ala      | His | Thr | Pro 115 | Ala     | Ser     | Thr    | Phe    | Ser    | Thr 120 | Leu     | Pro    | Val | His 125 | Leu     |         |  |
| Leu      | Glu | Lys | Glu 130 | Gln     | Gln     | Thr    | Trp    | Thr    | Ile 135 | Ala     | Asn    | Asn | Thr 140 | Gln     | Thr     |  |
| Ser 145  | Thr | Thr | Asp     | Ala     | Phe 150 | Gly    | Thr    | Ile    | Val     | Phe 155 | Gln    | Gly | Gly     | Ala     | His 160 |  |
| Ala      | His | Lys | Ala 165 | Gln     | Tyr     | Val    | Arg    | Leu    | Ser 170 | Tyr     | Asp    | Ser | Glu     | Pro 175 | Leu     |  |
| Asp      | Val | Met | Tyr 180 | Leu     | Met     | Glu    | Lys    | Val    | Trp 185 | Gly     | Leu    | Glu | Ala 190 | Pro     | Arg     |  |
| Leu      | Val | Ile | Thr 195 | Val     | His     | Gly    | Gly    | Met    | Ser 200 | Asn     | Phe    | Glu | Leu 205 | Glu     | Glu     |  |
| Arg      | Leu | Gly | Arg 210 | Leu     | Phe     | Arg    | Lys    | Gly    | Met 215 | Leu     | Lys    | Ala | Ala 220 | Gln     | Thr     |  |
| Thr 225  | Gly | Ala | Trp     | Ile     | Ile 230 | Thr    | Ser    | Gly    | Leu     | Asp 235 | Ser    | Gly | Val     | Val     | Arg 240 |  |
| His      | Val | Ala | Lys 245 | Ala     | Leu     | Asp    | Glu    | Ala    | Gly 250 | Ile     | Ser    | Ala | Arg     | Met 255 | Arg     |  |
| Ser      | Gln | Ile | Val 260 | Thr     | Ile     | Gly    | Ile    | Ala    | Pro 265 | Trp     | Gly    | Val | Ile 270 | Lys     | Arg     |  |
| Lys      | Glu | Arg | Leu 275 | Ile     | Arg     | Gln    | Asn    | Glu    | His 280 | Val     | Tyr    | Tyr | Asp 285 | Val     | His     |  |
| Ser      | Leu | Ser | Val 290 | Asn     | Ala     | Asn    | Val    | Gly    | Ile     | Leu     | Asn    | Asp | Arg     | His     | Ser     |  |
| Tyr 305  | Phe | Leu | Leu     | Ala     | Asp 310 | Asn    | Gly    | Thr    | Val     | Gly     | Arg    | Phe | Gly     | Ala     | Asp 320 |  |
| Leu      | His | Leu | Arg     | Gln 325 | Asn     | Leu    | Glu    | Asn    | His 330 | Ile     | Ala    | Thr | Phe     | Gly     | Cys 335 |  |
| Asn      | Gly | Arg | Lys 340 | Val     | Pro     | Val    | Val    | Cys    | Thr 345 | Leu     | Leu    | Glu | Gly     | Gly     | Ile 350 |  |
| Ser      | Ser | Ile | Asn 355 | Ala     | Ile     | His    | Asp    | Tyr    | Val 360 | Thr     | Met    | Lys | Pro     | Asp     | Ile 365 |  |

-23-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Ala | Ile | Val | Cys | Asp | Gly | Ser | Gly | Arg | Ala | Ala | Asp | Ile | Ile | Ser |
| 370 |     |     |     |     |     | 375 |     |     |     | 380 |     |     |     |     |     |
| Phe | Ala | Ala | Arg | Tyr | Ile | Asn | Ser | Asp | Gly | Thr | Phe | Ala | Ala | Glu | Val |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Gly | Glu | Lys | Leu | Arg | Asn | Leu | Ile | Lys | Met | Val | Phe | Pro | Glu | Thr | Asp |
|     |     |     |     | 405 |     |     |     |     | 410 |     |     |     |     | 415 |     |
| Gln | Glu | Glu | Met | Phe | Arg | Lys | Ile | Thr | Glu | Cys | Val | Ile | Arg | Asp | Asp |
|     |     |     | 420 |     |     |     |     |     | 425 |     |     |     | 430 |     |     |
| Leu | Leu | Arg | Ile | Phe | Arg | Tyr | Gly | Gln | Glu | Glu | Glu | Glu | Asp | Val | Asp |
|     |     | 435 |     |     |     |     | 440 |     |     |     |     |     | 445 |     |     |
| Phe | Val | Ile | Leu | Ser | Thr | Val | Leu | Gln | Lys | Gln | Asn | Leu | Pro | Pro | Asp |
|     | 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Glu | Gln | Leu | Ala | Leu | Thr | Leu | Ser | Trp | Asn | Arg | Val | Asp | Leu | Ala | Lys |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Ser | Cys | Leu | Phe | Ser | Asn | Gly | Arg | Lys | Trp | Ser | Ser | Asp | Val | Leu | Glu |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Lys | Ala | Met | Asn | Asp | Ala | Leu | Tyr | Trp | Asp | Arg | Val | Asp | Phe | Val | Glu |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Cys | Leu | Leu | Glu | Asn | Gly | Val | Ser | Met | Lys | Asn | Phe | Leu | Ser | Ile | Asn |
|     |     | 515 |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| Arg | Leu | Glu | Asn | Leu | Tyr | Asn | Met | Asp | Asp | Ile | Asn | Ser | Ala | His | Ser |
|     | 530 |     |     |     |     | 535 |     |     |     |     |     | 540 |     |     |     |
| Val | Arg | Asn | Trp | Met | Glu | Asn | Phe | Asp | Ser | Met | Asp | Pro | His | Thr | Tyr |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Leu | Thr | Ile | Pro | Met | Ile | Gly | Gln | Val | Val | Glu | Lys | Leu | Met | Gly | Asn |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |
| Ala | Phe | Gln | Leu | Tyr | Tyr | Thr | Ser | Arg | Ser | Phe | Lys | Gly | Lys | Tyr | Asp |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Arg | Tyr | Lys | Arg | Ile | Asn | Gln | Ser | Ser | Tyr | Phe | His | Arg | Lys | Arg | Lys |
|     |     | 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |
| Ile | Val | Gln | Lys | Glu | Leu | Phe | Lys | Lys | Lys | Ser | Asp | Asp | Gln | Ile | Asn |
|     | 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |
| Asp | Asn | Glu | Glu | Glu | Asp | Phe | Ser | Phe | Ala | Tyr | Pro | Phe | Asn | Asp | Leu |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Leu | Ile | Trp | Ala | Val | Leu | Thr | Ser | Arg | His | Gly | Met | Ala | Glu | Cys | Met |
|     |     |     | 645 |     |     |     |     |     | 650 |     |     |     |     | 655 |     |
| Trp | Val | His | Gly | Glu | Asp | Ala | Met | Ala | Lys | Cys | Leu | Leu | Ala | Ile | Arg |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Leu | Tyr | Lys | Ala | Thr | Ala | Lys | Ile | Ala | Glu | Asp | Glu | Tyr | Leu | Asp | Val |
|     |     | 675 |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |
| Glu | Glu | Ala | Lys | Arg | Leu | Phe | Asp | Asn | Ala | Val | Lys | Cys | Arg | Glu | Asp |
|     | 690 |     |     |     |     | 695 |     |     |     |     | 700 |     |     |     |     |
| Ala | Ile | Glu | Leu | Leu | Asp | Gln | Cys | Tyr | Arg | Ala | Asp | His | Asp | Arg | Thr |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     |     | 720 |
| Leu | Arg | Leu | Leu | Arg | Met | Glu | Leu | Pro | His | Trp | Gly | Asn | Asn | Asn | Cys |
|     |     |     | 725 |     |     |     |     |     | 730 |     |     |     |     | 735 |     |
| Leu | Ser | Leu | Ala | Val | Leu | Ala | Asn | Thr | Lys | Thr | Phe | Leu | Ala | His | Pro |
|     |     |     | 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |
| Cys | Cys | Gln | Ile | Leu | Leu | Ala | Glu | Leu | Trp | His | Gly | Ser | Leu | Lys | Val |
|     |     | 755 |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |
| Arg | Ser | Gly | Ser | Asn | Val | Arg | Val | Leu | Thr | Ala | Leu | Ile | Cys | Pro | Pro |
|     | 770 |     |     |     |     | 775 |     |     |     |     | 780 |     |     |     |     |
| Ala | Ile | Leu | Phe | Met | Ala | Tyr | Lys | Pro | Lys | His | Ser | Lys | Thr | Ala | Arg |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     |     | 800 |
| Leu | Leu | Ser | Glu | Glu | Thr | Pro | Glu | Gln | Leu | Pro | Tyr | Pro | Arg | Glu | Ser |
|     |     |     | 805 |     |     |     |     |     | 810 |     |     |     |     | 815 |     |
| Ile | Thr | Ser | Thr | Ser | Asn | Arg | Tyr | Arg | Tyr | Ser | Lys | Gly | Pro | Glu |     |
|     |     |     | 820 |     |     |     | 825 |     |     |     |     | 830 |     |     |     |
| Glu | Gln | Lys | Glu | Thr | Leu | Leu | Glu | Lys | Gly | Ser | Tyr | Thr | Lys | Lys | Val |
|     |     | 835 |     |     |     |     | 840 |     |     |     |     | 845 |     |     |     |

-24-

Thr Ile Ile Ser Ser Arg Lys Asn Ser Gly Val Ala Ser Val Tyr Gly  
 850 855 860  
 Ser Ala Ser Ser Met Met Phe Lys Arg Glu Pro Gln Leu Asn Lys Phe  
 865 870 875 880  
 Glu Arg Phe Arg Ala Phe Tyr Ser Ser Pro Ile Thr Lys Phe Trp Ser  
 885 890 895  
 Trp Cys Ile Ala Phe Leu Ile Phe Leu Thr Thr Gln Thr Cys Ile Leu  
 900 905 910  
 Leu Leu Glu Thr Ser Leu Lys Pro Ser Lys Tyr Glu Trp Ile Thr Phe  
 915 920 925  
 Ile Tyr Thr Val Thr Leu Ser Val Glu His Ile Arg Lys Leu Met Thr  
 930 935 940  
 Ser Glu Gly Ser Arg Ile Asn Glu Lys Val Lys Val Phe Tyr Ala Lys  
 945 950 955 960  
 Trp Tyr Asn Ile Trp Thr Ser Ala Ala Leu Leu Phe Phe Leu Val Gly  
 965 970 975  
 Tyr Gly Phe Arg Leu Val Pro Met Tyr Arg His Ser Trp Gly Arg Val  
 980 985 990  
 Leu Leu Ser Phe Ser Asn Val Leu Phe Tyr Met Lys Ile Phe Glu Tyr  
 995 1000 1005  
 Leu Ser Val His Pro Leu Leu Gly Pro Tyr Ile Gln Met Ala Ala Lys  
 1010 1015 1020  
 Met Val Trp Ser Met Cys Tyr Ile Cys Val Leu Leu Leu Val Pro Leu  
 1025 1030 1035 104  
 Met Ala Phe Gly Val Asn Arg Gln Ala Leu Thr Glu Pro Asn Val Lys  
 1045 1050 1055  
 Asp Trp His Trp Leu Leu Val Arg Asn Ile Phe Tyr Lys Pro Tyr Phe  
 1060 1065 1070  
 Met Leu Tyr Gly Glu Val Tyr Ala Gly Glu Ile Asp Thr Cys Gly Asp  
 1075 1080 1085  
 Glu Gly Ile Arg Cys Phe Pro Gly Tyr Phe Ile Pro Pro Leu Leu Met  
 1090 1095 1100  
 Val Ile Phe Leu Leu Val Ala Asn Ile Leu Leu Leu Asn Leu Leu Ile  
 1105 1110 1115 112  
 Ala Ile Phe Asn Asn Ile Tyr Asn Asp Ser Ile Glu Lys Ser Lys Glu  
 1125 1130 1135  
 Ile Trp Leu Phe Gln Arg Tyr Gln Gln Leu Met Glu Tyr His Asp Ser  
 1140 1145 1150  
 Pro Phe Leu Pro Pro Phe Ser Ile Phe Ala His Val Tyr His Phe  
 1155 1160 1165  
 Ile Asp Tyr Leu Tyr Asn Leu Arg Arg Pro Asp Thr Lys Arg Phe Arg  
 1170 1175 1180  
 Ser Glu His Ser Ile Lys Leu Ser Val Thr Glu Asp Glu Met Lys Arg  
 1185 1190 1195 120  
 Ile Gln Asp Phe Glu Glu Asp Cys Ile Asp Thr Leu Thr Arg Ile Arg  
 1205 1210 1215  
 Lys Leu Lys Leu Asn Thr Lys Glu Pro Leu Ser Val Thr Asp Leu Thr  
 1220 1225 1230  
 Glu Leu Thr Cys Gln Arg Val His Asp Leu Met Gln Glu Asn Phe Leu  
 1235 1240 1245  
 Leu Lys Ser Arg Val Tyr Asp Ile Glu Thr Lys Ile Asp His Ile Ser  
 1250 1255 1260  
 Asn Ser Ser Asp Glu Val Val Gln Ile Leu Lys Asn Lys Lys Leu Ser  
 1265 1270 1275 128  
 Gln Asn Phe Ala Ala Ser Ser Leu Ser Leu Pro Asp Thr Ser Ile Glu  
 1285 1290 1295  
 Val Pro Lys Ile Thr Lys Thr Leu Ile Asp Cys His Leu Ser Pro Val  
 1300 1305 1310  
 Ser Ile Glu Asp Arg Leu Ala Thr Arg Ser Pro Leu Leu Ala Asn Leu  
 1315 1320 1325

-25-

Gln Arg Asp His Thr Leu Arg Lys Leu Pro Thr Trp Glu Thr Ser Thr  
 1330 1335 1340  
 Ala Ser Thr Ser Ser Phe Glu Phe Val Phe Tyr Phe Thr Arg His Glu  
 1345 1350 1355 136  
 Gly Asn Glu Asn Lys Tyr Glu Phe Lys Lys Leu Glu Lys Gly Gly Phe  
 1365 1370 1375  
 Trp Arg Asn Asn Tyr Val Ile Ser Trp Arg Leu  
 1380 1385

<210> 15  
 <211> 1868  
 <212> PRT  
 <213> C. Elegans

<400> 15  
 Met Asn Leu Cys Tyr Arg Arg His Arg Tyr Ala Ser Ser Pro Glu Val  
 1 5 10 15  
 Trp Cys Thr Met Glu Ser Asp Glu Leu Gly Val Thr Arg Tyr Leu Gln  
 20 25 30  
 Ser Lys Gly Gly Asp Gln Val Pro Pro Thr Ser Thr Thr Thr Gly Gly  
 35 40 45  
 Ala Gly Gly Asp Gly Asn Ala Val Pro Thr Thr Ser Gln Ala Gln Ala  
 50 55 60  
 Gln Thr Phe Asn Ser Gly Arg Gln Thr Thr Gly Met Ser Ser Gly Asp  
 65 70 75 80  
 Arg Leu Asn Glu Asp Val Ser Ala Thr Ala Asn Ser Ala Gln Leu Val  
 85 90 95  
 Leu Pro Thr Pro Leu Phe Asn Gln Met Arg Phe Thr Glu Ser Asn Met  
 100 105 110  
 Ser Leu Asn Arg His Asn Trp Val Arg Glu Thr Phe Thr Arg Arg Glu  
 115 120 125  
 Cys Ser Arg Phe Ile Ala Ser Ser Arg Asp Leu His Lys Cys Gly Cys  
 130 135 140  
 Gly Arg Thr Arg Asp Ala His Arg Asn Ile Pro Glu Leu Thr Ser Glu  
 145 150 155 160  
 Phe Leu Arg Gln Lys Arg Ser Val Ala Ala Leu Glu Gln Gln Arg Ser  
 165 170 175  
 Ile Ser Asn Val Asn Asp Asp Ile Asn Thr Gln Asn Met Tyr Thr Lys  
 180 185 190  
 Arg Gly Ala Asn Glu Lys Trp Ser Leu Arg Lys His Thr Val Ser Leu  
 195 200 205  
 Ala Thr Asn Ala Phe Gly Gln Val Glu Phe Gln Gly Gly Pro His Pro  
 210 215 220  
 Tyr Lys Ala Gln Tyr Val Arg Val Asn Phe Asp Thr Glu Pro Ala Tyr  
 225 230 235 240  
 Ile Met Ser Leu Phe Glu His Val Trp Gln Ile Ser Pro Pro Arg Leu  
 245 250 255  
 Ile Ile Thr Val His Gly Gly Thr Ser Asn Phe Asp Leu Gln Pro Lys  
 260 265 270  
 Leu Ala Arg Val Phe Arg Lys Gly Leu Leu Lys Ala Ala Ser Thr Thr  
 275 280 285  
 Gly Ala Trp Ile Ile Thr Ser Gly Cys Asp Thr Gly Val Val Lys His  
 290 295 300  
 Val Ala Ala Ala Leu Glu Gly Ala Gln Ser Ala Gln Arg Asn Lys Ile  
 305 310 315 320  
 Val Cys Ile Gly Ile Ala Pro Trp Gly Leu Leu Lys Lys Arg Glu Asp  
 325 330 335  
 Phe Ile Gly Gln Asp Lys Thr Val Pro Tyr Tyr Pro Ser Ser Ser Lys  
 340 345 350  
 Gly Arg Phe Thr Gly Leu Asn Asn Arg His Ser Tyr Phe Leu Leu Val

-26-

|   |     |     |
|---|-----|-----|
| 355   | 360 | 365 |
| Asp Asn Gly Thr Val Gly Arg Tyr Gly Ala Glu Val Ile Leu Arg Lys |     |     |
| 370   | 375 | 380 |
| Arg Leu Glu Met Tyr Ile Ser Gln Lys Gln Lys Ile Phe Gly Gly Thr |     |     |
| 385   | 390 | 395 |
| Arg Ser Val Pro Val Val Cys Val Val Leu Glu Gly Gly Ser Cys Thr |     |     |
| 405   | 410 | 415 |
| Ile Arg Ser Val Leu Asp Tyr Val Thr Asn Val Pro Arg Val Pro Val |     |     |
| 420   | 425 | 430 |
| Val Val Cys Asp Gly Ser Gly Arg Ala Ala Asp Leu Leu Ala Phe Ala |     |     |
| 435   | 440 | 445 |
| His Gln Asn Val Thr Glu Asp Gly Leu Leu Pro Asp Asp Ile Arg Arg |     |     |
| 450   | 455 | 460 |
| Gln Val Leu Leu Leu Val Glu Thr Thr Phe Gly Cys Ser Glu Ala Ala |     |     |
| 465   | 470 | 475 |
| Ala His Arg Leu Leu His Glu Leu Thr Val Cys Ala Gln His Lys Asn |     |     |
| 485   | 490 | 495 |
| Leu Leu Thr Ile Phe Arg Leu Gly Glu Gln Gly Glu His Asp Val Asp |     |     |
| 500   | 505 | 510 |
| His Ala Ile Leu Thr Ala Leu Leu Lys Gly Gln Asn Leu Ser Ala Ala |     |     |
| 515   | 520 | 525 |
| Asp Gln Leu Ala Leu Ala Leu Ala Trp Asn Arg Val Asp Ile Ala Arg |     |     |
| 530   | 535 | 540 |
| Ser Asp Val Phe Ala Met Gly His Glu Trp Pro Gln Ala Ala Leu His |     |     |
| 545   | 550 | 555 |
| Asn Ala Met Met Glu Ala Leu Ile His Asp Arg Val Asp Phe Val Arg |     |     |
| 565   | 570 | 575 |
| Leu Leu Leu Glu Gln Gly Ile Asn Met Gln Lys Phe Leu Thr Ile Ser |     |     |
| 580   | 585 | 590 |
| Arg Leu Asp Glu Leu Tyr Asn Thr Asp Lys Gly Pro Pro Asn Thr Leu |     |     |
| 595   | 600 | 605 |
| Phe Tyr Ile Val Arg Asp Val Val Arg Val Arg Gln Gly Tyr Arg Phe |     |     |
| 610   | 615 | 620 |
| Lys Leu Pro Asp Ile Gly Leu Val Ile Glu Lys Leu Met Gly Asn Ser |     |     |
| 625   | 630 | 635 |
| Tyr Gln Cys Ser Tyr Thr Thr Ser Glu Phe Arg Asp Lys Tyr Lys Gln |     |     |
| 645   | 650 | 655 |
| Arg Met Lys Arg Val Lys His Ala Gln Lys Lys Ala Met Gly Val Phe |     |     |
| 660   | 665 | 670 |
| Ser Ser Arg Pro Ser Arg Thr Gly Ser Gly Ile Ala Ser Arg Gln Ser |     |     |
| 675   | 680 | 685 |
| Thr Glu Gly Met Gly Gly Val Gly Gly Gly Ser Ser Val Ala Gly Val |     |     |
| 690   | 695 | 700 |
| Phe Gly Asn Ser Phe Gly Asn Gln Asp Pro Pro Leu Asp Pro His Val |     |     |
| 705   | 710 | 715 |
| Asn Arg Ser Ala Leu Ser Gly Ser Arg Ala Leu Ser Asn His Ile Leu |     |     |
| 725   | 730 | 735 |
| Trp Arg Ser Ala Phe Arg Gly Asn Phe Pro Ala Asn Pro Met Arg Pro |     |     |
| 740   | 745 | 750 |
| Pro Asn Leu Gly Asp Ser Arg Asp Cys Gly Ser Glu Phe Asp Glu Glu |     |     |
| 755   | 760 | 765 |
| Leu Ser Leu Thr Ser Ala Ser Asp Gly Ser Gln Thr Glu Pro Asp Phe |     |     |
| 770   | 775 | 780 |
| Arg Tyr Pro Tyr Ser Glu Leu Met Ile Trp Ala Val Leu Thr Lys Arg |     |     |
| 785   | 790 | 795 |
| Gln Asp Met Ala Met Cys Met Trp Gln His Gly Glu Glu Ala Met Ala |     |     |
| 805   | 810 | 815 |
| Lys Ala Leu Val Ala Cys Arg Leu Tyr Lys Ser Leu Ala Thr Glu Ala |     |     |
| 820   | 825 | 830 |
| Ala Glu Asp Tyr Leu Glu Val Glu Ile Cys Glu Glu Leu Lys Lys Tyr |     |     |

-27-

|   |      |      |
|---|------|------|
| 835   | 840  | 845  |
| Ala Glu Glu Phe Arg Ile Leu Ser Leu Glu Leu Leu Asp His Cys Tyr |      |      |
| 850   | 855  | 860  |
| His Val Asp Asp Ala Gln Thr Leu Gln Leu Leu Thr Tyr Glu Leu Ser |      |      |
| 865   | 870  | 875  |
| Asn Trp Ser Asn Glu Thr Cys Leu Ala Leu Ala Val Ile Val Asn Asn |      |      |
| 885   | 890  | 895  |
| Lys His Phe Leu Ala His Pro Cys Cys Gln Ile Leu Leu Ala Asp Leu |      |      |
| 900   | 905  | 910  |
| Trp His Gly Gly Leu Arg Met Arg Thr His Ser Asn Ile Lys Val Val |      |      |
| 915   | 920  | 925  |
| Leu Gly Leu Ile Cys Pro Pro Phe Ile Gln Met Leu Glu Phe Lys Thr |      |      |
| 930   | 935  | 940  |
| Arg Glu Glu Leu Leu Asn Gln Pro Gln Thr Ala Ala Glu His Gln Asn |      |      |
| 945   | 950  | 955  |
| Asp Met Asn Tyr Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser     |      |      |
| 965   | 970  | 975  |
| Ser Ser Ser Ser Ser Asp Ser Ser Ser Phe Glu Asp Asp Asp Asp Glu |      |      |
| 980   | 985  | 990  |
| Asn Asn Ala His Asn His Asp Gln Lys Arg Thr Arg Lys Thr Ser Gln |      |      |
| 995   | 1000 | 1005 |
| Gly Ser Ala Gln Ser Leu Asn Ile Thr Ser Leu Phe His Ser Arg Arg |      |      |
| 1010  | 1015 | 1020 |
| Arg Lys Ala Lys Lys Asn Glu Lys Cys Asp Arg Glu Thr Asp Ala Ser |      |      |
| 1025  | 1030 | 1035 |
| Ala Cys Glu Ala Gly Asn Arg Gln Ile Gln Asn Gly Gly Leu Thr Ala |      |      |
| 1045  | 1050 | 1055 |
| Glu Tyr Gly Thr Phe Gly Glu Ser Asn Gly Val Ser Pro Pro Pro Pro |      |      |
| 1060  | 1065 | 1070 |
| Tyr Met Arg Ala Asn Ser Arg Ser Arg Tyr Asn Asn Arg Ser Asp Met |      |      |
| 1075  | 1080 | 1085 |
| Ser Lys Thr Ser Ser Val Ile Phe Gly Ser Asp Pro Asn Leu Ser Lys |      |      |
| 1090  | 1095 | 1100 |
| Leu Gln Lys Ser Asn Ile Thr Ser Thr Asp Arg Pro Asn Pro Met Glu |      |      |
| 1105  | 1110 | 1115 |
| Gln Phe Gln Gly Thr Arg Lys Ile Lys Met Arg Arg Arg Phe Tyr Glu |      |      |
| 1125  | 1130 | 1135 |
| Phe Tyr Ser Ala Pro Ile Ser Thr Phe Trp Ser Trp Thr Ile Ser Phe |      |      |
| 1140  | 1145 | 1150 |
| Ile Leu Phe Ile Thr Phe Phe Thr Tyr Thr Leu Leu Val Lys Thr Pro |      |      |
| 1155  | 1160 | 1165 |
| Pro Arg Pro Thr Val Ile Glu Tyr Ile Leu Ile Ala Tyr Val Ala Ala |      |      |
| 1170  | 1175 | 1180 |
| Phe Gly Leu Glu Gln Val Arg Lys Ile Ile Met Ser Asp Ala Lys Pro |      |      |
| 1185  | 1190 | 1195 |
| Phe Tyr Glu Lys Ile Arg Thr Tyr Val Cys Ser Phe Trp Asn Cys Val |      |      |
| 1205  | 1210 | 1215 |
| Thr Ile Leu Ala Ile Ile Phe Tyr Ile Val Gly Phe Phe Met Arg Cys |      |      |
| 1220  | 1225 | 1230 |
| Phe Gly Ser Val Ala Tyr Gly Arg Val Ile Leu Ala Cys Asp Ser Val |      |      |
| 1235  | 1240 | 1245 |
| Leu Trp Thr Met Lys Leu Leu Asp Tyr Met Ser Val His Pro Lys Leu |      |      |
| 1250  | 1255 | 1260 |
| Gly Pro Tyr Val Thr Met Ala Gly Lys Met Ile Gln Asn Met Ser Tyr |      |      |
| 1265  | 1270 | 1275 |
| Ile Ile Val Met Leu Val Val Thr Leu Leu Ser Phe Gly Leu Ala Arg |      |      |
| 1285  | 1290 | 1295 |
| Gln Ser Ile Thr Tyr Pro Asp Glu Thr Trp His Trp Ile Leu Val Arg |      |      |
| 1300  | 1305 | 1310 |
| Asn Ile Phe Leu Lys Pro Tyr Phe Met Leu Tyr Gly Glu Val Tyr Ala |      |      |



|   |      |      |
|---|------|------|
| 1315  | 1320 | 1325 |
| Asp Glu Ile Asp Thr Cys Gly Asp Glu Ala Trp Asp Gln His Leu Glu |      |      |
| 1330  | 1335 | 1340 |
| Asn Gly Gly Pro Val Ile Leu Gly Asn Gly Thr Thr Gly Leu Ser Cys |      |      |
| 1345  | 1350 | 1355 |
| Val Pro Gly Tyr Trp Ile Pro Pro Leu Leu Met Thr Phe Phe Leu Leu |      |      |
| 1365  | 1370 | 1375 |
| Ile Ala Asn Ile Leu Leu Met Ser Met Leu Ile Ala Ile Phe Asn His |      |      |
| 1380  | 1385 | 1390 |
| Ile Phe Asp Ala Thr Asp Glu Met Ser Gln Gln Ile Trp Leu Phe Gln |      |      |
| 1395  | 1400 | 1405 |
| Arg Tyr Lys Gln Val Met Glu Tyr Glu Ser Thr Pro Phe Leu Pro Pro |      |      |
| 1410  | 1415 | 1420 |
| Pro Leu Thr Pro Leu Tyr His Gly Val Leu Ile Leu Gln Phe Val Arg |      |      |
| 1425  | 1430 | 1435 |
| Thr Arg Leu Ser Cys Ser Lys Ser Gln Glu Arg Asn Pro Ile Leu Leu |      |      |
| 1445  | 1450 | 1455 |
| Leu Lys Ile Ala Glu Leu Phe Leu Asp Asn Asp Gln Ile Glu Lys Leu |      |      |
| 1460  | 1465 | 1470 |
| His Asp Phe Glu Glu Asp Cys Met Glu Asp Leu Ala Arg Gln Lys Leu |      |      |
| 1475  | 1480 | 1485 |
| Asn Glu Lys Asn Thr Ser Asn Glu Gln Arg Ile Leu Arg Ala Asp Ile |      |      |
| 1490  | 1495 | 1500 |
| Arg Thr Asp Gln Ile Leu Asn Arg Leu Ile Asp Leu Gln Ala Lys Glu |      |      |
| 1505  | 1510 | 1515 |
| Ser Met Gly Arg Asp Val Ile Asn Asp Val Glu Ser Arg Leu Ala Ser |      |      |
| 1525  | 1530 | 1535 |
| Val Glu Lys Ala Gln Asn Glu Ile Leu Glu Cys Val Arg Ala Leu Leu |      |      |
| 1540  | 1545 | 1550 |
| Asn Gln Asn Asn Ala Pro Thr Ala Ile Gly Arg Cys Phe Ser Pro Ser |      |      |
| 1555  | 1560 | 1565 |
| Pro Asp Pro Leu Val Glu Thr Ala Asn Gly Thr Pro Gly Pro Leu Leu |      |      |
| 1570  | 1575 | 1580 |
| Leu Lys Leu Pro Gly Thr Asp Pro Ile Leu Glu Glu Lys Asp His Asp |      |      |
| 1585  | 1590 | 1595 |
| Ser Gly Glu Asn Ser Asn Ser Leu Pro Pro Gly Arg Ile Arg Arg Asn |      |      |
| 1605  | 1610 | 1615 |
| Arg Thr Ala Thr Ile Cys Gly Gly Tyr Val Ser Glu Glu Arg Asn Met |      |      |
| 1620  | 1625 | 1630 |
| Met Leu Leu Ser Pro Lys Pro Ser Asp Val Ser Gly Ile Pro Gln Gln |      |      |
| 1635  | 1640 | 1645 |
| Arg Leu Met Ser Val Thr Ser Met Asp Pro Leu Pro Leu Pro Leu Ala |      |      |
| 1650  | 1655 | 1660 |
| Lys Leu Ser Thr Met Ser Ile Arg Arg Arg His Glu Glu Tyr Thr Ser |      |      |
| 1665  | 1670 | 1675 |
| Ile Thr Asp Ser Ile Ala Ile Arg His Pro Glu Arg Arg Ile Arg Asn |      |      |
| 1685  | 1690 | 1695 |
| Asn Arg Ser Asn Ser Ser Glu His Asp Glu Ser Ala Val Asp Ser Glu |      |      |
| 1700  | 1705 | 1710 |
| Gly Gly Gly Asn Val Thr Ser Ser Pro Arg Lys Arg Ser Thr Arg Asp |      |      |
| 1715  | 1720 | 1725 |
| Leu Arg Met Thr Pro Ser Ser Gln Val Glu Glu Ser Thr Ser Arg Asp |      |      |
| 1730  | 1735 | 1740 |
| Gln Ile Phe Glu Ile Asp His Pro Glu His Glu Glu Asp Glu Ala Gln |      |      |
| 1745  | 1750 | 1755 |
| Ala Asp Cys Glu Leu Thr Asp Val Ile Thr Glu Glu Glu Asp Glu Glu |      |      |
| 1765  | 1770 | 1775 |
| Glu Asp Asp Glu Glu Asp Asp Ser His Glu Arg His His Ile His Pro |      |      |
| 1780  | 1785 | 1790 |
| Arg Arg Lys Ser Ser Arg Gln Asn Arg Gln Pro Ser His Thr Leu Glu |      |      |

-29-

1795                      1800                      1805  
 Thr Asp Leu Ser Glu Gly Glu Glu Val Asp Pro Leu Asp Val Leu Lys  
 1810                      1815                      1820  
 Met Lys Glu Leu Pro Ile Ile His Gln Ile Leu Asn Glu Glu Glu Gln  
 1825                      1830                      1835                      184  
 Ala Gly Ala Pro His Ser Thr Pro Val Ile Ala Ser Pro Ser Ser Ser  
 1845                      1850                      1855  
 Arg Ala Asp Leu Thr Ser Gln Lys Cys Ser Asp Val  
 1860                      1865

<210> 16  
 <211> 489  
 <212> DNA  
 <213> Mus Musculus

<400> 16  
 cccTgaaaga ctcgacttct gctgctagcg ctggagctga gttagttttg agaagggttc 60  
 ccggggctgt ccttggtcgg tggcccgTgc caccgcctcc ggagacgctt tccgatagat 120  
 ggctgcaggc cgcggagggtg gaggaggagc cgctgccctt ccggagtcgg ccccgTgagg 180  
 agaatgtccc agaaatcctg gatagagagc actttgacca agagggagtg Tgtatatatt 240  
 ataccaagct ccaaagaccc tcacagatgt cttccaggat gtcagatttg tcagcaactt 300  
 gtCagatgtt tctgtggtcg tttggtcaag caacatgcTat gctttactgc aagtcttgcc 360  
 atgaaatact cagatgtgaa attgggtgaa cactttaacc aggcaataga agaatggtct 420  
 gtggaagc acacggagca gagcccaaca gatgcttatg gagtcatcaa ttttcaaggg 480  
 ggttctcat 489

<210> 17  
 <211> 102  
 <212> PRT  
 <213> Mus Musculus

<400> 17  
 Met Ser Gln Lys Ser Trp Ile Glu Ser Thr Leu Thr Lys Arg Glu Cys  
 1                      5                      10                      15  
 Val Tyr Ile Ile Pro Ser Ser Lys Asp Pro His Arg Cys Leu Pro Gly  
 20                      25                      30  
 Cys Gln Ile Cys Gln Gln Leu Val Arg Cys Phe Cys Gly Arg Leu Val  
 35                      40                      45  
 Lys Gln His Ala Cys Phe Thr Ala Ser Leu Ala Met Lys Tyr Ser Asp  
 50                      55                      60  
 Val Lys Leu Gly Glu His Phe Asn Gln Ala Ile Glu Glu Trp Ser Val  
 65                      70                      75                      80  
 Glu Lys His Thr Glu Gln Ser Pro Thr Asp Ala Tyr Gly Val Ile Asn  
 85                      90                      95  
 Phe Gln Gly Gly Ser His  
 100

<210> 18  
 <211> 410  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> unsure  
 <222> (6)...(6)  
 <221> unsure  
 <222> (58)...(58)  
 <221> unsure

-30-

&lt;222&gt; (89)...(89)

&lt;221&gt; unsure

&lt;222&gt; (406)...(406)

&lt;400&gt; 18

|            |            |            |            |             |            |     |
|------------|------------|------------|------------|-------------|------------|-----|
| gccgcnggag | cctgagcggg | gggtgtgctc | agcctcgcca | gcggggggccc | cgggctgngc | 60  |
| cattgcctca | ctgagccagc | gcctgcctnc | tacctcgccg | acagctggaa  | ccagtgcgac | 120 |
| ctagtggctc | tcacctgctt | cctcctgggc | gtgggctgcc | ggctgacccc  | gggtttgtac | 180 |
| caacctgggc | gcactgtcct | ctgcatcgac | ttcatgggtt | tcacgggtgc  | gctgcttcac | 240 |
| atcttcacgg | tcaacaaaca | gctggggccc | aagatcgta  | tcgtgagcaa  | gatgatgaag | 300 |
| gacgtgttct | tcttcctctt | cttcctcggc | gtgtggctgg | tagctatggg  | ttgggccacg | 360 |
| gaggggttcc | tgaggccacg | ggacagtgc  | ttcccaagta | tcctgncgcc  |            | 410 |

&lt;210&gt; 19

&lt;211&gt; 131

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (15)...(15)

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (25)...(25)

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (131)...(131)

&lt;223&gt; UNKNOWN

&lt;400&gt; 19

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Glu | Gly | Val | Arg | Ser | Leu | Ala | Ser | Gly | Gly | Pro | Gly | Leu | Xaa | His |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Cys | Leu | Thr | Glu | Pro | Ala | Pro | Ala | Xaa | Tyr | Leu | Ala | Asp | Ser | Trp | Asn |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Gln | Cys | Asp | Leu | Val | Ala | Leu | Thr | Cys | Phe | Leu | Leu | Gly | Val | Gly | Cys |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Arg | Leu | Thr | Pro | Gly | Leu | Tyr | His | Leu | Gly | Arg | Thr | Val | Leu | Cys | Ile |
|     |     | 50  |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Asp | Phe | Met | Val | Phe | Thr | Val | Arg | Leu | Leu | His | Ile | Phe | Thr | Val | Asn |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Lys | Gln | Leu | Gly | Pro | Lys | Ile | Val | Ile | Val | Ser | Lys | Met | Met | Lys | Asp |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Val | Phe | Phe | Phe | Leu | Phe | Phe | Leu | Gly | Val | Trp | Leu | Val | Ala | Met | Gly |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Trp | Ala | Thr | Glu | Gly | Phe | Leu | Arg | Pro | Arg | Asp | Ser | Asp | Phe | Pro | Ser |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Ile | Leu | Xaa |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 130 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

&lt;210&gt; 20

&lt;211&gt; 389

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 20

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| caaatttttt | gttagtacac | catctcatcc | aaattgcaaa | agtcacatgg | aaactggaac | 60  |
| caaagatcaa | gaaactgttt | gctctaaagc | tacagaagga | gataatacag | aatttgagac | 120 |

-31-

|              |            |            |            |            |            |     |
|--------------|------------|------------|------------|------------|------------|-----|
| attttagtagga | cacagagata | gcatggattt | acagagggtt | aaagaaacat | caaacaagat | 180 |
| aaaaataacta  | tccaataaca | atacttctga | aaacactttg | aaacgagtga | gttctcttgc | 240 |
| tggatttact   | gactgtcaca | gaacttccat | tcctgttcat | tcaaaacgag | aaaagatcag | 300 |
| tagaaggcca   | tctaccgaag | acactcatga | agtagattcc | aaagcagctt | taataccggt | 360 |
| ttgtagattt   | caactaaaca | gatatatat  |            |            |            | 389 |

&lt;210&gt; 21

&lt;211&gt; 415

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 21

|             |            |            |            |            |             |     |
|-------------|------------|------------|------------|------------|-------------|-----|
| atttctagtt  | tttcaaattt | gccagtcttt | ttgaatagta | tctccttctt | ttctcatggt  | 60  |
| ttatatattaa | aactttttta | tgtccatcat | cacttttaac | atacttattt | tgatcatctat | 120 |
| aaccaataat  | tccactatct | tatcagaaat | caaataccgt | ttatgtaagt | tgactcccat  | 180 |
| gagttctaaa  | ttgccattgt | gaggtcatct | tcggttaggc | tttaatttgt | tgcaaagttg  | 240 |
| tgcagctcag  | ggtcaggaag | agtccctcca | gaaaggagga | tttgttactg | tgaatctctt  | 300 |
| tgtttaactaa | cctctttccc | cactgaaata | acttttttca | ataacatgat | tttaacaaca  | 360 |
| taatctctct  | atgccagaac | agatatatat | gaatgtaagt | caatattttc | ttgag       | 415 |

&lt;210&gt; 22

&lt;211&gt; 405

&lt;212&gt; DNA

&lt;213&gt; Mus Musculus

&lt;400&gt; 22

|             |            |            |            |            |            |     |
|-------------|------------|------------|------------|------------|------------|-----|
| ttattatggc  | ttatcatgaa | aaaccagtcc | tgccctctcc | tcttatcatc | ctcagccata | 60  |
| tagtttcaact | gttttgcgtg | gtatgcaaaa | gaagaaagaa | agataagact | tccgatgggc | 120 |
| caaaaactttt | cttaacagaa | gaagatcaaa | agaaactcca | tgattttgaa | gagcagtgtg | 180 |
| ttgagatgta  | ctttgatgag | aaagatgaca | aattcaattc | tgggagtga  | gagagaatcc | 240 |
| gggtcacttt  | tgaagagtg  | gagcagatga | gcattcagat | taaagaagtt | ggagatcgtg | 300 |
| tcaactacat  | aaaaagatca | ttacagtctt | tagattctca | aattggtcac | ctgcaagatc | 360 |
| tctcagccct  | aacagtagat | acattgaaaa | cacttacagc | ccaga      |            | 405 |

&lt;210&gt; 23

&lt;211&gt; 5117

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (2382)...(2382)

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; (4664)...(4664)

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; (4682)...(4682)

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; (4702)...(4702)

&lt;223&gt; unknown

&lt;221&gt; unsure

&lt;222&gt; (5038)...(5039)

&lt;223&gt; unknown

<221> unsure  
 <222> (5056)... (5056)  
 <223> unknown

<221> unsure  
 <222> (5071)... (5072)

<400> 23

|             |             |            |            |            |            |      |
|-------------|-------------|------------|------------|------------|------------|------|
| gatggcaaca  | tgggtgaagaa | tcaatggcta | aagcattagt | tgcctgtaag | atctatcggt | 60   |
| caatggcata  | tgaagcaaa   | cagagtgaac | tggtagatga | tacttcagaa | gaactaaaac | 120  |
| agtattccaa  | tgattttgg   | cagttggccg | ttgaattatt | agaacagtc  | ttcagacaag | 180  |
| atgaaacat   | ggctatgaaa  | ttgctcactt | atgaactgaa | gaactggagt | aattcaacct | 240  |
| gccttaagtt  | agcagtttct  | tcaagactta | gaccttttgt | agctcacacc | tgtacacaaa | 300  |
| tggtgttatc  | tgatatgtgg  | atgggaaggc | tgaatatgag | gaaaaattcc | tggtacaagg | 360  |
| tcatactaag  | cattttagtt  | ccacctgcca | tattgctggt | agagtataaa | actaaggctg | 420  |
| aaatgtccca  | tatcccacaa  | tctcaagatg | ctcatcagat | gacaatggat | gacagcgaaa | 480  |
| acaactttca  | gaacataaca  | gaagagatcc | ccatggaagt | gtttaaagaa | gtacggattt | 540  |
| tgatattcaa  | tgaaggaaa   | aatgagatgg | agatacaaat | gaaatcaaaa | aagcttccaa | 600  |
| ttacgcgaaa  | gttttatgcc  | ttttatcatg | caccaattgt | aaaattctgg | tttaacacgt | 660  |
| tggtcatatt  | aggattttct  | atgctttata | catttgggtg | tcttgtacaa | atggaacagt | 720  |
| taccttcagt  | tcaagaatgg  | attgttattg | cttatatttt | tacttatgcc | attgagaaa  | 780  |
| tccgtgagat  | ctttatgtct  | gaagctggga | aagtaaacca | gaagattaaa | gtatggttta | 840  |
| gtgattactt  | caacatcagt  | gatacaattg | ccataatttc | tttcttcatt | ggatttggac | 900  |
| taagatttgg  | agcaaaatgg  | aactttgcaa | atgcataatg | taatcatgtt | tttgtggctg | 960  |
| gaagattaat  | ttactgtctt  | aacataatat | tttggtatgt | gcgcttgcta | gattttctag | 1020 |
| ctgtaaatca  | acaggcagga  | ccttatgtaa | tgatgattgg | aaaaatggtg | gccaatatgt | 1080 |
| tctacattgt  | agtgattatg  | gctcttgtat | tacttagttt | tggtgttccc | agaaaggcaa | 1140 |
| tactttatcc  | tcatgaagca  | ccatcttgga | ctcttgctaa | agatatagtt | tttcacccat | 1200 |
| actggatgat  | ttttggtgaa  | gtttatgcat | acgaaattga | tgtgtgtgca | aatgattctg | 1260 |
| ttatccctca  | aatctgtggg  | cctgggacgt | ggttgactcc | atttcttcaa | gcagtctacc | 1320 |
| tctttgtaca  | gtatatcatt  | atggttaatc | ttcttattgc | atttttcaac | aatgtgtatt | 1380 |
| tacaagtga   | ggcaatttcc  | aatattgtat | ggaagtacca | gcgttatcat | tttattatgg | 1440 |
| cttatcatga  | gaaaccagtt  | ctgcctcttc | cacttatcat | tcttagccat | atagtttctc | 1500 |
| tgttttgctg  | catatgtaag  | agaagaaaga | aagataagac | ttccgatgga | ccaaaacttt | 1560 |
| tcttaacaga  | agaagatcaa  | aagaaacttc | atgattttga | agagcagtg  | gttgaaatgt | 1620 |
| atttcaatga  | aaaagatgac  | aaatttcttc | ctgggagtga | agagagaatt | cgtgtcactt | 1680 |
| ttgaaagagt  | ggaacagatg  | tgcattcaga | ttaaagaagt | tggagatcgt | gtcaactaca | 1740 |
| taaaaagatc  | attacaatca  | ttagattctc | aaattggcca | tttgcaagat | ctttcagccc | 1800 |
| tgacggtaga  | tacattaaaa  | acactcactg | cccagaaagc | gtcgggaagc | agcaaagttc | 1860 |
| ataatgaaat  | cacacgagaa  | ctgagcattt | ccaaacactt | ggctcaaaac | cttattgatg | 1920 |
| atggtcctgt  | aagaccttct  | gtatggaaaa | agcatgggtg | tgtaaataca | cttagctcct | 1980 |
| ctcttcctca  | agggtgatct  | gaaagtaata | atccttttca | ttgtaatat  | ttaatgaaag | 2040 |
| atgacaaaga  | tccccagtg   | aatatatatt | gtcaagactt | acctgcagta | ccccagagaa | 2100 |
| aagaatttaa  | ttttccagag  | gctgggtcct | cttctgggtg | cttattccca | agtgtgtttt | 2160 |
| cccctccaga  | actgcgacag  | agactacatg | gggtagaact | cttaaaaata | tttaataaaa | 2220 |
| atcaaaaatt  | aggcagttca  | tctactagca | taccacatct | gtcatcccca | ccaaccaa   | 2280 |
| tttttgtag   | tacaccatct  | cagccaagtt | gcaaaagcca | cttggaact  | ggaaccaa   | 2340 |
| atcaagaaac  | tgtttgctct  | aaagctacag | aaggagataa | tncagaattt | ggagcatttg | 2400 |
| taggacacag  | agatagcatg  | gatttacaga | ggtttaaaga | aacatcaaac | aagataaaaa | 2460 |
| tactatccaa  | taacaatact  | tctgaaaaca | ctttgaaacg | agtgaattct | cttgctggat | 2520 |
| ttactgactg  | tcacagaact  | tccattcctg | ttcattccaa | acaagcagaa | aaaatcagta | 2580 |
| gaaggccatc  | taccgaagac  | actcatgaag | tagattccaa | agcagcttta | ataccggatt | 2640 |
| ggttacaaga  | tagaccatca  | aacagagaaa | tgccatctga | agaaggaaca | ttaaatggtc | 2700 |
| tcacttctcc  | atttaagcca  | gctatggata | caaattacta | ttattcagct | gtggaaagaa | 2760 |
| ataacttgat  | gagggttatca | cagagcattc | catttacacc | tgtgcctcca | agaggggagc | 2820 |
| ctgtcacagt  | gtatcgtttg  | gaagagagtt | cacccaacat | actaaataac | agcatgtctt | 2880 |
| cttggtcaca  | actagccctc  | tgtgccaata | tagagttttt | aagcaaagag | gagatgggag | 2940 |
| gagggtttacg | aagagctgtc  | aaagtacagt | gtacgtggtc | agaacatgat | atcctcaaat | 3000 |
| cagggtcatct | ttatattatc  | aaatcttttc | ttccagaggt | ggttaataca | tggtcaagta | 3060 |
| tttataaaga  | agatacagtt  | ctgcatctct | gtctgagaga | aattcaacaa | cagagagcag | 3120 |

-33-

```

cacaaaagct tacgtttgcc tttaatcaaa tgaaacccaa atccatacca tattctccaa 3180
ggttccttga agttttcctg ctgtattgcc attcagcagg acagtgggtt gctgtggaag 3240
aatgtatgac tggagaattt agaaaataca acaataataa tggagatgag attattccaa 3300
ctaatactct ggaagagatc atgctagcct ttagccactg gacttacgaa tatacaagag 3360
gggagttact ggtacttgat ttgcaagggt ttggtgaaaa tttgactgac ccatctgtga 3420
taaaagcaga agaaaagaga tcctgtgata tggtttttgg cccagcaa ataggagaag 3480
atgcaattaa aaacttcaga gcaaaacatc actgtaattc ttgctgtaga aagcttaaac 3540
ttccagatct gaagaggaat gattatacgc ctgataaaat tatatttcct caggatgagc 3600
cttcagattt gaatcttcag cctggaaatt ccaccaaaga atcagaatca gctaattctg 3660
ttcgtctgat gttataatat taatattact gaatcattgg ttttgcctgc acctcacaga 3720
aatgttactt tgtcactttt ccctcgaggag gaaattgttt ggtaatatag aaaggtgtat 3780
gcaagttgaa tttgctgact ccagcacagt taaaagggtca atattctttt gacctgatta 3840
atcagtcaga aagtccttat aggatagagc tggcagctga gaaattttaa aggtaattga 3900
taattagtat ttgtaacttt ttaaagggct ctttgtatag cagaggatct catttgactt 3960
tgttttgatg aggggtgatgc cctctcttat gtggtacaat accattaacc aaaggtaggt 4020
gtccatgcag atttttattgg cagctgtttt attgccattc aactagggaa atgaagaaat 4080
cacgcagcct tttggttaaa tggcagtcaa aattttcctc agtgtattta gtgtgttcag 4140
tgatgatatc actggttccc aactagatgc ttgttgcca cggaaggga aatgacttgt 4200
tctaattcta gggtcacaga ggtatgagaa gcctgaactg aagaccattt tcaagaggga 4260
cggtatttat gaatcagggt taggctccat atttaaagat agagccagtt ttttttttaa 4320
atagaacca aattgtgtaa aaatgttaat tgggtttttt aaacattgtt ttatcaagtc 4380
actgttaagt agaagaaagc catggtaaac tgatacataa cctaaattat aaaagcagaa 4440
acctaaactc ctctgcaagg gaagttacct tttgaggaaa gttaaagtac ttttttcctt 4500
atctgtatct atagcaacaa ccagaactt acaaacttct ccaaagattt tattgattgt 4560
tatatcaaat cagaatgtaa acatgaactc ttgcataat ttaaaattgt gttggaacat 4620
ttgaacatga atgctgtttg ggtacttaag aaattrattc agtnggatta tcattatgtg 4680
anactggcag attgcagtgc anctttatgc caataaaatg taatttaaca gccccagata 4740
ttgttgaata ttcaacaata acaagaaaag cttttcatct aagttttatg ctttaatttt 4800
ttttcttttt ttttcttttt cttttgtttc cttggtacta attttaattt ttatttgga 4860
gggagcagta taaagcttat ttgtatttag tagtgtatct catagataca gacaaggcaa 4920
gagatgataa gctgttttaa tagtgtttaa tattgttg gggtggggag aaagaaaaag 4980
tgtattactt aaagatacta tatacgtttt gtatatcatt aaatctttaa aagaaatnna 5040
ataaatttat tgttttcaaa aaaaaaaccc nntaaaaaaa aaagggcggc ccctctagag 5100
gatccctcga ggggcc 5117

```

<210> 24  
 <211> 1224  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (794) ... (794)  
 <223> UNKNOWN

<400> 24  
 Trp Gln His Gly Glu Ser Met Ala Lys Ala Leu Val Ala Cys Lys  
 1 5 10 15  
 Ile Tyr Arg Ser Met Ala Tyr Glu Ala Lys Gln Ser Asp Leu Val Asp  
 20 25 30  
 Asp Thr Ser Glu Glu Leu Lys Gln Tyr Ser Asn Asp Phe Gly Gln Leu  
 35 40 45  
 Ala Val Glu Leu Leu Glu Gln Ser Phe Arg Gln Asp Glu Thr Met Ala  
 50 55 60  
 Met Lys Leu Leu Thr Tyr Glu Leu Lys Asn Trp Ser Asn Ser Thr Cys  
 65 70 75 80  
 Leu Lys Leu Ala Val Ser Ser Arg Leu Arg Pro Phe Val Ala His Thr  
 85 90 95

-34-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Thr | Gln | Met | Leu | Leu | Ser | Asp | Met | Trp | Met | Gly | Arg | Leu | Asn | Met | 100 | 105 | 110 |
| Arg | Lys | Asn | Ser | Trp | Tyr | Lys | Val | Ile | Leu | Ser | Ile | Leu | Val | Pro | Pro | 115 | 120 | 125 |
| Ala | Ile | Leu | Leu | Glu | Tyr | Lys | Thr | Lys | Ala | Glu | Met | Ser | His | Ile |     | 130 | 135 | 140 |
| Pro | Gln | Ser | Gln | Asp | Ala | His | Gln | Met | Thr | Met | Asp | Asp | Ser | Glu | Asn | 145 | 150 | 155 |
| Asn | Phe | Gln | Asn | Ile | Thr | Glu | Glu | Ile | Pro | Met | Glu | Val | Phe | Lys | Glu | 165 | 170 | 175 |
| Val | Arg | Ile | Leu | Asp | Ser | Asn | Glu | Gly | Lys | Asn | Glu | Met | Glu | Ile | Gln | 180 | 185 | 190 |
| Met | Lys | Ser | Lys | Lys | Leu | Pro | Ile | Thr | Arg | Lys | Phe | Tyr | Ala | Phe | Tyr | 195 | 200 | 205 |
| His | Ala | Pro | Ile | Val | Lys | Phe | Trp | Phe | Asn | Thr | Leu | Ala | Tyr | Leu | Gly | 210 | 215 | 220 |
| Phe | Leu | Met | Leu | Tyr | Thr | Phe | Val | Val | Leu | Val | Gln | Met | Glu | Gln | Leu | 225 | 230 | 235 |
| Pro | Ser | Val | Gln | Glu | Trp | Ile | Val | Ile | Ala | Tyr | Ile | Phe | Thr | Tyr | Ala | 245 | 250 | 255 |
| Ile | Glu | Lys | Val | Arg | Glu | Ile | Phe | Met | Ser | Glu | Ala | Gly | Lys | Val | Asn | 260 | 265 | 270 |
| Gln | Lys | Ile | Lys | Val | Trp | Phe | Ser | Asp | Tyr | Phe | Asn | Ile | Ser | Asp | Thr | 275 | 280 | 285 |
| Ile | Ala | Ile | Ile | Ser | Phe | Phe | Ile | Gly | Phe | Gly | Leu | Arg | Phe | Gly | Ala | 290 | 295 | 300 |
| Lys | Trp | Asn | Phe | Ala | Asn | Ala | Tyr | Asp | Asn | His | Val | Phe | Val | Ala | Gly | 305 | 310 | 315 |
| Arg | Leu | Ile | Tyr | Cys | Leu | Asn | Ile | Ile | Phe | Trp | Tyr | Val | Arg | Leu | Leu | 325 | 330 | 335 |
| Asp | Phe | Leu | Ala | Val | Asn | Gln | Gln | Ala | Gly | Pro | Tyr | Val | Met | Met | Ile | 340 | 345 | 350 |
| Gly | Lys | Met | Val | Ala | Asn | Met | Phe | Tyr | Ile | Val | Val | Ile | Met | Ala | Leu | 355 | 360 | 365 |
| Val | Leu | Leu | Ser | Phe | Gly | Val | Pro | Arg | Lys | Ala | Ile | Leu | Tyr | Pro | His | 370 | 375 | 380 |
| Glu | Ala | Pro | Ser | Trp | Thr | Leu | Ala | Lys | Asp | Ile | Val | Phe | His | Pro | Tyr | 385 | 390 | 395 |
| Trp | Met | Ile | Phe | Gly | Glu | Val | Tyr | Ala | Tyr | Glu | Ile | Asp | Val | Cys | Ala | 405 | 410 | 415 |
| Asn | Asp | Ser | Val | Ile | Pro | Gln | Ile | Cys | Gly | Pro | Gly | Thr | Trp | Leu | Thr | 420 | 425 | 430 |
| Pro | Phe | Leu | Gln | Ala | Val | Tyr | Leu | Phe | Val | Gln | Tyr | Ile | Ile | Met | Val | 435 | 440 | 445 |
| Asn | Leu | Leu | Ile | Ala | Phe | Phe | Asn | Asn | Val | Tyr | Leu | Gln | Val | Lys | Ala | 450 | 455 | 460 |
| Ile | Ser | Asn | Ile | Val | Trp | Lys | Tyr | Gln | Arg | Tyr | His | Phe | Ile | Met | Ala | 465 | 470 | 475 |
| Tyr | His | Glu | Lys | Pro | Val | Leu | Pro | Pro | Pro | Leu | Ile | Ile | Leu | Ser | His | 485 | 490 | 495 |
| Ile | Val | Ser | Leu | Phe | Cys | Cys | Ile | Cys | Lys | Arg | Arg | Lys | Lys | Asp | Lys | 500 | 505 | 510 |
| Thr | Ser | Asp | Gly | Pro | Lys | Leu | Phe | Leu | Thr | Glu | Glu | Asp | Gln | Lys | Lys | 515 | 520 | 525 |
| Leu | His | Asp | Phe | Glu | Glu | Gln | Cys | Val | Glu | Met | Tyr | Phe | Asn | Glu | Lys | 530 | 535 | 540 |
| Asp | Asp | Lys | Phe | His | Ser | Gly | Ser | Glu | Glu | Arg | Ile | Arg | Val | Thr | Phe | 545 | 550 | 555 |
| Glu | Arg | Val | Glu | Gln | Met | Cys | Ile | Gln | Ile | Lys | Glu | Val | Gly | Asp | Arg | 565 | 570 | 575 |

-35-

|      |      |     |      |      |     |      |     |      |     |      |      |      |     |      |     |
|------|------|-----|------|------|-----|------|-----|------|-----|------|------|------|-----|------|-----|
| Val  | Asn  | Tyr | Ile  | Lys  | Arg | Ser  | Leu | Gln  | Ser | Leu  | Asp  | Ser  | Gln | Ile  | Gly |
|      |      |     | 580  |      |     |      |     | 585  |     |      |      |      | 590 |      |     |
| His  | Leu  | Gln | Asp  | Leu  | Ser | Ala  | Leu | Thr  | Val | Asp  | Thr  | Leu  | Lys | Thr  | Leu |
|      |      | 595 |      |      |     |      | 600 |      |     |      |      | 605  |     |      |     |
| Thr  | Ala  | Gln | Lys  | Ala  | Ser | Glu  | Ala | Ser  | Lys | Val  | His  | Asn  | Glu | Ile  | Thr |
|      | 610  |     |      |      |     | 615  |     |      |     | 620  |      |      |     |      |     |
| Arg  | Glu  | Leu | Ser  | Ile  | Ser | Lys  | His | Leu  | Ala | Gln  | Asn  | Leu  | Ile | Asp  | Asp |
| 625  |      |     |      | 630  |     |      |     |      |     | 635  |      |      |     |      | 640 |
| Gly  | Pro  | Val | Arg  | Pro  | Ser | Val  | Trp | Lys  | Lys | His  | Gly  | Val  | Val | Asn  | Thr |
|      |      |     | 645  |      |     |      |     | 650  |     |      |      |      |     | 655  |     |
| Leu  | Ser  | Ser | Ser  | Leu  | Pro | Gln  | Gly | Asp  | Leu | Glu  | Ser  | Asn  | Asn | Pro  | Phe |
|      |      |     | 660  |      |     |      |     | 665  |     |      |      |      |     | 670  |     |
| His  | Cys  | Asn | Ile  | Leu  | Met | Lys  | Asp | Asp  | Lys | Asp  | Pro  | Gln  | Cys | Asn  | Ile |
|      |      | 675 |      |      |     |      | 680 |      |     |      |      | 685  |     |      |     |
| Phe  | Gly  | Gln | Asp  | Leu  | Pro | Ala  | Val | Pro  | Gln | Arg  | Lys  | Glu  | Phe | Asn  | Phe |
|      | 690  |     |      |      |     | 695  |     |      |     | 700  |      |      |     |      |     |
| Pro  | Glu  | Ala | Gly  | Ser  | Ser | Ser  | Gly | Ala  | Leu | Phe  | Pro  | Ser  | Ala | Val  | Ser |
| 705  |      |     |      | 710  |     |      |     |      |     | 715  |      |      |     |      | 720 |
| Pro  | Pro  | Glu | Leu  | Arg  | Gln | Arg  | Leu | His  | Gly | Val  | Glu  | Leu  | Leu | Lys  | Ile |
|      |      |     | 725  |      |     |      |     |      | 730 |      |      |      |     | 735  |     |
| Phe  | Asn  | Lys | Asn  | Gln  | Lys | Leu  | Gly | Ser  | Ser | Ser  | Thr  | Ser  | Ile | Pro  | His |
|      |      | 740 |      |      |     |      | 745 |      |     |      |      |      | 750 |      |     |
| Leu  | Ser  | Ser | Pro  | Pro  | Thr | Lys  | Phe | Phe  | Val | Ser  | Thr  | Pro  | Ser | Gln  | Pro |
|      |      | 755 |      |      |     |      | 760 |      |     |      |      | 765  |     |      |     |
| Ser  | Cys  | Lys | Ser  | His  | Leu | Glu  | Thr | Gly  | Thr | Lys  | Asp  | Gln  | Glu | Thr  | Val |
|      | 770  |     |      |      |     | 775  |     |      |     |      | 780  |      |     |      |     |
| Cys  | Ser  | Lys | Ala  | Thr  | Glu | Gly  | Asp | Asn  | Xaa | Glu  | Phe  | Gly  | Ala | Phe  | Val |
| 785  |      |     |      | 790  |     |      |     |      |     | 795  |      |      |     |      | 800 |
| Gly  | His  | Arg | Asp  | Ser  | Met | Asp  | Leu | Gln  | Arg | Phe  | Lys  | Glu  | Thr | Ser  | Asn |
|      |      |     | 805  |      |     |      |     | 810  |     |      |      |      |     | 815  |     |
| Lys  | Ile  | Lys | Ile  | Leu  | Ser | Asn  | Asn | Asn  | Thr | Ser  | Glu  | Asn  | Thr | Leu  | Lys |
|      |      |     | 820  |      |     |      |     | 825  |     |      |      |      | 830 |      |     |
| Arg  | Val  | Ser | Ser  | Leu  | Ala | Gly  | Phe | Thr  | Asp | Cys  | His  | Arg  | Thr | Ser  | Ile |
|      |      | 835 |      |      |     |      | 840 |      |     |      |      | 845  |     |      |     |
| Pro  | Val  | His | Ser  | Lys  | Gln | Ala  | Glu | Lys  | Ile | Ser  | Arg  | Arg  | Pro | Ser  | Thr |
|      |      | 850 |      |      |     | 855  |     |      |     |      | 860  |      |     |      |     |
| Glu  | Asp  | Thr | His  | Glu  | Val | Asp  | Ser | Lys  | Ala | Ala  | Leu  | Ile  | Pro | Asp  | Trp |
| 865  |      |     |      | 870  |     |      |     |      |     | 875  |      |      |     |      | 880 |
| Leu  | Gln  | Asp | Arg  | Pro  | Ser | Asn  | Arg | Glu  | Met | Pro  | Ser  | Glu  | Glu | Gly  | Thr |
|      |      |     | 885  |      |     |      |     | 890  |     |      |      |      |     | 895  |     |
| Leu  | Asn  | Gly | Leu  | Thr  | Ser | Pro  | Phe | Lys  | Pro | Ala  | Met  | Asp  | Thr | Asn  | Tyr |
|      |      | 900 |      |      |     |      |     | 905  |     |      |      |      | 910 |      |     |
| Tyr  | Tyr  | Ser | Ala  | Val  | Glu | Arg  | Asn | Asn  | Leu | Met  | Arg  | Leu  | Ser | Gln  | Ser |
|      |      | 915 |      |      |     |      | 920 |      |     |      |      | 925  |     |      |     |
| Ile  | Pro  | Phe | Thr  | Pro  | Val | Pro  | Pro | Arg  | Gly | Glu  | Pro  | Val  | Thr | Val  | Tyr |
|      | 930  |     |      |      |     | 935  |     |      |     |      | 940  |      |     |      |     |
| Arg  | Leu  | Glu | Glu  | Ser  | Ser | Pro  | Asn | Ile  | Leu | Asn  | Asn  | Ser  | Met | Ser  | Ser |
| 945  |      |     |      | 950  |     |      |     |      |     | 955  |      |      |     |      | 960 |
| Trp  | Ser  | Gln | Leu  | Gly  | Leu | Cys  | Ala | Lys  | Ile | Glu  | Phe  | Leu  | Ser | Lys  | Glu |
|      |      |     | 965  |      |     |      |     | 970  |     |      |      |      |     | 975  |     |
| Glu  | Met  | Gly | Gly  | Gly  | Leu | Arg  | Arg | Ala  | Val | Lys  | Val  | Gln  | Cys | Thr  | Trp |
|      |      | 980 |      |      |     |      |     | 985  |     |      |      |      | 990 |      |     |
| Ser  | Glu  | His | Asp  | Ile  | Leu | Lys  | Ser | Gly  | His | Leu  | Tyr  | Ile  | Ile | Lys  | Ser |
|      |      | 995 |      |      |     | 1000 |     |      |     |      |      | 1005 |     |      |     |
| Phe  | Leu  | Pro | Glu  | Val  | Val | Asn  | Thr | Trp  | Ser | Ser  | Ile  | Tyr  | Lys | Glu  | Asp |
|      | 1010 |     |      |      |     | 1015 |     |      |     |      | 1020 |      |     |      |     |
| Thr  | Val  | Leu | His  | Leu  | Cys | Leu  | Arg | Glu  | Ile | Gln  | Gln  | Gln  | Arg | Ala  | Ala |
| 1025 |      |     |      | 1030 |     |      |     |      |     | 1035 |      |      |     |      | 104 |
| Gln  | Lys  | Leu | Thr  | Phe  | Ala | Phe  | Asn | Gln  | Met | Lys  | Pro  | Lys  | Ser | Ile  | Pro |
|      |      |     | 1045 |      |     |      |     | 1050 |     |      |      |      |     | 1055 |     |



-36-

Tyr Ser Pro Arg Phe Leu Glu Val Phe Leu Leu Tyr Cys His Ser Ala  
 1060 1065 1070  
 Gly Gln Trp Phe Ala Val Glu Glu Cys Met Thr Gly Glu Phe Arg Lys  
 1075 1080 1085  
 Tyr Asn Asn Asn Asn Gly Asp Glu Ile Ile Pro Thr Asn Thr Leu Glu  
 1090 1095 1100  
 Glu Ile Met Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr Arg Gly  
 1105 1110 1115 112  
 Glu Leu Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn Leu Thr Asp  
 1125 1130 1135  
 Pro Ser Val Ile Lys Ala Glu Glu Lys Arg Ser Cys Asp Met Val Phe  
 1140 1145 1150  
 Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Lys Asn Phe Arg Ala Lys  
 1155 1160 1165  
 His His Cys Asn Ser Cys Cys Arg Lys Leu Lys Leu Pro Asp Leu Lys  
 1170 1175 1180  
 Arg Asn Asp Tyr Thr Pro Asp Lys Ile Ile Phe Pro Gln Asp Glu Pro  
 1185 1190 1195 120  
 Ser Asp Leu Asn Leu Gln Pro Gly Asn Ser Thr Lys Glu Ser Glu Ser  
 1205 1210 1215  
 Ala Asn Ser Val Arg Leu Met Leu  
 1220

&lt;210&gt; 25

&lt;211&gt; 2180

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 25

|            |            |            |             |             |             |      |
|------------|------------|------------|-------------|-------------|-------------|------|
| tcgaggccaa | gaattcggca | cgagggcctc | gggcaggccc  | cctggagcga  | cctgcttctt  | 60   |
| tgggcactgt | tgctgaacag | ggcacagatg | gccatgtact  | tctgggagat  | gggttccaat  | 120  |
| gcagtttctt | cagctcttgg | ggcctgtttg | ctgctccggg  | tgatggcacg  | cctggagcct  | 180  |
| gacgtgagg  | aggcagcacg | gaggaaagac | ctggcggttca | agtttgaggg  | gatgggcgtt  | 240  |
| gacctctttg | gcgagtgcta | tcgcagcagt | gaggtgaggg  | ctgcccgcct  | cctcctccgt  | 300  |
| cgctgcccgc | tctgggggga | tgccacttgc | ctccagctgg  | ccatgcaagc  | tgacgcccgt  | 360  |
| gccttctttg | cccaggatgg | ggtacagtct | ctgctgacac  | agaagtgggtg | gggagatatg  | 420  |
| gccagcacta | cacccatctg | ggccttggtt | ctgcgcttct  | tttgccctcc  | actcatctac  | 480  |
| acccgcctca | tcaccttcag | gaaatcagaa | gaggagccca  | cacgggagga  | gctagagttt  | 540  |
| gacatggata | gtgtcattaa | tggggaaggg | cctgtcggga  | cgccggagcc  | agccgagaag  | 600  |
| acgcgcctgg | gggtcccgcg | ccagtcgggc | cgctccgggtt | gctgcggggg  | ccgctgcggg  | 660  |
| gggcgcgggt | gcctacgccg | ctggttccac | ttctggggcg  | cgccggtgac  | catcttcatg  | 720  |
| ggcaacgtgg | tcagctacct | gctgttccgt | ctgcttttct  | cgcggtgct   | gctcgtggat  | 780  |
| ttccagccgg | cgccgcccgg | ctccctggag | ctgctgctct  | atttctgggc  | tttcacgctg  | 840  |
| ctgtgcgagg | aactgcgcca | gggcctgagc | ggaggcgggg  | gcagcctcgc  | cagcgggggc  | 900  |
| cccgggcctg | gccatgcctc | actgagccag | cgctgcgcgc  | tctacctcgc  | cgacagctgg  | 960  |
| aaccagtgcg | acctagtggc | tctcacctgc | ttcctcctgg  | gcgtgggctg  | ccggctgacc  | 1020 |
| ccgggtttgt | accacctggg | ccgcactgtc | ctctgcatcg  | acttcatggt  | tttcacgggtg | 1080 |
| cggctgcttc | acatcttcac | ggtcaacaaa | cagctggggc  | ccaagatcgt  | catcgtgagc  | 1140 |
| aagatgatga | aggacgtggt | cttcttctct | ttcttctctg  | gcgtgtgggt  | ggtagcctat  | 1200 |
| ggcgtggcca | cggaggggct | cctgaggcca | cgggacagtg  | acttcccaag  | tatcctgcgc  | 1260 |
| cgcgtcttct | accgtcccta | cctgcagatc | ttcgggcaga  | ttccccagga  | ggacatggac  | 1320 |
| gtggccctca | tggagcacag | caactgctcg | tcggagcccg  | gcttctgggc  | acaccctcct  | 1380 |
| ggggcccagg | cgggcacctg | cgtctcccag | tatgccaaact | ggctgggtggt | gctgctcctc  | 1440 |
| gtcatcttcc | tgtcgtggc  | caacatcctg | ctgggtcaact | tgctcattgc  | catgttcatg  | 1500 |
| tacacattcg | gcaaagtaca | gggcaacagc | gatctctact  | ggaaggcgca  | gcgttaccgc  | 1560 |
| ctcatccggg | aattccactc | tcggcccgcg | ctggccccgc  | cctttatcgt  | catctccac   | 1620 |
| ttgcgcctcc | tgctcaggca | attgtgcagg | cgaccscgga  | gccccagcc   | gtcctcccgc  | 1680 |
| gcctcagagc | atttccgggt | ttacctttct | aagggaagccg | agcggaagct  | gctaacgtgg  | 1740 |
| gaatcgggtc | ataaggagaa | ctttctgctg | gcacgcgcta  | gggacaagcg  | ggagagcgac  | 1800 |
| tccgagmgtc | tgaagcgcac | gtcccagaag | gtggacttgg  | cactgaaaca  | gctgggacac  | 1860 |

-37-

```

atccgcgagt acgaacagcg cctgaaagtg ctggagcggg aggtccagca gtgtacctcg 1920
gccccgcac ctgggtggcct tgtccttgag gtgagcccca tgtccatctg ggccactgtc 1980
aggaccacct ttgggagtgt catccttaca aaccacagca tgcccggtc ctccagaac 2040
cagtcccagc ctgggaggat caaggcctgg atcccrggcc gttatccatc tggaggctgc 2100
agggtccttg gggtaacagg gaccacagac cctcaccac tcacagattc ctcacactgg 2160
ggaaataaag ccatttcaga                                2180

```

<210> 26  
 <211> 725  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (553)...(553)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (603)...(603)  
 <223> UNKNOWN

<400> 26

```

Ser Arg Pro Arg Ile Arg His Glu Gly Leu Gly Gln Ala Pro Trp Ser
1      5      10      15
Asp Leu Leu Leu Trp Ala Leu Leu Leu Asn Arg Ala Gln Met Ala Met
20      25      30
Tyr Phe Trp Glu Met Gly Ser Asn Ala Val Ser Ser Ala Leu Gly Ala
35      40      45
Cys Leu Leu Leu Arg Val Met Ala Arg Leu Glu Pro Asp Ala Glu Glu
50      55      60
Ala Ala Arg Arg Lys Asp Leu Ala Phe Lys Phe Glu Gly Met Gly Val
65      70      75      80
Asp Leu Phe Gly Glu Cys Tyr Arg Ser Ser Glu Val Arg Ala Ala Arg
85      90      95
Leu Leu Leu Arg Arg Cys Pro Leu Trp Gly Asp Ala Thr Cys Leu Gln
100     105     110
Leu Ala Met Gln Ala Asp Ala Arg Ala Phe Phe Ala Gln Asp Gly Val
115     120     125
Gln Ser Leu Leu Thr Gln Lys Trp Trp Gly Asp Met Ala Ser Thr Thr
130     135     140
Pro Ile Trp Ala Leu Val Leu Ala Phe Phe Cys Pro Pro Leu Ile Tyr
145     150     155     160
Thr Arg Leu Ile Thr Phe Arg Lys Ser Glu Glu Glu Pro Thr Arg Glu
165     170     175
Glu Leu Glu Phe Asp Met Asp Ser Val Ile Asn Gly Glu Gly Pro Val
180     185     190
Gly Thr Ala Asp Pro Ala Glu Lys Thr Pro Leu Gly Val Pro Arg Gln
195     200     205
Ser Gly Arg Pro Gly Cys Cys Gly Gly Arg Cys Gly Gly Arg Arg Cys
210     215     220
Leu Arg Arg Trp Phe His Phe Trp Gly Ala Pro Val Thr Ile Phe Met
225     230     235     240
Gly Asn Val Val Ser Tyr Leu Leu Phe Leu Leu Phe Ser Arg Val
245     250     255
Leu Leu Val Asp Phe Gln Pro Ala Pro Pro Gly Ser Leu Glu Leu Leu
260     265     270
Leu Tyr Phe Trp Ala Phe Thr Leu Leu Cys Glu Glu Leu Arg Gln Gly
275     280     285
Leu Ser Gly Gly Gly Gly Ser Leu Ala Ser Gly Gly Pro Gly Pro Gly
290     295     300

```

-38-

His Ala Ser Leu Ser Gln Arg Leu Arg Leu Tyr Leu Ala Asp Ser Trp  
 305 310 315 320  
 Asn Gln Cys Asp Leu Val Ala Leu Thr Cys Phe Leu Leu Gly Val Gly  
 325 330 335  
 Cys Arg Leu Thr Pro Gly Leu Tyr His Leu Gly Arg Thr Val Leu Cys  
 340 345 350  
 Ile Asp Phe Met Val Phe Thr Val Arg Leu Leu His Ile Phe Thr Val  
 355 360 365  
 Asn Lys Gln Leu Gly Pro Lys Ile Val Ile Val Ser Lys Met Met Lys  
 370 375 380  
 Asp Val Phe Phe Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr  
 385 390 395 400  
 Gly Val Ala Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro  
 405 410 415  
 Ser Ile Leu Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gln Ile Phe Gly  
 420 425 430  
 Gln Ile Pro Gln Glu Asp Met Asp Val Ala Leu Met Glu His Ser Asn  
 435 440 445  
 Cys Ser Ser Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gln Ala  
 450 455 460  
 Gly Thr Cys Val Ser Gln Tyr Ala Asn Trp Leu Val Val Leu Leu Leu  
 465 470 475 480  
 Val Ile Phe Leu Leu Val Ala Asn Ile Leu Leu Val Asn Leu Leu Ile  
 485 490 495  
 Ala Met Phe Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu  
 500 505 510  
 Tyr Trp Lys Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg  
 515 520 525  
 Pro Ala Leu Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu  
 530 535 540  
 Leu Arg Gln Leu Cys Arg Arg Pro Xaa Ser Pro Gln Pro Ser Ser Pro  
 545 550 555 560  
 Ala Leu Glu His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys  
 565 570 575  
 Leu Leu Thr Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg  
 580 585 590  
 Ala Arg Asp Lys Arg Glu Ser Asp Ser Glu Xaa Leu Lys Arg Thr Ser  
 595 600 605  
 Gln Lys Val Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr  
 610 615 620  
 Glu Gln Arg Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Thr Ser  
 625 630 635 640  
 Ala Pro Ala Pro Gly Gly Leu Val Leu Glu Val Ser Pro Met Ser Ile  
 645 650 655  
 Trp Ala Thr Val Arg Thr Thr Phe Gly Ser Val Ile Leu Thr Asn His  
 660 665 670  
 Ser Met Pro Gly Ser Ser Gln Asn Gln Ser Gln Pro Gly Arg Ile Lys  
 675 680 685  
 Ala Trp Ile Pro Gly Arg Tyr Pro Ser Gly Gly Cys Arg Val Leu Gly  
 690 695 700  
 Val Thr Gly Thr Thr Asp Pro Ser Pro Leu Thr Asp Ser Ser His Trp  
 705 710 715 720  
 Gly Asn Lys Ala Ile  
 725

&lt;210&gt; 27

&lt;211&gt; 7419

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 27

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| cggggaccga  | tccagcctcc  | ggactctagc  | ctaggctttt  | gcaaaaagct  | atttaggtga  | 60   |
| cactatagaa  | ggtacgcctg  | caggtaccgg  | tccggaattc  | ccgggtcgac  | ccacgcgtcc  | 120  |
| gcagccccgt  | cgccggcgga  | ggcgggcgcg  | ggcgcgtnc   | ctgtggccag  | tcacccgag   | 180  |
| gagttggtcg  | cacaattatg  | aaagactcgg  | cttctgctgc  | tagcgccgga  | gctgagttag  | 240  |
| ttctgagaag  | gtttccctgg  | gcgttccttg  | tccggcggcc  | tctgctgccg  | cctccggaga  | 300  |
| cgcttcccgga | tagatggcta  | caggcccgcg  | aggaggagga  | ggtggagtgt  | ctgcccttcc  | 360  |
| ggagtccgcc  | ccgtgaggag  | aatgtcccag  | aaatcctgga  | tagaaaagcac | tttgaccaag  | 420  |
| agggaatgtg  | tatatattat  | accaagttcc  | aaggaccctc  | acagatgcct  | tccaggatgt  | 480  |
| caaatttgctc | agcaactcgt  | caggtgtttt  | tgtggtcgct  | tggccaagca  | acatgcttgt  | 540  |
| tttactgcaa  | gtcttgccat  | gaaatactca  | gatgtgaaat  | tgggtgacca  | ttttaatcag  | 600  |
| gcaatagaag  | aatggtctgt  | ggaaaagcat  | acagaacaga  | gccaacgga   | tgcttatgga  | 660  |
| gtcataaatt  | ttcaaggggg  | ttctcattcc  | tacagagcta  | agtatgtgag  | gctatcatat  | 720  |
| gacaccaaac  | ctgaagtcac  | tctgcaactt  | ctgcttaaa   | aatggcaaat  | ggagttaccc  | 780  |
| aaacttggtta | tctctgtaca  | tgggggcatg  | cagaaatttg  | agcttcaccc  | acgaatcaag  | 840  |
| cagttgcttg  | gaaaaggtct  | tattaaagct  | gcagttacaa  | ctggagcctg  | gattttaact  | 900  |
| ggaggagtaa  | acacaggtgt  | ggcaaaacat  | gttgagatg   | ccctcaaaga  | acatgcttcc  | 960  |
| agatcatctc  | gaaagatttg  | cactatcgga  | atagctccat  | ggggagtgat  | tgaaaacaga  | 1020 |
| aatgatcttg  | ttgggagaga  | tgtggttgct  | ccttatcaaa  | ccttattgaa  | ccccctgagc  | 1080 |
| aaattgaatg  | ttttgaataa  | tctgcattcc  | catttcatat  | tgggtggatga | tgggcactgtt | 1140 |
| ggaaagtatg  | ggcggaagt   | cagactgaga  | agagaacttg  | aaaaaactat  | taatcagcaa  | 1200 |
| agaattcatg  | ctaggattgg  | ccagggtgtc  | cctgtgggtg  | cacttatatt  | tgaggggtgg  | 1260 |
| ccaaatgtta  | tcctcacagt  | tcttgaatac  | cttcaggaaa  | gccccctgt   | tccagtagtt  | 1320 |
| gtgtgtgaag  | gaacaggcag  | agctgcagat  | ctgctagcgt  | atattcataa  | acaaacagaa  | 1380 |
| gaaggaggga  | atcttctctga | tgcagcagag  | cccgatatta  | tttccactat  | caaaaaaaca  | 1440 |
| tttaactttg  | gccagaatga  | agcacttcat  | ttatttcaaa  | cactgatgga  | gtgcatgaaa  | 1500 |
| agaaaggagc  | ttatcactgt  | tttccatatt  | gggtcagatg  | aacatcaaga  | tatagatgta  | 1560 |
| gcaatactta  | ctgcactgct  | aaaaggctac  | aatgcactct  | catttgacca  | gcttatcctt  | 1620 |
| acattggcat  | gggatagagt  | tgacattgct  | aaaaatcatg  | tatttgttta  | tggacagcag  | 1680 |
| tggctgggtg  | gataccttga  | acaagctatg  | cttgatgctc  | ttgtaatgga  | tagagttgca  | 1740 |
| tttgtaaaac  | ttcttattga  | aaatggagta  | agcatgcata  | aattccttac  | cattccgaga  | 1800 |
| ctggaagaac  | tttacaacac  | taaacaaggt  | ccaactaatc  | caatgctgtt  | tcatcttggt  | 1860 |
| cgagacgtca  | aacaggga    | tcttccctcca | ggatataaga  | tcactctgat  | tgatatagga  | 1920 |
| cttggttattg | aatatctcat  | gggaggaacc  | tacagatgca  | cctatactag  | gaaacgtttt  | 1980 |
| cgattaatat  | ataatagtct  | tgggtggaat  | aatcggaggt  | ctggccgaaa  | tacctccagc  | 2040 |
| agcactcctc  | agttgcgaaa  | gagtcagtaa  | tcttttgcca  | atagggcaga  | taaaaaggaa  | 2100 |
| aaaatgaggc  | ataaccattt  | cattaagaca  | gcacagccct  | tccgaccaa   | gattgataca  | 2160 |
| gttatggaag  | aaggaaagaa  | gaaaagaacc  | aaagatgaaa  | ttgtagacat  | tgatgatcca  | 2220 |
| gaaaccaagc  | gctttcctta  | tccacttaat  | gaacttttaa  | tttgggcttg  | ccttatgaag  | 2280 |
| aggcagggtca | tggcccgttt  | tttatggcaa  | catggtgaag  | aatcaatggc  | taaagcatta  | 2340 |
| gttgctgtga  | agatctatcg  | ttcaatggca  | tatgaagcaa  | agcagagtga  | cctggtagat  | 2400 |
| gatacttcag  | aagaactaaa  | acagtattcc  | aatgattttg  | gtcagttggc  | cgttgataat  | 2460 |
| ttagaacagt  | ccttcagaca  | agatgaaacc  | atggctatga  | aattgctcac  | ttatgaactg  | 2520 |
| aagaactgga  | gtaattcaac  | ctgccttaag  | ttagcagttt  | cttcaagact  | tagacctttt  | 2580 |
| gtagctcaca  | cctgtacaca  | aatgttggtta | tctgatatgt  | ggatgggaag  | gctgaatatg  | 2640 |
| aggaaaaatt  | cctggtacaa  | ggtcatacta  | agcatttttag | ttccacctgc  | catatttgctg | 2700 |
| ttagagtata  | aaactaaggc  | tgaaatgtcc  | catatcccac  | aatctcaaga  | tgctcatcag  | 2760 |
| atgacaatgg  | atgacagcga  | aaacaacttt  | cagaacataa  | cagaagagat  | ccccatggaa  | 2820 |
| gtgtttaaag  | aagtacggat  | tttggtatagt | aatgaaggaa  | agaatgagat  | ggagatacaa  | 2880 |
| atgaaatcaa  | aaaagcttcc  | aattacgcga  | aagttttatg  | ccttttatca  | tgcaccaatt  | 2940 |
| gtaaaattct  | ggtttaacac  | gttggcatat  | ttaggatttc  | tgatgcttta  | tacatttggtg | 3000 |
| gttcttgtac  | aaatggaaca  | gttaccttca  | gttcaagaat  | ggattgttat  | tgcttatatt  | 3060 |
| tttacttatg  | ccattgagaa  | agtccgtgag  | atcttttatgt | ctgaagctgg  | gaaagtaaac  | 3120 |
| cagaagatta  | aagtatggtt  | tagtgattac  | ttcaacatca  | gtgatacaat  | tgccataatt  | 3180 |
| tctttcttca  | ttggatttgg  | actaagattt  | ggagcaaaat  | ggaactttgc  | aaatgcatat  | 3240 |
| gataatcatg  | tttttgtggc  | tggaaagatta | atttactgtc  | ttaacataat  | attttggtat  | 3300 |
| gtgcgtttgc  | tagattttct  | agctgtaaat  | caacaggcag  | gaccttatgt  | aatgatgatt  | 3360 |
| ggaaaaatgg  | tggccaatat  | gttctacatt  | gtagtgatta  | tggctcttgt  | attacttagt  | 3420 |
| tttgggtgtc  | ccagaaaggc  | aatactttat  | cctcatgaag  | caccatcttg  | gactcttgct  | 3480 |
| aaagatatag  | tttttcaccc  | atactggatg  | atttttggtg  | aagtttatgc  | atacgaaatt  | 3540 |

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| gatgtgtgtg  | caaattgattc | tgttatccct  | caaatctgtg  | gtcctgggac  | gtggttgact  | 3600 |
| ccatttcttc  | aagcagtcta  | cctctttgtg  | cagtataat   | ttatggttaa  | tcttcttatt  | 3660 |
| gcattttttca | acaatgtgta  | tttacaagtg  | aaggcaattt  | ccaatattgt  | atgggaagtac | 3720 |
| cagcggtatc  | attttattat  | ggcttatcat  | gagaaaccag  | ttctgcctcc  | tccacttattc | 3780 |
| attcttagcc  | atatagtttc  | tctgttttgc  | tgcataatga  | agagaagaaa  | gaaagataag  | 3840 |
| acttccgatg  | gacccaaaact | tttcttaaca  | gaagaagatc  | aaaagaaaact | tcatgattttt | 3900 |
| gaagagcagt  | gtgttgaaat  | gtattttcaat | gaaaaagatg  | acaaattttca | ttctgggagt  | 3960 |
| gaagagagaa  | ttcgtgtcac  | ttttgaaaga  | gtggaacaga  | tgtgcattca  | gattaaagaa  | 4020 |
| gttggagatc  | gtgtcaacta  | cataaaaaga  | tcattacaat  | cattagattc  | tcaaattggc  | 4080 |
| catttgcaag  | atctttcagc  | cctgacggta  | gatacattaa  | aaacactcac  | tgcccagaaa  | 4140 |
| gcgtcggaag  | ctagcaaagt  | tcataatgaa  | atcacacgag  | aactgagcat  | ttccaaacac  | 4200 |
| ttggctcaaa  | accttattga  | tgatggctct  | gtaagacctt  | ctgtatggaa  | aaagcatggt  | 4260 |
| gttgtaaaata | cacttagctc  | ctctcttctc  | caagggtgatc | ttgaaagtaa  | taatcctttt  | 4320 |
| cattgtaata  | ttttaatgaa  | agatgacaaa  | gatccccagt  | gtaatatatt  | tggtcagagc  | 4380 |
| ttacctgcag  | taccccagag  | aaaagaattt  | aattttccag  | aggctgggtc  | ctcttctggt  | 4440 |
| gccttatttc  | caagtgtgt   | ttcccctcca  | gaactgcgac  | agagactaca  | tggggtagaa  | 4500 |
| ctcttaaaaa  | tatttaataa  | aaatcaaaaa  | ttaggcagtt  | catctactag  | cataccacat  | 4560 |
| ctgtcatccc  | caccaaccaa  | attttttgtt  | agtacaccat  | ctcagccaag  | ttgcaaaagc  | 4620 |
| cacttggaag  | ctggaaccac  | agatcaagaa  | actgtttgct  | ctaaagctac  | agaaggagat  | 4680 |
| aatacagaat  | ttggagcatt  | tgtaggacac  | agagatagca  | tggatttaca  | gaggtttaa   | 4740 |
| gaaacatcaa  | acaagataaa  | aatactatcc  | aataacaata  | cttctgaaaa  | cactttgaaa  | 4800 |
| cgagtgcagt  | ctcttgctgg  | atttactgac  | tgtcacagaa  | cttccattcc  | tgttcattca  | 4860 |
| aaacaagcag  | aaaaaatcag  | tagaaggcca  | tctaccgaa   | acactcatga  | agtagattcc  | 4920 |
| aaagcagctt  | taataccgga  | ttggttaca   | gatagaccat  | caaacagaga  | aatgccatct  | 4980 |
| gaagaaggaa  | cattaaatgg  | tctcacttct  | ccatttaagc  | cagctatgga  | tacaaattac  | 5040 |
| tattattcag  | ctgtggaaag  | aaataacttg  | atgaggttat  | cacagagcat  | tccatttaca  | 5100 |
| cctgtgcctc  | caagagggga  | gcctgtcaca  | gtgtatcggt  | tggaaagagag | ttcaccaca   | 5160 |
| atactaaata  | acagcatgtc  | ttcttgggtc  | caactaggcc  | tctgtgccaa  | aatagagttt  | 5220 |
| ttaagcaaa   | aggagatggg  | aggaggttta  | cgaagagctg  | tcaaagtaca  | gtgtacctgg  | 5280 |
| tcagaacatg  | atatcctcaa  | atcagggcac  | ctttatatta  | tcaaactctt  | tcttcagag   | 5340 |
| gtggttaata  | catggtcaag  | tattttataa  | gaagatacag  | ttctgcatct  | ctgtctgaga  | 5400 |
| gaaattcaac  | aacagagagc  | agcacaaaag  | cttacgtttg  | cctttaatca  | aatgaaaccc  | 5460 |
| aaatccatac  | catattctcc  | aagggtcctt  | gaagttttcc  | tgtgtatttg  | ccattcagca  | 5520 |
| ggacagtggt  | ttgctgtgga  | agaatgtatg  | actggagaat  | ttagaaaaata | caacaataat  | 5580 |
| aatggagatg  | agattattcc  | aactaatact  | ctggaagaga  | tcatgctagc  | ctttagccac  | 5640 |
| tggacttacg  | aataatacaag | aggggagtta  | ctggtacttg  | atttgcaagg  | tgttggtgaa  | 5700 |
| aatttgactg  | acccatctgt  | gataaaaagca | gaagaaaaga  | gatcctgtga  | tatggttttt  | 5760 |
| ggcccagcaa  | atctaggaga  | agatgcaatt  | aaaaacttca  | gagcaaaaaca | tcactgtaat  | 5820 |
| tcttgctgta  | gaaagcttaa  | acttccagat  | ctgaagagga  | atgattatac  | gcctgataaa  | 5880 |
| attatatttc  | ctcaggatga  | gccttcagat  | ttgaatcttc  | agcctggaaa  | ttccacaaaa  | 5940 |
| gaatcagaat  | caactaattc  | tgttcgtctg  | atgttataat  | attaatatta  | ctgaatcatt  | 6000 |
| ggttttgctt  | gcacctcaca  | gaaatgttac  | tgtgtcactt  | ttccctcggt  | aggaaattgt  | 6060 |
| ttggtaatat  | agaaagggtg  | atgcaagttg  | aatttgctga  | ctccagcaca  | gttaaaagg   | 6120 |
| caatattctt  | ttgacctgat  | taatcagtea  | gaaagtccct  | ataggataga  | gctggcagct  | 6180 |
| gagaaatttt  | aaaggttaatt | gataattagt  | atttgaact   | ttttaaaagg  | ctctttgtat  | 6240 |
| agcagaggat  | ctcatttgac  | tttgttttga  | tgagggtgat  | gcctctctt   | atgtggtaca  | 6300 |
| ataccattaa  | ccaaaggtag  | gtgtccatgc  | agattttatt  | ggcagctggt  | ttattgccat  | 6360 |
| tcaactaggg  | aaatgaagaa  | atcacgcagc  | cttttggtta  | aatggcagtc  | aaaattttcc  | 6420 |
| tcagtgtatt  | tagtgtgttc  | agtgtgata   | tcaactgggt  | ccaactagat  | gcttgttggc  | 6480 |
| cacgggaagg  | gaaatgactt  | gttctaattc  | taggttcaca  | gaggtatgag  | aagcctgaac  | 6540 |
| tgaagaccat  | tttcaagagg  | gacggtattt  | atgaatcagg  | gttaggctcc  | atatttaaa   | 6600 |
| atagagccag  | tttttttttt  | aaatagaacc  | caaattgtgt  | aaaaatgtta  | attgggtttt  | 6660 |
| ttaaacattg  | ttttatcaag  | tactgttaa   | gtagaagaaa  | gccatggtaa  | actgatacat  | 6720 |
| aacctaaatt  | ataaaagcag  | aaacctaat   | cactcgtcaa  | gggaagttac  | cttttgagga  | 6780 |
| aagttaaagt  | acttttttcc  | ctatctgtat  | ctatagcaac  | aaccagaac   | ttacaaaact  | 6840 |
| ctccaaagat  | tttattgatt  | gttataatca  | atcagaatgt  | aaacatgaac  | tcttgcatat  | 6900 |
| atttaaaatt  | gtgttggaac  | atttgaacat  | gaatgctgtt  | tgggtactta  | agaaattrat  | 6960 |
| tcagtnngat  | tatcattatg  | tganaactggc | agattgcagt  | gcanccttat  | gccaaataaaa | 7020 |
| tgtaaatttar | cagccccaga  | tattgttgaa  | tattcaacaa  | taacaagaaa  | agcttttcat  | 7080 |
| ctaagtttta  | tgctttaatt  | ttttttcttt  | ttttttcttt  | ttcttttgtt  | tccttggtac  | 7140 |

-41-

|            |            |            |            |            |            |      |
|------------|------------|------------|------------|------------|------------|------|
| taattttaat | ttttatttgg | aagggagcag | tataaagctt | atttgtattt | agtagtgtat | 7200 |
| ctcatagata | cagacaaggc | aagagatgat | aagctgttta | aatagtgktt | aatattgatt | 7260 |
| gggggtgggg | agaaagaaaa | agtgtattac | ttaaagatac | tatatacskt | ttktatatca | 7320 |
| ttaaatcttt | aaaagaaatn | naataaattt | attgttttnc | aaaaaaaaac | ccnntaaaaa | 7380 |
| aaaaagggcg | gcccctctag | aggatccctc | gaggggccc  |            |            | 7419 |

&lt;210&gt; 28

&lt;211&gt; 1865

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 28

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ser | Gln | Lys | Ser | Trp | Ile | Glu | Ser | Thr | Leu | Thr | Lys | Arg | Glu | Cys |
| 1   |     |     | 5   |     |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Val | Tyr | Ile | Ile | Pro | Ser | Ser | Lys | Asp | Pro | His | Arg | Cys | Leu | Pro | Gly |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Cys | Gln | Ile | Cys | Gln | Gln | Leu | Val | Arg | Cys | Phe | Cys | Gly | Arg | Leu | Val |
|     |     |     | 35  |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Lys | Gln | His | Ala | Cys | Phe | Thr | Ala | Ser | Leu | Ala | Met | Lys | Tyr | Ser | Asp |
|     |     |     | 50  |     |     |     | 55  |     |     |     | 60  |     |     |     |     |
| Val | Lys | Leu | Gly | Asp | His | Phe | Asn | Gln | Ala | Ile | Glu | Glu | Trp | Ser | Val |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Glu | Lys | His | Thr | Glu | Gln | Ser | Pro | Thr | Asp | Ala | Tyr | Gly | Val | Ile | Asn |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Phe | Gln | Gly | Gly | Ser | His | Ser | Tyr | Arg | Ala | Lys | Tyr | Val | Arg | Leu | Ser |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Tyr | Asp | Thr | Lys | Pro | Glu | Val | Ile | Leu | Gln | Leu | Leu | Leu | Lys | Glu | Trp |
|     |     |     | 115 |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Gln | Met | Glu | Leu | Pro | Lys | Leu | Val | Ile | Ser | Val | His | Gly | Gly | Met | Gln |
|     |     |     | 130 |     |     |     | 135 |     |     |     | 140 |     |     |     |     |
| Lys | Phe | Glu | Leu | His | Pro | Arg | Ile | Lys | Gln | Leu | Leu | Gly | Lys | Gly | Leu |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Ile | Lys | Ala | Ala | Val | Thr | Thr | Gly | Ala | Trp | Ile | Leu | Thr | Gly | Gly | Val |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Asn | Thr | Gly | Val | Ala | Lys | His | Val | Gly | Asp | Ala | Leu | Lys | Glu | His | Ala |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Ser | Arg | Ser | Ser | Arg | Lys | Ile | Cys | Thr | Ile | Gly | Ile | Ala | Pro | Trp | Gly |
|     |     |     | 195 |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Val | Ile | Glu | Asn | Arg | Asn | Asp | Leu | Val | Gly | Arg | Asp | Val | Val | Ala | Pro |
|     |     |     | 210 |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Tyr | Gln | Thr | Leu | Leu | Asn | Pro | Leu | Ser | Lys | Leu | Asn | Val | Leu | Asn | Asn |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
| Leu | His | Ser | His | Phe | Ile | Leu | Val | Asp | Asp | Gly | Thr | Val | Gly | Lys | Tyr |
|     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |
| Gly | Ala | Glu | Val | Arg | Leu | Arg | Arg | Glu | Leu | Glu | Lys | Thr | Ile | Asn | Gln |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Gln | Arg | Ile | His | Ala | Arg | Ile | Gly | Gln | Gly | Val | Pro | Val | Val | Ala | Leu |
|     |     |     | 275 |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Ile | Phe | Glu | Gly | Gly | Pro | Asn | Val | Ile | Leu | Thr | Val | Leu | Glu | Tyr | Leu |
|     |     |     | 290 |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Gln | Glu | Ser | Pro | Pro | Val | Pro | Val | Val | Val | Cys | Glu | Gly | Thr | Gly | Arg |
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |
| Ala | Ala | Asp | Leu | Leu | Ala | Tyr | Ile | His | Lys | Gln | Thr | Glu | Glu | Gly | Gly |
|     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |
| Asn | Leu | Pro | Asp | Ala | Ala | Glu | Pro | Asp | Ile | Ile | Ser | Thr | Ile | Lys | Lys |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |
| Thr | Phe | Asn | Phe | Gly | Gln | Asn | Glu | Ala | Leu | His | Leu | Phe | Gln | Thr | Leu |
|     |     |     | 355 |     |     |     | 360 |     |     |     |     |     | 365 |     |     |

-42-

Met Glu Cys Met Lys Arg Lys Glu Leu Ile Thr Val Phe His Ile Gly  
 370 375 380  
 Ser Asp Glu His Gln Asp Ile Asp Val Ala Ile Leu Thr Ala Leu Leu  
 385 390 395 400  
 Lys Gly Thr Asn Ala Ser Ala Phe Asp Gln Leu Ile Leu Thr Leu Ala  
 405 410 415  
 Trp Asp Arg Val Asp Ile Ala Lys Asn His Val Phe Val Tyr Gly Gln  
 420 425 430  
 Gln Trp Leu Val Gly Ser Leu Glu Gln Ala Met Leu Asp Ala Leu Val  
 435 440 445  
 Met Asp Arg Val Ala Phe Val Lys Leu Leu Ile Glu Asn Gly Val Ser  
 450 455 460  
 Met His Lys Phe Leu Thr Ile Pro Arg Leu Glu Glu Leu Tyr Asn Thr  
 465 470 475 480  
 Lys Gln Gly Pro Thr Asn Pro Met Leu Phe His Leu Val Arg Asp Val  
 485 490 495  
 Lys Gln Gly Asn Leu Pro Pro Gly Tyr Lys Ile Thr Leu Ile Asp Ile  
 500 505 510  
 Gly Leu Val Ile Glu Tyr Leu Met Gly Gly Thr Tyr Arg Cys Thr Tyr  
 515 520 525  
 Thr Arg Lys Arg Phe Arg Leu Ile Tyr Asn Ser Leu Gly Gly Asn Asn  
 530 535 540  
 Arg Arg Ser Gly Arg Asn Thr Ser Ser Ser Thr Pro Gln Leu Arg Lys  
 545 550 555 560  
 Ser His Glu Ser Phe Gly Asn Arg Ala Asp Lys Lys Glu Lys Met Arg  
 565 570 575  
 His Asn His Phe Ile Lys Thr Ala Gln Pro Phe Arg Pro Lys Ile Asp  
 580 585 590  
 Thr Val Met Glu Glu Gly Lys Lys Lys Arg Thr Lys Asp Glu Ile Val  
 595 600 605  
 Asp Ile Asp Asp Pro Glu Thr Lys Arg Phe Pro Tyr Pro Leu Asn Glu  
 610 615 620  
 Leu Leu Ile Trp Ala Cys Leu Met Lys Arg Gln Val Met Ala Arg Phe  
 625 630 635 640  
 Leu Trp Gln His Gly Glu Glu Ser Met Ala Lys Ala Leu Val Ala Cys  
 645 650 655  
 Lys Ile Tyr Arg Ser Met Ala Tyr Glu Ala Lys Gln Ser Asp Leu Val  
 660 665 670  
 Asp Asp Thr Ser Glu Glu Leu Lys Gln Tyr Ser Asn Asp Phe Gly Gln  
 675 680 685  
 Leu Ala Val Glu Leu Leu Glu Gln Ser Phe Arg Gln Asp Glu Thr Met  
 690 695 700  
 Ala Met Lys Leu Leu Thr Tyr Glu Leu Lys Asn Trp Ser Asn Ser Thr  
 705 710 715 720  
 Cys Leu Lys Leu Ala Val Ser Ser Arg Leu Arg Pro Phe Val Ala His  
 725 730 735  
 Thr Cys Thr Gln Met Leu Leu Ser Asp Met Trp Met Gly Arg Leu Asn  
 740 745 750  
 Met Arg Lys Asn Ser Trp Tyr Lys Val Ile Leu Ser Ile Leu Val Pro  
 755 760 765  
 Pro Ala Ile Leu Leu Leu Glu Tyr Lys Thr Lys Ala Glu Met Ser His  
 770 775 780  
 Ile Pro Gln Ser Gln Asp Ala His Gln Met Thr Met Asp Asp Ser Glu  
 785 790 795 800  
 Asn Asn Phe Gln Asn Ile Thr Glu Glu Ile Pro Met Glu Val Phe Lys  
 805 810 815  
 Glu Val Arg Ile Leu Asp Ser Asn Glu Gly Lys Asn Glu Met Glu Ile  
 820 825 830  
 Gln Met Lys Ser Lys Lys Leu Pro Ile Thr Arg Lys Phe Tyr Ala Phe  
 835 840 845

-43-

Tyr His Ala Pro Ile Val Lys Phe Trp Phe Asn Thr Leu Ala Tyr Leu  
 850 855 860  
 Gly Phe Leu Met Leu Tyr Thr Phe Val Val Leu Val Gln Met Glu Gln  
 865 870 875 880  
 Leu Pro Ser Val Gln Glu Trp Ile Val Ile Ala Tyr Ile Phe Thr Tyr  
 885 890 895  
 Ala Ile Glu Lys Val Arg Glu Ile Phe Met Ser Glu Ala Gly Lys Val  
 900 905 910  
 Asn Gln Lys Ile Lys Val Trp Phe Ser Asp Tyr Phe Asn Ile Ser Asp  
 915 920 925  
 Thr Ile Ala Ile Ile Ser Phe Phe Ile Gly Phe Gly Leu Arg Phe Gly  
 930 935 940  
 Ala Lys Trp Asn Phe Ala Asn Ala Tyr Asp Asn His Val Phe Val Ala  
 945 950 955 960  
 Gly Arg Leu Ile Tyr Cys Leu Asn Ile Ile Phe Trp Tyr Val Arg Leu  
 965 970 975  
 Leu Asp Phe Leu Ala Val Asn Gln Gln Ala Gly Pro Tyr Val Met Met  
 980 985 990  
 Ile Gly Lys Met Val Ala Asn Met Phe Tyr Ile Val Val Ile Met Ala  
 995 1000 1005  
 Leu Val Leu Leu Ser Phe Gly Val Pro Arg Lys Ala Ile Leu Tyr Pro  
 1010 1015 1020  
 His Glu Ala Pro Ser Trp Thr Leu Ala Lys Asp Ile Val Phe His Pro  
 1025 1030 1035 1040  
 Tyr Trp Met Ile Phe Gly Glu Val Tyr Ala Tyr Glu Ile Asp Val Cys  
 1045 1050 1055  
 Ala Asn Asp Ser Val Ile Pro Gln Ile Cys Gly Pro Gly Thr Trp Leu  
 1060 1065 1070  
 Thr Pro Phe Leu Gln Ala Val Tyr Leu Phe Val Gln Tyr Ile Ile Met  
 1075 1080 1085  
 Val Asn Leu Leu Ile Ala Phe Phe Asn Asn Val Tyr Leu Gln Val Lys  
 1090 1095 1100  
 Ala Ile Ser Asn Ile Val Trp Lys Tyr Gln Arg Tyr His Phe Ile Met  
 1105 1110 1115 1120  
 Ala Tyr His Glu Lys Pro Val Leu Pro Pro Leu Ile Ile Leu Ser  
 1125 1130 1135  
 His Ile Val Ser Leu Phe Cys Cys Ile Cys Lys Arg Arg Lys Lys Asp  
 1140 1145 1150  
 Lys Thr Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp Gln Lys  
 1155 1160 1165  
 Lys Leu His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe Asn Glu  
 1170 1175 1180  
 Lys Asp Asp Lys Phe His Ser Gly Ser Glu Glu Arg Ile Arg Val Thr  
 1185 1190 1195 1200  
 Phe Glu Arg Val Glu Gln Met Cys Ile Gln Ile Lys Glu Val Gly Asp  
 1205 1210 1215  
 Arg Val Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser Gln Ile  
 1220 1225 1230  
 Gly His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu Lys Thr  
 1235 1240 1245  
 Leu Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn Glu Ile  
 1250 1255 1260  
 Thr Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu Ile Asp  
 1265 1270 1275 1280  
 Asp Gly Pro Val Arg Pro Ser Val Trp Lys Lys His Gly Val Val Asn  
 1285 1290 1295  
 Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Leu Glu Ser Asn Asn Pro  
 1300 1305 1310  
 Phe His Cys Asn Ile Leu Met Lys Asp Asp Lys Asp Pro Gln Cys Asn  
 1315 1320 1325



-44-

Ile Phe Gly Gln Asp Leu Pro Ala Val Pro Gln Arg Lys Glu Phe Asn  
 1330 1335 1340  
 Phe Pro Glu Ala Gly Ser Ser Ser Gly Ala Leu Phe Pro Ser Ala Val  
 1345 1350 1355 1360  
 Ser Pro Pro Glu Leu Arg Gln Arg Leu His Gly Val Glu Leu Leu Lys  
 1365 1370 1375  
 Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Ser Thr Ser Ile Pro  
 1380 1385 1390  
 His Leu Ser Ser Pro Pro Thr Lys Phe Phe Val Ser Thr Pro Ser Gln  
 1395 1400 1405  
 Pro Ser Cys Lys Ser His Leu Glu Thr Gly Thr Lys Asp Gln Glu Thr  
 1410 1415 1420  
 Val Cys Ser Lys Ala Thr Glu Gly Asp Asn Thr Glu Phe Gly Ala Phe  
 1425 1430 1435 1440  
 Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser  
 1445 1450 1455  
 Asn Lys Ile Lys Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn Thr Leu  
 1460 1465 1470  
 Lys Arg Val Ser Ser Leu Ala Gly Phe Thr Asp Cys His Arg Thr Ser  
 1475 1480 1485  
 Ile Pro Val His Ser Lys Gln Ala Glu Lys Ile Ser Arg Arg Pro Ser  
 1490 1495 1500  
 Thr Glu Asp Thr His Glu Val Asp Ser Lys Ala Ala Leu Ile Pro Asp  
 1505 1510 1515 1520  
 Trp Leu Gln Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu Glu Gly  
 1525 1530 1535  
 Thr Leu Asn Gly Leu Thr Ser Pro Phe Lys Pro Ala Met Asp Thr Asn  
 1540 1545 1550  
 Tyr Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met Arg Leu Ser Gln  
 1555 1560 1565  
 Ser Ile Pro Phe Thr Pro Val Pro Pro Arg Gly Glu Pro Val Thr Val  
 1570 1575 1580  
 Tyr Arg Leu Glu Glu Ser Ser Pro Asn Ile Leu Asn Asn Ser Met Ser  
 1585 1590 1595 1600  
 Ser Trp Ser Gln Leu Gly Leu Cys Ala Lys Ile Glu Phe Leu Ser Lys  
 1605 1610 1615  
 Glu Glu Met Gly Gly Gly Leu Arg Arg Ala Val Lys Val Gln Cys Thr  
 1620 1625 1630  
 Trp Ser Glu His Asp Ile Leu Lys Ser Gly His Leu Tyr Ile Ile Lys  
 1635 1640 1645  
 Ser Phe Leu Pro Glu Val Val Asn Thr Trp Ser Ser Ile Tyr Lys Glu  
 1650 1655 1660  
 Asp Thr Val Leu His Leu Cys Leu Arg Glu Ile Gln Gln Gln Arg Ala  
 1665 1670 1675 1680  
 Ala Gln Lys Leu Thr Phe Ala Phe Asn Gln Met Lys Pro Lys Ser Ile  
 1685 1690 1695  
 Pro Tyr Ser Pro Arg Phe Leu Glu Val Phe Leu Leu Tyr Cys His Ser  
 1700 1705 1710  
 Ala Gly Gln Trp Phe Ala Val Glu Glu Cys Met Thr Gly Glu Phe Arg  
 1715 1720 1725  
 Lys Tyr Asn Asn Asn Asn Gly Asp Glu Ile Ile Pro Thr Asn Thr Leu  
 1730 1735 1740  
 Glu Glu Ile Met Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr Arg  
 1745 1750 1755 1760  
 Gly Glu Leu Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn Leu Thr  
 1765 1770 1775  
 Asp Pro Ser Val Ile Lys Ala Glu Glu Lys Arg Ser Cys Asp Met Val  
 1780 1785 1790  
 Phe Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Lys Asn Phe Arg Ala  
 1795 1800 1805

-45-

Lys His His Cys Asn Ser Cys Cys Arg Lys Leu Lys Leu Pro Asp Leu  
 1810 1815 1820  
 Lys Arg Asn Asp Tyr Thr Pro Asp Lys Ile Ile Phe Pro Gln Asp Glu  
 1825 1830 1835 1840  
 Pro Ser Asp Leu Asn Leu Gln Pro Gly Asn Ser Thr Lys Glu Ser Glu  
 1845 1850 1855  
 Ser Thr Asn Ser Val Arg Leu Met Leu  
 1860 1865

<210> 29  
 <211> 4061  
 <212> DNA  
 <213> Homo Sapiens

<400> 29  
 ggtctggaag cagagccggc ggagggagcg ccggggccct gggctgcagg aggttgcggc 60  
 ggccgcggca gcatggtggt gccggagaag gagcagagct ggatcccaa gatcttcaag 120  
 aagaagacct gcacgacgtt catagttagc tccacagatc cgggaggagc cttgtgccag 180  
 tgtgggcggc cccggaccgc ccaccccgca gtggccatgg aggatgcctt cggggcagcc 240  
 gtggtgaccg tgtgggacag cgatgcacac accacggaga agcccaccga tgcctacgga 300  
 gagctggact tcacgggggc cggccgcaag cacagcaatt tcctccggct ctctgaccga 360  
 acggatccag ctgcagtta tagtctggtc acacgcacat ggggcttccg tgccccgaac 420  
 ctggtggtgt cagtgtctgg gggatcgggg ggccccgtcc tccagacctg gctgcaggac 480  
 ctgctgcgtc gtgggctggt gcgggctgcc cagagcacag gagcctggat tgtactggg 540  
 ggtctgcaca cgggcatcgg ccggcatggt ggtgtggctg tacgggacca tcagatggcc 600  
 agcactgggg gcaccaagggt ggtggccatg ggtgtggccc cctgggggtg ggtccggaat 660  
 agagacaccc tcatcaaccc caagggtctg ttccctgcga ggtaccggtg gcgcggtgac 720  
 ccggaggacg ggggtccagt tcccctggac tacaactact cggccttctt cctggtggac 780  
 gacggcacac acggtgcct ggggggcgag aaccgcttcc gcttgcgcct ggagtcctac 840  
 atctcacagc agaagacggg cgtgggaggg actggaattg acatccctgt cctgctctc 900  
 ctgattgatg gtgatgagaa gatgttgacg cgaatagaga acgccacca ggctcagctc 960  
 ccatgtctcc tegtggctgg ctcaggggga gctgcggact gcctggcgga gaccctggaa 1020  
 gacactctgg ccccagggag tgggggagcc aggcaaggcg aagcccgaga tcgaatcagg 1080  
 cgtttctttc ccaaagggga ccttgaggtc ctgcaggccc aggtggagag gattatgacc 1140  
 cggaaggagc tcctgacagt ctattcttct gaggtagggt ctgaggaatt cgagaccata 1200  
 gttttgaagg cccttgtaga ggcctgtggg agctcggagg cctcagccta cctggatgag 1260  
 ctgcgttttg ctgtggcttg gaaccgcgtg gacattgccc agagtgaact ctttcggggg 1320  
 gacatccaat ggcggtcctt ccatctcgaa gcttccctca tggacgccct gctgaatgac 1380  
 cggcctgagt tegtgcgtt gctcatttcc caccgacctc gcctgggcca cttcctgacc 1440  
 ccgatgcgcc tggcccaact ctacagcgcg gcgcctcca actcgctcat ccgcaacctt 1500  
 ttggaccagg cgtcccacag cgcaggcacc aaagccccag ccctaaaagg gggagctgcg 1560  
 gagctccggc cccctgacgt ggggcattgt ctgaggatgc tgctggggaa gatgtgcgcg 1620  
 ccgaggtacc cctccggggg cgcctgggac cctcaccag gccagggctt cggggagagc 1680  
 atgtatctgc tctcggacaa ggccacctcg ccgctctcgc tggatgctgg cctcgggcag 1740  
 gccccctgga gcgacctgct tctttgggca ctggtgctga acagggcaca gatggccatg 1800  
 tacttctggg agatgggttc caatgcagtt tcctcagctc ttggggcctg tttgctgctc 1860  
 cgggtgatgg cagcctgga gcctgacgt gaggaggcag cacggaggaa agacctggcg 1920  
 ttcaagtttg aggggatgg cggtgacctc tttggcgagt gctatcgag cagtgagggt 1980  
 agggctgccc gcctcctcct ccgtcgctgc ccgctctggg gggatgccac ttgcctccag 2040  
 ctggccatgc aagctgacgc ccgtgccttc tttgcccagg atggggtaca gtctctgctg 2100  
 acacagaagt ggtggggaga tatggccagc actacaccca tctgggccct ggttctcgcc 2160  
 ttcttttgcc ctccactcat ctacaccgcg ctcatcacct tcaggaaatc agaagaggag 2220  
 cccacacggg aggagctaga gtttgacatg gatagtgtca ttaatgggga agggcctgtc 2280  
 gggacggcgg acccagccga gaagacggcg ctgggggtcc cgcgccagtc gggccgtccg 2340  
 ggttgctgcg ggggcccgtg cggggggcgc cgggtgcctac gccgctggtt ccacttctgg 2400  
 ggcgcgccgg tgaccatctt catgggcaac gtggtcagct acctgctgtt cctgctgctt 2460  
 ttctcgcggg tctgctcgt ggatttccag ccggcgccgc ccggtccct ggagctgctg 2520  
 ctctatttct gggctttcac gctgctgtgc gaggaactgc gccagggcct gagcggaggc 2580  
 gggggcagcc tcgccagcgg gggccccggg cctggccatg cctcactgag ccagcgccgt 2640  
 cgctctacc tcgccgacag ctggaaccag tgcgacctag tggctctcac ctgcttctc 2700

-46-

```

ctgggcgtgg gctgccggct gaccccggtt ttgtaccacc tgggccgcac tgtcctctgc 2760
atcgacttca tggttttcac ggtgcggctg cttcacatct tcacggtcaa caaacagctg 2820
gggccaaga tcgtcatcgt gagcaagatg atgaaggacg tgtttcttct cctcttcttc 2880
ctcggcggtg ggctggtagc ctatggcggt gccacggagg ggctcctgag gccacgggac 2940
agtgaattcc caagtatcct gcgcgcgtc ttctaccgtc cctacctgca gatcttcggg 3000
cagattcccc aggaggacat ggacgtggcc ctcatggagc acagcaactg ctcgtcggag 3060
cccggcttct gggcacaccc tcctggggcc caggcgggca cctgcgtctc ccagtatgcc 3120
aactggctgg tgggtgctgt cctcgtcatc ttctgctcgt tggccaacat cctgctggtc 3180
aacttgctca ttgccatgtt cagttacaca ttcggaagag tacagggcaa cagcgatctc 3240
tactggaagg cgcagcggtta ccgcctcatc cgggaattcc actctcggcc cgcgctggcc 3300
ccgccttta tcgtcatctc ccaattgcgc ctctgctca ggcaattgtg caggcgaccc 3360
cggagcccc agcgcctc cccggccctc gagcatttcc gggtttacct ttctaaggaa 3420
gccgagcggg agctgctaac gtgggaatcg gtgcataagg agaactttct gctggcacgc 3480
gctagggaca agcgggagag cgactccgag cgtctgaagc gcacgtccca gaaggtggac 3540
ttggcactga aacagctggg acacatccgc gactacgaac agcgcctgaa agtgctggag 3600
cgggaggtcc agcagtgtag ccgcgtcctg ggggtgggtg ccgaggccct gagccgctct 3660
gccttgctgc ccccaggtgg gccgccaccc cctgacctgc ctgggtccaa agactgagcc 3720
ctgctggcgg acttcaagga gaagccccc caggggattt tgctcctaga gtaaggctca 3780
tctgggcctc ggccccgca cctggtggcc ttgtccttga ggtgagcccc atgtccatct 3840
gggcaactgt caggaccacc tttgggagtg tcatccttac aaaccacagc atgcccggt 3900
cctcccagaa ccagtcccag cctgggagga tcaaggcctg gatccccggc cgttatccat 3960
ctggaggtg cagggtcctt ggggtaacag ggaccacaga cccctcacca ctcacagatt 4020
ctcacactg gggaaataaa gccatttcag aggaaaaaa a 4061

```

&lt;210&gt; 30

&lt;211&gt; 1214

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 30

```

Met Val Val Pro Glu Lys Glu Gln Ser Trp Ile Pro Lys Ile Phe Lys
 1          5          10          15
Lys Lys Thr Cys Thr Thr Phe Ile Val Asp Ser Thr Asp Pro Gly Gly
 20          25          30
Thr Leu Cys Gln Cys Gly Arg Pro Arg Thr Ala His Pro Ala Val Ala
 35          40          45
Met Glu Asp Ala Phe Gly Ala Ala Val Val Thr Val Trp Asp Ser Asp
 50          55          60
Ala His Thr Thr Glu Lys Pro Thr Asp Ala Tyr Gly Glu Leu Asp Phe
 65          70          75          80
Thr Gly Ala Gly Arg Lys His Ser Asn Phe Leu Arg Leu Ser Asp Arg
 85          90          95
Thr Asp Pro Ala Ala Val Tyr Ser Leu Val Thr Arg Thr Trp Gly Phe
100          105          110
Arg Ala Pro Asn Leu Val Val Ser Val Leu Gly Gly Ser Gly Gly Pro
115          120          125
Val Leu Gln Thr Trp Leu Gln Asp Leu Leu Arg Arg Gly Leu Val Arg
130          135          140
Ala Ala Gln Ser Thr Gly Ala Trp Ile Val Thr Gly Gly Leu His Thr
145          150          155          160
Gly Ile Gly Arg His Val Gly Val Ala Val Arg Asp His Gln Met Ala
165          170          175
Ser Thr Gly Gly Thr Lys Val Val Ala Met Gly Val Ala Pro Trp Gly
180          185          190
Val Val Arg Asn Arg Asp Thr Leu Ile Asn Pro Lys Gly Ser Phe Pro
195          200          205
Ala Arg Tyr Arg Trp Arg Gly Asp Pro Glu Asp Gly Val Gln Phe Pro
210          215          220
Leu Asp Tyr Asn Tyr Ser Ala Phe Phe Leu Val Asp Asp Gly Thr His
225          230          235          240

```

-47-

Gly Cys Leu Gly Gly Glu Asn Arg Phe Arg Leu Arg Leu Glu Ser Tyr  
 245 250 255  
 Ile Ser Gln Gln Lys Thr Gly Val Gly Gly Thr Gly Ile Asp Ile Pro  
 260 265 270  
 Val Leu Leu Leu Leu Ile Asp Gly Asp Glu Lys Met Leu Thr Arg Ile  
 275 280 285  
 Glu Asn Ala Thr Gln Ala Gln Leu Pro Cys Leu Leu Val Ala Gly Ser  
 290 295 300  
 Gly Gly Ala Ala Asp Cys Leu Ala Glu Thr Leu Glu Asp Thr Leu Ala  
 305 310 315 320  
 Pro Gly Ser Gly Gly Ala Arg Gln Gly Glu Ala Arg Asp Arg Ile Arg  
 325 330 335  
 Arg Phe Phe Pro Lys Gly Asp Leu Glu Val Leu Gln Ala Gln Val Glu  
 340 345 350  
 Arg Ile Met Thr Arg Lys Glu Leu Thr Val Tyr Ser Ser Glu Asp  
 355 360 365  
 Gly Ser Glu Glu Phe Glu Thr Ile Val Leu Lys Ala Leu Val Lys Ala  
 370 375 380  
 Cys Gly Ser Ser Glu Ala Ser Ala Tyr Leu Asp Glu Leu Arg Leu Ala  
 385 390 395 400  
 Val Ala Trp Asn Arg Val Asp Ile Ala Gln Ser Glu Leu Phe Arg Gly  
 405 410 415  
 Asp Ile Gln Trp Arg Ser Phe His Leu Glu Ala Ser Leu Met Asp Ala  
 420 425 430  
 Leu Leu Asn Asp Arg Pro Glu Phe Val Arg Leu Leu Ile Ser His Gly  
 435 440 445  
 Leu Ser Leu Gly His Phe Leu Thr Pro Met Arg Leu Ala Gln Leu Tyr  
 450 455 460  
 Ser Ala Ala Pro Ser Asn Ser Leu Ile Arg Asn Leu Leu Asp Gln Ala  
 465 470 475 480  
 Ser His Ser Ala Gly Thr Lys Ala Pro Ala Leu Lys Gly Gly Ala Ala  
 485 490 495  
 Glu Leu Arg Pro Asp Val Gly His Val Leu Arg Met Leu Leu Gly  
 500 505 510  
 Lys Met Cys Ala Pro Arg Tyr Pro Ser Gly Gly Ala Trp Asp Pro His  
 515 520 525  
 Pro Gly Gln Gly Phe Gly Glu Ser Met Tyr Leu Leu Ser Asp Lys Ala  
 530 535 540  
 Thr Ser Pro Leu Ser Leu Asp Ala Gly Leu Gly Gln Ala Pro Trp Ser  
 545 550 555 560  
 Asp Leu Leu Leu Trp Ala Leu Leu Leu Asn Arg Ala Gln Met Ala Met  
 565 570 575  
 Tyr Phe Trp Glu Met Gly Ser Asn Ala Val Ser Ser Ala Leu Gly Ala  
 580 585 590  
 Cys Leu Leu Arg Val Met Ala Arg Leu Glu Pro Asp Ala Glu Glu  
 595 600 605  
 Ala Ala Arg Arg Lys Asp Leu Ala Phe Lys Phe Glu Gly Met Gly Val  
 610 615 620  
 Asp Leu Phe Gly Glu Cys Tyr Arg Ser Ser Glu Val Arg Ala Ala Arg  
 625 630 635 640  
 Leu Leu Leu Arg Arg Cys Pro Leu Trp Gly Asp Ala Thr Cys Leu Gln  
 645 650 655  
 Leu Ala Met Gln Ala Asp Ala Arg Ala Phe Phe Ala Gln Asp Gly Val  
 660 665 670  
 Gln Ser Leu Leu Thr Gln Lys Trp Trp Gly Asp Met Ala Ser Thr Thr  
 675 680 685  
 Pro Ile Trp Ala Leu Val Leu Ala Phe Phe Cys Pro Pro Leu Ile Tyr  
 690 695 700  
 Thr Arg Leu Ile Thr Phe Arg Lys Ser Glu Glu Pro Thr Arg Glu  
 705 710 715 720

-48-

Glu Leu Glu Phe Asp Met Asp Ser Val Ile Asn Gly Glu Gly Pro Val  
 725 730 735  
 Gly Thr Ala Asp Pro Ala Glu Lys Thr Pro Leu Gly Val Pro Arg Gln  
 740 745 750  
 Ser Gly Arg Pro Gly Cys Cys Gly Gly Arg Cys Gly Gly Arg Arg Cys  
 755 760 765  
 Leu Arg Arg Trp Phe His Phe Trp Gly Ala Pro Val Thr Ile Phe Met  
 770 775 780  
 Gly Asn Val Val Ser Tyr Leu Leu Phe Leu Leu Phe Ser Arg Val  
 785 790 795 800  
 Leu Leu Val Asp Phe Gln Pro Ala Pro Pro Gly Ser Leu Glu Leu Leu  
 805 810 815  
 Leu Tyr Phe Trp Ala Phe Thr Leu Leu Cys Glu Glu Leu Arg Gln Gly  
 820 825 830  
 Leu Ser Gly Gly Gly Gly Ser Leu Ala Ser Gly Gly Pro Gly Pro Gly  
 835 840 845  
 His Ala Ser Leu Ser Gln Arg Leu Arg Leu Tyr Leu Ala Asp Ser Trp  
 850 855 860  
 Asn Gln Cys Asp Leu Val Ala Leu Thr Cys Phe Leu Leu Gly Val Gly  
 865 870 875 880  
 Cys Arg Leu Thr Pro Gly Leu Tyr His Leu Gly Arg Thr Val Leu Cys  
 885 890 895  
 Ile Asp Phe Met Val Phe Thr Val Arg Leu Leu His Ile Phe Thr Val  
 900 905 910  
 Asn Lys Gln Leu Gly Pro Lys Ile Val Ile Val Ser Lys Met Met Lys  
 915 920 925  
 Asp Val Phe Phe Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr  
 930 935 940  
 Gly Val Ala Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro  
 945 950 955 960  
 Ser Ile Leu Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gln Ile Phe Gly  
 965 970 975  
 Gln Ile Pro Gln Glu Asp Met Asp Val Ala Leu Met Glu His Ser Asn  
 980 985 990  
 Cys Ser Ser Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gln Ala  
 995 1000 1005  
 Gly Thr Cys Val Ser Gln Tyr Ala Asn Trp Leu Val Val Leu Leu Leu  
 1010 1015 1020  
 Val Ile Phe Leu Leu Val Ala Asn Ile Leu Leu Val Asn Leu Leu Ile  
 1025 1030 1035 1040  
 Ala Met Phe Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu  
 1045 1050 1055  
 Tyr Trp Lys Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg  
 1060 1065 1070  
 Pro Ala Leu Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu  
 1075 1080 1085  
 Leu Arg Gln Leu Cys Arg Arg Pro Arg Ser Pro Gln Pro Ser Ser Pro  
 1090 1095 1100  
 Ala Leu Glu His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys  
 1105 1110 1115 1120  
 Leu Leu Thr Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg  
 1125 1130 1135  
 Ala Arg Asp Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser  
 1140 1145 1150  
 Gln Lys Val Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr  
 1155 1160 1165  
 Glu Gln Arg Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Ser Arg  
 1170 1175 1180  
 Val Leu Gly Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro  
 1185 1190 1195 1200

Pro Gly Gly Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp  
1205 1210

<210> 31  
<211> 4646  
<212> DNA  
<213> Homo Sapiens

<400> 31  
tcgacccacg cgtccgcccc cgcgtccgcc caccgcgtccg cccacgcgtc cgccccacgcg 60  
tccgccccacg cgtccgggggt gaaagmramy cmygcktsms aaaaaccgtc acttaggaaa 120  
agatgtcctt tcgggcagcc aggtcagca tgaggaacag aaggaatgac actctggaca 180  
gcacccggac cctgtactcc agcgcgtctc ggagcacaga cttgtcttac agtgaaagcg 240  
acttggtgaa ttttattcaa gcaaatttta agaaacgaga atgtgtcttc tttaccaaag 300  
attccaaggc cacggagaat gtgtgcaagt gtggctatgc ccagagccag cacatggaag 360  
gcacccagat caaccaaagt gagaaatgga actacaagaa acacaccaag gaatttccta 420  
ccgacgcctt tggggatatt cagtttgaga cactggggaa gaaagggaag tatatacgtc 480  
tgtcctgcga cccggacgcg gaaatccttt acgagctgct gacccagcac tggcacctga 540  
aaacacccaa cctggtcatt tctgtgaccg ggggcgccaa gaacttcgcc ctgaagccgc 600  
gcattgcgcaa gatcttcagc cggtcatctt acatcgcgca gtccaaagggt gcttggattc 660  
tcacgggagg caccattat ggctgatga agtacatcg ggaggtggtg agagataaca 720  
ccatcagcag gatttcagag gagaatattg tggccattgg catagcagct tggggcatgg 780  
tctccaaccg ggacaccctc atcaggaatt gcgatgctga gggctatttt ttagccagct 840  
accttatgga tgacttcaca agagatccac tgtgtatcct ggacaacaac cacacacatt 900  
tgctgctcgt ggacaatggc tgtcatggac atcccactgt cgaagcaaag ctccggaatc 960  
agctagagaa gtatatctct gagcgcaacta ttcaagattc caactatggt ggcaagatcc 1020  
ccattgtgtg ttttgcccaa ggaggtggaa aagagacttt gaaagccatc aatacctcca 1080  
tcaaaaataa aattccttgt gtggtggtgg aaggctcggg ccagatcgct gatgtgatcg 1140  
ctagcctggt ggaggtggag gatgccctga catcttctgc cgtcaaggag aagctggtgc 1200  
gctttttacc ccgcacgggtg tcccggtctgc ctgaggagga gactgagagt tggatcaaat 1260  
ggctcaaaga aattctcgaa tgttctcacc tattaacagt tattaanaatg gaagaagctg 1320  
gggatgaaat tgtgagcaat gccatctcct acgctctata caaagccttc agcaccagtg 1380  
agcaagacaa ggataactgg aatgggcagc tgaagcttct gctggagtgg aaccagctgg 1440  
acttagccaa tgatgagatt ttcaccaatg accgcgatg ggagtctgct gaccttcaag 1500  
aagtcattgt tacggctctc ataaaggaca gaccaaagtt tgtccgcctc tttctggaga 1560  
atggcttgaa cctacggaag tttctcacc atgatgtcct cactgaactc tttctcaacc 1620  
acttcagcac gcttgtgtac cggaaatctgc agatcgccaa gaattcctat aatgatgccc 1680  
tcctcacggt tgtctggaaa ctggttgcaa acttcggaag aggtctccgg aaggaagaca 1740  
gaaatggccg ggacgagatg gacatagaac tccacgacgt gtctcctatt actcggcacc 1800  
ccctgcaagc tctcttcac tggggcattc ttcagaataa gaaggaaactc tccaaagtca 1860  
tttgggagca gaccaggggc tgcactctgg cagccctggg agccagcaag cttctgaaga 1920  
ctctggccaa agtgaagaac gacatcaatg ctgctgggga gtccgaggag ctggctaagt 1980  
agtacgagac ccgggtctgt gagctgttca ctgagtgtta cagcagcgat gaagacttgg 2040  
cagaacagct gctggtctat tccgtggaag cttggggtgg aagcaactgt ctggagctgg 2100  
cgggtggaggc cacagaccag catttcacg cccagcctgg ggtccagaat tttctttcta 2160  
agcaatggta tggagagatt tcccgagaca ccaagaactg gaagattatc ctgtgtctgt 2220  
ttattatacc cttggtgggc tgtggctttg tatcatttag gaagaaacct gtcgacaagc 2280  
acaagaagct gctttggtac tatgtggcgt tcttcacctc ccccttcgtg gtcttctcct 2340  
ggaatgtggt cttctacatc gccttcctcc tgcgttttgc ctacgtgctg ctcatggatt 2400  
tccattcggt gccacacccc cccgagctgg tccgtgactc gctgggtctt gtccctctct 2460  
gtgatgaagt gagacagtgg tacgtaaatg ggggtaatta ttttactgac ctgtggaatg 2520  
tgatggacac gctggggctt ttttacttca tagcaggaat tgtatttcgg ctccactctt 2580  
ctaataaaaag ctctttgtat tctggacgag tcattttctg tctggactac attattttca 2640  
ctctaagatt gatccacatt tttactgtaa gcagaaactt aggacccaag attataatgc 2700  
tgcagaggat gctgatcgat gtgttcttct tccgttccct ctttgcggtg tggatggtg 2760  
cctttggcgt ggccaggcaa gggatcctta ggcagaatga gcagcgctgg aggtggatat 2820  
tccgttcggt catctacgag ccctacctgg ccatgttccg ccaggtgcc aagtacgtgg 2880  
atggtaccac gtatgacttt gccactgca ccttactgg gaatgagtc aagccactgt 2940  
gtgtggagct ggatgagcac aacctgcccc ggttccccga gtggatcacc atccccctgg 3000  
tgtgcatcta catgttatcc accaacatcc tgctggtcaa cctgctggtc gccatgtttg 3060

-50-

```

gctacacggt gggcaccgtc caggagaaca atgaccaggt ctggaagttc cagaggtact 3120
tcttgggtgca ggagtactgc agccgcctca atatccctt ccccttcac gtcttcgctt 3180
acttctacat ggtggtgaag aagtgttca agtgttgctg caaggagaaa aacatggagt 3240
cttctgtctg ctgtttcaaa aatgaagaca atgagactct ggcatgggag ggtgtcatga 3300
aggaaaacta ccttgtcaag atcaacacaa aagccaacga cacctcagag gaaatgaggc 3360
atcgatttag acaactggat acaaagctta atgatctcaa ggtcttctg aaagagattg 3420
ctaataaaat caaataaaac tgtatgaact ctaatggaga aaaatctaata tatagcaaga 3480
tcatattaag gaatgctgat gaacaatttt gctatcgact actaaatgag agattttcag 3540
acccctgggt acatggtgga tgattttaaa tcaccctagt gtgctgagac cttgagaata 3600
aagtgtgtga ttggtttcat acttgaagac ggatataaag gaagaatatt tcctttatgt 3660
gtttctccag aatggtgcct gtttctctct gtgtctcaat gcctgggact ggaggttgat 3720
agtttaagtg tgttcttacc gcctcctttt tcctttaatc ttatttttga tgaacacata 3780
tataggagaa catctatcct atgaataaga acctggatcat gctttactcc tgtattgtta 3840
ttttgttcat ttccaattga ttctctactt ttcccttttt tgtattatgt gactaattag 3900
ttggcatatt gtwaagaagtc tctcaaatta ggccagattc taaaacatgc tgcagcaaga 3960
ggaccccgct ctcttcagga aaagtgtttt catttctcag gatgcttctt acctgtcaga 4020
ggaggtgaca aggcagtctc ttgctctctt ggactcacca ggctcctatt gaaggaacca 4080
ccccatttcc taaatatgtg aaaagtgcgc caaaatgcaa ccttgaaagg cactactgac 4140
tttgttctta ttggatactc ctcttattta ttatttttcc attaaaaata atagctggct 4200
attatagaaa atttagacca tacagagatg tagaagaac ataaattgtc cccattacct 4260
taaggtaatc actgctaaca atttctggat ggtttttcaa gtctattttt tttctatgta 4320
tgtctcaatt ctctttcaaa attttacaga atgttatcat actacatata tactttttat 4380
gtaagctttt tcacttagta ttttatcaaa tatgttttta ttatattcat agccttctta 4440
aacattatat caataattgc ataataggca acctctagcg attaccataa ttttgctcat 4500
tgaaggctat ctccagttga tcattgggat gagcatcttt gtgcatgaat cctattgctg 4560
tatttgggaa aattttccaa ggttagattc caataaatat ctatttatta ttaaaaaaaa 4620
aaaaaaaaag gcggccgctc tagagt 4646

```

&lt;210&gt; 32

&lt;211&gt; 1104

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 32

```

Met Ser Phe Arg Ala Ala Arg Leu Ser Met Arg Asn Arg Arg Asn Asp
1          5          10          15
Thr Leu Asp Ser Thr Arg Thr Leu Tyr Ser Ser Ala Ser Arg Ser Thr
20          25          30
Asp Leu Ser Tyr Ser Glu Ser Asp Leu Val Asn Phe Ile Gln Ala Asn
35          40          45
Phe Lys Lys Arg Glu Cys Val Phe Phe Thr Lys Asp Ser Lys Ala Thr
50          55          60
Glu Asn Val Cys Lys Cys Gly Tyr Ala Gln Ser Gln His Met Glu Gly
65          70          75          80
Thr Gln Ile Asn Gln Ser Glu Lys Trp Asn Tyr Lys Lys His Thr Lys
85          90          95
Glu Phe Pro Thr Asp Ala Phe Gly Asp Ile Gln Phe Glu Thr Leu Gly
100         105         110
Lys Lys Gly Lys Tyr Ile Arg Leu Ser Cys Asp Thr Asp Ala Glu Ile
115         120         125
Leu Tyr Glu Leu Leu Thr Gln His Trp His Leu Lys Thr Pro Asn Leu
130         135         140
Val Ile Ser Val Thr Gly Gly Ala Lys Asn Phe Ala Leu Lys Pro Arg
145         150         155         160
Met Arg Lys Ile Phe Ser Arg Leu Ile Tyr Ile Ala Gln Ser Lys Gly
165         170         175
Ala Trp Ile Leu Thr Gly Gly Thr His Tyr Gly Leu Met Lys Tyr Ile
180         185         190
Gly Glu Val Val Arg Asp Asn Thr Ile Ser Arg Ser Ser Glu Glu Asn
195         200         205

```

-51-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Val | Ala | Ile | Gly | Ile | Ala | Ala | Trp | Gly | Met | Val | Ser | Asn | Arg | Asp |
| 210 |     |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Thr | Leu | Ile | Arg | Asn | Cys | Asp | Ala | Glu | Gly | Tyr | Phe | Leu | Ala | Gln | Tyr |
| 225 |     |     |     | 230 |     |     |     |     |     | 235 |     |     |     |     | 240 |
| Leu | Met | Asp | Asp | Phe | Thr | Arg | Asp | Pro | Leu | Cys | Ile | Leu | Asp | Asn | Asn |
|     |     |     |     | 245 |     |     |     |     |     | 250 |     |     |     | 255 |     |
| His | Thr | His | Leu | Leu | Leu | Val | Asp | Asn | Gly | Cys | His | Gly | His | Pro | Thr |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Val | Glu | Ala | Lys | Leu | Arg | Asn | Gln | Leu | Glu | Lys | Tyr | Ile | Ser | Glu | Arg |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Thr | Ile | Gln | Asp | Ser | Asn | Tyr | Gly | Gly | Lys | Ile | Pro | Ile | Val | Cys | Phe |
|     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Ala | Gln | Gly | Gly | Gly | Lys | Glu | Thr | Leu | Lys | Ala | Ile | Asn | Thr | Ser | Ile |
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |
| Lys | Asn | Lys | Ile | Pro | Cys | Val | Val | Val | Glu | Gly | Ser | Gly | Gln | Ile | Ala |
|     |     |     |     | 325 |     |     |     |     |     | 330 |     |     |     | 335 |     |
| Asp | Val | Ile | Ala | Ser | Leu | Val | Glu | Val | Glu | Asp | Ala | Leu | Thr | Ser | Ser |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |
| Ala | Val | Lys | Glu | Lys | Leu | Val | Arg | Phe | Leu | Pro | Arg | Thr | Val | Ser | Arg |
|     |     | 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |     |     |
| Leu | Pro | Glu | Glu | Glu | Thr | Glu | Ser | Trp | Ile | Lys | Trp | Leu | Lys | Glu | Ile |
|     |     | 370 |     |     |     | 375 |     |     |     |     |     | 380 |     |     |     |
| Leu | Glu | Cys | Ser | His | Leu | Leu | Thr | Val | Ile | Lys | Met | Glu | Glu | Ala | Gly |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Asp | Glu | Ile | Val | Ser | Asn | Ala | Ile | Ser | Tyr | Ala | Leu | Tyr | Lys | Ala | Phe |
|     |     |     |     | 405 |     |     |     |     | 410 |     |     |     |     | 415 |     |
| Ser | Thr | Ser | Glu | Gln | Asp | Lys | Asp | Asn | Trp | Asn | Gly | Gln | Leu | Lys | Leu |
|     |     |     | 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Leu | Leu | Glu | Trp | Asn | Gln | Leu | Asp | Leu | Ala | Asn | Asp | Glu | Ile | Phe | Thr |
|     |     | 435 |     |     |     | 440 |     |     |     |     |     | 445 |     |     |     |
| Asn | Asp | Arg | Arg | Trp | Glu | Ser | Ala | Asp | Leu | Gln | Glu | Val | Met | Phe | Thr |
|     |     | 450 |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Ala | Leu | Ile | Lys | Asp | Arg | Pro | Lys | Phe | Val | Arg | Leu | Phe | Leu | Glu | Asn |
| 465 |     |     |     |     | 470 |     |     |     | 475 |     |     |     |     |     | 480 |
| Gly | Leu | Asn | Leu | Arg | Lys | Phe | Leu | Thr | His | Asp | Val | Leu | Thr | Glu | Leu |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Phe | Ser | Asn | His | Phe | Ser | Thr | Leu | Val | Tyr | Arg | Asn | Leu | Gln | Ile | Ala |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Lys | Asn | Ser | Tyr | Asn | Asp | Ala | Leu | Leu | Thr | Phe | Val | Trp | Lys | Leu | Val |
|     |     | 515 |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| Ala | Asn | Phe | Arg | Arg | Gly | Phe | Arg | Lys | Glu | Asp | Arg | Asn | Gly | Arg | Asp |
|     |     | 530 |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |
| Glu | Met | Asp | Ile | Glu | Leu | His | Asp | Val | Ser | Pro | Ile | Thr | Arg | His | Pro |
| 545 |     |     |     |     | 550 |     |     |     | 555 |     |     |     |     |     | 560 |
| Leu | Gln | Ala | Leu | Phe | Ile | Trp | Ala | Ile | Leu | Gln | Asn | Lys | Lys | Glu | Leu |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |
| Ser | Lys | Val | Ile | Trp | Glu | Gln | Thr | Arg | Gly | Cys | Thr | Leu | Ala | Ala | Leu |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Gly | Ala | Ser | Lys | Leu | Leu | Lys | Thr | Leu | Ala | Lys | Val | Lys | Asn | Asp | Ile |
|     |     | 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |
| Asn | Ala | Ala | Gly | Glu | Ser | Glu | Glu | Leu | Ala | Asn | Glu | Tyr | Glu | Thr | Arg |
|     |     | 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |
| Ala | Val | Glu | Leu | Phe | Thr | Glu | Cys | Tyr | Ser | Ser | Asp | Glu | Asp | Leu | Ala |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Glu | Gln | Leu | Leu | Val | Tyr | Ser | Cys | Glu | Ala | Trp | Gly | Gly | Ser | Asn | Cys |
|     |     |     |     | 645 |     |     |     |     |     | 650 |     |     |     | 655 |     |
| Leu | Glu | Leu | Ala | Val | Glu | Ala | Thr | Asp | Gln | His | Phe | Ile | Ala | Gln | Pro |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Gly | Val | Gln | Asn | Phe | Leu | Ser | Lys | Gln | Trp | Tyr | Gly | Glu | Ile | Ser | Arg |
|     |     |     | 675 |     |     |     | 680 |     |     |     |     | 685 |     |     |     |



|      |     |     |     |     |      |      |      |     |     |      |      |      |     |     |      |
|------|-----|-----|-----|-----|------|------|------|-----|-----|------|------|------|-----|-----|------|
| Asp  | Thr | Lys | Asn | Trp | Lys  | Ile  | Ile  | Leu | Cys | Leu  | Phe  | Ile  | Ile | Pro | Leu  |
| 690  |     |     |     |     |      | 695  |      |     |     |      | 700  |      |     |     |      |
| Val  | Gly | Cys | Gly | Phe | Val  | Ser  | Phe  | Arg | Lys | Lys  | Pro  | Val  | Asp | Lys | His  |
| 705  |     |     |     |     | 710  |      |      |     |     | 715  |      |      |     |     | 720  |
| Lys  | Lys | Leu | Leu | Trp | Tyr  | Tyr  | Val  | Ala | Phe | Phe  | Thr  | Ser  | Pro | Phe | Val  |
|      |     |     |     | 725 |      |      |      |     | 730 |      |      |      |     |     | 735  |
| Val  | Phe | Ser | Trp | Asn | Val  | Val  | Phe  | Tyr | Ile | Ala  | Phe  | Leu  | Leu | Leu | Phe  |
|      |     |     | 740 |     |      |      |      | 745 |     |      |      |      | 750 |     |      |
| Ala  | Tyr | Val | Leu | Leu | Met  | Asp  | Phe  | His | Ser | Val  | Pro  | His  | Pro | Pro | Gly  |
|      |     |     | 755 |     |      |      | 760  |     |     |      |      | 765  |     |     |      |
| Leu  | Val | Leu | Tyr | Ser | Leu  | Val  | Phe  | Val | Leu | Phe  | Cys  | Asp  | Glu | Val | Arg  |
|      |     |     | 770 |     |      |      | 775  |     |     |      |      | 780  |     |     |      |
| Gln  | Trp | Tyr | Val | Asn | Gly  | Val  | Asn  | Tyr | Phe | Thr  | Asp  | Leu  | Trp | Asn | Val  |
| 785  |     |     |     |     | 790  |      |      |     |     | 795  |      |      |     |     | 800  |
| Met  | Asp | Thr | Leu | Gly | Leu  | Phe  | Tyr  | Phe | Ile | Ala  | Gly  | Ile  | Val | Phe | Arg  |
|      |     |     |     | 805 |      |      |      |     | 810 |      |      |      |     | 815 |      |
| Leu  | His | Ser | Ser | Asn | Lys  | Ser  | Ser  | Leu | Tyr | Ser  | Gly  | Arg  | Val | Ile | Phe  |
|      |     |     | 820 |     |      |      |      | 825 |     |      |      |      | 830 |     |      |
| Cys  | Leu | Asp | Tyr | Ile | Ile  | Phe  | Thr  | Leu | Arg | Leu  | Ile  | His  | Ile | Phe | Thr  |
|      |     |     | 835 |     |      |      | 840  |     |     |      |      | 845  |     |     |      |
| Val  | Ser | Arg | Asn | Leu | Gly  | Pro  | Lys  | Ile | Ile | Met  | Leu  | Gln  | Arg | Met | Leu  |
|      |     |     |     |     |      | 855  |      |     |     |      | 860  |      |     |     |      |
| Ile  | Asp | Val | Phe | Phe | Phe  | Leu  | Phe  | Leu | Phe | Ala  | Val  | Trp  | Met | Val | Ala  |
| 865  |     |     |     |     | 870  |      |      |     |     | 875  |      |      |     |     | 880  |
| Phe  | Gly | Val | Ala | Arg | Gln  | Gly  | Ile  | Leu | Arg | Gln  | Asn  | Glu  | Gln | Arg | Trp  |
|      |     |     |     | 885 |      |      |      |     | 890 |      |      |      |     | 895 |      |
| Arg  | Trp | Ile | Phe | Arg | Ser  | Val  | Ile  | Tyr | Glu | Pro  | Tyr  | Leu  | Ala | Met | Phe  |
|      |     |     | 900 |     |      |      |      | 905 |     |      |      |      | 910 |     |      |
| Gly  | Gln | Val | Pro | Ser | Asp  | Val  | Asp  | Gly | Thr | Thr  | Tyr  | Asp  | Phe | Ala | His  |
|      |     |     | 915 |     |      |      | 920  |     |     |      |      | 925  |     |     |      |
| Cys  | Thr | Phe | Thr | Gly | Asn  | Glu  | Ser  | Lys | Pro | Leu  | Cys  | Val  | Glu | Leu | Asp  |
|      |     |     |     |     |      | 935  |      |     |     |      | 940  |      |     |     |      |
| Glu  | His | Asn | Leu | Pro | Arg  | Phe  | Pro  | Glu | Trp | Ile  | Thr  | Ile  | Pro | Leu | Val  |
| 945  |     |     |     |     | 950  |      |      |     |     | 955  |      |      |     |     | 960  |
| Cys  | Ile | Tyr | Met | Leu | Ser  | Thr  | Asn  | Ile | Leu | Leu  | Val  | Asn  | Leu | Leu | Val  |
|      |     |     |     | 965 |      |      |      |     | 970 |      |      |      |     | 975 |      |
| Ala  | Met | Phe | Gly | Tyr | Thr  | Val  | Gly  | Thr | Val | Gln  | Glu  | Asn  | Asn | Asp | Gln  |
|      |     |     | 980 |     |      |      |      | 985 |     |      |      |      | 990 |     |      |
| Val  | Trp | Lys | Phe | Gln | Arg  | Tyr  | Phe  | Leu | Val | Gln  | Glu  | Tyr  | Cys | Ser | Arg  |
|      |     |     | 995 |     |      |      | 1000 |     |     |      |      | 1005 |     |     |      |
| Leu  | Asn | Ile | Pro | Phe | Pro  | Phe  | Ile  | Val | Phe | Ala  | Tyr  | Phe  | Tyr | Met | Val  |
|      |     |     |     |     |      | 1015 |      |     |     |      | 1020 |      |     |     |      |
| Val  | Lys | Lys | Cys | Phe | Lys  | Cys  | Cys  | Cys | Lys | Glu  | Lys  | Asn  | Met | Glu | Ser  |
| 1025 |     |     |     |     | 1030 |      |      |     |     | 1035 |      |      |     |     | 1040 |
| Ser  | Val | Cys | Cys | P   |      |      |      |     |     |      |      |      |     |     |      |

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/29996

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/705 C12N15/12 C12Q1/68 C12N5/10 C07K16/28  
G01N33/53 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE, SCISEARCH, EMBASE, BIOTECHNOLOGY  
ABS, CHEM ABS Data, STRAND, GENSEQ, EMBL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.  |
|------------|---|------------------------|
| X          | DATABASE GENEMBL 'Online!<br>16 February 1998 (1998-02-16)<br>STRAUSBERG, R.: "ob70f05.s1 NCI_CGAP_GCB1<br>Homo sapiens cDNA clone IMAGE:1336737 3',<br>mRNA sequence"<br>XP002138823<br>Accession AA809355 | 1,2,<br>6-19,<br>25-35 |
| X          | DATABASE GENEMBL 'Online!<br>10 July 1998 (1998-07-10)<br>MARRA ET AL.: "ub28d10.r1 Soares 2NbMT Mus<br>musculus cDNA clone IMAGE:1379059 5' mRNA<br>sequence"<br>XP002149803<br>Accession AI050262         | 1,6-19,<br>25-35       |
|            | -/--  |                        |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 October 2000

Date of mailing of the international search report

30. 10. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG., A

## INTERNATIONAL SEARCH REPORT

Inv. International Application No

PCT/US 99/29996

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.   |
|------------|--|-------------------------|
| X          | DATABASE GENEMBL 'Online!<br>19 July 1997 (1997-07-19)<br>STRAUSBERG, R.: "ni64e11.s1 NCI_CGAP_Pr12<br>Homo sapiens cDNA clone IMAGE:981644 mRNA<br>sequence"<br>XP002148641<br>Accession AA523749<br>---  | 1,3,<br>10-19,<br>25-35 |
| X          | WO 98 15657 A (ABBOTT LAB)<br>16 April 1998 (1998-04-16)<br><br>page 4, line 7 -page 5, line 13<br>page 5, line 24 -page 7, line 28  | 1,4,<br>6-19,<br>25-35  |
| Y          | SEQ ID NOs. 9 and 25<br>---  | 20-24                   |
| X          | WO 98 37093 A (CORIXA CORP)<br>27 August 1998 (1998-08-27)<br><br>page 7, paragraph 2<br>page 9, paragraphs 2,3<br>page 13 -page 17<br>page 21, paragraph 3  | 1,4,<br>6-19,<br>25-35  |
| Y          | SEQ ID NOs: 109 and 112<br>---   | 20-24                   |
| X          | DATABASE GENEMBL 'Online!<br>18 November 1997 (1997-11-18)<br>STRAUSBERG, R.: "nt76b07.s1 NCI_CGAP_Pr3<br>Homo sapiens cDNA clone IMAGE:1204405,<br>mRNA"<br>XP002148642   | 1,5-19,<br>25-35        |
| Y          | Accession AA654650<br>---  | 20-24                   |
| Y          | DATABASE GENEMBL 'Online!<br>30 November 1998 (1998-11-30)<br>SHIMIZU, N.: "Homo sapiens mRNA complete<br>cds."<br>XP002148643<br>Accession number AB001535<br>-& NAGAMINE ET AL.: "Molecular cloning of<br>a novel putative Ca2+ channel protein<br>(TRPC7) highly expressed in brain"<br>GENOMICS,<br>vol. 54, 15 November 1998 (1998-11-15),<br>pages 124-131, XP000938744<br>the whole document<br>---<br>-/-- | 20-24                   |

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/29996

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.               |
|------------|---|-------------------------------------|
| A          | ZHU, XI ET AL: "Molecular cloning of a widely expressed human homologue for the <i>Drosophila</i> trp gene."<br>FEBS LETTERS, (1995) VOL. 373, NO. 3, PP. 193-198.,<br>XP000907241<br>page 194; figures 1,3<br>---  | 20,21,<br>23,25,<br>26,28,<br>29,31 |
| A          | HUNTER JOHN J ET AL: "Chromosomal localization and genomic characterization of the mouse melastatin gene ( <i>Mln1</i> )."<br>GENOMICS NOV. 15, 1998,<br>vol. 54, no. 1,<br>15 November 1998 (1998-11-15), pages 116-123, XP000910696<br>ISSN: 0888-7543<br>cited in the application<br>page 119; figure 2<br>--- | 20,21,23                            |
| A          | WES PAUL D ET AL: "TRPC1, a human homolog of a <i>Drosophila</i> store-operated channel."<br>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1995,<br>vol. 92, no. 21, 1995, pages 9652-9656,<br>XP002138820<br>ISSN: 0027-8424<br>the whole document<br>---                      | 20,21,<br>23,25,<br>26,28,<br>29,31 |
| A          | ZHU, XI ET AL: "Trp, A novel mammalian gene family essential for agonist-activated capacitative Ca-2+ entry."<br>CELL,<br>vol. 85, no. 5, 1996, pages 661-671,<br>XP000907242<br>page 662<br>page 665<br>figures 1,5,6<br>---   | 20,21,<br>25,26,<br>28,29,31        |
| A          | GARCIA REYNALDO L ET AL: "Differential expression of mammalian TRP homologues across tissues and cell lines."<br>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1997,<br>vol. 239, no. 1, 1997, pages 279-283,<br>XP002138822<br>ISSN: 0006-291X<br>See Materials and Methods<br>figure 1<br>---<br>-/-      | 25,26,<br>28-30                     |

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/29996

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                         |
|--|---|-------------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.   |
| A  | SINKINS WILLIAM G ET AL: "Functional expression of TrpC1: A human homologue of the Drosophila Trp channel."<br>BIOCHEMICAL JOURNAL APRIL, 1998, vol. 331, no. 1, April 1998 (1998-04), pages 331-339, XP000864583<br>ISSN: 0264-6021<br>page 333-335; figures 3-5   | 24                      |
| A  | PREUSS KLAUS-DIETER ET AL: "Expression and characterization of a trp1 homolog from rat."<br>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS NOV. 7, 1997, vol. 240, no. 1, 7 November 1997 (1997-11-07), pages 167-172, XP002138821<br>ISSN: 0006-291X<br>figure 2  | 24                      |
| A  | OBUKHOV, ALEXANDER G. ET AL: "Direct activation of trp1 cation channels by G-alpha-11 subunits."<br>EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, (1996) VOL. 15, NO. 21, PP. 5833-5838.,<br>XP000907243<br>figure 2  | 24                      |
| P,X  | WO 99 09199 A (RYAZANOV ALEXEY G ;PAVUR KAREN S (US); HAIT WILLIAM N (US); UNIV M)<br>25 February 1999 (1999-02-25)<br>see melanome kinase polynucleotide and polypeptide sequences on page 16-17   | 1,3,<br>10-19,<br>25-36 |
| P,X  | WO 99 09166 A (SHAPERO MICHAEL H ;DENDREON CORP (US); LAUS REINER (US); TSAVALER)<br>25 February 1999 (1999-02-25)<br>page 17, line 24 -page 18, line 9<br>page 25, line 19-32<br>page 28, line 1-4<br>SEQ ID NOs: 27, 28 and 31.   | 1,5-19,<br>25-35        |
| T  | SCHARENBERG A M ET AL: "MLSN-1/SOC-1 defines a widely expressed Ca2+/cation channel family involved in Ca2+ homeostasis and store-operated Ca2+ signaling."<br>FIFTY-THIRD ANNUAL MEETING OF THE SOCIETY OF GENERAL PHYSIOLOGISTS;WOODS HOLE, MASSACHUSETTS, USA; SEPTEMBER 9-11, 1999, vol. 114, no. 1, July 1999 (1999-07), page 14a XP000910708<br>Journal of General Physiology July, 1999<br>ISSN: 0022-1295 |                         |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/29996

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
1-36
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☒ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1-5, 10-13, 16-19, 32-35 relate to an extremely large number of possible polynucleotides, polypeptides encoded by them, binding polypeptides, and kits and pharmaceutical compositions containing said polypeptides and polynucleotides. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the polynucleotide of SEQ ID NOs: 1, 27, 29 and 31 and the corresponding polypeptide of SEQ ID NOs: 2, 28, 30 and 32.

Present claims 16 and 17 relate to an extremely large number of possible compounds, namely, a polypeptide that binds to the polypeptide of the invention. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to an antibody, antibody fragment, F(ab)2 fragment or a fragment including a CDR3 region selective for the polypeptides of the invention.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 6-36 (partially) and 2 (complete)

An isolated nucleic acid molecule comprising a nucleic acid molecule that hybridizes to a nucleic acid molecule of SEQ ID NO:1 and which code for a SOC/CRAC polypeptide, nucleic acid molecules that differ in codon sequence due to degeneracy of the genetic code and complement thereof, polynucleotides which are not identical to the SEQ ID or sequences of GenBank accession number of Table 1; expression vector, host cells; polypeptide encoded thereof (SEQ ID NO:2); polypeptides binding to the polypeptide of SEQ ID NO:2, including antibodies; kits comprising agents that selectively bind to the polynucleotide (SEQ ID NO:1) or polypeptide (SEQ ID NO:2) of the invention; pharmaceutical compositions containing the polynucleotide or polypeptides of the invention; a method for isolating the SOC/CRAC molecule having SOC/CRAC calcium channel activity comprising contacting a binding molecule that is SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample containing SOC/CRAC molecules allowing the formation of the complex, detecting the formation of the complex, isolating the SOC/CRAC molecule and determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity; a method for identifying agents useful in the modulation of SOC/CRAC calcium channel activity; a method to determine the level of SOC/CRAC expression in a subject, including expression of SOC/CRAC polypeptide or mRNA in a tissue or biological fluid sample using PCR, Northern blotting, and mono- and polyclonal antisera and a method for identifying agents useful in the modulation of the SOC/CRAC polypeptide kinase activity, comprising the use of aminoacids 999-1180 from SEQ ID NO:4 as a candidate kinase.

2. Claims: 1,6-36 (partially)

As subject 1, but referred to the polynucleotide of SEQ ID NO:3 and to the encoded polypeptide of SEQ ID NO:4

3. Claims: 1,6-36 (partially)

As subject 1, but referred to the polynucleotide of SEQ ID NO:5 and to the encoded polypeptide of SEQ ID NO:6

4. Claims: 1,6-36 (partially)

As subject 1, but referred to the polynucleotide of SEQ ID NO:7 and to the encoded polypeptide of SEQ ID NO:8



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. Claims: 1,6-36 (partially) and 37 (complete)

As subject 1, but referred to the polynucleotide of SEQ ID NO:23 and to the encoded polypeptide of SEQ ID NO:24

6. Claims: 1,6-36 (partially)

As subject 1, but referred to the polynucleotide of SEQ ID NO:25 and to the encoded polypeptide of SEQ ID NO:26

7. Claims: 1,10-36 (partially) and 3 (complete)

As subject 1, but referred to the polynucleotide of SEQ ID NO:27 and to the encoded polypeptide of SEQ ID NO:28

8. Claims: 1,6-36 (partially) and 4 (complete)

As subject 1, but referred to the polynucleotide of SEQ ID NO:29 and to the encoded polypeptide of SEQ ID NO:30

9. Claims: 1,6-36 (partially) and 5 (complete)

As subject 1, but referred to the polynucleotide of SEQ ID NO:31 and to the encoded polypeptide of SEQ ID NO:32.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In tional Application No

PCT/US 99/29996

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---------------------|--|--|
| WO 9815657 A                              | 16-04-1998          | US 5919638 A<br>EP 0954599 A<br>US 6110675 A   | 06-07-1999<br>10-11-1999<br>29-08-2000   |
| WO 9837093 A                              | 27-08-1998          | AU 6181898 A<br>CN 1252837 T<br>EP 1005546 A<br>NO 994069 A<br>PL 335348 A<br>ZA 9801585 A | 09-09-1998<br>10-05-2000<br>07-06-2000<br>22-10-1999<br>25-04-2000<br>04-09-1998 |
| WO 9909199 A                              | 25-02-1999          | AU 9110098 A   | 08-03-1999   |
| WO 9909166 A                              | 25-02-1999          | AU 9021898 A<br>EP 1005549 A   | 08-03-1999<br>07-06-2000   |

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
13 July 2000 (13.07.2000)

PCT

(10) International Publication Number  
WO 00/40614 A3

- (51) International Patent Classification<sup>7</sup>: C07K 14/705, C12N 15/12, C12Q 1/68, C12N 5/10, C07K 16/28, G01N 33/53, A61K 38/17
- (74) Agent: PLUMER, Elizabeth, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (21) International Application Number: PCT/US99/29996
- (22) International Filing Date:  
20 December 1999 (20.12.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/114,220 30 December 1998 (30.12.1998) US  
60/120,018 29 January 1999 (29.01.1999) US  
60/140,415 22 June 1999 (22.06.1999) US
- (81) Designated States (*national*): AU, CA, JP, US.
- (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
22 February 2001
- (48) Date of publication of this corrected version:  
30 August 2001
- (71) Applicant (*for all designated States except US*): BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; 1 Deaconess Road, Boston, MA 02215 (US).
- (15) Information about Correction:  
see PCT Gazette No. 35/2001 of 30 August 2001, Section II
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): SCHARENBERG, Andrew, M. [US/US]; 12 Skyview Road, Lexington, MA 02420 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHARACTERIZATION OF THE SOC/CRAC CALCIUM CHANNEL PROTEIN FAMILY



(57) Abstract: Nucleic acids encoding SOC/CRAC calcium channel polypeptides, including fragments and biologically functional variants thereof and encoded polypeptides are provided. The nucleic acids and polypeptides disclosed herein are useful as therapeutic and diagnostic agents. Agents that selectively bind to the foregoing polypeptides and genes also are provided.



WO 00/40614 A3

**CHARACTERIZATION OF A CALCIUM CHANNEL FAMILY****Field of the Invention**

This invention relates to nucleic acids coding for a novel family of calcium channel polypeptides, the encoded polypeptides, unique fragments of the foregoing, and methods of making and using same.

**Background of the Invention**

Calcium channels are membrane-spanning, multi-subunit proteins that facilitate the controlled transport ("flux") of  $\text{Ca}^{2+}$  ions into and out of cells. Cells throughout the animal kingdom, and at least some bacterial, fungal and plant cells, possess one or more types of calcium channels. In general, "excitable" cells, such as neurons of the central nervous system, peripheral nerve cells, and muscle cells, including those of skeletal muscles, cardiac muscles, and venous and arterial smooth muscles, possess voltage-dependent calcium channels. In a voltage-dependent calcium channel, the transport of  $\text{Ca}^{2+}$  ions into and out of the cells requires a certain minimal level of depolarization (the difference in potential between the inside of the cell bearing the channel and the extracellular environment) with the rate of  $\text{Ca}^{2+}$  cell flux dependent on the difference in potential. In "non-excitable" cells, calcium influx is thought to occur predominantly in response to stimuli which cause the release of calcium from intracellular stores. This process, termed *store operated calcium influx*, is not well understood.

Characterization of a particular type of calcium channel by analysis of whole cells is complicated by the presence of mixed populations of different types of calcium channels in the majority of cells. Although single-channel recording methods can be used to examine individual calcium channels, such analysis does not reveal information related to the molecular structure or biochemical composition of the channel. Furthermore, in this type of analysis, the channel is isolated from other cellular constituents that might be important for the channel's natural functions and pharmacological interactions. To study the calcium channel structure-function relationship, large amounts of pure channel protein are needed. However, acquiring large amounts of pure protein is difficult in view of the complex nature of these multisubunit proteins, the varying concentrations of calcium channel proteins in tissue sources, the presence of mixed populations of calcium channel proteins in tissues, and the modifications of the native protein that can occur during the isolation procedure.

### Summary of the Invention

The invention is based on the identification of a novel family of calcium channel polypeptides and the molecular cloning and partial characterization of a novel member of this family that is expressed predominantly in human hematopoietic cells, liver, and kidney. This newly identified family of calcium channel polypeptides is designated, "SOC" or "CRAC" or "ICRAC", for Store Operated Channels or Calcium Release Activated Channels. Although not wishing to be bound to any particular theory or mechanism, it is believed that the SOC/CRAC calcium channel polypeptides are transmembrane polypeptides that modulate  $\text{Ca}^{2+}$  flux "into" and "out of" a cell, for example, in certain instances they may be activated upon depletion of  $\text{Ca}^{2+}$  from intracellular calcium stores, allowing  $\text{Ca}^{2+}$  influx into the cell. Accordingly, the compositions disclosed herein are believed to be useful for modulating calcium transport into and out of such intracellular stores and for the treatment of disorders that are characterized by aberrant calcium transport into and out of such intracellular stores. In particular, we believe that the SOC/CRAC calcium channel polypeptides disclosed herein play an important role in the influx of extracellular calcium by mediating the refilling of intracellular calcium stores following their depletion. Accordingly, we believe that the compositions for expressing functional SOC/CRAC calcium channel polypeptides in cells, as disclosed herein, are useful for treating patients having conditions that are characterized by reduced extracellular calcium influx into their SOC/CRAC-expressing cells. Additionally, the compositions of the invention are useful for delivering therapeutic and/or imaging agents to cells which preferentially express SOC/CRAC calcium channel polypeptides and, in particular, for delivering such agents to hematopoietic cells, liver, heart, spleen, and kidney to modulate proliferation and growth of these cells. Moreover, in view of the importance of cellular calcium levels to cell viability, we believe that SOC-2/CRAC-1, SOC-3/CRAC-2, and SOC-4/CRAC-3 as disclosed herein, and/or other members of the SOC/CRAC family of calcium channel polypeptides, represent an ideal target for designing and/or identifying (e.g., from molecular libraries) small molecule inhibitors that block lymphocyte proliferation, as well as other binding agents that selectively bind to SOC/CRAC polypeptides to which drugs or toxins can be conjugated for delivery to SOC/CRAC polypeptide expressing cells.

The invention is based, in part, on the molecular cloning and sequence analysis of the novel SOC/CRAC calcium channel molecules disclosed herein (also referred to as a "SOC-2/CRAC-1 molecule," a "SOC-3/CRAC-2 molecule," and/or "SOC-4/CRAC-3 molecule") that are predominantly expressed in human hematopoietic cells, liver, spleen, heart, and

kidney (SOC-2/CRAC-1), kidney and colon (SOC-3/CRAC-2), and prostate (SOC-4/CRAC-3 molecule). As used herein, a "SOC/CRAC molecule" embraces a "SOC/CRAC calcium channel nucleic acid" (or "SOC/CRAC nucleic acid") and a "SOC/CRAC calcium channel polypeptide" (or "SOC/CRAC polypeptide"). Homologs and alleles also are embraced within  
5 the meaning of a SOC/CRAC calcium channel molecule.

According to one aspect of the invention, isolated SOC/CRAC nucleic acids which code for one or more member(s) of the SOC/CRAC family of calcium channel polypeptides or unique fragments thereof are provided. The isolated nucleic acids refer to one or more of the following:

10 (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective  
15 SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

The invention in another aspect provides an isolated nucleic acid molecule selected  
20 from the group consisting of (a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29, and SEQ ID NO:31, (b) complements of (a), provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from a sequence group consisting of (1) sequences having  
25 the SEQ. ID NOS. or GenBank accession numbers of Table I, (2) complements of (1), and (3) fragments of (1) and (2).

According to yet another aspect of the invention, isolated SOC/CRAC polypeptides are provided. The isolated SOC/CRAC polypeptide molecules are encoded by one or more SOC/CRAC nucleic acid molecules of the invention. Preferably, the SOC/CRAC polypeptide  
30 contains one or more polypeptides selected from the group consisting of the polypeptides having SEQ. ID Nos. 2, 4, 6, 8, 24, 26, 28, 30, and 32. In other embodiments, the isolated polypeptide may be a fragment or variant of the foregoing SOC/CRAC polypeptide molecules of sufficient length to represent a sequence unique within the human genome, and identifying

with a polypeptide that functions as a calcium channel, provided that the fragment excludes a sequence of contiguous amino acids identified in Table II, and/or excludes a sequence of contiguous amino acids encoded for by a nucleic acid sequence identified in Table I. In another embodiment, immunogenic fragments of the polypeptide molecules described above are provided.

According to another aspect of the invention, isolated SOC/CRAC binding agents (e.g., polypeptides) are provided which selectively bind to a SOC/CRAC molecule (e.g., a SOC/CRAC polypeptide encoded by the isolated nucleic acid molecules of the invention). Preferably, the isolated binding agents selectively bind to a polypeptide which comprises the sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32, or unique fragments thereof. In the preferred embodiments, the isolated binding polypeptides include antibodies and fragments of antibodies (e.g., Fab, F(ab)<sub>2</sub>, Fd and antibody fragments which include a CDR3 region which binds selectively to a SOC/CRAC polypeptide). Preferably, the antibodies for human therapeutic applications are human antibodies.

According to another aspect of the invention, a pharmaceutical composition containing a pharmaceutically effective amount of an isolated SOC/CRAC nucleic acid, an isolated SOC/CRAC polypeptide, or an isolated SOC/CRAC binding polypeptide in a pharmaceutically acceptable carrier also is provided. The pharmaceutical compositions are useful in accordance with therapeutic methods disclosed herein.

According to yet another aspect of the invention, a method for isolating a SOC/CRAC molecule is provided. The method involves:

a) contacting a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample that is believed to contain one or more SOC/CRAC molecules, under conditions to form a complex of the SOC/CRAC nucleic acid or the SOC/CRAC binding polypeptide and the SOC/CRAC molecule;

b) detecting the presence of the complex;

c) isolating the SOC/CRAC molecule from the complex; and

d) determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity. As used herein "SOC/CRAC calcium channel activity" refers to the transport of Ca<sup>2+</sup> into and out of intracellular stores that is mediated by a SOC/CRAC

polypeptide. In general, the SOC/CRAC calcium channel activity is initiated by a reduction or depletion of intracellular calcium stores.

In certain embodiments, the SOC/CRAC nucleic acid is a SOC-2/CRAC-1 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 27, or complements thereof); in certain other  
5       embodiments, the SOC/CRAC nucleic acid is a SOC-3/CRAC-2 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 29, or complements thereof); in further embodiments, the SOC/CRAC nucleic acid is a SOC-4/CRAC-3 nucleic acid (e.g., a nucleic acid having SEQ. ID NO. 31, or complements thereof). In yet other embodiments, the SOC/CRAC polypeptide is a SOC-2/CRAC-1 binding polypeptide (e.g., an antibody that selectively binds to a SOC-  
10       2/CRAC-1 polypeptide). In yet further embodiments, the SOC/CRAC polypeptide is a SOC-3/CRAC-2 binding polypeptide (e.g., an antibody that selectively binds to a SOC-3/CRAC-2 polypeptide). In some embodiments, the SOC/CRAC polypeptide is a SOC-4/CRAC-3 binding polypeptide (e.g., an antibody that selectively binds to a SOC-4/CRAC-3 polypeptide). In the preferred embodiments, the isolated binding polypeptides include  
15       antibodies and fragments of antibodies (e.g., Fab, F(ab)<sub>2</sub>, Fd and antibody fragments which include a CDR3 region which binds selectively to a SOC-2/CRAC-1, to a SOC-3/CRAC-2, and/or to a SOC-4/CRAC-3 polypeptide). Preferably the isolated binding polypeptides or other binding agents selectively bind to a single SOC/CRAC molecule, i.e., are capable of distinguishing between different members of the SOC/CRAC family. Accordingly, one or  
20       more SOC/CRAC binding agents can be contained in a single composition (e.g., a pharmaceutical composition) to identify multiple SOC/CRAC molecules *in vivo* or *in vitro*.

According to yet another aspect of the invention, a method for identifying agents useful in the modulation of SOC/CRAC calcium channel activity is provided. The method involves:

25       a) contacting a SOC/CRAC polypeptide with a candidate agent suspected of modulating SOC/CRAC calcium channel activity, under conditions sufficient to allow the candidate agent to interact selectively with (e.g. bind to) the SOC/CRAC polypeptide;

      b) detecting a Ca<sup>2+</sup> concentration of step (b) associated with the SOC/CRAC calcium channel activity of the SOC/CRAC polypeptide in the presence of the candidate agent; and

30       c) comparing the Ca<sup>2+</sup> concentration of step (b) with a control Ca<sup>2+</sup> concentration of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC calcium channel activity.



According to another aspect of the invention, a method for identifying agents useful in the modulation of a SOC/CRAC polypeptide kinase activity is provided. The method involves:

a) contacting a SOC/CRAC polypeptide with kinase activity with a candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity;

b) detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and

c) comparing the kinase activity of step (b) with a control kinase activity of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC kinase activity. In some embodiments the SOC/CRAC polypeptide comprises amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24), or a fragment thereof that retains the kinase activity.

According to yet another aspect of the invention, a method for determining the level of expression of a SOC/CRAC polypeptide in a subject is provided. The method involves:

a) measuring the expression of a SOC/CRAC polypeptide in a test sample, and

b) comparing the measured expression of the SOC/CRAC polypeptide in the test sample to the expression of a SOC/CRAC polypeptide in a control containing a known level of expression to determine the level of SOC/CRAC expression in the subject. Expression is defined as SOC/CRAC mRNA expression or SOC/CRAC polypeptide expression. Various methods can be used to measure expression. The preferred embodiments of the invention utilize PCR and Northern blotting for measuring mRNA expression, and monoclonal or polyclonal SOC/CRAC antisera as reagents for measuring SOC/CRAC polypeptide expression. In preferred embodiments, the SOC/CRAC molecule (nucleic acid and/or polypeptide) is SOC-2/CRAC-1. In other preferred embodiments, the SOC/CRAC molecule is SOC-3/CRAC-2. In yet further preferred embodiments, the SOC/CRAC molecule is SOC-4/CRAC-3. In certain embodiments, the test samples include biopsy samples and biological fluids such as blood. The method is useful, e.g., for assessing the presence or absence or stage of a proliferative disorder in a subject.

The invention also contemplates kits comprising a package including assays for SOC/CRAC epitopes, SOC/CRAC nucleic acids, and instructions, and optionally related materials such as controls, for example, a number, color chart, or an epitope of the expression product of the foregoing isolated nucleic acid molecules of the invention for comparing, for

example, the level of SOC/CRAC polypeptides or SOC/CRAC nucleic acid forms (wild-type or mutant) in a test sample to the level in a control sample having a known amount of a SOC/CRAC nucleic acid or SOC/CRAC polypeptide. This comparison can be used to assess in a subject a risk of developing a cancer or the progression of a cancer. The kits may also include assays for other known genes, and expression products thereof, associated with, for example, proliferative disorders (e.g., BRCA, p53, etc.). In a preferred embodiment, the kit comprises a package containing: (a) a binding agent that selectively binds to an isolated nucleic acid of the invention or an expression product thereof to obtain a measured test value, (b) a control containing a known amount of a SOC/CRAC nucleic acid or a SOC/CRAC polypeptide to obtain a measured control value, and (c) instructions for comparing the measured test value to the measured control value to determine the amount of SOC/CRAC nucleic acid or expression product thereof in a sample.

The invention provides isolated nucleic acid molecules, unique fragments thereof, expression vectors containing the foregoing, and host cells containing the foregoing. The invention also provides isolated binding polypeptides and binding agents which bind such polypeptides, including antibodies, and pharmaceutical compositions containing any of the compositions of the invention. The foregoing can be used, *inter alia*, in the diagnosis or treatment of conditions characterized by the aberrant expression levels and/or the presence of mutant forms of a SOC/CRAC nucleic acid or polypeptide. The invention also provides methods for identifying agents that alter the function of the SOC/CRAC polypeptide.

These and other aspects of the invention, as well as various advantages and utilities, will be more apparent with reference to the detailed description of the preferred embodiments.

#### **Brief Description of the Sequences**

SEQ ID NO:1 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:2 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:1).

SEQ ID NO:3 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:4 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:3).

SEQ ID NO:5 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:6 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:5).

-8-

SEQ ID NO:7 is a partial nucleotide sequence of the mouse homologue (mSOC-2/CRAC-1) of the human SOC-2/CRAC-1 cDNA.

SEQ ID NO:8 is the predicted amino acid sequence of the translation product of the mSOC-2/CRAC-1 cDNA (SEQ ID NO:7).

5 SEQ ID NO:9 is the nucleotide sequence of the mouse MLSN-1 (SOC-1) cDNA.

SEQ ID NO:10 is the predicted amino acid sequence of the translation product of the mouse MLSN-1 (SOC-1) cDNA (SEQ ID NO:9).

SEQ ID NO:11 is the nucleotide sequence of a human calcium channel cDNA with GenBank Acc. no.: AB001535.

10 SEQ ID NO:12 is the predicted amino acid sequence of the translation product of the human calcium channel cDNA with GenBank Acc. no.: AB001535 (SEQ ID NO:11).

SEQ ID NO:13 is the amino acid sequence of a *C. Elegans* polypeptide at the c05c12.3 locus.

15 SEQ ID NO:14 is the amino acid sequence of a *C. Elegans* polypeptide at the F54D1 locus.

SEQ ID NO:15 is the amino acid sequence of a *C. Elegans* polypeptide at the t01H8 locus.

SEQ ID NO:16 is the nucleotide sequence of a mouse kidney cDNA with GenBank Acc. no.: AI226731.

20 SEQ ID NO:17 is the predicted amino acid sequence of the translation product of the mouse kidney cDNA with GenBank Acc. no.: AI226731 (SEQ ID NO:16).

SEQ ID NO:18 is the nucleotide sequence of a human brain cDNA with GenBank Acc. no.: H18835.

25 SEQ ID NO:19 is the predicted amino acid sequence of the translation product of the human brain cDNA with GenBank Acc. no.: H18835 (SEQ ID NO:18).

SEQ ID NO:20 is the nucleotide sequence of the human EST with GenBank Acc. no.: AA419592.

SEQ ID NO:21 is the nucleotide sequence of the human EST with GenBank Acc. no.: AA419407.

30 SEQ ID NO:22 is the nucleotide sequence of the mouse EST with GenBank Acc. no.: AI098310.

SEQ ID NO:23 is a partial nucleotide sequence of the human SOC-2/CRAC-1 cDNA that contains the SOC-2/CRAC-1 sequences of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5.

5 SEQ ID NO:24 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:23).

SEQ ID NO:25 is a partial nucleotide sequence of the human SOC-3/CRAC-2 cDNA.

SEQ ID NO:26 is the predicted amino acid sequence of the translation product of human SOC-3/CRAC-2 cDNA (SEQ ID NO:25).

SEQ ID NO:27 is the full nucleotide sequence of the human SOC-2/CRAC-1 cDNA.

10 SEQ ID NO:28 is the predicted amino acid sequence of the translation product of human SOC-2/CRAC-1 cDNA (SEQ ID NO:27).

SEQ ID NO:29 is the full nucleotide sequence of the human SOC-3/CRAC-2 cDNA.

SEQ ID NO:30 is the predicted amino acid sequence of the translation product of human SOC-3/CRAC-2 cDNA (SEQ ID NO:29).

15 SEQ ID NO:31 is the full nucleotide sequence of the human SOC-4/CRAC-3 cDNA.

SEQ ID NO:32 is the predicted amino acid sequence of the translation product of human SOC-4/CRAC-3 cDNA (SEQ ID NO:31).

#### **Brief Description of the Drawings**

20 Figure 1 is a schematic depicting the intron/exon organization of the chicken SOC-2/CRAC-1 genomic sequence, as well as the putative transmembrane (TM) domains, and the targeting constructs utilized in the knockout experiments.

#### **Detailed Description of the Invention**

One aspect of the invention involves the partial cloning of cDNAs encoding members of a novel family of calcium channel polypeptides, referred to herein as "SOC/CRAC" (designated "SOC" or "CRAC" or "ICRAC", for Sore Operated Channels or Calcium Release Activated Channels, or CECH). Although not intending to be bound to any particular mechanism or theory, we believe that a SOC/CRAC family member is a transmembrane calcium channel that modulates  $\text{Ca}^{2+}$  flux "into" and "out of" a cell; in certain instances it may be activated upon depletion of  $\text{Ca}^{2+}$  from intracellular calcium stores, allowing  $\text{Ca}^{2+}$  influx into the cell.

30 The first three isolated SOC/CRAC members disclosed herein, define a new family of calcium channels which is distinct from previously described calcium channels, such as voltage gated calcium channels, ryanodine receptor/inositol-1,4,5-triphosphate receptor

channels, and Transient Receptor Potential (TRP) channels. The SOC/CRAC family of calcium channels exhibits high selectivity (with a  $P_{Ca}/P_{Na}$  ratio near 1000), a unitary conductance below the detection level of the patch clamp method (the conductance estimated at approximately 0.2 picosiemens), and are subject to inhibition by high intracellular calcium levels. Although not intending to be bound to any particular mechanism or theory, we believe that SOC/CRAC calcium channels are responsible for the majority of, for example, calcium entry which occurs when intracellular calcium stores are depleted, and that SOC/CRAC currents are important for initiating various types of calcium-dependent processes. Thus, we believe that SOC/CRAC calcium channels play an important role in cellular calcium homeostasis by, e.g., modulating the supply of calcium to refill intracellular stores when depleted.

The isolated full-length sequence of a representative, first member of the SOC/CRAC family, human SOC/CRAC nucleic acid (cDNA), SOC-2/CRAC-1, is represented as the nucleic acid of SEQ ID NO:27. This nucleic acid sequence codes for the SOC-2/CRAC-1 polypeptide with the predicted amino acid sequence disclosed herein as SEQ ID NO:28. A homologous mouse cDNA sequence (>90% identity to the human at the nucleotide level) is represented as the nucleic acid of SEQ ID NO:7, and codes for a unique fragment of a mouse SOC-2/CRAC-1 polypeptide having the predicted, partial amino acid sequence represented as SEQ ID NO:8. Analysis of the SOC-2/CRAC-1 partial sequence by comparison to nucleic acid and protein databases show that SOC-2/CRAC-1 shares a limited homology to mouse MLSN-1 (SOC-1, SEQ ID NOs: 9 and 10). Limited homology is also shared between SOC-2/CRAC-1 and three *C. Elegans* polypeptides (SEQ ID NOs: 13, 14, and 15). We further believe that SOC-2/CRAC-1 plays a role in the regulation of cellular  $Ca^{2+}$  fluxing and, in particular, lymphocyte  $Ca^{2+}$  fluxing.

A second member of the human SOC/CRAC family of calcium channels, SOC-3/CRAC-2, is represented as the nucleic acid of SEQ ID NO:29, and codes for the human SOC-3/CRAC-2 polypeptide having the predicted amino acid sequence represented as SEQ ID NO:30 (this molecule may also be referred to as CECH2). SOC-3/CRAC-2 is predominantly expressed in human hematopoietic cells (including peripheral blood lymphocytes, liver, bone marrow, spleen, thymus, lymph nodes, heart, and kidney. Expression can also be detected (at lesser levels) in brain, skeletal muscle colon, small intestine, placenta, lung, and cells (cell lines) such as HL-60, HeLa, K562, MOLT-4, SW-480, A459, and G361.

A third member of the human SOC/CRAC family of calcium channels, SOC-4/CRAC-3, is represented as the nucleic acid of SEQ ID NO:31, and codes for the human SOC-4/CRAC-3 polypeptide having the predicted amino acid sequence represented as SEQ ID NO:32 (this molecule may also be referred to as CECH6). It specifically expressed in the prostate gland/cells.

As used herein, a SOC/CRAC calcium channel nucleic acid (also referred to herein as a "SOC/CRAC nucleic acid" refers to a nucleic acid molecule which: (1) hybridizes under stringent conditions to one or more of the nucleic acids having the sequences of SEQ. ID NOS. 7, 27, 29, and/or 31 (sequences of the mouse and human SOC-2/CRAC-1, human SOC-3/CRAC-2, and human SOC-4/CRAC-3 nucleic acids), and (2) codes for a SOC-2/CRAC-1, a SOC-3/CRAC-2 or a SOC-4/CRAC-3 calcium channel polypeptide, respectively, or unique fragments of said SOC-2/CRAC-1, SOC-3/CRAC-2, or SOC-4/CRAC-3 polypeptide.

As used herein, a SOC/CRAC calcium channel polypeptide (also referred to herein as a "SOC/CRAC polypeptide") refers to a polypeptide that is coded for by a SOC-2/CRAC-1, a SOC-3/CRAC-2, and/or a SOC-4/CRAC-3 nucleic acid. Preferably, the above-identified SOC/CRAC polypeptides mediate transport of calcium into and out of a cell.

SOC/CRAC polypeptides also are useful as immunogenic molecules for the generation of binding polypeptides (e.g., antibodies) which bind selectively to SOC/CRAC (e.g., SOC-2/CRAC-1, SOC-3/CRAC-2, and/or SOC-4/CRAC-3) polypeptides. Such antibodies can be used in diagnostic assays to identify and/or quantify the presence of a SOC/CRAC polypeptide in a sample, such as a biological fluid or biopsy sample. SOC/CRAC polypeptides further embrace functionally equivalent fragments, variants, and analogs of the preferred SOC/CRAC polypeptides, provided that the fragments, variants, and analogs also are useful in mediating calcium transport into and out of intracellular calcium stores.

As used herein, "SOC/CRAC calcium channel activity" refers to  $\text{Ca}^{2+}$  transport (" $\text{Ca}^{2+}$  fluxing") across the plasma membrane that is mediated by a SOC/CRAC calcium channel polypeptide. The SOC/CRAC calcium channel polypeptide typically has one or more of the following properties: high selectivity, a unitary conductance below the detection level of the patch clamp method, and are subject to inhibition by high intracellular calcium levels. Such activity can be easily detected using standard methodology well known in the art. See, e.g., the Examples and Neher, E., "Ion channels for communication between and within cells",

Science, 1992; 256:498-502; and Hoth, M., and Penner, R., "Depletion of intracellular calcium stores activates a calcium current in mast cells", Nature, 1992; 355 (6358):353-6.

According to one aspect of the invention, isolated nucleic acid molecules which code for one or more member(s) of the SOC/CRAC family of calcium channel polypeptides are provided. The isolated nucleic acid molecules are selected from the following groups:

(a) nucleic acid molecules which hybridize under stringent conditions to one or more nucleic acid molecules selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

In certain embodiments, the isolated nucleic acid molecule comprises one or more of nucleotides 1-1212 of SEQ ID NO:1; nucleotides 1-739 of SEQ ID NO:3; nucleotides 1-1579 of SEQ ID NO:5; nucleotides 1-5117 of SEQ ID NO:23; the mouse homolog for SOC-2/CRAC-1 corresponding to SEQ ID NO:7; nucleotides 1-2180 of SEQ ID NO:25; nucleotides 382-5976 of SEQ ID NO:27; nucleotides 73-3714 of SEQ ID NO:29; and nucleotides 23-3434 of SEQ ID NO:31. In yet other embodiments, the isolated nucleic acid molecule comprises a molecule which encodes a polypeptide having one or more sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

According to yet another aspect of the invention, an isolated nucleic acid molecule is provided which is selected from the group consisting of:

(a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, (of sufficient length to represent a sequence unique within the human genome); and (b) complements of (a), provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to a sequence in the prior art as represented by the sequence group consisting of: (1) sequences having the SEQ ID NOs or GenBank accession numbers of Table I, (2) complements of (1), and (3) fragments of (1) and (2).

In some embodiments, the sequence of contiguous nucleotides is selected from the group consisting of (1) at least two contiguous nucleotides nonidentical to the sequence group, (2) at least three contiguous nucleotides nonidentical to the sequence group, (3) at least four contiguous nucleotides nonidentical to the sequence group, (4) at least five contiguous nucleotides nonidentical to the sequence group, (5) at least six contiguous nucleotides nonidentical to the sequence group, (6) at least seven contiguous nucleotides nonidentical to the sequence group.

In other embodiments, the unique fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 40 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

According to another aspect of the invention, expression vectors and host cells containing (e.g., transformed or transfected with) expression vectors comprising the nucleic acid molecules disclosed herein operably linked to a promoter are provided. In certain preferred embodiments, the host cells are eukaryotic cells.

The isolated nucleic acid molecules disclosed herein have various utilities, including their use as probes and primers to identify additional members of the SOC/CRAC family of calcium channels, as diagnostic reagents for identifying the presence of SOC/CRAC polypeptides in biological or other samples, and as agents for generating SOC/CRAC binding polypeptides (e.g., antibodies) that can be used as reagents in diagnostic and therapeutic assays to identify the presence, absence, and/or amounts of a SOC/CRAC nucleic acid or polypeptide in a biological or other sample.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulatable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the



material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulatable by standard techniques known to those of ordinary skill in the art.

As used herein with respect to polypeptides (discussed below), the term "isolated" means separated from its native environment in sufficiently pure form so that it can be manipulated or used for any one of the purposes of the invention. Thus, isolated means sufficiently pure to be used (i) to raise and/or isolate antibodies, (ii) as a reagent in an assay, or (iii) for sequencing, etc.

Homologs and alleles of the SOC/CRAC nucleic acids of the invention can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for SOC/CRAC polypeptides and which hybridize to a nucleic acid molecule selected from a group consisting of the nucleic acid of SEQ ID NO:1, the nucleic acid of SEQ ID NO:3, the nucleic acid of SEQ ID NO:5, the nucleic acid of SEQ ID NO:7, the nucleic acid of SEQ ID NO:23, the nucleic acid of SEQ ID NO:25, the nucleic acid of SEQ ID NO:27, the nucleic acid of SEQ ID NO:29, and the nucleic acid of SEQ ID NO:31, under stringent conditions. The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH<sub>2</sub>PO<sub>4</sub>(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, and would result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of the SOC/CRAC nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such

molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and/or SEQ ID NO:31, and SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, respectively. In some instances sequences will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances sequences will share at least 60% nucleotide identity and/or at least 75% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for SOC/CRAC related genes, such as homologs and alleles of SOC-2/CRAC-1 and/or SOC-3/CRAC-2, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film or a phosphorimager plate to detect the radioactive signal.

Given that the expression of the SOC/CRAC gene is prominent in certain human tissues (e.g., SOC-2/CRAC-1: lymphoid tissue/heart, SOC-3/CRAC-2: kidney/colon, SOC-4/CRAC-3: prostate), and given the teachings herein of partial human SOC/CRAC cDNA clones, full-length and other mammalian sequences corresponding to the human SOC/CRAC partial nucleic acid sequences can be isolated from, for example, a cDNA library prepared from one or more of the tissues in which SOC-2/CRAC-1 expression is prominent, SOC-3/CRAC-2 is prominent, and/or SOC-4/CRAC-3 expression is prominent, using standard colony hybridization techniques.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the

art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating SOC/CRAC polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides isolated unique fragments of an isolated nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31. A unique fragment is one that is a 'signature' for the larger nucleic acid. For example, the unique fragment is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the SOC/CRAC nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome.

Unique fragments, however, exclude fragments completely composed of the nucleotide sequences of any of GenBank accession numbers and SEQ ID NOs listed in Table I (SEQ ID NO:9, AB001535, AI226731, H18835, AA419592, AA261842, AA419407, AI098310, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853), or other previously published sequences as of the filing date of this application.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits and SEQ ID NO:9, is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, as demonstrated in the Examples, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the SOC/CRAC polypeptides, useful, for example, in the preparation of antibodies, immunoassays or therapeutic applications. Unique fragments further can be used as antisense molecules to inhibit the expression of SOC/CRAC nucleic acids and polypeptides, respectively.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and complements thereof, will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides long (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases) or more, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide, (provided the sequence is unique as described above). Virtually any segment of the region of SEQ ID NO:1 beginning at nucleotide 1 and ending at nucleotide 1212, or SEQ ID NO:3 beginning at nucleotide 1 and ending at nucleotide 739, or SEQ ID NO:5 beginning at nucleotide 1 and ending at nucleotide 1579, or SEQ ID NO:7 beginning at nucleotide 1 and ending at nucleotide 3532, or SEQ ID NO:23 beginning at nucleotide 1 and ending at nucleotide 5117, SEQ ID NO:25 beginning at nucleotide 1 and ending at nucleotide 2180, SEQ ID NO:27 beginning at nucleotide 1 and ending at nucleotide 7419, or SEQ ID NO:29 beginning at nucleotide 1 and ending at nucleotide 4061, or SEQ ID NO:31 beginning at nucleotide 1 and ending at nucleotide 4646, or complements thereof, that is 20 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique

fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a SOC/CRAC polypeptide, to decrease SOC/CRAC calcium channel activity. When using antisense preparations of the invention, slow intravenous administration is preferred.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nat. Med.* 1(11):1116-1118, 1995). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In

addition, 3'-untranslated regions may be targeted by antisense oligonucleotides. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although, SEQ ID No:1 discloses a cDNA sequence, one of ordinary skill in the art may easily derive the genomic DNA corresponding to this sequence. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31. Similarly, antisense to allelic or homologous SOC/CRAC cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include

-20-

oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding SOC/CRAC polypeptides, together with pharmaceutically acceptable carriers. Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.

The invention also involves expression vectors coding for SOC/CRAC proteins and fragments and variants thereof and host cells containing those expression vectors. Virtually any cells, prokaryotic or eukaryotic, which can be transformed with heterologous DNA or RNA and which can be grown or maintained in culture, may be used in the practice of the invention. Examples include bacterial cells such as E.coli and eukaryotic cells such as mouse, hamster, pig, goat, primate, yeast, xenopous, etc. They may be of a wide variety of tissue types, including mast cells, fibroblasts, oocytes and lymphocytes, and they may be primary cells or cell lines. Specific examples include CHO cells and COS cells. Cell-free transcription systems also may be used in lieu of cells.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to,

plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g.,  $\beta$ -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed



and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

According to yet another aspect of the invention, isolated SOC/CRAC polypeptides are provided. Preferably, the isolated SOC/CRAC polypeptides are encoded by the isolated SOC/CRAC nucleic acid molecules disclosed herein. More preferably, the isolated SOC/CRAC polypeptides of the invention are encoded by the nucleic acid molecules having SEQ ID Nos. 1, 3, 5, 7, 23, 25, 27, 29, and 31. In yet other embodiments, the isolated SOC/CRAC polypeptides of the invention have an amino acid sequence selected from the group consisting of SEQ ID Nos. 2, 4, 6, 8, 24, 26, 28, 30 and 32. Preferably, the isolated SOC/CRAC polypeptides are of sufficient length to represent a sequence unique within the human genome. Thus, the preferred embodiments include a sequence of contiguous amino acids which is not identical to a prior art sequence as represented by the sequence group consisting of the contiguous amino acids identified in Table II (SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19 and GenBank Acc. Nos. AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572).

In certain embodiments, the isolated SOC/CRAC polypeptides are immunogenic and can be used to generate binding polypeptides (e.g., antibodies) for use in diagnostic and therapeutic applications. Such binding polypeptides also are useful for detecting the presence, absence, and/or amounts of a SOC/CRAC nucleic acid or polypeptide in a sample such as a biological fluid or biopsy sample. Preferably, the SOC/CRAC polypeptides that are useful for generating binding polypeptides are unique polypeptides and, therefore, binding of the antibody to a SOC/CRAC polypeptide in a sample is selective for the SOC/CRAC polypeptide.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al.,

*Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a SOC/CRAC polypeptide or fragment or variant thereof. The heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen, Carlsbad, CA), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the above described, SOC/CRAC cDNA sequence containing expression vectors, to transfect host cells and cell lines, by these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include dendritic cells, U293 cells, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The invention also permits the construction of SOC/CRAC gene

"knock-outs" in cells and in animals, providing materials for studying certain aspects of SOC/CRAC calcium channel activity.

The invention also provides isolated polypeptides (including whole proteins and partial proteins), encoded by the foregoing SOC/CRAC nucleic acids, and include the polypeptides of SEQ ID NO:2, 4, 6, 8, 24, 26, 28, 30, 32, and unique fragments thereof. Such polypeptides are useful, for example, to regulate calcium transport-mediated cell growth, differentiation and proliferation, to generate antibodies, as components of immunoassays, etc. Polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a SOC/CRAC polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 and 12 amino acids long or more, including each integer up to the full length, >1,000 amino acids long). Virtually any segment of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32, excluding the ones that share identity with it (the polypeptides identified in Table II - SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, and GenBank Acc. Nos. AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572) that is 9 or more amino acids in length will be unique.

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include  $\text{Ca}^{2+}$  fluxing, high selectivity, a unitary

conductance below the detection level of the patch clamp method, and/or and are subject to inhibition by high intracellular calcium levels.

One important aspect of a unique fragment is its ability to act as a signature for identifying the polypeptide. Optionally, another aspect of a unique fragment is its ability to provide an immune response in an animal. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the SOC/CRAC polypeptides described above. As used herein, a "variant" of a SOC/CRAC polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a SOC/CRAC polypeptide. Modifications which create a SOC/CRAC polypeptide variant are typically made to the nucleic acid which encodes the SOC/CRAC polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and addition of amino acids or non-amino acid moieties to: 1) reduce or eliminate a calcium channel activity of a SOC/CRAC polypeptide; 2) enhance a property of a SOC/CRAC polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) provide a novel activity or property to a SOC/CRAC polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to a SOC/CRAC polypeptide receptor or other molecule. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the SOC/CRAC amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant SOC/CRAC polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a SOC/CRAC calcium channel polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

1 Variants can include SOC/CRAC polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a SOC/CRAC polypeptide by  
5 eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

10 Mutations of a nucleic acid which encodes a SOC/CRAC polypeptide preferably preserve the amino acid reading frame of the coding sequence and, preferably, do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

15 Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant SOC/CRAC polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., E. coli, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a SOC/CRAC gene or cDNA clone to enhance expression of the polypeptide.

20 The skilled artisan will realize that conservative amino acid substitutions may be made in SOC/CRAC polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., the variants retain the functional capabilities of the SOC/CRAC polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein  
25 in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al.,  
30 eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the SOC/CRAC polypeptides include conservative amino acid substitutions of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and/or SEQ ID NO:32. Conservative substitutions of amino acids

include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Thus functionally equivalent variants of SOC/CRAC polypeptides, i.e., variants of SOC/CRAC polypeptides which retain the function of the natural SOC/CRAC polypeptides, are contemplated by the invention. Conservative amino-acid substitutions in the amino acid sequence of SOC/CRAC polypeptides to produce functionally equivalent variants of SOC/CRAC polypeptides typically are made by alteration of a nucleic acid encoding SOC/CRAC polypeptides (e.g., SEQ ID NOs:1, 3, 5, 7, 23, 25, 27, 29, 31). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a SOC/CRAC polypeptide. The activity of functionally equivalent fragments of SOC/CRAC polypeptides can be tested by cloning the gene encoding the altered SOC/CRAC polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered SOC/CRAC polypeptide, and testing for a functional capability of the SOC/CRAC polypeptides as disclosed herein (e.g., SOC/CRAC calcium channel activity).

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of SOC/CRAC polypeptides, including the isolation of the complete SOC/CRAC polypeptide. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated SOC/CRAC molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of SOC/CRAC mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce SOC/CRAC polypeptides. Those skilled in the art also can readily follow known methods for isolating SOC/CRAC polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from SOC/CRAC polypeptides. A dominant negative polypeptide is an

inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative inactive SOC/CRAC calcium channel which interacts normally with the cell membrane but which does not mediate calcium transport can reduce calcium transport in a cell. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

According to another aspect, the invention provides a method for isolating a SOC/CRAC molecule having SOC/CRAC calcium channel activity. The method involves contacting a binding molecule that is a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample containing one or more SOC/CRAC molecules under conditions that allow such binding (see earlier discussion) to form a complex, detecting the presence of the complex, isolating the SOC/CRAC molecule from the complex, and determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity. Thus, the invention is useful for identifying and isolating full length complementary (cDNA) or genomic nucleic acids encoding SOC/CRAC polypeptides having SOC/CRAC calcium channel activity. Identification and isolation of such nucleic acids and polypeptides may be accomplished by hybridizing/binding, under appropriate conditions well known in the art, libraries and/or restriction enzyme-digested human nucleic acids, with a labeled SOC/CRAC molecular probe. As used herein, a "label" includes molecules that are incorporated into, for

example, a SOC/CRAC molecule (nucleic acid or peptide), that can be directly or indirectly detected. A wide variety of detectable labels are well known in the art that can be used, and include labels that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc), or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseshoe peroxidase, etc.). The label may be bound to a SOC/CRAC binding partner, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradioactive energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art. Once a library clone or hybridizing fragment is identified in the hybridization/binding reaction, it can be further isolated by employing standard isolation/cloning techniques known to those of skill in the art. See, generally, Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press. In addition, nucleic acid amplification techniques well known in the art, may also be used to locate splice variants of calcium channel (or calcium channel subunits) with SOC/CRAC calcium channel activity. Size and sequence determinations of the amplification products can reveal splice variants.

The foregoing isolated nucleic acids and polypeptides may then be compared to the nucleic acids and polypeptides of the present invention in order to identify homogeneity or divergence of the sequences, and be further characterized functionally to determine whether they belong to a family of molecules with SOC/CRAC calcium channel activity (for methodology see under the Examples section).

The isolation of the SOC/CRAC cDNA and/or partial sequences thereof also makes it possible for the artisan to diagnose a disorder characterized by an aberrant expression of SOC/CRAC. These methods involve determining expression of the SOC/CRAC gene, and/or SOC/CRAC polypeptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes as exemplified below. In the latter situation, such determination can be carried out via any standard immunological assay using, for example, antibodies which bind to the SOC/CRAC protein.



The invention also embraces isolated peptide binding agents which, for example, can be antibodies or fragments of antibodies ("binding polypeptides"), having the ability to selectively bind to SOC/CRAC polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology. In certain embodiments, the invention excludes binding agents (e.g., antibodies) that bind to the polypeptides encoded by the nucleic acids of SEQ ID NOs: 10, 12, 13, 14, 15, 17, and 19.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs

are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves binding polypeptides of numerous size and type that bind selectively to SOC/CRAC polypeptides, and complexes containing SOC/CRAC polypeptides. These binding polypeptides also may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form, as bacterial flagella peptide display libraries or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptides and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the SOC/CRAC polypeptide or a complex containing a SOC/CRAC polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the SOC/CRAC polypeptide or complex. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear

portion of the sequence that binds to the SOC/CRAC polypeptide or complex can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to  
5 identify polypeptides that bind to the SOC/CRAC polypeptides. Thus, the SOC/CRAC polypeptides of the invention, or a fragment thereof, or complexes of SOC/CRAC can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding polypeptides that selectively bind to the SOC/CRAC polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for  
10 interfering directly with the functioning of SOC/CRAC and for other purposes that will be apparent to those of ordinary skill in the art.

A SOC/CRAC polypeptide, or a fragment thereof, also can be used to isolate naturally occurring, polypeptide binding partners which may associate with the SOC/CRAC polypeptide in the membrane of a cell. Isolation of binding partners may be performed  
15 according to well-known methods. For example, isolated SOC/CRAC polypeptides can be attached to a substrate, and then a solution suspected of containing an SOC/CRAC binding partner may be applied to the substrate. If the binding partner for SOC/CRAC polypeptides is present in the solution, then it will bind to the substrate-bound SOC/CRAC polypeptide. The binding partner then may be isolated. Other proteins which are binding partners for  
20 SOC/CRAC, may be isolated by similar methods without undue experimentation.

The invention also provides novel kits which could be used to measure the levels of the nucleic acids of the invention, expression products of the invention or anti-SOC/CRAC antibodies. In the case of nucleic acid detection, pairs of primers for amplifying SOC/CRAC nucleic acids can be included. The preferred kits would include controls such as known  
25 amounts of nucleic acid probes, SOC/CRAC epitopes (such as SOC/CRAC expression products) or anti-SOC/CRAC antibodies, as well as instructions or other printed material. In certain embodiments the printed material can characterize risk of developing a disorder that is characterized by aberrant SOC/CRAC polypeptide expression based upon the outcome of the assay. The reagents may be packaged in containers and/or coated on wells in predetermined  
30 amounts, and the kits may include standard materials such as labeled immunological reagents (such as labeled anti-IgG antibodies) and the like. One kit is a packaged polystyrene microtiter plate coated with a SOC/CRAC polypeptide and a container containing labeled anti-human IgG antibodies. A well of the plate is contacted with, for example, serum, washed

and then contacted with the anti-IgG antibody. The label is then detected. A kit embodying features of the present invention is comprised of the following major elements: packaging an agent of the invention, a control agent, and instructions. Packaging is a box-like structure for holding a vial (or number of vials) containing an agent of the invention, a vial (or number of vials) containing a control agent, and instructions. Individuals skilled in the art can readily modify packaging to suit individual needs.

Another aspect of the invention is a method for determining the level of SOC/CRAC expression in a subject. As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments, human subjects are preferred. Expression is defined either as SOC/CRAC mRNA expression or SOC/CRAC polypeptide expression. Various methods can be used to measure expression. Preferred embodiments of the invention include PCR and Northern blotting for measuring mRNA expression, and monoclonal or polyclonal SOC/CRAC antisera as reagents to measure SOC/CRAC polypeptide expression. In certain embodiments, test samples such as biopsy samples, and biological fluids such as blood, are used as test samples. SOC/CRAC expression in a test sample of a subject is compared to SOC/CRAC expression in control sample to, e.g., assess the presence or absence or stage of a proliferative disorder (e.g., a lymphocyte proliferative disorder) in a subject.

SOC/CRAC polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts. Recombinantly produced SOC/CRAC polypeptides include chimeric proteins comprising a fusion of a SOC/CRAC protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the SOC/CRAC polypeptide under assay conditions, or providing a detectable moiety, such as green fluorescent protein. A polypeptide fused to a SOC/CRAC polypeptide or fragment may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

The invention is also useful in the generation of transgenic non-human animals. As used herein, "transgenic non-human animals" includes non-human animals having one or more exogenous nucleic acid molecules incorporated in germ line cells and/or somatic cells. Thus the transgenic animal include "knockout" animals having a homozygous or heterozygous gene disruption by homologous recombination, animals having episomal or chromosomally incorporated expression vectors, etc. Knockout animals can be prepared by

homologous recombination using embryonic stem cells as is well known in the art. The recombination may be facilitated using, for example, the cre/lox system or other recombinase systems known to one of ordinary skill in the art. In certain embodiments, the recombinase system itself is expressed conditionally, for example, in certain tissues or cell types, at certain embryonic or post-embryonic developmental stages, inducibly by the addition of a compound which increases or decreases expression, and the like. In general, the conditional expression vectors used in such systems use a variety of promoters which confer the desired gene expression pattern (e.g., temporal or spatial). Conditional promoters also can be operably linked to SOC/CRAC nucleic acid molecules to increase expression of SOC/CRAC in a regulated or conditional manner. *Trans*-acting negative regulators of SOC/CRAC calcium channel activity or expression also can be operably linked to a conditional promoter as described above. Such *trans*-acting regulators include antisense SOC/CRAC nucleic acids molecules, nucleic acid molecules which encode dominant negative SOC/CRAC molecules, ribozyme molecules specific for SOC/CRAC nucleic acids, and the like. The transgenic non-human animals are useful in experiments directed toward testing biochemical or physiological effects of diagnostics or therapeutics for conditions characterized by increased or decreased SOC/CRAC expression. Other uses will be apparent to one of ordinary skill in the art.

The invention further provides efficient methods of identifying agents or lead compounds for agents active at the level of a SOC/CRAC polypeptide (e.g., a SOC/CRAC polypeptide) or SOC/CRAC fragment dependent cellular function. In particular, such functions include interaction with other polypeptides or fragments thereof, and selective binding to certain molecules (e.g., agonists and antagonists). Generally, the screening methods involve assaying for compounds which interfere with SOC/CRAC calcium channel activity, although compounds which enhance SOC/CRAC calcium channel activity also can be assayed using the screening methods. Such methods are adaptable to automated, high throughput screening of compounds. The target therapeutic indications for pharmacological agents detected by the screening methods are limited only in that the target cellular function be subject to modulation by alteration of the formation of a complex comprising a SOC/CRAC polypeptide or fragment thereof and one or more SOC/CRAC binding targets. Target indications include cellular processes modulated by SOC/CRAC such as  $\text{Ca}^{2+}$  fluxing, and affected by SOC/CRAC ability to form complexes with other molecules and polypeptides as, for example, may be present in the cell membrane.

A wide variety of assays for pharmacological agents are provided, including, expression assays, labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays, cell-based assays such as calcium transport assays, etc. For example, two-hybrid screens are used to rapidly examine the effect of transfected nucleic acids on the intracellular binding of SOC/CRAC or SOC/CRAC fragments to specific intracellular targets (e.g. a tyrosine kinase). The transfected nucleic acids can encode, for example, combinatorial peptide libraries or cDNA libraries. Convenient reagents for such assays, e.g., GAL4 fusion proteins, are known in the art. An exemplary cell-based assay involves transfecting a cell with a nucleic acid encoding a SOC/CRAC polypeptide fused to a GAL4 DNA binding domain and a nucleic acid encoding a reporter gene operably linked to a gene expression regulatory region, such as one or more GAL4 binding sites. Activation of reporter gene transcription occurs when the SOC/CRAC and reporter fusion polypeptides bind such as to enable transcription of the reporter gene. Agents which modulate a SOC/CRAC polypeptide mediated cell function are then detected through a change in the expression of reporter gene. Methods for determining changes in the expression of a reporter gene are known in the art.

In an expression system, for example, a SOC/CRAC polypeptide is attached to a membrane, the membrane preferably separating two fluid environments and being otherwise not permeable to  $\text{Ca}^{2+}$ . Such separation is preferred so that a change in  $\text{Ca}^{2+}$  concentration on either side of the membrane is mediated only through the attached SOC/CRAC polypeptide. Preferably, a SOC/CRAC polypeptide is expressed in an intact cell and is present on the cell-membrane (as in physiologic conditions). The cell expressing the SOC/CRAC polypeptide is preferably a eukaryotic cell, and the SOC/CRAC polypeptide is preferably recombinantly expressed, although cells naturally expressing a SOC/CRAC polypeptide may also be used. Synthetic membranes, however, containing SOC/CRAC polypeptides may also be used. See, e.g., K. Kiselyov, et al., Functional interaction between InsP3 receptors and store-operated Htrp3 channels, Nature 396, 478-82 (1998).

The cell expressing the SOC/CRAC polypeptide is incubated under conditions which, in the absence of the candidate agent, permit calcium flux into the cell and allow detection of a reference calcium concentration. For example, depletion of intracellular calcium stores with thapsigargin or other agents (Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997) would produce a given level of SOC/CRAC channel activation and a given reference calcium concentration. Detection of a decrease in the

foregoing activities (i.e., a decrease in the intracellular calcium concentration) relative to the reference calcium concentration indicates that the candidate agent is a lead compound for an agent to inhibit SOC/CRAC calcium channel activity. Preferred SOC/CRAC polypeptides include the polypeptides of claim 15.

5 SOC/CRAC fragments used in the methods, when not produced by a transfected nucleic acid are added to an assay mixture as an isolated polypeptide. SOC/CRAC polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts or chemically synthesized. Recombinantly produced SOC/CRAC polypeptides include chimeric proteins comprising a fusion of a SOC/CRAC  
10 protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the SOC/CRAC polypeptide under assay conditions, or providing a detectable moiety, such as green fluorescent protein or Flag epitope.

The assay mixture is comprised of a SOC/CRAC polypeptide binding target  
15 (candidate agent) capable of interacting with a SOC/CRAC polypeptide. While natural SOC/CRAC binding targets may be used, it is frequently preferred to use portions (e.g., peptides or nucleic acid fragments) or analogs (i.e., agents which mimic the SOC/CRAC binding properties of the natural binding target for purposes of the assay) of the SOC/CRAC binding target so long as the portion or analog provides binding affinity and avidity to the  
20 SOC/CRAC polypeptide (or fragment thereof) measurable in the assay.

The assay mixture also comprises a candidate agent (binding target, e.g., agonist/antagonist). Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or  
25 at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes, although typically they are organic compounds. Preferably, the candidate agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for  
30 structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or

polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids as defined herein are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily modified through conventional chemical, physical, and biochemical means. Further, known agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents. Non-SOC/CRAC calcium channel agonists and antagonists, for example, include agents such as dihydropyridines (DHPs), phenylalkylamines, omega conotoxin (omega.-CgTx) and pyrazonoylguanidines.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein, protein-nucleic acid, and/or protein/membrane component binding association. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease, inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate agent, the SOC/CRAC polypeptide specifically binds the cellular binding target, a portion thereof or analog thereof. The order of addition of components, incubation temperature, time of incubation, and other perimeters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically



are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of specific binding between the SOC/CRAC polypeptide and one or more binding targets is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximum signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as two- or three-hybrid screens. The transcript resulting from a reporter gene transcription assay of SOC/CRAC polypeptide interacting with a target molecule typically encodes a directly or indirectly detectable product, e.g.,  $\beta$ -galactosidase activity, luciferase activity, and the like. For cell-free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc.) or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to a SOC/CRAC binding partner, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly

detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, strepavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

Of particular importance in any of the foregoing assays and binding studies is the use  
5 of a specific sequence motif identified in the SOC-2/CRAC-1 polypeptide sequence as a kinase catalytic domain. According to the invention, amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24) (or a fragment thereof), show a localized homology with the catalytic domains of eukaryotic elongation factor-2 kinase (eEF-2 kinase, GenBank Acc. no. U93850) and *Dictyostelium* myocin heavy chain kinase A (MHCK A, GenBank Acc.  
10 no. U16856), as disclosed in Ryazanov AG, et al., *Proc Natl Acad Sci U S A*, 1997, 94(10):4884-4889. Therefore, according to the invention, a method for identifying agents useful in the modulation of SOC/CRAC polypeptide kinase activity is provided. The method involves contacting a SOC/CRAC polypeptide with kinase activity, that includes, for example, amino acids 999-1180 of the SOC-2/CRAC-1 polypeptide (SEQ ID NO:24) with a  
15 candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity; detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and comparing the kinase activity in the previous step with a control kinase activity of a SOC/CRAC polypeptide in the absence of the  
20 candidate agent to determine whether the candidate agent modulates (increases or decreases) SOC/CRAC kinase activity. Other controls for kinase activity can also be performed at the same time, for example, by utilizing eEF-2 kinase and/or *Dictyostelium* MHC Kinase A, in a similar manner to the SOC/CRAC member. Methods for performing such kinase activity assays are well known in the art.

25 The invention thus provides SOC/CRAC-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, SOC/CRAC-specific agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with altered SOC/CRAC and SOC/CRAC calcium channel fluxing characteristics. Novel  
30 SOC/CRAC-specific binding agents include SOC/CRAC-specific antibodies and other natural intracellular and extracellular binding agents identified with assays such as two hybrid screens, and non-natural intracellular and extracellular binding agents identified in screens of chemical libraries and the like.

In general, the specificity of SOC/CRAC binding to a specific molecule is determined by binding equilibrium constants. Targets which are capable of selectively binding a SOC/CRAC polypeptide preferably have binding equilibrium constants of at least about  $10^7$   $M^{-1}$ , more preferably at least about  $10^8$   $M^{-1}$ , and most preferably at least about  $10^9$   $M^{-1}$ . The wide variety of cell based and cell free assays may be used to demonstrate SOC/CRAC-specific binding. Cell based assays include one, two and three hybrid screens, assays in which SOC/CRAC-mediated transcription is inhibited or increased, etc. Cell free assays include SOC/CRAC-protein binding assays, immunoassays, etc. Other assays useful for screening agents which bind SOC/CRAC polypeptides include fluorescence resonance energy transfer (FRET), and electrophoretic mobility shift analysis (EMSA).

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid- $CaPO_4$  precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. For example, where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the anti-inflammatory agent, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones,

-41-

polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

Use of a long-term sustained release implant may be particularly suitable for treatment of chronic conditions. Long-term release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above.

The invention also contemplates gene therapy. The procedure for performing *ex vivo* gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject which contains a defective copy of the gene, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* gene therapy using vectors such as adenovirus, retroviruses, herpes virus, and targeted liposomes also is contemplated according to the invention. See, e.g., U.S. Patent Nos. 5,670,488, entitled "Adenovirus Vector for Gene Therapy", issued to Gregory et al., and 5,672,344, entitled "Viral-Mediated Gene Transfer System", issued to Kelley et al.

The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

### Examples

5 As an initial approach to identifying SOC/CRAC channels, we considered publicly available data and hypothesized that the following characteristics are likely to be exhibited by SOC/CRAC calcium channels: i) SOC/CRAC calcium channels would be integral membrane proteins related (probably distantly) to one of the known calcium channel families (e.g. voltage gated, ligand gated, Trp), and therefore should have a pore region formed by a tetramer of 6-7 transmembrane (TM) regions; ii) high calcium selectivity was likely to come  
10 at the price of complexity, and therefore these were likely to be large proteins; iii) the high calcium selectivity of this type of channel was likely to be useful and, therefore, highly conserved; and iv) these channels should be expressed in one or more types of lymphocytes, since ICRAC is best defined in those cell types. Since the full genome of the nematode *C. elegans* is nearing completion, and IP3-dependent calcium signals have recently been shown  
15 to be required for one or more aspects of *C. elegans* development, we took the set of proteins encoded by this genome (at the time this search was initiated WORMPEP14 was the available predicted protein set) and began searching for proteins which fit the criteria above. This search began by proceeding in alphabetical order through WORMPEP14 and arbitrarily  
20 excluding all proteins below approximately 1000 amino acids in size, followed by focusing on remaining proteins with clear TM spanning regions similar to those of other calcium channels. We stopped this screen on encountering a protein designated C05C12.3, a predicted protein of 1816 amino acids (SEQ ID NO:13). C05C12.3 was notable because its central pore region had some sequence similarity to but was clearly distinct from members of the Trp  
25 family of calcium channels, and the hydrophobicity plot of this region showed a characteristically wide spacing between the fifth and sixth TM regions for the amino acid residues which are thought to line the channel pore region and mediate the calcium selectivity of the channels. In addition, it lacked any ankyrin repeats in the region amino-terminal to its pore region, further distinguishing it from other Trp family proteins.

30 We then used C05C12.3 for BLAST alignment screening of the rest of the *C. elegans* genome and also mammalian databases for homologous proteins, revealing two other *C. elegans* homologues (SEQ ID NO:14 and SEQ ID NO:15), and also a recently cloned mammalian protein named melastatin-1 (MLSN-1/SOC-1, SEQ ID NOs:9 and 10, and

GenBank Acc. No. AF071787). Using these sequences, we subsequently performed an exhaustive screening of publicly accessible EST databases in search of lymphocyte homologues, but were unsuccessful in detecting any homologous transcripts in any lymphocyte lines. Since MLSN-1 (SEQ ID NOs:9 and 10) was expressed exclusively in melanocytes and retina by Northern blot hybridization and by EST database searching, there was no evidence that this type of channel was expressed in the type of cell in which ICRAC-like currents were best defined. Subsequent BLAST searches picked up mouse EST sequence AI098310 (SEQ ID NO:22) from a monocyte cell line. The I.M.A.G.E. consortium clone containing the above-identified EST was then purchased from ATCC (clone ID. 1312756, Manassas, VA) and was further characterized. Using other portions of this sequence in EST searches, we subsequently picked up similar sequences in human B-cells (SEQ ID NOs:20 and 21), and other cell types as well (SEQ ID NOs: 11, 12, 16, 17, 18, and 19). Most of these sequences were subsequently identified to be part of the 3'-UTR or of the carboxy terminal region of the proteins, which are not readily identifiable as Trp channels, providing an explanation for the art's inability to detect any type of Trp related transcripts in lymphocytes. Partial sequences from the 5' and/or 3' ends of the above identified clones were then used to screen leukocyte and kidney cDNA libraries to extend the original sequences more toward the 5' and/or 3' ends.

In view of the foregoing, it was concluded that channels of this type were expressed in many types of lymphocytes, and therefore were members of a new family of SOC/CRAC calcium channels.

#### Experimental Procedures

##### Screening of the cDNA libraries

Leukocyte and kidney cDNA libraries from Life Technologies (Gaithersburg, MD) were screened using the Gene Trapper II methodology (Life Technologies) according to manufacturer's recommendation, using the inserts of I.M.A.G.E. clone ID nos. 1312756 and 1076485 from ATCC (Manassas, VA), under stringent hybridization conditions. Using standard methodology ( *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York), individual cDNA clones were subjected to 3-4 rounds of amplification and purification under the same hybridization conditions.

After excision from the vector and subcloning of inserts into the plasmid forms, several clones were sequenced by the Beth Israel Deaconess Medical Center's Automated

-44-

Sequencing Facility. Molecular biological techniques such as restriction enzyme treatment, subcloning, DNA extraction, bacterial culture and purification of DNA fragments were performed according to methods well known in the art. Computer analyses of protein and DNA sequences was done using "Assemblylign" (Oxford Molecular, Cambell, CA). Multiple  
5 alignments of the SOC/CRAC family members were produced using the CLUSTAL facility of the MacVector program. Restriction endonucleases, expression vectors, and modifying enzymes were purchased from commercial sources (Gibco-BRL). Sequencing vectors for DNA were purchased from Stratagene (La Jolla, CA).

Once the first members of what appeared to be a novel family of calcium channel  
10 receptors were identified and characterized, additional BLAST alignments were performed with the newly characterized nucleic acid sequences. An initial match was with genomic DNA fragment NH0332L11 (Genbank Acc. No. AC005538). Using this genomic sequence, promoters were designed and a number of cDNA libraries was surveyed by PCR. A prostate specific message was identified and characterized, leading to the isolation and  
15 characterization of SOC-4/CRAC-3 (SEQ ID NOs: 31 and 32).

### Functional Assays

#### Transient Expression of SOC/CRAC

In our initial transient expression experiments, we expressed or expect to express a SOC/CRAC molecule transiently in RBL-2H3 mast cells, Jurkat T cells, and A20  
20 B-lymphocytes using both electroporation and vaccinia virus-driven expression, and measured the calcium influx produced by depletion of intracellular calcium stores with thapsigargin. Each of the foregoing techniques is well known to those of ordinary skill in the art and can be performed using various methods (see, e.g., Current Methods in Molecular Biology, eds. Ausubal, F.M., et al. 1987, Green Publishers and Wiley Interscience, N.Y.,  
25 N.Y.). Exemplary methods are described herein.

Depletion of intracellular calcium stores is accomplished by treating the cells with 1 micromolar thapsigargin; alternative agents which function to deplete intracellular stores are described in by Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997 and include, for example, ionomycin, cyclopiazonic acid, and DBHQ.

30 Calcium influx is determined by measuring cytoplasmic calcium as indicated using the fura-2 fluorescent calcium indicator (see, e.g., G. Grynkiewicz, M. Poenie, R. Y. Tsien, A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties, J. Biol

Chem 260, 3440-50 (1985), and M. Poenie, R. Tsien, Fura-2: a powerful new tool for measuring and imaging  $[Ca^{2+}]_i$  in single cells, Prog Clin Biol Res 210, 53-6 (1986)).

Patch Clamp Analysis and Determining Selectivity of SOC/CRAC

Patch clamp analysis of cells injected with SOC/CRAC cRNA is performed by using the general patch technique as described in Neher, E., "Ion channels for communication between and within cells", Science, 1992; 256:498-502. Specific techniques for applying the patch clamp analysis to RBL cells are described in Hoth, M., and Penner, R., "Depletion of intracellular calcium stores activates a calcium current in mast cells", Nature, 1992; 355:3535-3555. Additional protocols for applying the patch clamp technique to other cell types are described in Putney, J.W. Jr., in Capacitative Calcium Entry, R.G. Landes Co. and Chapman & Hall, 1997

An exemplary protocol for patch clamp analysis of SOC/CRAC molecule expressed in RBL-2H3 mast cells using a recombinant vaccinia virus is as follows. The currents elicited by store depletion are determined using the whole cell configuration (Neher, E., Science, 1992; 256:498-502). Currents in SOC/CRAC expressing cells are compared to currents in control cells expressing an irrelevant protein or a classic Trp family calcium channel known as VR1 (M. J. Caterina, et al., The capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments], Nature 389, 816-24 (1997)) in order to assess the contribution of SOC/CRAC expression. In addition, the magnitude of whole cell currents in the presence of extracellular calcium (10 mM), barium (10 mM), or magnesium (10 mM) are compared to determine the relative permeability of the channels to each of these ions (Hoth, M., and Penner, R., Nature, 1992; 355:3535-3555) and, thereby, determine the ionic selectivity.

Pharmacologic Behavior of SOC/CRAC

For analysis of the pharmacologic behavior of a SOC/CRAC molecule, a SOC/CRAC molecule is expressed in RBL-2H3 mast cells using a recombinant vaccinia virus, and the degree of calcium influx elicited by store depletion is monitored using a bulk spectrofluorimeter or a fluorescence microscope and the calcium sensitive dye fura-2 (G. Grynkiewicz, M. Poenie, R. Y. Tsien, A new generation of  $Ca^{2+}$  indicators with greatly improved fluorescence properties, J Biol Chem 260, 3440-50 (1985) and M. Poenie, R. Tsien, Fura-2: a powerful new tool for measuring and imaging  $[Ca^{2+}]_i$  in single cells, Prog Clin Biol Res 210, 53-6 (1986)). The level of cytoplasmic calcium in SOC/CRAC expressing cells is compared to the level achieved in control cells expressing an irrelevant protein or a classic Trp. family calcium channels known as VR1 (M. J. Caterina, et al., The



capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments], Nature 389, 816-24 (1997)). These cells then are pre-incubated with the desired pharmacologic reagent, and again the response to store depletion is monitored. Comparison of the effect of depleting stores in SOC/CRAC expressing cells relative to controls in the presence or absence of the pharmacologic reagent is used to assess the ability of that reagent to modulate SOC/CRAC activity. Sphingosine is an exemplary molecule that can be used as pharmacologic reagents for pharmacologic characterization of SOC/CRAC calcium channels. See, e.g., Mathes, C., et al., Calcium release activated calcium current as a direct target for sphingosine, J Biol Chem 273(39):25020-25030 (1998). Other non-specific calcium channel inhibitors that can be used for this purpose include SKR96365 (Calbiochem) and Lanthanum.

#### Bulk Calcium Assays

Bulk calcium assays can be performed in a PTI Deltascan bulk spectrofluorometer using fura-2 as described in Scharenberg AM, et al., EMBO J, 1995, 14(14):3385-94.

#### Gene Targeting

The method (and reagents) described by Buerstedde JM et al, (Cell, 1991, Oct 4;67(1):179-88), was used to generate "knockouts" in cells. Briefly, part of the chicken SOC-2/CRAC-1 genomic sequence coding for the transmembrane region was cloned utilizing the human sequence as the probe in a chicken library screen. Chicken SOC-2/CRAC-1 clones were isolated and characterized using standard methodology. The putative exon and domain arrangement of the chicken SOC-2/CRAC-1, is depicted in Figure 1. The exons coding for TM5 (pore region) and TM6, were replaced with promoter/antibiotic cassettes (see Figure1). These targeting vectors were then used to target (and replace) the endogenous gene in DT-40 cells (chicken B lymphocyte cells).

#### Results

##### Example 1: Transient Expression of SOC/CRAC

In the above-identified cell lines and using both of the foregoing expression techniques, SOC/CRAC expression enhances thapsigargin-dependent influx. In addition, SOC/CRAC expression also enhances the amount of intracellular calcium stores. That this effect is likely due to SOC/CRAC acting as a plasma membrane calcium channel can be confirmed by producing an in-frame carboxy-terminal translational fusion with green fluorescent protein followed by confocal microscopy, revealing that SOC/CRAC is expressed predominantly as a plasma membrane calcium channel.

##### Example 2: Patch Clamp Analysis

The biophysical characteristics of SOC/CRAC enhanced currents when expressed in *Xenopus* oocytes are determined. SOC/CRAC cRNA injection is able to enhance thapsigargin-dependent whole cell currents. In addition, SOC/CRAC does not alter the reversal potential of these currents and the determination of the  $P_{Ca}/P_{Na}$  ratio shows that SOC/CRAC channels are highly calcium selective.

**Example 3: *Pharmacologic Behavior of SOC/CRAC***

The pharmacologic behavior of SOC/CRAC is evaluated as described above. SOC/CRAC-enhanced influx is inhibited by sphingosine in a manner that is substantially the same as that of endogenous thapsigargin-dependent calcium influx.

**Example 4: *Gene targeting***

Transfection of DT-40 cells with the foregoing targeting vectors, selection for antibiotic resistance, and screening, is collectively referred to, herein, as a round of targeting. For the first round of targeting SOC-2/CRAC-1, 18/24 clones with homologous recombination of the targeting construct into one of the endogenous SOC-2/CRAC-1 alleles were obtained. On the second round of targeting (in order to target the second allele and therefore generate a homozygous SOC-2/CRAC-1 mutant cell), 0/48 clones were obtained. These results indicate that a "null" SOC-2/CRAC-1 mutation is detrimental to DT-40 cells, and that SOC-2/CRAC-1 is required for cell viability.

**Table I. Nucleotide Sequences with homologies to SOC/CRAC nucleic acids**

|  |
|--|
| Sequences with SEQ ID NOs and GenBank accession numbers:   |
| SEQ ID NO:9, AB001535, AI226731, H18835, AA419592, AA261842, AA419407, AA592910, D86107, AI098310, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, AC005538, AA654650, AA370110, AA313170, AA493512, AI670079, AI671853. |

**Table II. Amino Acid Sequences with homologies to SOC/CRAC polypeptides**

|   |
|---|
| Sequences with SEQ ID NOs and GenBank accession numbers:  |
| SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, AB001535, AA592910, D86107, AF071787, Z77132, Z83117, Z68333, AA708532, AA551759, AA932133, R47363, N31660, NP003298, CAB00861, NP002411, CAA92726, CAB05572. |

All references, patents, and patent documents disclosed herein are incorporated by reference herein in their entirety.

What is claimed is presented below and is followed by a Sequence Listing. We claim:

Claims

1. An isolated nucleic acid molecule, comprising:

(a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC polypeptide;

(b) deletions, additions and substitutions of (a) which code for a respective SOC/CRAC polypeptide;

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:1.

3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:27.

4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:29.

5. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:31.

6. An isolated nucleic acid molecule selected from the group consisting of

(a) a unique fragment of a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29, and SEQ ID NO:31,

(b) complements of (a),  
provided that the unique fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from a sequence group consisting of

(1) sequences having the SEQ. ID NOS. or GenBank accession numbers of Table I,

(2) complements of (1), and

(3) fragments of (1) and (2).

7. The isolated nucleic acid molecule of claim 6, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

- (1) at least two contiguous nucleotides nonidentical to the sequence group,
- (2) at least three contiguous nucleotides nonidentical to the sequence group,
- 5 (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

10 8. The isolated nucleic acid molecule of claim 6, wherein the unique fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

15 9. The isolated nucleic acid molecule of claim 6, wherein the molecule encodes a polypeptide which is immunogenic.

10. An expression vector comprising the isolated nucleic acid molecule of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 operably linked to a promoter.

11. A host cell transformed or transfected with the expression vector of claim 10.

20 12. An isolated polypeptide encoded by the isolated nucleic acid molecule according to anyone of claims 1 or 6, wherein the polypeptide comprises a SOC/CRAC polypeptide or a unique fragment thereof.

13. The isolated polypeptide of claim 12, wherein the isolated polypeptide is encoded by the isolated nucleic acid molecule of claim 2, 3, 4, or 5.

25 14. The isolated polypeptide of claim 13, wherein the isolated polypeptide comprises a polypeptide having the sequence of amino acids selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

-50-

15. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, 4, or 5, wherein the polypeptide, or unique fragment thereof is immunogenic.

16. An isolated binding polypeptide which binds selectively to a polypeptide encoded by the isolated nucleic acid molecule of claim 1, 2, 3, 4, or 5.

5 17. The isolated binding polypeptide of claim 16, wherein the isolated binding polypeptide binds to a polypeptide having the sequence of amino acids selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:32.

10 18. The isolated binding polypeptide of claim 17, wherein the isolated binding polypeptide is an antibody or an antibody fragment selected from the group consisting of a Fab fragment, a F(ab)<sub>2</sub> fragment or a fragment including a CDR3 region selective for the polypeptide.

15 19. An isolated polypeptide, comprising a unique fragment of the polypeptide of claim 12 of sufficient length to represent a sequence unique within the human genome, provided that the fragment excludes a sequence of contiguous amino acids identified in Table II.

20. A method for isolating a SOC/CRAC molecule having SOC/CRAC calcium channel activity, comprising:

20 a) contacting a binding molecule that is a SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample containing one or more SOC/CRAC molecules, under conditions sufficient to form a complex of the SOC/CRAC nucleic acid or the SOC/CRAC binding polypeptide and the SOC/CRAC molecule;

b) detecting the presence of the complex;

c) isolating the SOC/CRAC molecule from the complex; and

25 d) determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity.

21. The method of claim 20, wherein the binding molecule is a SOC/CRAC nucleic acid.

22. The method of claim 20, wherein the binding molecule is a SOC/CRAC binding polypeptide.

23. The method of claim 21, wherein the SOC/CRAC nucleic acid comprises at least 14 nucleotides from any contiguous portion of a sequence of nucleotides selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:31.

5 24. A method for identifying agents useful in the modulation of SOC/CRAC calcium channel activity, comprising:

a) contacting a SOC/CRAC polypeptide with a candidate agent suspected of modulating SOC/CRAC calcium channel activity, under conditions sufficient to allow the SOC/CRAC polypeptide to interact selectively with the candidate agent;

10 b) detecting a  $\text{Ca}^{2+}$  concentration associated with SOC/CRAC calcium channel activity of the SOC/CRAC polypeptide in the presence of the candidate agent; and

c) comparing the  $\text{Ca}^{2+}$  concentration of step (b) with a control  $\text{Ca}^{2+}$  concentration of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the candidate agent modulates SOC/CRAC calcium channel activity.

15

25. A method for determining the level of SOC/CRAC expression in a subject, comprising:

a) measuring the expression of SOC/CRAC in a test sample obtained from the subject, and

20 b) comparing the measured expression of SOC/CRAC in the test sample to the expression of the SOC/CRAC polypeptide in a control to determine the level of SOC/CRAC expression in the subject.

25

26. The method of claim 25, wherein the expression of SOC/CRAC in (b) is SOC/CRAC mRNA expression.

27. The method of claim 25, wherein the expression of SOC/CRAC in (b) is SOC/CRAC polypeptide expression.

28. The method of claim 25, wherein the test sample is tissue.

29. The method of claim 25, wherein the test sample is a biological fluid.

30. The method of claim 26, wherein SOC/CRAC mRNA expression is measured using the Polymerase Chain Reaction (PCR).

31. The method of claim 26, wherein SOC/CRAC mRNA expression is measured using a method selected from the group consisting of northern blotting, monoclonal antisera to  
5 SOC/CRAC and polyclonal antisera to SOC/CRAC.

32. A kit, comprising a package containing:

an agent that selectively binds to the isolated nucleic acid of claim 1 or an expression product thereof, and

10 a control for comparing to a measured value of binding of said agent to said isolated nucleic acid of claim 1 or expression product thereof.

33. The kit of claim 32, wherein the control comprises an epitope of the expression product of the nucleic acid of claim 1.

34. A pharmaceutical composition comprising:

15 a pharmaceutically effective amount of an agent comprising of an isolated nucleic acid molecule of claim 1 or an expression product thereof, and

a pharmaceutically acceptable carrier.

35. The pharmaceutical composition of claim 34, wherein the agent is an expression product of the isolated nucleic acid molecule of claim 1.

20 36. A method for identifying agents useful in the modulation of a SOC/CRAC polypeptide kinase activity, comprising:

a) contacting a SOC/CRAC polypeptide with kinase activity with a candidate agent suspected of modulating SOC/CRAC kinase activity, under conditions sufficient to allow the  
25 candidate agent to interact with the SOC/CRAC polypeptide and modulate its kinase activity;

b) detecting a kinase activity associated with the SOC/CRAC polypeptide in the presence of the candidate agent; and

c) comparing the kinase activity of step (b) with a control kinase activity of a SOC/CRAC polypeptide in the absence of the candidate agent to determine whether the  
30 candidate agent modulates SOC/CRAC kinase activity.

37. The method of claim 36, wherein the SOC/CRAC polypeptide comprises amino acids 999-1180 of the sequence represented as SEQ ID NO:24, or a fragment thereof that retains the kinase activity.

1/1




Fig. 1



-1-

## SEQUENCE LISTING

<110> Beth Israel Deaconess Medical Center, Inc.  
Scharenberg, Andrew

<120> CHARACTERIZATION OF A CALCIUM CHANNEL FAMILY

<130> B0662/7026WO/ERP/KA

<150> U.S. 60/114,220

<151> 1998-12-30

<150> U.S. 60/120,018

<151> 1999-01-29

<150> U.S. 60/140,415

<151> 1999-06-22

<160> 32

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1212

<212> DNA

<213> Homo Sapiens

<400> 1

```
gcacgaggca aattttttgt tagtacacca tctcagccaa gttgcaaaaag ccacttggaa      60
actggaacca aagatcaaga aactgtttgc tctaaagcta cagaaggaga taatacagaa      120
tttgagcat ttgtaggaca cagagatagc atggatttac agaggtttaa agaaacatca      180
aacaagataa aaatactatc caataacaat acttctgaaa acactttgaa acgagtgagt      240
tctcttgctg gatttactga ctgtcacaga acttccattc ctgttcattc aaaacaagaa      300
aaaatcagta gaaggccatc taccgaagac actcatgaag tagattccaa agcagcttta      360
ataccggttt gtagatttca actaaacaga tatatattat taaatacatt aaactttttt      420
agataagatc tacaaagtgg tgatatattg gactatatca aaaattcaaa aaaatttttc      480
ttaagaaaaa tgacttttag atagtagcag ttacagaaaa gtttcttaca gtgaatagtc      540
aggaatttta aagaaaaaatt tatgcagaat aaaggcagga atctcttttt gtttgaattg      600
aagctaatta tatgaactca tttccagcta actgcgataa tgattgattt tgcaaattcc      660
ctttaaaagc acacactgac aagacaaaaa gctcaggaaa aggcagaaaa attactcctt      720
tataatcaag tattatatat aagtcagtgc tcataatttt gctcaagaaa atattgactt      780
acattcatat atatctgttc tggcatagag agattatgtt gttaaaatca tgttattgaa      840
aaaagttatt tcagtgggga aagaggttag ttaacaaaga gattcacagt aacaaatcct      900
cctttctgga gggactcttc ctgaccctga gctgcacaac tttgcaacaa attaaagcct      960
aaccgaagat gacctcacia tggcaattta gaactcatgg gagtcaactt acataaacgg      1020
tatttgattt ctgataagat agtggaatta ttggttatag atgacaaaat aagtatgttt      1080
aaagtgatga tggacataaa aaagttttta atataaaaaca tgagaaaaga aggagatact      1140
attcaaaaag actggcaaat ttgaaaaaact agaaataaaaa aaaaaaaaaa aaaatgagcg      1200
gccgaagct tt                                     1212
```

<210> 2

<211> 141

<212> PRT

<213> Homo Sapiens

<400> 2

```
Ala Arg Gly Lys Phe Phe Val Ser Thr Pro Ser Gln Pro Ser Cys Lys
  1           5           10          15
Ser His Leu Glu Thr Gly Thr Lys Asp Gln Glu Thr Val Cys Ser Lys
          20           25           30
```

-2-

Ala Thr Glu Gly Asp Asn Thr Glu Phe Gly Ala Phe Val Gly His Arg  
           35                          40                          45  
 Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser Asn Lys Ile Lys  
           50                          55                          60  
 Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn Thr Leu Lys Arg Val Ser  
 65                          70                          75                          80  
 Ser Leu Ala Gly Phe Thr Asp Cys His Arg Thr Ser Ile Pro Val His  
                           85                          90                          95  
 Ser Lys Gln Glu Lys Ile Ser Arg Arg Pro Ser Thr Glu Asp Thr His  
                           100                          105                          110  
 Glu Val Asp Ser Lys Ala Ala Leu Ile Pro Val Cys Arg Phe Gln Leu  
           115                          120                          125  
 Asn Arg Tyr Ile Leu Leu Asn Thr Leu Asn Phe Phe Arg  
           130                          135                          140

<210> 3  
 <211> 739  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> unsure  
 <222> (5)...(5)  
 <223> UNKNOWN

<221> unsure  
 <222> (21)...(22)  
 <223> UNKNOWN

<221> unsure  
 <222> (29)...(29)  
 <223> UNKNOWN

<400> 3  
 tcgantaggg gtcttccacc nncatactng gatgatgggtt ggtgaagtct atgcatacga 60  
 aattgatgtg tgtgcaaacg attctgttat ccctcaaatc tgtggtcctg ggacgtgggtt 120  
 gactccattt cttcaagcag tctacctctt tgwacagtat atcattatgg ttaatcttct 180  
 tattgcattt ytcaacaatg tgtattttaca agtgaaggca atttccaata ttgyatggaa 240  
 gtaccagcgt tatcatttta ttatggctta tcatgagaaa ccagttctgc ctccctccact 300  
 tatcattctt agccatatag tttctctggtt ttgctgcata tgtaagagaa gaaagaaaga 360  
 taagacttcc gatggaccaa aacttttctt aacagaagaa gatcaaaaga aacttcatga 420  
 ttttgaagag cagtgtgttg aaatgtattt caatgaaaaa gatgacaaat ttcattctgg 480  
 gagtgaagag agaattcgtg tcaacttttga aagagtggaa cagatgtgca ttcagattaa 540  
 agaagttgga gatccgtgtc aactacataa aaagatcatt acaatcatta gatttctcaa 600  
 ttggccattt gcaagatctt tcagccctga cggtagatac attaaaaaca ctactggcc 660  
 aaaagcgtcg gaagctagca aagttcataa tgaaatcaca cgagaactga gcatttccaa 720  
 acacttggct caaaacctt 739

<210> 4  
 <211> 235  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (41)...(41)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (54)...(54)

-3-

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (68)...(68)

&lt;223&gt; UNKNOWN

&lt;400&gt; 4

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Met | Val | Gly | Glu | Val | Tyr | Ala | Tyr | Glu | Ile | Asp | Val | Cys | Ala | Asn |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Asp | Ser | Val | Ile | Pro | Gln | Ile | Cys | Gly | Pro | Gly | Thr | Trp | Leu | Thr | Pro |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Phe | Leu | Gln | Ala | Val | Tyr | Leu | Phe | Xaa | Gln | Tyr | Ile | Ile | Met | Val | Asn |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Leu | Leu | Ile | Ala | Phe | Xaa | Asn | Asn | Val | Tyr | Leu | Gln | Val | Lys | Ala | Ile |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Ser | Asn | Ile | Xaa | Trp | Lys | Tyr | Gln | Arg | Tyr | His | Phe | Ile | Met | Ala | Tyr |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     | 80  |     |
| His | Glu | Lys | Pro | Val | Leu | Pro | Pro | Pro | Leu | Ile | Ile | Leu | Ser | His | Ile |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Val | Ser | Leu | Phe | Cys | Cys | Ile | Cys | Lys | Arg | Arg | Lys | Lys | Asp | Lys | Thr |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Ser | Asp | Gly | Pro | Lys | Leu | Phe | Leu | Thr | Glu | Glu | Asp | Gln | Lys | Lys | Leu |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| His | Asp | Phe | Glu | Glu | Gln | Cys | Val | Glu | Met | Tyr | Phe | Asn | Glu | Lys | Asp |
|     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Asp | Lys | Phe | His | Ser | Gly | Ser | Glu | Glu | Arg | Ile | Arg | Val | Thr | Phe | Glu |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Arg | Val | Glu | Gln | Met | Cys | Ile | Gln | Ile | Lys | Glu | Val | Gly | Asp | Pro | Cys |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Gln | Leu | His | Lys | Lys | Ile | Ile | Thr | Ile | Ile | Arg | Phe | Ser | Asn | Trp | Pro |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Phe | Ala | Arg | Ser | Phe | Ser | Pro | Asp | Gly | Arg | Tyr | Ile | Lys | Asn | Thr | His |
|     | 195 |     |     |     |     | 200 |     |     |     |     |     | 205 |     |     |     |
| Trp | Pro | Lys | Ala | Ser | Glu | Ala | Ser | Lys | Val | His | Asn | Glu | Ile | Thr | Arg |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Glu | Leu | Ser | Ile | Ser | Lys | His | Leu | Ala | Gln | Asn |     |     |     |     |     |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     |     |

&lt;210&gt; 5

&lt;211&gt; 1579

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (368)...(368)

&lt;223&gt; g or c

&lt;221&gt; unsure

&lt;222&gt; (372)...(372)

&lt;223&gt; g or c

&lt;221&gt; unsure

&lt;222&gt; (374)...(374)

&lt;223&gt; g or a

&lt;221&gt; unsure

&lt;222&gt; (375)...(375)

&lt;223&gt; g or c

-4-

&lt;221&gt; unsure

&lt;222&gt; (387)...(387)

&lt;221&gt; unsure

&lt;222&gt; (482)...(482)

&lt;400&gt; 5

```

acgtcgccctg caggtagcgg tccggaattc ccgggtcgac ccacgcgtcc ggcatgggtgt      60
tgtaaatata ctttagctcct ctcttcctca aggtgatctt gaaagtaata atcctttttca      120
ttgtaaatatt ttaatgaaag atgacaaaga tccccagtggt aatatatttg gtcaagactt      180
acctgcagta cccagagaa aagaatttaa tttccagag gctggttctt cttctggtgc      240
cttattccca agtgctgttt cccctccaga actgcgacag agactacatg gggtagaact      300
cttaaaaaata ttaataaaaa atcaaaaatt aggcagttca tctactagca taccacatct      360
gtcatccsca csarscaaat tttttgntag tacaccatct cagccaagtt gcaaaaagcca      420
cttggaact ggaaccaaag atcaagaaac tgtttgctct aaagctacag aaggagataa      480
tncagaattt ggagcatttg taggacacag agatagcatg gatttacaga ggtttaaga      540
aacatcaaac aagataaaaa tactatccaa taacaatact tctgaaaaca ctttgaaacg      600
agtgagttct cttgctggat ttactgactg tcacagaact tccattcctg ttcattcaaa      660
acaagaaaaa atcagtagaa ggccatctac cgaagacact catgaagtag attccaaagc      720
agctttaata ccggtttgta gatttcaact aaacagatat atattattaa atacattaaa      780
cttttttaga taagatctac aaagtgggta tatttgggac tatatcaaaa attcaaaaaa      840
atttttctta agaaaactga ctttagcata gtagcagtta cagaaaagtt tcttacagtg      900
aatagtcagg aattttaaaag aaaaatttat gcagaataaa ggcaggaatc tctttttggt      960
tgaattgaag ctaattatat gaactcattt ccagctaact gcgataatga ttgattttgc      1020
aaattccctt taaaagcaca cactgacaag acaaaaagct caggaaaagg cagaaaaatt      1080
actcctttat aatcaagtat tatatataag tcagtgtctc taattttgct caagaaaata      1140
ttgacttaca ttcatatata tctgttctgg catagagaga ttatgttggt aaaatcatgt      1200
tattgaaaaa agttatttca gtggggaaaag aggttagtta acaaagagat tcacagtaac      1260
aaatcctcct ttctggaggg actcttcctg accctgagct gcacaacttt gcaacaaatt      1320
aaagcctaac cgaagatgac ctcaaatgg caatttagaa ctcatgggag tcaacttaca      1380
taaacggtat ttgatttctg ataagatagt ggaattattg gttatagatg acaaaaataag      1440
tatgtttaaa gtgatgatgg acataaaaaa gttttaata taaaacatga gaaaagaagg      1500
agatactatt caaaaagact ggcaaatgtg aaaaactaga aataaaaaaa aaaaaaaaaa      1560
atgagcggcc gcaagcttt

```

&lt;210&gt; 6

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (103)...(105)

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (109)...(109)

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (141)...(141)

&lt;223&gt; UNKNOWN

&lt;400&gt; 6

```

Val Asn Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Leu Glu Ser Asn
 1           5           10          15
Asn Pro Phe His Cys Asn Ile Leu Met Lys Asp Asp Lys Asp Pro Gln
          20          25          30
Cys Asn Ile Phe Gly Gln Asp Leu Pro Ala Val Pro Gln Arg Lys Glu
          35          40          45

```

-5-

Phe Asn Phe Pro Glu Ala Gly Ser Ser Ser Gly Ala Leu Phe Pro Ser  
     50                    55                    60  
 Ala Val Ser Pro Pro Glu Leu Arg Gln Arg Leu His Gly Val Glu Leu  
     65                    70                    75                    80  
 Leu Lys Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Ser Thr Ser  
                     85                    90                    95  
 Ile Pro His Leu Ser Ser Xaa Xaa Xaa Lys Phe Phe Xaa Ser Thr Pro  
                     100                    105                    110  
 Ser Gln Pro Ser Cys Lys Ser His Leu Glu Thr Gly Thr Lys Asp Gln  
                     115                    120                    125  
 Glu Thr Val Cys Ser Lys Ala Thr Glu Gly Asp Asn Xaa Glu Phe Gly  
                     130                    135                    140  
 Ala Phe Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu  
     145                    150                    155                    160  
 Thr Ser Asn Lys Ile Lys Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn  
                     165                    170                    175  
 Thr Leu Lys Arg Val Ser Ser Leu Ala Gly Phe Thr Asp Cys His Arg  
                     180                    185                    190  
 Thr Ser Ile Pro Val His Ser Lys Gln Glu Lys Ile Ser Arg Arg Pro  
                     195                    200                    205  
 Ser Thr Glu Asp Thr His Glu Val Asp Ser Lys Ala Ala Leu Ile Pro  
                     210                    215                    220  
 Val Cys Arg Phe Gln Leu Asn Arg Tyr Ile Leu Leu Asn Thr Leu Asn  
     225                    230                    235                    240  
 Phe Phe Arg

<210> 7  
 <211> 3532  
 <212> DNA  
 <213> Mus Musculus

<220>  
 <221> unsure  
 <222> (2420)...(2420)  
 <223> unknown

<221> unsure  
 <222> (2434)...(2434)  
 <223> unknown

<221> unsure  
 <222> (2461)...(2461)  
 <223> unknown

<221> unsure  
 <222> (2466)...(2466)  
 <223> unknown

<221> unsure  
 <222> (2470)...(2470)  
 <223> unknown

<400> 7  
 attatggctt atcatgaaaa accagtcctg cctcctcctc ttatcatcct cagccatata 60  
 gtttcactgt tttgctgtgt atgcaaaaaga agaaagaaaag ataagacttc cgatgggcca 120  
 aaacttttct taacagaaga agatcaaaaag aaactccatg attttgaaga gcagtgtgtt 180  
 gagatgtact ttgatgagaa agatgacaaa ttcaattctg ggagtgaaga gagaatccgg 240  
 gtcacttttg aaagagtggg gcagatgagc attcagatta aagaagttgg agatcgtgtc 300  
 aactacataa aaagatcatt acagtcctta gattctcaaa ttggtcatct gcaagatctc 360

-6-

|             |             |             |             |            |             |      |
|-------------|-------------|-------------|-------------|------------|-------------|------|
| tcagccctaa  | cagtagatac  | attgaaaaca  | cttacagccc  | agaaagcttc | agaagctagt  | 420  |
| aaagtgcaca  | atgagatcac  | acgagaattg  | agtattttcca | aacacttggc | tcagaatcct  | 480  |
| attgatgatg  | ttcctgtaag  | acctttgtgg  | gaagaaccta  | gtgctgtaaa | cacactgagt  | 540  |
| tcctctcttc  | ctcaaggtga  | tcgggaaagt  | aataatcctt  | ttctttgtaa | tatttttatg  | 600  |
| aaagatgaaa  | aagaccccca  | atataatctg  | tttggaacaag | atttgcccgt | gataccccag  | 660  |
| agaaaagaat  | tcaacattcc  | agaggctggt  | tcctcctgtg  | gtgccttatt | cccaagtgtc  | 720  |
| gtttctcccc  | cagaattacg  | acagagacga  | catggggtag  | aaatgttaaa | aatatttaat  | 780  |
| aaaaatcaaa  | aattaggcag  | ttcacctaata | agttcaccac  | atatgtcctc | cccaccaacc  | 840  |
| aaattttctg  | ttagtacccc  | atcccagcca  | agttgcaaaa  | gtcacttgga | atccacaacc  | 900  |
| aaagatcaag  | aaccattttt  | ctataaagct  | gcagaagggg  | ataacataga | atttggagca  | 960  |
| tttgtgggac  | acagagatag  | tatggactta  | cagagggtta  | aagaaacatc | aaacaaaata  | 1020 |
| agagaactgt  | tatctaatag  | tactcctgaa  | aacactctga  | aacatgtggg | tgctgctgga  | 1080 |
| tatagtgaat  | gttgtaagac  | ttctacttct  | cttcactcgg  | tgcaagcaga | aagctgtagt  | 1140 |
| agaagagcgt  | cgacgggaaga | ctctccagaa  | gtcgattcta  | aagcagcttt | gttaccggat  | 1200 |
| tggttacgag  | atagaccatc  | aaacagagaa  | atgccatctg  | aaggaggaac | attaaattggt | 1260 |
| cttgcttctc  | catttaagcc  | cgttttggat  | acaaattact  | attattcagc | tgtggaaaga  | 1320 |
| aataaacctga | tgagggtgtc  | acagagtatt  | cccttcgttc  | ctgtacctcc | acgaggcgag  | 1380 |
| cctgtcacag  | tgtaccgtct  | ggaggagagt  | tctcccagta  | tactgaataa | cagcatgtct  | 1440 |
| tcatggtctc  | agctaggcct  | ctgtgccaaa  | attgagtttt  | taagtaaaga | ggaaatggaa  | 1500 |
| ggtggtttac  | gaagagcagt  | caaagtgtctg | tgtacctggt  | cagagcacga | tatcctgaag  | 1560 |
| tcagggcac   | tctatatcat  | taagtcatct  | cttcctgagg  | tgataaacac | atggtcaagc  | 1620 |
| atttataaag  | aagatacggg  | ttacatctc   | tgtctcagag  | aaatacaaca | acagagagca  | 1680 |
| gcacaaaagc  | tcacatttgc  | ctttaatcag  | atgaaaccca  | aatccatacc | atattctcca  | 1740 |
| aggttccttg  | aagttttcct  | gttgtactgc  | cattcagcag  | ggcagtggtt | tgctgtagaa  | 1800 |
| gagtgcatga  | ctggtgaatt  | tagaaaatac  | aacaacaata  | atggtgatga | aatcattcct  | 1860 |
| acaaatactc  | tagaagagat  | catgctagcc  | tttagccact  | ggacctatga | atataaccaga | 1920 |
| ggggagttac  | tggtacttga  | cttacaagga  | gtgggagaaa  | acttgactga | cccactctga  | 1980 |
| ataaaaagctg | aagaaaaaag  | atcctgtgac  | atggtttttg  | gccctgcaa  | tctaggagaa  | 2040 |
| gatgcaataa  | aaaacttcaa  | gagccaaaca  | tccactgtaa  | ttcttgctgt | cgaaagctta  | 2100 |
| aacttcccag  | atttgaagag  | gaatgactac  | acgcccttga  | taaaattata | tttctcagg   | 2160 |
| atgagtcac   | agatttgaat  | cttcaatctg  | gaaattccac  | caaagaatca | gaagcaacaa  | 2220 |
| attctgttcg  | tctgatgtta  | tagtgctgag  | tcattgggtt  | ttgcctacac | ttcacaaaag  | 2280 |
| tgtaactgtc  | agttttcctt  | tcgggggaat  | tgatgatata  | ggaagatgtg | tgcaaaatga  | 2340 |
| gcttgctggc  | cccacacata  | gtctagaggt  | aatgttctca  | ttgaaaaacg | cctggagggtg | 2400 |
| gaggctgcag  | atgccagtg   | aaagtgtctg  | ctgncagaga  | gtcagtgtc  | tcgggctggt  | 2460 |
| naaggncggn  | acccttgctg  | ctgagagtgg  | tggttctctt  | cacctgggtg | aggaccatta  | 2520 |
| accaaagtca  | agtcttcaga  | tttgattggc  | tgctcagtca  | cagcccatc  | agctaaggaa  | 2580 |
| actaaattgc  | gcagcttttt  | aaatggctga  | agtcttcctc  | agtttgtgtc | ctatgataat  | 2640 |
| gatgttagct  | ctcaactagg  | tgtttgtggc  | cacgggagaa  | ctactcctta | caattttgct  | 2700 |
| tcacaggcat  | gttacaaagc  | ctgcactgaa  | aaccgtttgt  | cttccctctc | tcctccctc   | 2760 |
| ttttccctgt  | agtattgagg  | atcaaaccac  | gggcctcatg  | aagaccattt | tctaagagac  | 2820 |
| attttattta  | agaatcaact  | atagagtcta  | gttttatgga  | tacagccagt | ttttgttaaa  | 2880 |
| caaaacctga  | attgtgcaaa  | agggtttttt  | aacattttatc | aatgttaagt | aaaagaaagc  | 2940 |
| catgataaat  | aagaattaac  | tcactgttca  | atgggtgttt  | cctgtgagga | aggttacagt  | 3000 |
| tgtaacagcc  | tgcaagttga  | tacatctcca  | aagatttaca  | gacttagtgt | atcaaatcag  | 3060 |
| agtgtcatgt  | gagctctcac  | attgaaaatt  | ctataggaat  | gtgtcaatgt | gaattctatt  | 3120 |
| tctggtactt  | aagaaatcag  | ttgttggtat  | atccttatac  | agtataggga | gatcacataa  | 3180 |
| caactttatg  | ccaataaaat  | ctaacttaat  | tgcccagata  | tttttgcata | tttagcaaca  | 3240 |
| agaaaagctt  | atcatttgac  | tcaagtttta  | tgctttctct  | ttcttttcat | ttcctaggta  | 3300 |
| ctaattttta  | tttttatttg  | gaaggagcag  | tgtaaaagctt | acttgtattc | aatagtgtat  | 3360 |
| ctcatagata  | cagacaaggc  | cgagagata   | agctgtttaa  | tagtgtttta | tggtgatgtg  | 3420 |
| gagagaaagg  | tgtattactt  | aaaaatacta  | taccatatac  | gttttgtata | tcattaaatc  | 3480 |
| tttaaaagaa  | attaaattta  | ttcttgttta  | aaaaaaaaaa  | aaaaaaaaaa | aa          | 3532 |

&lt;210&gt; 8

&lt;211&gt; 475

&lt;212&gt; PRT

&lt;213&gt; Mus Musculus

&lt;400&gt; 8

-7-

Ile Met Ala Tyr His Glu Lys Pro Val Leu Pro Pro Pro Leu Ile Ile  
 1 5 10 15  
 Leu Ser His Ile Val Ser Leu Phe Cys Cys Val Cys Lys Arg Arg Lys  
 20 25 30  
 Lys Asp Lys Thr Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp  
 35 40 45  
 Gln Lys Lys Leu His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe  
 50 55 60  
 Asp Glu Lys Asp Asp Lys Phe Asn Ser Gly Ser Glu Glu Arg Ile Arg  
 65 70 75 80  
 Val Thr Phe Glu Arg Val Glu Gln Met Ser Ile Gln Ile Lys Glu Val  
 85 90 95  
 Gly Asp Arg Val Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser  
 100 105 110  
 Gln Ile Gly His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu  
 115 120 125  
 Lys Thr Leu Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn  
 130 135 140  
 Glu Ile Thr Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu  
 145 150 155 160  
 Ile Asp Asp Val Pro Val Arg Pro Leu Trp Glu Glu Pro Ser Ala Val  
 165 170 175  
 Asn Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Arg Glu Ser Asn Asn  
 180 185 190  
 Pro Phe Leu Cys Asn Ile Phe Met Lys Asp Glu Lys Asp Pro Gln Tyr  
 195 200 205  
 Asn Leu Phe Gly Gln Asp Leu Pro Val Ile Pro Gln Arg Lys Glu Phe  
 210 215 220  
 Asn Ile Pro Glu Ala Gly Ser Ser Cys Gly Ala Leu Phe Pro Ser Ala  
 225 230 235 240  
 Val Ser Pro Pro Glu Leu Arg Gln Arg Arg His Gly Val Glu Met Leu  
 245 250 255  
 Lys Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Pro Asn Ser Ser  
 260 265 270  
 Pro His Met Ser Ser Pro Pro Thr Lys Phe Ser Val Ser Thr Pro Ser  
 275 280 285  
 Gln Pro Ser Cys Lys Ser His Leu Glu Ser Thr Thr Lys Asp Gln Glu  
 290 295 300  
 Pro Ile Phe Tyr Lys Ala Ala Glu Gly Asp Asn Ile Glu Phe Gly Ala  
 305 310 315 320  
 Phe Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr  
 325 330 335  
 Ser Asn Lys Ile Arg Glu Leu Leu Ser Asn Asp Thr Pro Glu Asn Thr  
 340 345 350  
 Leu Lys His Val Gly Ala Ala Gly Tyr Ser Glu Cys Cys Lys Thr Ser  
 355 360 365  
 Thr Ser Leu His Ser Val Gln Ala Glu Ser Cys Ser Arg Arg Ala Ser  
 370 375 380  
 Thr Glu Asp Ser Pro Glu Val Asp Ser Lys Ala Ala Leu Leu Pro Asp  
 385 390 395 400  
 Trp Leu Arg Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu Gly Gly  
 405 410 415  
 Thr Leu Asn Gly Leu Ala Ser Pro Phe Lys Pro Val Leu Asp Thr Asn  
 420 425 430  
 Tyr Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met Arg Leu Ser Gln  
 435 440 445  
 Ser Ile Pro Phe Val Pro Val Pro Pro Arg Gly Glu Pro Val Thr Val  
 450 455 460  
 Tyr Pro Ser Gly Gly Arg Val Leu Pro Val Tyr  
 465 470 475

<210> 9  
 <211> 5433  
 <212> DNA  
 <213> Mus Musculus

<220>  
 <221> unsure  
 <222> (5094)...(5094)  
 <223> unknown

<400> 9  
 ggctgaaaga gcctgagctg tgccctctcca ttccactgct gtggcagggt cagaaatctt 60  
 ggatagagaa aaccttttgc aaacgggaat gtatctttgt aattcctagc acgaaagact 120  
 ctaacagggtg ttgctgtggc cagttcacca accagcata cccccctctg ccaagtgcaa 180  
 caccagcaa aaatgaagag gaaagcaaac aggtggagac tcagcctgag aaatggctctg 240  
 ttgccaaagca caccagagc taccacaacag attcctatgg agttcttgaa ttccagggtg 300  
 gcggatattc caataaagcc atgtatatcc gtgtatccta tgacaccaag ccagactcac 360  
 tgctccatct catggtgaaa gattggcagc tggaactccc caagctctta atatctgtgc 420  
 atggaggcct ccagaacttt gagatgcagc ccaagctgaa acaagtcttt gggaaaggcc 480  
 tgatcaaggc tgctatgacc accggggcct ggatcttcac cgggggtgtc agcacagggtg 540  
 ttatcagcca cgtaggggat gccttgaaa accactcctc caagtccaga ggccgggttt 600  
 gtgctatagg aattgctcca tggggcatcg tggagaataa ggaagacctg gttggaaaag 660  
 atgtaacaag agtgtaccag accatgtcca accctctaag taagctctct gtgctcaaca 720  
 actccacac ccacttcac ctggctgaca atggcaccct gggcaagtat ggcgcgagg 780  
 tgaagctgcg aaggctgctg gaaaagcaca tctccctcca gaagatcaac acaagactgg 840  
 ggcaggcgt gccctcgtg ggtctcgtg tggaggggg ccctaactgtg gtgtccatcg 900  
 tcttgaata cctgcaagaa gagcctcca tccctgtgtg gatttggat ggcagcggac 960  
 gtgctcggc catcctgtcc ttgctgcaca agtatgtga agaaggcgga ataataaag 1020  
 agtccctcag ggagcagctt ctagttaaca ttcagaaaac atttaattat aataaggcac 1080  
 aatcacatca gctgtttgca attataatgg agtgcataga gaagaaagaa ctgctcactg 1140  
 tgttcagaat gggttctgag ggccagcagg acatcgagat ggcaatttta actgccctgc 1200  
 tgaagggaac aaacgtatct gctccagatc agctgagctt ggcaatttta actgccctgc 1260  
 tggacatagc acgaagccag atctttgtct ttgggcccc ctggacgccc ctgggaagcc 1320  
 tggcaccccc gacggacagc aaagccacgg agaaggagaa gaagccaccc atggccacca 1380  
 ccaaggagg aagaggaaa gggaaaggca agaagaaagg gaaagtgaag gaggaagtgg 1440  
 aggaagaaac tgaccccgag aagatagagc tgctgaactg ggtgaatgct ttggagcaag 1500  
 cgatgctaga tgctttagtc ttagatcgct tgcactttgt gaagctcctg attgaaaacg 1560  
 gagtgaacat gcaacacttt ctgaccatc cgaggctgga ggagctctat aacacaagac 1620  
 tgggtccacc aaacacactt catctgctgg tgagggatgt gaaaaagagc aaccttccgc 1680  
 ctgattacca catcagcctc atagacatcg ggctcgtgct ggagtacctc atgggaggag 1740  
 cctaccgctg caactacact cggaaaaact ttcggaccct ttacaacaac ttgtttggac 1800  
 caaagaggcc taaagctctt aaacttctgg gaattggaaga tgatgagcct ccagctaaag 1860  
 ggaagaaaaa aaaaaaaag aaaaaggagg aagagatcga cattgatgtg gacgacctg 1920  
 ccgtgagtcg gttccagtat cccttccacg agctgatggt gtgggcagtg ctgatgaaac 1980  
 gccagaaaat ggcagtgttc ctctggcagc gaggggaaga gagcatggcc aaggccctgg 2040  
 tggcctgcaa gctctacaag gccatggccc acgagctcct cgagagtgat ctggtggatg 2100  
 acatctccca ggacttgat aacaattcca aagacttcgg ccagcttgct ttggagttat 2160  
 tagaccagtc ctataagcat gacgagcaga tcgctatgaa actcctgacc tacgagctga 2220  
 aaaactggag caactcgacc tgccctcaaac tggccgtggc agccaaacac cgggacttca 2280  
 ttgctcacac ctgacgccag atgctgctga ccgatatgtg gatgggaaga ctgaggatgc 2340  
 ggaagaaccc cggcctgaag gttatcatgg ggattcttct acccccacc atcttgtttt 2400  
 tggaatttcg cacatatgat gatttctcgt atcaaacatc caaggaaaac gaggatggca 2460  
 aagaaaaaga agagaaaaat acggatgcaa atgcagatgc tggctcaaga aagggggatg 2520  
 aggagaacga gcataaaaaa cagagaagta tccccatcg aacaaagatc tgtgaattct 2580  
 ataacgcgcc cattgtcaag ttctggtttt acacaatata atacttggc tacctgtctg 2640  
 tgtttaacta cgtcatcctg gtgcggtg atgctggccc gtccctccag gagtggatcg 2700  
 tcctctccta catctgagc ctggcgtagc agaagatacg agagatcctc atgtcagaac 2760  
 caggcaaac cagccagaaa atcaaatgtt ggcttcagga gtactggaac atcacagatc 2820  
 tcgtggccat ttccacattc atgattggag caattctctg cctacagaac cagccctaca 2880



-9-

```

tgggctatgg ccgggtgatc tactgtgtgg atatcatctt ctggtacatc cgtgtcctgg 2940
acatcttttg tgtcaacaag tatctggggc catabgtgat gatgattgga aagatgatga 3000
tcgacatgct gtactttgtg gtcacatgct tggctgtgct catgagtttc ggagtagccc 3060
gtcaagccat tctgcatcca gaggagaagc cctcttgaa actggcccga aacatcttct 3120
acatgcccta ctggatgatc tatggagagg tgtttgcaga ccagatagac ctctacgcc 3180
tggaaattaa tcctccttgt ggtgagaacc tatatgatga ggagggaag cggcttcctc 3240
cctgtatccc cggcgcctgg ctactccag cactcatggc gtgctatcta ctggtcgcca 3300
acatcctgct ggtgaacctg ctgattgctg tgttcaaca tactttcttt gaagtaaaat 3360
caatatccaa ccaggtgtgg aagttccagc gatatcagct gattatgaca tttcatgaca 3420
ggccagtcct gcccccaccg atgacattt taagccacat ctacatcatc attatgcgtc 3480
tcagcggccg ctgcaggaaa aagagagaag gggaccaaga ggaacgggat cgtggattga 3540
agctcttctc tagcgacgag gagctaaaga ggctgcatga gttcgaggag cagtgcgtgc 3600
aggagcactt ccgggagaag gaggatgagc agcagtcgtc cagcgacgag cgcacccggg 3660
tcacttctga aagagttgaa aatatgtcaa tgaggttga agaaatcaat gaaagagaaa 3720
cttttatgaa aacttcctg cagactgttg accttcgact tgctcagcta gaagaattat 3780
ctaacagaat ggtgaatgct cttgaaaatc ttgcgggaat cgacaggtct gacctgatcc 3840
aggcacggtc ccgggcttct tctgaatgtg aggcaacgta tcttctccgg caaagcagca 3900
tcaatagcgc tgatggctac agcttgtatc gatatcattt taacggagaa gagttattat 3960
ttgaggatac atctctctcc acgtcaccag ggacaggagt caggaaaaaa acctgttcct 4020
tccgtataaa ggaagagaag gacgtgaaaa cgcacctagt cccagaatgt cagaacagtc 4080
ttcaccttct actgggcaca agcacatcag caaccccaga tggcagtcac cttgcagtag 4140
atgacttaaa gaacgtgaa gagtcaaaat taggtccaga tattgggatt tcaaaggaa 4200
atgatgaaa acagacagac tctaaaaaag aagaaactat ttccccagt ttaataaaaa 4260
cagatgtgat acatggacag gacaaatcag atgttcaaaa cactcagcta acagtggaaa 4320
cgacaaatat agaaggcact atttcctatc ccctggaaga aacaaaaatt acacgctatt 4380
tccccgatga aacgatcaat gcttgtaaaa caatgaagtc cagaagcttc gtctattccc 4440
ggggaagaaa gctggtcggg ggggttaacc aggatgtaga gtacagttca atcacggacc 4500
agcaattgac gacggaatgg caatgccaa ggacaaagat cagcgctct catagcacag 4560
atattcctta cattgtgtcg gaagctgcag tgcaagctga gcaaaaagag cagtttgag 4620
atatgcaaga tgaacacat gtctgtgaag caattcctcg aatccctcg ttgtccctaa 4680
ccattactga cagaaatggg atggaaaact tactgtctgt gaagccagat caaactttgg 4740
gattcccatc tctcaggtca aaaagtttac atggacatcc taggaatgtg aaatccattc 4800
agggaaagt agacagatct ggacatgccg gtagtgtaag cagcttagta attgtgtctg 4860
gaatgacagc agaagaaaaa aagggttaaga aagagaaaagc ttccacagaa actgaatgct 4920
agtctgtttt gtttctttaa ttttttttt taacagtcag aaaccacta atgggtgtca 4980
tcttgccca tctaaacac atmtccaatt tcttaaaaac attttccctt aaaaaatttt 5040
ggaaattcag acttgattta caatttaatg cactaaaagt agtattttgt tagnatatgt 5100
tagtaggctt agttttttca gttgcagtag tatcaaatga aagtgatgat actgtaacga 5160
agataaattg gctaatacag atacaagatt atacaatctc tttattactg agggccacca 5220
aatagcctag gaagtgccct cgagcactga agtcaccatt aggtcactca agaagtaagc 5280
aactagctgg gcacagtggc tcatgcctgt aatcctagca ctttgaggag ccaaggcaga 5340
aagatagctt gagtccagga gtttgagacc agcctgggca acatagtgat accccatctc 5400
ttaaaaaaaa aaaaaaaaaa ctgccctcgt gcc 5433

```

&lt;210&gt; 10

&lt;211&gt; 1533

&lt;212&gt; PRT

&lt;213&gt; Mus Musculus

&lt;400&gt; 10

```

Met Tyr Ile Arg Val Ser Tyr Asp Thr Lys Pro Asp Ser Leu Leu His
1           5           10           15
Leu Met Val Lys Asp Trp Gln Leu Glu Leu Pro Lys Leu Leu Ile Ser
20           25           30
Val His Gly Gly Leu Gln Asn Phe Glu Met Gln Pro Lys Leu Lys Gln
35           40           45
Val Phe Gly Lys Gly Leu Ile Lys Ala Ala Met Thr Thr Gly Ala Trp
50           55           60

```

-10-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Phe | Thr | Gly | Gly | Val | Ser | Thr | Gly | Val | Ile | Ser | His | Val | Gly | Asp | 65  | 70  | 75  | 80  |
| Ala | Leu | Lys | Asp | His | Ser | Ser | Lys | Ser | Arg | Gly | Arg | Val | Cys | Ala | Ile | 85  | 90  | 95  |     |
| Gly | Ile | Ala | Pro | Trp | Gly | Ile | Val | Glu | Asn | Lys | Glu | Asp | Leu | Val | Gly | 100 | 105 | 110 |     |
| Lys | Asp | Val | Thr | Arg | Val | Tyr | Gln | Thr | Met | Ser | Asn | Pro | Leu | Ser | Lys | 115 | 120 | 125 |     |
| Leu | Ser | Val | Leu | Asn | Asn | Ser | His | Thr | His | Phe | Ile | Leu | Ala | Asp | Asn | 130 | 135 | 140 |     |
| Gly | Thr | Leu | Gly | Lys | Tyr | Gly | Ala | Glu | Val | Lys | Leu | Arg | Arg | Leu | Leu | 145 | 150 | 155 | 160 |
| Glu | Lys | His | Ile | Ser | Leu | Gln | Lys | Ile | Asn | Thr | Arg | Leu | Gly | Gln | Gly | 165 | 170 | 175 |     |
| Val | Pro | Leu | Val | Gly | Leu | Val | Val | Glu | Gly | Gly | Pro | Asn | Val | Val | Ser | 180 | 185 | 190 |     |
| Ile | Val | Leu | Glu | Tyr | Leu | Gln | Glu | Pro | Pro | Ile | Pro | Val | Val | Ile |     | 195 | 200 | 205 |     |
| Cys | Asp | Gly | Ser | Gly | Arg | Ala | Ser | Asp | Ile | Leu | Ser | Phe | Ala | His | Lys | 210 | 215 | 220 |     |
| Tyr | Cys | Glu | Glu | Gly | Gly | Ile | Ile | Asn | Glu | Ser | Leu | Arg | Glu | Gln | Leu | 225 | 230 | 235 | 240 |
| Leu | Val | Thr | Ile | Gln | Lys | Thr | Phe | Asn | Tyr | Asn | Lys | Ala | Gln | Ser | His | 245 | 250 | 255 |     |
| Gln | Leu | Phe | Ala | Ile | Ile | Met | Glu | Cys | Met | Lys | Lys | Lys | Glu | Leu | Val | 260 | 265 | 270 |     |
| Thr | Val | Phe | Arg | Met | Gly | Ser | Glu | Gly | Gln | Gln | Asp | Ile | Glu | Met | Ala | 275 | 280 | 285 |     |
| Ile | Leu | Thr | Ala | Leu | Leu | Lys | Gly | Thr | Asn | Val | Ser | Ala | Pro | Asp | Gln | 290 | 295 | 300 |     |
| Leu | Ser | Leu | Ala | Leu | Ala | Trp | Asn | Arg | Val | Asp | Ile | Ala | Arg | Ser | Gln | 305 | 310 | 315 | 320 |
| Ile | Phe | Val | Phe | Gly | Pro | His | Trp | Thr | Pro | Leu | Gly | Ser | Leu | Ala | Pro | 325 | 330 | 335 |     |
| Pro | Thr | Asp | Ser | Lys | Ala | Thr | Glu | Lys | Glu | Lys | Lys | Pro | Pro | Met | Ala | 340 | 345 | 350 |     |
| Thr | Thr | Lys | Gly | Gly | Arg | Gly | Lys | Gly | Lys | Gly | Lys | Lys | Lys | Gly | Lys | 355 | 360 | 365 |     |
| Val | Lys | Glu | Glu | Val | Glu | Glu | Glu | Thr | Asp | Pro | Arg | Lys | Ile | Glu | Leu | 370 | 375 | 380 |     |
| Leu | Asn | Trp | Val | Asn | Ala | Leu | Glu | Gln | Ala | Met | Leu | Asp | Ala | Leu | Val | 385 | 390 | 395 | 400 |
| Leu | Asp | Arg | Val | Asp | Phe | Val | Lys | Leu | Leu | Ile | Glu | Asn | Gly | Val | Asn | 405 | 410 | 415 |     |
| Met | Gln | His | Phe | Leu | Thr | Ile | Pro | Arg | Leu | Glu | Glu | Leu | Tyr | Asn | Thr | 420 | 425 | 430 |     |
| Arg | Leu | Gly | Pro | Pro | Asn | Thr | Leu | His | Leu | Leu | Val | Arg | Asp | Val | Lys | 435 | 440 | 445 |     |
| Lys | Ser | Asn | Leu | Pro | Pro | Asp | Tyr | His | Ile | Ser | Leu | Ile | Asp | Ile | Gly | 450 | 455 | 460 |     |
| Leu | Val | Leu | Glu | Tyr | Leu | Met | Gly | Gly | Ala | Tyr | Arg | Cys | Asn | Tyr | Thr | 465 | 470 | 475 | 480 |
| Arg | Lys | Asn | Phe | Arg | Thr | Leu | Tyr | Asn | Asn | Leu | Phe | Gly | Pro | Lys | Arg | 485 | 490 | 495 |     |
| Pro | Lys | Ala | Leu | Lys | Leu | Leu | Gly | Met | Glu | Asp | Asp | Glu | Pro | Pro | Ala | 500 | 505 | 510 |     |
| Lys | Gly | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Glu | Glu | Glu | Ile | Asp | Ile | 515 | 520 | 525 |     |
| Asp | Val | Asp | Asp | Pro | Ala | Val | Ser | Arg | Phe | Gln | Tyr | Pro | Phe | His | Glu | 530 | 535 | 540 |     |

-11-

|     |      |     |     |     |     |     |      |     |     |     |     |      |     |     |     |
|-----|------|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|------|-----|-----|-----|
| Leu | Met  | Val | Trp | Ala | Val | Leu | Met  | Lys | Arg | Gln | Lys | Met  | Ala | Val | Phe |
| 545 |      |     |     |     | 550 |     |      |     |     | 555 |     |      |     |     | 560 |
| Leu | Trp  | Gln | Arg | Gly | Glu | Glu | Ser  | Met | Ala | Lys | Ala | Leu  | Val | Ala | Cys |
|     |      |     |     | 565 |     |     |      |     | 570 |     |     |      |     |     | 575 |
| Lys | Leu  | Tyr | Lys | Ala | Met | Ala | His  | Glu | Ser | Ser | Glu | Ser  | Asp | Leu | Val |
|     |      |     | 580 |     |     |     |      | 585 |     |     |     |      | 590 |     |     |
| Asp | Asp  | Ile | Ser | Gln | Asp | Leu | Asp  | Asn | Asn | Ser | Lys | Asp  | Phe | Gly | Gln |
|     |      | 595 |     |     |     |     | 600  |     |     |     |     | 605  |     |     |     |
| Leu | Ala  | Leu | Glu | Leu | Leu | Asp | Gln  | Ser | Tyr | Lys | His | Asp  | Glu | Gln | Ile |
|     | 610  |     |     |     |     | 615 |      |     |     |     | 620 |      |     |     |     |
| Ala | Met  | Lys | Leu | Leu | Thr | Tyr | Glu  | Leu | Lys | Asn | Trp | Ser  | Asn | Ser | Thr |
| 625 |      |     |     |     | 630 |     |      |     |     | 635 |     |      |     |     | 640 |
| Cys | Leu  | Lys | Leu | Ala | Val | Ala | Ala  | Lys | His | Arg | Asp | Phe  | Ile | Ala | His |
|     |      |     |     | 645 |     |     |      |     | 650 |     |     |      |     |     | 655 |
| Thr | Cys  | Ser | Gln | Met | Leu | Leu | Thr  | Asp | Met | Trp | Met | Gly  | Arg | Leu | Arg |
|     |      |     | 660 |     |     |     |      | 665 |     |     |     |      | 670 |     |     |
| Met | Arg  | Lys | Asn | Pro | Gly | Leu | Lys  | Val | Ile | Met | Gly | Ile  | Leu | Leu | Pro |
|     |      | 675 |     |     |     |     | 680  |     |     |     |     | 685  |     |     |     |
| Pro | Thr  | Ile | Leu | Phe | Leu | Glu | Phe  | Arg | Thr | Tyr | Asp | Asp  | Phe | Ser | Tyr |
|     | 690  |     |     |     |     | 695 |      |     |     |     | 700 |      |     |     |     |
| Gln | Thr  | Ser | Lys | Glu | Asn | Glu | Asp  | Gly | Lys | Glu | Lys | Glu  | Glu | Glu | Asn |
| 705 |      |     |     |     | 710 |     |      |     |     | 715 |     |      |     |     | 720 |
| Thr | Asp  | Ala | Asn | Ala | Asp | Ala | Gly  | Ser | Arg | Lys | Gly | Asp  | Glu | Glu | Asn |
|     |      |     | 725 |     |     |     |      | 730 |     |     |     |      |     |     | 735 |
| Glu | His  | Lys | Lys | Gln | Arg | Ser | Ile  | Pro | Ile | Gly | Thr | Lys  | Ile | Cys | Glu |
|     |      |     | 740 |     |     |     |      | 745 |     |     |     |      | 750 |     |     |
| Phe | Tyr  | Asn | Ala | Pro | Ile | Val | Lys  | Phe | Trp | Phe | Tyr | Thr  | Ile | Ser | Tyr |
|     | 755  |     |     |     |     |     | 760  |     |     |     |     | 765  |     |     |     |
| Leu | Gly  | Tyr | Leu | Leu | Leu | Phe | Asn  | Tyr | Val | Ile | Leu | Val  | Arg | Met | Asp |
|     | 770  |     |     |     |     | 775 |      |     |     | 780 |     |      |     |     |     |
| Gly | Trp  | Pro | Ser | Leu | Gln | Glu | Trp  | Ile | Val | Ile | Ser | Tyr  | Ile | Val | Ser |
| 785 |      |     |     |     | 790 |     |      |     |     | 795 |     |      |     |     | 800 |
| Leu | Ala  | Leu | Glu | Lys | Ile | Arg | Glu  | Ile | Leu | Met | Ser | Glu  | Pro | Gly | Lys |
|     |      |     | 805 |     |     |     |      | 810 |     |     |     |      |     |     | 815 |
| Leu | Ser  | Gln | Lys | Ile | Lys | Val | Trp  | Leu | Gln | Glu | Tyr | Trp  | Asn | Ile | Thr |
|     |      | 820 |     |     |     |     |      | 825 |     |     |     |      | 830 |     |     |
| Asp | Leu  | Val | Ala | Ile | Ser | Thr | Phe  | Met | Ile | Gly | Ala | Ile  | Leu | Arg | Leu |
|     | 835  |     |     |     |     |     | 840  |     |     |     |     | 845  |     |     |     |
| Gln | Asn  | Gln | Pro | Tyr | Met | Gly | Tyr  | Gly | Arg | Val | Ile | Tyr  | Cys | Val | Asp |
|     | 850  |     |     |     | 855 |     |      |     |     | 860 |     |      |     |     |     |
| Ile | Ile  | Phe | Trp | Tyr | Ile | Arg | Val  | Leu | Asp | Ile | Phe | Gly  | Val | Asn | Lys |
| 865 |      |     |     |     | 870 |     |      |     |     | 875 |     |      |     |     | 880 |
| Tyr | Leu  | Gly | Pro | Tyr | Val | Met | Met  | Ile | Gly | Lys | Met | Met  | Ile | Asp | Met |
|     |      |     | 885 |     |     |     |      | 890 |     |     |     |      |     | 895 |     |
| Leu | Tyr  | Phe | Val | Val | Ile | Met | Leu  | Val | Val | Leu | Met | Ser  | Phe | Gly | Val |
|     |      | 900 |     |     |     |     |      | 905 |     |     |     |      | 910 |     |     |
| Ala | Arg  | Gln | Ala | Ile | Leu | His | Pro  | Glu | Glu | Lys | Pro | Ser  | Trp | Lys | Leu |
|     | 915  |     |     |     |     |     | 920  |     |     |     |     | 925  |     |     |     |
| Ala | Arg  | Asn | Ile | Phe | Tyr | Met | Pro  | Tyr | Trp | Met | Ile | Tyr  | Gly | Glu | Val |
|     | 930  |     |     |     | 935 |     |      |     |     | 940 |     |      |     |     |     |
| Phe | Ala  | Asp | Gln | Ile | Asp | Leu | Tyr  | Ala | Met | Glu | Ile | Asn  | Pro | Pro | Cys |
| 945 |      |     |     |     | 950 |     |      |     |     | 955 |     |      |     |     | 960 |
| Gly | Glu  | Asn | Leu | Tyr | Asp | Glu | Glu  | Gly | Lys | Arg | Leu | Pro  | Pro | Cys | Ile |
|     |      |     | 965 |     |     |     |      | 970 |     |     |     |      |     |     | 975 |
| Pro | Gly  | Ala | Trp | Leu | Thr | Pro | Ala  | Leu | Met | Ala | Cys | Tyr  | Leu | Leu | Val |
|     |      | 980 |     |     |     |     |      | 985 |     |     |     |      | 990 |     |     |
| Ala | Asn  | Ile | Leu | Leu | Val | Asn | Leu  | Leu | Ile | Ala | Val | Phe  | Asn | Asn | Thr |
|     | 995  |     |     |     |     |     | 1000 |     |     |     |     | 1005 |     |     |     |
| Phe | Phe  | Glu | Val | Lys | Ser | Ile | Ser  | Asn | Gln | Val | Trp | Lys  | Phe | Gln | Arg |
|     | 1010 |     |     |     |     |     | 1015 |     |     |     |     | 1020 |     |     |     |

-12-

Tyr Gln Leu Ile Met Thr Phe His Asp Arg Pro Val Leu Pro Pro Pro  
 1025 1030 1035 104  
 Met Ile Ile Leu Ser His Ile Tyr Ile Ile Met Arg Leu Ser Gly  
 1045 1050 1055  
 Arg Cys Arg Lys Lys Arg Glu Gly Asp Gln Glu Glu Arg Asp Arg Gly  
 1060 1065 1070  
 Leu Lys Leu Phe Leu Ser Asp Glu Glu Leu Lys Arg Leu His Glu Phe  
 1075 1080 1085  
 Glu Glu Gln Cys Val Gln Glu His Phe Arg Glu Lys Glu Asp Glu Gln  
 1090 1095 1100  
 Gln Ser Ser Ser Asp Glu Arg Ile Arg Val Thr Ser Glu Arg Val Glu  
 1105 1110 1115 112  
 Asn Met Ser Met Arg Leu Glu Glu Ile Asn Glu Arg Glu Thr Phe Met  
 1125 1130 1135  
 Lys Thr Ser Leu Gln Thr Val Asp Leu Arg Leu Ala Gln Leu Glu Glu  
 1140 1145 1150  
 Leu Ser Asn Arg Met Val Asn Ala Leu Glu Asn Leu Ala Gly Ile Asp  
 1155 1160 1165  
 Arg Ser Asp Leu Ile Gln Ala Arg Ser Arg Ala Ser Ser Glu Cys Glu  
 1170 1175 1180  
 Ala Thr Tyr Leu Leu Arg Gln Ser Ser Ile Asn Ser Ala Asp Gly Tyr  
 1185 1190 1195 120  
 Ser Leu Tyr Arg Tyr His Phe Asn Gly Glu Glu Leu Leu Phe Glu Asp  
 1205 1210 1215  
 Thr Ser Leu Ser Thr Ser Pro Gly Thr Gly Val Arg Lys Lys Thr Cys  
 1220 1225 1230  
 Ser Phe Arg Ile Lys Glu Glu Lys Asp Val Lys Thr His Leu Val Pro  
 1235 1240 1245  
 Glu Cys Gln Asn Ser Leu His Leu Ser Leu Gly Thr Ser Thr Ser Ala  
 1250 1255 1260  
 Thr Pro Asp Gly Ser His Leu Ala Val Asp Asp Leu Lys Asn Ala Glu  
 1265 1270 1275 128  
 Glu Ser Lys Leu Gly Pro Asp Ile Gly Ile Ser Lys Glu Asp Asp Glu  
 1285 1290 1295  
 Arg Gln Thr Asp Ser Lys Lys Glu Glu Thr Ile Ser Pro Ser Leu Asn  
 1300 1305 1310  
 Lys Thr Asp Val Ile His Gly Gln Asp Lys Ser Asp Val Gln Asn Thr  
 1315 1320 1325  
 Gln Leu Thr Val Glu Thr Thr Asn Ile Glu Gly Thr Ile Ser Tyr Pro  
 1330 1335 1340  
 Leu Glu Glu Thr Lys Ile Thr Arg Tyr Phe Pro Asp Glu Thr Ile Asn  
 1345 1350 1355 136  
 Ala Cys Lys Thr Met Lys Ser Arg Ser Phe Val Tyr Ser Arg Gly Arg  
 1365 1370 1375  
 Lys Leu Val Gly Gly Val Asn Gln Asp Val Glu Tyr Ser Ser Ile Thr  
 1380 1385 1390  
 Asp Gln Gln Leu Thr Thr Glu Trp Gln Cys Gln Val Gln Lys Ile Thr  
 1395 1400 1405  
 Arg Ser His Ser Thr Asp Ile Pro Tyr Ile Val Ser Glu Ala Ala Val  
 1410 1415 1420  
 Gln Ala Glu Gln Lys Glu Gln Phe Ala Asp Met Gln Asp Glu His His  
 1425 1430 1435 144  
 Val Ala Glu Ala Ile Pro Arg Ile Pro Arg Leu Ser Leu Thr Ile Thr  
 1445 1450 1455  
 Asp Arg Asn Gly Met Glu Asn Leu Leu Ser Val Lys Pro Asp Gln Thr  
 1460 1465 1470  
 Leu Gly Phe Pro Ser Leu Arg Ser Lys Ser Leu His Gly His Pro Arg  
 1475 1480 1485  
 Asn Val Lys Ser Ile Gln Gly Lys Leu Asp Arg Ser Gly His Ala Ser  
 1490 1495 1500

-13-

Ser Val Ser Ser Leu Val Ile Val Ser Gly Met Thr Ala Glu Glu Lys  
 1505 1510 1515 152  
 Lys Val Lys Lys Glu Lys Ala Ser Thr Glu Thr Glu Cys  
 1525 1530

<210> 11  
 <211> 6220  
 <212> DNA  
 <213> Homo Sapiens

<400> 11  
 tgtgcagaat tgtacagttg cgaaccatg tcgctggcag ctggtgctgg cgggtggagac 60  
 ttccctgtgc ggtgctcagt gcatctgcac ccgtggggga gggagctctt tctctggccc 120  
 tgcagtcacc tgaggttggt accattatga acggccgctg ggacccccgc atgtgcatgt 180  
 actccccag agtgtccggg ggccccagcc aagggacaca tctcacgcag ctgggaacat 240  
 gtgcaggctg atgaagagaa ccgcatgagg gcttcacatg aggaagcatg tggccaggtc 300  
 ctctcagaac atcagcctca tcttcctgtc tctgatctat ttcaccaacc acccatgtg 360  
 tctctagaac cccagtgtag cgagctggag agaggactgt cctgagggca gcaggcctgg 420  
 ttgcagctgg cgtgggggtc tcagaaatgga gccctcagcc ctgagggaaag ctggctcggg 480  
 gcaggaggag ggctttgagg ggctgccag aagggctcact gacctgggga tggctctcaa 540  
 tctccggcgc agcaacagca gcctcttcaa gagctggagg ctacagtgcc ccttcggcaa 600  
 caatgacaag caagaaagcc tcagtctgtg gattcctgaa aacatcaaga agaaagaatg 660  
 cgtgtatttt gtggaaagt ccaaactgtc tgatgctggg aaggtggtgt gtcagtgtgg 720  
 ctacacgcat gagcagcact tggaggaggc taccagccc cacaccttc agggcacaca 780  
 gtgggaccca aagaaacatg tccaggagat gccaaaccgat gcccttgccg acatcgtctt 840  
 caggggcctg agccagaagg tgaaaaagta cgtccgagtc tcccaggaca cgccctccag 900  
 cgtgatctac cacctcatga cccagcactg ggggctggac gtccccaatc tcttgatctc 960  
 ggtgaccggg ggggccaaga acttcaacat gaagccgcgg ctgaagagca ttttccgcag 1020  
 aggctgtgtc aaggtggctc agaccacagg gccctggatc atcacagggg ggtcccacac 1080  
 cggcgtcatg aagcaggtag gcgaggcggg gcgggacttc agcctgagca gcagctaaa 1140  
 ggaaggcgag ctcatcacca tcggagtcgc cacctggggc actgtccacc gccgcgagg 1200  
 cctgatccat cccacgggca gcttccccgc caggtacata ctggatgagg atggccaagg 1260  
 gaacctgacc tgcctagaca gcaaccactc tcaactcatc ctctgagacg acgggaccca 1320  
 cggccagtac ggggtggaga ttctcttgag gaccaggctg gagaagttca tatcgagca 1380  
 gaccaaggaa agaggaggtg tggccatcaa gatccccatc gtgtgctgtg tgctggaggg 1440  
 cggcccgggc acgttgaca ccatcgacaa cgccaccacc aacggcaccc cctgtgtggt 1500  
 tgtggagggc tggggcccg cggccgacgt cattgccag gtggccaacc tgcctgtctc 1560  
 ggacatcact atctccctga tccagcagaa actgagcgtg ttcttccagg agatgtttga 1620  
 gaccttcacg gaaagcagga ttgtcgagt gacaaaaaag atccaagata ttgtccggag 1680  
 gcggcagctg ctgactgtct tccgggaagg caaggatggt cagcaggacg tggatgtggc 1740  
 catcttgacg gccttgctga aagcctcacg gagccaagac cactttggcc acgagaactg 1800  
 ggaccaccag ctgaaactgg cagtggcatg gaatcgctg gacattgccc gcagtggat 1860  
 cttcatggat gagtggcagt ggaagccttc agatctgcac cccacgatga cagctgcact 1920  
 catctccaac aagcctgagt ttgtgaagct ctctctggaa aacgggggtg agctgaagga 1980  
 gtttgtcacc tgggacacct tgctctacct gtacgagaac ctggaccctt cctgcctgtt 2040  
 ccacagcaag ctgcaaaaagg tgctggtgga ggatcccgag cgcccggtt gcgcgcccgc 2100  
 ggcgccccgc ctgcagatgc accacgtggc ccagggtgtg cgggagctgc tgggggactt 2160  
 cagcgagccg ctttatcccc ggccccggca caacgaccgg ctgcggtctc tgctgcccgt 2220  
 tccccacgtc aagctcaacg tgcaggaggt gagcctccgg tccctctaca agcgttctc 2280  
 aggccatgtg accttcacca tggaccccat ccgtgacct ctcatttggg ccattgtcca 2340  
 gaaccgtcgg gagctggcag gaatcatctg ggctcagagc caggactgca tcgcagcggc 2400  
 cttggcctgc agcaagatcc tgaaggaaact gtccaaaggag gaggaggaca cggacagctc 2460  
 ggaggagatg ctggcgctgg cggaggagta tgagcacaga gccatcgggg tcttcaccga 2520  
 gtgctaccgg aaggacgaag agagagccca gaaactgtc acccgctgt ccgaggcctg 2580  
 ggggaagacc acctgcctgc agctcgccct ggaggccaag gacatgaagt ttgtgtctca 2640  
 cgggggcatc caggccttcc tgaccaaggt gtggtggggc cagctctccg tggacaatgg 2700  
 gctgtggcgt gtgaccctgt gcatgctggc ctcccgctg ctctcaacc gcctcatctc 2760  
 cttcaggagg aagaggctgc aggatgtggg caccctcgcc gccgcgccc gtgcctctt 2820  
 caccgcacc gtggtggtct tccacctgaa catcctctcc tacttgcct tctctgcct 2880  
 gtgcgctac gtgctcatgg tggacttcca gcctgtgccc tcctggtgag agtgtgccat 2940

|             |            |             |             |             |             |      |
|-------------|------------|-------------|-------------|-------------|-------------|------|
| ctacctctgg  | ctcttctcct | tgggtgtgca  | ggagatgagg  | cagctcttct  | atgaccctga  | 3000 |
| cgagtgcggg  | ctgatgaaga | aggcagcctt  | gtacttcagt  | gacttctgga  | ataagctgga  | 3060 |
| cgtcggcgca  | atcttgctct | tcgtggcagg  | gctgacctgc  | aggctcatcc  | cggcgacgct  | 3120 |
| gtaccccggg  | cgcgtcatcc | tctctctgga  | cttcatcctg  | ttctgcctcc  | ggctcatgca  | 3180 |
| catttttacc  | atcagtaaga | cgctggggcc  | caagatcatc  | attgtgaagc  | ggatgatgaa  | 3240 |
| ggacgtcttc  | ttcttctcct | tcctgctggc  | tggtgtgggtg | gtgtccttcg  | gggtggccaa  | 3300 |
| gcaggccatc  | ctcatccaca | acgagcgccg  | ggtggactgg  | ctgttccgag  | gggccgtcta  | 3360 |
| ccactcctac  | ctcaccatct | tcgggcagat  | cccgggctac  | atcgacgggtg | tgaacttcaa  | 3420 |
| cccggagcac  | tgcagcccca | atggcaccga  | ccctacaag   | cctaagtgcc  | ccgagagcga  | 3480 |
| cgcgacgcga  | cagaggccgg | ccttccctga  | gtgctgacg   | gtcctcctac  | tctgcctcta  | 3540 |
| cctgctcttc  | accaacatcc | tgctgctcaa  | cctcctcatc  | gccatgttca  | actacacctt  | 3600 |
| ccagcaggtg  | caggagcaca | cggaccagat  | ttggaagttc  | cagcgccatg  | acctgatcga  | 3660 |
| ggagtaccac  | ggccgccccg | ccgcgcggcc  | cccttcctac  | ctcctcagcc  | acctgcagct  | 3720 |
| cttcatcaag  | aggggtggtc | tgaagactcc  | ggccaagagg  | cacaagcagc  | tcaagaacaa  | 3780 |
| gctggagaag  | aacgaggagg | cggccctgct  | atcctgggag  | atctacctga  | aggagaacta  | 3840 |
| cctccagaac  | cgacagttcc | agcaaaagca  | gcggccccag  | cagaagatcg  | aggacatcag  | 3900 |
| caataaggtt  | gacgccatgg | tggacctgct  | ggacctggac  | ccactgaaga  | ggtcgggctc  | 3960 |
| catggagcag  | aggttggcct | ccctggagga  | gcaggtggcc  | cagacagccc  | gagccctgca  | 4020 |
| ctggatcgtg  | aggacgctgc | gggcccagcg  | cttcagctcg  | gaggcggacg  | tccccactct  | 4080 |
| ggcctcccag  | aaggccggcg | aggagccgga  | tgctgagccg  | ggaggcagga  | agaagacgga  | 4140 |
| ggagccgggc  | gacagctacc | acgtgaatgc  | ccggcacctc  | ctctacccca  | actgccctgt  | 4200 |
| cacgcgcttc  | cccgtgcccc | acgagaaggt  | gccttgggag  | acggagtctc  | tgatctatga  | 4260 |
| cccacccttt  | tacacggcag | agaggaagga  | cgcggccgcc  | atggacccca  | tgggagacac  | 4320 |
| cctggagcca  | ctgtccacga | tccagtacaa  | cgtgtgggat  | ggcctgaggg  | accgccggag  | 4380 |
| cttccacggg  | ccgtacacag | tgcaggccgg  | gttgcctctg  | aaccccatgg  | gccgcacagg  | 4440 |
| actgcgtggg  | cgcgggagcc | tcagctgctt  | cggacccaac  | cacacgctgt  | accccatggg  | 4500 |
| cacgcggttg  | aggcgaacg  | aggatggagc  | catctgcagg  | aagagcataa  | agaagatgct  | 4560 |
| ggaagtgtctg | gtgtgtaagc | tccctctctc  | cgagcactgg  | gcctgcctg   | ggggctcccg  | 4620 |
| ggagccaggg  | gagatgctac | ctcggaagct  | gaagcggatc  | ctccggcagg  | agcactggcc  | 4680 |
| gtcttttgaa  | aacttgctga | agtgcggcat  | ggaggtgtac  | aaaggctaca  | tggatgaccc  | 4740 |
| gaggaacacg  | gacaatgcct | ggatcgagac  | ggtggccgtc  | agcgtccact  | tcagggacca  | 4800 |
| gaatgacgtg  | gagctgaaca | ggctgaactc  | taacctgcac  | gcctgcgact  | cgggggcctc  | 4860 |
| catccgatgg  | caggtgggtg | acaggcgcac  | cccactctat  | gcgaaccaca  | agaccctcct  | 4920 |
| ccagaaggca  | gccgctgagt | tcggggctca  | ctactgactg  | tgccctcagg  | ctgggcggct  | 4980 |
| ccagtccata  | gacgttcccc | ccagaaacca  | gggttctctc  | ctcctgagcc  | tggccaggac  | 5040 |
| tcaggtgtt   | cctggggcct | gcacatgatg  | gggtttggtg  | gacccagtgc  | ccctcacggc  | 5100 |
| tgccgaagt   | ctgtgcaga  | tgactctatg  | aactggaagg  | ggtcaagggtg | acccgggagg  | 5160 |
| agagctcaag  | acagggcaca | ggctactcag  | agctgagggg  | cccctgggac  | ccttggccat  | 5220 |
| caggcgaggg  | gctgggcctg | tgcagctggg  | cccttggcca  | gagtccactc  | ccttctctggc | 5280 |
| tgtgtcacc   | cgagcagctc | atccaccatg  | gaggtcattg  | gcctgaggca  | agttccccgg  | 5340 |
| agagtccgga  | tccctgtgtg | ccccctcagg  | cctatgtctg  | tgagggaagg  | gccctgccac  | 5400 |
| tctccccaag  | agggcctcca | tgtttcgagg  | tgctcaaca   | tggagccttg  | cctggcctgg  | 5460 |
| gctaggggca  | ctgtctgaac | tcctgactgt  | caggataaac  | tccgtggggg  | tacaggagcc  | 5520 |
| cagacaaagc  | ccaggcctgt | caagagacgc  | agagggcocc  | tgccagggtt  | ggccccaggg  | 5580 |
| accctggggc  | gaggctgcag | aagctctccc  | tccctactcc  | ctgggagcca  | cgtgctggcc  | 5640 |
| atgtggccag  | ggacggcatg | agcaggaggc  | ggggacgtgg  | gggccttctg  | gtttggtgtc  | 5700 |
| aacagctcac  | aggagcgtga | accatgaggg  | ccctcaggag  | gggaacgtgg  | taaaacccaa  | 5760 |
| gacattaaat  | ctgccatctc | aggcctggct  | ggctcttctg  | tgctttccac  | aaataaagtt  | 5820 |
| cctgacacgt  | ccagggccag | gggtgtgtgtg | acggctgcct  | gaagtctctc  | tcgatcccc   | 5880 |
| ggtgagcttc  | ctgcagcctg | tggatgtcct  | gcagccctc   | agccctaccc  | ccaagtctct  | 5940 |
| cctctgaacc  | atcagctccc | tgtcttcatt  | ttcctaaacc  | tgggctccag  | catcgtcccc  | 6000 |
| aagcccacca  | ggccaggatg | caggcatcca  | catgccctcc  | tccttggctt  | cccctgcgtg  | 6060 |
| gtgggtccaa  | tgtgccctgg | cacccctgca  | gaggctccgg  | atggagcctg  | gggctgcctg  | 6120 |
| gccactgagc  | actggccgag | gtgatgcca   | cccttccctg  | gacaggcctc  | tgtcttccac  | 6180 |
| ctgacccaaa  | gctctctagc | cacccctctg  | tccccagtat  |             |             | 6220 |

&lt;210&gt; 12

&lt;211&gt; 1503

-15-

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 12

```

Met Glu Pro Ser Ala Leu Arg Lys Ala Gly Ser Glu Gln Glu Gly
 1          5          10          15
Phe Glu Gly Leu Pro Arg Arg Val Thr Asp Leu Gly Met Val Ser Asn
          20          25          30
Leu Arg Arg Ser Asn Ser Ser Leu Phe Lys Ser Trp Arg Leu Gln Cys
          35          40          45
Pro Phe Gly Asn Asn Asp Lys Gln Glu Ser Leu Ser Ser Trp Ile Pro
          50          55          60
Glu Asn Ile Lys Lys Lys Glu Cys Val Tyr Phe Val Glu Ser Ser Lys
65          70          75          80
Leu Ser Asp Ala Gly Lys Val Val Cys Gln Cys Gly Tyr Thr His Glu
          85          90          95
Gln His Leu Glu Glu Ala Thr Lys Pro His Thr Phe Gln Gly Thr Gln
          100          105          110
Trp Asp Pro Lys Lys His Val Gln Glu Met Pro Thr Asp Ala Phe Gly
          115          120          125
Asp Ile Val Phe Thr Gly Leu Ser Gln Lys Val Lys Lys Tyr Val Arg
130          135          140
Val Ser Gln Asp Thr Pro Ser Ser Val Ile Tyr His Leu Met Thr Gln
145          150          155          160
His Trp Gly Leu Asp Val Pro Asn Leu Leu Ile Ser Val Thr Gly Gly
          165          170          175
Ala Lys Asn Phe Asn Met Lys Pro Arg Leu Lys Ser Ile Phe Arg Arg
          180          185          190
Gly Leu Val Lys Val Ala Gln Thr Thr Gly Ala Trp Ile Ile Thr Gly
          195          200          205
Gly Ser His Thr Gly Val Met Lys Gln Val Gly Glu Ala Val Arg Asp
210          215          220
Phe Ser Leu Ser Ser Ser Tyr Lys Glu Gly Glu Leu Ile Thr Ile Gly
225          230          235          240
Val Ala Thr Trp Gly Thr Val His Arg Arg Glu Gly Leu Ile His Pro
          245          250          255
Thr Gly Ser Phe Pro Ala Glu Tyr Ile Leu Asp Glu Asp Gly Gln Gly
260          265          270
Asn Leu Thr Cys Leu Asp Ser Asn His Ser His Phe Ile Leu Val Asp
          275          280          285
Asp Gly Thr His Gly Gln Tyr Gly Val Glu Ile Pro Leu Arg Thr Arg
290          295          300
Leu Glu Lys Phe Ile Ser Glu Gln Thr Lys Glu Arg Gly Gly Val Ala
305          310          315          320
Ile Lys Ile Pro Ile Val Cys Val Val Leu Glu Gly Gly Pro Gly Thr
          325          330          335
Leu His Thr Ile Asp Asn Ala Thr Thr Asn Gly Thr Pro Cys Val Val
          340          345          350
Val Glu Gly Ser Gly Arg Val Ala Asp Val Ile Ala Gln Val Ala Asn
          355          360          365
Leu Pro Val Ser Asp Ile Thr Ile Ser Leu Ile Gln Gln Lys Leu Ser
370          375          380
Val Phe Phe Gln Glu Met Phe Glu Thr Phe Thr Glu Ser Arg Ile Val
385          390          395          400
Glu Trp Thr Lys Lys Ile Gln Asp Ile Val Arg Arg Arg Gln Leu Leu
          405          410          415
Thr Val Phe Arg Glu Gly Lys Asp Gly Gln Gln Asp Val Asp Val Ala
          420          425          430
Ile Leu Gln Ala Leu Leu Lys Ala Ser Arg Ser Gln Asp His Phe Gly
          435          440          445

```

-16-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Glu | Asn | Trp | Asp | His | Gln | Leu | Lys | Leu | Ala | Val | Ala | Trp | Asn | Arg |
| 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |     |
| Val | Asp | Ile | Ala | Arg | Ser | Glu | Ile | Phe | Met | Asp | Glu | Trp | Gln | Trp | Lys |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Pro | Ser | Asp | Leu | His | Pro | Thr | Met | Thr | Ala | Ala | Leu | Ile | Ser | Asn | Lys |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Pro | Glu | Phe | Val | Lys | Leu | Phe | Leu | Glu | Asn | Gly | Val | Gln | Leu | Lys | Glu |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Phe | Val | Thr | Trp | Asp | Thr | Leu | Leu | Tyr | Leu | Tyr | Glu | Asn | Leu | Asp | Pro |
|     |     | 515 |     |     |     | 520 |     |     |     |     |     | 525 |     |     |     |
| Ser | Cys | Leu | Phe | His | Ser | Lys | Leu | Gln | Lys | Val | Leu | Val | Glu | Asp | Pro |
| 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |     |
| Glu | Arg | Pro | Ala | Cys | Ala | Pro | Ala | Ala | Pro | Arg | Leu | Gln | Met | His | His |
| 545 |     |     |     | 550 |     |     |     |     |     | 555 |     |     |     |     | 560 |
| Val | Ala | Gln | Val | Leu | Arg | Glu | Leu | Leu | Gly | Asp | Phe | Thr | Gln | Pro | Leu |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |
| Tyr | Pro | Arg | Pro | Arg | His | Asn | Asp | Arg | Leu | Arg | Leu | Leu | Leu | Pro | Val |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Pro | His | Val | Lys | Leu | Asn | Val | Gln | Gly | Val | Ser | Leu | Arg | Ser | Leu | Tyr |
|     |     | 595 |     |     |     | 600 |     |     |     |     |     | 605 |     |     |     |
| Lys | Arg | Ser | Ser | Gly | His | Val | Thr | Phe | Thr | Met | Asp | Pro | Ile | Arg | Asp |
| 610 |     |     |     |     | 615 |     |     |     |     |     | 620 |     |     |     |     |
| Leu | Leu | Ile | Trp | Ala | Ile | Val | Gln | Asn | Arg | Arg | Glu | Leu | Ala | Gly | Ile |
| 625 |     |     |     | 630 |     |     |     |     |     | 635 |     |     |     |     | 640 |
| Ile | Trp | Ala | Gln | Ser | Gln | Asp | Cys | Ile | Ala | Ala | Ala | Leu | Ala | Cys | Ser |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |
| Lys | Ile | Leu | Lys | Glu | Leu | Ser | Lys | Glu | Glu | Glu | Asp | Thr | Asp | Ser | Ser |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Glu | Glu | Met | Leu | Ala | Leu | Ala | Glu | Glu | Tyr | Glu | His | Arg | Ala | Ile | Gly |
|     |     | 675 |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |
| Val | Phe | Thr | Glu | Cys | Tyr | Arg | Lys | Asp | Glu | Glu | Arg | Ala | Gln | Lys | Leu |
|     | 690 |     |     |     |     | 695 |     |     |     |     | 700 |     |     |     |     |
| Leu | Thr | Arg | Val | Ser | Glu | Ala | Trp | Gly | Lys | Thr | Thr | Cys | Leu | Gln | Leu |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     |     | 720 |
| Ala | Leu | Glu | Ala | Lys | Asp | Met | Lys | Phe | Val | Ser | His | Gly | Gly | Ile | Gln |
|     |     |     |     | 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |
| Ala | Phe | Leu | Thr | Lys | Val | Trp | Trp | Gly | Gln | Leu | Ser | Val | Asp | Asn | Gly |
|     |     |     | 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |
| Leu | Trp | Arg | Val | Thr | Leu | Cys | Met | Leu | Ala | Phe | Pro | Leu | Leu | Leu | Thr |
|     | 755 |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |     |
| Gly | Leu | Ile | Ser | Phe | Arg | Glu | Lys | Arg | Leu | Gln | Asp | Val | Gly | Thr | Pro |
| 770 |     |     |     |     | 775 |     |     |     |     |     | 780 |     |     |     |     |
| Ala | Ala | Arg | Ala | Arg | Ala | Phe | Phe | Thr | Ala | Pro | Val | Val | Val | Phe | His |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     |     | 800 |
| Leu | Asn | Ile | Leu | Ser | Tyr | Phe | Ala | Phe | Leu | Cys | Leu | Phe | Ala | Tyr | Val |
|     |     |     |     | 805 |     |     |     |     | 810 |     |     |     |     | 815 |     |
| Leu | Met | Val | Asp | Phe | Gln | Pro | Val | Pro | Ser | Trp | Cys | Glu | Cys | Ala | Ile |
|     |     |     | 820 |     |     |     |     | 825 |     |     |     |     | 830 |     |     |
| Tyr | Leu | Trp | Leu | Phe | Ser | Leu | Val | Cys | Glu | Glu | Met | Arg | Gln | Leu | Phe |
|     | 835 |     |     |     |     | 840 |     |     |     |     |     | 845 |     |     |     |
| Tyr | Asp | Pro | Asp | Glu | Cys | Gly | Leu | Met | Lys | Lys | Ala | Ala | Leu | Tyr | Phe |
| 850 |     |     |     |     |     | 855 |     |     |     |     | 860 |     |     |     |     |
| Ser | Asp | Phe | Trp | Asn | Lys | Leu | Asp | Val | Gly | Ala | Ile | Leu | Leu | Phe | Val |
| 865 |     |     |     |     | 870 |     |     |     |     | 875 |     |     |     |     | 880 |
| Ala | Gly | Leu | Thr | Cys | Arg | Leu | Ile | Pro | Ala | Thr | Leu | Tyr | Pro | Gly | Arg |
|     |     |     |     | 885 |     |     |     |     | 890 |     |     |     |     | 895 |     |
| Val | Ile | Leu | Ser | Leu | Asp | Phe | Ile | Leu | Phe | Cys | Leu | Arg | Leu | Met | His |
|     |     |     | 900 |     |     |     |     | 905 |     |     |     |     | 910 |     |     |
| Ile | Phe | Thr | Ile | Ser | Lys | Thr | Leu | Gly | Pro | Lys | Ile | Ile | Ile | Val | Lys |
|     |     | 915 |     |     |     |     | 920 |     |     |     |     |     | 925 |     |     |



-17-

Arg Met Met Lys Asp Val Phe Phe Phe Leu Phe Leu Leu Ala Val Trp  
 930 935 940  
 Val Val Ser Phe Gly Val Ala Lys Gln Ala Ile Leu Ile His Asn Glu  
 945 950 955 960  
 Arg Arg Val Asp Trp Leu Phe Arg Gly Ala Val Tyr His Ser Tyr Leu  
 965 970 975  
 Thr Ile Phe Gly Gln Ile Pro Gly Tyr Ile Asp Gly Val Asn Phe Asn  
 980 985 990  
 Pro Glu His Cys Ser Pro Asn Gly Thr Asp Pro Tyr Lys Pro Lys Cys  
 995 1000 1005  
 Pro Glu Ser Asp Ala Thr Gln Gln Arg Pro Ala Phe Pro Glu Trp Leu  
 1010 1015 1020  
 Thr Val Leu Leu Leu Cys Leu Tyr Leu Leu Phe Thr Asn Ile Leu Leu  
 1025 1030 1035 104  
 Leu Asn Leu Leu Ile Ala Met Phe Asn Tyr Thr Phe Gln Gln Val Gln  
 1045 1050 1055  
 Glu His Thr Asp Gln Ile Trp Lys Phe Gln Arg His Asp Leu Ile Glu  
 1060 1065 1070  
 Glu Tyr His Gly Arg Pro Ala Ala Pro Pro Pro Phe Ile Leu Leu Ser  
 1075 1080 1085  
 His Leu Gln Leu Phe Ile Lys Arg Val Val Leu Lys Thr Pro Ala Lys  
 1090 1095 1100  
 Arg His Lys Gln Leu Lys Asn Lys Leu Glu Lys Asn Glu Glu Ala Ala  
 1105 1110 1115 112  
 Leu Leu Ser Trp Glu Ile Tyr Leu Lys Glu Asn Tyr Leu Gln Asn Arg  
 1125 1130 1135  
 Gln Phe Gln Gln Lys Gln Arg Pro Glu Gln Lys Ile Glu Asp Ile Ser  
 1140 1145 1150  
 Asn Lys Val Asp Ala Met Val Asp Leu Leu Asp Leu Asp Pro Leu Lys  
 1155 1160 1165  
 Arg Ser Gly Ser Met Glu Gln Arg Leu Ala Ser Leu Glu Glu Gln Val  
 1170 1175 1180  
 Ala Gln Thr Ala Arg Ala Leu His Trp Ile Val Arg Thr Leu Arg Ala  
 1185 1190 1195 120  
 Ser Gly Phe Ser Ser Glu Ala Asp Val Pro Thr Leu Ala Ser Gln Lys  
 1205 1210 1215  
 Ala Ala Glu Glu Pro Asp Ala Glu Pro Gly Gly Arg Lys Lys Thr Glu  
 1220 1225 1230  
 Glu Pro Gly Asp Ser Tyr His Val Asn Ala Arg His Leu Leu Tyr Pro  
 1235 1240 1245  
 Asn Cys Pro Val Thr Arg Phe Pro Val Pro Asn Glu Lys Val Pro Trp  
 1250 1255 1260  
 Glu Thr Glu Phe Leu Ile Tyr Asp Pro Pro Phe Tyr Thr Ala Glu Arg  
 1265 1270 1275 128  
 Lys Asp Ala Ala Ala Met Asp Pro Met Gly Asp Thr Leu Glu Pro Leu  
 1285 1290 1295  
 Ser Thr Ile Gln Tyr Asn Val Val Asp Gly Leu Arg Asp Arg Arg Ser  
 1300 1305 1310  
 Phe His Gly Pro Tyr Thr Val Gln Ala Gly Leu Pro Leu Asn Pro Met  
 1315 1320 1325  
 Gly Arg Thr Gly Leu Arg Gly Arg Gly Ser Leu Ser Cys Phe Gly Pro  
 1330 1335 1340  
 Asn His Thr Leu Tyr Pro Met Val Thr Arg Trp Arg Arg Asn Glu Asp  
 1345 1350 1355 136  
 Gly Ala Ile Cys Arg Lys Ser Ile Lys Lys Met Leu Glu Val Leu Val  
 1365 1370 1375  
 Val Lys Leu Pro Leu Ser Glu His Trp Ala Leu Pro Gly Gly Ser Arg  
 1380 1385 1390  
 Glu Pro Gly Glu Met Leu Pro Arg Lys Leu Lys Arg Ile Leu Arg Gln  
 1395 1400 1405

-18-

Glu His Trp Pro Ser Phe Glu Asn Leu Leu Lys Cys Gly Met Glu Val  
 1410 1415 1420  
 Tyr Lys Gly Tyr Met Asp Asp Pro Arg Asn Thr Asp Asn Ala Trp Ile  
 1425 1430 1435 144  
 Glu Thr Val Ala Val Ser Val His Phe Gln Asp Gln Asn Asp Val Glu  
 1445 1450 1455  
 Leu Asn Arg Leu Asn Ser Asn Leu His Ala Cys Asp Ser Gly Ala Ser  
 1460 1465 1470  
 Ile Arg Trp Gln Val Val Asp Arg Arg Ile Pro Leu Tyr Ala Asn His  
 1475 1480 1485  
 Lys Thr Leu Leu Gln Lys Ala Ala Ala Glu Phe Gly Ala His Tyr  
 1490 1495 1500

<210> 13  
 <211> 1816  
 <212> PRT  
 <213> C. Elegans

<400> 13  
 Met Ile Thr Asp Lys Asn Leu Phe Ser Arg Leu Leu Ile Lys Lys Asn  
 1 5 10 15  
 Pro Ile Arg Met His Ser Pro Ser Phe Ser Phe Ser Leu Ile Thr Ser  
 20 25 30  
 Leu Phe Phe Thr Gln Phe Phe Met Phe Gln Leu Ser Ser Met Ala Tyr  
 35 40 45  
 Phe Phe Leu Thr Leu Ile Ala Gly Val Thr His Phe Tyr Phe Pro Glu  
 50 55 60  
 Lys Leu Leu Gly Lys Ser Glu Asn Leu Asp His Arg Tyr Gln Ser Ser  
 65 70 75 80  
 Glu Gln Lys Val Leu Ile Glu Trp Thr Glu Asn Lys Ala Val Ala Glu  
 85 90 95  
 Ser Leu Arg Ala Asn Ser Val Thr Val Glu Glu Asn Glu Ser Glu Arg  
 100 105 110  
 Glu Thr Glu Thr Gln Thr Lys Arg Arg Arg Lys Lys Gln Arg Ser Thr  
 115 120 125  
 Ser Ser Asp Lys Ala Pro Leu Asn Ser Ala Pro Arg His Val Gln Lys  
 130 135 140  
 Phe Asp Trp Lys Asp Met Leu His Leu Ala Asp Ile Ser Gly Arg Lys  
 145 150 155 160  
 Arg Gly Asn Ser Thr Thr Ser His Ser Gly His Ala Thr Arg Ala Gly  
 165 170 175  
 Ser Leu Lys Gly Lys Asn Trp Ile Glu Cys Arg Leu Lys Met Arg Gln  
 180 185 190  
 Cys Ser Tyr Phe Val Pro Ser Gln Arg Phe Ser Glu Arg Cys Gly Cys  
 195 200 205  
 Gly Lys Glu Arg Ser Lys His Thr Glu Glu Val Leu Glu Arg Ser Gln  
 210 215 220  
 Asn Lys Asn His Pro Leu Asn His Leu Thr Leu Pro Gly Ile His Glu  
 225 230 235 240  
 Val Asp Thr Thr Asp Ala Asp Ala Asp Asn Glu Val Asn Leu Thr  
 245 250 255  
 Pro Gly Arg Trp Ser Ile Gln Ser His Thr Glu Ile Val Pro Thr Asp  
 260 265 270  
 Ala Tyr Gly Asn Ile Val Phe Glu Gly Thr Ala His His Ala Gln Tyr  
 275 280 285  
 Ala Arg Ile Ser Phe Asp Ser Asp Pro Arg Asp Ile Val His Leu Met  
 290 295 300  
 Met Lys Val Trp Lys Leu Lys Pro Pro Lys Leu Ile Ile Thr Ile Asn  
 305 310 315 320  
 Gly Gly Leu Thr Lys Phe Asp Leu Gln Pro Lys Leu Ala Arg Thr Phe

[illegible]

|      |     |     |     |     |     |     |     |     |     |      |      |     |      |      |     |      |      |  |  |
|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|-----|------|------|-----|------|------|--|--|
|      |     |     |     |     |     |     |     |     |     | 805  |      |     | 810  |      |     | 815  |      |  |  |
| Asn  | Met | Asp | Phe | Thr | Phe | Arg | Tyr | Pro | Tyr | Ser  | Asp  | Leu | Met  | Ile  | Trp |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 820  |      |     | 825  |      |     | 830  |      |  |  |
| Ala  | Val | Leu | Thr | Lys | Arg | Gln | Lys | Met | Ala | Lys  | Leu  | Met | Trp  | Thr  | His |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 835  |      |     | 840  |      |     | 845  |      |  |  |
| Gly  | Glu | Glu | Gly | Met | Ala | Lys | Ala | Leu | Val | Ala  | Ser  | Arg | Leu  | Tyr  | Val |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 850  |      |     | 855  |      |     | 860  |      |  |  |
| Ser  | Leu | Ala | Lys | Thr | Ala | Ser | Leu | Ala | Thr | Gly  | Glu  | Ile | Gly  | Met  | Ser |      |      |  |  |
| 865  |     |     |     |     |     |     |     |     |     |      | 870  |     |      | 875  |     |      | 880  |  |  |
| Gln  | Asp | Phe | Thr | Glu | Phe | Ser | Asp | Glu | Phe | Ser  | Glu  | Leu | Ala  | Val  | Glu |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 885  |      |     | 890  |      |     | 895  |      |  |  |
| Val  | Leu | Glu | Tyr | Cys | Thr | Lys | His | Gly | Arg | Asp  | Gln  | Thr | Leu  | Arg  | Leu |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 900  |      |     | 905  |      |     | 910  |      |  |  |
| Leu  | Thr | Cys | Glu | Leu | Ala | Asn | Trp | Gly | Asp | Glu  | Thr  | Cys | Leu  | Ser  | Leu |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 915  |      |     | 920  |      |     | 925  |      |  |  |
| Ala  | Ala | Asn | Asn | Gly | His | Arg | Lys | Phe | Leu | Ala  | His  | Pro | Cys  | Cys  | Gln |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 930  |      |     | 935  |      |     | 940  |      |  |  |
| Met  | Leu | Leu | Ser | Asp | Leu | Trp | Gln | Gly | Gly | Leu  | Leu  | Met | Lys  | Asn  | Asn |      |      |  |  |
| 945  |     |     |     |     |     |     |     |     |     |      | 950  |     |      | 955  |     |      | 960  |  |  |
| Gln  | Asn | Ser | Lys | Val | Leu | Thr | Cys | Leu | Ala | Ala  | Pro  | Pro | Leu  | Ile  | Phe |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 965  |      |     | 970  |      |     | 975  |      |  |  |
| Leu  | Leu | Gly | Phe | Lys | Thr | Lys | Glu | Gln | Leu | Met  | Leu  | Gln | Pro  | Lys  | Thr |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 980  |      |     | 985  |      |     | 990  |      |  |  |
| Ala  | Ala | Glu | His | Asp | Glu | Glu | Met | Ser | Asp | Ser  | Glu  | Met | Asn  | Ser  | Ala |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 995  |      |     | 1000 |      |     | 1005 |      |  |  |
| Glu  | Asp | Thr | Asp | Thr | Ser | Ser | Asp | Ser | Ser | Ser  | Asp  | Ser | Asp  | Asp  | Ser |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1010 |      |     | 1015 |      |     | 1020 |      |  |  |
| Asp  | Glu | Glu | Asp | Ala | Lys | Leu | Arg | Ala | Gln | Ser  | Leu  | Ser | Ala  | Asp  | Gln |      |      |  |  |
| 1025 |     |     |     |     |     |     |     |     |     |      | 1030 |     |      | 1035 |     |      | 1040 |  |  |
| Pro  | Leu | Ser | Ile | His | Arg | Leu | Val | Arg | Asp | Lys  | Leu  | Asn | Phe  | Ser  | Glu |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1045 |      |     | 1050 |      |     | 1055 |      |  |  |
| Lys  | Lys | Lys | Pro | Asp | Met | Gly | Ile | Ser | Arg | Ile  | Val  | Val | Ala  | Pro  | Pro |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1060 |      |     | 1065 |      |     | 1070 |      |  |  |
| Ile  | Val | Thr | Gly | Arg | Asn | Arg | Ala | Arg | Thr | Met  | Ser  | Ile | Lys  | Lys  | Ser |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1075 |      |     | 1080 |      |     | 1085 |      |  |  |
| Lys  | Lys | Asn | Val | Ile | Lys | Pro | Pro | Ala | Cys | Leu  | Lys  | Ile | Glu  | Thr  | Ser |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1090 |      |     | 1095 |      |     | 1100 |      |  |  |
| Asp  | Asp | Asp | Glu | Gln | Glu | Gln | Lys | Lys | Ala | Thr  | Glu  | Met | Cys  | Lys  | Ser |      |      |  |  |
| 1105 |     |     |     |     |     |     |     |     |     |      | 1110 |     |      | 1115 |     |      | 1120 |  |  |
| Thr  | Phe | Phe | Asp | Phe | Phe | Asp | Phe | Pro | Tyr | Ile  | Asn  | Arg | Thr  | Gly  |     |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1125 |      |     | 1130 |      |     | 1135 |      |  |  |
| Lys  | Arg | Gly | Ser | Val | Ala | Val | Ala | Met | Asn | His  | Asp  | Asp | Met  | Tyr  | Ile |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1140 |      |     | 1145 |      |     | 1150 |      |  |  |
| Asp  | Pro | Ser | Glu | Glu | Leu | Asp | Thr | Gln | Thr | Arg  | Gln  | Lys | Ser  | Ser  | Arg |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1155 |      |     | 1160 |      |     | 1165 |      |  |  |
| Glu  | Phe | Ser | Ser | Ser | Arg | Asn | Val | Thr | Val | Gln  | Val  | Tyr | Thr  | Gln  | Arg |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1170 |      |     | 1175 |      |     | 1180 |      |  |  |
| Pro  | Leu | Ser | Trp | Lys | Lys | Lys | Ile | Met | Glu | Phe  | Tyr  | Lys | Ala  | Pro  | Ile |      |      |  |  |
| 1185 |     |     |     |     |     |     |     |     |     |      | 1190 |     |      | 1195 |     |      | 1200 |  |  |
| Thr  | Thr | Tyr | Trp | Leu | Trp | Phe | Phe | Ala | Phe | Ile  | Trp  | Phe | Leu  | Ile  | Leu |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     | 1205 |      |     | 1210 |      |     | 1215 |      |  |  |
| Leu  | Thr | Tyr | Asn | Leu | Leu | Val | Lys | Thr | Gln | Arg  | Ile  | Ala | Ser  | Trp  | Ser |      |      |  |  |
|      |     |     |     |     |     |     |     |     |     |      |      |     |      |      |     |      |      |  |  |

[illegible]

-22-

1765 1770 1775  
 Glu Asp Asp Phe Tyr Ala Asp Ser Pro Val Pro Met Pro Met Thr Pro  
 1780 1785 1790  
 Val Gln Pro Ala Asp Gly Ser Phe Phe Gly Glu Asn Asp Ser Arg Tyr  
 1795 1800 1805  
 Gln Arg Asp Asp Ser Asp Tyr Glu  
 1810 1815

<210> 14  
 <211> 1387  
 <212> PRT  
 <213> C. Elegans

<400> 14  
 Met Arg Lys Ser Arg Arg Val Arg Lys Leu Val Arg His Ala Ser Leu  
 1 5 10 15  
 Ile Glu Asn Ile Arg His Arg Thr Ser Phe Leu Arg Leu Leu Asn  
 20 25 30  
 Ala Pro Arg Asn Ser Met Cys Asn Ala Asn Thr Val His Ser Ile Ser  
 35 40 45  
 Ser Phe Arg Ser Asp His Leu Ser Arg Lys Ser Thr His Lys Phe Leu  
 50 55 60  
 Asp Asn Pro Asn Leu Phe Ala Ile Glu Leu Thr Glu Lys Leu Ser Pro  
 65 70 75 80  
 Pro Trp Ile Glu Asn Thr Phe Glu Lys Arg Glu Cys Ile Arg Phe Ala  
 85 90 95  
 Ala Leu Pro Lys Asp Pro Glu Arg Cys Gly Cys Gly Arg Pro Leu Ser  
 100 105 110  
 Ala His Thr Pro Ala Ser Thr Phe Ser Thr Leu Pro Val His Leu  
 115 120 125  
 Leu Glu Lys Glu Gln Gln Thr Trp Thr Ile Ala Asn Asn Thr Gln Thr  
 130 135 140  
 Ser Thr Thr Asp Ala Phe Gly Thr Ile Val Phe Gln Gly Gly Ala His  
 145 150 155 160  
 Ala His Lys Ala Gln Tyr Val Arg Leu Ser Tyr Asp Ser Glu Pro Leu  
 165 170 175  
 Asp Val Met Tyr Leu Met Glu Lys Val Trp Gly Leu Glu Ala Pro Arg  
 180 185 190  
 Leu Val Ile Thr Val His Gly Gly Met Ser Asn Phe Glu Leu Glu Glu  
 195 200 205  
 Arg Leu Gly Arg Leu Phe Arg Lys Gly Met Leu Lys Ala Ala Gln Thr  
 210 215 220  
 Thr Gly Ala Trp Ile Ile Thr Ser Gly Leu Asp Ser Gly Val Val Arg  
 225 230 235 240  
 His Val Ala Lys Ala Leu Asp Glu Ala Gly Ile Ser Ala Arg Met Arg  
 245 250 255  
 Ser Gln Ile Val Thr Ile Gly Ile Ala Pro Trp Gly Val Ile Lys Arg  
 260 265 270  
 Lys Glu Arg Leu Ile Arg Gln Asn Glu His Val Tyr Tyr Asp Val His  
 275 280 285  
 Ser Leu Ser Val Asn Ala Asn Val Gly Ile Leu Asn Asp Arg His Ser  
 290 295 300  
 Tyr Phe Leu Leu Ala Asp Asn Gly Thr Val Gly Arg Phe Gly Ala Asp  
 305 310 315 320  
 Leu His Leu Arg Gln Asn Leu Glu Asn His Ile Ala Thr Phe Gly Cys  
 325 330 335  
 Asn Gly Arg Lys Val Pro Val Val Cys Thr Leu Leu Glu Gly Gly Ile  
 340 345 350  
 Ser Ser Ile Asn Ala Ile His Asp Tyr Val Thr Met Lys Pro Asp Ile  
 355 360 365

-23-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Ala | Ile | Val | Cys | Asp | Gly | Ser | Gly | Arg | Ala | Ala | Asp | Ile | Ile | Ser |
| 370 |     |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |
| Phe | Ala | Ala | Arg | Tyr | Ile | Asn | Ser | Asp | Gly | Thr | Phe | Ala | Ala | Glu | Val |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Gly | Glu | Lys | Leu | Arg | Asn | Leu | Ile | Lys | Met | Val | Phe | Pro | Glu | Thr | Asp |
|     |     |     |     | 405 |     |     |     |     | 410 |     |     |     |     | 415 |     |
| Gln | Glu | Glu | Met | Phe | Arg | Lys | Ile | Thr | Glu | Cys | Val | Ile | Arg | Asp | Asp |
|     |     |     | 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Leu | Leu | Arg | Ile | Phe | Arg | Tyr | Gly | Gln | Glu | Glu | Glu | Glu | Asp | Val | Asp |
|     |     | 435 |     |     |     |     | 440 |     |     |     |     | 445 |     |     |     |
| Phe | Val | Ile | Leu | Ser | Thr | Val | Leu | Gln | Lys | Gln | Asn | Leu | Pro | Pro | Asp |
|     | 450 |     |     |     |     | 455 |     |     |     | 460 |     |     |     |     |     |
| Glu | Gln | Leu | Ala | Leu | Thr | Leu | Ser | Trp | Asn | Arg | Val | Asp | Leu | Ala | Lys |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Ser | Cys | Leu | Phe | Ser | Asn | Gly | Arg | Lys | Trp | Ser | Ser | Asp | Val | Leu | Glu |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Lys | Ala | Met | Asn | Asp | Ala | Leu | Tyr | Trp | Asp | Arg | Val | Asp | Phe | Val | Glu |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Cys | Leu | Leu | Glu | Asn | Gly | Val | Ser | Met | Lys | Asn | Phe | Leu | Ser | Ile | Asn |
|     |     | 515 |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| Arg | Leu | Glu | Asn | Leu | Tyr | Asn | Met | Asp | Asp | Ile | Asn | Ser | Ala | His | Ser |
|     | 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |
| Val | Arg | Asn | Trp | Met | Glu | Asn | Phe | Asp | Ser | Met | Asp | Pro | His | Thr | Tyr |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Leu | Thr | Ile | Pro | Met | Ile | Gly | Gln | Val | Val | Glu | Lys | Leu | Met | Gly | Asn |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |
| Ala | Phe | Gln | Leu | Tyr | Tyr | Thr | Ser | Arg | Ser | Phe | Lys | Gly | Lys | Tyr | Asp |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Arg | Tyr | Lys | Arg | Ile | Asn | Gln | Ser | Ser | Tyr | Phe | His | Arg | Lys | Arg | Lys |
|     |     | 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |
| Ile | Val | Gln | Lys | Glu | Leu | Phe | Lys | Lys | Lys | Ser | Asp | Asp | Gln | Ile | Asn |
|     | 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |
| Asp | Asn | Glu | Glu | Glu | Asp | Phe | Ser | Phe | Ala | Tyr | Pro | Phe | Asn | Asp | Leu |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Leu | Ile | Trp | Ala | Val | Leu | Thr | Ser | Arg | His | Gly | Met | Ala | Glu | Cys | Met |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |
| Trp | Val | His | Gly | Glu | Asp | Ala | Met | Ala | Lys | Cys | Leu | Leu | Ala | Ile | Arg |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Leu | Tyr | Lys | Ala | Thr | Ala | Lys | Ile | Ala | Glu | Asp | Glu | Tyr | Leu | Asp | Val |
|     |     | 675 |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |
| Glu | Glu | Ala | Lys | Arg | Leu | Phe | Asp | Asn | Ala | Val | Lys | Cys | Arg | Glu | Asp |
|     | 690 |     |     |     |     | 695 |     |     |     | 700 |     |     |     |     |     |
| Ala | Ile | Glu | Leu | Leu | Asp | Gln | Cys | Tyr | Arg | Ala | Asp | His | Asp | Arg | Thr |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     |     | 720 |
| Leu | Arg | Leu | Leu | Arg | Met | Glu | Leu | Pro | His | Trp | Gly | Asn | Asn | Asn | Cys |
|     |     |     |     | 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |
| Leu | Ser | Leu | Ala | Val | Leu | Ala | Asn | Thr | Lys | Thr | Phe | Leu | Ala | His | Pro |
|     |     |     | 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |
| Cys | Cys | Gln | Ile | Leu | Leu | Ala | Glu | Leu | Trp | His | Gly | Ser | Leu | Lys | Val |
|     |     | 755 |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |
| Arg | Ser | Gly | Ser | Asn | Val | Arg | Val | Leu | Thr | Ala | Leu | Ile | Cys | Pro | Pro |
|     | 770 |     |     |     |     | 775 |     |     |     |     | 780 |     |     |     |     |
| Ala | Ile | Leu | Phe | Met | Ala | Tyr | Lys | Pro | Lys | His | Ser | Lys | Thr | Ala | Arg |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     |     | 800 |
| Leu | Leu | Ser | Glu | Glu | Thr | Pro | Glu | Gln | Leu | Pro | Tyr | Pro | Arg | Glu | Ser |
|     |     |     |     | 805 |     |     |     |     | 810 |     |     |     |     | 815 |     |
| Ile | Thr | Ser | Thr | Thr | Ser | Asn | Arg | Tyr | Arg | Tyr | Ser | Lys | Gly | Pro | Glu |
|     |     |     | 820 |     |     |     |     | 825 |     |     |     |     | 830 |     |     |
| Glu | Gln | Lys | Glu | Thr | Leu | Leu | Glu | Lys | Gly | Ser | Tyr | Thr | Lys | Lys | Val |
|     |     | 835 |     |     |     |     | 840 |     |     |     |     |     | 845 |     |     |

-24-

|      |     |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|------|-----|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| Thr  | Ile | Ile  | Ser  | Ser  | Arg  | Lys  | Asn  | Ser  | Gly  | Val  | Ala  | Ser  | Val  | Tyr  | Gly  |
| 850  |     |      |      |      |      | 855  |      |      |      |      | 860  |      |      |      |      |
| Ser  | Ala | Ser  | Ser  | Met  | Met  | Phe  | Lys  | Arg  | Glu  | Pro  | Gln  | Leu  | Asn  | Lys  | Phe  |
| 865  |     |      |      |      | 870  |      |      |      |      | 875  |      |      |      |      | 880  |
| Glu  | Arg | Phe  | Arg  | Ala  | Phe  | Tyr  | Ser  | Ser  | Pro  | Ile  | Thr  | Lys  | Phe  | Trp  | Ser  |
|      |     |      |      | 885  |      |      |      |      | 890  |      |      |      |      |      | 895  |
| Trp  | Cys | Ile  | Ala  | Phe  | Leu  | Ile  | Phe  | Leu  | Thr  | Thr  | Gln  | Thr  | Cys  | Ile  | Leu  |
|      |     |      | 900  |      |      |      |      | 905  |      |      |      |      | 910  |      |      |
| Leu  | Leu | Glu  | Thr  | Ser  | Leu  | Lys  | Pro  | Ser  | Lys  | Tyr  | Glu  | Trp  | Ile  | Thr  | Phe  |
|      |     | 915  |      |      |      |      | 920  |      |      |      |      | 925  |      |      |      |
| Ile  | Tyr | Thr  | Val  | Thr  | Leu  | Ser  | Val  | Glu  | His  | Ile  | Arg  | Lys  | Leu  | Met  | Thr  |
| 930  |     |      |      |      |      | 935  |      |      |      |      | 940  |      |      |      |      |
| Ser  | Glu | Gly  | Ser  | Arg  | Ile  | Asn  | Glu  | Lys  | Val  | Lys  | Val  | Phe  | Tyr  | Ala  | Lys  |
| 945  |     |      |      |      | 950  |      |      |      |      | 955  |      |      |      |      | 960  |
| Trp  | Tyr | Asn  | Ile  | Trp  | Thr  | Ser  | Ala  | Ala  | Leu  | Leu  | Phe  | Phe  | Leu  | Val  | Gly  |
|      |     |      |      | 965  |      |      |      |      | 970  |      |      |      |      |      | 975  |
| Tyr  | Gly | Phe  | Arg  | Leu  | Val  | Pro  | Met  | Tyr  | Arg  | His  | Ser  | Trp  | Gly  | Arg  | Val  |
|      |     |      | 980  |      |      |      |      | 985  |      |      |      |      | 990  |      |      |
| Leu  | Leu | Ser  | Phe  | Ser  | Asn  | Val  | Leu  | Phe  | Tyr  | Met  | Lys  | Ile  | Phe  | Glu  | Tyr  |
|      |     | 995  |      |      |      |      | 1000 |      |      |      |      | 1005 |      |      |      |
| Leu  | Ser | Val  | His  | Pro  | Leu  | Leu  | Gly  | Pro  | Tyr  | Ile  | Gln  | Met  | Ala  | Ala  | Lys  |
| 1010 |     |      |      |      |      | 1015 |      |      |      |      | 1020 |      |      |      |      |
| Met  | Val | Trp  | Ser  | Met  | Cys  | Tyr  | Ile  | Cys  | Val  | Leu  | Leu  | Leu  | Val  | Pro  | Leu  |
| 1025 |     |      |      |      | 1030 |      |      |      |      | 1035 |      |      |      |      | 104  |
| Met  | Ala | Phe  | Gly  | Val  | Asn  | Arg  | Gln  | Ala  | Leu  | Thr  | Glu  | Pro  | Asn  | Val  | Lys  |
|      |     |      |      | 1045 |      |      |      |      |      | 1050 |      |      |      |      | 1055 |
| Asp  | Trp | His  | Trp  | Leu  | Leu  | Val  | Arg  | Asn  | Ile  | Phe  | Tyr  | Lys  | Pro  | Tyr  | Phe  |
|      |     |      | 1060 |      |      |      |      | 1065 |      |      |      |      | 1070 |      |      |
| Met  | Leu | Tyr  | Gly  | Glu  | Val  | Tyr  | Ala  | Gly  | Glu  | Ile  | Asp  | Thr  | Cys  | Gly  | Asp  |
|      |     | 1075 |      |      |      |      | 1080 |      |      |      |      | 1085 |      |      |      |
| Glu  | Gly | Ile  | Arg  | Cys  | Phe  | Pro  | Gly  | Tyr  | Phe  | Ile  | Pro  | Pro  | Leu  | Leu  | Met  |
| 1090 |     |      |      |      |      | 1095 |      |      |      |      | 1100 |      |      |      |      |
| Val  | Ile | Phe  | Leu  | Leu  | Val  | Ala  | Asn  | Ile  | Leu  | Leu  | Leu  | Asn  | Leu  | Leu  | Ile  |
| 1105 |     |      |      |      | 1110 |      |      |      |      |      | 1115 |      |      |      | 112  |
| Ala  | Ile | Phe  | Asn  | Asn  | Ile  | Tyr  | Asn  | Asp  | Ser  | Ile  | Glu  | Lys  | Ser  | Lys  | Glu  |
|      |     |      | 1125 |      |      |      |      |      |      | 1130 |      |      |      |      | 1135 |
| Ile  | Trp | Leu  | Phe  | Gln  | Arg  | Tyr  | Gln  | Gln  | Leu  | Met  | Glu  | Tyr  | His  | Asp  | Ser  |
|      |     |      | 1140 |      |      |      |      | 1145 |      |      |      |      | 1150 |      |      |
| Pro  | Phe | Leu  | Pro  | Pro  | Pro  | Phe  | Ser  | Ile  | Phe  | Ala  | His  | Val  | Tyr  | His  | Phe  |
|      |     | 1155 |      |      |      |      | 1160 |      |      |      |      | 1165 |      |      |      |
| Ile  | Asp | Tyr  | Leu  | Tyr  | Asn  | Leu  | Arg  | Arg  | Pro  | Asp  | Thr  | Lys  | Arg  | Phe  | Arg  |
| 1170 |     |      |      |      | 1175 |      |      |      |      |      | 1180 |      |      |      |      |
| Ser  | Glu | His  | Ser  | Ile  | Lys  | Leu  | Ser  | Val  | Thr  | Glu  | Asp  | Glu  | Met  | Lys  | Arg  |
| 1185 |     |      |      |      | 1190 |      |      |      |      | 1195 |      |      |      |      | 120  |
| Ile  | Gln | Asp  | Phe  | Glu  | Glu  | Asp  | Cys  | Ile  | Asp  | Thr  | Leu  | Thr  | Arg  | Ile  | Arg  |
|      |     |      | 1205 |      |      |      |      |      | 1210 |      |      |      |      | 1215 |      |
| Lys  | Leu | Lys  | Leu  | Asn  | Thr  | Lys  | Glu  | Pro  | Leu  | Ser  | Val  | Thr  | Asp  | Leu  | Thr  |
|      |     |      | 1220 |      |      |      |      | 1225 |      |      |      |      | 1230 |      |      |
| Glu  | Leu | Thr  | Cys  | Gln  | Arg  | Val  | His  | Asp  | Leu  | Met  | Gln  | Glu  | Asn  | Phe  | Leu  |
|      |     | 1235 |      |      |      |      | 1240 |      |      |      |      | 1245 |      |      |      |
| Leu  | Lys | Ser  | Arg  | Val  | Tyr  | Asp  | Ile  | Glu  | Thr  | Lys  | Ile  | Asp  | His  | Ile  | Ser  |
| 1250 |     |      |      |      |      | 1255 |      |      |      |      | 1260 |      |      |      |      |
| Asn  | Ser | Ser  | Asp  | Glu  | Val  | Val  | Gln  | Ile  | Leu  | Lys  | Asn  | Lys  | Lys  | Leu  | Ser  |
| 1265 |     |      |      |      | 1270 |      |      |      |      | 1275 |      |      |      |      | 128  |
| Gln  | Asn | Phe  | Ala  | Ala  | Ser  | Ser  | Leu  | Ser  | Leu  | Pro  | Asp  | Thr  | Ser  | Ile  | Glu  |
|      |     |      | 1285 |      |      |      |      |      |      | 1290 |      |      |      | 1295 |      |
| Val  | Pro | Lys  | Ile  | Thr  | Lys  | Thr  | Leu  | Ile  | Asp  | Cys  | His  | Leu  | Ser  | Pro  | Val  |
|      |     | 1300 |      |      |      |      | 1305 |      |      |      |      | 1310 |      |      |      |
| Ser  | Ile | Glu  | Asp  | Arg  | Leu  | Ala  | Thr  | Arg  | Ser  | Pro  | Leu  | Leu  | Ala  | Asn  | Leu  |
|      |     | 1315 |      |      |      |      | 1320 |      |      |      |      | 1325 |      |      |      |



-25-

Gln Arg Asp His Thr Leu Arg Lys Leu Pro Thr Trp Glu Thr Ser Thr  
 1330 1335 1340  
 Ala Ser Thr Ser Ser Phe Glu Phe Val Phe Tyr Phe Thr Arg His Glu  
 1345 1350 1355 136  
 Gly Asn Glu Asn Lys Tyr Glu Phe Lys Lys Leu Glu Lys Gly Gly Phe  
 1365 1370 1375  
 Trp Arg Asn Asn Tyr Val Ile Ser Trp Arg Leu  
 1380 1385

<210> 15  
 <211> 1868  
 <212> PRT  
 <213> C. Elegans

<400> 15  
 Met Asn Leu Cys Tyr Arg Arg His Arg Tyr Ala Ser Ser Pro Glu Val  
 1 5 10 15  
 Trp Cys Thr Met Glu Ser Asp Glu Leu Gly Val Thr Arg Tyr Leu Gln  
 20 25 30  
 Ser Lys Gly Gly Asp Gln Val Pro Pro Thr Ser Thr Thr Gly Gly  
 35 40 45  
 Ala Gly Gly Asp Gly Asn Ala Val Pro Thr Thr Ser Gln Ala Gln Ala  
 50 55 60  
 Gln Thr Phe Asn Ser Gly Arg Gln Thr Thr Gly Met Ser Ser Gly Asp  
 65 70 75 80  
 Arg Leu Asn Glu Asp Val Ser Ala Thr Ala Asn Ser Ala Gln Leu Val  
 85 90 95  
 Leu Pro Thr Pro Leu Phe Asn Gln Met Arg Phe Thr Glu Ser Asn Met  
 100 105 110  
 Ser Leu Asn Arg His Asn Trp Val Arg Glu Thr Phe Thr Arg Arg Glu  
 115 120 125  
 Cys Ser Arg Phe Ile Ala Ser Ser Arg Asp Leu His Lys Cys Gly Cys  
 130 135 140  
 Gly Arg Thr Arg Asp Ala His Arg Asn Ile Pro Glu Leu Thr Ser Glu  
 145 150 155 160  
 Phe Leu Arg Gln Lys Arg Ser Val Ala Ala Leu Glu Gln Gln Arg Ser  
 165 170 175  
 Ile Ser Asn Val Asn Asp Asp Ile Asn Thr Gln Asn Met Tyr Thr Lys  
 180 185 190  
 Arg Gly Ala Asn Glu Lys Trp Ser Leu Arg Lys His Thr Val Ser Leu  
 195 200 205  
 Ala Thr Asn Ala Phe Gly Gln Val Glu Phe Gln Gly Gly Pro His Pro  
 210 215 220  
 Tyr Lys Ala Gln Tyr Val Arg Val Asn Phe Asp Thr Glu Pro Ala Tyr  
 225 230 235 240  
 Ile Met Ser Leu Phe Glu His Val Trp Gln Ile Ser Pro Pro Arg Leu  
 245 250 255  
 Ile Ile Thr Val His Gly Gly Thr Ser Asn Phe Asp Leu Gln Pro Lys  
 260 265 270  
 Leu Ala Arg Val Phe Arg Lys Gly Leu Leu Lys Ala Ala Ser Thr Thr  
 275 280 285  
 Gly Ala Trp Ile Ile Thr Ser Gly Cys Asp Thr Gly Val Val Lys His  
 290 295 300  
 Val Ala Ala Ala Leu Glu Gly Ala Gln Ser Ala Gln Arg Asn Lys Ile  
 305 310 315 320  
 Val Cys Ile Gly Ile Ala Pro Trp Gly Leu Leu Lys Lys Arg Glu Asp  
 325 330 335  
 Phe Ile Gly Gln Asp Lys Thr Val Pro Tyr Tyr Pro Ser Ser Ser Lys  
 340 345 350  
 Gly Arg Phe Thr Gly Leu Asn Asn Arg His Ser Tyr Phe Leu Leu Val

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |     |     |     |     |
| Asp | Asn | Gly | Thr | Val | Gly | Arg | Tyr | Gly | Ala | Glu | Val | Ile | Leu | Arg | Lys |
| 370 |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |     |
| Arg | Leu | Glu | Met | Tyr | Ile | Ser | Gln | Lys | Gln | Lys | Ile | Phe | Gly | Gly | Thr |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     |     |
| Arg | Ser | Val | Pro | Val | Val | Cys | Val | Val | Leu | Glu | Gly | Gly | Ser | Cys | Thr |
| 405 |     |     |     |     | 410 |     |     |     |     | 415 |     |     |     |     |     |
| Ile | Arg | Ser | Val | Leu | Asp | Tyr | Val | Thr | Asn | Val | Pro | Arg | Val | Pro | Val |
| 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |     |     |     |
| Val | Val | Cys | Asp | Gly | Ser | Gly | Arg | Ala | Ala | Asp | Leu | Leu | Ala | Phe | Ala |
| 435 |     |     |     |     | 440 |     |     |     |     | 445 |     |     |     |     |     |
| His | Gln | Asn | Val | Thr | Glu | Asp | Gly | Leu | Leu | Pro | Asp | Asp | Ile | Arg | Arg |
| 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |     |
| Gln | Val | Leu | Leu | Leu | Val | Glu | Thr | Thr | Phe | Gly | Cys | Ser | Glu | Ala | Ala |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     |     |
| Ala | His | Arg | Leu | Leu | His | Glu | Leu | Thr | Val | Cys | Ala | Gln | His | Lys | Asn |
| 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |     |     |     |     |
| Leu | Leu | Thr | Ile | Phe | Arg | Leu | Gly | Glu | Gln | Gly | Glu | His | Asp | Val | Asp |
| 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |     |     |     |
| His | Ala | Ile | Leu | Thr | Ala | Leu | Leu | Lys | Gly | Gln | Asn | Leu | Ser | Ala | Ala |
| 515 |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |     |     |
| Asp | Gln | Leu | Ala | Leu | Ala | Leu | Ala | Trp | Asn | Arg | Val | Asp | Ile | Ala | Arg |
| 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |     |
| Ser | Asp | Val | Phe | Ala | Met | Gly | His | Glu | Trp | Pro | Gln | Ala | Ala | Leu | His |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     |     |
| Asn | Ala | Met | Met | Glu | Ala | Leu | Ile | His | Asp | Arg | Val | Asp | Phe | Val | Arg |
| 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |     |     |     |     |
| Leu | Leu | Leu | Glu | Gln | Gly | Ile | Asn | Met | Gln | Lys | Phe | Leu | Thr | Ile | Ser |
| 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |     |     |     |
| Arg | Leu | Asp | Glu | Leu | Tyr | Asn | Thr | Asp | Lys | Gly | Pro | Pro | Asn | Thr | Leu |
| 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |     |     |
| Phe | Tyr | Ile | Val | Arg | Asp | Val | Val | Arg | Val | Arg | Gln | Gly | Tyr | Arg | Phe |
| 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |     |
| Lys | Leu | Pro | Asp | Ile | Gly | Leu | Val | Ile | Glu | Lys | Leu | Met | Gly | Asn | Ser |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     |     |
| Tyr | Gln | Cys | Ser | Tyr | Thr | Thr | Ser | Glu | Phe | Arg | Asp | Lys | Tyr | Lys | Gln |
| 645 |     |     |     |     | 650 |     |     |     |     | 655 |     |     |     |     |     |
| Arg | Met | Lys | Arg | Val | Lys | His | Ala | Gln | Lys | Lys | Ala | Met | Gly | Val | Phe |
| 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |     |     |     |
| Ser | Ser | Arg | Pro | Ser | Arg | Thr | Gly | Ser | Gly | Ile | Ala | Ser | Arg | Gln | Ser |
| 675 |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |     |     |
| Thr | Glu | Gly | Met | Gly | Gly | Val | Gly | Gly | Gly | Ser | Ser | Val | Ala | Gly | Val |
| 690 |     |     |     |     | 695 |     |     |     |     | 700 |     |     |     |     |     |
| Phe | Gly | Asn | Ser | Phe | Gly | Asn | Gln | Asp | Pro | Pro | Leu | Asp | Pro | His | Val |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     |     |     |
| Asn | Arg | Ser | Ala | Leu | Ser | Gly | Ser | Arg | Ala | Leu | Ser | Asn | His | Ile | Leu |
| 725 |     |     |     |     | 730 |     |     |     |     | 735 |     |     |     |     |     |
| Trp | Arg | Ser | Ala | Phe | Arg | Gly | Asn | Phe | Pro | Ala | Asn | Pro | Met | Arg | Pro |
| 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |     |     |     |
| Pro | Asn | Leu | Gly | Asp | Ser | Arg | Asp | Cys | Gly | Ser | Glu | Phe | Asp | Glu | Glu |
| 755 |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |     |     |
| Leu | Ser | Leu | Thr | Ser | Ala | Ser | Asp | Gly | Ser | Gln | Thr | Glu | Pro | Asp | Phe |
| 770 |     |     |     |     | 775 |     |     |     |     | 780 |     |     |     |     |     |
| Arg | Tyr | Pro | Tyr | Ser | Glu | Leu | Met | Ile | Trp | Ala | Val | Leu | Thr | Lys | Arg |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     |     |     |
| Gln | Asp | Met | Ala | Met | Cys | Met | Trp | Gln | His | Gly | Glu | Glu | Ala | Met | Ala |
| 805 |     |     |     |     | 810 |     |     |     |     | 815 |     |     |     |     |     |
| Lys | Ala | Leu | Val | Ala | Cys | Arg | Leu | Tyr | Lys | Ser | Leu | Ala | Thr | Glu | Ala |
| 820 |     |     |     |     | 825 |     |     |     |     | 830 |     |     |     |     |     |
| Ala | Glu | Asp | Tyr | Leu | Glu | Val | Glu | Ile | Cys | Glu | Glu | Leu | Lys | Lys | Tyr |

|   |      |      |
|---|------|------|
| 835   | 840  | 845  |
| Ala Glu Phe Arg Ile Leu Ser Leu Glu Leu Leu Asp His Cys Tyr     |      |      |
| 850   | 855  | 860  |
| His Val Asp Asp Ala Gln Thr Leu Gln Leu Leu Thr Tyr Glu Leu Ser |      |      |
| 865   | 870  | 875  |
| Asn Trp Ser Asn Glu Thr Cys Leu Ala Leu Ala Val Ile Val Asn Asn |      |      |
| 885   | 890  | 895  |
| Lys His Phe Leu Ala His Pro Cys Cys Gln Ile Leu Leu Ala Asp Leu |      |      |
| 900   | 905  | 910  |
| Trp His Gly Gly Leu Arg Met Arg Thr His Ser Asn Ile Lys Val Val |      |      |
| 915   | 920  | 925  |
| Leu Gly Leu Ile Cys Pro Pro Phe Ile Gln Met Leu Glu Phe Lys Thr |      |      |
| 930   | 935  | 940  |
| Arg Glu Glu Leu Leu Asn Gln Pro Gln Thr Ala Ala Glu His Gln Asn |      |      |
| 945   | 950  | 955  |
| Asp Met Asn Tyr Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser     |      |      |
| 965   | 970  | 975  |
| Ser Ser Ser Ser Ser Asp Ser Ser Ser Phe Glu Asp Asp Asp Asp Glu |      |      |
| 980   | 985  | 990  |
| Asn Asn Ala His Asn His Asp Gln Lys Arg Thr Arg Lys Thr Ser Gln |      |      |
| 995   | 1000 | 1005 |
| Gly Ser Ala Gln Ser Leu Asn Ile Thr Ser Leu Phe His Ser Arg Arg |      |      |
| 1010  | 1015 | 1020 |
| Arg Lys Ala Lys Lys Asn Glu Lys Cys Asp Arg Glu Thr Asp Ala Ser |      |      |
| 1025  | 1030 | 1035 |
| Ala Cys Glu Ala Gly Asn Arg Gln Ile Gln Asn Gly Gly Leu Thr Ala |      |      |
| 1045  | 1050 | 1055 |
| Glu Tyr Gly Thr Phe Gly Glu Ser Asn Gly Val Ser Pro Pro Pro Pro |      |      |
| 1060  | 1065 | 1070 |
| Tyr Met Arg Ala Asn Ser Arg Ser Arg Tyr Asn Asn Arg Ser Asp Met |      |      |
| 1075  | 1080 | 1085 |
| Ser Lys Thr Ser Ser Val Ile Phe Gly Ser Asp Pro Asn Leu Ser Lys |      |      |
| 1090  | 1095 | 1100 |
| Leu Gln Lys Ser Asn Ile Thr Ser Thr Asp Arg Pro Asn Pro Met Glu |      |      |
| 1105  | 1110 | 1115 |
| Gln Phe Gln Gly Thr Arg Lys Ile Lys Met Arg Arg Arg Phe Tyr Glu |      |      |
| 1125  | 1130 | 1135 |
| Phe Tyr Ser Ala Pro Ile Ser Thr Phe Trp Ser Trp Thr Ile Ser Phe |      |      |
| 1140  | 1145 | 1150 |
| Ile Leu Phe Ile Thr Phe Phe Thr Tyr Thr Leu Leu Val Lys Thr Pro |      |      |
| 1155  | 1160 | 1165 |
| Pro Arg Pro Thr Val Ile Glu Tyr Ile Leu Ile Ala Tyr Val Ala Ala |      |      |
| 1170  | 1175 | 1180 |
| Phe Gly Leu Glu Gln Val Arg Lys Ile Ile Met Ser Asp Ala Lys Pro |      |      |
| 1185  | 1190 | 1195 |
| Phe Tyr Glu Lys Ile Arg Thr Tyr Val Cys Ser Phe Trp Asn Cys Val |      |      |
| 1205  | 1210 | 1215 |
| Thr Ile Leu Ala Ile Ile Phe Tyr Ile Val Gly Phe Phe Met Arg Cys |      |      |
| 1220  | 1225 | 1230 |
| Phe Gly Ser Val Ala Tyr Gly Arg Val Ile Leu Ala Cys Asp Ser Val |      |      |
| 1235  | 1240 | 1245 |
| Leu Trp Thr Met Lys Leu Leu Asp Tyr Met Ser Val His Pro Lys Leu |      |      |
| 1250  | 1255 | 1260 |
| Gly Pro Tyr Val Thr Met Ala Gly Lys Met Ile Gln Asn Met Ser Tyr |      |      |
| 1265  | 1270 | 1275 |
| Ile Ile Val Met Leu Val Val Thr Leu Leu Ser Phe Gly Leu Ala Arg |      |      |
| 1285  | 1290 | 1295 |
| Gln Ser Ile Thr Tyr Pro Asp Glu Thr Trp His Trp Ile Leu Val Arg |      |      |
| 1300  | 1305 | 1310 |
| Asn Ile Phe Leu Lys Pro Tyr Phe Met Leu Tyr Gly Glu Val Tyr Ala |      |      |

-28-

|   |      |      |
|---|------|------|
| 1315  | 1320 | 1325 |
| Asp Glu Ile Asp Thr Cys Gly Asp Glu Ala Trp Asp Gln His Leu Glu |      |      |
| 1330  | 1335 | 1340 |
| Asn Gly Gly Pro Val Ile Leu Gly Asn Gly Thr Thr Gly Leu Ser Cys |      |      |
| 1345  | 1350 | 1355 |
| Val Pro Gly Tyr Trp Ile Pro Pro Leu Leu Met Thr Phe Phe Leu Leu |      |      |
| 1365  | 1370 | 1375 |
| Ile Ala Asn Ile Leu Leu Met Ser Met Leu Ile Ala Ile Phe Asn His |      |      |
| 1380  | 1385 | 1390 |
| Ile Phe Asp Ala Thr Asp Glu Met Ser Gln Gln Ile Trp Leu Phe Gln |      |      |
| 1395  | 1400 | 1405 |
| Arg Tyr Lys Gln Val Met Glu Tyr Glu Ser Thr Pro Phe Leu Pro Pro |      |      |
| 1410  | 1415 | 1420 |
| Pro Leu Thr Pro Leu Tyr His Gly Val Leu Ile Leu Gln Phe Val Arg |      |      |
| 1425  | 1430 | 1435 |
| Thr Arg Leu Ser Cys Ser Lys Ser Gln Glu Arg Asn Pro Ile Leu Leu |      |      |
| 1445  | 1450 | 1455 |
| Leu Lys Ile Ala Glu Leu Phe Leu Asp Asn Asp Gln Ile Glu Lys Leu |      |      |
| 1460  | 1465 | 1470 |
| His Asp Phe Glu Glu Asp Cys Met Glu Asp Leu Ala Arg Gln Lys Leu |      |      |
| 1475  | 1480 | 1485 |
| Asn Glu Lys Asn Thr Ser Asn Glu Gln Arg Ile Leu Arg Ala Asp Ile |      |      |
| 1490  | 1495 | 1500 |
| Arg Thr Asp Gln Ile Leu Asn Arg Leu Ile Asp Leu Gln Ala Lys Glu |      |      |
| 1505  | 1510 | 1515 |
| Ser Met Gly Arg Asp Val Ile Asn Asp Val Glu Ser Arg Leu Ala Ser |      |      |
| 1525  | 1530 | 1535 |
| Val Glu Lys Ala Gln Asn Glu Ile Leu Glu Cys Val Arg Ala Leu Leu |      |      |
| 1540  | 1545 | 1550 |
| Asn Gln Asn Asn Ala Pro Thr Ala Ile Gly Arg Cys Phe Ser Pro Ser |      |      |
| 1555  | 1560 | 1565 |
| Pro Asp Pro Leu Val Glu Thr Ala Asn Gly Thr Pro Gly Pro Leu Leu |      |      |
| 1570  | 1575 | 1580 |
| Leu Lys Leu Pro Gly Thr Asp Pro Ile Leu Glu Glu Lys Asp His Asp |      |      |
| 1585  | 1590 | 1595 |
| Ser Gly Glu Asn Ser Asn Ser Leu Pro Pro Gly Arg Ile Arg Arg Asn |      |      |
| 1605  | 1610 | 1615 |
| Arg Thr Ala Thr Ile Cys Gly Gly Tyr Val Ser Glu Glu Arg Asn Met |      |      |
| 1620  | 1625 | 1630 |
| Met Leu Leu Ser Pro Lys Pro Ser Asp Val Ser Gly Ile Pro Gln Gln |      |      |
| 1635  | 1640 | 1645 |
| Arg Leu Met Ser Val Thr Ser Met Asp Pro Leu Pro Leu Pro Leu Ala |      |      |
| 1650  | 1655 | 1660 |
| Lys Leu Ser Thr Met Ser Ile Arg Arg Arg His Glu Glu Tyr Thr Ser |      |      |
| 1665  | 1670 | 1675 |
| Ile Thr Asp Ser Ile Ala Ile Arg His Pro Glu Arg Arg Ile Arg Asn |      |      |
| 1685  | 1690 | 1695 |
| Asn Arg Ser Asn Ser Ser Glu His Asp Glu Ser Ala Val Asp Ser Glu |      |      |
| 1700  | 1705 | 1710 |
| Gly Gly Gly Asn Val Thr Ser Ser Pro Arg Lys Arg Ser Thr Arg Asp |      |      |
| 1715  | 1720 | 1725 |
| Leu Arg Met Thr Pro Ser Ser Gln Val Glu Glu Ser Thr Ser Arg Asp |      |      |
| 1730  | 1735 | 1740 |
| Gln Ile Phe Glu Ile Asp His Pro Glu His Glu Glu Asp Glu Ala Gln |      |      |
| 1745  | 1750 | 1755 |
| Ala Asp Cys Glu Leu Thr Asp Val Ile Thr Glu Glu Glu Asp Glu Glu |      |      |
| 1765  | 1770 | 1775 |
| Glu Asp Asp Glu Glu Asp Asp Ser His Glu Arg His His Ile His Pro |      |      |
| 1780  | 1785 | 1790 |
| Arg Arg Lys Ser Ser Arg Gln Asn Arg Gln Pro Ser His Thr Leu Glu |      |      |

-29-

1795                      1800                      1805  
 Thr Asp Leu Ser Glu Gly Glu Glu Val Asp Pro Leu Asp Val Leu Lys  
 1810                      1815                      1820  
 Met Lys Glu Leu Pro Ile Ile His Gln Ile Leu Asn Glu Glu Glu Gln  
 1825                      1830                      1835                      184  
 Ala Gly Ala Pro His Ser Thr Pro Val Ile Ala Ser Pro Ser Ser Ser  
                          1845                      1850                      1855  
 Arg Ala Asp Leu Thr Ser Gln Lys Cys Ser Asp Val  
                          1860                      1865

<210> 16  
 <211> 489  
 <212> DNA  
 <213> Mus Musculus

<400> 16  
 ccctgaaaga ctgcacttct gctgctagcg ctggagctga gttagttttg agaaggtttc 60  
 ccgggggtgt ccttggttcg tggcccgtgc caccgcctcc ggagacgctt tccgatagat 120  
 ggctgcaggc cgcggagggt gaggaggagc cgctgccctt ccggagtcg ccccgtaggg 180  
 agaatgtccc agaaatcctg gatagagagc actttgacca agagggagtg tgtatatatt 240  
 ataccaagct ccaaagaccc tcacagatgt cttccaggat gtcagatttg tcagcaactt 300  
 gtcagatgtt tctgtggtcg tttggtcaag caacatgcat gctttactgc aagtcttgcc 360  
 atgaaatact catagtgtaa attgggtgaa cactttaacc aggcaataga agaatggtct 420  
 gtggaaaagc acacggagca gagcccaaca gatgcttatg gagtcatcaa ttttcaaggg 480  
 ggttctcat 489

<210> 17  
 <211> 102  
 <212> PRT  
 <213> Mus Musculus

<400> 17  
 Met Ser Gln Lys Ser Trp Ile Glu Ser Thr Leu Thr Lys Arg Glu Cys  
 1                      5                      10                      15  
 Val Tyr Ile Ile Pro Ser Ser Lys Asp Pro His Arg Cys Leu Pro Gly  
                          20                      25                      30  
 Cys Gln Ile Cys Gln Gln Leu Val Arg Cys Phe Cys Gly Arg Leu Val  
                          35                      40                      45  
 Lys Gln His Ala Cys Phe Thr Ala Ser Leu Ala Met Lys Tyr Ser Asp  
                          50                      55                      60  
 Val Lys Leu Gly Glu His Phe Asn Gln Ala Ile Glu Glu Trp Ser Val  
 65                      70                      75                      80  
 Glu Lys His Thr Glu Gln Ser Pro Thr Asp Ala Tyr Gly Val Ile Asn  
                          85                      90                      95  
 Phe Gln Gly Gly Ser His  
                          100

<210> 18  
 <211> 410  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> unsure  
 <222> (6)...(6)  
  
 <221> unsure  
 <222> (58)...(58)  
  
 <221> unsure

-30-

&lt;222&gt; (89)...(89)

&lt;221&gt; unsure

&lt;222&gt; (406)...(406)

&lt;400&gt; 18

|            |            |            |            |             |             |     |
|------------|------------|------------|------------|-------------|-------------|-----|
| gccgcnggag | cctgagcgga | gggtgtgcgc | agcctcgcca | gcggggggccc | cgggctgngc  | 60  |
| cattgcctca | ctgagccagc | gcctgcctnc | tacctcgccg | acagctggaa  | ccagtgcgac  | 120 |
| ctagtggctc | tcacctgctt | cctcctgggc | gtgggctgcc | ggctgacccc  | gggtttgtac  | 180 |
| cacctggggc | gcactgtcct | ctgcatcgac | ttcatggttt | tcacgggtgcg | gctgcttcac  | 240 |
| atcttcacgg | tcaacaaaca | gctggggccc | aagatcgtca | tcgtgagcaa  | gatgatgaag  | 300 |
| gacgtgttct | tcttcctctt | cttcctcggc | gtgtggctgg | tagctatggg  | ttggggccacg | 360 |
| gaggggttcc | tgaggccacg | ggacagtgac | ttcccaagta | tcctgncgcc  |             | 410 |

&lt;210&gt; 19

&lt;211&gt; 131

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (15)...(15)

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (25)...(25)

&lt;223&gt; UNKNOWN

&lt;221&gt; UNSURE

&lt;222&gt; (131)...(131)

&lt;223&gt; UNKNOWN

&lt;400&gt; 19

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Glu | Gly | Val | Arg | Ser | Leu | Ala | Ser | Gly | Gly | Pro | Gly | Leu | Xaa | His |
| 1   |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |     |
| Cys | Leu | Thr | Glu | Pro | Ala | Pro | Ala | Xaa | Tyr | Leu | Ala | Asp | Ser | Trp | Asn |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     | 30  |     |     |     |
| Gln | Cys | Asp | Leu | Val | Ala | Leu | Thr | Cys | Phe | Leu | Leu | Gly | Val | Gly | Cys |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Arg | Leu | Thr | Pro | Gly | Leu | Tyr | His | Leu | Gly | Arg | Thr | Val | Leu | Cys | Ile |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Asp | Phe | Met | Val | Phe | Thr | Val | Arg | Leu | Leu | His | Ile | Phe | Thr | Val | Asn |
|     | 65  |     |     |     | 70  |     |     |     |     | 75  |     |     |     | 80  |     |
| Lys | Gln | Leu | Gly | Pro | Lys | Ile | Val | Ile | Val | Ser | Lys | Met | Met | Lys | Asp |
|     |     |     | 85  |     |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Val | Phe | Phe | Phe | Leu | Phe | Phe | Leu | Gly | Val | Trp | Leu | Val | Ala | Met | Gly |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Trp | Ala | Thr | Glu | Gly | Phe | Leu | Arg | Pro | Arg | Asp | Ser | Asp | Phe | Pro | Ser |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Ile | Leu | Xaa |     |     |     |     |     |     |     |     |     |     |     |     |     |
|     |     |     | 130 |     |     |     |     |     |     |     |     |     |     |     |     |

&lt;210&gt; 20

&lt;211&gt; 389

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 20

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| caaatttttt | gttagtacac | catctcatcc | aaattgcaaa | agtcacatgg | aaactggaac | 60  |
| caaagatcaa | gaaactgttt | gctctaaagc | tacagaagga | gataatacag | aatttgagc  | 120 |

-31-

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| attttagga  | cacagagata | gcatggatt  | acagaggttt | aaagaaacat | caaacaagat | 180 |
| aaaaatacta | tccaataaca | atacttctga | aaacactttg | aaacgagtga | gttctcttgc | 240 |
| tggatttact | gactgtcaca | gaacttccat | tcctgttcat | tcaaaacgag | aaaagatcag | 300 |
| tagaaggcca | tctaccgaag | acactcatga | agtagattcc | aaagcagctt | taataccggt | 360 |
| ttgtagattt | caactaaaca | gatatatat  |            |            |            | 389 |

<210> 21  
 <211> 415  
 <212> DNA  
 <213> Homo Sapiens

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| atttctagtt | tttcaaattt | gccagtcttt | ttgaatagta | tctccttctt | ttctcatggt | 60  |
| ttatatTTaa | aactttttta | tgtccatcat | cactttaaac | atacttattt | tgtcatctat | 120 |
| aaccaataat | tccactatct | tatcagaaat | caaataccgt | ttatgtaagt | tgactcccat | 180 |
| gagttctaaa | ttgccattgt | gaggtcatct | tcggttaggc | tttaatttgt | tgcaaagtgt | 240 |
| tgcagctcag | ggtcaggaag | agtccctcca | gaaaggagga | tttgttactg | tgaatctctt | 300 |
| tgttactaa  | cctctttccc | cactgaaata | acttttttca | ataacatgat | tttaacaaca | 360 |
| taatctctct | atgccagaac | agatatatat | gaatgtaagt | caatatTTtc | ttgag      | 415 |

<210> 22  
 <211> 405  
 <212> DNA  
 <213> Mus Musculus

|             |            |            |            |            |            |     |
|-------------|------------|------------|------------|------------|------------|-----|
| ttattatggc  | ttatcatgaa | aaaccagtcc | tgcctcctcc | tcttatcacc | ctcagccata | 60  |
| tagtttcaact | gttttgctgt | gtatgcaaaa | gaagaaagaa | agataagact | tccgatgggc | 120 |
| caaaactttt  | cttaacagaa | gaagatcaaa | agaaactcca | tgattttgaa | gagcagtgtg | 180 |
| ttgagatgta  | ctttgatgag | aaagatgaca | aattcaattc | tgggagtga  | gagagaatcc | 240 |
| gggtcacttt  | tgaagagtgt | gagcagatga | gcattcagat | taaagaagtt | ggagatcgtg | 300 |
| tcaactacat  | aaaaagatca | ttacagtctt | tagattctca | aattggtcac | ctgcaagatc | 360 |
| tctcagccct  | aacagtagat | acattgaaaa | cacttacagc | ccaga      |            | 405 |

<210> 23  
 <211> 5117  
 <212> DNA  
 <213> Homo Sapiens

<220>  
 <221> unsure  
 <222> (2382)...(2382)  
 <223> unknown

<221> unsure  
 <222> (4664)...(4664)  
 <223> unknown

<221> unsure  
 <222> (4682)...(4682)  
 <223> unknown

<221> unsure  
 <222> (4702)...(4702)  
 <223> unknown

<221> unsure  
 <222> (5038)...(5039)  
 <223> unknown

<221> unsure  
 <222> (5056) ... (5056)  
 <223> unknown

<221> unsure  
 <222> (5071) ... (5072)

<400> 23

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| gatggcaaca  | tgggtgaagaa | tcaatggcta  | aagcattagt  | tgcctgtaag  | atctatcggt  | 60   |
| caatggcata  | tgaagcaaag  | cagagtgacc  | tggtagatga  | tacttcagaa  | gaactaaaac  | 120  |
| agtattccaa  | tgattttggg  | cagttggccg  | ttgaattatt  | agaacagtcc  | ttcagacaag  | 180  |
| atgaaaccaa  | ggctatgaaa  | ttgctcactt  | atgaaactgaa | gaactggagt  | aattcaacct  | 240  |
| gccttaagtt  | agcagtttct  | tcaagactta  | gaccttttgt  | agctcacacc  | tgtacacaaa  | 300  |
| tgtttgtatc  | tgatatgtgg  | atgggaaggc  | tgaatatgag  | gaaaaattcc  | tgggtacaag  | 360  |
| tcatactaag  | catttttagtt | ccacctgcca  | tattgctgtt  | agagtataaa  | actaaggctg  | 420  |
| aaatgtccca  | tatcccacaa  | tctcaagatg  | ctcatcagat  | gacaatggat  | gacagcgaaa  | 480  |
| acaactttca  | gaacataaca  | gaagagatcc  | ccatggaagt  | gtttaaagaa  | gtacggattt  | 540  |
| tggatagtaa  | tgaaggaaaag | aatgagatgg  | agatacaaat  | gaaatcaaaa  | aagcttccaa  | 600  |
| ttacgcgaaa  | gttttatgcc  | ttttatcatg  | caccaattgt  | aaaattctgg  | tttaacacgt  | 660  |
| tggcatattt  | aggatttctg  | atgctttata  | catttgtggt  | tcttgtacaa  | atggaacagt  | 720  |
| taccttcagt  | tcaagaatgg  | attgttattg  | cttatatttt  | tacttatgcc  | attgagaaaag | 780  |
| tccgtgagat  | ctttatgtct  | gaagctggga  | aagtaaacca  | gaagattaaa  | gtatggttta  | 840  |
| gtgattactt  | caacatcagt  | gatacaattg  | ccataatttc  | tttcttcatt  | ggatttggac  | 900  |
| taagatttgg  | agcaaaatgg  | aactttgcaa  | atgcatatga  | taatcatggt  | tttgtggctg  | 960  |
| gaagattaat  | ttactgtctt  | aacataatat  | tttggtatgt  | gcgtttgcta  | gattttctag  | 1020 |
| ctgtaaataca | acaggcagga  | ccttatgtaa  | tgatgattgg  | aaaaatgggt  | gccaatatgt  | 1080 |
| tctacattgt  | agtgattatg  | gctcttgtat  | tacttagttt  | tgggtgtccc  | agaaaggcaa  | 1140 |
| tactttatcc  | tcatgaagca  | ccatcttgga  | ctcttgctaa  | agatatagtt  | tttcacccat  | 1200 |
| actggatgat  | ttttgggtgaa | gtttatgcat  | acgaaattga  | tgtgtgtgca  | aatgattctg  | 1260 |
| ttatccctca  | aatctgtggg  | cctgggacgt  | ggttgactcc  | atttcttcaa  | gcagctacc   | 1320 |
| tctttgtaca  | gtatataatt  | atggttaatc  | ttcttattgc  | atttttcaac  | aatgtgtatt  | 1380 |
| tacaagtgaa  | ggcaatttcc  | aatattgtat  | ggaagtacca  | gcgttatcat  | tttattatgg  | 1440 |
| cttatcatga  | gaaaccagtt  | ctgcctcttc  | cacttatcat  | tcttagccat  | atagtttctc  | 1500 |
| tgttttgctg  | catatgtaag  | agaagaaaaga | aagataagac  | ttccgatgga  | ccaaaacttt  | 1560 |
| tcttaacaga  | agaagatcaa  | aagaaacttc  | atgattttga  | agagcagtg   | gttgaaatgt  | 1620 |
| atttcaatga  | aaaagatgac  | aaatttcttc  | ctgggagtga  | agagagaatt  | cgtgtcactt  | 1680 |
| ttgaaagagt  | ggaacagatg  | tgcattcaga  | ttaaagaagt  | tggagatcgt  | gtcaactaca  | 1740 |
| taaaaagatc  | attacaatca  | ttagattctc  | aaattggcca  | tttgcaagat  | ctttcagccc  | 1800 |
| tgaaggtaga  | tacattaaaa  | acactcactg  | cccagaaagc  | gtcgggaagct | agcaaagttc  | 1860 |
| ataatgaaat  | cacacgagaa  | ctgagcattt  | ccaaacactt  | ggctcaaaac  | cttattgatg  | 1920 |
| atgggtcctgt | aagaccttct  | gtatggaaaa  | agcatgggtg  | tgtaaataca  | cttagctcct  | 1980 |
| ctcttcctca  | agggtgatctt | gaaagtaata  | atccttttca  | ttgtaatat   | ttaatgaaag  | 2040 |
| atgacaaaga  | tccccagtgt  | aatatatttg  | gtcaagactt  | acctgcagta  | ccccagagaa  | 2100 |
| aagaatttaa  | ttttccagag  | gctgggtcct  | cttctgggtc  | cttattccca  | agtgtctgtt  | 2160 |
| cccctccaga  | actgcgacag  | agactacatg  | gggtagaact  | cttaaaaaata | tttaataaaa  | 2220 |
| atcaaaaatt  | aggcagttca  | tctactagca  | taccacatct  | gtcatcccca  | ccaaccaa    | 2280 |
| tttttgtag   | tacaccatct  | cagccaagtt  | gcaaaagcca  | cttggaact   | ggaaccaaag  | 2340 |
| atcaagaaac  | tgtttgctct  | aaagctacag  | aaggagataa  | tncagaattt  | ggagcatttg  | 2400 |
| taggacacag  | agatagcatg  | gatttacaga  | ggtttaaaga  | aacatcaaac  | aagataaaaa  | 2460 |
| tactatccaa  | taacaatact  | tctgaaaaca  | ctttgaaacg  | agtgaattct  | cttgctggat  | 2520 |
| ttactgactg  | tcacagaact  | tccattcctg  | ttcattcaaa  | acaagcagaa  | aaaatcagta  | 2580 |
| gaaggccatc  | taccgaagac  | actcatgaag  | tagattccaa  | agcagcttta  | ataccggatt  | 2640 |
| ggttacaaga  | tagaccatca  | aacagagaaa  | tgccatctga  | agaaggaaca  | ttaaatggtc  | 2700 |
| tcacttctcc  | atttaagcca  | gctatggata  | caaattacta  | ttattcagct  | gtggaaagaa  | 2760 |
| ataacttgat  | gaggttatca  | cagagcattc  | catttacacc  | tgtgcctcca  | agaggggagc  | 2820 |
| ctgtcacagt  | gtatcgtttg  | gaagagagtt  | caccaacat   | actaaataac  | agcatgtctt  | 2880 |
| cttgggtcaca | actagccctc  | tgtgccaata  | tagagttttt  | aagcaaaagag | gagatgggag  | 2940 |
| gaggtttacg  | aagagctgtc  | aaagtacagt  | gtacctgggtc | agaacatgat  | atcctcaaat  | 3000 |
| cagggtcatct | ttatattatc  | aaatcttttc  | ttccagaggt  | ggttaaataca | tgggtcaagta | 3060 |
| tttataaaga  | agatacagtt  | ctgcatctct  | gtctgagaga  | aattcaacaa  | cagagagcag  | 3120 |



-33-

```

cacaaaagct tacgtttgcc tttaatcaaa tgaaacccaa atccatacca tattctccaa 3180
ggttccttga agttttcctg ctgtattgcc attcagcagg acagtgggtt gctgtggaag 3240
aatgtatgac tggagaattt agaaaataca acaataataa tggagatgag attattccaa 3300
ctaatactct ggaagagatc atgctagcct ttagccactg gacttacgaa tatacaagag 3360
gggagttact ggtacttgat ttgcaagggt ttgggtgaaaa ttgactgac ccatctgtga 3420
taaaagcaga agaaaagaga tcctgtgata tgggttttgg cccagcaa at taggagaag 3480
atgcaattaa aaacttcaga gcaaaacatc actgtaattc ttgctgtaga aagcttaa ac 3540
ttccagatct gaagaggaat gattatacgc ctgataaa at tatatttcct caggatgagc 3600
cttcagattt gaatcttcag cctggaaatt ccaccaaaga atcagaatca gctaattctg 3660
ttcgtctgat gttataatat taatattact gaatcattgg tttgcctgc acctcacaga 3720
aatgttactg tgtcactttt ccctcgggag gaaattgttt ggtaatatag aaaggtgtat 3780
gcaagttgaa tttgctgact ccagcacagt taaaagggtca atattctttt gacctgatta 3840
atcagtcaga aagtcacctat aggatagagc tggcagctga gaaattttta aggtaattga 3900
taattagtat ttgtaacttt ttaaagggtt ctttgtatag cagaggatct catttgactt 3960
tgttttgatg aggggtgatgc cctctcttat gtggtacaat accattaacc aaaggtaggt 4020
gtccatgcag attttattgg cagctgtttt attgccattc aactaggga atgaagaa at 4080
cacgcagcct tttggttaaa tggcagtc aaattttcctc agtgtattta gtgtgttcag 4140
tgatgatata actggttccc aactagatgc ttgttggcca cggaaggga aatgacttgt 4200
tctaattcta ggttcacaga ggtatgagaa gcctgaactg aagaccattt tcaagaggga 4260
cgggtatttt gaatcagggt taggctccat atttaaagat agagccagtt ttttttttaa 4320
atagaacca aattgtgtaa aaatgttaat tgggtttttt aaacatttgt ttatcaagtc 4380
actgttaagt agaagaaagc catggtaa ac tgatacataa cctaaattat aaaagcagaa 4440
acctaactca ctgcgtaagg gaagttacct tttgaggaaa gttaaagtac ttttttcctt 4500
atctgtatct atagcaacaa cccagaactt acaaacttct ccaaagattt tattgattgt 4560
tatatcaaat cagaatgtaa acatgaactc ttgcatatat ttaaaattgt gttggaacat 4620
ttgaacatga atgctgtttg ggtacttaag aaattrattc agtnggatta tcattatgtg 4680
anactggcag attgcagtgc anccttatgc caataaaatg taatttaaca gccccagata 4740
ttgttgataa ttcaacaata acaagaaaag cttttcatct aagttttatg ctttaatttt 4800
ttttcttttt ttttcttttt cttttgtttc cttgggtacta attttaattt ttatttgga 4860
gggagcagta taaagcttat ttgtatttag tagtgtatct catagataca gacaaggcaa 4920
gagatgataa gctgttttaa tagtgtttaa tattgattgg ggggtggggag aaagaaaaag 4980
tgtattactt aaagatacta tatacgtttt gtatatcatt aaatctttta aagaaatnna 5040
ataaatttat tgttttcaaa aaaaaaaccc nntaaaaaaa aaagggcggc ccctctagag 5100
gatccctcga ggggcc 5117

```

<210> 24  
 <211> 1224  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (794) ... (794)  
 <223> UNKNOWN

<400> 24  
 Trp Gln His Gly Glu Ser Met Ala Lys Ala Leu Val Ala Cys Lys  
 1 5 10 15  
 Ile Tyr Arg Ser Met Ala Tyr Glu Ala Lys Gln Ser Asp Leu Val Asp  
 20 25 30  
 Asp Thr Ser Glu Glu Leu Lys Gln Tyr Ser Asn Asp Phe Gly Gln Leu  
 35 40 45  
 Ala Val Glu Leu Leu Glu Gln Ser Phe Arg Gln Asp Glu Thr Met Ala  
 50 55 60  
 Met Lys Leu Leu Thr Tyr Glu Leu Lys Asn Trp Ser Asn Ser Thr Cys  
 65 70 75 80  
 Leu Lys Leu Ala Val Ser Ser Arg Leu Arg Pro Phe Val Ala His Thr  
 85 90 95

-34-

Cys Thr Gln Met Leu Leu Ser Asp Met Trp Met Gly Arg Leu Asn Met  
 100 105 110  
 Arg Lys Asn Ser Trp Tyr Lys Val Ile Leu Ser Ile Leu Val Pro Pro  
 115 120 125  
 Ala Ile Leu Leu Leu Glu Tyr Lys Thr Lys Ala Glu Met Ser His Ile  
 130 135 140  
 Pro Gln Ser Gln Asp Ala His Gln Met Thr Met Asp Asp Ser Glu Asn  
 145 150 155 160  
 Asn Phe Gln Asn Ile Thr Glu Glu Ile Pro Met Glu Val Phe Lys Glu  
 165 170 175  
 Val Arg Ile Leu Asp Ser Asn Glu Gly Lys Asn Glu Met Glu Ile Gln  
 180 185 190  
 Met Lys Ser Lys Lys Leu Pro Ile Thr Arg Lys Phe Tyr Ala Phe Tyr  
 195 200 205  
 His Ala Pro Ile Val Lys Phe Trp Phe Asn Thr Leu Ala Tyr Leu Gly  
 210 215 220  
 Phe Leu Met Leu Tyr Thr Phe Val Val Leu Val Gln Met Glu Gln Leu  
 225 230 235 240  
 Pro Ser Val Gln Glu Trp Ile Val Ile Ala Tyr Ile Phe Thr Tyr Ala  
 245 250 255  
 Ile Glu Lys Val Arg Glu Ile Phe Met Ser Glu Ala Gly Lys Val Asn  
 260 265 270  
 Gln Lys Ile Lys Val Trp Phe Ser Asp Tyr Phe Asn Ile Ser Asp Thr  
 275 280 285  
 Ile Ala Ile Ile Ser Phe Phe Ile Gly Phe Gly Leu Arg Phe Gly Ala  
 290 295 300  
 Lys Trp Asn Phe Ala Asn Ala Tyr Asp Asn His Val Phe Val Ala Gly  
 305 310 315 320  
 Arg Leu Ile Tyr Cys Leu Asn Ile Ile Phe Trp Tyr Val Arg Leu Leu  
 325 330 335  
 Asp Phe Leu Ala Val Asn Gln Gln Ala Gly Pro Tyr Val Met Met Ile  
 340 345 350  
 Gly Lys Met Val Ala Asn Met Phe Tyr Ile Val Val Ile Met Ala Leu  
 355 360 365  
 Val Leu Leu Ser Phe Gly Val Pro Arg Lys Ala Ile Leu Tyr Pro His  
 370 375 380  
 Glu Ala Pro Ser Trp Thr Leu Ala Lys Asp Ile Val Phe His Pro Tyr  
 385 390 395 400  
 Trp Met Ile Phe Gly Glu Val Tyr Ala Tyr Glu Ile Asp Val Cys Ala  
 405 410 415  
 Asn Asp Ser Val Ile Pro Gln Ile Cys Gly Pro Gly Thr Trp Leu Thr  
 420 425 430  
 Pro Phe Leu Gln Ala Val Tyr Leu Phe Val Gln Tyr Ile Ile Met Val  
 435 440 445  
 Asn Leu Leu Ile Ala Phe Phe Asn Asn Val Tyr Leu Gln Val Lys Ala  
 450 455 460  
 Ile Ser Asn Ile Val Trp Lys Tyr Gln Arg Tyr His Phe Ile Met Ala  
 465 470 475 480  
 Tyr His Glu Lys Pro Val Leu Pro Pro Pro Leu Ile Ile Leu Ser His  
 485 490 495  
 Ile Val Ser Leu Phe Cys Cys Ile Cys Lys Arg Arg Lys Lys Asp Lys  
 500 505 510  
 Thr Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp Gln Lys Lys  
 515 520 525  
 Leu His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe Asn Glu Lys  
 530 535 540  
 Asp Asp Lys Phe His Ser Gly Ser Glu Glu Arg Ile Arg Val Thr Phe  
 545 550 555 560  
 Glu Arg Val Glu Gln Met Cys Ile Gln Ile Lys Glu Val Gly Asp Arg  
 565 570 575

-35-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |      |      |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|
| Val | Asn | Tyr | Ile | Lys | Arg | Ser | Leu | Gln | Ser | Leu | Asp | Ser | Gln | Ile | Gly | 580  | 585  | 590  |
| His | Leu | Gln | Asp | Leu | Ser | Ala | Leu | Thr | Val | Asp | Thr | Leu | Lys | Thr | Leu | 595  | 600  | 605  |
| Thr | Ala | Gln | Lys | Ala | Ser | Glu | Ala | Ser | Lys | Val | His | Asn | Glu | Ile | Thr | 610  | 615  | 620  |
| Arg | Glu | Leu | Ser | Ile | Ser | Lys | His | Leu | Ala | Gln | Asn | Leu | Ile | Asp | Asp | 625  | 630  | 635  |
| Gly | Pro | Val | Arg | Pro | Ser | Val | Trp | Lys | Lys | His | Gly | Val | Val | Asn | Thr | 645  | 650  | 655  |
| Leu | Ser | Ser | Ser | Leu | Pro | Gln | Gly | Asp | Leu | Glu | Ser | Asn | Asn | Pro | Phe | 660  | 665  | 670  |
| His | Cys | Asn | Ile | Leu | Met | Lys | Asp | Asp | Lys | Asp | Pro | Gln | Cys | Asn | Ile | 675  | 680  | 685  |
| Phe | Gly | Gln | Asp | Leu | Pro | Ala | Val | Pro | Gln | Arg | Lys | Glu | Phe | Asn | Phe | 690  | 695  | 700  |
| Pro | Glu | Ala | Gly | Ser | Ser | Ser | Gly | Ala | Leu | Phe | Pro | Ser | Ala | Val | Ser | 705  | 710  | 715  |
| Pro | Pro | Glu | Leu | Arg | Gln | Arg | Leu | His | Gly | Val | Glu | Leu | Leu | Lys | Ile | 725  | 730  | 735  |
| Phe | Asn | Lys | Asn | Gln | Lys | Leu | Gly | Ser | Ser | Thr | Ser | Ile | Pro | His |     | 740  | 745  | 750  |
| Leu | Ser | Ser | Pro | Pro | Thr | Lys | Phe | Phe | Val | Ser | Thr | Pro | Ser | Gln | Pro | 755  | 760  | 765  |
| Ser | Cys | Lys | Ser | His | Leu | Glu | Thr | Gly | Thr | Lys | Asp | Gln | Glu | Thr | Val | 770  | 775  | 780  |
| Cys | Ser | Lys | Ala | Thr | Glu | Gly | Asp | Asn | Xaa | Glu | Phe | Gly | Ala | Phe | Val | 785  | 790  | 795  |
| Gly | His | Arg | Asp | Ser | Met | Asp | Leu | Gln | Arg | Phe | Lys | Glu | Thr | Ser | Asn | 805  | 810  | 815  |
| Lys | Ile | Lys | Ile | Leu | Ser | Asn | Asn | Asn | Thr | Ser | Glu | Asn | Thr | Leu | Lys | 820  | 825  | 830  |
| Arg | Val | Ser | Ser | Leu | Ala | Gly | Phe | Thr | Asp | Cys | His | Arg | Thr | Ser | Ile | 835  | 840  | 845  |
| Pro | Val | His | Ser | Lys | Gln | Ala | Glu | Lys | Ile | Ser | Arg | Arg | Pro | Ser | Thr | 850  | 855  | 860  |
| Glu | Asp | Thr | His | Glu | Val | Asp | Ser | Lys | Ala | Ala | Leu | Ile | Pro | Asp | Trp | 865  | 870  | 875  |
| Leu | Gln | Asp | Arg | Pro | Ser | Asn | Arg | Glu | Met | Pro | Ser | Glu | Glu | Gly | Thr | 885  | 890  | 895  |
| Leu | Asn | Gly | Leu | Thr | Ser | Pro | Phe | Lys | Pro | Ala | Met | Asp | Thr | Asn | Tyr | 900  | 905  | 910  |
| Tyr | Tyr | Ser | Ala | Val | Glu | Arg | Asn | Asn | Leu | Met | Arg | Leu | Ser | Gln | Ser | 915  | 920  | 925  |
| Ile | Pro | Phe | Thr | Pro | Val | Pro | Pro | Arg | Gly | Glu | Pro | Val | Thr | Val | Tyr | 930  | 935  | 940  |
| Arg | Leu | Glu | Glu | Ser | Ser | Pro | Asn | Ile | Leu | Asn | Asn | Ser | Met | Ser | Ser | 945  | 950  | 955  |
| Trp | Ser | Gln | Leu | Gly | Leu | Cys | Ala | Lys | Ile | Glu | Phe | Leu | Ser | Lys | Glu | 965  | 970  | 975  |
| Glu | Met | Gly | Gly | Gly | Leu | Arg | Arg | Ala | Val | Lys | Val | Gln | Cys | Thr | Trp | 980  | 985  | 990  |
| Ser | Glu | His | Asp | Ile | Leu | Lys | Ser | Gly | His | Leu | Tyr | Ile | Ile | Lys | Ser | 995  | 1000 | 1005 |
| Phe | Leu | Pro | Glu | Val | Val | Asn | Thr | Trp | Ser | Ser | Ile | Tyr | Lys | Glu | Asp | 1010 | 1015 | 1020 |
| Thr | Val | Leu | His | Leu | Cys | Leu | Arg | Glu | Ile | Gln | Gln | Gln | Arg | Ala | Ala | 1025 | 1030 | 1035 |
| Gln | Lys | Leu | Thr | Phe | Ala | Phe | Asn | Gln | Met | Lys | Pro | Lys | Ser | Ile | Pro | 1045 | 1050 | 1055 |

-36-

Tyr Ser Pro Arg Phe Leu Glu Val Phe Leu Leu Tyr Cys His Ser Ala  
 1060 1065 1070  
 Gly Gln Trp Phe Ala Val Glu Glu Cys Met Thr Gly Glu Phe Arg Lys  
 1075 1080 1085  
 Tyr Asn Asn Asn Asn Gly Asp Glu Ile Ile Pro Thr Asn Thr Leu Glu  
 1090 1095 1100  
 Glu Ile Met Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr Arg Gly  
 1105 1110 1115 112  
 Glu Leu Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn Leu Thr Asp  
 1125 1130 1135  
 Pro Ser Val Ile Lys Ala Glu Glu Lys Arg Ser Cys Asp Met Val Phe  
 1140 1145 1150  
 Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Lys Asn Phe Arg Ala Lys  
 1155 1160 1165  
 His His Cys Asn Ser Cys Cys Arg Lys Leu Lys Leu Pro Asp Leu Lys  
 1170 1175 1180  
 Arg Asn Asp Tyr Thr Pro Asp Lys Ile Ile Phe Pro Gln Asp Glu Pro  
 1185 1190 1195 120  
 Ser Asp Leu Asn Leu Gln Pro Gly Asn Ser Thr Lys Glu Ser Glu Ser  
 1205 1210 1215  
 Ala Asn Ser Val Arg Leu Met Leu  
 1220

&lt;210&gt; 25

&lt;211&gt; 2180

&lt;212&gt; DNA

&lt;213&gt; Homo Sapiens

&lt;400&gt; 25

|            |            |             |             |             |             |      |
|------------|------------|-------------|-------------|-------------|-------------|------|
| tcgaggccaa | gaattcgcca | cgagggcctc  | gggcaggccc  | cctggagcga  | cctgcttctt  | 60   |
| tgggcactgt | tgctgaacag | ggcacagatg  | gccatgtact  | tctgggagat  | gggttccaat  | 120  |
| gcagtttctt | cagctcttgg | ggcctgtttg  | ctgctccggg  | tgatggcacg  | cctggagcct  | 180  |
| gacgctgagg | aggcagcacg | gaggaaaagac | ctggcggttca | agtttgaggg  | gatgggcgtt  | 240  |
| gacctctttg | gcgagtgtta | tcgcagcagt  | gaggtgaggg  | ctgcccgcct  | cctcctccgt  | 300  |
| cgctgcccgc | tctgggggga | tgccacttgc  | ctccagctgg  | ccatgcaagc  | tgacgcccgt  | 360  |
| gccttctttg | cccaggatgg | ggtacagtct  | ctgctgacac  | agaagtgggt  | gggagatatg  | 420  |
| gccagcacta | cacccatctg | ggccctggtt  | ctgccttctt  | tttgccctcc  | actcatctac  | 480  |
| acccgcctca | tcaccttcag | gaaatcagaa  | gaggagccca  | cacgggagga  | gctagagttt  | 540  |
| gacatggata | gtgtcattaa | tggggaagg   | cctgtcggga  | cggcggaccc  | agccgagaag  | 600  |
| acgccgctgg | gggtcccgcg | ccagtcgggc  | cgtcggggtt  | gctgcggggg  | ccgctgcggg  | 660  |
| gggcgcgggt | gcctacgccg | ctggttccac  | ttctggggcg  | cgccgggtgac | catcttcatg  | 720  |
| ggcaacgtgg | tcagctacct | gctgttcttg  | ctgtcttctt  | cgcgggtgct  | gctcgtggat  | 780  |
| ttccagccgg | cgccgcccgg | ctccctggag  | ctgctgtctt  | atttctgggc  | tttcacgctg  | 840  |
| ctgtgcgagg | aactgcgcca | gggcctgagc  | ggaggcgggg  | gcagcctcgc  | cagcgggggc  | 900  |
| cccgggcctg | gccatgcctc | actgagccag  | cgcttgcgcc  | tctacctcgc  | cgacagctgg  | 960  |
| aaccagtgcg | acctagtggc | tctcacctgc  | ttcctcctgg  | gcgtgggctg  | ccggtgacc   | 1020 |
| ccgggtttgt | accacctggg | ccgcactgtc  | ctctgcctcg  | acttcatggt  | tttcacgggtg | 1080 |
| cggctgcttc | acatcttcac | ggtcaacaaa  | cagctggggc  | ccaagatcgt  | catcgtgagc  | 1140 |
| aagatgatga | aggacgtgtt | cttcttcctc  | ttcttctcgc  | gcgtgtggct  | ggtagcctat  | 1200 |
| ggcgtggcca | cggagggtct | cctgaggcca  | cgggacagtg  | acttcccaag  | tatcctgcgc  | 1260 |
| cgctcttctt | accgtcccta | cctgcagatc  | ttcgggcaga  | ttccccagga  | ggacatggac  | 1320 |
| gtggccctca | tggagcacag | caactgctcg  | tcggagcccg  | gcttctgggc  | acaccctcct  | 1380 |
| ggggcccagg | cgggcacctg | cgtctcccag  | tatgccaaact | ggctgggtgt  | gctgtctctc  | 1440 |
| gtcatcttcc | tgctcgtggc | caacatcctg  | ctgggtcaact | tgctcattgc  | catgttccagt | 1500 |
| tacacattcg | gcaaagtaca | gggcaacagc  | gatctctact  | ggaaggcgca  | gcgttaccgc  | 1560 |
| ctcatccggg | aattccactc | tcggcccgcg  | ctggcccgcg  | cctttatcgt  | catctccac   | 1620 |
| ttgcgcctcc | tgctcaggca | attgtgcagg  | cgaccscgga  | gccccagcc   | gtcctccccg  | 1680 |
| gccctcgagc | atttccgggt | ttacctttct  | aaggaagccg  | agcggaagct  | gctaacgtgg  | 1740 |
| gaatcggtgc | ataaggagaa | ctttctgctg  | gcacgcgcta  | gggacaagcg  | ggagagcgac  | 1800 |
| tccgagmgtc | tgaagcgcac | gtcccagaag  | gtggacttgg  | caactgaaaca | gctgggacac  | 1860 |

-37-

```

atccgcgagt acgaacagcg cctgaaagtg ctggagcggg aggtccagca gtgtacctcg 1920
gccccgcac ctgggtggcct tgccttgag gtgagcccca tgtccatctg ggccactgtc 1980
aggaccacct ttgggagtgt catccttaca aaccacagca tgcccggctc ctcccagaac 2040
cagtcccagc ctgggaggat caaggcctgg atcccrggcc gttatccatc tggaggctgc 2100
agggtccttg gggtaacagg gaccacagac ccctcaccac tcacagattc ctcacactgg 2160
ggaaataaag ccatttcaga 2180

```

<210> 26  
 <211> 725  
 <212> PRT  
 <213> Homo Sapiens

<220>  
 <221> UNSURE  
 <222> (553)...(553)  
 <223> UNKNOWN

<221> UNSURE  
 <222> (603)...(603)  
 <223> UNKNOWN

<400> 26

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Arg | Pro | Arg | Ile | Arg | His | Glu | Gly | Leu | Gly | Gln | Ala | Pro | Trp | Ser |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Asp | Leu | Leu | Leu | Trp | Ala | Leu | Leu | Leu | Asn | Arg | Ala | Gln | Met | Ala | Met |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Tyr | Phe | Trp | Glu | Met | Gly | Ser | Asn | Ala | Val | Ser | Ser | Ala | Leu | Gly | Ala |
|     |     | 35  |     |     |     | 40  |     |     |     |     |     | 45  |     |     |     |
| Cys | Leu | Leu | Leu | Arg | Val | Met | Ala | Arg | Leu | Glu | Pro | Asp | Ala | Glu | Glu |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Ala | Ala | Arg | Arg | Lys | Asp | Leu | Ala | Phe | Lys | Phe | Glu | Gly | Met | Gly | Val |
| 65  |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     |     | 80  |
| Asp | Leu | Phe | Gly | Glu | Cys | Tyr | Arg | Ser | Ser | Glu | Val | Arg | Ala | Ala | Arg |
|     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |     |
| Leu | Leu | Leu | Arg | Arg | Cys | Pro | Leu | Trp | Gly | Asp | Ala | Thr | Cys | Leu | Gln |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Leu | Ala | Met | Gln | Ala | Asp | Ala | Arg | Ala | Phe | Phe | Ala | Gln | Asp | Gly | Val |
|     |     | 115 |     |     |     | 120 |     |     |     |     |     | 125 |     |     |     |
| Gln | Ser | Leu | Leu | Thr | Gln | Lys | Trp | Trp | Gly | Asp | Met | Ala | Ser | Thr | Thr |
|     |     | 130 |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Pro | Ile | Trp | Ala | Leu | Val | Leu | Ala | Phe | Phe | Cys | Pro | Pro | Leu | Ile | Tyr |
| 145 |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     |     | 160 |
| Thr | Arg | Leu | Ile | Thr | Phe | Arg | Lys | Ser | Glu | Glu | Glu | Pro | Thr | Arg | Glu |
|     |     |     | 165 |     |     |     |     | 170 |     |     |     |     |     | 175 |     |
| Glu | Leu | Glu | Phe | Asp | Met | Asp | Ser | Val | Ile | Asn | Gly | Glu | Gly | Pro | Val |
|     |     | 180 |     |     |     | 185 |     |     |     |     |     | 190 |     |     |     |
| Gly | Thr | Ala | Asp | Pro | Ala | Glu | Lys | Thr | Pro | Leu | Gly | Val | Pro | Arg | Gln |
|     |     | 195 |     |     |     | 200 |     |     |     |     |     | 205 |     |     |     |
| Ser | Gly | Arg | Pro | Gly | Cys | Cys | Gly | Gly | Arg | Cys | Gly | Gly | Arg | Arg | Cys |
|     | 210 |     |     |     | 215 |     |     |     |     |     | 220 |     |     |     |     |
| Leu | Arg | Arg | Trp | Phe | His | Phe | Trp | Gly | Ala | Pro | Val | Thr | Ile | Phe | Met |
| 225 |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     |     | 240 |
| Gly | Asn | Val | Val | Ser | Tyr | Leu | Leu | Phe | Leu | Leu | Leu | Phe | Ser | Arg | Val |
|     |     |     | 245 |     |     |     |     | 250 |     |     |     |     |     | 255 |     |
| Leu | Leu | Val | Asp | Phe | Gln | Pro | Ala | Pro | Pro | Gly | Ser | Leu | Glu | Leu | Leu |
|     |     | 260 |     |     |     |     | 265 |     |     |     |     |     | 270 |     |     |
| Leu | Tyr | Phe | Trp | Ala | Phe | Thr | Leu | Leu | Cys | Glu | Glu | Leu | Arg | Gln | Gly |
|     | 275 |     |     |     |     | 280 |     |     |     |     |     | 285 |     |     |     |
| Leu | Ser | Gly | Gly | Gly | Gly | Ser | Leu | Ala | Ser | Gly | Gly | Pro | Gly | Pro | Gly |
|     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |

-38-

His Ala Ser Leu Ser Gln Arg Leu Arg Leu Tyr Leu Ala Asp Ser Trp  
 305 310 315 320  
 Asn Gln Cys Asp Leu Val Ala Leu Thr Cys Phe Leu Leu Gly Val Gly  
 325 330 335  
 Cys Arg Leu Thr Pro Gly Leu Tyr His Leu Gly Arg Thr Val Leu Cys  
 340 345 350  
 Ile Asp Phe Met Val Phe Thr Val Arg Leu Leu His Ile Phe Thr Val  
 355 360 365  
 Asn Lys Gln Leu Gly Pro Lys Ile Val Ile Val Ser Lys Met Met Lys  
 370 375 380  
 Asp Val Phe Phe Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr  
 385 390 395 400  
 Gly Val Ala Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro  
 405 410 415  
 Ser Ile Leu Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gln Ile Phe Gly  
 420 425 430  
 Gln Ile Pro Gln Glu Asp Met Asp Val Ala Leu Met Glu His Ser Asn  
 435 440 445  
 Cys Ser Ser Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gln Ala  
 450 455 460  
 Gly Thr Cys Val Ser Gln Tyr Ala Asn Trp Leu Val Val Leu Leu Leu  
 465 470 475 480  
 Val Ile Phe Leu Leu Val Ala Asn Ile Leu Leu Val Asn Leu Leu Ile  
 485 490 495  
 Ala Met Phe Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu  
 500 505 510  
 Tyr Trp Lys Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg  
 515 520 525  
 Pro Ala Leu Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu  
 530 535 540  
 Leu Arg Gln Leu Cys Arg Arg Pro Xaa Ser Pro Gln Pro Ser Ser Pro  
 545 550 555 560  
 Ala Leu Glu His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys  
 565 570 575  
 Leu Leu Thr Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg  
 580 585 590  
 Ala Arg Asp Lys Arg Glu Ser Asp Ser Glu Xaa Leu Lys Arg Thr Ser  
 595 600 605  
 Gln Lys Val Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr  
 610 615 620  
 Glu Gln Arg Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Thr Ser  
 625 630 635 640  
 Ala Pro Ala Pro Gly Gly Leu Val Leu Glu Val Ser Pro Met Ser Ile  
 645 650 655  
 Trp Ala Thr Val Arg Thr Thr Phe Gly Ser Val Ile Leu Thr Asn His  
 660 665 670  
 Ser Met Pro Gly Ser Ser Gln Asn Gln Ser Gln Pro Gly Arg Ile Lys  
 675 680 685  
 Ala Trp Ile Pro Gly Arg Tyr Pro Ser Gly Gly Cys Arg Val Leu Gly  
 690 695 700  
 Val Thr Gly Thr Thr Asp Pro Ser Pro Leu Thr Asp Ser Ser His Trp  
 705 710 715 720  
 Gly Asn Lys Ala Ile  
 725

<210> 27  
 <211> 7419  
 <212> DNA  
 <213> Homo Sapiens

&lt;400&gt; 27

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| cggggaccga  | tocagcctcc  | ggactctagc  | ctaggctttt  | gcaaaaagct  | atttaggtga  | 60   |
| cactatagaa  | ggtacgcctg  | caggtaccgg  | tccggaattc  | ccgggtcgac  | ccacgcgtcc  | 120  |
| gcagccccgt  | cgccggcgga  | ggcgggcgcg  | ggcgcgtnc   | ctgtggccag  | tcacccggag  | 180  |
| gagttggctg  | cacaattatg  | aaagactcgg  | cttctgctgc  | tagcgccgga  | gctgagttag  | 240  |
| ttctgagaag  | gtttccctgg  | gcgttccttg  | tccggcgggc  | tctgctgccg  | cctccggaga  | 300  |
| cgcttcccga  | tagatggcta  | caggcccgcg  | aggaggagga  | ggtggagtgt  | ctgcccttcc  | 360  |
| ggagtccgcc  | ccgtgaggag  | aatgtcccag  | aaatcctgga  | tagaaaagcac | tttgaccaag  | 420  |
| agggaaatgtg | tatatattat  | accaagttcc  | aaggaccctc  | acagatgcct  | tccaggatgt  | 480  |
| caaatttgct  | agcaactcgt  | caggtgtttt  | tgtggctcgt  | tggccaagca  | acatgcttgt  | 540  |
| tttactgcaa  | gtcttgccat  | gaaatactca  | gatgtgaaat  | tgggtgacca  | ttttaatcag  | 600  |
| gcaatagaag  | aatggtctgt  | ggaaaagcat  | acagaacaga  | gccaacgga   | tgcttatgga  | 660  |
| gtcataaatt  | ttcaaggggg  | ttctcattcc  | tacagagcta  | agtatgtgag  | gctatcatat  | 720  |
| gacaccaaac  | ctgaagtcac  | tctgcaactt  | ctgcttaaac  | aatggcaaat  | ggagttaccc  | 780  |
| aaacttgcta  | tctctgtaca  | tgggggcatg  | cagaaatttg  | agcttcaccc  | acgaatcaag  | 840  |
| cagttgcttg  | gaaaaggtct  | tattaaagct  | gcagttacaa  | ctggagcctg  | gattttaact  | 900  |
| ggaggagtaa  | acacaggtgt  | ggcaaaacat  | gttgagatg   | ccctcaagaa  | acatgcttcc  | 960  |
| agatcatctc  | gaaagatttg  | cactatcgga  | atagctccat  | ggggagtgat  | tgaaaacaga  | 1020 |
| aatgatcttg  | ttgggagaga  | tgtggttgct  | ccttatcaaa  | ccttattgaa  | ccccctgagc  | 1080 |
| aaattgaatg  | ttttgaataa  | tctgcattcc  | catttcatat  | tgggtggatga | tggaactggt  | 1140 |
| ggaaagtatg  | gggcggaagt  | cagactgaga  | agagaacttg  | aaaaaactat  | taatcagcaa  | 1200 |
| agaatttcag  | ctaggattgg  | ccaggggtgc  | cctgtgggtg  | cacttatatt  | tgaggggtgg  | 1260 |
| ccaaatgcta  | tcctcacagt  | tcttgaatac  | cttcaggaaa  | gccccctgt   | tccagtgtgt  | 1320 |
| gtgtgtgaag  | gaacaggcag  | agctgcagat  | ctgctagcgt  | atattcataa  | acaaacagaa  | 1380 |
| gaaggaggga  | atcttctctga | tgcagcagag  | ccgatatta   | tttccactat  | caaaaaaaca  | 1440 |
| tttaactttg  | gccagaatga  | agcacttcat  | ttatttcaaa  | cactgatgga  | gtgcatgaaa  | 1500 |
| agaaaggagc  | ttatcactgt  | tttccatatt  | gggtcagatg  | aacatcaaga  | tatagatgta  | 1560 |
| gcaatactta  | ctgcactgct  | aaaagggtact | aatgcactctg | catttgacca  | gcttatcctt  | 1620 |
| acattggcat  | gggatagagt  | tgacattgcc  | aaaaactcatg | tatttggtta  | tgagcagcag  | 1680 |
| tggtgtgttg  | gactccttga  | acaagctatg  | cttgatgctc  | ttgtaatgga  | tagagttgca  | 1740 |
| tttgtaaaac  | ttcttattga  | aaatggagta  | agcatgcata  | aattccttac  | cattccgaga  | 1800 |
| ctggaagaac  | tttacaacac  | taaacaaggt  | ccaactaatc  | caatgctgtt  | tcatcttggt  | 1860 |
| cgagacgtca  | aacagggaac  | tcttcctcca  | ggatataaga  | tcaactctgat | tgatatagga  | 1920 |
| cttggtattg  | aatatctcat  | gggaggaacc  | tacagatgca  | cctatactag  | gaaacgtttt  | 1980 |
| cgattaatat  | ataatagtct  | tgggtggaat  | aatcggaggt  | ctggccgaaa  | tacctccagc  | 2040 |
| agcactcctc  | agttgcgaaa  | gagtcatgaa  | tcttttgcca  | atagggcaga  | taaaaaggaa  | 2100 |
| aaaatgaggc  | ataaccattt  | cattaagaca  | gcacagccct  | tccgaccaa   | gattgataca  | 2160 |
| gttatggaag  | aaggaaagaa  | gaaaagaacc  | aaagatgaaa  | ttgtagacat  | tgatgatcca  | 2220 |
| gaaaccaagc  | gctttcctta  | tccacttaat  | gaacttttaa  | tttgggcttg  | ccttatgaag  | 2280 |
| aggcaggtca  | tggcccgttt  | tttatggcaa  | catggtgaag  | aatcaatggc  | taaagcatta  | 2340 |
| gttgctgtga  | agatctatcg  | ttcaatggca  | tatgaagcaa  | agcagagtga  | cctggtagat  | 2400 |
| gatacttcag  | aagaactaaa  | acagtattcc  | aatgattttg  | gtcagttggc  | cgttgaatta  | 2460 |
| ttagaacagt  | ccttcagaca  | agatgaaacc  | atggctatga  | aattgctcac  | ttatgaactg  | 2520 |
| aagaactgga  | gtaattcaac  | ctgccttaag  | ttagcagttt  | cttcaagact  | tagacctttt  | 2580 |
| gtagctcaca  | cctgtacaca  | aatgttggtt  | tctgatatgt  | ggatgggaag  | gctgaatatg  | 2640 |
| aggaaaaatt  | cctggtagaa  | ggtcatacta  | agcatttttag | ttccacctgc  | catattgctg  | 2700 |
| ttagagtata  | aaactaaggc  | tgaaatgtcc  | catatcccac  | aatctcaaga  | tgctcatcag  | 2760 |
| atgacaatgg  | atgacagcga  | aaacaacttt  | cagaacataa  | cagaagagat  | ccccatggaa  | 2820 |
| gtgtttaaag  | aagtacggat  | tttggaagt   | aatgaaggaa  | agaatgagat  | ggagatacaa  | 2880 |
| atgaaatcaa  | aaaagcttcc  | aattacgcga  | aagttttatg  | ccttttatca  | tgaccaaat   | 2940 |
| gtaaaattct  | ggtttaacac  | gttggcatat  | ttaggatttc  | tgatgcttta  | tacatttggt  | 3000 |
| gttcttgtag  | aaatggaaca  | gttaccttca  | gttcaagaat  | ggattgttat  | tgcttatatt  | 3060 |
| tttacttatg  | ccattgagaa  | agtccgtgag  | atctttatgt  | ctgaagctgg  | gaaagtaaac  | 3120 |
| cagaagatta  | aagtatggtt  | tagtgattac  | ttcaacatca  | gtgatacaat  | tgccataatt  | 3180 |
| tctttcttca  | ttggatttgg  | actaagattt  | ggagcaaaa   | ggaactttgc  | aaatgcatat  | 3240 |
| gataatcatg  | tttttgggc   | tggaagatta  | atttactgtc  | ttaacataat  | attttgggtat | 3300 |
| gtgcgtttgt  | tagattttct  | agctgtaaat  | caacaggcag  | gaccttatgt  | aatgatgatt  | 3360 |
| ggaaaaatgg  | tggccaatat  | gttctacatt  | gtagtgatta  | tggctcttgt  | attacttagt  | 3420 |
| tttggtgttc  | ccagaaaggc  | aatactttat  | cctcatgaag  | caccatcttg  | gactcttgct  | 3480 |
| aaagatatag  | tttttcaccc  | atactggatg  | attttgggtg  | aagtttatgc  | atacgaat    | 3540 |

-40-

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| gatgtgtgtg  | caaatgattc  | tgttatccct  | caaatctgtg  | gtcctgggac  | gtgggtgact  | 3600 |
| ccattttctt  | aagcagtcta  | cctctttgta  | caztatatca  | ttaiggttaa  | tcttcttatt  | 3660 |
| gcattttttca | acaatgtgta  | tttacaagtg  | aazgcaattt  | ccaatattgt  | atggaagtac  | 3720 |
| cagcgttatc  | atatttattat | ggcttatcat  | gagaaaccag  | ttctgcctcc  | tccacttatc  | 3780 |
| attcttagcc  | atatagtttc  | tctgttttgc  | tgcataatgta | agagaagaaa  | gaaagataag  | 3840 |
| acttccgatg  | gacccaaaact | tttcttaaca  | gaagaagatc  | aaaagaaaact | tcatgatttt  | 3900 |
| gaagagcagt  | gtgttgaaat  | gtatttcaat  | gaaaaagatg  | acaaatttca  | ttctgggagt  | 3960 |
| gaagagagaa  | ttcgtgtcac  | ttttgaaaga  | gtggaacaga  | tgtgcattca  | gattaaagaa  | 4020 |
| gttgagagtc  | gtgtcaacta  | cataaaaaga  | tcattacaat  | cattagattc  | tcaaatgggc  | 4080 |
| catttgcaag  | atctttcagc  | cctgacggta  | gatacattaa  | aaacactcac  | tgcccagaaa  | 4140 |
| gcgtcggaag  | ctagcaaagt  | tcataatgaa  | atcacacgag  | aactgagcat  | ttccaaacac  | 4200 |
| ttggctcaaa  | accttattga  | tgatggctct  | gtaagacctt  | ctgtatggaa  | aaagcatggg  | 4260 |
| gttgtaaaata | cacttagctc  | ctctcttcct  | caagggtgatc | ttgaaagtaa  | taatcctttt  | 4320 |
| cattgtaata  | ttttaatgaa  | agatgacaaa  | gatccccagt  | gtaatatatt  | tgggtcaagac | 4380 |
| ttacctgacg  | taccccagag  | aaaagaattt  | aattttccag  | aggtctgggtc | ctcttctggg  | 4440 |
| gcctttattcc | caagtgtctg  | ttcccctcca  | gaactgcgac  | agagactaca  | tggggtagaa  | 4500 |
| ctcttaaaaa  | tatttaataa  | aatcaaaaaa  | ttaggcagtt  | catctactag  | cataccacat  | 4560 |
| ctgtcatccc  | caccaaccaa  | attttttgtt  | agtacaccat  | ctcagccaag  | ttgcaaaagc  | 4620 |
| cacttggaag  | ctggaaccaa  | agatcaagaa  | actgtttgct  | ctaaagctac  | agaaggagat  | 4680 |
| aatacagaat  | ttggagcatt  | tgtaggacac  | agagatagca  | tggattttaca | gagggtttaaa | 4740 |
| gaaacatcaa  | acaagataaa  | aatactatcc  | aataacaata  | cttctgaaaa  | cactttgaaa  | 4800 |
| cgagtgaagt  | ctctttgctgg | atttactgac  | tgtcacagaa  | cttccattcc  | tgttcattca  | 4860 |
| aaacaagcag  | aaaaaatcag  | tagaaggcca  | cttaccgaag  | acactcatga  | agtagattcc  | 4920 |
| aaagcagctt  | taataccgga  | ttggttacaa  | gatagaccat  | caaacagaga  | aatgccatct  | 4980 |
| gaagaaggaa  | cattaaatgg  | tctcacttct  | ccatttaagc  | cagctatgga  | tacaaattac  | 5040 |
| tattattcag  | ctgtggaag   | aaataaactg  | atgagggttat | cacagagcat  | tccattttaca | 5100 |
| cctgtgcctc  | caagagggga  | gcctgtcaca  | gtgtatcggt  | tggaagagag  | ttcacccaac  | 5160 |
| atactaaata  | acagcatgtc  | ttcttgggtca | caactaggcc  | tctgtgccaa  | aatagagttt  | 5220 |
| ttaagcaag   | aggagatggg  | aggaggttta  | cgaagagctg  | tcaaagtaca  | gtgtacctgg  | 5280 |
| tcagaacatg  | atatcctcaa  | atcagggcat  | ctttatatta  | tcaaactctt  | tcttccagag  | 5340 |
| gtgggttaata | catggtcaag  | tattttataaa | gaagatacag  | ttctgcatct  | ctgtctgaga  | 5400 |
| gaaattcaac  | aacagagagc  | agcacaaaag  | cttacgtttg  | cctttaatca  | aatgaaaccc  | 5460 |
| aaatccatac  | catattctcc  | aaggttccct  | gaagttttcc  | tgctgtattg  | ccattcagca  | 5520 |
| ggacagtggg  | ttgctgtgga  | agaatgtatg  | actggagaat  | ttagaaaaata | caacaataat  | 5580 |
| aatggagatg  | agattattcc  | aactaatact  | ctggaagaga  | tcatgctagc  | ctttagccac  | 5640 |
| tggacttaag  | aataatacag  | aggggagtta  | ctggtagctg  | atttgcaagg  | tgttggtgaa  | 5700 |
| aatttgactg  | acccatctgt  | gataaaaagca | gaagaaaaga  | gatcctgtga  | tatgggtttt  | 5760 |
| ggcccagcaa  | atctaggaga  | agatgcaatt  | aaaaacttca  | gagcaaaaca  | tactgtaat   | 5820 |
| tcttgctgta  | gaaagcttaa  | acttccagat  | ctgaagagga  | atgattatac  | gcctgataaa  | 5880 |
| atttatatttc | ctcaggatga  | gccttcagat  | ttgaatcttc  | agcctggaaa  | ttccacccaa  | 5940 |
| gaatcagaat  | caactaattc  | tgttcgtctg  | atgtttataat | attaatatta  | ctgaatcatt  | 6000 |
| ggttttgcct  | gcacctcaca  | gaaatgttac  | tgtgtcactt  | ttccctcggg  | aggaaattgt  | 6060 |
| ttggtaatat  | agaaagggtg  | atgcaagttg  | aattttgctga | ctccagcaca  | gttaaaagggt | 6120 |
| caatattctt  | ttgacctgat  | taatcagtc   | gaaagtccct  | ataggataga  | gctggcagct  | 6180 |
| gagaaatttt  | aaaggtaatt  | gataattagt  | atttgttaact | ttttaaaagg  | ctctttgtat  | 6240 |
| agcagaggat  | ctcatttgac  | tttgttttga  | tgagggtgat  | gccctctctt  | atgtggtaca  | 6300 |
| ataccattaa  | ccaaaggtag  | gtgtccatgc  | agattttatt  | ggcagctgtt  | ttattgccat  | 6360 |
| tcaactaggg  | aaatgaagaa  | atcacgcagc  | cttttggtta  | aatggcagtc  | aaaaatttcc  | 6420 |
| tcagtgtatt  | tagtgtgttc  | agtgatgata  | tcactgggtc  | ccaactagat  | gcttgtgggc  | 6480 |
| cacgggaagg  | gaaatgactt  | gttctaattc  | taggttcaca  | gaggtagag   | aagcctgaac  | 6540 |
| tgaagaccat  | tttcaagagg  | gacgggtattt | atgaatcagg  | gttaggctcc  | atatttaaaag | 6600 |
| atagagccag  | tttttttttt  | aaatagaacc  | caaattgtgt  | aaaaatgtta  | attgggtttt  | 6660 |
| ttaaacattg  | ttttatcaag  | tcactgttaa  | gtagaagaaa  | gccatggtaa  | actgatacat  | 6720 |
| aacctaaatt  | ataaaagcag  | aaacctaaact | cactcgtcaa  | gggaagtta   | cttttgagga  | 6780 |
| aagttaaaagt | acttttttcc  | ctatctgtat  | ctatagcaac  | aaccagaac   | ttacaaactt  | 6840 |
| ctccaaagat  | tttattgatt  | gttatatcaa  | atcagaatgt  | aaacatgaac  | tcttgcatat  | 6900 |
| atttaaaatt  | gtgttggaac  | atgttgaaat  | gaatgctgtt  | tgggtactta  | agaaattrat  | 6960 |
| tcagtnggat  | tatcattatg  | tganactggc  | agattgcagt  | gcanccttat  | gccaataaaa  | 7020 |
| tgtaatthar  | cagccccaga  | tattgttgaa  | tattcaacaa  | taacaagaaa  | agcttttcat  | 7080 |
| ctaagtttta  | tgctttaatt  | ttttttcttt  | ttttttcttt  | ttcttttggt  | tccttggtac  | 7140 |



-41-

|             |            |            |             |            |            |      |
|-------------|------------|------------|-------------|------------|------------|------|
| taattttaat  | ttttatttgg | aagggagcag | tataaagcctt | atttgtattt | agtagtgtat | 7200 |
| ctcatagata  | cagacaaggc | aagagatgat | aagctgttta  | aatagtgktt | aatattgatt | 7260 |
| gggggtgggg  | agaaagaaaa | agtgtattac | ttaaagatac  | tatatacskt | ttktatatca | 7320 |
| ttaaattcttt | aaaagaaatn | naataaattt | attgttttnc  | aaaaaaaaac | ccnntaaaaa | 7380 |
| aaaaagggcg  | gccctcttag | aggatccctc | gaggggccc   |            |            | 7419 |

&lt;210&gt; 28

&lt;211&gt; 1865

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 28

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ser | Gln | Lys | Ser | Trp | Ile | Glu | Ser | Thr | Leu | Thr | Lys | Arg | Glu | Cys |
| 1   |     |     | 5   |     |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Val | Tyr | Ile | Ile | Pro | Ser | Ser | Lys | Asp | Pro | His | Arg | Cys | Leu | Pro | Gly |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Cys | Gln | Ile | Cys | Gln | Gln | Leu | Val | Arg | Cys | Phe | Cys | Gly | Arg | Leu | Val |
|     |     | 35  |     |     |     | 40  |     |     |     |     |     | 45  |     |     |     |
| Lys | Gln | His | Ala | Cys | Phe | Thr | Ala | Ser | Leu | Ala | Met | Lys | Tyr | Ser | Asp |
|     |     | 50  |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Val | Lys | Leu | Gly | Asp | His | Phe | Asn | Gln | Ala | Ile | Glu | Glu | Trp | Ser | Val |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     | 80  |     |
| Glu | Lys | His | Thr | Glu | Gln | Ser | Pro | Thr | Asp | Ala | Tyr | Gly | Val | Ile | Asn |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Phe | Gln | Gly | Gly | Ser | His | Ser | Tyr | Arg | Ala | Lys | Tyr | Val | Arg | Leu | Ser |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Tyr | Asp | Thr | Lys | Pro | Glu | Val | Ile | Leu | Gln | Leu | Leu | Leu | Lys | Glu | Trp |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Gln | Met | Glu | Leu | Pro | Lys | Leu | Val | Ile | Ser | Val | His | Gly | Gly | Met | Gln |
|     |     | 130 |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Lys | Phe | Glu | Leu | His | Pro | Arg | Ile | Lys | Gln | Leu | Leu | Gly | Lys | Gly | Leu |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Ile | Lys | Ala | Ala | Val | Thr | Thr | Gly | Ala | Trp | Ile | Leu | Thr | Gly | Gly | Val |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Asn | Thr | Gly | Val | Ala | Lys | His | Val | Gly | Asp | Ala | Leu | Lys | Glu | His | Ala |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Ser | Arg | Ser | Ser | Arg | Lys | Ile | Cys | Thr | Ile | Gly | Ile | Ala | Pro | Trp | Gly |
|     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Val | Ile | Glu | Asn | Arg | Asn | Asp | Leu | Val | Gly | Arg | Asp | Val | Val | Ala | Pro |
|     |     | 210 |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Tyr | Gln | Thr | Leu | Leu | Asn | Pro | Leu | Ser | Lys | Leu | Asn | Val | Leu | Asn | Asn |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     | 240 |     |
| Leu | His | Ser | His | Phe | Ile | Leu | Val | Asp | Asp | Gly | Thr | Val | Gly | Lys | Tyr |
|     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |
| Gly | Ala | Glu | Val | Arg | Leu | Arg | Arg | Glu | Leu | Glu | Lys | Thr | Ile | Asn | Gln |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Gln | Arg | Ile | His | Ala | Arg | Ile | Gly | Gln | Gly | Val | Pro | Val | Val | Ala | Leu |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Ile | Phe | Glu | Gly | Gly | Pro | Asn | Val | Ile | Leu | Thr | Val | Leu | Glu | Tyr | Leu |
|     |     | 290 |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Gln | Glu | Ser | Pro | Pro | Val | Pro | Val | Val | Val | Cys | Glu | Gly | Thr | Gly | Arg |
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     | 320 |     |
| Ala | Ala | Asp | Leu | Leu | Ala | Tyr | Ile | His | Lys | Gln | Thr | Glu | Glu | Gly | Gly |
|     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |
| Asn | Leu | Pro | Asp | Ala | Ala | Glu | Pro | Asp | Ile | Ile | Ser | Thr | Ile | Lys | Lys |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |
| Thr | Phe | Asn | Phe | Gly | Gln | Asn | Glu | Ala | Leu | His | Leu | Phe | Gln | Thr | Leu |
|     |     | 355 |     |     |     |     | 360 |     |     |     |     |     | 365 |     |     |

-42-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Cys | Met | Lys | Arg | Lys | Glu | Leu | Ile | Thr | Val | Phe | His | Ile | Gly |
| 370 |     |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |
| Ser | Asp | Glu | His | Gln | Asp | Ile | Asp | Val | Ala | Ile | Leu | Thr | Ala | Leu | Leu |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Lys | Gly | Thr | Asn | Ala | Ser | Ala | Phe | Asp | Gln | Leu | Ile | Leu | Thr | Leu | Ala |
|     |     |     |     | 405 |     |     |     |     | 410 |     |     |     |     |     | 415 |
| Trp | Asp | Arg | Val | Asp | Ile | Ala | Lys | Asn | His | Val | Phe | Val | Tyr | Gly | Gln |
|     |     |     | 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Gln | Trp | Leu | Val | Gly | Ser | Leu | Glu | Gln | Ala | Met | Leu | Asp | Ala | Leu | Val |
|     |     | 435 |     |     |     |     | 440 |     |     |     |     | 445 |     |     |     |
| Met | Asp | Arg | Val | Ala | Phe | Val | Lys | Leu | Leu | Ile | Glu | Asn | Gly | Val | Ser |
|     | 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Met | His | Lys | Phe | Leu | Thr | Ile | Pro | Arg | Leu | Glu | Glu | Leu | Tyr | Asn | Thr |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Lys | Gln | Gly | Pro | Thr | Asn | Pro | Met | Leu | Phe | His | Leu | Val | Arg | Asp | Val |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     |     | 495 |
| Lys | Gln | Gly | Asn | Leu | Pro | Pro | Gly | Tyr | Lys | Ile | Thr | Leu | Ile | Asp | Ile |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Gly | Leu | Val | Ile | Glu | Tyr | Leu | Met | Gly | Gly | Thr | Tyr | Arg | Cys | Thr | Tyr |
|     | 515 |     |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| Thr | Arg | Lys | Arg | Phe | Arg | Leu | Ile | Tyr | Asn | Ser | Leu | Gly | Gly | Asn | Asn |
|     | 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |
| Arg | Arg | Ser | Gly | Arg | Asn | Thr | Ser | Ser | Ser | Thr | Pro | Gln | Leu | Arg | Lys |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Ser | His | Glu | Ser | Phe | Gly | Asn | Arg | Ala | Asp | Lys | Lys | Glu | Lys | Met | Arg |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     |     | 575 |
| His | Asn | His | Phe | Ile | Lys | Thr | Ala | Gln | Pro | Phe | Arg | Pro | Lys | Ile | Asp |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Thr | Val | Met | Glu | Glu | Gly | Lys | Lys | Arg | Thr | Lys | Asp | Glu | Ile | Val |     |
|     | 595 |     |     |     |     |     | 600 |     |     |     | 605 |     |     |     |     |
| Asp | Ile | Asp | Asp | Pro | Glu | Thr | Lys | Arg | Phe | Pro | Tyr | Pro | Leu | Asn | Glu |
|     | 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |
| Leu | Leu | Ile | Trp | Ala | Cys | Leu | Met | Lys | Arg | Gln | Val | Met | Ala | Arg | Phe |
| 625 |     |     |     |     | 630 |     |     |     |     | 635 |     |     |     |     | 640 |
| Leu | Trp | Gln | His | Gly | Glu | Glu | Ser | Met | Ala | Lys | Ala | Leu | Val | Ala | Cys |
|     |     |     |     | 645 |     |     |     |     | 650 |     |     |     |     |     | 655 |
| Lys | Ile | Tyr | Arg | Ser | Met | Ala | Tyr | Glu | Ala | Lys | Gln | Ser | Asp | Leu | Val |
|     |     |     | 660 |     |     |     |     | 665 |     |     |     |     | 670 |     |     |
| Asp | Asp | Thr | Ser | Glu | Glu | Leu | Lys | Gln | Tyr | Ser | Asn | Asp | Phe | Gly | Gln |
|     | 675 |     |     |     |     |     | 680 |     |     |     |     | 685 |     |     |     |
| Leu | Ala | Val | Glu | Leu | Leu | Glu | Gln | Ser | Phe | Arg | Gln | Asp | Glu | Thr | Met |
|     | 690 |     |     |     |     | 695 |     |     |     |     | 700 |     |     |     |     |
| Ala | Met | Lys | Leu | Leu | Thr | Tyr | Glu | Leu | Lys | Asn | Trp | Ser | Asn | Ser | Thr |
| 705 |     |     |     |     | 710 |     |     |     |     | 715 |     |     |     |     | 720 |
| Cys | Leu | Lys | Leu | Ala | Val | Ser | Ser | Arg | Leu | Arg | Pro | Phe | Val | Ala | His |
|     |     |     |     | 725 |     |     |     |     | 730 |     |     |     |     |     | 735 |
| Thr | Cys | Thr | Gln | Met | Leu | Leu | Ser | Asp | Met | Trp | Met | Gly | Arg | Leu | Asn |
|     |     |     | 740 |     |     |     |     | 745 |     |     |     |     | 750 |     |     |
| Met | Arg | Lys | Asn | Ser | Trp | Tyr | Lys | Val | Ile | Leu | Ser | Ile | Leu | Val | Pro |
|     | 755 |     |     |     |     |     | 760 |     |     |     |     | 765 |     |     |     |
| Pro | Ala | Ile | Leu | Leu | Leu | Glu | Tyr | Lys | Thr | Lys | Ala | Glu | Met | Ser | His |
|     | 770 |     |     |     |     | 775 |     |     |     |     |     | 780 |     |     |     |
| Ile | Pro | Gln | Ser | Gln | Asp | Ala | His | Gln | Met | Thr | Met | Asp | Asp | Ser | Glu |
| 785 |     |     |     |     | 790 |     |     |     |     | 795 |     |     |     |     | 800 |
| Asn | Asn | Phe | Gln | Asn | Ile | Thr | Glu | Glu | Ile | Pro | Met | Glu | Val | Phe | Lys |
|     |     |     |     | 805 |     |     |     |     | 810 |     |     |     |     |     | 815 |
| Glu | Val | Arg | Ile | Leu | Asp | Ser | Asn | Glu | Gly | Lys | Asn | Glu | Met | Glu | Ile |
|     |     |     | 820 |     |     |     |     | 825 |     |     |     |     | 830 |     |     |
| Gln | Met | Lys | Ser | Lys | Lys | Leu | Pro | Ile | Thr | Arg | Lys | Phe | Tyr | Ala | Phe |
|     |     | 835 |     |     |     |     | 840 |     |     |     |     |     | 845 |     |     |

-43-

Tyr His Ala Pro Ile Val Lys Phe Trp Phe Asn Thr Leu Ala Tyr Leu  
 850 855 860  
 Gly Phe Leu Met Leu Tyr Thr Phe Val Val Leu Val Gln Met Glu Gln  
 865 870 875 880  
 Leu Pro Ser Val Gln Glu Trp Ile Val Ile Ala Tyr Ile Phe Thr Tyr  
 885 890 895  
 Ala Ile Glu Lys Val Arg Glu Ile Phe Met Ser Glu Ala Gly Lys Val  
 900 905 910  
 Asn Gln Lys Ile Lys Val Trp Phe Ser Asp Tyr Phe Asn Ile Ser Asp  
 915 920 925  
 Thr Ile Ala Ile Ile Ser Phe Phe Ile Gly Phe Gly Leu Arg Phe Gly  
 930 935 940  
 Ala Lys Trp Asn Phe Ala Asn Ala Tyr Asp Asn His Val Phe Val Ala  
 945 950 955 960  
 Gly Arg Leu Ile Tyr Cys Leu Asn Ile Ile Phe Trp Tyr Val Arg Leu  
 965 970 975  
 Leu Asp Phe Leu Ala Val Asn Gln Gln Ala Gly Pro Tyr Val Met Met  
 980 985 990  
 Ile Gly Lys Met Val Ala Asn Met Phe Tyr Ile Val Val Ile Met Ala  
 995 1000 1005  
 Leu Val Leu Leu Ser Phe Gly Val Pro Arg Lys Ala Ile Leu Tyr Pro  
 1010 1015 1020  
 His Glu Ala Pro Ser Trp Thr Leu Ala Lys Asp Ile Val Phe His Pro  
 1025 1030 1035 1040  
 Tyr Trp Met Ile Phe Gly Glu Val Tyr Ala Tyr Glu Ile Asp Val Cys  
 1045 1050 1055  
 Ala Asn Asp Ser Val Ile Pro Gln Ile Cys Gly Pro Gly Thr Trp Leu  
 1060 1065 1070  
 Thr Pro Phe Leu Gln Ala Val Tyr Leu Phe Val Gln Tyr Ile Ile Met  
 1075 1080 1085  
 Val Asn Leu Leu Ile Ala Phe Phe Asn Asn Val Tyr Leu Gln Val Lys  
 1090 1095 1100  
 Ala Ile Ser Asn Ile Val Trp Lys Tyr Gln Arg Tyr His Phe Ile Met  
 1105 1110 1115 1120  
 Ala Tyr His Glu Lys Pro Val Leu Pro Pro Pro Leu Ile Ile Leu Ser  
 1125 1130 1135  
 His Ile Val Ser Leu Phe Cys Cys Ile Cys Lys Arg Arg Lys Lys Asp  
 1140 1145 1150  
 Lys Thr Ser Asp Gly Pro Lys Leu Phe Leu Thr Glu Glu Asp Gln Lys  
 1155 1160 1165  
 Lys Leu His Asp Phe Glu Glu Gln Cys Val Glu Met Tyr Phe Asn Glu  
 1170 1175 1180  
 Lys Asp Asp Lys Phe His Ser Gly Ser Glu Glu Arg Ile Arg Val Thr  
 1185 1190 1195 1200  
 Phe Glu Arg Val Glu Gln Met Cys Ile Gln Ile Lys Glu Val Gly Asp  
 1205 1210 1215  
 Arg Val Asn Tyr Ile Lys Arg Ser Leu Gln Ser Leu Asp Ser Gln Ile  
 1220 1225 1230  
 Gly His Leu Gln Asp Leu Ser Ala Leu Thr Val Asp Thr Leu Lys Thr  
 1235 1240 1245  
 Leu Thr Ala Gln Lys Ala Ser Glu Ala Ser Lys Val His Asn Glu Ile  
 1250 1255 1260  
 Thr Arg Glu Leu Ser Ile Ser Lys His Leu Ala Gln Asn Leu Ile Asp  
 1265 1270 1275 1280  
 Asp Gly Pro Val Arg Pro Ser Val Trp Lys Lys His Gly Val Val Asn  
 1285 1290 1295  
 Thr Leu Ser Ser Ser Leu Pro Gln Gly Asp Leu Glu Ser Asn Asn Pro  
 1300 1305 1310  
 Phe His Cys Asn Ile Leu Met Lys Asp Asp Lys Asp Pro Gln Cys Asn  
 1315 1320 1325

-44-

Ile Phe Gly Gln Asp Leu Pro Ala Val Pro Gln Arg Lys Glu Phe Asn  
 1330 1335 1340  
 Phe Pro Glu Ala Gly Ser Ser Ser Gly Ala Leu Phe Pro Ser Ala Val  
 1345 1350 1355 1360  
 Ser Pro Pro Glu Leu Arg Gln Arg Leu His Gly Val Glu Leu Leu Lys  
 1365 1370 1375  
 Ile Phe Asn Lys Asn Gln Lys Leu Gly Ser Ser Ser Thr Ser Ile Pro  
 1380 1385 1390  
 His Leu Ser Ser Pro Pro Thr Lys Phe Phe Val Ser Thr Pro Ser Gln  
 1395 1400 1405  
 Pro Ser Cys Lys Ser His Leu Glu Thr Gly Thr Lys Asp Gln Glu Thr  
 1410 1415 1420  
 Val Cys Ser Lys Ala Thr Glu Gly Asp Asn Thr Glu Phe Gly Ala Phe  
 1425 1430 1435 1440  
 Val Gly His Arg Asp Ser Met Asp Leu Gln Arg Phe Lys Glu Thr Ser  
 1445 1450 1455  
 Asn Lys Ile Lys Ile Leu Ser Asn Asn Asn Thr Ser Glu Asn Thr Leu  
 1460 1465 1470  
 Lys Arg Val Ser Ser Leu Ala Gly Phe Thr Asp Cys His Arg Thr Ser  
 1475 1480 1485  
 Ile Pro Val His Ser Lys Gln Ala Glu Lys Ile Ser Arg Arg Pro Ser  
 1490 1495 1500  
 Thr Glu Asp Thr His Glu Val Asp Ser Lys Ala Ala Leu Ile Pro Asp  
 1505 1510 1515 1520  
 Trp Leu Gln Asp Arg Pro Ser Asn Arg Glu Met Pro Ser Glu Glu Gly  
 1525 1530 1535  
 Thr Leu Asn Gly Leu Thr Ser Pro Phe Lys Pro Ala Met Asp Thr Asn  
 1540 1545 1550  
 Tyr Tyr Tyr Ser Ala Val Glu Arg Asn Asn Leu Met Arg Leu Ser Gln  
 1555 1560 1565  
 Ser Ile Pro Phe Thr Pro Val Pro Pro Arg Gly Glu Pro Val Thr Val  
 1570 1575 1580  
 Tyr Arg Leu Glu Glu Ser Ser Pro Asn Ile Leu Asn Asn Ser Met Ser  
 1585 1590 1595 1600  
 Ser Trp Ser Gln Leu Gly Leu Cys Ala Lys Ile Glu Phe Leu Ser Lys  
 1605 1610 1615  
 Glu Glu Met Gly Gly Gly Leu Arg Arg Ala Val Lys Val Gln Cys Thr  
 1620 1625 1630  
 Trp Ser Glu His Asp Ile Leu Lys Ser Gly His Leu Tyr Ile Ile Lys  
 1635 1640 1645  
 Ser Phe Leu Pro Glu Val Val Asn Thr Trp Ser Ser Ile Tyr Lys Glu  
 1650 1655 1660  
 Asp Thr Val Leu His Leu Cys Leu Arg Glu Ile Gln Gln Gln Arg Ala  
 1665 1670 1675 1680  
 Ala Gln Lys Leu Thr Phe Ala Phe Asn Gln Met Lys Pro Lys Ser Ile  
 1685 1690 1695  
 Pro Tyr Ser Pro Arg Phe Leu Glu Val Phe Leu Leu Tyr Cys His Ser  
 1700 1705 1710  
 Ala Gly Gln Trp Phe Ala Val Glu Glu Cys Met Thr Gly Glu Phe Arg  
 1715 1720 1725  
 Lys Tyr Asn Asn Asn Asn Gly Asp Glu Ile Ile Pro Thr Asn Thr Leu  
 1730 1735 1740  
 Glu Glu Ile Met Leu Ala Phe Ser His Trp Thr Tyr Glu Tyr Thr Arg  
 1745 1750 1755 1760  
 Gly Glu Leu Leu Val Leu Asp Leu Gln Gly Val Gly Glu Asn Leu Thr  
 1765 1770 1775  
 Asp Pro Ser Val Ile Lys Ala Glu Glu Lys Arg Ser Cys Asp Met Val  
 1780 1785 1790  
 Phe Gly Pro Ala Asn Leu Gly Glu Asp Ala Ile Lys Asn Phe Arg Ala  
 1795 1800 1805

-45-

Lys His His Cys Asn Ser Cys Cys Arg Lys Leu Lys Leu Pro Asp Leu  
 1810 1815 1820  
 Lys Arg Asn Asp Tyr Thr Pro Asp Lys Ile Ile Phe Pro Gln Asp Glu  
 1825 1830 1835 1840  
 Pro Ser Asp Leu Asn Leu Gln Pro Gly Asn Ser Thr Lys Glu Ser Glu  
 1845 1850 1855  
 Ser Thr Asn Ser Val Arg Leu Met Leu  
 1860 1865

<210> 29  
 <211> 4061  
 <212> DNA  
 <213> Homo Sapiens

<400> 29  
 ggtctggaag cagagccggc ggagggagcg ccggggccct gggctgcagg aggttgccgc 60  
 ggccgcggca gcatgggtgt gccggagaag gagcagagct ggatcccca gatcttcaag 120  
 aagaagacct gcacgacgtt catagttgac tccacagatc cgggaggagc cttgtgccag 180  
 tgtgggcggc cccggaccgc ccaccccgca gtggccatgg aggatgcctt cggggcagcc 240  
 gtggtgaccg tgtgggacag cgatgcacac accacggaga agcccaccga tgcctacgga 300  
 gagctggact tcacgggggc cgcccgcaag cacagcaatt tctcctcggt ctctgaccga 360  
 acggatccag ctgcagttta tagtctgttc acacgcacat ggggcttccg tgccccgaac 420  
 ctggtgtgtgt cagtgtctgg gggatcgggg ggccccgtcc tccagacctg gctgcaggac 480  
 ctgctgcgtc gtgggctggt gcgggctgcc cagagcacag gagcctggat tgtcactggg 540  
 ggtctgcaca cgggcatcgg ccggcatgtt ggtgtggctg tacgggacca tcagatggcc 600  
 agcactgggg gcaccaaggt ggtggccatg ggtgtggccc cctgggggtgt ggtccggaat 660  
 agagacaccc tcatcaaccc caagggctcg ttccctgcga ggtaccggtg gcgcggtgac 720  
 ccggaggacg ggggtccagt tcccctggac tacaactact cggccttctt cctggtggaac 780  
 gacggcacac acggctgcct ggggggcgag aaccgcttcc gcttgcgcct ggagtcctac 840  
 atctcacagc agaagacggg cgtgggaggg actggaattg acatccctgt cctgctcctc 900  
 ctgattgatg gtgatgagaa gatgttgacg cgaatagaga acgccacca ggctcagctc 960  
 ccatgtctcc tcgtggctgg ctccaggggga gctgcggact gcctggcgga gaccctggaa 1020  
 gacactctgg ccccaggagag tgggggagcc aggcaaggcg aagcccgaga tcgaatcagg 1080  
 cgtttctttc ccaaagggga ccttgaggct ctgcaggccc aggtggagag gattatgacc 1140  
 cggaaggagc tcctgacagt ctattcttct gaggatgggt ctgaggaatt cgagaccata 1200  
 gttttgaagg cccttgtaga ggctgtggg agctcgagg cctcagccta cctggatgag 1260  
 ctgctgtttg ctgtggcttg gaaccgcgtg gacattgccc agagtgaact ctttcggggg 1320  
 gacatccaat ggcggtcctt ccatctcgaa gcttccctca tggacgccct gctgaatgac 1380  
 cggcctgagt tcgtgcgctt gctcatttcc cacggcctca gcctgggcca cttcctgacc 1440  
 ccgatgcgcc tggcccaact ctacagcgcg gcgcctcca actcgctcat ccgcaacctt 1500  
 ttggaccagg cgtcccacag cgcaggcacc aaagccccag ccctaaaagg gggagctgcg 1560  
 gagctccggc cccctgacgt ggggcatgtg ctgaggatgc tgctggggaa gatgtgcgcg 1620  
 ccgaggtacc cctccggggg cgccctgggac cctcaccag gccagggctt cggggagagc 1680  
 atgtatctgc tctcggacaa ggccacctcg ccgctctcgc tggatgctgg cctcgggcag 1740  
 gccccctgga gcgacctgct tctttgggca ctggtgctga acagggcaca gatggccatg 1800  
 tacttctggg agatgggttc caatgcagtt tctcagctc ttggggcctg tttgctgctc 1860  
 cgggtgatgg cacgcctgga gcctgacgct gaggaggcag cacggaggaa agacctggcg 1920  
 ttcaagtttg aggggatggg cggtgacctc tttggcgagt gctatcgag cagtgaagtg 1980  
 agggctgccc gccctcctct ccgtcgctgc ccgctctggg gggatgccac ttgcctccag 2040  
 ctggccatgc aagctgacgc ccgtgccttc tttgccagg atggggtaca gtctctgctg 2100  
 acacagaagt ggtggggaga tatggccagc actacacca tctgggccct ggttctcgcc 2160  
 ttcttttgcc ctccactcat ctacaccgcg ctcatcacct tcaggaaatc agaagaggag 2220  
 cccacacggg aggagctaga gtttgacatg gatagtgta ttaatgggga agggcctgtc 2280  
 gggacggcgg acccagccga gaagacggcg ctgggggtcc cgcgccagtc gggcgtccg 2340  
 ggttgctgcg ggggcccgtg cggggggcgc cggtgcctac gccgtgggtt ccacttctgg 2400  
 ggcgcgcggg tgacctctt catgggcaac gtggctcagct acctgctgtt cctgctgctt 2460  
 ttctcgcggg tgctgctcgt ggatttccag ccggcgccgc ccggctccct ggagctgctg 2520  
 ctctatttct gggttttcc gctgctgtgc gaggaactgc gccagggcct gagcggaggc 2580  
 gggggcagcc tcgccagcgg gggccccggg cctggccatg cctcactgag ccagcgctg 2640  
 cgcctctacc tcgccgacag ctggaaccag tgcgacctag tggtctcac ctgcttctc 2700

-46-

```

ctgggcggtg gctgccggt gaccccggt ttgtaccacc tgggcccgcac tgtcctctgc 2760
atcgacttca tggttttcac ggtgcggctg cttcacatct tcacgggtcaa caaacagctg 2820
gggccaaga tcgtcatcgt gagcaagatg atgaaggacg tgttcttctt cctcttcttc 2880
ctcggcggtg ggctggtagc ctatggcgtg gccacggagg ggctcctgag gccacgggac 2940
agtgacttcc caagtatcct gcgccgcgtc ttctaccgtc cctacctgca gatcttcggg 3000
cagattcccc aggaggacat ggacgtggcc ctcatggagc acagcaactg ctcgtcggag 3060
cccggcttct gggcacaccc tcctggggcc caggcgggca cctgcgtctc ccagtatgcc 3120
aactggctgg tgggtgctgt cctcgtcatc ttctgctcg tggccaacat cctgctggtc 3180
aacttgctca ttgccatgtt cagttacaca ttccggcaaag tacagggcaa cagcgatctc 3240
tactggaagg cgcagcgtta ccgcctcatc cgggaattcc actctcggcc cgcgctggcc 3300
ccgcccttta tcgtcatctc ccacttgccg ctctgctca ggcaattgtg caggcgaccc 3360
cggagcccc agccgtcctc cccggccctc gagcatttcc gggtttacct ttctaaggaa 3420
gccgagcggg agctgctaac gtgggaatcg gtgcataagg agaactttct gctggcacgc 3480
gctagggaca agcgggagag cgaactccgag cgtctgaagc gcacgtccca gaaggtggac 3540
ttggcactga aacagctggg acacatccgc gactacgaac agcgcttgaa agtgcggag 3600
cgggaggtcc agcagtgtag ccgcgtcctg ggggtgggtg ccgaggccct gagccgctct 3660
gccttgctgc ccccagggtg gccgccaccc cctgacctgc ctgggtccaa agactgagcc 3720
ctgtggcgg acttcaagga gaagcccca caggggattt tgctcctaga gtaaggctca 3780
tctgggcctc ggccccgca cctggtggcc ttgtccttga ggtgagcccc atgtccatct 3840
gggccactgt caggaccacc ttggggagtg tcactcttac aaaccacagc atgcccggct 3900
cctcccagaa ccagtcccag cctgggagga tcaaggcctg gatcccgggc cgttatccat 3960
ctggaggctg cagggtcctt ggggtaacag ggaccacaga cccctacca ctcacagatt 4020
cctcacactg gggaaataaa gccatttcag aggaaaaaa a 4061

```

<210> 30  
 <211> 1214  
 <212> PRT  
 <213> Homo Sapiens

<400> 30

```

Met Val Val Pro Glu Lys Glu Gln Ser Trp Ile Pro Lys Ile Phe Lys
 1          5          10          15
Lys Lys Thr Cys Thr Thr Phe Ile Val Asp Ser Thr Asp Pro Gly Gly
 20          25          30
Thr Leu Cys Gln Cys Gly Arg Pro Arg Thr Ala His Pro Ala Val Ala
 35          40          45
Met Glu Asp Ala Phe Gly Ala Ala Val Val Thr Val Trp Asp Ser Asp
 50          55          60
Ala His Thr Thr Glu Lys Pro Thr Asp Ala Tyr Gly Glu Leu Asp Phe
 65          70          75          80
Thr Gly Ala Gly Arg Lys His Ser Asn Phe Leu Arg Leu Ser Asp Arg
 85          90          95
Thr Asp Pro Ala Ala Val Tyr Ser Leu Val Thr Arg Thr Trp Gly Phe
100          105          110
Arg Ala Pro Asn Leu Val Val Ser Val Leu Gly Gly Ser Gly Gly Pro
115          120          125
Val Leu Gln Thr Trp Leu Gln Asp Leu Leu Arg Arg Gly Leu Val Arg
130          135          140
Ala Ala Gln Ser Thr Gly Ala Trp Ile Val Thr Gly Gly Leu His Thr
145          150          155          160
Gly Ile Gly Arg His Val Gly Val Ala Val Arg Asp His Gln Met Ala
165          170          175
Ser Thr Gly Gly Thr Lys Val Val Ala Met Gly Val Ala Pro Trp Gly
180          185          190
Val Val Arg Asn Arg Asp Thr Leu Ile Asn Pro Lys Gly Ser Phe Pro
195          200          205
Ala Arg Tyr Arg Trp Arg Gly Asp Pro Glu Asp Gly Val Gln Phe Pro
210          215          220
Leu Asp Tyr Asn Tyr Ser Ala Phe Phe Leu Val Asp Asp Gly Thr His
225          230          235          240

```

-47-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Cys | Leu | Gly | Gly | Glu | Asn | Arg | Phe | Arg | Leu | Arg | Leu | Glu | Ser | Tyr | 245 | 250 | 255 |
| Ile | Ser | Gln | Gln | Lys | Thr | Gly | Val | Gly | Gly | Thr | Gly | Ile | Asp | Ile | Pro | 260 | 265 | 270 |
| Val | Leu | Leu | Leu | Leu | Ile | Asp | Gly | Asp | Glu | Lys | Met | Leu | Thr | Arg | Ile | 275 | 280 | 285 |
| Glu | Asn | Ala | Thr | Gln | Ala | Gln | Leu | Pro | Cys | Leu | Leu | Val | Ala | Gly | Ser | 290 | 295 | 300 |
| Gly | Gly | Ala | Ala | Asp | Cys | Leu | Ala | Glu | Thr | Leu | Glu | Asp | Thr | Leu | Ala | 305 | 310 | 315 |
| Pro | Gly | Ser | Gly | Gly | Ala | Arg | Gln | Gly | Glu | Ala | Arg | Asp | Arg | Ile | Arg | 325 | 330 | 335 |
| Arg | Phe | Phe | Pro | Lys | Gly | Asp | Leu | Glu | Val | Leu | Gln | Ala | Gln | Val | Glu | 340 | 345 | 350 |
| Arg | Ile | Met | Thr | Arg | Lys | Glu | Leu | Leu | Thr | Val | Tyr | Ser | Ser | Glu | Asp | 355 | 360 | 365 |
| Gly | Ser | Glu | Glu | Phe | Glu | Thr | Ile | Val | Leu | Lys | Ala | Leu | Val | Lys | Ala | 370 | 375 | 380 |
| Cys | Gly | Ser | Ser | Glu | Ala | Ser | Ala | Tyr | Leu | Asp | Glu | Leu | Arg | Leu | Ala | 385 | 390 | 395 |
| Val | Ala | Trp | Asn | Arg | Val | Asp | Ile | Ala | Gln | Ser | Glu | Leu | Phe | Arg | Gly | 405 | 410 | 415 |
| Asp | Ile | Gln | Trp | Arg | Ser | Phe | His | Leu | Glu | Ala | Ser | Leu | Met | Asp | Ala | 420 | 425 | 430 |
| Leu | Leu | Asn | Asp | Arg | Pro | Glu | Phe | Val | Arg | Leu | Leu | Ile | Ser | His | Gly | 435 | 440 | 445 |
| Leu | Ser | Leu | Gly | His | Phe | Leu | Thr | Pro | Met | Arg | Leu | Ala | Gln | Leu | Tyr | 450 | 455 | 460 |
| Ser | Ala | Ala | Pro | Ser | Asn | Ser | Leu | Ile | Arg | Asn | Leu | Leu | Asp | Gln | Ala | 465 | 470 | 475 |
| Ser | His | Ser | Ala | Gly | Thr | Lys | Ala | Pro | Ala | Leu | Lys | Gly | Gly | Ala | Ala | 485 | 490 | 495 |
| Glu | Leu | Arg | Pro | Pro | Asp | Val | Gly | His | Val | Leu | Arg | Met | Leu | Leu | Gly | 500 | 505 | 510 |
| Lys | Met | Cys | Ala | Pro | Arg | Tyr | Pro | Ser | Gly | Gly | Ala | Trp | Asp | Pro | His | 515 | 520 | 525 |
| Pro | Gly | Gln | Gly | Phe | Gly | Glu | Ser | Met | Tyr | Leu | Leu | Ser | Asp | Lys | Ala | 530 | 535 | 540 |
| Thr | Ser | Pro | Leu | Ser | Leu | Asp | Ala | Gly | Leu | Gly | Gln | Ala | Pro | Trp | Ser | 545 | 550 | 555 |
| Asp | Leu | Leu | Leu | Trp | Ala | Leu | Leu | Leu | Asn | Arg | Ala | Gln | Met | Ala | Met | 565 | 570 | 575 |
| Tyr | Phe | Trp | Glu | Met | Gly | Ser | Asn | Ala | Val | Ser | Ser | Ala | Leu | Gly | Ala | 580 | 585 | 590 |
| Cys | Leu | Leu | Leu | Arg | Val | Met | Ala | Arg | Leu | Glu | Pro | Asp | Ala | Glu | Glu | 595 | 600 | 605 |
| Ala | Ala | Arg | Arg | Lys | Asp | Leu | Ala | Phe | Lys | Phe | Glu | Gly | Met | Gly | Val | 610 | 615 | 620 |
| Asp | Leu | Phe | Gly | Glu | Cys | Tyr | Arg | Ser | Ser | Glu | Val | Arg | Ala | Ala | Arg | 625 | 630 | 635 |
| Leu | Leu | Leu | Arg | Arg | Cys | Pro | Leu | Trp | Gly | Asp | Ala | Thr | Cys | Leu | Gln | 645 | 650 | 655 |
| Leu | Ala | Met | Gln | Ala | Asp | Ala | Arg | Ala | Phe | Phe | Ala | Gln | Asp | Gly | Val | 660 | 665 | 670 |
| Gln | Ser | Leu | Leu | Thr | Gln | Lys | Trp | Trp | Gly | Asp | Met | Ala | Ser | Thr | Thr | 675 | 680 | 685 |
| Pro | Ile | Trp | Ala | Leu | Val | Leu | Ala | Phe | Phe | Cys | Pro | Pro | Leu | Ile | Tyr | 690 | 695 | 700 |
| Thr | Arg | Leu | Ile | Thr | Phe | Arg | Lys | Ser | Glu | Glu | Glu | Pro | Thr | Arg | Glu | 705 | 710 | 715 |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 720 |

-48-

Glu Leu Glu Phe Asp Met Asp Ser Val Ile Asn Gly Glu Gly Pro Val  
 725 730 735  
 Gly Thr Ala Asp Pro Ala Glu Lys Thr Pro Leu Gly Val Pro Arg Gln  
 740 745 750  
 Ser Gly Arg Pro Gly Cys Cys Gly Gly Arg Cys Gly Gly Arg Arg Cys  
 755 760 765  
 Leu Arg Arg Trp Phe His Phe Trp Gly Ala Pro Val Thr Ile Phe Met  
 770 775 780  
 Gly Asn Val Val Ser Tyr Leu Leu Phe Leu Leu Phe Ser Arg Val  
 785 790 795 800  
 Leu Leu Val Asp Phe Gln Pro Ala Pro Pro Gly Ser Leu Glu Leu Leu  
 805 810 815  
 Leu Tyr Phe Trp Ala Phe Thr Leu Leu Cys Glu Glu Leu Arg Gln Gly  
 820 825 830  
 Leu Ser Gly Gly Gly Gly Ser Leu Ala Ser Gly Gly Pro Gly Pro Gly  
 835 840 845  
 His Ala Ser Leu Ser Gln Arg Leu Arg Leu Tyr Leu Ala Asp Ser Trp  
 850 855 860  
 Asn Gln Cys Asp Leu Val Ala Leu Thr Cys Phe Leu Leu Gly Val Gly  
 865 870 875 880  
 Cys Arg Leu Thr Pro Gly Leu Tyr His Leu Gly Arg Thr Val Leu Cys  
 885 890 895  
 Ile Asp Phe Met Val Phe Thr Val Arg Leu Leu His Ile Phe Thr Val  
 900 905 910  
 Asn Lys Gln Leu Gly Pro Lys Ile Val Ile Val Ser Lys Met Met Lys  
 915 920 925  
 Asp Val Phe Phe Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr  
 930 935 940  
 Gly Val Ala Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro  
 945 950 955 960  
 Ser Ile Leu Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gln Ile Phe Gly  
 965 970 975  
 Gln Ile Pro Gln Glu Asp Met Asp Val Ala Leu Met Glu His Ser Asn  
 980 985 990  
 Cys Ser Ser Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gln Ala  
 995 1000 1005  
 Gly Thr Cys Val Ser Gln Tyr Ala Asn Trp Leu Val Val Leu Leu Leu  
 1010 1015 1020  
 Val Ile Phe Leu Leu Val Ala Asn Ile Leu Leu Val Asn Leu Leu Ile  
 1025 1030 1035 1040  
 Ala Met Phe Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu  
 1045 1050 1055  
 Tyr Trp Lys Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg  
 1060 1065 1070  
 Pro Ala Leu Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu  
 1075 1080 1085  
 Leu Arg Gln Leu Cys Arg Arg Pro Arg Ser Pro Gln Pro Ser Ser Pro  
 1090 1095 1100  
 Ala Leu Glu His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys  
 1105 1110 1115 1120  
 Leu Leu Thr Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg  
 1125 1130 1135  
 Ala Arg Asp Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser  
 1140 1145 1150  
 Gln Lys Val Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr  
 1155 1160 1165  
 Glu Gln Arg Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Ser Arg  
 1170 1175 1180  
 Val Leu Gly Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro  
 1185 1190 1195 1200



-49-

Pro Gly Gly Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp  
1205 1210

<210> 31  
<211> 4646  
<212> DNA  
<213> Homo Sapiens

<400> 31  
tcgacccacg cgtccgcccc cgcgtccgcc cacgcgtccg cccacgcgtc cgccccacgcg 60  
tccgcccacg cgtccggggg gaaaamramy cmygcktsms aaaaaccgtc acttaggaaa 120  
agatgtcctt tcgggcagcc aggtcagca tgaggacag aaggaatgac actctggaca 180  
gcaccgggac cctgtactcc agcgcgtctc ggagcacaga cttgtcttac agtgaaagcg 240  
acttgggtgaa ttttattcaa gcaaatttta agaaacgaga atgtgtcttc tttaccaaag 300  
attccaaggc cacggagaat gtgtgcaagt gtggctatgc ccagagccag cacatggaag 360  
gcaccagat caaccaaagt gagaaatgga actacaagaa acacaccaag gaatttccta 420  
ccgacgcctt tggggatatt cagtttgaga cactggggaa gaaagggaag tatatacgtc 480  
tgtctgcgca caccgacgcg gaaatccttt acgagctgct gaccacgac tggcacctga 540  
aaacacccaa cctggtcatt tctgtgaccg ggggcgcca gaacttcgcc ctgaagccgc 600  
gcatgcgcaa gatcttcagc cggctcatct acatcgcgca gtccaaagggt gcttggattc 660  
tcacgggagg caccatttat ggcctgatga agtacatcg ggaggtggtg agagataaca 720  
ccatcagcag gagttcagag gagaatattg tggccattgg catagcagct tggggcatgg 780  
tctccaaccg ggacaccctc atcaggaatt gcgatgctga gggctatttt ttagccagct 840  
accttatgga tgacttcaca agagatccac tgtgtatcct ggacaacaac cacacacatt 900  
tgtgtctcgt ggacaatggc tgtcatggac atcccactgt cgaagcaaag ctccggaatc 960  
agctagagaa gtatatctct gagcgacta ttcaagattc caactatggt ggcaagatcc 1020  
ccattgtgtg ttttgcccaa ggaggtggaa aagagacttt gaaagccatc aatacctcca 1080  
tcaaaaataa aattccttgt gtggtggtgg aaggctcggg ccagatcgct gatgtgatcg 1140  
ctagcctggt ggaggtggag gatgccctga catcttctgc cgtcaaggag aagctgggtc 1200  
gctttttacc ccgcacggtg tcccggctgc ctgagaggag gactgagagt tggatcaaatt 1260  
ggctcaaaga aattctcgaa tgttctcacc tattaacagt tattaanaatg gaagaagctg 1320  
gggatgaaat tgtgagcaat gccatctcct acgctctata caaagccttc agcaccagtg 1380  
agcaagacaa ggataactgg aatgggcagc tgaagcttct gctggagtg aaccagctgg 1440  
acttagccaa tgatgagatt ttcaccaatg accgcgatg ggagtctgct gaccttcaag 1500  
aagtcattgt tacggctctc ataaaggaca gacccaagt tgtccgcctc tttctggaga 1560  
atggcttgaa cctacggaag tttctcacc atgatgtcct cactgaactc tttccaaacc 1620  
acttcagcac gcttgtgtac cggaaatctgc agatcgccaa gaattcctat aatgatgcc 1680  
tctcacggtt tgtctgaaa ctggttgcca acttccgaag aggttccgg aaggagaca 1740  
gaaatggccg ggacgagatg gacatagaac tccacgacgt gtctcctatt actcggcacc 1800  
ccctgcaagc tctcttcac tgggccattc ttcagaataa gaaggaaactc tccaaagtca 1860  
tttgggagca gaccaggggc tgcactctgg cagccctggg agccagcaag cttctgaaga 1920  
ctctggccaa agtgaagaac gacatcaatg ctgctgggga gtccgaggag ctggctaattg 1980  
agtacgagac ccgggctgtt gagctgttca ctgagtgtta cagcagcgat gaagacttgg 2040  
cagaacagct gctggtctat tctgtgaaag cttggggtgg aagcaactgt ctggagctgg 2100  
cggtggaggc cacagaccag catttcacg cccagcctgg ggtccagaat tttctttcta 2160  
agcaatggta tggagagatt tcccagagaca ccaagaactg gaagattatc ctgtgtctgt 2220  
ttattatacc cttggtgggc tgtggctttg tatcatttag gaagaaacct gtcgacaagc 2280  
acaagaagct gctttggtac tatgtggcgt tcttcacctc ccccttcgtg gtcttctcct 2340  
ggaatgtggt cttctacatc gccttctcct tgcgtgttgc ctacgtgctg ctcatggatt 2400  
tccattcggg gccacacccc ccgagctgg tctgtactc gctggtcttt gtcctcttct 2460  
gtgatgaagt gagacagtgg tacgtaaatg ggggtgaatta ttttactgac ctgtggaatg 2520  
tgatggacac gctggggctt ttttacttca tagcaggaat tgtatttcgg ctccactctt 2580  
ctaataaaaag ctctttgtat tctggacgag tcattttctg tctggactac attattttca 2640  
ctctaagatt gatccacatt tttactgtaa gcagaaactt aggacccaag attataatgc 2700  
tgcaaggagat gctgatcgat gtgttcttct tctgttctc ctttgcgtg tggatggtg 2760  
cctttggcgt gccagggcaa gggatcctta ggcagaatga gcagcgctgg aggtggatat 2820  
tccgttcggg catctacgag ccctacctgg ccatgttcgg ccaggtgccc agtgacgtgg 2880  
atggtagcac gtatgacttt gccactgca ccttactgga gaatgagtc aagccactgt 2940  
gtgtggagct ggatgagcac aacctgcccc ggttccccga gtggatcacc atccccctg 3000  
tgtgcactca catgttatcc accaacatcc tgcgtgtcaa cctgctggtc gccatgtttg 3060

-50-

```

gctacacggt gggcaccgtc caggagaaca atgaccaggt ctggaagtcc cagagggtact 3120
tcctgggtgca ggagtactgc agccgcccca atatccctt ccccttcacg gtcttcgctt 3180
acttctacat ggtggtgaag aagtgttca agtggtgctg caaggagaaa aacatggagt 3240
cttctgtctg ctgtttcaaa aatgaagaca atgagactct ggcatgggag ggtgtcatga 3300
aggaaaacta ccttgtcaag atcaacacaa aagccaacga caccctcagag gaaatgaggc 3360
atcgatttag acaactggat acaaagctta atgatctcaa gggctcttctg aaagagattg 3420
ctaataaaat caaataaaaac tgtatgaact ctaatggaga aaaatctaata tatagcaaga 3480
tcatattaag gaatgctgat gaacaatttt gctatcgact actaaatgag agattttcag 3540
acccctgggt acatgggtga tgattttaaa tcaccctagt gtgctgagac cttgagaata 3600
aagtgtgtga ttggtttcat acttgaagac ggatataaag gaagaatatt tcctttatgt 3660
gtttctccag aatgggtgct gtttctctct gtgtctcaat gcctgggact ggaggttgat 3720
agtttaagtg tggtcttacc gcctcctttt tcctttaatc ttatttttga tgaacacata 3780
tataggagaa catctatcct atgaataaga acctgggcat gctttactcc tgtattgtta 3840
ttttgttcat ttccaattga ttctctactt ttcccttttt tgtattatgt gactaattag 3900
ttggcatatt gtwaaaagtc tctcaaatta gccagattc taaaacatgc tgcagcaaga 3960
ggaccccgct ctcttcagga aaagtgtttt catttctcag gatgcttctt acctgtcaga 4020
ggaggtgaca aggcagtctc ttgctctctt ggactcacca ggctcctatt gaaggaacca 4080
ccccatttcc taaatatgtg aaaagtcgcc caaaatgcaa ccttgaaagg cactactgac 4140
tttgttctta ttggatactc ctcttattta ttatttttcc attaaaaata atagctggct 4200
attatagaaa atttagacca tacagagatg tagaagaagc ataaattgtc cccattacct 4260
taaggtaatc actgctaaca atttctggat ggtttttcaa gtctattttt tttctatgta 4320
tgtctcaatt ctctttcaaa attttacaga atgttatcat actacatata tactttttat 4380
gtaagctttt tcacttagta ttttatcaaa tatgttttta ttatattcat agccttctta 4440
aacattatat caataattgc ataataggca acctctagcg attaccataa tttgtctcat 4500
tgaaggctat ctccagttga tcattgggat gagcatcttt gtgcatgaat cctattgctg 4560
tatttgggaa aattttccaa ggtagattc caataaatat ctatttatta ttaaaaaaaa 4620
aaaaaaaagg gcggccgctc tagagt 4646

```

&lt;210&gt; 32

&lt;211&gt; 1104

&lt;212&gt; PRT

&lt;213&gt; Homo Sapiens

&lt;400&gt; 32

```

Met Ser Phe Arg Ala Arg Leu Ser Met Arg Asn Arg Arg Asn Asp
1      5      10      15
Thr Leu Asp Ser Thr Arg Thr Leu Tyr Ser Ser Ala Ser Arg Ser Thr
20      25      30
Asp Leu Ser Tyr Ser Glu Ser Asp Leu Val Asn Phe Ile Gln Ala Asn
35      40      45
Phe Lys Lys Arg Glu Cys Val Phe Phe Thr Lys Asp Ser Lys Ala Thr
50      55      60
Glu Asn Val Cys Lys Cys Gly Tyr Ala Gln Ser Gln His Met Glu Gly
65      70      75      80
Thr Gln Ile Asn Gln Ser Glu Lys Trp Asn Tyr Lys Lys His Thr Lys
85      90      95
Glu Phe Pro Thr Asp Ala Phe Gly Asp Ile Gln Phe Glu Thr Leu Gly
100     105     110
Lys Lys Gly Lys Tyr Ile Arg Leu Ser Cys Asp Thr Asp Ala Glu Ile
115     120     125
Leu Tyr Glu Leu Leu Thr Gln His Trp His Leu Lys Thr Pro Asn Leu
130     135     140
Val Ile Ser Val Thr Gly Gly Ala Lys Asn Phe Ala Leu Lys Pro Arg
145     150     155     160
Met Arg Lys Ile Phe Ser Arg Leu Ile Tyr Ile Ala Gln Ser Lys Gly
165     170     175
Ala Trp Ile Leu Thr Gly Gly Thr His Tyr Gly Leu Met Lys Tyr Ile
180     185     190
Gly Glu Val Val Arg Asp Asn Thr Ile Ser Arg Ser Ser Glu Glu Asn
195     200     205

```

-51-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Val | Ala | Ile | Gly | Ile | Ala | Ala | Trp | Gly | Met | Val | Ser | Asn | Arg | Asp | 210 | 215 | 220 |
| Thr | Leu | Ile | Arg | Asn | Cys | Asp | Ala | Glu | Gly | Tyr | Phe | Leu | Ala | Gln | Tyr | 225 | 230 | 235 |
| Leu | Met | Asp | Asp | Phe | Thr | Arg | Asp | Pro | Leu | Cys | Ile | Leu | Asp | Asn | Asn | 245 | 250 | 255 |
| His | Thr | His | Leu | Leu | Leu | Val | Asp | Asn | Gly | Cys | His | Gly | His | Pro | Thr | 260 | 265 | 270 |
| Val | Glu | Ala | Lys | Leu | Arg | Asn | Gln | Leu | Glu | Lys | Tyr | Ile | Ser | Glu | Arg | 275 | 280 | 285 |
| Thr | Ile | Gln | Asp | Ser | Asn | Tyr | Gly | Gly | Lys | Ile | Pro | Ile | Val | Cys | Phe | 290 | 295 | 300 |
| Ala | Gln | Gly | Gly | Gly | Lys | Glu | Thr | Leu | Lys | Ala | Ile | Asn | Thr | Ser | Ile | 305 | 310 | 315 |
| Lys | Asn | Lys | Ile | Pro | Cys | Val | Val | Val | Glu | Gly | Ser | Gly | Gln | Ile | Ala | 325 | 330 | 335 |
| Asp | Val | Ile | Ala | Ser | Leu | Val | Glu | Val | Glu | Asp | Ala | Leu | Thr | Ser | Ser | 340 | 345 | 350 |
| Ala | Val | Lys | Glu | Lys | Leu | Val | Arg | Phe | Leu | Pro | Arg | Thr | Val | Ser | Arg | 355 | 360 | 365 |
| Leu | Pro | Glu | Glu | Glu | Thr | Glu | Ser | Trp | Ile | Lys | Trp | Leu | Lys | Glu | Ile | 370 | 375 | 380 |
| Leu | Glu | Cys | Ser | His | Leu | Leu | Thr | Val | Ile | Lys | Met | Glu | Glu | Ala | Gly | 385 | 390 | 395 |
| Asp | Glu | Ile | Val | Ser | Asn | Ala | Ile | Ser | Tyr | Ala | Leu | Tyr | Lys | Ala | Phe | 405 | 410 | 415 |
| Ser | Thr | Ser | Glu | Gln | Asp | Lys | Asp | Asn | Trp | Asn | Gly | Gln | Leu | Lys | Leu | 420 | 425 | 430 |
| Leu | Leu | Glu | Trp | Asn | Gln | Leu | Asp | Leu | Ala | Asn | Asp | Glu | Ile | Phe | Thr | 435 | 440 | 445 |
| Asn | Asp | Arg | Arg | Trp | Glu | Ser | Ala | Asp | Leu | Gln | Glu | Val | Met | Phe | Thr | 450 | 455 | 460 |
| Ala | Leu | Ile | Lys | Asp | Arg | Pro | Lys | Phe | Val | Arg | Leu | Phe | Leu | Glu | Asn | 465 | 470 | 475 |
| Gly | Leu | Asn | Leu | Arg | Lys | Phe | Leu | Thr | His | Asp | Val | Leu | Thr | Glu | Leu | 485 | 490 | 495 |
| Phe | Ser | Asn | His | Phe | Ser | Thr | Leu | Val | Tyr | Arg | Asn | Leu | Gln | Ile | Ala | 500 | 505 | 510 |
| Lys | Asn | Ser | Tyr | Asn | Asp | Ala | Leu | Leu | Thr | Phe | Val | Trp | Lys | Leu | Val | 515 | 520 | 525 |
| Ala | Asn | Phe | Arg | Arg | Gly | Phe | Arg | Lys | Glu | Asp | Arg | Asn | Gly | Arg | Asp | 530 | 535 | 540 |
| Glu | Met | Asp | Ile | Glu | Leu | His | Asp | Val | Ser | Pro | Ile | Thr | Arg | His | Pro | 545 | 550 | 555 |
| Leu | Gln | Ala | Leu | Phe | Ile | Trp | Ala | Ile | Leu | Gln | Asn | Lys | Lys | Glu | Leu | 565 | 570 | 575 |
| Ser | Lys | Val | Ile | Trp | Glu | Gln | Thr | Arg | Gly | Cys | Thr | Leu | Ala | Ala | Leu | 580 | 585 | 590 |
| Gly | Ala | Ser | Lys | Leu | Leu | Lys | Thr | Leu | Ala | Lys | Val | Lys | Asn | Asp | Ile | 595 | 600 | 605 |
| Asn | Ala | Ala | Gly | Glu | Ser | Glu | Glu | Leu | Ala | Asn | Glu | Tyr | Glu | Thr | Arg | 610 | 615 | 620 |
| Ala | Val | Glu | Leu | Phe | Thr | Glu | Cys | Tyr | Ser | Ser | Asp | Glu | Asp | Leu | Ala | 625 | 630 | 635 |
| Glu | Gln | Leu | Leu | Val | Tyr | Ser | Cys | Glu | Ala | Trp | Gly | Gly | Ser | Asn | Cys | 645 | 650 | 655 |
| Leu | Glu | Leu | Ala | Val | Glu | Ala | Thr | Asp | Gln | His | Phe | Ile | Ala | Gln | Pro | 660 | 665 | 670 |
| Gly | Val | Gln | Asn | Phe | Leu | Ser | Lys | Gln | Trp | Tyr | Gly | Glu | Ile | Ser | Arg | 675 | 680 | 685 |

-52-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |      |      |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|
| Asp | Thr | Lys | Asn | Trp | Lys | Ile | Ile | Leu | Cys | Leu | Phe | Ile | Ile | Pro | Leu | 690  | 695  | 700  |
| Val | Gly | Cys | Gly | Phe | Val | Ser | Phe | Arg | Lys | Lys | Pro | Val | Asp | Lys | His | 705  | 710  | 715  |
| Lys | Lys | Leu | Leu | Trp | Tyr | Tyr | Val | Ala | Phe | Phe | Thr | Ser | Pro | Phe | Val | 725  | 730  | 735  |
| Val | Phe | Ser | Trp | Asn | Val | Val | Phe | Tyr | Ile | Ala | Phe | Leu | Leu | Leu | Phe | 740  | 745  | 750  |
| Ala | Tyr | Val | Leu | Leu | Met | Asp | Phe | His | Ser | Val | Pro | His | Pro | Pro | Glu | 755  | 760  | 765  |
| Leu | Val | Leu | Tyr | Ser | Leu | Val | Phe | Val | Leu | Phe | Cys | Asp | Glu | Val | Arg | 770  | 775  | 780  |
| Gln | Trp | Tyr | Val | Asn | Gly | Val | Asn | Tyr | Phe | Thr | Asp | Leu | Trp | Asn | Val | 785  | 790  | 795  |
| Met | Asp | Thr | Leu | Gly | Leu | Phe | Tyr | Phe | Ile | Ala | Gly | Ile | Val | Phe | Arg | 805  | 810  | 815  |
| Leu | His | Ser | Ser | Asn | Lys | Ser | Ser | Leu | Tyr | Ser | Gly | Arg | Val | Ile | Phe | 820  | 825  | 830  |
| Cys | Leu | Asp | Tyr | Ile | Ile | Phe | Thr | Leu | Arg | Leu | Ile | His | Ile | Phe | Thr | 835  | 840  | 845  |
| Val | Ser | Arg | Asn | Leu | Gly | Pro | Lys | Ile | Ile | Met | Leu | Gln | Arg | Met | Leu | 850  | 855  | 860  |
| Ile | Asp | Val | Phe | Phe | Phe | Leu | Phe | Leu | Phe | Ala | Val | Trp | Met | Val | Ala | 865  | 870  | 875  |
| Phe | Gly | Val | Ala | Arg | Gln | Gly | Ile | Leu | Arg | Gln | Asn | Glu | Gln | Arg | Trp | 885  | 890  | 895  |
| Arg | Trp | Ile | Phe | Arg | Ser | Val | Ile | Tyr | Glu | Pro | Tyr | Leu | Ala | Met | Phe | 900  | 905  | 910  |
| Gly | Gln | Val | Pro | Ser | Asp | Val | Asp | Gly | Thr | Thr | Tyr | Asp | Phe | Ala | His | 915  | 920  | 925  |
| Cys | Thr | Phe | Thr | Gly | Asn | Glu | Ser | Lys | Pro | Leu | Cys | Val | Glu | Leu | Asp | 930  | 935  | 940  |
| Glu | His | Asn | Leu | Pro | Arg | Phe | Pro | Glu | Trp | Ile | Thr | Ile | Pro | Leu | Val | 945  | 950  | 955  |
| Cys | Ile | Tyr | Met | Leu | Ser | Thr | Asn | Ile | Leu | Val | Asn | Leu | Leu | Val |     | 965  | 970  | 975  |
| Ala | Met | Phe | Gly | Tyr | Thr | Val | Gly | Thr | Val | Gln | Glu | Asn | Asn | Asp | Gln | 980  | 985  | 990  |
| Val | Trp | Lys | Phe | Gln | Arg | Tyr | Phe | Leu | Val | Gln | Glu | Tyr | Cys | Ser | Arg | 995  | 1000 | 1005 |
| Leu | Asn | Ile | Pro | Phe | Pro | Phe | Ile | Val | Phe | Ala | Tyr | Phe | Tyr | Met | Val | 1010 | 1015 | 1020 |
| Val | Lys | Lys | Cys | Phe | Lys | Cys | Cys | Cys | Lys | Glu | Lys | Asn | Met | Glu | Ser | 1025 | 1030 | 1035 |
| Ser | Val | Cys | Cys | Phe | Lys | Asn | Glu | Asp | Asn | Glu | Thr | Leu | Ala | Trp | Glu | 1045 | 1050 | 1055 |
| Gly | Val | Met | Lys | Glu | Asn | Tyr | Leu | Val | Lys | Ile | Asn | Thr | Lys | Ala | Asn | 1060 | 1065 | 1070 |
| Asp | Thr | Ser | Glu | Glu | Met | Arg | His | Arg | Phe | Arg | Gln | Leu | Asp | Thr | Lys | 1075 | 1080 | 1085 |
| Leu | Asn | Asp | Leu | Lys | Gly | Leu | Leu | Lys | Glu | Ile | Ala | Asn | Lys | Ile | Lys | 1090 | 1095 | 1100 |

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/29996

|  |   |                        |
|--|---|------------------------|
| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC 7 C07K14/705 C12N15/12 C12Q1/68 C12N5/10 C07K16/28<br>G01N33/53 A61K38/17  |   |                        |
| According to International Patent Classification (IPC) or to both national classification and IPC  |   |                        |
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>IPC 7 C12N C07K C12Q A61K G01N   |   |                        |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  |   |                        |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used)<br>BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE, SCISEARCH, EMBASE, BIOTECHNOLOGY<br>ABS, CHEM ABS Data, STRAND, GENSEQ, EMBL   |   |                        |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>  |   |                        |
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.  |
| X  | DATABASE GENEMBL 'Online!<br>16 February 1998 (1998-02-16)<br>STRAUSBERG, R.: "ob70f05.s1 NCI_CGAP_GCB1<br>Homo sapiens cDNA clone IMAGE:1336737 3',<br>mRNA sequence"<br>XP002138823<br>Accession AA809355 | 1,2,<br>6-19,<br>25-35 |
| X  | DATABASE GENEMBL 'Online!<br>10 July 1998 (1998-07-10)<br>MARRA ET AL.: "ub28d10.r1 Soares 2NbMT Mus<br>musculus cDNA clone IMAGE:1379059 5' mRNA<br>sequence"<br>XP002149803<br>Accession AI050262         | 1,6-19,<br>25-35       |
| -/--   |   |                        |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.  |   |                        |
| * Special categories of cited documents :<br><div style="display: flex; justify-content: space-between;"> <div style="width: 45%;">           *A* document defining the general state of the art which is not considered to be of particular relevance<br/>           *E* earlier document but published on or after the international filing date<br/>           *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br/>           *O* document referring to an oral disclosure, use, exhibition or other means<br/>           *P* document published prior to the international filing date but later than the priority date claimed         </div> <div style="width: 45%;">           *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br/>           *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br/>           *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.<br/>           *&amp;* document member of the same patent family         </div> </div> |   |                        |
| Date of the actual completion of the international search  | Date of mailing of the international search report  |                        |
| 16 October 2000  | 30. 10. 00  |                        |
| Name and mailing address of the ISA<br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax: (+31-70) 340-3016   | Authorized officer<br><br>ALCONADA RODRIG..., A   |                        |

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/29996

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                         |
|--|---|-------------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.   |
| X  | <p>DATABASE GENEMBL 'Online!<br/>19 July 1997 (1997-07-19)<br/>STRAUSBERG, R.: "ni64e11.s1 NCI_CGAP_Pr12<br/>Homo sapiens cDNA clone IMAGE:981644 mRNA<br/>sequence"<br/>XP002148641<br/>Accession AA523749</p>   | 1,3,<br>10-19,<br>25-35 |
| X  | <p>WO 98 15657 A (ABBOTT LAB)<br/>16 April 1998 (1998-04-16)</p>  | 1,4,<br>6-19,<br>25-35  |
| Y  | <p>page 4, line 7 -page 5, line 13<br/>page 5, line 24 -page 7, line 28<br/>SEQ ID NOs. 9 and 25</p>  | 20-24                   |
| X  | <p>WO 98 37093 A (CORIXA CORP)<br/>27 August 1998 (1998-08-27)</p>  | 1,4,<br>6-19,<br>25-35  |
| Y  | <p>page 7, paragraph 2<br/>page 9, paragraphs 2,3<br/>page 13 -page 17<br/>page 21, paragraph 3<br/>SEQ ID NOs: 109 and 112</p>   | 20-24                   |
| X  | <p>DATABASE GENEMBL 'Online!<br/>18 November 1997 (1997-11-18)<br/>STRAUSBERG, R.: "nt76b07.s1 NCI_CGAP_Pr3<br/>Homo sapiens cDNA clone IMAGE:1204405,<br/>mRNA"<br/>XP002148642<br/>Accession AA654650</p>   | 1,5-19,<br>25-35        |
| Y  | <p>Accession AA654650</p>   | 20-24                   |
| Y  | <p>DATABASE GENEMBL 'Online!<br/>30 November 1998 (1998-11-30)<br/>SHIMIZU, N.: "Homo sapiens mRNA complete<br/>cds."<br/>XP002148643<br/>Accession number AB001535<br/>-&amp; NAGAMINE ET AL.: "Molecular cloning of<br/>a novel putative Ca<sup>2+</sup> channel protein<br/>(TRPC7) highly expressed in brain"<br/>GENOMICS,<br/>vol. 54, 15 November 1998 (1998-11-15),<br/>pages 124-131, XP000938744<br/>the whole document</p> | 20-24                   |

---  
-/--

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/29996

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |  |  |
|--|--|--|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.                            |
| A  | <p>ZHU, XI ET AL: "Molecular cloning of a widely expressed human homologue for the <i>Drosophila</i> trp gene."<br/> FEBS LETTERS, (1995) VOL. 373, NO. 3, PP. 193-198.,<br/> XP000907241<br/> page 194; figures 1,3</p> <p style="text-align: center;">---</p>  | <p>20,21,<br/> 23,25,<br/> 26,28,<br/> 29,31</p> |
| A  | <p>HUNTER JOHN J ET AL: "Chromosomal localization and genomic characterization of the mouse melastatin gene (<i>Mln1</i>)."<br/> GENOMICS NOV. 15, 1998,<br/> vol. 54, no. 1,<br/> 15 November 1998 (1998-11-15), pages 116-123, XP000910696<br/> ISSN: 0888-7543<br/> cited in the application<br/> page 119; figure 2</p> <p style="text-align: center;">---</p>                               | <p>20,21,23</p>                                  |
| A  | <p>WES PAUL D ET AL: "TRPC1, a human homolog of a <i>Drosophila</i> store-operated channel."<br/> PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1995,<br/> vol. 92, no. 21, 1995, pages 9652-9656,<br/> XP002138820<br/> ISSN: 0027-8424<br/> the whole document</p> <p style="text-align: center;">---</p>  | <p>20,21,<br/> 23,25,<br/> 26,28,<br/> 29,31</p> |
| A  | <p>ZHU, XI ET AL: "Trp, A novel mammalian gene family essential for agonist-activated capacitative Ca-2+ entry."<br/> CELL,<br/> vol. 85, no. 5, 1996, pages 661-671,<br/> XP000907242<br/> page 662<br/> page 665<br/> figures 1,5,6</p> <p style="text-align: center;">---</p>   | <p>20,21,<br/> 25,26,<br/> 28,29,31</p>          |
| A  | <p>GARCIA REYNALDO L ET AL: "Differential expression of mammalian TRP homologues across tissues and cell lines."<br/> BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1997,<br/> vol. 239, no. 1, 1997, pages 279-283,<br/> XP002138822<br/> ISSN: 0006-291X<br/> See Materials and Methods<br/> figure 1</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p> | <p>25,26,<br/> 28-30</p>                         |

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/29996

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |   |                         |
|--|---|-------------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.   |
| A  | SINKINS WILLIAM G ET AL: "Functional expression of TrpCl: A human homologue of the Drosophila Trp channel."<br>BIOCHEMICAL JOURNAL APRIL, 1998, vol. 331, no. 1, April 1998 (1998-04), pages 331-339, XP000864583<br>ISSN: 0264-6021<br>page 333-335; figures 3-5   | 24                      |
| A  | PREUSS KLAUS-DIETER ET AL: "Expression and characterization of a trpl homolog from rat."<br>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS NOV. 7, 1997, vol. 240, no. 1, 7 November 1997 (1997-11-07), pages 167-172, XP002138821<br>ISSN: 0006-291X<br>figure 2  | 24                      |
| A  | OBUKHOV, ALEXANDER G. ET AL: "Direct activation of trpl cation channels by G-alpha-11 subunits."<br>EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, (1996) VOL. 15, NO. 21, PP. 5833-5838., XP000907243<br>figure 2   | 24                      |
| P,X  | WO 99 09199 A (RYAZANOV ALEXEY G ;PAVUR KAREN S (US); HAIT WILLIAM N (US); UNIV M) 25 February 1999 (1999-02-25)<br>see melanome kinase polynucleotide and polypeptide sequences on page 16-17  | 1,3,<br>10-19,<br>25-36 |
| P,X  | WO 99 09166 A (SHAPERO MICHAEL H ;DENDREON CORP (US); LAUS REINER (US); TSAVALER) 25 February 1999 (1999-02-25)<br>page 17, line 24 -page 18, line 9<br>page 25, line 19-32<br>page 28, line 1-4<br>SEQ ID NOs: 27, 28 and 31.  | 1,5-19,<br>25-35        |
| T  | SCHARENBERG A M ET AL: "MLSN-1/SOC-1 defines a widely expressed Ca2+/cation channel family involved in Ca2+ homeostasis and store-operated Ca2+ signaling."<br>FIFTY-THIRD ANNUAL MEETING OF THE SOCIETY OF GENERAL PHYSIOLOGISTS;WOODS HOLE, MASSACHUSETTS, USA; SEPTEMBER 9-11, 1999, vol. 114, no. 1, July 1999 (1999-07), page 14a XP000910708<br>Journal of General Physiology July, 1999<br>ISSN: 0022-1295 |                         |



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/29996

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
1-36
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1-5, 10-13, 16-19, 32-35 relate to an extremely large number of possible polynucleotides, polypeptides encoded by them, binding polypeptides, and kits and pharmaceutical compositions containing said polypeptides and polynucleotides. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the polynucleotide of SEQ ID NOs: 1, 27, 29 and 31 and the corresponding polypeptide of SEQ ID NOs: 2, 28, 30 and 32.

Present claims 16 and 17 relate to an extremely large number of possible compounds, namely, a polypeptide that binds to the polypeptide of the invention. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to an antibody, antibody fragment, F(ab)2 fragment or a fragment including a CDR3 region selective for the polypeptides of the invention.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 6-36 (partially) and 2 (complete)

An isolated nucleic acid molecule comprising a nucleic acid molecule that hybridizes to a nucleic acid molecule of SEQ ID NO:1 and which code for a SOC/CRAC polypeptide, nucleic acid molecules that differ in codon sequence due to degeneracy of the genetic code and complement thereof, polynucleotides which are not identical to the SEQ ID or sequences of GenBank accession number of Table 1; expression vector, host cells; polypeptide encoded thereof (SEQ ID NO:2); polypeptides binding to the polypeptide of SEQ ID NO:2, including antibodies; kits comprising agents that selectively bind to the polynucleotide (SEQ ID NO:1) or polypeptide (SEQ ID NO:2) of the invention; pharmaceutical compositions containing the polynucleotide or polypeptides of the invention; a method for isolating the SOC/CRAC molecule having SOC/CRAC calcium channel activity comprising contacting a binding molecule that is SOC/CRAC nucleic acid or a SOC/CRAC binding polypeptide with a sample containing SOC/CRAC molecules allowing the formation of the complex, detecting the formation of the complex, isolating the SOC/CRAC molecule and determining whether the isolated SOC/CRAC molecule has SOC/CRAC calcium channel activity; a method for identifying agents useful in the modulation of SOC/CRAC calcium channel activity; a method to determine the level of SOC/CRAC expression in a subject, including expression of SOC/CRAC polypeptide or mRNA in a tissue or biological fluid sample using PCR, Northern blotting, and mono- and polyclonal antisera and a method for identifying agents useful in the modulation of the SOC/CRAC polypeptide kinase activity, comprising the use of aminoacids 999-1180 from SEQ ID NO:4 as a candidate kinase.

2. Claims: 1,6-36 (partially)

As subject 1, but referred to the polynucleotide of SEQ ID NO:3 and to the encoded polypeptide of SEQ ID NO:4

3. Claims: 1,6-36 (partially)

As subject 1, but referred to the polynucleotide of SEQ ID NO:5 and to the encoded polypeptide of SEQ ID NO:6

4. Claims: 1,6-36 (partially)

As subject 1, but referred to the polynucleotide of SEQ ID NO:7 and to the encoded polypeptide of SEQ ID NO:8

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. Claims: 1,6-36 (partially) and 37 (complete)

As subject 1, but referred to the polynucleotide of SEQ ID NO:23 and to the encoded polypeptide of SEQ ID NO:24

6. Claims: 1,6-36 (partially)

As subject 1, but referred to the polynucleotide of SEQ ID NO:25 and to the encoded polypeptide of SEQ ID NO:26

7. Claims: 1,10-36 (partially) and 3 (complete)

As subject 1, but referred to the polynucleotide of SEQ ID NO:27 and to the encoded polypeptide of SEQ ID NO:28

8. Claims: 1,6-36 (partially) and 4 (complete)

As subject 1, but referred to the polynucleotide of SEQ ID NO:29 and to the encoded polypeptide of SEQ ID NO:30

9. Claims: 1,6-36 (partially) and 5 (complete)

As subject 1, but referred to the polynucleotide of SEQ ID NO:31 and to the encoded polypeptide of SEQ ID NO:32.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/US 99/29996

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---------------------|--|--|
| WO 9815657 A                              | 16-04-1998          | US 5919638 A<br>EP 0954599 A<br>US 6110675 A   | 06-07-1999<br>10-11-1999<br>29-08-2000   |
| WO 9837093 A                              | 27-08-1998          | AU 6181898 A<br>CN 1252837 T<br>EP 1005546 A<br>NO 994069 A<br>PL 335348 A<br>ZA 9801585 A | 09-09-1998<br>10-05-2000<br>07-06-2000<br>22-10-1999<br>25-04-2000<br>04-09-1998 |
| WO 9909199 A                              | 25-02-1999          | AU 9110098 A   | 08-03-1999   |
| WO 9909166 A                              | 25-02-1999          | AU 9021898 A<br>EP 1005549 A   | 08-03-1999<br>07-06-2000   |